        <DOC>
            	<DOCNO>s_2494_0_0</DOCNO>
            	<TEXT>subject5410</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_0_1</DOCNO>
            	<TEXT>My screen name on yahoo is ROBERT S. I will also be posting on this board under the name subject5410</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_0</DOCNO>
            	<TEXT>THE MISSION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_1</DOCNO>
            	<TEXT>THE MISSION Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_2</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_3</DOCNO>
            	<TEXT>The mission of NAMRU-3 is to ensure warfighter readiness through detecting, deterring, and responding to infectious disease threats through integration with partners throughout U.S. Africa Command (AFRICOM), Central Command (CENTCOM), and European Command (EUCOM) areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_4</DOCNO>
            	<TEXT>The purpose of this collaboration is to perform infectious disease research that guides the Department of Defense (DoD), informs public health policy of host nation partners, and improves medical readiness of the U.S. Armed Forces across NAMRU-3 areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_5</DOCNO>
            	<TEXT>Through shared resources and logistical support, the overall goal of this research cooperation will be to conduct research on current, emerging and re-emerging infectious diseases, to enhance Force Health Protection, and provide critical data regarding countermeasures to mitigate infectious disease transmission including surveillance and product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_6</DOCNO>
            	<TEXT>READ THAT LAST PARAGRAPH AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_7</DOCNO>
            	<TEXT>It's starts with the mission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_8</DOCNO>
            	<TEXT>Our US Armed Forces MISSION.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_9</DOCNO>
            	<TEXT>Our US Armed Forces are the BEST IN THE WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_10</DOCNO>
            	<TEXT>And don't you forget it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_11</DOCNO>
            	<TEXT>Continue reading please... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) The initial focus of the collaboration will be to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostics and COVIDROPS/COVI-AMG outpatient neutralizing antibody treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_12</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_13</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_14</DOCNO>
            	<TEXT>https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/) Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_15</DOCNO>
            	<TEXT>A previously completed safety study conducted in the US at doses up to 60 mg in healthy subjects showed a comparable safety profile to placebo with all reported adverse effects being mild in severity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_16</DOCNO>
            	<TEXT>The UK study will complement Phase 2 trials currently being started in the US and should the results of these studies demonstrate that COVIDROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, UK, Canada, India, Mexico and European Union as well as other territories. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_17</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical) Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_18</DOCNO>
            	<TEXT>Read that last line again please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_19</DOCNO>
            	<TEXT>Just a SINGLE Intranasal Dose.... Just one 10 or 20 MG Dose. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_20</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12](https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12) Sorrento Therapeutics is on a MISSION and I believe they will be successful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_1_21</DOCNO>
            	<TEXT>My Screen name on Yahoo is Robert S and you can now find me on REDDIT as subject5410</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_0</DOCNO>
            	<TEXT>Quality  amp; Compliance for COVISTIX and COVIDROPS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_1</DOCNO>
            	<TEXT>Quality  amp; Compliance for COVISTIX and COVIDROPS Bioserv is currently registered with the United States Food and Drug Administration (U.S. FDA) for both Pharmaceutical and Medical Device manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_2</DOCNO>
            	<TEXT>The FDA Drug Center has inspected the facility for routine inspections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_3</DOCNO>
            	<TEXT>The FDA Device Centers have performed inspections of the facility for routine inspections and for pre and post market approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_4</DOCNO>
            	<TEXT>Bioserv is currently licensed by the State of California for Pharmaceutical and Medical Device manufacturing, and for interstate commerce.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_5</DOCNO>
            	<TEXT>That's right Bioserv is registered with the United States Food and Drug Administration (U.S. FDA) for both Pharmaceutical and Medical Device manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_6</DOCNO>
            	<TEXT>The FDA Drug Center has inspected the facility for routine inspections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_7</DOCNO>
            	<TEXT>DOES THIS MEAN COVISTIX CAN BE MANUFACTURED IN CALIFORNIA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_8</DOCNO>
            	<TEXT>I believe it now can be Manufactured in their home State.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_9</DOCNO>
            	<TEXT>Bioserv is also ISO ISO 13485:2016 Certified (FM 77429).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_10</DOCNO>
            	<TEXT>Although the scope of Bioservs ISO Certification is limited to Medical Devices at this time, Bioserv is one (1) Quality System that is suitable for both Medical Devices and Pharmaceutical production.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_11</DOCNO>
            	<TEXT>The Company also produces sterile products compliant for use in the EU.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_12</DOCNO>
            	<TEXT>WOW They can produce sterile products compliant for use in the EU.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_13</DOCNO>
            	<TEXT>European Union DOES THIS MEAN THEY CAN MANUFACTURE COVIDROPS FOR THE EU?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_14</DOCNO>
            	<TEXT>I believe it can be Manufactured after they receive the EUA approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_15</DOCNO>
            	<TEXT>Please read for yourselves. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_2_16</DOCNO>
            	<TEXT>https://www.bioservamerica.com/quality-compliance/](https://www.bioservamerica.com/quality-compliance/) Please visit me on REDDIT as subject5410 ROBERT S. is my screen name on Yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_0</DOCNO>
            	<TEXT>Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_1</DOCNO>
            	<TEXT>SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to rapidly develop a DNA-based neutralizing antibody that can be given to people as an intramuscular injection to block infection by COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_2</DOCNO>
            	<TEXT>We have used our tool box to create a scalable and cost-effective solution for creating pop-up immunity in people against coronavirus that has the capability to be rapidly scaled to deliver millions of doses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_3</DOCNO>
            	<TEXT>Our solution starts with our novel DNA plasmid that can express protein in muscle for weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_4</DOCNO>
            	<TEXT>This plasmid will be used to express an antibody capable of binding to and neutralizing the SARS-CoV-2 virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_5</DOCNO>
            	<TEXT>This type of DNA plasmid has already been produced for other products in a fully cGMP-compliant manner and at significant quantities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_6</DOCNO>
            	<TEXT>We plan to combine this DNA with a new, GMP-compliant polymer solution that may significantly enhance DNA expression in skeletal muscle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_7</DOCNO>
            	<TEXT>This polymer has been demonstrated to have the kind of safety profile to make it appropriate for use in humans.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_8</DOCNO>
            	<TEXT>These two components would be delivered together through a standard hypodermic needlea standard approach typically used in vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_9</DOCNO>
            	<TEXT>Our approach eliminates the need for electroporation devices, which are currently being used in the delivery of these types of DNA-based antibody treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_10</DOCNO>
            	<TEXT>So on November 27th 2020 please click and read [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) Please read the last sentence in this paragraph from a statement on November 27th.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_11</DOCNO>
            	<TEXT>Dr. Henry Ji, CEO of Sorrento, commented, We are excited that DARPA and JPEO have recognized our Gene MAbs platform as a potential rapid countermeasure for COVID-19 and the potential value for other applications to combat future viral diseases of pandemic potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_12</DOCNO>
            	<TEXT>We acquired SmartPharm with the vision of combining the power of our antibody and biologic therapies for cancer and infectious diseases with next-generation gene-encoded technologies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_13</DOCNO>
            	<TEXT>We look forward to working with our Department of Defense partners to potentially add a novel approach to the arsenal of solutions for combating this devastating disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_14</DOCNO>
            	<TEXT>Please read the sentence again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_15</DOCNO>
            	<TEXT>We look forward to working with our Department of Defense partners to potentially add a novel approach to the arsenal of solutions for combating this devastating disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_16</DOCNO>
            	<TEXT>Since then on June 22nd 2021 please click and read.. [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) The initial focus of the collaboration will be to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostics and COVIDROPS/COVI-AMG outpatient neutralizing antibody treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_17</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_18</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_19</DOCNO>
            	<TEXT>1 + 1 = 2 I believe NAMRU working with the DoD realizes the potential to the arsenal of solutions Sorrento Therapeutics has in their tool box.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_3_20</DOCNO>
            	<TEXT>My screen name on Yahoo is ROBERT S. and you can also follow me on REDDIT as subject5410.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_4_0</DOCNO>
            	<TEXT>TOP 10 COMPANIES-MOST-COVID-19 TREATMENTS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_0</DOCNO>
            	<TEXT>Sorrento is seeking major global partnership(s) to co-develop and co-commercialize Abivertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_1</DOCNO>
            	<TEXT>Sorrento is seeking major global partnership(s) to co-develop and co-commercialize Abivertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_2</DOCNO>
            	<TEXT>Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND B-CELL LYMPHOMA: This is a value-inflection acquisition for Sorrento as we bring in multiple NCE drug product candidates, including the previously licensed Abivertinib as an anchoring small molecule drug product for treating many different cancers and autoimmune diseases, said Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_3</DOCNO>
            	<TEXT>With broad-spectrum and synergistic infrastructures and expertise in pharmaceutical and biological drug discovery, development and manufacturing, and expanded geographic coverage in China and North America, we envision Sorrento becoming a leading biopharmaceutical company to develop and commercialize innovative medicines that will save and improve lives globally.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_4</DOCNO>
            	<TEXT>With perfectly aligned missions, ACEA and Sorrento are both committed to developing innovative drugs and providing therapeutic solutions for unmet medical needs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_5</DOCNO>
            	<TEXT>The successful integration of ACEA small molecule drug pipelines to Sorrento large molecule and cell therapy platforms will significantly strengthen and facilitate the innovative drug development in the field of cancer and autoimmune diseases, said Xiao Xu, M.D, President of ACEA Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_6</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-completes-acquisition-acea-therapeutics-creating-major](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-completes-acquisition-acea-therapeutics-creating-major) [https://clinicaltrials.gov/ct2/show/NCT04528667?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4](https://clinicaltrials.gov/ct2/show/NCT04528667?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4) Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_7</DOCNO>
            	<TEXT>Lets read this press release again from June 22nd 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_8</DOCNO>
            	<TEXT>Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21 [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have) We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_9</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_10</DOCNO>
            	<TEXT>Sorrento is seeking a global partnership.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_11</DOCNO>
            	<TEXT>Who will partner with Sorrento Therapeutics?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_5_12</DOCNO>
            	<TEXT>THE KEY TO BRAZIL [https://www.synovahealth.com/](https://www.synovahealth.com/) Top 5 Brazilian Pharma Companies [https://pharmaboardroom.com/articles/top-5-brazilian-pharma-companies/](https://pharmaboardroom.com/articles/top-5-brazilian-pharma-companies/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_0</DOCNO>
            	<TEXT>CONGRATULATIONS THE SCRIPPS RESEARCH INSTITUTE OF LA JOLLA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_1</DOCNO>
            	<TEXT>AMERICAN CHEMICAL SOCIETY Publication date August 2nd 2021 Congratulations to The Scripps Research Institute of La Jolla.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_2</DOCNO>
            	<TEXT>SARS-CoV-2 virus has recently given rise to the current COVID-19 pandemic where infected individuals can range from being asymptomatic, yet highly contagious, to dying from acute respiratory distress syndrome.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_3</DOCNO>
            	<TEXT>Although the world has mobilized to create antiviral vaccines and therapeutics to combat the scourge, their long-term efficacy remains in question especially with the emergence of new variants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_4</DOCNO>
            	<TEXT>In this work, we exploit a class of compounds that has previously shown success against various viruses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_5</DOCNO>
            	<TEXT>A salicylanilide library was first screened in a SARS-CoV-2 activity assay in Vero cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_6</DOCNO>
            	<TEXT>The most efficacious derivative was further evaluated in a prophylactic mouse model of SARS-CoV-2 infection unveiling a salicylanilide that can reduce viral loads, modulate key cytokines, and mitigate severe weight loss involved in COVID-19 infections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_7</DOCNO>
            	<TEXT>The combination of anti-SARS-CoV-2 activity, cytokine inhibitory activity, and a previously established favorable pharmacokinetic profile for the lead salicylanilide renders salicylanilides in general as promising therapeutics for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_8</DOCNO>
            	<TEXT>Please click and read the abstract.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_9</DOCNO>
            	<TEXT>The Salicylanilides Neutralizes the endoscomal pH, BLOCKING CYTOSOLIC ENTRY OF RNA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_10</DOCNO>
            	<TEXT>100% NEUTRALIZATION [https://pubs.acs.org/doi/10.1021/acsinfecdis.1c00253](https://pubs.acs.org/doi/10.1021/acsinfecdis.1c00253) Syrian Hamsters are used before human trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_11</DOCNO>
            	<TEXT>Please CLICK and read where it says READ ONLINE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_6_12</DOCNO>
            	<TEXT>PLEASE SCROLL DOWN S2 PLEASE VIEW THE GRAPH 100% NEUTRALIZATION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_7_0</DOCNO>
            	<TEXT>COVI-STIX APPROVED FOR PUBLICATION/ISSUE REVIEW COMPLETE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_7_1</DOCNO>
            	<TEXT>This means Sorrento Therapeutics is currently using the MARK in publication.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_7_2</DOCNO>
            	<TEXT>This is great news now they can advertise throughout Mexico  amp; Latin America and in the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_7_3</DOCNO>
            	<TEXT>I would believe Sorrento Mexico LTD will now start advertising in all Airports and Sporting Events, Hotels, Resorts . [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_7_4</DOCNO>
            	<TEXT>https://trademarks.justia.com/901/96/covi-90196893.html](https://trademarks.justia.com/901/96/covi-90196893.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_8_0</DOCNO>
            	<TEXT>$200 Billion dollar Company in three years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_8_1</DOCNO>
            	<TEXT>Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (BR) NEW PHASE 2 STUDY COVI-MSC [https://clinicaltrials.gov/ct2/show/NCT04992247?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9](https://clinicaltrials.gov/ct2/show/NCT04992247?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9) KEEP THEM COMING!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_8_2</DOCNO>
            	<TEXT>THE BEST IS YET TO COME!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_0</DOCNO>
            	<TEXT>Sorrento has an exclusive license to commercialize four Biobetters that have completed Phase 3 studies in China for the North American, European and Japan markets MABPHARM is a biopharma company focusing on the R amp;D and production of new drugs and Biobetters for cancer and autoimmune diseases R  amp;</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_1</DOCNO>
            	<TEXT>Sorrento has an exclusive license to commercialize four Biobetters that have completed Phase 3 studies in China for the North American, European and Japan markets MABPHARM is a biopharma company focusing on the R amp;D and production of new drugs and Biobetters for cancer and autoimmune diseases R  amp; D We have developed efficient R amp;D capabilities, broad and advanced preparation technologies and low-cost drug production capabilities that will allow us to offer high quality and affordable innovative biopharmaceutical products to patients in China and emerging markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_2</DOCNO>
            	<TEXT>Within our product pipeline, we currently have three Core Products under the phase III clinical development and two other products approved for clinical trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_3</DOCNO>
            	<TEXT>We own a number of patents for our core technologies, including antibody engineering and humanization technologies, efficient expression vector construction technologies, efficient clone screening technologies, as well as a proprietary research and development animal model.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_4</DOCNO>
            	<TEXT>We focus on the research and development of monoclonal antibodies, and our core R amp;D team members have more than 16 years of experience in this area.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_5</DOCNO>
            	<TEXT>We believe research and development is critical to our future growth and our ability to remain competitive in the biologics industry in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_6</DOCNO>
            	<TEXT>Our research and development activities are mainly focused on: Pre-clinical and clinical development of new monoclonal antibody drugs; Developing next generation technologies relating to mAb discovery and manufacturing; Research and development of biosimilar monoclonal antibody drugs with huge market demand; and Continuous improvement of the quality and cost efficiency of our products. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_7</DOCNO>
            	<TEXT>http://www.mabpharm.cn/en/research\_develop.php](http://www.mabpharm.cn/en/research_develop.php) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-its-partner-mabpharm-has-received-marketing](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-its-partner-mabpharm-has-received-marketing) Please read this again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_9_8</DOCNO>
            	<TEXT>Sorrento has an exclusive license to commercialize four Biobetters that have completed Phase 3 studies in China for the North American, European and Japan markets</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_0</DOCNO>
            	<TEXT>SORRENTO IS WAY AHEAD OF THE EIGHT BALL</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_1</DOCNO>
            	<TEXT>SORRENTO IS WAY AHEAD OF THE EIGHT BALL Long COVID: A mysterious syndrome with no clear pattern of symptoms Infectious Disease News spoke with experts about the questions surrounding long COVID and the patients it affects, known commonly as long-haulers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_2</DOCNO>
            	<TEXT>8/5/21 Sorrento Therapeutics added a NEW PHASE 2 STUDY. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_3</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04992247?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9](https://clinicaltrials.gov/ct2/show/NCT04992247?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9) Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells to Treat Post COVID-19 "Long Haul" Pulmonary Compromise (BR).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_4</DOCNO>
            	<TEXT>Please read the article that was written on July 21st 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_5</DOCNO>
            	<TEXT>It goes into detail what the CDC is looking for. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_6</DOCNO>
            	<TEXT>https://www.healio.com/news/infectious-disease/20210713/long-covid-a-mysterious-syndrome-with-no-clear-pattern-of-symptoms](https://www.healio.com/news/infectious-disease/20210713/long-covid-a-mysterious-syndrome-with-no-clear-pattern-of-symptoms) It goes into detail about POST COVID-19 LONG HAUL PULMONARY COMPROMISE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_7</DOCNO>
            	<TEXT>Sorrento is way ahead of the eight ball.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_8</DOCNO>
            	<TEXT>National effort to address long COVID To help solve some of the mysteries surrounding long COVID, the NIH announced an early initiative to identify cases and ultimately a means of prevention and treatment for long-haulers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_10_9</DOCNO>
            	<TEXT>Sorrento is on the path to .. DETECT EARLY TREAT TIMELY TREAT POST COVID-19 LONG HAUL Sorrento has all the exits covered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_0</DOCNO>
            	<TEXT>4Q RESULTS WILL BE RELEASED BY CHRISTMAS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_1</DOCNO>
            	<TEXT>HERE IS THE PROBLEM Chronic pain affects 116 million Americans and costs the U.S. as much as $635 billion each year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_2</DOCNO>
            	<TEXT>More than 50% of U.S. opioid prescriptions are for the treatment of chronic low back pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_3</DOCNO>
            	<TEXT>In the U.S., more than 30 million people live with low back and radicular pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_4</DOCNO>
            	<TEXT>Opioid prescriptions account for about 40 percent of the chronic pain market and carry a well-known risk of abuse and misuse.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_5</DOCNO>
            	<TEXT>In 2018, more than 67,000 drug overdose deaths occurred in the United States14 of which almost 47,000 (70%) were opioid-related.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_6</DOCNO>
            	<TEXT>Over 70% of the 70,630 deaths in 2019 involved an opioid.15 By 2022, the overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is expected to be 12.1 million HERE IS THE ANSWER Scilex Holding Company (Scilex), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), today announced complete enrollment of SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program, a corticosteroid injectable dexamethasone sodium phosphate gel for the treatment of lumbosacral radicular pain, or sciatica.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_7</DOCNO>
            	<TEXT>SP-102 has received Fast Track status from the FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_8</DOCNO>
            	<TEXT>SP-102 is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_9</DOCNO>
            	<TEXT>We are very pleased to have achieved this important milestone and would like to commend the experienced investigators and advisors of the C.L.E.A.R. trial for their persistence and diligence in enrolling sciatica patients through the COVID-19 pandemic and enabling Scilex to achieve a landmark milestone following treatment of 400 sciatica patients in the C.L.E.A.R. trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_10</DOCNO>
            	<TEXT>The clinical results for the pivotal SP-102 Phase 3 trial may provide encouraging news for the many millions of people worldwide who are confronting painful radicular pain (sciatica) and we look forward to sharing results later this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_11</DOCNO>
            	<TEXT>We believe that SP-102 could be the first FDA-approved epidural steroid gel injection product for patients suffering from this common, very painful condition, said Jaisim Shah, President and Chief Executive Officer of Scilex Holding Company. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_12</DOCNO>
            	<TEXT>https://www.scilexpharma.com/press-release/scilex-holding-company-a-sorrento-company-announces-complete-enrollment-on-non-opioid-injectable-sp-102-semdexa-phase-3-pivotal-trial-c-l-e-a-r-program-for-sciatica-pain-management/](https://www.scilexpharma.com/press-release/scilex-holding-company-a-sorrento-company-announces-complete-enrollment-on-non-opioid-injectable-sp-102-semdexa-phase-3-pivotal-trial-c-l-e-a-r-program-for-sciatica-pain-management/) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete) The best part is .. There were no serious adverse events observed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_11_13</DOCNO>
            	<TEXT>4Q RESULTS WILL BE RELEASED BY CHRISTMAS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_12_0</DOCNO>
            	<TEXT>SHORTS WILL NEED 11.35 DAYS TO COVER</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_12_1</DOCNO>
            	<TEXT>SHORTS WILL NEED 11.35 DAYS TO COVER SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest 48,325,970 shares Short Interest Ratio 11.35 Days to Cover Short Interest % Float 18.93% Time Since Last Change Timestamp (UTC) US:SRNE Short Shares Availability 2h 2021-08-09 16:02:39.613 1,500,000 5h 2021-08-09 12:55:58.86 200,000 5h 2021-08-09 12:24:59.846 150,000 6h 2021-08-09 11:22:42.549 80,000 7h 2021-08-09 10:51:40.63 400,000 08-06 2021-08-06 13:47:06.436 350,000 08-06 2021-08-06 13:15:59.545 200,000 08-06 2021-08-06 12:44:58.571 150,000 08-06 2021-08-06 11:43:19.101 65,000 08-06 2021-08-06 09:39:05.449 250,000 Two hours ago they made 1,500,000 million more shares available to borrow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_12_2</DOCNO>
            	<TEXT>Why not just hang yourself with a six foot rope and a chair instead.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_13_0</DOCNO>
            	<TEXT>THE BEST HAS BEEN MADE TO FIGHT COVID-19</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_13_1</DOCNO>
            	<TEXT>THE BEST HAS BEEN MADE [https://investors.sorrentotherapeutics.com/static-files/75caa2e3-2048-4bf9-b935-7bb8c24fb39a](https://investors.sorrentotherapeutics.com/static-files/75caa2e3-2048-4bf9-b935-7bb8c24fb39a) THE BEST IS ON IT'S WAY At 12pm today they made 1.5M shares available for short traders to borrow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_13_2</DOCNO>
            	<TEXT>That's a short fix to help the shorts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_13_3</DOCNO>
            	<TEXT>The way I see it is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_13_4</DOCNO>
            	<TEXT>Keep shorting and you will ruin your family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_13_5</DOCNO>
            	<TEXT>Jump on board the magic carpet to the next trading level.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_13_6</DOCNO>
            	<TEXT>The Asian markets will add more shares and tomorrow will be more painful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_0</DOCNO>
            	<TEXT>ROYAL FLUSH</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_1</DOCNO>
            	<TEXT>ROYAL FLUSH Sorrento Therapeutics is holding a ROYAL FLUSH.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_2</DOCNO>
            	<TEXT>Why would a company with the largest COVID-19 pipeline in the World want to do a vaccine now?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_3</DOCNO>
            	<TEXT>What took them so long?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_4</DOCNO>
            	<TEXT>Does it really matter how long it would take?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_5</DOCNO>
            	<TEXT>The answer is NO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_6</DOCNO>
            	<TEXT>Because the current vaccines are not 100% affective.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_7</DOCNO>
            	<TEXT>Why are the current vaccines 100% affective?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_8</DOCNO>
            	<TEXT>Because they were rushed?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_9</DOCNO>
            	<TEXT>Because the vaccinated are creating the deadly Delta variant?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_10</DOCNO>
            	<TEXT>When you're a small fish in a big barrel you try not to get in the way during feeding time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_11</DOCNO>
            	<TEXT>So what do you do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_12</DOCNO>
            	<TEXT>You go about your business and develop and add and add more and more COVID-19 therapies until all the rest of the big fish in the barrel are DEAD from over feeding.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_13</DOCNO>
            	<TEXT>DARPA, NAMRU, DoD, Mt Sinai, ACEA, Synova Health, knows that Sorrento Therapeutics is holding a winning hand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_14</DOCNO>
            	<TEXT>Soon we should be getting an update from DARPA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_15</DOCNO>
            	<TEXT>Remember DARPA gave Sorrento $34M to fund TWO PHASE TWO CLINICAL TRIALS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_16</DOCNO>
            	<TEXT>Once successful more funding will be provided.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_17</DOCNO>
            	<TEXT>My Guess would be a contract for 300 Million COVIDROPS  amp; 300 COVI-AMG and fund the rest of the trials through PHASE THREE with FAST TRACKING into EUA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_18</DOCNO>
            	<TEXT>Sofusa MuVaxx technology to administer a vaccine with micro needles takes away the fear of long needles.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_19</DOCNO>
            	<TEXT>Remember when you were a kid getting your shots and the doctor would say this shot doesn't hurt it's small needles?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_20</DOCNO>
            	<TEXT>And you felt at ease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_21</DOCNO>
            	<TEXT>The new MultiValent mRNA COVID-19 Vaccine Sorrento has developed is so powerful it's only 1mg.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_22</DOCNO>
            	<TEXT>So they can develop 300 Million Doses for every single American.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_23</DOCNO>
            	<TEXT>That my friends is a ROYAL FLUSH if I've ever seen one.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_24</DOCNO>
            	<TEXT>For those of you that have not read the release yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_14_25</DOCNO>
            	<TEXT>Please click and read and open and read the presentation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_0</DOCNO>
            	<TEXT>BAND OF BROTHERS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_1</DOCNO>
            	<TEXT>BAND OF BROTHERS There's certain people on this board I consider to be loyal true longs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_2</DOCNO>
            	<TEXT>I consider them as my BAND OF BROTHERS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_3</DOCNO>
            	<TEXT>No matter how nasty or evil the short traders can get.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_4</DOCNO>
            	<TEXT>They will not let them destroy this company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_5</DOCNO>
            	<TEXT>Because we will stick together and support one another.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_6</DOCNO>
            	<TEXT>We've had our ups and downs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_7</DOCNO>
            	<TEXT>We still stuck together and moved forward.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_8</DOCNO>
            	<TEXT>We are entering the next phase and the next level up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_9</DOCNO>
            	<TEXT>I want to to say Thank You to all of my brothers  amp; sisters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_15_10</DOCNO>
            	<TEXT>THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_16_0</DOCNO>
            	<TEXT>BAND OF BROTHERS OF SRNE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_16_1</DOCNO>
            	<TEXT>Please join the group BANDOFBROTHERSOFSRNE THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_17_0</DOCNO>
            	<TEXT>THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_17_1</DOCNO>
            	<TEXT>Please join our group of true long term investors of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_17_2</DOCNO>
            	<TEXT>I will be posting in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_17_3</DOCNO>
            	<TEXT>I'm hoping all the true longs on this board can unite and help everyone who needs help.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_17_4</DOCNO>
            	<TEXT>Thank you and stay tuned.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_18_0</DOCNO>
            	<TEXT>REINVENTING BIOLOGIC VACCINE AND DRUG DEVELOPMENT  amp; PRODUCTION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_18_1</DOCNO>
            	<TEXT>REINVENTING BIOLOGIC VACCINE AND DRUG DEVELOPMENT  amp; PRODUCTION Everyone please watch the Dyadic C1 Technology Video.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_18_2</DOCNO>
            	<TEXT>Sorrento and Dyadic Announce Binding Term Sheet to License Dyadics Lead COVID-19 Vaccine Candidate DYAI-100 and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_18_3</DOCNO>
            	<TEXT>https://www.dyadic.com/](https://www.dyadic.com/) After listening to the video I can understand why Sorrento went into an agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_18_4</DOCNO>
            	<TEXT>Please pass this video along and have a great day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_0</DOCNO>
            	<TEXT>Sorrento now has exclusive rights in 60% of the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_1</DOCNO>
            	<TEXT>Sorrento now has exclusive rights in 60% of the world ..."to utilize Dyadics C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadics lead COVID-19 vaccine candidate."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_2</DOCNO>
            	<TEXT>Quite apart from the vaccine DYAI-100, the C1 technology can be applied across Sorrento's entire Covid portfolio.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_3</DOCNO>
            	<TEXT>It will greatly reduce costs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_4</DOCNO>
            	<TEXT>For example, Sorrento could now have not only the world's BEST COVID ANTIBODIES but also the world's MOST AFFORDABLE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_5</DOCNO>
            	<TEXT>We know that even now, because they are so powerful, they require only small doses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_6</DOCNO>
            	<TEXT>They can be delivered in 2 minute injections rather than 4 hour infusions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_7</DOCNO>
            	<TEXT>They can be delivered in small nasal drops.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_8</DOCNO>
            	<TEXT>They can be delivered in small amounts utilizing the SOFUSA technology.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_19_9</DOCNO>
            	<TEXT>Add to that substantial production cost savings using the C1 technology and Sorrento will have enormous pricing advantages which health systems like!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_0</DOCNO>
            	<TEXT>GREAT STUFF FROM DYADICS CONFERENCE CALL</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_1</DOCNO>
            	<TEXT>Great stuff from Dyadics conference call Mark Emalfarb Well, I can't share with you what Sorrento's terms and conditions are but obviously, based on your math, if you had 100 million doses at $15, which is approximately half the price per dose, and you had, I think you said 5%, that I believe, equals $75 million.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_2</DOCNO>
            	<TEXT>And if we have an epidemic, not just a pandemic, which some people think this is going to be a sustainable market for years to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_3</DOCNO>
            	<TEXT>Just at 100 million doses, no matter what the number is, there's a lot of potential for Sorrento and a great potential for Dyadic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_4</DOCNO>
            	<TEXT>It's a win-win situation, actually, win-win-win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_5</DOCNO>
            	<TEXT>Patients, first, low-cost access to a vaccine that can save lives and reduce pain and suffering, and we can make profits both at Sorrento and Dyadic and everybody wins In terms of the deal with these guys at this company, they were working initially on mRNA vaccine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_6</DOCNO>
            	<TEXT>They had made several announcements in the past months on it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_7</DOCNO>
            	<TEXT>And it seems as though they also were working during that same period on animal studies with the DYAI-100, with your product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_8</DOCNO>
            	<TEXT>And it seems obvious to me that somewhere along the line, they determined that the way to go and the home run for them was with the DYAI-100 product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_20_9</DOCNO>
            	<TEXT>And obviously, that's why they've signed this deal with you [https://www.google.com/amp/s/seekingalpha.com/amp/article/4448965-dyadic-international-inc-dyai-ceo-mark-emalfarb-on-q2-2021-results-earnings-call-transcript](https://www.google.com/amp/s/seekingalpha.com/amp/article/4448965-dyadic-international-inc-dyai-ceo-mark-emalfarb-on-q2-2021-results-earnings-call-transcript)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_0</DOCNO>
            	<TEXT>Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2021 Results - Earnings Call Transcript</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_1</DOCNO>
            	<TEXT>Dyadic International, Inc. (DYAI) CEO Mark Emalfarb on Q2 2021 Results - Earnings Call Transcript Since March, we entered into foreign collaborations, including the recently announced binding term sheet with Sorrento Therapeutics, a NASDAQ-listed clinical-stage antibody-centric biopharmaceutical company, developing new treatments for COVID-19, cancer, and pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_2</DOCNO>
            	<TEXT>The Sorrento license agreement when executed will mark a significant milestone in our corporate development efforts, as we will have begun to monetize our COVID-19 development efforts to licensing our C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein diagnostics solely for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate to a drug development partner that has the resources and the expertise to advance coronavirus vaccines, therapeutics, and diagnostics, both clinically and commercially.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_3</DOCNO>
            	<TEXT>Due to confidentiality agreements, we are often unable to publicly announce certain ongoing collaborations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_4</DOCNO>
            	<TEXT>Over the past 6 months, as noted by Sorrento's Chairman and CEO, Dr. Henry Ji, Sorrento carried out several promising preclinical animal studies using the C1 produced RBD antigen and Dyadic's lead COVID-19 vaccine candidate, DYAI-100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_5</DOCNO>
            	<TEXT>Sorrento extensively studied Dyadic's lead COVID-19 vaccine, which utilizes the SARS-CoV-2 spike protein, receptor binding domain, RBD antigen, in vitro and in in vivo for its induction of high titer neutralization activities in vaccinated animals against the SARS-CoV-2 us and its major variants of concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_6</DOCNO>
            	<TEXT>The goal - their goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across their current and future coronavirus programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_7</DOCNO>
            	<TEXT>Our mutual goal, as highlighted in yesterday's press release, as we continue to work together to develop and commercialize a protein-based COVID-19 vaccine that can be rapidly manufactured in very large quantities in Sorrento's existing cGMP and other cGMP facilities, and stored and transported at either room temperature or 2 to 8 degrees in order to increase the access and affordability to underserved populations globally.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_8</DOCNO>
            	<TEXT>Sorrento reported that a multivalent COVID-19 vaccine is under development using the SARS-CoV-2 RBDs for the variants of concern such as delta, alpha, beta, gamma, and Lambda and is being designed to cover all known and emerging variants of concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_9</DOCNO>
            	<TEXT>This is a significant event for Dyadic, having achieved our goal of creating a pathway that addresses the COVID-19 production, commercialization, and distribution gap for mass-scale immunizations across the globe quickly and efficiently.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_10</DOCNO>
            	<TEXT>This Sorrento license fills the gap for the remaining potential COVID-19 immunization, production, and distribution across all other territories, not already covered by Dyadic's existing agreements with Medytox, Syngene, and the Rubic Consortium.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_11</DOCNO>
            	<TEXT>The Sorrento license agreement, when executed, will grant Sorrento exclusive rights for human health and nonexclusive for animal health in their territory to utilize Dyadic's C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics solely for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_12</DOCNO>
            	<TEXT>And we'll include upfront payments of $10 million in cash and stock up to $4 million in reimbursements for DYAI-100's preclinical and clinical development milestones and development costs incurred by Dyadic up to $33 million of potential milestone payments for the successful developments of vaccines, therapeutics in humans and animals as well as additional royalty payments based on net sales.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_13</DOCNO>
            	<TEXT>All future development costs related to this license will be incurred by Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_21_14</DOCNO>
            	<TEXT>The following is a brief overview of our other strategic C1 COVID-19 collaborations that can potentially reach upwards of an additional 3.7 billion people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_0</DOCNO>
            	<TEXT>HELP IS ON THE WAY</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_1</DOCNO>
            	<TEXT>Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_2</DOCNO>
            	<TEXT>After COVI-STIX (COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST) obtained Emergency Use Authorization (EUA) approval from the Mexican Comisin Federal para la Proteccin contra Riesgos Sanitarios (COFEPRIS), Sorrento and Mexican INMEGEN (Instituto Nacional de Medicina Genomica) have held meetings to explore collaboration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_3</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico (Sorrento Mexico) and INMEGEN have executed an MOU to further collaborate on clinical development of a broad pipeline of COVID products, including diagnostics, multivalent mRNA-based vaccines and therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_4</DOCNO>
            	<TEXT>Sorrento provides its most comprehensive portfolios and a one-stop-shop" of potential solutions for governments interested in a multi-modal detect and treat approach to the COVID-19 pandemic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_5</DOCNO>
            	<TEXT>Sorrento Mexico plans to install local clinical research and development capabilities within the INMEGEN facilities and personnel in Mexico City and will work closely with Mexican hospitals and clinical institutions on clinical protocols, regulatory registration and approval requirements for the COVID-19 product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_6</DOCNO>
            	<TEXT>SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc., Inc. (Nasdaq: SRNE, "Sorrento") today announced that its subsidiary company, Sorrento Therapeutics Mexico (Sorrento Mexico), has entered into an MOU agreement with the National Institute of Genomic Medicine INMEGEN (Instituto National de Medicine Genomica) to cooperate in the development, testing and support of multiple COVID-19 related products Sorrento plans to commercialize in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_7</DOCNO>
            	<TEXT>Sorrento Mexico and INMEGEN will expand its collaboration to include additional Sorrento COVID pipeline products spanning diagnostics, therapeutics and multivalent vaccines, including the following product candidates: COVITRACK: COVID-19 antibody detection diagnostic test for vaccinated people; STI-2020 (COVI-AMG): Affinity matured neutralizing antibody against SARS-CoV-2 for outpatient COVID patients; STI-2099 (COVIDROPS): Intranasal neutralizing antibody version of COVI-AMG for newly diagnosed COVID patients; COVISHIELD: Cocktail of neutralizing antibodies against variants of concern of SARS-CoV-2; STI-5656 (Abivertinib): BTK inhibitor for the treatment of acute respiratory distress syndrome (ARDS) in hospitalized COVID patients; STI-8282 (COVI-MSC): Allogeneic mesenchymal stem cells for the treatment of COVID-associated ARDS in severe COVID patients; and Multivalent mRNA Vaccines: mRNA-based multivariant vaccines protecting against SARS-CoV-2 virus, Alpha, Beta, Delta and Gamma variants of concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_8</DOCNO>
            	<TEXT>Sorrento Mexico plans to establish a local research laboratory within INMEGENs facilities to ensure close collaboration between the INMEGEN and Sorrento teams for testing, clinical trials and development of COVID related products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_22_9</DOCNO>
            	<TEXT>We are excited about our close collaboration with INMEGEN and intend to have Sorrento Mexico as a gateway to all Latin American countries for our innovative COVID diagnostic, vaccine and therapeutic product candidates, said Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_0</DOCNO>
            	<TEXT>Quality  amp; Compliance (U.S. FDA) for both Pharmaceutical and Medical Device manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_1</DOCNO>
            	<TEXT>Bioservs integrated approach to quality through our one Quality System and strategic quality plan, together with our culture of continuous improvement ensures compliance with the ever changing regulatory requirements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_2</DOCNO>
            	<TEXT>Our objective is to ensure total transparency of our quality processes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_3</DOCNO>
            	<TEXT>Bioserv welcomes the opportunity to discuss the Quality System during on site customer audits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_4</DOCNO>
            	<TEXT>Bioserv is currently registered with the United States Food and Drug Administration (U.S. FDA) for both Pharmaceutical and Medical Device manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_5</DOCNO>
            	<TEXT>The FDA Drug Center has inspected the facility for routine inspections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_6</DOCNO>
            	<TEXT>The FDA Device Centers have performed inspections of the facility for routine inspections and for pre and post market approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_7</DOCNO>
            	<TEXT>Bioserv is currently licensed by the State of California for Pharmaceutical and Medical Device manufacturing, and for interstate commerce.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_8</DOCNO>
            	<TEXT>Bioserv is also ISO ISO 13485:2016 Certified (FM 77429).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_9</DOCNO>
            	<TEXT>Although the scope of Bioservs ISO Certification is limited to Medical Devices at this time, Bioserv is one (1) Quality System that is suitable for both Medical Devices and Pharmaceutical production.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_10</DOCNO>
            	<TEXT>The Company also produces sterile products compliant for use in the EU. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_11</DOCNO>
            	<TEXT>https://www.bioservamerica.com/quality-compliance/](https://www.bioservamerica.com/quality-compliance/) Labeling  amp; Packaging Bioserv offers custom cGMP labeling and packaging services which includes printing services, labeling, custom kit assembly, and packaging services.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_12</DOCNO>
            	<TEXT>In addition, Bioservs labeling and packaging team can assemble kits configured to meeting customer specific applications or they can routinely label and assemble product ranging from pharmaceutical products to support Phase I-III clinical trials through commercial scale.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_13</DOCNO>
            	<TEXT>Bioserv manufactures in accordance with FDA guidelines in the United States as well as products that support medical devices, life science reagents, and medical diagnostics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_14</DOCNO>
            	<TEXT>Whether it is through longstanding relations with key packaging design firms or by drawing on its 25 plus years of industry experience in developing integrated and optimized package design solutions, Bioserv is here to meet all of its clients labeling and packaging needs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_15</DOCNO>
            	<TEXT>Could COVISTIX be manufactured in California?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_23_16</DOCNO>
            	<TEXT>I assume they can be now if they need be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_0</DOCNO>
            	<TEXT>No unexpected AEs were reported.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_1</DOCNO>
            	<TEXT>Please look at the timelines for ACEA Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_2</DOCNO>
            	<TEXT>ACEA Therapeutics, Inc. today announced that on July 16, 2020, the FDA cleared the IND to initiate a Phase 2 trial of Abivertinib in patients with COVID-19 who have moderate to severe pulmonary symptoms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_3</DOCNO>
            	<TEXT>The Trial, A Phase 2, Double Blinded, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19 (NCT04440007), will be initially conducted in centers in the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_4</DOCNO>
            	<TEXT>Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Brutons tyrosine kinase (BTK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_5</DOCNO>
            	<TEXT>ACEA announced an exclusive license of abibvertinib to Sorrento across all indications outside of China on 21MAY2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_6</DOCNO>
            	<TEXT>ACEA will continue developing abivertinib all indications in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_7</DOCNO>
            	<TEXT>Abivertinib irreversibly binds to the BTK receptor, preventing the phosphorylation of the receptor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_8</DOCNO>
            	<TEXT>Due to this effect, it has shown potent immunomodulatory activities by inhibiting key pro-inflammatory cytokine production, including IL-1beta, IL-6 and TNF-alpha.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_9</DOCNO>
            	<TEXT>These cytokines are associated with COVID disease progression and poor outcomes in patients with acute respiratory distress syndrome (ARDS).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_10</DOCNO>
            	<TEXT>Since abivertinib targets multiple cytokines simultaneously, we anticipate the effects with Abivertinib will be incremental to the initial findings of others which primarily reduce IL-6, and the clinical benefits more pronounced given the broader range of anti-cytokine activity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_11</DOCNO>
            	<TEXT>Abivertinib has been studied in over 600 patients worldwide in various oncologic indications, including one registration trial in non-small cell lung cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_12</DOCNO>
            	<TEXT>Most treatment-related AEs were grade 1 or 2, the most common of which were transaminase elevations and diarrhea, which are generally considered common for TKIs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_13</DOCNO>
            	<TEXT>Other common treatment-related AEs included anemia, neutropenia and thrombocytopenia, and all generally considered typical AEs with long-term use of TKIs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_14</DOCNO>
            	<TEXT>No unexpected AEs were reported.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_15</DOCNO>
            	<TEXT>That's correct there were NO UNEXPECTED AEs REPORTED Abivertinib has been studied in over 600 patients worldwide in various oncologic indications, including one registration trial in non-small cell lung cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_16</DOCNO>
            	<TEXT>So what does Sorrento Therapeutics do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_17</DOCNO>
            	<TEXT>June 2nd 2021 Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-completes-acquisition-acea-therapeutics-creating-major](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-completes-acquisition-acea-therapeutics-creating-major) June 22nd 2021 Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21 [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have) Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_18</DOCNO>
            	<TEXT>Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_19</DOCNO>
            	<TEXT>Studies are complementary and address both dose duration and disease stage variations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_20</DOCNO>
            	<TEXT>Data from both studies is expected to be available for review by the end of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_21</DOCNO>
            	<TEXT>Currently we're in 3Q and by the end of September will receive the results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_22</DOCNO>
            	<TEXT>We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_23</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_24_24</DOCNO>
            	<TEXT>THE BEST IS YET TO COME IN SEPTEMBER</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_0</DOCNO>
            	<TEXT>Acute Respiratory Distress Syndrome (ARDS) HELP IS ON IT'S WAY</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_1</DOCNO>
            	<TEXT>Acute Respiratory Distress Syndrome (ARDS) HELP IS ON IT'S WAY Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that allows fluid to leak into the lungs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_2</DOCNO>
            	<TEXT>Breathing becomes difficult and oxygen cannot get into the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_3</DOCNO>
            	<TEXT>Most people who get ARDS are already at the hospital for trauma or illness.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_4</DOCNO>
            	<TEXT>How Is ARDS Treated?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_5</DOCNO>
            	<TEXT>There is no cure for ARDS at this time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_6</DOCNO>
            	<TEXT>Treatment focuses on supporting the patient while the lungs heal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_7</DOCNO>
            	<TEXT>The goal of supportive care is getting enough oxygen into the blood and delivered to your body to prevent damage and removing the injury that caused ARDS to develop.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_8</DOCNO>
            	<TEXT>Ventilator support All patients with ARDS will require extra oxygen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_9</DOCNO>
            	<TEXT>Oxygen alone is usually not enough, and high levels of oxygen can also injure the lung.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_10</DOCNO>
            	<TEXT>A ventilator is a machine used to open airspaces that have shut down and help with the work of breathing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_11</DOCNO>
            	<TEXT>The ventilator is connected to the patient through a mask on the face or a tube inserted into the windpipe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_12</DOCNO>
            	<TEXT>Prone positioning ARDS patients are typically in bed on their back.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_13</DOCNO>
            	<TEXT>When oxygen and ventilator therapies are at high levels and blood oxygen is still low, ARDS patients are sometimes turned over on their stomach to get more oxygen into the blood.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_14</DOCNO>
            	<TEXT>This is called proning and may help improve oxygen levels in the blood for a while.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_15</DOCNO>
            	<TEXT>It is a complicated task and some patients are too sick for this treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_16</DOCNO>
            	<TEXT>Sedation and medications to prevent movement To relieve shortness of breath and prevent agitation, the ARDS patient usually needs sedation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_17</DOCNO>
            	<TEXT>Sometimes added medications called paralytics are needed up front to help the patient adjust to the ventilator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_18</DOCNO>
            	<TEXT>These medications have significant side effects and their risks and benefits must be continuously monitored.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_19</DOCNO>
            	<TEXT>Fluid management Doctors may give ARDS patients a medication called a diuretic to increase urination in hopes of removing excess fluid from the body to help prevent fluid from building up in the lungs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_20</DOCNO>
            	<TEXT>This must be done carefully, because too much fluid removal can lower blood pressure and lead to kidney problems.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_21</DOCNO>
            	<TEXT>Extracorporeal membrane oxygenation (ECMO) ECMO is a very complicated treatment that takes blood outside of your body and pumps it through a membrane that adds oxygen, removes carbon dioxide and then returns the blood to your body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_22</DOCNO>
            	<TEXT>This is a high-risk therapy with many potential complications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_23</DOCNO>
            	<TEXT>It is not suitable for every ARDS patient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_24</DOCNO>
            	<TEXT>Recovering from ARDS ARDS patients may require ventilation for long periods of time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_25</DOCNO>
            	<TEXT>On average this is seven to 14 days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_26</DOCNO>
            	<TEXT>Beyond this time, doctors may suggest a tube be placed directly into the windpipe through the neck (tracheostomy) by a surgeon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_27</DOCNO>
            	<TEXT>Usually the doctor believes it may take weeks more to recover from ventilator support.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_28</DOCNO>
            	<TEXT>This tube can easily be removed once the patient is free of the need for a ventilator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_29</DOCNO>
            	<TEXT>It is important to note that most people survive ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_30</DOCNO>
            	<TEXT>They will not require oxygen on a long-term basis and will regain most of their lung function.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_31</DOCNO>
            	<TEXT>Others will struggle with muscle weakness and may require re-hospitalization or pulmonary rehabilitation to regain their strength. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_32</DOCNO>
            	<TEXT>https://www.lung.org/lung-health-diseases/lung-disease-lookup/ards/ards-treatment-and-recovery](https://www.lung.org/lung-health-diseases/lung-disease-lookup/ards/ards-treatment-and-recovery) HELP IS ON IT'S WAY Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21 [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have) We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_33</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_34</DOCNO>
            	<TEXT>Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-0](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-0) We are very satisfied with the progress made in Brazil so far, and we have developed strong local relationships in support of multiple studies, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_35</DOCNO>
            	<TEXT>We shall wake up one morning smelling the Brazilian coffee brewing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_36</DOCNO>
            	<TEXT>Sorrento should be partnering up with a very big Brazilian Pharmaceutical company very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_37</DOCNO>
            	<TEXT>The American Lung Association says there's no cure for ARDS at this time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_25_38</DOCNO>
            	<TEXT>But help is on it's way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_0</DOCNO>
            	<TEXT>As Covid Cases Spread, Vaccines Wont Be Enough August 16th 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_1</DOCNO>
            	<TEXT>As cases of Covid-19 continue to climb in the U.S., some analysts are arguing that vaccines arent enough to fight the virus, and that a substantial commercial opportunity remains for companies that develop effective therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_2</DOCNO>
            	<TEXT>The U.S. is reporting 130,800 new cases of Covid-19 per day as of Sunday, up 64% over the last 14 days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_3</DOCNO>
            	<TEXT>The number of deaths per day has doubled over the past two weeks, to 660.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_4</DOCNO>
            	<TEXT>While the rate of growth in new Covid-19 cases appears to be slowing, the daily new case count in the U.S. is now higher than its been at any point during the pandemic other than the period between mid-November and early February, when cases peaked.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_5</DOCNO>
            	<TEXT>Federal health officials on Friday authorized third doses of the Covid-19 vaccines developed by Pfizer (ticker: PFE) and Moderna (MRNA) for certain people with compromised immune systems, though were cautious not to refer to them as booster doses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_6</DOCNO>
            	<TEXT>Eligible people are already receiving those third doses: Local media in Oklahoma reported that one immunocompromised patient had received a third dose on Saturday at a pharmacy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_7</DOCNO>
            	<TEXT>The timing of booster shots for a broader population remains unclear.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_8</DOCNO>
            	<TEXT>Were looking at it on a daily and weekly basis in cohorts not only in the United States, but in other countries to determine if, when and to whom we should be giving this, Dr. Anthony Fauci, President Joe Bidens chief medical advisor, said on CBSs Face the Nation on Sunday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_9</DOCNO>
            	<TEXT>So if it turns out as the data come in, we see we do need to give an additional dose to people in nursing homes, actually, or people who are elderly, we will be absolutely prepared to do that very quickly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_10</DOCNO>
            	<TEXT>Shares of Moderna were down 0.7% in premarket trading on Monday, after a wild week last week in which the share price rose and fell sharply amid questions about the stocks valuation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_11</DOCNO>
            	<TEXT>Shares of Novavax (NVAX), which is struggling to bring its own Covid-19 vaccine to market, were down 0.9%, after climbing 4.1% on Friday, while shares of Pfizer were down 0.8%, after climbing 2.6% on Friday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_12</DOCNO>
            	<TEXT>S amp;P 500 futures were down 0.3%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_13</DOCNO>
            	<TEXT>On Monday, analysts at Jefferies wrote that the continued emergence of new Covid-19 variants demonstrates that vaccines wont be enough to fight the virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_14</DOCNO>
            	<TEXT>Few treatments have been developed so far, and among those, few are particularly effective.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_15</DOCNO>
            	<TEXT>The analysts say that a substantial commercial opportunity remains for the company that develops a good Covid-19 therapeutic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_16</DOCNO>
            	<TEXT>Despite their relative lack of efficacy and lack of convenience, the small number of approved and authorized products still managed to achieve collective 1QCY21 sales of more than $3bn, the analysts wrote.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_17</DOCNO>
            	<TEXT>An effective and convenient treatment could potentially achieve peak annual sales in excess of $10bn.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_18</DOCNO>
            	<TEXT>The note highlights a long list of companies that are working on Covid-19 therapeutics as potential investment opportunities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_19</DOCNO>
            	<TEXT>An orally available broad-spectrum antiviral, suited for immediate administration to newly diagnosed cases, would be ideal, the analysts write.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_20</DOCNO>
            	<TEXT>With new Cov19 diagnoses are currently running in excess of 500,000 per day, such a drug would likely have huge commercial potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_21</DOCNO>
            	<TEXT>The analysts write that Roche (RHHBY), the Japanese pharmaceutical company Shionogi (SGIOY), and the Hong Kong-listed Kintor Pharmaceutical (9939.HK), are all working on such orally available broad-spectrum antivirals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_22</DOCNO>
            	<TEXT>The analysts say that other approaches could work, too, including neutralizing antibodies under development by AstraZeneca (AZN) and others, or immune system modulators like those being developed by Evelo Biosciences (EVLO). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_26_23</DOCNO>
            	<TEXT>https://www.marketwatch.com/articles/covid-cases-vaccines-therapeutics-variants-51629117705?mod=mw\_latestnews](https://www.marketwatch.com/articles/covid-cases-vaccines-therapeutics-variants-51629117705?mod=mw_latestnews) HELP IS ON IT'S WAY [https://sorrentotherapeutics.com/research/pipeline/](https://sorrentotherapeutics.com/research/pipeline/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_27_0</DOCNO>
            	<TEXT>STATE STREET CORP OWNS 10,232,527 SHARES AVG COST $8.98 PER SHARE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_27_1</DOCNO>
            	<TEXT>STATE STREET CORP OWNS 10,232,527 SHARES AVG COST $8.98 PER SHARE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_27_2</DOCNO>
            	<TEXT>2021-08-16 13F State Street Corp 8.98 10,232,527 SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest 48,422,291 shares Short Interest Ratio 9.02 Days to Cover Short Interest % Float 18.96% Short Squeeze Score The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_27_3</DOCNO>
            	<TEXT>The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_27_4</DOCNO>
            	<TEXT>The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_27_5</DOCNO>
            	<TEXT>Update Frequency: Intraday See Short Squeeze Explorer, which provides a list of highest-ranking companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_27_6</DOCNO>
            	<TEXT>69.98 1019 out of 9097 See Highest Ranking Stocks Follow the money trial and that's how people become wealthy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_0</DOCNO>
            	<TEXT>HOW COME BLACKROCK, STATE STREET, and VANGUARD GROUP OWN 43,480,440 SHARES?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_1</DOCNO>
            	<TEXT>HOW COME BLACKROCK, STATE STREET, and VANGUARD GROUP OWN 43,480,440 SHARES?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_2</DOCNO>
            	<TEXT>How come they each have an Average cost of $8.98 per share?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_3</DOCNO>
            	<TEXT>Totaling $390,454,350 The numbers do not lie.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_4</DOCNO>
            	<TEXT>There's a reason for everything.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_5</DOCNO>
            	<TEXT>It clearly shows that there purchasing their shares at the same time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_6</DOCNO>
            	<TEXT>For a possible take over?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_7</DOCNO>
            	<TEXT>When could this happen?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_8</DOCNO>
            	<TEXT>Could this happen?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_9</DOCNO>
            	<TEXT>My guess is and it's my guess once Sorrento receives a Monumental Approval and they look to acquire a market that big pharma wants to protect from losing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_10</DOCNO>
            	<TEXT>Everything and anything is possible. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_11</DOCNO>
            	<TEXT>https://fintel.io/s/us/srne](https://fintel.io/s/us/srne) Remember this one thing I repeat over and over everyday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_28_12</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_0</DOCNO>
            	<TEXT>Not everyones immune system has the same ability to mount a protective response after vaccination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_1</DOCNO>
            	<TEXT>Monoclonal antibodies are typically used to treat disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_2</DOCNO>
            	<TEXT>But here we are interested in preventing disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_3</DOCNO>
            	<TEXT>The number of sick people to be treated for a disease may be limited, but the number of people that need to be treated to prevent a disease is much, much larger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_4</DOCNO>
            	<TEXT>For the current coronavirus infection, the number of people that will need to be vaccinated or treated will be in the millions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_5</DOCNO>
            	<TEXT>In the face of this required scale, mAbs have two important limitations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_6</DOCNO>
            	<TEXT>The first is cost.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_7</DOCNO>
            	<TEXT>Therapeutic antibodies can be priced at tens and hundreds of thousands of dollars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_8</DOCNO>
            	<TEXT>This is obviously not a practical approach to protecting millions of people from infection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_9</DOCNO>
            	<TEXT>Part of the challenge in the use of antibodies is their relatively high cost of production.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_10</DOCNO>
            	<TEXT>Facilities to produce mAbs for treating large populations can cost $300-$500 million to build and require thousands of people to staff.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_11</DOCNO>
            	<TEXT>They are also expensive to produce, with costs of commercial mAbs at about greater than $100 per dose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_12</DOCNO>
            	<TEXT>The other limitation of antibodies is that many of them require intravenous administration, which again is not feasible when millions of people need to be treated or protected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_13</DOCNO>
            	<TEXT>SmartPharm Approach: Gene MAbs for Coronavirus SmartPharm is applying our non-viral gene therapy platform to develop an effective preventive treatment for SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_14</DOCNO>
            	<TEXT>We are using DNA designed to produce in the muscle of the person who receives the gene a monoclonal antibody (Gene Mab) that could be protective against the SARS-CoV-2 virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_15</DOCNO>
            	<TEXT>To do this, we are utilizing a novel DNA vector with low immunogenicity, durable expression potential and cost-effective manufacturing up to millions of doses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_16</DOCNO>
            	<TEXT>We are coupling this type of DNA vector with a delivery system that significantly enhances DNA expression in the muscle and is also capable of high-volume, economic production.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_17</DOCNO>
            	<TEXT>Coupled together, these represent a way to generate protective mAbs in many people to provide pop-up immunity in this population against COVID-19 regardless of their immune status or their infection status.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_18</DOCNO>
            	<TEXT>The first step in developing a Gene MAb against SARS-CoV-2 is to determine a mAb sequence that possesses both a high binding affinity to the coronavirus (so it stays attached to the virus for a long time) and the ability to neutralize the virus (block it from invading cells or attract immune response against the virus).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_19</DOCNO>
            	<TEXT>We have implemented strategic partnerships with a number of organizations to do this, including Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_20</DOCNO>
            	<TEXT>Sorrento has initiated an accelerated program to identify potent neutralizing antibodies against SARS-CoV-2 that can be used for either treatment or prophylaxis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_21</DOCNO>
            	<TEXT>Based on this collaboration as well as internal work, SmartPharm will define a DNA that can express these antibodies in human skeletal muscle and use a delivery technology designed to allow the DNA to be delivered directly into the muscle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_22</DOCNO>
            	<TEXT>The SmartPharm delivery system is designed to be used with a standard hypodermic needle, the way most vaccines are delivered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_23</DOCNO>
            	<TEXT>After delivery in the muscle, the DNA is designed to produce antibodies in the muscles within a matter of hours.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_24</DOCNO>
            	<TEXT>Within a day or twoa much faster time than a typical vaccineprotective levels of antibody could be produced, resulting in what we refer to as pop up-immunity: a rapidly-established window of immune protection against the virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_25</DOCNO>
            	<TEXT>Antibody production lasts a number of weeks or even months and is effective regardless of what the recipients immune system is like or whether they are infected or not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_26</DOCNO>
            	<TEXT>Creating pop-up immunity with Gene MAbs, which are both cost-effective and scalable for large population protection, introduces a way to quickly mount a protective immune barrier in treated people and reduce the infectivity of the virus in larger populations. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_27</DOCNO>
            	<TEXT>https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus](https://smartpharmtx.com/gene-encoded-antibodies-for-coronavirus) Millions of people will need to be treated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_28</DOCNO>
            	<TEXT>The US Military will need to treat all of their service members.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_29</DOCNO>
            	<TEXT>Please click and read. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_30</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) The initial focus of the collaboration will be to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostics and COVIDROPS/COVI-AMG outpatient neutralizing antibody treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_31</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_32</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_29_33</DOCNO>
            	<TEXT>Please read this again and again.. Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced a broad multi-year Cooperative Research and Development Agreement (CRADA) with NAMRU-3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_0</DOCNO>
            	<TEXT>WHY IS SORRENTO EXPANDING THEIR PHARMACEUTICAL SPACE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_1</DOCNO>
            	<TEXT>On July 1, 2021, Sorrento Therapeutics, Inc. (the Company) entered into a binding term sheet (the Term Sheet) with HCP Life Science REIT, Inc. (Landlord) setting forth the terms and conditions by which the Company will lease premises located at 4930 Directors Place, San Diego, California (the Building).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_2</DOCNO>
            	<TEXT>The lease (the Lease) will have an initial 188-month term and include approximately 163,205 rentable square feet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_3</DOCNO>
            	<TEXT>The commencement date of the Lease will be determined at a later date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_4</DOCNO>
            	<TEXT>The initial rent for the Lease is approximately $5.10 per square foot and is subject to an annual increase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_5</DOCNO>
            	<TEXT>Pursuant to the Term Sheet, not less than twelve months prior to the expiration of the then-current term of the Lease, the Company has an option to extend the Lease term for up to two additional five-year terms at then current market rates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_6</DOCNO>
            	<TEXT>Pursuant to the Term Sheet, the Companys existing lease agreements with the Landlord for 9380 Judicial Drive, 4921 Directors Place, 4955 Directors Place and 4939 Directors Place (the Other Leases) shall be extended to be coterminous with the term of the Lease and the initial rent for the extension period of each of the Other Leases shall be at then current market rates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_7</DOCNO>
            	<TEXT>That's a total of 25 1/2 year lease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_8</DOCNO>
            	<TEXT>Why are they expanding?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_9</DOCNO>
            	<TEXT>Because of potential monumental FDA approvals that are expected?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_10</DOCNO>
            	<TEXT>Pharmaceutical Companies don't expand unless there's something big on the horizon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_11</DOCNO>
            	<TEXT>The overall markets is down because of the Feds tapering before the end of the year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_12</DOCNO>
            	<TEXT>So what does that mean for us long term holders?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_13</DOCNO>
            	<TEXT>Interests rates may go up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_14</DOCNO>
            	<TEXT>HF will be taking profits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_15</DOCNO>
            	<TEXT>The shorts will make you believe there's something wrong.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_16</DOCNO>
            	<TEXT>If anything I will be buying more shares on the dips.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_30_17</DOCNO>
            	<TEXT>Don't be a fool and be shaken off the tree.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_0</DOCNO>
            	<TEXT>TERMS OF USE Effective Date: June 14, 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_1</DOCNO>
            	<TEXT>This Terms of Use (the Terms of Use) is entered into between Sorrento Therapeutics, Inc., in the name of and on behalf of our subsidiaries and affiliates (Sorrento, us, we, or our) and you, or if you represent an entity or other organization, that entity or organization (in either case, you).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_2</DOCNO>
            	<TEXT>These Terms of Use govern your access to and/or use of our websites, applications, and portals that we operate and that link to this Terms of Use (collectively, the Site), and the services and resources enabled via the Site (each a Service and collectively, the Services).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_3</DOCNO>
            	<TEXT>These Terms of Use do not apply to other sites and services provided by Sorrento, such as our clinical trials, patient laboratory services, or COVI-STIX products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_4</DOCNO>
            	<TEXT>PLEASE READ THESE TERMS OF USE CAREFULLY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_5</DOCNO>
            	<TEXT>BY BROWSING OR ACCESSING THE SITE AND/OR USING THE SERVICES, YOU REPRESENT THAT (1) YOU HAVE READ, UNDERSTAND, AND AGREE TO BE BOUND BY THE TERMS OF USE, (2) YOU ARE OF LEGAL AGE TO FORM A BINDING CONTRACT WITH SORRENTO, AND (3) YOU HAVE THE AUTHORITY TO ENTER INTO THE TERMS OF USE PERSONALLY OR ON BEHALF OF THE COMPANY YOU HAVE NAMED AS THE USER, AND TO BIND THAT COMPANY TO THE TERMS OF USE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_6</DOCNO>
            	<TEXT>THE TERM YOU REFERS TO THE INDIVIDUAL OR LEGAL ENTITY, AS APPLICABLE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_7</DOCNO>
            	<TEXT>IF YOU DO NOT AGREE TO BE BOUND BY THE TERMS OF USE, YOU MAY NOT ACCESS OR USE THE SITE OR THE SERVICES.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_8</DOCNO>
            	<TEXT>PLEASE NOTE THAT THESE TERMS OF USE ARE SUBJECT TO CHANGE BY SORRENTO IN ITS SOLE DISCRETION AT ANY TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_9</DOCNO>
            	<TEXT>Sorrento will inform you of the presence of any changes to this Terms of Use by posting those changes on the Site, by changing the date at the top of the Terms of Use, and/or by providing you with notice through the Site or other means (including by sending you notice to any email address provided to Sorrento).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_10</DOCNO>
            	<TEXT>Unless otherwise stated, any modifications will be effective immediately upon posting on the Site or delivery of such notice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_11</DOCNO>
            	<TEXT>You may terminate the Terms of Use as set forth below if you object to any such modifications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_12</DOCNO>
            	<TEXT>However, you will be deemed to have agreed to any and all modifications through your continued use of the Site or Services following such notice period.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_13</DOCNO>
            	<TEXT>PLEASE REGULARLY CHECK THE SITE TO VIEW THE THEN-CURRENT TERMS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_14</DOCNO>
            	<TEXT>Your use of, and participation in, certain Services may be subject to additional terms, including any applicable terms between Sorrento and your employer or organization and any terms presented to you for your acceptance when you use a supplemental Service (Supplemental Terms).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_15</DOCNO>
            	<TEXT>If the Terms of Use are inconsistent with the Supplemental Terms, the Supplemental Terms shall control with respect to such Service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_16</DOCNO>
            	<TEXT>The Terms of Use and any applicable Supplemental Terms are referred to herein as the Agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_17</DOCNO>
            	<TEXT>Please click and fully read the term and use of the UK COVIDROPS trial which began on June 14th 2021 [https://sorrentotherapeutics.com/terms-of-use/](https://sorrentotherapeutics.com/terms-of-use/) I answered the questions and was cleared to enter the clinical trial. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_18</DOCNO>
            	<TEXT>https://www.covid201.com/COVID201](https://www.covid201.com/COVID201) I answered YES YES NO NO YES YES and I was cleared to take off. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_31_19</DOCNO>
            	<TEXT>https://www.covid201.com/COVID201/Referral/SignUp?referral=pba7b6pGC9FceoQocHFRW4t8I9F9%2BznpiSUAbmnHXt4V5YdGFX3Oh9DCQ4ILVbUH4epJEElsCkxhlYiRBo7jZA%3D%3D](https://www.covid201.com/COVID201/Referral/SignUp?referral=pba7b6pGC9FceoQocHFRW4t8I9F9%2BznpiSUAbmnHXt4V5YdGFX3Oh9DCQ4ILVbUH4epJEElsCkxhlYiRBo7jZA%3D%3D) If you live in the UK your cleared to take off.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_32_0</DOCNO>
            	<TEXT>Potentially ACT a universal booster for other COVID-19 vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_32_1</DOCNO>
            	<TEXT>A MultiValent RBD-based vaccine utilizing the RBDs from SARS-CoV-2 and its major VoCs is in development to potentially serve as a universal vaccine and potentially as a universal booster for other COVID-19 vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_32_2</DOCNO>
            	<TEXT>READ THIS LINE AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_32_3</DOCNO>
            	<TEXT>Potentially ACT a universal booster for other COVID-19 vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_32_4</DOCNO>
            	<TEXT>Lets not forget Sorrento signed a multi 5 year agreement with [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_32_5</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19 This gives the DoD the green light to develop DYAI-100 into a COVID BOOSTER.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_33_0</DOCNO>
            	<TEXT>ABSTRACT - INTRODUCTION - RESULTS - DISCUSSION - MATERIALS and METHODS - FIGURES</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_33_1</DOCNO>
            	<TEXT>Please click and read and forward to all message boards [https://www.biorxiv.org/content/10.1101/2021.08.17.456704v1.full.pdf](https://www.biorxiv.org/content/10.1101/2021.08.17.456704v1.full.pdf) HELP TO FIGHT COVID-19 IS ON IT'S WAY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_0</DOCNO>
            	<TEXT>THE MISSION TO COLLABORATE WITH SORRENTO</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_1</DOCNO>
            	<TEXT>The purpose of this collaboration is to perform infectious disease research that guides the Department of Defense (DoD), informs public health policy of host nation partners, and improves medical readiness of the U.S. Armed Forces across NAMRU-3 areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_2</DOCNO>
            	<TEXT>PLEASE READ THIS AGAIN!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_3</DOCNO>
            	<TEXT>PLEASE READ THIS AGAIN The mission of NAMRU-3 is to ensure warfighter readiness through detecting, deterring, and responding to infectious disease threats through integration with partners throughout U.S. Africa Command (AFRICOM), Central Command (CENTCOM), and European Command (EUCOM) areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_4</DOCNO>
            	<TEXT>The purpose of this collaboration is to perform infectious disease research that guides the Department of Defense (DoD), informs public health policy of host nation partners, and improves medical readiness of the U.S. Armed Forces across NAMRU-3 areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_5</DOCNO>
            	<TEXT>Through shared resources and logistical support, the overall goal of this research cooperation will be to conduct research on current, emerging and re-emerging infectious diseases, to enhance Force Health Protection, and provide critical data regarding countermeasures to mitigate infectious disease transmission including surveillance and product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_6</DOCNO>
            	<TEXT>DOES EVERYONE UNDERSTAND THAT THIS IS A MISSION!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_7</DOCNO>
            	<TEXT>PLEASE READ THIS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_8</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_9</DOCNO>
            	<TEXT>PLEASE READ AGAIN!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_10</DOCNO>
            	<TEXT>Collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_11</DOCNO>
            	<TEXT>Folks DoD is leading the way to evaluate all of Sorrento's COVID-19 products. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_12</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) DOES EVERYONE REMEMBER NOV 2020?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_13</DOCNO>
            	<TEXT>PLEASE CLICK AND READ!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_14</DOCNO>
            	<TEXT>DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) PLEASE READ THIS PARAGRAPH The contract would provide SmartPharm up to USD $34 million for development through Phase 2 clinical studies of a gene-encoded antibody (Gene MAb) that could enable rapid protection from and/or treatment of SARS-CoV-2 infection and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_15</DOCNO>
            	<TEXT>Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_16</DOCNO>
            	<TEXT>Ladies and Gentlemen Sorrento is days, weeks away from reporting MONUMENTAL EUA DEVELOPMENTS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_17</DOCNO>
            	<TEXT>As I always say THE BEST IS YET TO COME WHY ELSE WOULD DARPA  amp; DoD want a piece of Sorrento?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_34_18</DOCNO>
            	<TEXT>Have a nice weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_0</DOCNO>
            	<TEXT>HOW CAN YOU TELL SORRENTO THERAPEUTICS IS DEVELOPING INTO A BIG PHARMA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_1</DOCNO>
            	<TEXT>In 2020 Sorrento Therapeutics had a total of 31 press releases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_2</DOCNO>
            	<TEXT>Employed a total of 500 and 100 PHDs, MDs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_3</DOCNO>
            	<TEXT>Had 300,000 SF Research and cGMP Manufacturing Facilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_4</DOCNO>
            	<TEXT>In 2021 Sorrento Therapeutics has had a total of 45 press releases in less then 8 months to date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_5</DOCNO>
            	<TEXT>Currently employs 700 Employees Worldwide 100 Employees with PHDs  amp; MDs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_6</DOCNO>
            	<TEXT>500,000 SF Research and cGMP Manufacturing Facilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_7</DOCNO>
            	<TEXT>Went into agreement to lease an additional 163,000 SF Brand new building being built.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_8</DOCNO>
            	<TEXT>Which would bring the total to 663,000 SF of Research and cGMP Manufacturing Facilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_9</DOCNO>
            	<TEXT>So in the last 20 months Sorrento Therapeutics pretty much almost doubled in size.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_10</DOCNO>
            	<TEXT>Let me explain about the first pharmaceutical company that I ever invested in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_11</DOCNO>
            	<TEXT>Approx 27 years ago my wife and I invested $30,000 into Regeneron Pharmaceuticals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_12</DOCNO>
            	<TEXT>They were leasing space at the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_13</DOCNO>
            	<TEXT>They struggled for a few years and it was frustrating.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_14</DOCNO>
            	<TEXT>At the same time they started to expand into leasing more space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_15</DOCNO>
            	<TEXT>Working hard collaborating with other pharma's just like Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_16</DOCNO>
            	<TEXT>Gradually and slowly it took ten years before we saw the light at the end of the tunnel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_17</DOCNO>
            	<TEXT>There were times we wanted to give up and walk away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_18</DOCNO>
            	<TEXT>Thank the good Lord we did not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_19</DOCNO>
            	<TEXT>Our $30,000 investment turned into $3M. We were able to build a brand new house and put all my kids through College.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_20</DOCNO>
            	<TEXT>We still own a few shares of Regeneron.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_21</DOCNO>
            	<TEXT>I've sold a few shares in 2020  amp; 2021 to purchase Sorrento stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_22</DOCNO>
            	<TEXT>Regeneron 27 years ago had 1 drug in the pipeline at the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_23</DOCNO>
            	<TEXT>Now look at Sorrento's pipeline and you can now imagine why we sold some shares of Regeneron.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_24</DOCNO>
            	<TEXT>Sorrento Therapeutics is by far the best long term investment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_25</DOCNO>
            	<TEXT>Why else would BlackRock, State Street, and Vanguard Group invest over $375M. It's a long term investment for them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_26</DOCNO>
            	<TEXT>It's a long term investment for me as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_27</DOCNO>
            	<TEXT>The remaining 3Q and the 4Q of 2021 is going to be very exciting and very profitable to all of us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_28</DOCNO>
            	<TEXT>We will have multiple studies with MONUMENTAL results that will be released.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_29</DOCNO>
            	<TEXT>Compared to waiting ten years with Regeneron to 20 months with Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_30</DOCNO>
            	<TEXT>It's a no brainer for me and my family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_31</DOCNO>
            	<TEXT>We all know the 3 big HFs control Sorrento at the moment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_32</DOCNO>
            	<TEXT>They lend out shares to help short the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_33</DOCNO>
            	<TEXT>To keep it down until one morning or afternoon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_34</DOCNO>
            	<TEXT>When we see a MONUMENTAL FDA APPROVAL and she will run and fly up high and high and high to the moon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_35</DOCNO>
            	<TEXT>The next 3 years Sorrento Therapeutics could grow into a $200 Billion Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_36</DOCNO>
            	<TEXT>Today is my 56th Birthday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_37</DOCNO>
            	<TEXT>My wife asked me what do you want to do this morning for your Birthday?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_38</DOCNO>
            	<TEXT>I told her I want to spend it with my Sorrento Family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_39</DOCNO>
            	<TEXT>I respect everyone on this board good or bad for their hard work and judgements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_40</DOCNO>
            	<TEXT>Some have a job to do to bash our stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_41</DOCNO>
            	<TEXT>I believe it's the wrong thing to do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_42</DOCNO>
            	<TEXT>They too can also be shorting it as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_43</DOCNO>
            	<TEXT>I have a little bit of advice for them as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_44</DOCNO>
            	<TEXT>Regeneron was a very shorted stock at the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_45</DOCNO>
            	<TEXT>The shorts one morning lost everything.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_46</DOCNO>
            	<TEXT>Our day will come very very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_47</DOCNO>
            	<TEXT>Thank you and have a great weekend to you all. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_35_48</DOCNO>
            	<TEXT>https://www.regeneron.com/about/history](https://www.regeneron.com/about/history) [https://investors.sorrentotherapeutics.com/](https://investors.sorrentotherapeutics.com/) THE BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_36_0</DOCNO>
            	<TEXT>COULD THIS MEAN FDA APPROVAL?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_36_1</DOCNO>
            	<TEXT>Hey check this out!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_36_2</DOCNO>
            	<TEXT>Sorrento is going to publish COVI-STIX and COVI-MOBILE on August 31st 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_36_3</DOCNO>
            	<TEXT>Can anyone please tell me what does that mean? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_36_4</DOCNO>
            	<TEXT>https://uspto.report/TM/90104375](https://uspto.report/TM/90104375) Could this mean USA approval?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_37_0</DOCNO>
            	<TEXT>LET THE GOOD TIMES ROLL</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_37_1</DOCNO>
            	<TEXT>Scilex expects SP-102 to be the first FDA-approved non-opioid epidural injection for sciatica with the potential to replace the current 10 to 12 million off-label epidural steroid injections administered each year in the U.S. [https://www.scilexpharma.com/scilex-patch-animation/](https://www.scilexpharma.com/scilex-patch-animation/) Chronic pain affects 116 million Americans and costs the U.S. as much as $635 billion each year, according to a recent report from the Institute of Medicine (IOM) that called for changes in how chronic pain is managed6 and nearly 30 million patients suffer from lower back pain in the U.S.8 Government agencies, physicians, patients, and payers are looking for alternatives to opioids to reduce the risk of dependency or addiction, and serious side effects (such as respiratory depression and constipation), while still offering potent solutions for people living with chronic pain. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_37_2</DOCNO>
            	<TEXT>We are very pleased to have achieved this important milestone and would like to commend the experienced investigators and advisors of the C.L.E.A.R. trial for their persistence and diligence in enrolling sciatica patients through the COVID-19 pandemic and enabling Scilex to achieve a landmark milestone following treatment of 400 sciatica patients in the C.L.E.A.R. trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_37_3</DOCNO>
            	<TEXT>The clinical results for the pivotal SP-102 Phase 3 trial may provide encouraging news for the many millions of people worldwide who are confronting painful radicular pain (sciatica) and we look forward to sharing results later this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_37_4</DOCNO>
            	<TEXT>We believe that SP-102 could be the first FDA-approved epidural steroid gel injection product for patients suffering from this common, very painful condition, said Jaisim Shah, President and Chief Executive Officer of Scilex Holding Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_37_5</DOCNO>
            	<TEXT>THE BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_0</DOCNO>
            	<TEXT>LOOK WHAT ALSO UPDATED TODAY https://www.arkanimalhealth.com/ Looking for an NDA in 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_1</DOCNO>
            	<TEXT>[https://clinicaltrials.gov/ct2/show/NCT00804154?term=sorrento amp;recrs=a amp;draw=2 amp;rank=7](https://clinicaltrials.gov/ct2/show/NCT00804154?term=sorrento amp;recrs=a amp;draw=2 amp;rank=7) [https://sorrentotherapeutics.com/research/pain/](https://sorrentotherapeutics.com/research/pain/) RTX (resiniferatoxin) is a unique neural intervention molecule that is highly selective and may be applied peripherally (e.g., nerve block, intra-articular) or centrally (e.g., epidural), to control chronic pain across multiple conditions including arthritis and cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_2</DOCNO>
            	<TEXT>RTX has the potential to be a first-in-class drug addressing currently intractable pain in a novel and unique way, by targeting the nerves responsible for the chronic debilitating pain signal transmission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_3</DOCNO>
            	<TEXT>RTX strongly binds to TRPV1 receptors and forces open calcium channels located in the end-terminal of the nerve or the soma of the neuron (depending upon the route of administration).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_4</DOCNO>
            	<TEXT>This in turn generates a slow and sustained cation influx that rapidly leads to the deletion of TRPV1-positive cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_5</DOCNO>
            	<TEXT>RTX directly interacts with afferent nerve cells without affecting sensations such as touch, pressure, acute prickling pain, vibration sense or muscle coordination function.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_6</DOCNO>
            	<TEXT>Administration at the peripheral nerve ending results in a sustained temporal effect to treat pain associated with arthritis of the knee.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_7</DOCNO>
            	<TEXT>RTX can potentially help patients with terminal cancer pain, after a single epidural injection, by permanently blocking the pain signal transmission from the tumor tissue to the dorsal root ganglion (DRG) in the spinal cord, without the undesirable side effects associated with high and repeated doses of opioids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_8</DOCNO>
            	<TEXT>If opioids remain part of the therapeutic arsenal for these patients, RTX has the potential to significantly reduce the amount and frequency of opioid use.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_9</DOCNO>
            	<TEXT>RTX has been granted Orphan Drug Status by the US Food and Drug Administration for the treatment of end-stage diseases, including intractable cancer pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_10</DOCNO>
            	<TEXT>Sorrento has successfully completed a positive Phase Ib clinical proof of concept trial with the National Institutes of Health under a Cooperative Research and Development Agreement (CRADA) which showed improved pain and reduced opioid consumption after intrathecal administration (directly into the spinal cord space).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_38_11</DOCNO>
            	<TEXT>The company will be initiating pivotal studies in 2020 and is aiming for an NDA filing in 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_39_0</DOCNO>
            	<TEXT>IVD Manufacturing Associate I-III (10 openings) TEN NEW POSITIONS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_39_1</DOCNO>
            	<TEXT>[https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=472](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=472) WHAT WE ARE LOOKING FOR: Sorrento Therapeutics (Sorrento) is seeking a experienced Manufacturing Associates who will be responsible for: 1) Inventory and material control; 2) QA and Documentation control; 3) IVD components production; 4) QC testing; and 5) IVD kit manufacture, packing, shipping, and tracking.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_0</DOCNO>
            	<TEXT>Sorrento is FOCUSED.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_1</DOCNO>
            	<TEXT>It has 3 priority portfolios.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_2</DOCNO>
            	<TEXT>Sorrento is FOCUSED.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_3</DOCNO>
            	<TEXT>It has 3 priority portfolios.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_4</DOCNO>
            	<TEXT>1.The immediate focus is Covid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_5</DOCNO>
            	<TEXT>It has 16 programs that deal with every stage of Covid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_6</DOCNO>
            	<TEXT>It already has one EUA with many to follow in the next few months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_7</DOCNO>
            	<TEXT>The latest C1 vaccine and oral MPro inhibitors have enormous potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_8</DOCNO>
            	<TEXT>Each EUA will bring in a generous revenue stream.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_9</DOCNO>
            	<TEXT>2.The second area of focus is non-opioid pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_10</DOCNO>
            	<TEXT>It already has a marketed product with sales projected to be about $100 million this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_11</DOCNO>
            	<TEXT>SP-102 sales are expected in 2022 and are projected in the billions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_12</DOCNO>
            	<TEXT>The longer term focus is cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_13</DOCNO>
            	<TEXT>Abivertinib sales in China could start any day and in ROW next year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_14</DOCNO>
            	<TEXT>ADNAB,CAR-T, DAR-T and several other technologies are targeting dozens of indications with many in phase two.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_40_15</DOCNO>
            	<TEXT>With hundreds of millions worth of very wise investments, many near-term potential worldwide partnerships, the large potential PSS lawsuit windfall and rapidly increasing revenue streams ... IMO Sorrento is very well funded to achieve success in all 3 priority portfolios!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_41_0</DOCNO>
            	<TEXT>INCREASE IN OWNERSHIP</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_41_1</DOCNO>
            	<TEXT>State Street Corp reports 4.55% increase in ownership of SRNE / Sorrento Therapeutics Inc 2021-08-16 - State Street Corp has filed a 13F-HR form disclosing ownership of 10,232,527 shares of Sorrento Therapeutics Inc (US:SRNE) with total holdings valued at $99,153,000 USD as of 2021-06-30.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_41_2</DOCNO>
            	<TEXT>State Street Corp had filed a previous 13F-HR/A on 2021-07-09 disclosing 9,786,760 shares of Sorrento Therapeutics Inc at a value of $80,937,000 USD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_41_3</DOCNO>
            	<TEXT>This represents a change in shares of 4.55 percent and a change in value of 22.51 percent during the quarter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_41_4</DOCNO>
            	<TEXT>Other investors with positions similar to State Street Corp include BlackRock Inc., and Vanguard Group Inc. [https://fintel.io/so/us/srne/state-street](https://fintel.io/so/us/srne/state-street)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_0</DOCNO>
            	<TEXT>Abivertinib</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_1</DOCNO>
            	<TEXT>Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Brutons tyrosine kinase (BTK) to treat Non-Small Cell Lung Cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_2</DOCNO>
            	<TEXT>More than 600 patients have been treated with Abivertinib at different oral doses up to 300 mg bid in multiple trials through registration trial (NCT03856697) in patients with non-small cell lung cancer (NSCLC) and B cell malignancies (Phase 1) conducted in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_3</DOCNO>
            	<TEXT>Favorable safety, tolerability and efficacy in patients with NSCLC or relapsed/refractory B-cell malignancies were demonstrated in the studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_4</DOCNO>
            	<TEXT>Abivertinib is also being tested as a potential treatment for cytokine storm associated with COVID-19 and as a potential treatment for cytokine release syndrome associated with CAR-T. We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_5</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_6</DOCNO>
            	<TEXT>Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21 As we near the end of the 3Q we will see BlackRock, State Street, Vanguard Group, add more and more shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_7</DOCNO>
            	<TEXT>3Q ends September 30th.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_8</DOCNO>
            	<TEXT>Less then 5 weeks way before lift off. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_42_9</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_43_0</DOCNO>
            	<TEXT>KEY TO BRAZIL</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_43_1</DOCNO>
            	<TEXT>[https://www.synovahealth.com/](https://www.synovahealth.com/) Please click and watch the video Synova Health is contracted for Sorrento's Abivertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_43_2</DOCNO>
            	<TEXT>We should expect results before the end of September.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_43_3</DOCNO>
            	<TEXT>For the big HFs to add shares last month and last week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_43_4</DOCNO>
            	<TEXT>Makes me very comfortable to add more shares myself.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_0</DOCNO>
            	<TEXT>OPEN UP THE SAILS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_1</DOCNO>
            	<TEXT>Everyone is on board and Sorrento has the wind in her sails.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_2</DOCNO>
            	<TEXT>The HFs are hoisting the sails BECAUSE the wind is on her back.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_3</DOCNO>
            	<TEXT>BlackRock, State Street, Vanguard all increased their sales last month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_4</DOCNO>
            	<TEXT>Which tells me their confident there's more STRONG WINDS that will sail Sorrento around the WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_5</DOCNO>
            	<TEXT>COVISTIX sales are hitting the register.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_6</DOCNO>
            	<TEXT>The Company has doubled in size in 20 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_7</DOCNO>
            	<TEXT>Positive read outs are in 3Q and the 4Q. Lawsuit settlement before the end of 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_8</DOCNO>
            	<TEXT>We have a BEHEMOTH ship loaded with 26 Clinical trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_9</DOCNO>
            	<TEXT>The Master and Commander DR Ji has set course.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_10</DOCNO>
            	<TEXT>In three years Sorrento will be a $200 Billion Pharmaceutical Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_11</DOCNO>
            	<TEXT>Why else would they lease another 163,000 SQ FT brand new building next door?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_12</DOCNO>
            	<TEXT>DARPA  amp; DoD signing multi year agreements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_44_13</DOCNO>
            	<TEXT>THE BEST HAS SET SAIL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_0</DOCNO>
            	<TEXT>Win, win, win!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_1</DOCNO>
            	<TEXT>Here is one Dr. stressing need for monoclonal antibodies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_2</DOCNO>
            	<TEXT>COVI-DROPS could be the answer!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_3</DOCNO>
            	<TEXT>Rapid delivery, low doses at a lower cost!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_4</DOCNO>
            	<TEXT>Win, win, win! "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_5</DOCNO>
            	<TEXT>What people don't understand is that the protection you get from the vaccine seems so far to correlate with antibody titers (levels) achieved in the serum.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_6</DOCNO>
            	<TEXT>These wane fairly quickly over time and so you depend on memory B cells to generate up antibody quickly when you are re-exposed to prevent serious illness.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_7</DOCNO>
            	<TEXT>Some people aren't able to do that before becoming seriously ill.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_8</DOCNO>
            	<TEXT>The monoclonal antibodies deliver a huge load of specific antibodies (far more than a body could ever make) that supercharge the serum.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_9</DOCNO>
            	<TEXT>They are critical for high risk patients who have weaker immune systems (people over 60-65 and those with transplants and other diseases e.g. diabetes, obesity hypertension, etc).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_10</DOCNO>
            	<TEXT>Monoclonals could save 10s of thousands if not hundred of thousands of lives in the US alone and take pressure off hospitals so other diseases can be treated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_11</DOCNO>
            	<TEXT>Monoclonal clinics should be the #1 national priority at this point.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_45_12</DOCNO>
            	<TEXT>People that want the vaccine have already gotten it."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_0</DOCNO>
            	<TEXT>Abivertinib EGFR  amp; BTK Inhibitor</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_1</DOCNO>
            	<TEXT>Abivertinib (AC0010) is a potent, irreversible, third-generation small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_2</DOCNO>
            	<TEXT>Abivertinib inhibits the T790M gatekeeper mutation of EGFR and common activating mutations (L858R and del19) but has minimal inhibitory activity towards the normal (wild-type) receptor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_3</DOCNO>
            	<TEXT>The T790M mutation of EGFR is the major cause of acquired resistance and is detected in more than half of patients treated with first-generation EGFR TKIs, such as Tarceva (erlotinib) and Iressa (gefitinib).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_4</DOCNO>
            	<TEXT>Abivertinib is initially being developed as an oral treatment for patients with NSCLC in whom prior EGFR-directed therapy has failed due to the emergence of the EGFR T790M mutation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_5</DOCNO>
            	<TEXT>ACEA is also evaluating abivertinib as first-line therapy for NSCLC patients with confirmed EGFR mutational status.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_6</DOCNO>
            	<TEXT>Several Phase 1 and 2 clinical trials have been completed, with over 600 NSCLC patients receiving treatment with abivertinib in China, the U.S., and Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_7</DOCNO>
            	<TEXT>We have recently submitted a new drug application (NDA) to the Chinese FDA and anticipate a positive recommendation for abivertinib as a treatment for NSCLC in China in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_8</DOCNO>
            	<TEXT>Abivertinib also have clinical utility as an inhibitor of Brutons tyrosine kinase (BTK) which impacts B cell proliferation and survival and is currently being investigated in clinical trials for B cell lymphoma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_9</DOCNO>
            	<TEXT>In addition, BTK places critical role in immune regulation and host inflammatory responses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_10</DOCNO>
            	<TEXT>Sorrento Therapeutics is conducting global trials of Abivertinib for patients hospitalized with Covid-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_11</DOCNO>
            	<TEXT>Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_12</DOCNO>
            	<TEXT>Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_13</DOCNO>
            	<TEXT>Studies are complementary and address both dose duration and disease stage variations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_14</DOCNO>
            	<TEXT>Data from both studies is expected to be available for review by the end of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_15</DOCNO>
            	<TEXT>Which means any day now we can get the read out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_16</DOCNO>
            	<TEXT>HFs are increasing ownership Short interest is dropping lowest level in a year SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest 46,641,269 shares Short Interest Ratio 8.64 Days to Cover Short Interest % Float 18.27% This tells me that the HFs are ready for a breakout. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_46_17</DOCNO>
            	<TEXT>https://www.aceatherapeutics.com/pipeline/abivertinib/](https://www.aceatherapeutics.com/pipeline/abivertinib/) [https://fintel.io/ss/us/srne](https://fintel.io/ss/us/srne)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_0</DOCNO>
            	<TEXT>Why Shares of Sorrento Therapeutics Jumped This Week</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_1</DOCNO>
            	<TEXT>The clinical-stage biopharmaceutical company published promising news in two separate studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_2</DOCNO>
            	<TEXT>Sorrento had a series of positive announcements that drove up the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_3</DOCNO>
            	<TEXT>On Monday, the company said that its Sofusa technology, while delivering Enbrel (a drug marketed in the U.S. by Amgen) through the skin and lymphatic system, achieved a strong response in a phase 1B study against rheumatoid arthritis after 12 weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_4</DOCNO>
            	<TEXT>The key point was by using a different delivery system, the company got the result using 50% of the typical Enbrel dose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_5</DOCNO>
            	<TEXT>On Thursday, the company announced it had promising preclinical results for STI mRNA, its mRNA (ribonucleic acid) vaccine as a therapy to fight COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_6</DOCNO>
            	<TEXT>Sorrento said the vaccine was able to produce cellular and humoral (body fluid) immunity in mice against the initial WA-1 virus as well as emerging variants, Alpha, Beta, Gamma, Delta, and Lambda.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_7</DOCNO>
            	<TEXT>The key part of the findings was the company's MuVaxx lymphatic delivery system was 400% more effective using a tenth of the dose typically used in vaccines that are administered intramuscularly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_8</DOCNO>
            	<TEXT>This press release came later today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_9</DOCNO>
            	<TEXT>Sorrento Exercises Exclusive Option Agreement With Texas A amp;M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-exercises-exclusive-option-agreement-texas-am](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-exercises-exclusive-option-agreement-texas-am) Please click open and read.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_10</DOCNO>
            	<TEXT>Please read this paragraph over and over.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_11</DOCNO>
            	<TEXT>Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_12</DOCNO>
            	<TEXT>MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_13</DOCNO>
            	<TEXT>Exclusive license for MPro inhibitors supports rapidly growing small molecule development portfolio for combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_14</DOCNO>
            	<TEXT>Just another incredible agreement Today the markets were dampened by the tragic events in Afghanistan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_15</DOCNO>
            	<TEXT>I pray for the loves ones that lost a service member.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_16</DOCNO>
            	<TEXT>Their Hero's and they will never be forgotten.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_17</DOCNO>
            	<TEXT>I also pray that everyone gets out safely.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_18</DOCNO>
            	<TEXT>Then I hope we drop them a few good bye gifts from 35,000 feet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_47_19</DOCNO>
            	<TEXT>God Bless them all.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_0</DOCNO>
            	<TEXT>Texas A amp;M Researcher: New Drug Could Be Game Changer Against COVID-19</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_1</DOCNO>
            	<TEXT>A discovery by Wenshe Ray Liu and his team leads to an agreement with a California biopharmaceutical company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_2</DOCNO>
            	<TEXT>A drug created by a Texas A amp;M University professor could be the most effective treatment yet of patients with COVID-19, including the aggressive variants of the virus such as Delta and others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_3</DOCNO>
            	<TEXT>The drug compound, called MPI8, has stopped the replication of the virus in laboratory tests.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_4</DOCNO>
            	<TEXT>It was created by a Texas A amp;M research team led by biological chemist Wenshe Ray Liu, a 2018 Texas A amp;M Presidential Impact Fellow and holder of the Gradipore Chair in the Department of Chemistry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_5</DOCNO>
            	<TEXT>The potential effectiveness of MPI8 led Sorrento Therapeutics of San Diego, Calif., to seek exclusive intellectual property rights to the ingredient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_6</DOCNO>
            	<TEXT>An agreement between the company and The Texas A amp;M University System was announced Tuesday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_7</DOCNO>
            	<TEXT>Liu said that Sorrento hopes to complete pre-clinical studies of MPI8 by the end of the year and seek FDA approval to begin clinical trials on humans in early 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_8</DOCNO>
            	<TEXT>MPI8 could be the best weapon yet in the fight against the COVID-19 virus, Liu said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_9</DOCNO>
            	<TEXT>If it can be approved clinically, this will be a game changer, he said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_10</DOCNO>
            	<TEXT>Only one treatment, a drug called remdesivir, has been approved by the FDA and studies indicate it may provide only modest benefit to patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_11</DOCNO>
            	<TEXT>A few other treatments have FDAs emergency use authorization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_12</DOCNO>
            	<TEXT>A wide range of potential treatments are in early stages of research, including several others being pursued by Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_13</DOCNO>
            	<TEXT>In January 2020, Liu was among the co-authors of the first paper to identify remdesivir as a viable treatment for SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_14</DOCNO>
            	<TEXT>Liu said MPI8 shows the potential to be highly effective in treating not only the original COVID-19 viral strain, but also the more aggressive strains such as Delta, Alpha, Beta and Gamma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_15</DOCNO>
            	<TEXT>The Delta variant was first identified in India in December of 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_16</DOCNO>
            	<TEXT>In just a few months, it spread to 98 countries around the world, becoming the dominant variant in numerous nations, including India, the U.K., Israel and the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_17</DOCNO>
            	<TEXT>Delta is now responsible for almost 85 percent of the COVID-19 cases being reported in the U.S., according to the Centers for Disease Control and Prevention (CDC).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_18</DOCNO>
            	<TEXT>Henry Ji, chairman and CEO of Sorrento, said the new findings by Liu and his team might turn out to be critical in the fight against COVID-19 and other diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_19</DOCNO>
            	<TEXT>We are excited to be collaborating with Dr. Liu and his team at Texas A amp;M and look forward to advancing the development of these novel drug candidates to address COVID-19 and a multitude of other respiratory viruses, Ji said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_20</DOCNO>
            	<TEXT>Here is the most exciting part to comprehend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_21</DOCNO>
            	<TEXT>Professor biological chemist Wenshe Ray Liu and his team decided to collaborate with Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_22</DOCNO>
            	<TEXT>WHY DID THEY CHOSE SORRENTO?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_23</DOCNO>
            	<TEXT>Why not Lilly, Pfizer, Moderna, Regeneron, Johnson and Johnson ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_24</DOCNO>
            	<TEXT>In January 2020, Liu was among the co-authors of the first paper to identify remdesivir as a viable treatment for SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_25</DOCNO>
            	<TEXT>Believe it or not biological chemists know who has the BEST scientists and have the best ability for success.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_26</DOCNO>
            	<TEXT>Sorrento Therapeutics has the largest COVID-19 pipeline in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_27</DOCNO>
            	<TEXT>Now they have by far the best BIOOGICAL CHEMISTS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_28</DOCNO>
            	<TEXT>DR Ji said, In May of 2020 we have a prized fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_29</DOCNO>
            	<TEXT>A very very strong fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_30</DOCNO>
            	<TEXT>We're now going to add more and more fighters to our fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_31</DOCNO>
            	<TEXT>To make him stronger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_32</DOCNO>
            	<TEXT>Sorrento is an Aircraft Carrier loaded with the best weapons in the WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_33</DOCNO>
            	<TEXT>Why else would DARPA, DoD, and the USA Navy go into a multi year agreement?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_34</DOCNO>
            	<TEXT>BECAUSE SORRENTO HAS THE BEST COVID-19 WEAPONS. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_48_35</DOCNO>
            	<TEXT>https://today.tamu.edu/2021/08/25/texas-am-researcher-new-drug-could-be-game-changer-against-covid-19/](https://today.tamu.edu/2021/08/25/texas-am-researcher-new-drug-could-be-game-changer-against-covid-19/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_49_0</DOCNO>
            	<TEXT>Antibody Drug Conjugates Having Derivatives of Amatoxin As The Drug.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_49_1</DOCNO>
            	<TEXT>NEW PATENT!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_49_2</DOCNO>
            	<TEXT>New Patent file yesterday. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_49_3</DOCNO>
            	<TEXT>https://uspto.report/patent/app/20210260211](https://uspto.report/patent/app/20210260211) [https://en.wikipedia.org/wiki/Amatoxin](https://en.wikipedia.org/wiki/Amatoxin)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_50_0</DOCNO>
            	<TEXT>Sorrento is the ONE STOP COVID SHOP!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_50_1</DOCNO>
            	<TEXT>I can think of 18 Covid related tests, antibodies and drugs mentioned by Sorrento!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_50_2</DOCNO>
            	<TEXT>1.COVITRACE (Diagnostic Test for the Detection of SARS-CoV-2 in Nasal Swab and Saliva) 2.COVISTIX (Antigen Test for the Detection of SARS-CoV-2 Virus in Nasal Swab)Mexico EUA APPROVED 3.COVITRACK Platinum (Antibody Test for the Detection of Antibodies to SARS-CoV-2 in Blood) 4.COVIGUARD (Neutralizing Antibody STI 1499) 5.COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody STI 2020) 6.COVIDROPS (Intranasal COVI-AMG Neutralizing Antibody STI 2099) 7.COVISHIELD (Neutralizing Antibody Cocktail) 8.COVIDTRAP (ACE2 Receptor Decoy STI 4398) 9.ABIVERTINIB (Cytokine Storm STI 5656) 10.SALICYN-30 (Anti-viral STI 2030) 11.COVI-MSC (Acute Respiratory Distress Syndrome STI 8282) 12.ARK-301 long-haul Covid symptoms 13.mRNA-based multivalent vaccine 14.low cost C1 based multivalent vaccine(rights to 60% of world population) 15.MP18 oral antiviral MPro inhibitor 16.Combination oral antiviral drug cocktail 17.RESPISTIX Combination Covid/seasonal flu tests 18.Combination Covid/seasonal flu vaccines This is Don's post from yahoo message board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_50_3</DOCNO>
            	<TEXT>He's one of out top posters that always has the best lists.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_50_4</DOCNO>
            	<TEXT>Lets Thank Don with lots of likes for his hard work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_51_0</DOCNO>
            	<TEXT>Texas A amp;M Chemists Target Drug Candidates to Treat COVID-19</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_51_1</DOCNO>
            	<TEXT>[https://science.tamu.edu/news/2020/04/texas-am-chemist-cautiously-optimistic-regarding-remdesivir-clinical-trial-results/](https://science.tamu.edu/news/2020/04/texas-am-chemist-cautiously-optimistic-regarding-remdesivir-clinical-trial-results/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_0</DOCNO>
            	<TEXT>Manufacturing Specialist Wanted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_1</DOCNO>
            	<TEXT>What are they manufacturing?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_2</DOCNO>
            	<TEXT>Let's take a look.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_3</DOCNO>
            	<TEXT>Manufacturing Specialist Wanted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_4</DOCNO>
            	<TEXT>What are they manufacturing?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_5</DOCNO>
            	<TEXT>Let's take a look.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_6</DOCNO>
            	<TEXT>WHAT YOULL DO: Perform product batch reviews and inspections per sampling plans and specifications, determine and document results to identify and contain details of inspections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_7</DOCNO>
            	<TEXT>Document all defective/suspect product and generate NCMRs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_8</DOCNO>
            	<TEXT>Ensure materials and products are in accordance with established quality specifications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_9</DOCNO>
            	<TEXT>Work closely with operations and engineering to maintain compliance by ensuring all policies and procedures follow FDA, state, OSHA, and ISO regulations and standards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_10</DOCNO>
            	<TEXT>ESSENTIAL DUTIES AND RESPONSIBILITIES: Support IVD Manufacture in Sorrento Therapeutics Quality system processes in compliance with ISO 13485, 21CFR820 Review and release product batch records to ensure accuracy and cGMP compliance Inspect materials or finish goods Assist in performing Line Clearance to ensure manufacturing areas are set-up correctly Write and update DHRs Assist in revising, reviewing, and authoring SOPs, work instructions and other related documents Initiate and collaborate on CAPA/NCMR/Change Order Identify and generate non-conformance reports Assist with special projects and internal audits, as needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_11</DOCNO>
            	<TEXT>Maintain, review, and archive manufacturing quality control records Perform other duties as assigned. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_12</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=483](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=483) Overview of IVD Regulation [https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation#1](https://www.fda.gov/medical-devices/ivd-regulatory-assistance/overview-ivd-regulation#1) ISO 13485 MEDICAL DEVICES [https://www.iso.org/iso-13485-medical-devices.html](https://www.iso.org/iso-13485-medical-devices.html) Quality System (QS) Regulation/Medical Device Good Manufacturing Practices [https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-system-qs-regulationmedical-device-good-manufacturing-practices](https://www.fda.gov/medical-devices/postmarket-requirements-devices/quality-system-qs-regulationmedical-device-good-manufacturing-practices) Implementing Procedures for CAPA, NCMR  amp; Receiving Inspection [https://medicaldeviceacademy.com/implementing-procedures/](https://medicaldeviceacademy.com/implementing-procedures/) Now lets read this paragraph again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_13</DOCNO>
            	<TEXT>Sorrento Therapeutics (Sorrento) is seeking an experienced Manufacturing Specialist to support the documentation review process for our IVD manufacturing team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_14</DOCNO>
            	<TEXT>So they need someone to help to support their IVD manufacturing team in SD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_15</DOCNO>
            	<TEXT>Manufacturing team in SD?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_16</DOCNO>
            	<TEXT>What are they manufacturing in SD?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_17</DOCNO>
            	<TEXT>A. COVISTIX?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_18</DOCNO>
            	<TEXT>B. COVITRACK?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_19</DOCNO>
            	<TEXT>C. COVITRACE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_52_20</DOCNO>
            	<TEXT>D. ALL OF THE ABOVE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_0</DOCNO>
            	<TEXT>Delivering Next-Gen Biomanufacturing Capability (RPM) Reimagining Protein Manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_1</DOCNO>
            	<TEXT>[https://www.darpa.mil/news-events/2021-08-25](https://www.darpa.mil/news-events/2021-08-25) Looks like DARPA and the DoD know exactly what they want.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_2</DOCNO>
            	<TEXT>Slow production methods and reliance on a global supply chain currently limit DoD access to critical proteins such as medical countermeasures (MCMs) (i.e. antibodies, vaccines, and clotting factors), diagnostic components, and key enzymes for producing nucleic acids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_3</DOCNO>
            	<TEXT>State-of-the-art protein-based MCM production calls for massive centralized infrastructure and complex pipelines that require lengthy cellular engineering, sufficient growth of cells, and intensive purification and quality control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_4</DOCNO>
            	<TEXT>Current response times are several months for production, with additional time needed for dispersing MCMs to vulnerable populations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_5</DOCNO>
            	<TEXT>Distributed manufacturing paradigms may transform these timelines into those relevant to DoD response, especially in denied, degraded, or disrupted operational environments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_6</DOCNO>
            	<TEXT>To address these challenges, the Reimagining Protein Manufacturing (RPM) program aims to establish the foundational technologies needed for fully distributed, on-demand manufacturing of biologics-based MCMs and their associated raw materials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_7</DOCNO>
            	<TEXT>DARPA programs, such as Make-It, Nucleic Acids on Demand (NOW), and Battlefield Medicine, have invested in distributed manufacturing of pharmaceuticals and nucleic acids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_8</DOCNO>
            	<TEXT>Continuing DARPAs role in challenging manufacturing paradigms, RPM focuses on the complex process of protein production, and will attend to the biochemistry challenges associated with producing bioactive proteins at high yields with short lead times.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_9</DOCNO>
            	<TEXT>As was reinforced during the COVID-19 pandemic, many crucial building blocks for proteins, therapeutics and diagnostics are currently manufactured outside of the United States, stated Dr. Amy Jenkins, RPM program manager.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_10</DOCNO>
            	<TEXT>The RPM program will serve warfighters by strengthening the U.S. biomanufacturing supply chain and providing new methods for timely development of protein-based therapeutics and enzymes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_11</DOCNO>
            	<TEXT>The 50-month RPM program will address two technical areas (TAs).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_12</DOCNO>
            	<TEXT>TA1 Production Yield and Time focuses on protein synthesis technologies for near-immediate synthesis of proteins at high yields.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_13</DOCNO>
            	<TEXT>TA2 Post-Translational Modifications seeks novel protein production approaches to add PTMs in a controlled manner to ensure the final product is bioactive and of high quality.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_14</DOCNO>
            	<TEXT>The U.S. Government will utilize Independent Validation and Verification (IV amp;V) partners throughout the program to assess the function, stability, and composition of the proteins produced through a series of field recognized analytical techniques.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_15</DOCNO>
            	<TEXT>If successful, RPM will result in novel protein production technologies not previously deployed, added Jenkins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_16</DOCNO>
            	<TEXT>Additional details of the program schedule and metrics are available in the broad agency announcement at [https://sam.gov/opp/9711cee39a984d57ba681390bc1a4564/view](https://sam.gov/opp/9711cee39a984d57ba681390bc1a4564/view). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_17</DOCNO>
            	<TEXT>https://www.darpa.mil/program/battlefield-medicine](https://www.darpa.mil/program/battlefield-medicine) THEN LOOK AT WHAT HAPPENED News Release Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_18</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19 June 22, 2021 at 1:46 PM EDT Download PDF Broad multi-year agreement between Sorrento Therapeutics and U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_19</DOCNO>
            	<TEXT>3 (NAMRU-3) headquartered in Sigonella, Italy with Laboratory Detachments in Cairo, Egypt, Camp Lemonnier, Djibouti, and Accra, Ghana.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_20</DOCNO>
            	<TEXT>Scope includes infectious diseases research and development, product validation, and disease surveillance to inform public health policy of host nation partners, and to improve medical readiness of the U.S. Armed Forces for NAMRU-3 areas of responsibility (U.S. European Command, U.S. Central Command, U.S. Africa Command) Initial focus of the collaboration is to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostic Tests and COVIDROPS/COVI-AMG neutralizing antibody treatments for COVID-19 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_21</DOCNO>
            	<TEXT>LOOK AT WHAT HAPPENED NEXT! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_22</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-and-dyadic-announce-binding-term-sheet-license-dyadics](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-and-dyadic-announce-binding-term-sheet-license-dyadics) LOOK AT WHAT HAPPENED NEXT [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-unveils-overview-its-multivalent-mrna-covid-19-vaccine](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-unveils-overview-its-multivalent-mrna-covid-19-vaccine) PLEASE READ THIS SENTENCE Development of equipotent lyophilized dose forms that may further enhance the potential for vaccine delivery to underserved populations due to cold-chain storage and transportation issues.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_23</DOCNO>
            	<TEXT>This is what DARPA wants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_24</DOCNO>
            	<TEXT>DARPA and the DoD started a 50 month program to get Battle Ready.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_25</DOCNO>
            	<TEXT>Sorrento went into a 5 year multi year contract with the DoD. Some people were asking what the 163,000 SQ FT BRAND NEW BUILDING will be used for.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_53_26</DOCNO>
            	<TEXT>My guess is RPM.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_0</DOCNO>
            	<TEXT>DARPA - Taking Guess Work out of Vaccine Development 8/27/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_1</DOCNO>
            	<TEXT>AIM Program aims to leverage host immune mechanisms to determine if vaccine candidates will provide long-lasting immune protection Military service members rely on effective vaccination for the prevention of communicable disease and to guard against biothreat exposure, but current vaccine development is expensive, time-consuming and prone to failure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_2</DOCNO>
            	<TEXT>Many current vaccines do not provide effective protection over long periods of time, and there are multiple pathogens that lack prophylactic options.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_3</DOCNO>
            	<TEXT>Immune response to vaccines is unpredictable, transient and ineffective, largely due to a lack of understanding of the complex mechanisms of action underlying immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_4</DOCNO>
            	<TEXT>The Assessing Immune Memory (AIM) program seeks to develop a platform capability to predict immune memory informed by a systems-level view of the host response to vaccination and its mechanisms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_5</DOCNO>
            	<TEXT>Standard methods for measuring immune system response, such as antibody levels and select immune cell type markers, do not capture the breadth of immune system responses possible.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_6</DOCNO>
            	<TEXT>AIM will uncover new biomolecular correlates collections of measured responses from organisms to an immune system challenge, such as vaccination using leading edge technologies to enable earlier response detection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_7</DOCNO>
            	<TEXT>These correlates will be used to predict and understand why successful vaccines produce long-lasting protection from early host responses rather than waiting years for clinical trial results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_8</DOCNO>
            	<TEXT>It is a significant challenge in vaccine development to be able to predict how long a vaccine will be protective before it is administered to humans, and more importantly, why protection is conveyed or not, stated Dr. Tristan McClure-Begley, AIM program manager.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_9</DOCNO>
            	<TEXT>The AIM program will incorporate next-generation analytical and computational approaches to determine the host response mechanisms that lead to long-lasting protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_10</DOCNO>
            	<TEXT>The five-year program will be divided into two sequential phases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_11</DOCNO>
            	<TEXT>The goal of Phase 1, Immune Memory Road Map is to identify cell and signaling contributors to generate a road map of immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_12</DOCNO>
            	<TEXT>Phase 2, Road Map Generalizability and Tool Validation will focus on assembling and validating a research and evaluation tool for predicting vaccine duration of protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_13</DOCNO>
            	<TEXT>Teams must propose to both phases to develop comprehensive, enduring solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_14</DOCNO>
            	<TEXT>Success with AIM will provide the nation with upfront assessments of vaccine duration of protection early in development and help reduce the need for constant re-vaccination of operators upon deployment, added McClure-Begley.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_15</DOCNO>
            	<TEXT>The U.S. Government will utilize Independent Validation and Verification (IV amp;V) partners throughout the program to aid in the evaluation of program progress and intermediate program demonstrations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_16</DOCNO>
            	<TEXT>By the end of Phase 1, a demonstration will be completed to determine entry into Phase 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_17</DOCNO>
            	<TEXT>Upon successful demonstration of the underlying principles of AIM, the same technology can be explored for use in a prognostic capacity to predict individual levels of immune protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_18</DOCNO>
            	<TEXT>Additional details of the program schedule and metrics are available in the broad agency announcement at [https://sam.gov/opp/ddbd04d4961f49acb576c529f837af93/view](https://sam.gov/opp/ddbd04d4961f49acb576c529f837af93/view).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_19</DOCNO>
            	<TEXT>I'm sure Sorrento will be Appling for this grant. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_20</DOCNO>
            	<TEXT>https://www.darpa.mil/news-events/2021-08-27](https://www.darpa.mil/news-events/2021-08-27) Why do you think DARPA, DoD, and the Navy went into a multiple year agreement to use Sorrento's COVID-19 pipeline?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_54_21</DOCNO>
            	<TEXT>Lets not forget Sorrento has the largest COVID-19 pipeline in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_0</DOCNO>
            	<TEXT>WHO WANTS TO PLAY A GAME OF CHESS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_1</DOCNO>
            	<TEXT>Who wants to play a game of chess with DR Ji?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_2</DOCNO>
            	<TEXT>Who on this board thinks he can beat DR Ji?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_3</DOCNO>
            	<TEXT>Not me and let me tell you why.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_4</DOCNO>
            	<TEXT>Because he's castled and built his defense and has all of his pieces.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_5</DOCNO>
            	<TEXT>Modera and Pfizer went on offense not protecting their Queen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_6</DOCNO>
            	<TEXT>Believe it or not they lost a lot and fear they may lose their QUEEN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_7</DOCNO>
            	<TEXT>The only reason they have their queen is because Fauci is their King.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_8</DOCNO>
            	<TEXT>But not for long.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_9</DOCNO>
            	<TEXT>A bird flew and sent me a message the other day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_10</DOCNO>
            	<TEXT>Fauci is in big trouble.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_11</DOCNO>
            	<TEXT>Because in Arizona the State electors in September are releasing the true election results after months after a forensic audit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_12</DOCNO>
            	<TEXT>If Donald Trump won Arizona.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_13</DOCNO>
            	<TEXT>And Donald Trump is put back as President.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_14</DOCNO>
            	<TEXT>Fauci and his Queen wife are gone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_15</DOCNO>
            	<TEXT>A new administration will come in and completely clean house.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_16</DOCNO>
            	<TEXT>Biden and his team probably has instructed the FDA not to approve and new PCR tests.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_17</DOCNO>
            	<TEXT>Because they want everyone to vaccinate in stead of getting tested everyday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_18</DOCNO>
            	<TEXT>I've been holding back my feelings about our current President.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_19</DOCNO>
            	<TEXT>I do not want to draw a line in the sand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_20</DOCNO>
            	<TEXT>Like your with me or not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_21</DOCNO>
            	<TEXT>Lets be real here for a minute.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_22</DOCNO>
            	<TEXT>They passed $50B IN NEW TESTING for COVID-19 and they only approved only one more at HOME test?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_23</DOCNO>
            	<TEXT>Ok hold that thought!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_24</DOCNO>
            	<TEXT>Go to youtube and watch every video of DR Ji speaking with interviewers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_25</DOCNO>
            	<TEXT>What does he say?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_26</DOCNO>
            	<TEXT>The mutations are what we have to watch out for.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_27</DOCNO>
            	<TEXT>What has he done?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_28</DOCNO>
            	<TEXT>He's been building the most intriguing COVID-19 pipeline in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_29</DOCNO>
            	<TEXT>Building, adding, acquiring, agreements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_30</DOCNO>
            	<TEXT>DR Ji knows how to play chess.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_31</DOCNO>
            	<TEXT>He's not watching the stock price like us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_32</DOCNO>
            	<TEXT>He knows where the revenue is coming from.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_33</DOCNO>
            	<TEXT>He knows when he's gonna get it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_34</DOCNO>
            	<TEXT>He's like Babe Ruth pointing to center field before swinging the bat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_35</DOCNO>
            	<TEXT>He's told us in three years Sorrento will be valued at $200 Billion dollars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_36</DOCNO>
            	<TEXT>You don't make those statements unless you know how to play CHESS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_37</DOCNO>
            	<TEXT>We have less then one month less in the 3Q. We had 11 press releases so far for August.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_38</DOCNO>
            	<TEXT>I believe September DR Ji will make another very important move.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_39</DOCNO>
            	<TEXT>I think his next move is in Brazil and South America contracts with COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_40</DOCNO>
            	<TEXT>Don't ever under estimate DR Ji.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_55_41</DOCNO>
            	<TEXT>THE BEST MOVE IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_0</DOCNO>
            	<TEXT>When Insiders Buy Should Investors Join Them?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_1</DOCNO>
            	<TEXT>Tips for beating the market tend to come and go quickly, but one has held up extremely well: if executives, directors, or others with inside knowledge of a public company are buying or selling shares, investors should consider doing the same thing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_2</DOCNO>
            	<TEXT>Research shows that insider trading activity is a valuable barometer of broad shifts in market and sector sentiment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_3</DOCNO>
            	<TEXT>But before chasing each insider move, outsiders need to consider the factors that dictate the timing of trades and the factors that conceal the motivations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_4</DOCNO>
            	<TEXT>KEY TAKEAWAYS When company insiders start buying shares of the company, it may be a signal for outside investors to follow suit, but looking at which insiders are acting matters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_5</DOCNO>
            	<TEXT>One of the greatest investors of all time, Peter Lynch, was noted as saying that "insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_6</DOCNO>
            	<TEXT>Information of insider activity can be found for free on several financial websites.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_7</DOCNO>
            	<TEXT>Reasons to Follow Insider Trading The argument for shadowing insiders makes a lot of sense.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_8</DOCNO>
            	<TEXT>Executives and directors have the most up-to-date information on their companies' prospects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_9</DOCNO>
            	<TEXT>Intimately acquainted with cyclical trends, order flow, supply and production bottlenecks, costs, and other key ingredients of business success, these insiders are way ahead of analysts and portfolio managers, not to mention individual investors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_10</DOCNO>
            	<TEXT>Insiders' decisions (legal or not) to trade in their own companies' stocks are certainly worth examining.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_11</DOCNO>
            	<TEXT>Research supports the view that insider information works best in the aggregate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_12</DOCNO>
            	<TEXT>Independent research firm Market Profile Theorem (MPT) showed that insider trading trends signal an up-and-coming shift in market sentiment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_13</DOCNO>
            	<TEXT>To identify trends, MPT analysts employ the Brooks ratio, which divides total insider sales of a company by total insider trades (purchases and sales) and then averages this ratio for thousands of stocks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_14</DOCNO>
            	<TEXT>If the average Brooks ratio is less than 40%, the market outlook is bullish; above 60% signals a bearish outlook. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_15</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/financial-information/sec-filings](https://investors.sorrentotherapeutics.com/financial-information/sec-filings) [https://www.investopedia.com/articles/02/121002.asp](https://www.investopedia.com/articles/02/121002.asp) So lets get this straight!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_16</DOCNO>
            	<TEXT>Insiders are buying and BlackRock, State Street Vanguard, JPM, and the Swiss Bank have done the same.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_17</DOCNO>
            	<TEXT>So what are we supposed to do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_18</DOCNO>
            	<TEXT>Silence the noise on this board and purchase more shares and hold our shares tight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_56_19</DOCNO>
            	<TEXT>Because the BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_57_0</DOCNO>
            	<TEXT>The COVID-19 Therapeutics Market to Record an Exponential Growth During the Period of 2021-2030</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_57_1</DOCNO>
            	<TEXT>According to the latest market intelligence report by InsightAce Analytic, the global COVID-19 therapeutics market size is valued at US$ 5.26 Billion in 2020, and it is expected to reach US$ 25.6 Billion in 2030, recording a promising CAGR of 10.7% from 2021 to 2030.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_57_2</DOCNO>
            	<TEXT>Some of the key Players of COVID-19 therapeutics market are Atea Pharmaceuticals, Inc., CytoDyn, Celltrion, Eli Lilly and Company, NRX Pharmaceuticals, Shanghai Junshi Biosciences Co., Ltd., Veru Inc., Humanigen, Inc., Catalent, Inc., Cipla Limited, Molecular Partners AG, Merck, Novartis International AG, Regeneron Pharmaceuticals, Inc., Vir Biotechnology, Revive Therapeutics Ltd., Brii Biosciences Limited, GlaxoSmithKline plc, APEIRON Biologics AG, Bristol Myers Squibb, Janssen Pharmaceuticals, Trevena Inc, Ono Pharmaceutical Co., Ltd., Constant Therapeutics LLC, Amarin Corporation plc, FUJIFILM Toyama Chemical Co., Ltd., NeuroBo Pharmaceuticals, Inc., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, SORRENTO THERAPEUTICS, PhaseBio, Pfizer, Takeda, BioAegis Therapeutics, Roivant Sciences, A.I. Therapeutics, Inc., Celltex Therapeutics, Blade Therapeutics, Marinomed Biotech AG, Synairgen, SAb Biotherapeutics, Romark Laboratories, L.C., Kiniksa Pharmaceuticals, UNION therapeutics A/S, Fulcrum Therapeutics, and Other Prominent Players.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_57_3</DOCNO>
            	<TEXT>AUGUST 27TH 2021 Please click and read Sorrento Therapeutics is listed as a key player. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_57_4</DOCNO>
            	<TEXT>https://www.medgadget.com/2021/08/the-covid-19-therapeutics-market-to-record-an-exponential-growth-during-the-period-of-2021-2030.html](https://www.medgadget.com/2021/08/the-covid-19-therapeutics-market-to-record-an-exponential-growth-during-the-period-of-2021-2030.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_0</DOCNO>
            	<TEXT>Vaccines are limited in addressing the current coronavirus pandemic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_1</DOCNO>
            	<TEXT>Vaccines are dependent on the condition of the recipients immune system and infectivity status; additional preventative approaches are likely to be needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_2</DOCNO>
            	<TEXT>Monoclonal antibodies offer a window of protection Antibodies given to people that neutralize SARS-CoV-2 can provide a window of protection against coronavirus infection regardless of the status of the recipients immune system or infectivity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_3</DOCNO>
            	<TEXT>Antibodies have successfully been used to protect people from infectious viruses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_4</DOCNO>
            	<TEXT>The use of monoclonal antibodies as a prophylaxis for COVID-19 is a limited option Their high cost and typical requirements for intravenous administration make it unlikely they can be given to millions of people for population protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_5</DOCNO>
            	<TEXT>SmartPharm's Gene Mabs offers a creative solution SmartPharms Gene Mab platform combines a novel DNA plasmid with long duration of expression and a safe, effective delivery system for use with standard hypodermic injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_6</DOCNO>
            	<TEXT>Giving people a DNA plasmid injection to the muscle that can produce the needed neutralizing antibody in their bodies over a matter of weeks or months potentially offers a more scalable and cost-effective way of providing population protection against COVID-19 than directly giving them monoclonal antibodies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_7</DOCNO>
            	<TEXT>One of the key countermeasures under development to protect people from SARS-Cov-2 (the virus that causes COVID-19 infection) is vaccination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_8</DOCNO>
            	<TEXT>Vaccines have the benefit of being widely distributable as a means of protection populations from disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_9</DOCNO>
            	<TEXT>However, they have some key limitations for COVID-19 prevention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_10</DOCNO>
            	<TEXT>One of the main issues, is that they are dependent on the recipients immune system to develop a protective response against the coronavirus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_11</DOCNO>
            	<TEXT>Not everyones immune system has the same ability to mount a protective response after vaccination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_12</DOCNO>
            	<TEXT>This is particularly true of the elderly, who are one of the high-risk groups for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_13</DOCNO>
            	<TEXT>Other groups that have trouble mounting a good immune response are infants, people who are immunosuppressed (like organ transplant patients) and people with certain diseases, like people with heart or lung disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_14</DOCNO>
            	<TEXT>A second issue with using vaccines to create immune protection, is that establishing immunity takes time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_15</DOCNO>
            	<TEXT>It can be weeks before the level of immune response is adequate in some diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_16</DOCNO>
            	<TEXT>It is unknown how long it will take for people to mount protective immunity against SARS-CoV-2; successful vaccination may ultimately require multiple injections over time, like vaccines against hepatitis or human papillomavirus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_17</DOCNO>
            	<TEXT>Another limitation of infectious disease vaccines is that they are typically intended for protecting healthy people and do not have much effect if someone is already infected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_18</DOCNO>
            	<TEXT>SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to rapidly develop a DNA-based neutralizing antibody that can be given to people as an intramuscular injection to block infection by COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_19</DOCNO>
            	<TEXT>DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies November 27, 2020 at 8:00 AM EST Download PDF Initial funding of up to $34 million for the project Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAbTM through Phase 2 clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_20</DOCNO>
            	<TEXT>STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_21</DOCNO>
            	<TEXT>STI-2020-encoded Gene MAb products can potentially be stored at refrigerator temperatures, avoiding some of the cold chain management challenges associated with the deployment of COVID-19 vaccines currently in development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_22</DOCNO>
            	<TEXT>Sorrento has a cGMP facility in place to meet initial production demand and Sorrento expects that STI-2020-encoded Gene MAb can be produced in large quantity to meet potentially high demand. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_23</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) Nov 2020 DARPA gave Sorrento Therapeutics $34M to fund two phase 2 trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_24</DOCNO>
            	<TEXT>Any day now we should receive an update on the on going trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_25</DOCNO>
            	<TEXT>Please click the click above and please read this sentence over again... Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_58_26</DOCNO>
            	<TEXT>Please follow me on REDDIT as subject5410 in the new chat group BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_0</DOCNO>
            	<TEXT>Vaccines are limited in addressing the current coronavirus pandemic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_1</DOCNO>
            	<TEXT>Vaccines are dependent on the condition of the recipients immune system and infectivity status; additional preventative approaches are likely to be needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_2</DOCNO>
            	<TEXT>Monoclonal antibodies offer a window of protection Antibodies given to people that neutralize SARS-CoV-2 can provide a window of protection against coronavirus infection regardless of the status of the recipients immune system or infectivity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_3</DOCNO>
            	<TEXT>Antibodies have successfully been used to protect people from infectious viruses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_4</DOCNO>
            	<TEXT>The use of monoclonal antibodies as a prophylaxis for COVID-19 is a limited option Their high cost and typical requirements for intravenous administration make it unlikely they can be given to millions of people for population protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_5</DOCNO>
            	<TEXT>SmartPharm's Gene Mabs offers a creative solution SmartPharms Gene Mab platform combines a novel DNA plasmid with long duration of expression and a safe, effective delivery system for use with standard hypodermic injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_6</DOCNO>
            	<TEXT>Giving people a DNA plasmid injection to the muscle that can produce the needed neutralizing antibody in their bodies over a matter of weeks or months potentially offers a more scalable and cost-effective way of providing population protection against COVID-19 than directly giving them monoclonal antibodies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_7</DOCNO>
            	<TEXT>One of the key countermeasures under development to protect people from SARS-Cov-2 (the virus that causes COVID-19 infection) is vaccination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_8</DOCNO>
            	<TEXT>Vaccines have the benefit of being widely distributable as a means of protection populations from disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_9</DOCNO>
            	<TEXT>However, they have some key limitations for COVID-19 prevention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_10</DOCNO>
            	<TEXT>One of the main issues, is that they are dependent on the recipients immune system to develop a protective response against the coronavirus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_11</DOCNO>
            	<TEXT>Not everyones immune system has the same ability to mount a protective response after vaccination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_12</DOCNO>
            	<TEXT>This is particularly true of the elderly, who are one of the high-risk groups for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_13</DOCNO>
            	<TEXT>Other groups that have trouble mounting a good immune response are infants, people who are immunosuppressed (like organ transplant patients) and people with certain diseases, like people with heart or lung disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_14</DOCNO>
            	<TEXT>A second issue with using vaccines to create immune protection, is that establishing immunity takes time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_15</DOCNO>
            	<TEXT>It can be weeks before the level of immune response is adequate in some diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_16</DOCNO>
            	<TEXT>It is unknown how long it will take for people to mount protective immunity against SARS-CoV-2; successful vaccination may ultimately require multiple injections over time, like vaccines against hepatitis or human papillomavirus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_17</DOCNO>
            	<TEXT>Another limitation of infectious disease vaccines is that they are typically intended for protecting healthy people and do not have much effect if someone is already infected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_18</DOCNO>
            	<TEXT>SmartPharm Therapeutics has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to rapidly develop a DNA-based neutralizing antibody that can be given to people as an intramuscular injection to block infection by COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_19</DOCNO>
            	<TEXT>DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies November 27, 2020 at 8:00 AM EST Download PDF Initial funding of up to $34 million for the project Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAbTM through Phase 2 clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_20</DOCNO>
            	<TEXT>STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_21</DOCNO>
            	<TEXT>STI-2020-encoded Gene MAb products can potentially be stored at refrigerator temperatures, avoiding some of the cold chain management challenges associated with the deployment of COVID-19 vaccines currently in development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_22</DOCNO>
            	<TEXT>Sorrento has a cGMP facility in place to meet initial production demand and Sorrento expects that STI-2020-encoded Gene MAb can be produced in large quantity to meet potentially high demand. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_23</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) Nov 2020 DARPA gave Sorrento Therapeutics $34M to fund two phase 2 trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_24</DOCNO>
            	<TEXT>Any day now we should receive an update on the on going trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_59_25</DOCNO>
            	<TEXT>Please click the click above and please read this sentence over again... Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_0</DOCNO>
            	<TEXT>Desperation on Variants Paints Path for Long-Term Vaccine Thesis (DYAI, MRNA, PFE, JNJ, NVAX, BNTX, AZN, SRNE) LOOK AT WHO'S IN THE NEWS THESE DAYS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_1</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) has become one of the most interesting emerging names in the space given its strong recent results and its new deal with Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to kickstart the next stage of bringing its truly unique vaccine solution to market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_2</DOCNO>
            	<TEXT>As the story has progressed, investors have started to spot the name, driving shares over 60% higher in recent weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_3</DOCNO>
            	<TEXT>But that could be just the tip of the iceberg here if this is the real deal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_4</DOCNO>
            	<TEXT>The company has a special edge with its fungal-based C1 technology platform, which uses a different vector for producing more vaccine volume faster and cheaper, and its vaccine solution (now starting human testing) is easier to store, produce, transport, and distribute, and cheaper to manufacture quickly, than the mRNA solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_5</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) recently announced, along with Sorrento Therapeutics, Inc. (NASDAQ:SRNE), the signing of a binding term sheet to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_6</DOCNO>
            	<TEXT>The final terms of the license will be set forth in a definitive agreement to be entered into between the parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_7</DOCNO>
            	<TEXT>Sorrento Chairman and CEO, Dr. Henry Ji, commented, "We look forward to continuing our collaboration with Dyadic, which began last year, initially with a goal of developing and commercializing a protein-based COVID-19 vaccine that can be rapidly manufactured in large quantities in our existing cGMP facilities, and stored and transported at room temperature, in order to increase access and affordability to underserved populations globally."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_8</DOCNO>
            	<TEXT>continued, "Over the past six months we have carried out several promising preclinical animal studies using the C1-produced RBD antigen in Dyadic's lead COVID-19 vaccine candidate, DYAI-100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_9</DOCNO>
            	<TEXT>Our goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across our current and future coronavirus programs."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_10</DOCNO>
            	<TEXT>Mark Emalfarb, Dyadic's President and Chief Executive Officer noted, "We are delighted to have executed a binding term sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_11</DOCNO>
            	<TEXT>This marks a significant milestone in our corporate development efforts as we expect the license agreement we will enter into to enable us to monetize our internal COVID-19 development efforts with a partner that has the resources and expertise to advance vaccines, therapeutics, and diagnostics both clinically and commercially."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_12</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) generated research and development revenue of $937k in the quarter ended June 30, 2021 versus $524,000 in the second quarter of 2020, up 79% year over year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_13</DOCNO>
            	<TEXT>Cash and equivalents balance as of June 30, 2021 totaled $25.6 million. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_60_14</DOCNO>
            	<TEXT>https://www.theglobeandmail.com/investing/markets/stocks/SRNE/pressreleases/2330721/](https://www.theglobeandmail.com/investing/markets/stocks/SRNE/pressreleases/2330721/) Please join our new BANDOFBROTHERSOFSRNE chat room.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_0</DOCNO>
            	<TEXT>Desperation on Variants Paints Path for Long-Term Vaccine Thesis (DYAI, MRNA, PFE, JNJ, NVAX, BNTX, AZN, SRNE) LOOK AT WHO'S IN THE NEWS THESE DAYS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_1</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) has become one of the most interesting emerging names in the space given its strong recent results and its new deal with Sorrento Therapeutics, Inc. (NASDAQ:SRNE) to kickstart the next stage of bringing its truly unique vaccine solution to market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_2</DOCNO>
            	<TEXT>As the story has progressed, investors have started to spot the name, driving shares over 60% higher in recent weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_3</DOCNO>
            	<TEXT>But that could be just the tip of the iceberg here if this is the real deal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_4</DOCNO>
            	<TEXT>The company has a special edge with its fungal-based C1 technology platform, which uses a different vector for producing more vaccine volume faster and cheaper, and its vaccine solution (now starting human testing) is easier to store, produce, transport, and distribute, and cheaper to manufacture quickly, than the mRNA solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_5</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) recently announced, along with Sorrento Therapeutics, Inc. (NASDAQ:SRNE), the signing of a binding term sheet to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_6</DOCNO>
            	<TEXT>The final terms of the license will be set forth in a definitive agreement to be entered into between the parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_7</DOCNO>
            	<TEXT>Sorrento Chairman and CEO, Dr. Henry Ji, commented, "We look forward to continuing our collaboration with Dyadic, which began last year, initially with a goal of developing and commercializing a protein-based COVID-19 vaccine that can be rapidly manufactured in large quantities in our existing cGMP facilities, and stored and transported at room temperature, in order to increase access and affordability to underserved populations globally."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_8</DOCNO>
            	<TEXT>continued, "Over the past six months we have carried out several promising preclinical animal studies using the C1-produced RBD antigen in Dyadic's lead COVID-19 vaccine candidate, DYAI-100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_9</DOCNO>
            	<TEXT>Our goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across our current and future coronavirus programs."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_10</DOCNO>
            	<TEXT>Mark Emalfarb, Dyadic's President and Chief Executive Officer noted, "We are delighted to have executed a binding term sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_11</DOCNO>
            	<TEXT>This marks a significant milestone in our corporate development efforts as we expect the license agreement we will enter into to enable us to monetize our internal COVID-19 development efforts with a partner that has the resources and expertise to advance vaccines, therapeutics, and diagnostics both clinically and commercially."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_12</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) generated research and development revenue of $937k in the quarter ended June 30, 2021 versus $524,000 in the second quarter of 2020, up 79% year over year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_13</DOCNO>
            	<TEXT>Cash and equivalents balance as of June 30, 2021 totaled $25.6 million. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_61_14</DOCNO>
            	<TEXT>https://www.theglobeandmail.com/investing/markets/stocks/SRNE/pressreleases/2330721/](https://www.theglobeandmail.com/investing/markets/stocks/SRNE/pressreleases/2330721/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_62_0</DOCNO>
            	<TEXT>LANDSTEINER SCIENTIFIC LABORATORIO FARMACEUTICO</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_62_1</DOCNO>
            	<TEXT>Distributing COVISTIX in Mexico? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_62_2</DOCNO>
            	<TEXT>https://www.gob.mx/cms/uploads/attachment/file/643058/COVI-STIX\_\_COVID-19\_Virus\_Rapid\_Antigen\_Detection\_Test\_\_Landsteiner\_Scientific\_\_S.A.\_de\_C.V.\_.pdf](https://www.gob.mx/cms/uploads/attachment/file/643058/COVI-STIX__COVID-19_Virus_Rapid_Antigen_Detection_Test__Landsteiner_Scientific__S.A._de_C.V._.pdf)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_63_0</DOCNO>
            	<TEXT>LANDSTEINER SCIENTIFIC LABORATORIO FARMACEUTICO</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_63_1</DOCNO>
            	<TEXT>Distributing COVISTIX in Mexico? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_63_2</DOCNO>
            	<TEXT>https://www.gob.mx/cms/uploads/attachment/file/643058/COVI-STIX\_\_COVID-19\_Virus\_Rapid\_Antigen\_Detection\_Test\_\_Landsteiner\_Scientific\_\_S.A.\_de\_C.V.\_.pdf](https://www.gob.mx/cms/uploads/attachment/file/643058/COVI-STIX__COVID-19_Virus_Rapid_Antigen_Detection_Test__Landsteiner_Scientific__S.A._de_C.V._.pdf)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_0</DOCNO>
            	<TEXT>VANGUARD IS BUYING and the SHORTS are decreasing since last year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_1</DOCNO>
            	<TEXT>When they BUY WE BUY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_2</DOCNO>
            	<TEXT>VANGUARD IS BUYING and the SHORTS are deceasing since last year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_3</DOCNO>
            	<TEXT> 2021-08-30 NP VTSMX - Vanguard Total Stock Market Index Fund Investor Shares \[click for advisory\] 8.98 7,711,550  2021-08-30 NP VEXMX - Vanguard Extended Market Index Fund Investor Shares \[click for advisory\] 8.98 3,385,653  SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest 46,641,269 shares Short Interest Ratio 10.78 Days to Cover Short Interest % Float 17.43%  Short Squeeze Score The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_4</DOCNO>
            	<TEXT>The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_5</DOCNO>
            	<TEXT>The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_6</DOCNO>
            	<TEXT> Update Frequency: Intraday  See Short Squeeze Explorer, which provides a list of highest-ranking companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_64_7</DOCNO>
            	<TEXT> 64.77 797 out of 5531 See Highest Ranking Stocks  When they BUY WE BUY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_0</DOCNO>
            	<TEXT>All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_1</DOCNO>
            	<TEXT>Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_2</DOCNO>
            	<TEXT>A total of 10 patients (8 males/2 females; age range 24-65 years; 8 Caucasian/2 Asian; 7 Hispanic/Latino/3 non-Hispanic/Latino; height 64 to 70 inches; weight 66 to 130 kg) were enrolled and all were discharged from the hospital to home within three days of their last infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_3</DOCNO>
            	<TEXT>At baseline, all patients required oxygen supplementation and had PaO2/FiO2 ratios ranging from 135 to 256 (normal 400).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_4</DOCNO>
            	<TEXT>All patients had various medical co-morbidities in addition to obesity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_5</DOCNO>
            	<TEXT>The 10th patient had been under treatment for nearly 2 weeks without improvement and was discharged after the 2nd COVI-MSC infusion with oxygen saturations in the high 90s on room air.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_6</DOCNO>
            	<TEXT>On follow up days later, the patient was still doing well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_7</DOCNO>
            	<TEXT>Lets remember COVI-MSC was given after everything else failed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_8</DOCNO>
            	<TEXT>If we were to ask those ten patients one question.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_9</DOCNO>
            	<TEXT>One question only after Sorrento Therapeutics saved their lives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_10</DOCNO>
            	<TEXT>What would your question be?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_11</DOCNO>
            	<TEXT>My question to all ten patients would be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_12</DOCNO>
            	<TEXT>Q. Would you recommend COVI-MSC to anyone who was in your condition?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_13</DOCNO>
            	<TEXT>I believe their answer would be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_14</DOCNO>
            	<TEXT>Please click and read the full release from April. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_15</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm) They then applied and were given the green light to proceed with a PHASE 2 TRIAL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_16</DOCNO>
            	<TEXT>Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-0](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-0) We are very satisfied with the progress made in Brazil so far, and we have developed strong local relationships in support of multiple studies, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_17</DOCNO>
            	<TEXT>By focusing on the geographies most impacted by COVID-19, we are able to implement synergistic programs to answer safety and efficacy questions related to our product candidates while helping patients where the disease has been spreading the most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_18</DOCNO>
            	<TEXT>We expect this next Phase 2 Pivotal study to confirm the clinical benefits initially observed in our recently completed open label Phase 1b study.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_19</DOCNO>
            	<TEXT>If confirmed, we are ready to establish a plan for development and manufacturing commitments that are required by ANVISA to take the product candidate from clinical trials to emergency use authorization (EUA) approval, including generating the data needed to support making the drug accessible prior to any full registration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_20</DOCNO>
            	<TEXT>READ THIS ONE MORE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_21</DOCNO>
            	<TEXT>Priority access to multiple trials is being given to Brazilian patients following the rapid and openly collaborative interactions Sorrento has been able to establish with ANVISA regulators.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_22</DOCNO>
            	<TEXT>WHAT'S NEXT?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_23</DOCNO>
            	<TEXT>Sorrento will soon begin enrollment for two additional Phase 2 studies with COVI-MSC: A parallel Phase 2 placebo-controlled Phase 2 safety study to be conducted across multiple sites in the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_24</DOCNO>
            	<TEXT>A pulmonary long-hauler Phase 2 safety and efficacy study across multiple sites in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_25</DOCNO>
            	<TEXT>First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_26</DOCNO>
            	<TEXT>Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_27</DOCNO>
            	<TEXT>Personalized Stem Cells, Inc.(PSC) is Sorrentos GMP manufacturing partner for COVI-MSC. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_28</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-enrollment-first-subject-brazil-phase-2-study](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-enrollment-first-subject-brazil-phase-2-study) WHAT'S NEXT?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_65_29</DOCNO>
            	<TEXT>THE BEST 100% DISCHARGE RATE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_0</DOCNO>
            	<TEXT>All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_1</DOCNO>
            	<TEXT>Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_2</DOCNO>
            	<TEXT>A total of 10 patients (8 males/2 females; age range 24-65 years; 8 Caucasian/2 Asian; 7 Hispanic/Latino/3 non-Hispanic/Latino; height 64 to 70 inches; weight 66 to 130 kg) were enrolled and all were discharged from the hospital to home within three days of their last infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_3</DOCNO>
            	<TEXT>At baseline, all patients required oxygen supplementation and had PaO2/FiO2 ratios ranging from 135 to 256 (normal 400).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_4</DOCNO>
            	<TEXT>All patients had various medical co-morbidities in addition to obesity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_5</DOCNO>
            	<TEXT>The 10th patient had been under treatment for nearly 2 weeks without improvement and was discharged after the 2nd COVI-MSC infusion with oxygen saturations in the high 90s on room air.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_6</DOCNO>
            	<TEXT>On follow up days later, the patient was still doing well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_7</DOCNO>
            	<TEXT>Lets remember COVI-MSC was given after everything else failed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_8</DOCNO>
            	<TEXT>If we were to ask those ten patients one question.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_9</DOCNO>
            	<TEXT>One question only after Sorrento Therapeutics saved their lives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_10</DOCNO>
            	<TEXT>What would your question be?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_11</DOCNO>
            	<TEXT>My question to all ten patients would be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_12</DOCNO>
            	<TEXT>Q. Would you recommend COVI-MSC to anyone who was in your condition?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_13</DOCNO>
            	<TEXT>I believe their answer would be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_14</DOCNO>
            	<TEXT>Please click and read the full release from April. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_15</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm) They then applied and were given the green light to proceed with a PHASE 2 TRIAL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_16</DOCNO>
            	<TEXT>Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of COVI-MSC in Hospitalized COVID-19 Patients With Acute Respiratory Distress Syndrome [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-0](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/brazilian-health-regulatory-agency-anvisa-authorizes-sorrento-0) We are very satisfied with the progress made in Brazil so far, and we have developed strong local relationships in support of multiple studies, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_17</DOCNO>
            	<TEXT>By focusing on the geographies most impacted by COVID-19, we are able to implement synergistic programs to answer safety and efficacy questions related to our product candidates while helping patients where the disease has been spreading the most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_18</DOCNO>
            	<TEXT>We expect this next Phase 2 Pivotal study to confirm the clinical benefits initially observed in our recently completed open label Phase 1b study.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_19</DOCNO>
            	<TEXT>If confirmed, we are ready to establish a plan for development and manufacturing commitments that are required by ANVISA to take the product candidate from clinical trials to emergency use authorization (EUA) approval, including generating the data needed to support making the drug accessible prior to any full registration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_20</DOCNO>
            	<TEXT>READ THIS ONE MORE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_21</DOCNO>
            	<TEXT>Priority access to multiple trials is being given to Brazilian patients following the rapid and openly collaborative interactions Sorrento has been able to establish with ANVISA regulators.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_22</DOCNO>
            	<TEXT>WHAT'S NEXT?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_23</DOCNO>
            	<TEXT>Sorrento will soon begin enrollment for two additional Phase 2 studies with COVI-MSC: A parallel Phase 2 placebo-controlled Phase 2 safety study to be conducted across multiple sites in the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_24</DOCNO>
            	<TEXT>A pulmonary long-hauler Phase 2 safety and efficacy study across multiple sites in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_25</DOCNO>
            	<TEXT>First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_26</DOCNO>
            	<TEXT>Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_27</DOCNO>
            	<TEXT>Personalized Stem Cells, Inc.(PSC) is Sorrentos GMP manufacturing partner for COVI-MSC. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_28</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-enrollment-first-subject-brazil-phase-2-study](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-enrollment-first-subject-brazil-phase-2-study) WHAT'S NEXT?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_66_29</DOCNO>
            	<TEXT>THE BEST 100% DISCHARGE RATE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_0</DOCNO>
            	<TEXT>BULLS ARE IN CONTROL - BULLS ARE BUYING- WHEN THEY BUY WE BUY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_1</DOCNO>
            	<TEXT>Please look at all the new GREEN NEW BUYS! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_2</DOCNO>
            	<TEXT>https://fintel.io/so/us/kplt](https://fintel.io/so/us/kplt) KPLT Institutional Ownership - Katapult Holdings, Inc. Institutional Owners 92 total, 86 long only, 0 short only, 6 long/short Shares Outstanding 96,821,615 shares (source: Capital IQ) Institutional Shares 31,107,016 - 32.13% (ex 13D/G) Institutional Value $ 306,815 USD ($1000) Short Squeeze Score The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_3</DOCNO>
            	<TEXT>The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_4</DOCNO>
            	<TEXT>The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_5</DOCNO>
            	<TEXT>Update Frequency: Intraday See Short Squeeze Explorer, which provides a list of highest-ranking companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_6</DOCNO>
            	<TEXT>76.25 243 out of 5506 See Highest Ranking Stocks Short Borrow Fee Rates KPLT / Katapult Holdings, Inc. short borrow fee rates are shown in the following table.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_7</DOCNO>
            	<TEXT>This table shows the interest rate that must be paid by a short seller of US:KPLT to the lender of that security.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_8</DOCNO>
            	<TEXT>This fee is shown as an annual percentage rate (APR).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_9</DOCNO>
            	<TEXT>Lenders are funds or individuals that own the security that have indicated to the broker that they are willing to lend it out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_10</DOCNO>
            	<TEXT>Dividends paid to a shorted security go to the owner/lender of the security, not to the borrower.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_11</DOCNO>
            	<TEXT>We update our database every 30 minutes but only display changes, in order to improve readability.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_12</DOCNO>
            	<TEXT>Update Frequency: Intraday Last update: 15m Time Since Last Change Timestamp (UTC) US:KPLT Short Borrow Fee Rate (%) 17h 2021-09-03 20:42:58.967 12.15 09-02 2021-09-02 22:43:12.894 6.82 09-02 2021-09-02 20:27:29.934 6.79 09-02 2021-09-02 16:44:28.04 6.56 09-02 2021-09-02 14:35:21.629 6.20 09-01 2021-09-01 20:38:10.473 6.68 09-01 2021-09-01 18:33:57.13 6.61 09-01 2021-09-01 16:29:12.117 6.70 09-01 2021-09-01 14:24:36.756 7.01 08-31 2021-08-31 21:22:54.532 4.36 They raised the borrowing rate to 12.1% The short squeeze score is a 76.25 Everyone is buying!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_13</DOCNO>
            	<TEXT>MASSIVE AMOUNT OF NEW BUYS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_67_14</DOCNO>
            	<TEXT>I wouldn't be surprised if we didn't see a massive break out on Tuesday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_0</DOCNO>
            	<TEXT>SOMETIMES YOU NEED THAT HELPING HAND</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_1</DOCNO>
            	<TEXT>STOP and REFLECT and SUPPORT everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_2</DOCNO>
            	<TEXT>Don't think we don't have the answers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_3</DOCNO>
            	<TEXT>The technology is there we only need the access.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_4</DOCNO>
            	<TEXT>DR Robin L Smith's own words during the Unite To Prevent and Unite To Cure at the Vatican back on May6th thru the 8th.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_5</DOCNO>
            	<TEXT>Please click and watch the video [https://vaticanconference2021.org/](https://vaticanconference2021.org/) Please click Day 1 session and watch the introduction with DR Robin L. Smith in her own words she says... While the battle isn't over yet it's clear we will win!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_6</DOCNO>
            	<TEXT>Please click and listen to.. Novel Approaches and Platforms for Treating Disease Part II: Comprehensive COVID-19 Solutions Listen to Max Gomez interview DR Ji. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_7</DOCNO>
            	<TEXT>https://vaticanconference2021.org/highlights/](https://vaticanconference2021.org/highlights/) After you click and listen to this video below you will understand completely why DR Robin L. Smith exercised her stock options and paid money out of her pocket. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_8</DOCNO>
            	<TEXT>https://www.youtube.com/watch?v=T5cn7Thw9OU](https://www.youtube.com/watch?v=T5cn7Thw9OU) After you listen to this video please forward it to everyone that you know.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_68_9</DOCNO>
            	<TEXT>And let them know that.. THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_0</DOCNO>
            	<TEXT>Clinical Data Expected End of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_1</DOCNO>
            	<TEXT>17 Trading days left for the 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_2</DOCNO>
            	<TEXT>Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21 Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_3</DOCNO>
            	<TEXT>Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_4</DOCNO>
            	<TEXT>Studies are complementary and address both dose duration and disease stage variations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_5</DOCNO>
            	<TEXT>Data from both studies is expected to be available for review by the end of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_6</DOCNO>
            	<TEXT>At any day between today and within the next 16 days we should be receiving the results of both studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_7</DOCNO>
            	<TEXT>I believe we all know what the results will be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_8</DOCNO>
            	<TEXT>Just think why would they double their employment size in 20 months?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_9</DOCNO>
            	<TEXT>Why would they lease a brand new building 163,000 SQ FT next door to their exciting one?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_10</DOCNO>
            	<TEXT>Why would they acquire ACEA Therapeutics?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_11</DOCNO>
            	<TEXT>Why would DR Robin L. Smith exercise her options to purchase $775,000 out of pocket?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_12</DOCNO>
            	<TEXT>Why were the Board members of Sorrento awarded 4,000,000 shares?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_13</DOCNO>
            	<TEXT>Why did BlackRock, Vanguard, State Street, JPM, Swiss Bank all increase their holding to over $500M?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_14</DOCNO>
            	<TEXT>Why has the short interest decreased to the lowest level in 12 months?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_15</DOCNO>
            	<TEXT>If you don't know why?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_69_16</DOCNO>
            	<TEXT>You better read the last 8 months of positive press releases [https://investors.sorrentotherapeutics.com/](https://investors.sorrentotherapeutics.com/) Now is the time to hold your shares and add more if you can afford too.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_70_0</DOCNO>
            	<TEXT>CHECK OUT THE SHORT SQUEEZE SCORE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_70_1</DOCNO>
            	<TEXT>##### Short Squeeze Score The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_70_2</DOCNO>
            	<TEXT>The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_70_3</DOCNO>
            	<TEXT>The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_70_4</DOCNO>
            	<TEXT>Update Frequency: Intraday [See Short Squeeze Explorer, which provides a list of highest-ranking companies.](https://fintel.io/shortSqueeze) ## 94.39 8 out of 5505[See Highest Ranking Stocks](https://fintel.io/shortSqueeze)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_71_0</DOCNO>
            	<TEXT>DON'T TAKE SORRENTO FOR GRANTED</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_71_1</DOCNO>
            	<TEXT>GRANTED SEPTEMBER 7TH 2021 [https://uspto.report/patent/grant/11,111,304](https://uspto.report/patent/grant/11,111,304) [https://uspto.report/patent/grant/11,110,066](https://uspto.report/patent/grant/11,110,066) Abstract An implantable delivery device and method for utilizing the device to delivery a bioactive agent to a subject in need thereof is described.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_71_2</DOCNO>
            	<TEXT>The device includes a pattern of structures fabricated on a surface of the device to form a nanotopography.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_71_3</DOCNO>
            	<TEXT>A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_71_4</DOCNO>
            	<TEXT>The device may be located adjacent tissue such as an endovascular implant or a perivascular implant, and may deliver the bioactive agent without triggering an immune or foreign body response to the bioactive agent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_71_5</DOCNO>
            	<TEXT>Yesterday the bashers were looking for answers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_71_6</DOCNO>
            	<TEXT>Meanwhile the grants quietly keep coming in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_0</DOCNO>
            	<TEXT>Sofusa does what subcutaneous injections can never do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_1</DOCNO>
            	<TEXT>[http://www.sofusa.com/technology/](http://www.sofusa.com/technology/) Please click and watch the video.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_2</DOCNO>
            	<TEXT>Novel Nanotechnology The revolutionary nanotopography of Sofusa has been shown by in vitro studies to perturbate the extracellular matrix, enabling drug flow through tight cellular junctions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_3</DOCNO>
            	<TEXT>Lymphatic Targeting With proprietary microneedle technology, the Sofusa platform is designed to access lymphatic capillaries just below the epidermis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_4</DOCNO>
            	<TEXT>Tunable Distribution The Sofusa proprietary distributor block is adaptable to a range of pharmacokinetic requirements and helps ensure precise, consistent drug flow through the microneedle array.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_5</DOCNO>
            	<TEXT>Advantaged Lymphatic Absorption Nanotopography draped microneedles infuse drug within the epidermis to access both the systemic and lymphatic capillaries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_6</DOCNO>
            	<TEXT>This creates an efficient mass transfer system and helps to avoid the inherent inefficiencies of subcutaneous drug delivery.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_7</DOCNO>
            	<TEXT>Tunable Pharmacokinetics The Sofusa platform can be tuned to deliver controllable, consistent drug flow with potential to enable superior efficacy and fewer adverse events.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_72_8</DOCNO>
            	<TEXT>How tiny innovations inspired huge opportunities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_0</DOCNO>
            	<TEXT>(NASDAQ:DYAI) is one of the most interesting dark-horse plays emerging here.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_1</DOCNO>
            	<TEXT>The company recently signed a landmark deal with Sorrento Therapeutics, Inc. (NASDAQ:SRNE), a major player in the biotech space on the vaccine side, as part of a plan to boost its unique vaccine solution to market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_2</DOCNO>
            	<TEXT>The company has a special edge with its fungal-based C1 technology platform, which uses a different vector for producing more vaccine volume faster and cheaper, and its vaccine solution (now starting human testing) is easier to store, produce, transport, and distribute, and cheaper to manufacture quickly, than the mRNA solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_3</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) recently announced, along with SRNE, the signing of a binding term sheet to enter into an exclusive license agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic's lead COVID-19 vaccine candidate, DYAI-100, produced using Dyadic's proprietary and patented C1-cell protein production platform.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_4</DOCNO>
            	<TEXT>The final terms of the license will be set forth in a definitive agreement to be entered into between the parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_5</DOCNO>
            	<TEXT>Sorrento Chairman and CEO, Dr. Henry Ji, commented, "We look forward to continuing our collaboration with Dyadic, which began last year, initially with a goal of developing and commercializing a protein-based COVID-19 vaccine that can be rapidly manufactured in large quantities in our existing cGMP facilities, and stored and transported at room temperature, in order to increase access and affordability to underserved populations globally."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_6</DOCNO>
            	<TEXT>continued, "Over the past six months we have carried out several promising preclinical animal studies using the C1-produced RBD antigen in Dyadic's lead COVID-19 vaccine candidate, DYAI-100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_7</DOCNO>
            	<TEXT>Our goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across our current and future coronavirus programs."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_8</DOCNO>
            	<TEXT>Mark Emalfarb, Dyadic's President and Chief Executive Officer noted, "We are delighted to have executed a binding term sheet with Sorrento Therapeutics to license the C1 technology for the development and commercialization of coronavirus vaccines, therapeutics, and diagnostics, including COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_9</DOCNO>
            	<TEXT>This marks a significant milestone in our corporate development efforts as we expect the license agreement we will enter into to enable us to monetize our internal COVID-19 development efforts with a partner that has the resources and expertise to advance vaccines, therapeutics, and diagnostics both clinically and commercially."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_10</DOCNO>
            	<TEXT>Dyadic International, Inc. (NASDAQ:DYAI) generated research and development revenue of $937k in the quarter ended June 30, 2021 versus $524,000 in the second quarter of 2020, up 79% year over year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_11</DOCNO>
            	<TEXT>Cash and equivalents balance as of June 30, totaled $25.6 million.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_12</DOCNO>
            	<TEXT>DYAI could be the most underappreciated name in the space at this point, for multiple reasons. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_73_13</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/the-vaccine-revolution-portfolio-mrna-pfe-jnj-nvax-bntx-azn-dyai-2021-09-08?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/the-vaccine-revolution-portfolio-mrna-pfe-jnj-nvax-bntx-azn-dyai-2021-09-08?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_0</DOCNO>
            	<TEXT>Everyone please listen to this news video from 6 years ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_1</DOCNO>
            	<TEXT>It's very interesting to watch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_2</DOCNO>
            	<TEXT>Sorrento was working to develop Cynviloq to fight Cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_3</DOCNO>
            	<TEXT>What ever happened?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_4</DOCNO>
            	<TEXT>Patrick Soon is being sued for a catch and kill?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_5</DOCNO>
            	<TEXT>When is the arbitration resuming?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_6</DOCNO>
            	<TEXT>After you watch the news video please click and view the March Presentation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_7</DOCNO>
            	<TEXT>Please scroll down to where you see IN THE BIG GREEN BOX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_8</DOCNO>
            	<TEXT>In the box you will see .. [https://www.youtube.com/watch?v=0h\_Keql85OU](https://www.youtube.com/watch?v=0h_Keql85OU) [https://investors.sorrentotherapeutics.com/events-and-presentations/presentations](https://investors.sorrentotherapeutics.com/events-and-presentations/presentations) [https://sorrentotherapeutics.com/partnership/](https://sorrentotherapeutics.com/partnership/) $90M Upfront + $1.2B + MILESTONES.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_9</DOCNO>
            	<TEXT>LIQUIDITY EVENTS What does this mean?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_10</DOCNO>
            	<TEXT>Does it mean Sorrento can liquidate the asset at anytime?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_11</DOCNO>
            	<TEXT>Also what do you think of LEE PHARM.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_12</DOCNO>
            	<TEXT>Sorrento has licensed exclusive rights to Lees Pharm to develop and commercialize the fully human anti-PD-L1 mAb STI-A1014 for the greater Chinese market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_13</DOCNO>
            	<TEXT>So what's happening with that?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_14</DOCNO>
            	<TEXT>I believe there in P3 and could report soon?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_15</DOCNO>
            	<TEXT>They can also get Milestone payment as well?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_16</DOCNO>
            	<TEXT>Sorrento is on the verge of a massive breakout once they receive the next FDA approval, EUA, Funding, Grants, or the next partnership agreement or the next MILESTONE partnership development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_74_17</DOCNO>
            	<TEXT>Hold on folks and be prepared for the BEST PRESS RELEASE THAT'S GONNA COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_0</DOCNO>
            	<TEXT>Phase 2 Study of COVI-MSC</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_1</DOCNO>
            	<TEXT>On September 2, 2021 Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_2</DOCNO>
            	<TEXT>First patient enrolled at first site in Phase 2 placebo-controlled study conducted in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_3</DOCNO>
            	<TEXT>Second site scheduled to start enrolling within one week, with multiple additional sites coming online within one month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_4</DOCNO>
            	<TEXT>So according to my calendar we should have two sites enrolling patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_5</DOCNO>
            	<TEXT>In three more weeks we should be enrolling in multiple States  amp; Multiple Cities in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_6</DOCNO>
            	<TEXT>Does everyone remember when they treated the first 4 patients that were on their deathbed?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_7</DOCNO>
            	<TEXT>After nothing worked they were given COVI-MSC and they walk out of the hospital after the second and third treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_8</DOCNO>
            	<TEXT>Does everyone remember when they were reporting 4 patients and then 9 patients and then all TEN patients walked out of the hospital?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_9</DOCNO>
            	<TEXT>I remember they said nobody has to die from COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_10</DOCNO>
            	<TEXT>Ask yourself this one question?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_11</DOCNO>
            	<TEXT>Do you think anyone that gets the placebo will walk out of the hospital?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_12</DOCNO>
            	<TEXT>Unfortunately I do not think so.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_13</DOCNO>
            	<TEXT>The patients that receive the placebo will most likely die.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_14</DOCNO>
            	<TEXT>May God Bless their souls.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_15</DOCNO>
            	<TEXT>So let's think about the results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_16</DOCNO>
            	<TEXT>So far 100% of all patients recovered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_17</DOCNO>
            	<TEXT>What % is necessary to convince the FDA that COVI-MSC should be approved for EUA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_18</DOCNO>
            	<TEXT>Let's remember after nothing else worked in the most severe ARDS patients Sorrento saved them all.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_19</DOCNO>
            	<TEXT>100% 10 for 10 Please review the press releases and please say a prayer for the patients that will receive the placebo. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_75_20</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/sorrento-announces-enrollment-of-first-subject-in-brazil-phase-2-study-of-covi-msc-for-treatment-of-covid-19-associated-acute-respiratory-distress-in-icu-patients-2021-09-02?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/sorrento-announces-enrollment-of-first-subject-in-brazil-phase-2-study-of-covi-msc-for-treatment-of-covid-19-associated-acute-respiratory-distress-in-icu-patients-2021-09-02?mod=mw_quote_news_seemore) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm) The best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_0</DOCNO>
            	<TEXT>Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_1</DOCNO>
            	<TEXT>Objectives: The acute respiratory distress syndrome (ARDS) secondary to viral pneumonitis is one of the main causes of high mortality in patients with COVID-19 (novel coronavirus disease 2019).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_2</DOCNO>
            	<TEXT>We systematically reviewed mortality in COVID-19 patients with ARDS and the potential role of systemic corticosteroids in COVID-19 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_3</DOCNO>
            	<TEXT>Methods: Electronic databases and country-specific healthcare databases were searched to identify relevant studies/reports.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_4</DOCNO>
            	<TEXT>The quality assessment of individual studies was conducted using the Newcastle-Ottawa Scale.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_5</DOCNO>
            	<TEXT>Country-specific proportion of individuals with COVID-19 who developed ARDS and reported death were combined in a random-effect meta-analysis to give a pooled mortality estimate of ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_6</DOCNO>
            	<TEXT>Results: The overall pooled mortality estimate among 10,815 ARDS cases in COVID-19 patients was 39% (95% CI: 23-56%).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_7</DOCNO>
            	<TEXT>The pooled mortality estimate for China was 69% (95% CI: 67-72%).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_8</DOCNO>
            	<TEXT>In Europe, the highest mortality estimate among COVID-19 patients with ARDS was reported in Poland (73%; 95% CI: 58-86%) while Germany had the lowest mortality estimate (13%; 95% CI: 2-29%) among COVID-19 patients with ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_9</DOCNO>
            	<TEXT>The median crude mortality rate of COVID-19 patients with reported corticosteroid use was 28.0% (lower quartile: 13.9%; upper quartile: 53.6%).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_10</DOCNO>
            	<TEXT>Conclusions: The high mortality in COVID-19 associated ARDS necessitates a prompt and aggressive treatment strategy which includes corticosteroids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_11</DOCNO>
            	<TEXT>Most of the studies included no information on the dosing regimen of corticosteroid therapy, however, low-dose corticosteroid therapy or pulse corticosteroid therapy appears to have a beneficial role in the management of severely ill COVID-19 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_12</DOCNO>
            	<TEXT>Can COVI-MSC made a difference?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_13</DOCNO>
            	<TEXT>Overview of Stem Cell Therapy for Acute Respiratory Distress Syndrome with Focus on COVID 19 Objective: There are as yet no effective strategies to treat the novel COVID-19 and to stem its symptoms, including ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_14</DOCNO>
            	<TEXT>This review examines recent research studies in humans to determine whether mesenchymal stem cells (MSCs) may be used effectively and safely to target potentially deadly lung damage that may follow infection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_15</DOCNO>
            	<TEXT>Methods: A literature search was conducted to find published manuscripts on the treatment of ARDS and COVID-19 symptoms, disease presentation, and available treatment regimens.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_16</DOCNO>
            	<TEXT>Electronic data bases of scientific articles and records of printed documents of JAMA journals were searched to find research publications on MSC treatment of ARDS and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_17</DOCNO>
            	<TEXT>Outcome variables included mortality over varying time periods, hospital days, days on ventilator, and biological factors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_18</DOCNO>
            	<TEXT>Results: Two randomized double-blind clinical trials, 2 pilot studies, and 2 case reports described MSC use to treat ARDS with specific focus on COVID-19 and lung symptoms of cytokine storm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_19</DOCNO>
            	<TEXT>The MSCs were well-tolerated across studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_20</DOCNO>
            	<TEXT>No significant differences in treatment outcome were found in randomized double-blind trials; however, results of 1 pilot study and 1 case report showed that MSCs led to lung symptom resolution and survival in severely ill treatment patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_21</DOCNO>
            	<TEXT>Conclusions: There is little published research on disease and survival outcomes among patients suffering severe lung disease associated with ARDS and COVID-19, and studies available are limited by lack of consistency in design and numerous flaws and limitations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_22</DOCNO>
            	<TEXT>Comparisons across studies are difficult.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_23</DOCNO>
            	<TEXT>Nevertheless, it is documented that 8 ARDS patients with COVID-19 experienced symptom recovery and survival subsequent to MSC administration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_24</DOCNO>
            	<TEXT>MSCs are potentially life-saving treatment approaches for some patients who exhibit severe lung distress and have not responded to standard treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_25</DOCNO>
            	<TEXT>This is an obviously exciting research and treatment option for COVID-19 and other life-threatening diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_26</DOCNO>
            	<TEXT>What has Sorrento done?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_27</DOCNO>
            	<TEXT>Please click and read. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_28</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-enrollment-first-subject-brazil-phase-2-study](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-enrollment-first-subject-brazil-phase-2-study) [https://pubmed.ncbi.nlm.nih.gov/32942797/](https://pubmed.ncbi.nlm.nih.gov/32942797/) [https://pubmed.ncbi.nlm.nih.gov/32734777/](https://pubmed.ncbi.nlm.nih.gov/32734777/) I'm expecting we will soon hear about all the ARDS patients walking out of the hospitals very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_29</DOCNO>
            	<TEXT>Thank you and have a great weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_76_30</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_0</DOCNO>
            	<TEXT>Does anyone know how many square feet of office  amp; lab space Sorrento is going to lease?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_1</DOCNO>
            	<TEXT>Hmmm I have a pretty good idea.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_2</DOCNO>
            	<TEXT>The Sorrento Gateway 4930 Directors Place is under construction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_3</DOCNO>
            	<TEXT>This brand new state of the art building.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_4</DOCNO>
            	<TEXT>Is being built as a class A office and lab.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_5</DOCNO>
            	<TEXT>Sorrento maxed out the space by adding subterranean outdoor kitchen  amp; dining room areas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_6</DOCNO>
            	<TEXT>It was only 151,000 but what the heck let's make it 163,205.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_7</DOCNO>
            	<TEXT>Why would they need more space?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_8</DOCNO>
            	<TEXT>Well the interior cafeteria probably not big enough to feed the hundreds of new employees.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_9</DOCNO>
            	<TEXT>They would probably rather have that space used for labs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_10</DOCNO>
            	<TEXT>So they need more dining  amp; eating space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_11</DOCNO>
            	<TEXT>Makes complete sense to me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_12</DOCNO>
            	<TEXT>The new lease agreement drafted on July 1, 2021 had something very interesting that most people didn't see.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_13</DOCNO>
            	<TEXT>They're also extending all of the existing leases for all of their four properties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_14</DOCNO>
            	<TEXT>9380 Judicial Drive, 4939 Directors Place, 4955 Directors Place, and 4921 Directors Place that's currently under major construction installing brand new big HVAC ducts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_15</DOCNO>
            	<TEXT>Maybe more cGMP labs?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_16</DOCNO>
            	<TEXT>So all in all Sorrento is leasing 399,976 square feet of office  amp; lab space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_17</DOCNO>
            	<TEXT>Why would they need to hire hundreds of people and lease that much space?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_18</DOCNO>
            	<TEXT>2 + 2 = 4 Let's do the math together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_19</DOCNO>
            	<TEXT>Would you build a bigger house next door to your house and hire a butler and a maid and servants if you can't afford it?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_20</DOCNO>
            	<TEXT>You would need to have another job to pay for it?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_21</DOCNO>
            	<TEXT>Or you're coming into some MONEY?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_22</DOCNO>
            	<TEXT>I believe you all get my point I'm trying to make.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_23</DOCNO>
            	<TEXT>You wouldn't build a bigger house and overextend yourself unless you have a plan in place to pay for it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_24</DOCNO>
            	<TEXT>DR Ji has a plan in place.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_25</DOCNO>
            	<TEXT>He also has 26 Clinical trials that have been filed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_26</DOCNO>
            	<TEXT>Partnered with the Mayo Clinic, Mt Sinai, Texas A  amp; M, Columbia, DARPA, DoD, and the NAVY and many more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_27</DOCNO>
            	<TEXT>He's building the next biggest Mammoth Pharmaceutical Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_28</DOCNO>
            	<TEXT>Which will be worth $200 Billion in 3 years. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_29</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/static-files/92955254-018a-4024-ba62-deb619e5ec9c](https://investors.sorrentotherapeutics.com/static-files/92955254-018a-4024-ba62-deb619e5ec9c) [https://www.cbre.us/resources/fileassets/US-SMPL-32323/a477c68f/e4abaeea-9da8-4188-a58f-4061babd65f9.pdf](https://www.cbre.us/resources/fileassets/US-SMPL-32323/a477c68f/e4abaeea-9da8-4188-a58f-4061babd65f9.pdf) PS - the 399,976 sq feet doesn't include ACEA space in China or any other partners, subsidiaries, etc.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_30</DOCNO>
            	<TEXT>PSS - BlackRock, State Street, Vanguard, JPM, Swiss Bank, and increase their shares and own over $500M in stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_77_31</DOCNO>
            	<TEXT>PSSS- If I missed adding something please add it to the list.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_0</DOCNO>
            	<TEXT>WHAT IS THIS FOR?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_1</DOCNO>
            	<TEXT>FUTURE PRODUCTS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_2</DOCNO>
            	<TEXT>WHICH FUTURE PRODUCTS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_3</DOCNO>
            	<TEXT>Develop Gross-to-Net Sales revenue recognition models for future products and distribution channels, engaging external consultants as needed for complex pricing and distribution channels.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_4</DOCNO>
            	<TEXT>Revenue Accountant/Sr.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_5</DOCNO>
            	<TEXT>Accountant Sorrento needs another Accountant to count all the future money?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_6</DOCNO>
            	<TEXT>Let's read and see what this Revenue Accountant/Sr.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_7</DOCNO>
            	<TEXT>Accountant will do... WHAT WE ARE LOOKING FOR: Sorrento Therapeutics (Sorrento) is seeking an experienced Revenue Accountant who will be responsible for accounting for revenues across all entities under Sorrento, in compliance with ASC 606 revenue recognition guidance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_8</DOCNO>
            	<TEXT>The position will be responsible for calculating and maintaining accounting support for Gross-to-Net Sales and Contract Adjustments, oversee insurance billings and collections, oversee accounting for deferred revenue and other revenue streams, and participate in technical accounting of revenue-related transactions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_9</DOCNO>
            	<TEXT>The ideal candidate demonstrate a strong understanding of the US Managed Markets landscape, healthcare pricing and contracting, insurance billing and collections analytical thinking, accounting acumen and attention to detail.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_10</DOCNO>
            	<TEXT>WHAT YOULL DO: Maintain Gross-to-Net Sales revenue recognition models for existing products (ZTlido), in close coordination with Commercial Operations and Market Access teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_11</DOCNO>
            	<TEXT>Develop Gross-to-Net Sales revenue recognition models for future products and distribution channels, engaging external consultants as needed for complex pricing and distribution channels.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_12</DOCNO>
            	<TEXT>Lead Gross-to-Net forecast processes and analyze, explain and summarize gross to net variances by channel and segment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_13</DOCNO>
            	<TEXT>Provide inputs to Gross-to-Net model based on changes in pricing, contracts and contract strategy, and payer strategies and business models.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_14</DOCNO>
            	<TEXT>Prepare calculations for insurance contract adjustments for revenue recognition entries Keep abreast with latest revenue accounting guidance (e.g. ASC 606) and ensure compliance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_15</DOCNO>
            	<TEXT>Assist Financial Planning and Analysis in preparing for revenue budgets and forecasts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_16</DOCNO>
            	<TEXT>Serve as subject matter expert on key drivers of gross-to-net through analysis of data sources, healthcare payer understanding and engagement with internal and external stakeholders Analyze pricing and contracting scenarios using the Gross-to-Net model.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_17</DOCNO>
            	<TEXT>Develop and cultivate cross-functional relationships to help business understand revenue drivers and support decision making process to improve profitability.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_18</DOCNO>
            	<TEXT>Other projects/duties as necessary [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=380](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=380) BTW in the last 20 months Sorrento has almost doubled in size.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_19</DOCNO>
            	<TEXT>They keep on hiring and hiring and leasing more and more space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_78_20</DOCNO>
            	<TEXT>Because DR Ji said, In three years Sorrento will be a $200 Billion dollar Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_0</DOCNO>
            	<TEXT>Clinical Data Expected End of 3Q21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_1</DOCNO>
            	<TEXT>Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21 .</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_2</DOCNO>
            	<TEXT>The key is with Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_3</DOCNO>
            	<TEXT>Please click and watch the video. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_4</DOCNO>
            	<TEXT>https://www.synovahealth.com/](https://www.synovahealth.com/) Everytime I watch this video I buy more shares of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_5</DOCNO>
            	<TEXT>At the same time Sorrento needs a partner in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_6</DOCNO>
            	<TEXT>I'm expecting that they will partner with one of these Mammoth Brazilian Companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_7</DOCNO>
            	<TEXT>Top 5 Brazilian Pharma Companies Ache.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_8</DOCNO>
            	<TEXT>With USD 996.5 million in annual sales, Ache is the largest Brazilian pharma company in the domestic market. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_9</DOCNO>
            	<TEXT>EMS Pharma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_10</DOCNO>
            	<TEXT>The second biggest Brazilian pharma player is EMS Pharma, with USD 849.1 million in annual sales. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_11</DOCNO>
            	<TEXT>Eurofarma. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_12</DOCNO>
            	<TEXT>Neo Qumica. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_13</DOCNO>
            	<TEXT>Mantecorp Farmasa.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_14</DOCNO>
            	<TEXT>We have 14 trading days to report the results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_15</DOCNO>
            	<TEXT>They can come any day now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_16</DOCNO>
            	<TEXT>Know what you own and the results will only be the beginning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_79_17</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_0</DOCNO>
            	<TEXT>Experience with buffer preparation, large volume preparation (50L 200L).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_1</DOCNO>
            	<TEXT>Sorrento Therapeutics (Sorrento) is seeking an experienced Senior Manufacturing Associate to join our Antibody Manufacturing team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_2</DOCNO>
            	<TEXT>Which Antibody are they making?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_3</DOCNO>
            	<TEXT>Senior Manufacturing Associate WHAT WE ARE LOOKING FOR: Sorrento Therapeutics (Sorrento) is seeking an experienced Senior Manufacturing Associate to join our Antibody Manufacturing team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_4</DOCNO>
            	<TEXT>WHAT YOULL DO: Direct downstream cGMP processing: facility, buffer preparation, and protein purification (primarily antibody).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_5</DOCNO>
            	<TEXT>Responsible for working with junior associates in all cleanroom GMP activities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_6</DOCNO>
            	<TEXT>Helping to develop junior staff capabilities, creating a culture of safety, maintain training objectives, compliance and collaboration while implementing process improvements where applicable.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_7</DOCNO>
            	<TEXT>Batch record, SOP, and inventory compliance with QA and Material Control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_8</DOCNO>
            	<TEXT>Understanding of QA/QC compliance: deviation management, training, cGMP compliance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_9</DOCNO>
            	<TEXT>ESSENTIAL DUTIES AND RESPONSIBILITIES: Demonstrated experience with cGMP-compliant downstream processes, notably in antibody purification.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_10</DOCNO>
            	<TEXT>Experience with buffer preparation, large volume preparation (50L 200L).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_11</DOCNO>
            	<TEXT>Familiarity with basic biochemistry concepts: pH, conductivity, solution concentrations, column chromatography, protein concentration determination, etc.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_12</DOCNO>
            	<TEXT>Experience with the AKTA process chromatography system (Unicorn software); column chromatography at the 6L to 30L bed volume scale.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_13</DOCNO>
            	<TEXT>Experience in BPG column pouring and qualification.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_14</DOCNO>
            	<TEXT>Experience with maintaining and executing cGMP-qualified protocols (batch records) and SOPs; cGMP documentation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_15</DOCNO>
            	<TEXT>Helping with junior staff oversite, willing to take responsibility for all cleanroom GMP activities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_16</DOCNO>
            	<TEXT>Desire to lead a team in all phases of GMP antibody production Youll have responsibilities in contributing to essential supply inventory, and the responsibility to ensure compliance with current Good Manufacturing Practices (cGMP), policies and safety practices for your team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_17</DOCNO>
            	<TEXT>Other duties as assigned. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_80_18</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=487](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=487)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_0</DOCNO>
            	<TEXT>Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_1</DOCNO>
            	<TEXT>September 13, 2021 at 9:00 AM EDT[Download PDF](https://investors.sorrentotherapeutics.com/node/12421/pdf) SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the **H.C.Wainwright 23rd** **Global Investment Conference** **(**[**www.hcwevents.com/annualconference**](https://www.globenewswire.com/Tracker?data=Bisf4I34l8q46XzNbNId1hmIfX656eVBoZoiScJYND0uNCMABipYWsx51Zu2ioVrik05-sAkUaIQTe1SpwLJjcre_e3zo4BxwcZlwd5FR_dFcYy6JkHOhLhtxODG_MXmVTEcKSNIerpG9f6M7adgPA==)**)**.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_2</DOCNO>
            	<TEXT>The conference is being held virtually on September 13-15, 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_3</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento, will provide corporate updates and highlights associated with Sorrentos product pipeline in the strategic focus areas of the company: COVID-19, Cancer and Autoimmune Therapeutics, and Non-Opioid Pain Management. ***</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_4</DOCNO>
            	<TEXT>COVID-19 Product Portfolio Highlights:*** * **COVISTIX:** COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_5</DOCNO>
            	<TEXT>Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_6</DOCNO>
            	<TEXT>COVIDROPS (STI-2099):** Intranasal neutralizing antibody (nAb) formulation in Phase 2 trials in UK, US and soon in Mexico for newly diagnosed COVID patients in an outpatient setting. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_7</DOCNO>
            	<TEXT>COVI-AMG (STI-2020):** Potentially highly potent/low dose antibody in a 2 minute IV-push in Phase 2 trials for systemic treatment in an outpatient setting. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_8</DOCNO>
            	<TEXT>COVISHIELD antibody (STI-9167):** Demonstrating potent *in vitro* virus neutralization across all currently known variants of concern (VoCs) and reducing replicating virus in the lungs of infected transgenic K18 mice (with human ACE2 receptor) to undetectable levels (following infection by SARS-CoV-2 WA-1 strain or VoCs including Alpha, Beta, Gamma, Delta, and Lambda). * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_9</DOCNO>
            	<TEXT>MPI-8 and its SAR-Improved Analog (1121):** Small molecule antiviral targeting SARS-CoV-2 main protease, demonstrating broad-spectrum, potent antiviral activities against SARS-CoV-2 and all currently known VoCs. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_10</DOCNO>
            	<TEXT>Multivalent mRNA COVID-19 Vaccine:** Elicited a stronger humoral immune response against Delta VoC as compared to SARS-CoV-2 intramuscular mRNA vaccine in preclinical studies. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_11</DOCNO>
            	<TEXT>Recombinant RBD Subunit Vaccine:** Demonstrated strong humoral immune response against WA-1 and Delta VoC in preclinical studies. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_12</DOCNO>
            	<TEXT>Abivertinib:** Phase 2 studies for treatment of acute respiratory distress syndrome (ARDS) in hospitalized COVID patients in US (96 Pts) and Brazil (400 Pts) are completed. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_13</DOCNO>
            	<TEXT>COVI-MSC:** Phase 2 for ARDS in ICU COVID patients are ongoing in US and Brazil. ***</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_14</DOCNO>
            	<TEXT>Cancer and Autoimmune Product Portfolio Highlights:*** * **Abivertinib:** Phase 3 topline data in NSCLC available Q4 2021. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_15</DOCNO>
            	<TEXT>Abivertinib:** IND for Phase 2 in Prostate Cancer to be filed Q4 2021. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_16</DOCNO>
            	<TEXT>PD-L1 antibody**: In Phase 3 for SCLC and NDA submission in China for recurrent or metastatic cervical cancer. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_17</DOCNO>
            	<TEXT>CD38 ADC:** In Phase 1 for Amyloidosis and Multiple Myeloma. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_18</DOCNO>
            	<TEXT>CD38 DAR-T:** In Phase 1 for Relapsed and Refractory Multiple Myeloma. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_19</DOCNO>
            	<TEXT>CD47 antibody:** In Phase 1 in solid tumors. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_20</DOCNO>
            	<TEXT>SOFUSA:** Lymphatic delivery of Enbrel in Phase 1b in refractory rheumatoid arthritis patients. ***</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_21</DOCNO>
            	<TEXT>Non-Opioid Pain Management Product Portfolio Highlights:*** * **ZTlido:** Commercial with strong sales growth and expanded coverage for up to 65% of lives nationally. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_22</DOCNO>
            	<TEXT>SP-102:** Phase 3/pivotal trial (US) completed full enrollment. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_23</DOCNO>
            	<TEXT>Resiniferatoxin (RTX):** In Phase 2 for Osteoarthritis pain management. * **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_24</DOCNO>
            	<TEXT>RTX:** In Phase 2 trial for intractable cancer pain (pending FDA clearance).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_81_25</DOCNO>
            	<TEXT>An updated corporate presentation will also be available at [www.sorrentotherapeutics.com](https://www.globenewswire.com/Tracker?data=U5ErXrPRn8hKha6y264OgOtoEz2musf74cSn5SNGkSCBa2CJvS_pA2BSwqBZHarnuMByCFk69VBTEWtSy7VwdDyvUz5G7YQhNIWbnfLLtfORthPGsVGPkb8gqA-gKgT-)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_82_0</DOCNO>
            	<TEXT>READ INBETWEEN THE LINES!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_82_1</DOCNO>
            	<TEXT>Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing) WHO EUL?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_82_2</DOCNO>
            	<TEXT>**COVISTIX:** COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_82_3</DOCNO>
            	<TEXT>Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_82_4</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-hc-wainwright](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-hc-wainwright)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_0</DOCNO>
            	<TEXT>Diagnostics laboratory emergency use listing</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_1</DOCNO>
            	<TEXT>EMERGENCY USE LISTING  The WHO Emergency Use Listing Procedure (EUL) is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of these products to people affected by a public health emergency.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_2</DOCNO>
            	<TEXT>This will assist interested UN procurement agencies and Member States in determining the acceptability of using specific products, based on an essential set of available quality, safety, and efficacy and performance data.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_3</DOCNO>
            	<TEXT> Diagnostics laboratory emergency use listing  [https://www.who.int/teams/regulation-prequalification/eul](https://www.who.int/teams/regulation-prequalification/eul)  Please view today's press release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_4</DOCNO>
            	<TEXT>Please read the 1st Highlight Sorrento will address.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_5</DOCNO>
            	<TEXT> COVISTIX: COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_6</DOCNO>
            	<TEXT>Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_83_7</DOCNO>
            	<TEXT> [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-hc-wainwright](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-hc-wainwright)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_0</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator ( WHO )</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_1</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator ( WHO ) Please click and view what the Access ACT-Accelerator is...[https://www.who.int/initiatives/act-accelerator](https://www.who.int/initiatives/act-accelerator) Sorrento's COVISTIX: COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_2</DOCNO>
            	<TEXT>Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_3</DOCNO>
            	<TEXT>Partnering?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_4</DOCNO>
            	<TEXT>Who is Sorrento partnering with?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_5</DOCNO>
            	<TEXT>Global commercialization?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_6</DOCNO>
            	<TEXT>How many COVI-STIX could Sorrento sell globally?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_7</DOCNO>
            	<TEXT>Please click where it says WHAT IS THE ACT-Accelerator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_8</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_9</DOCNO>
            	<TEXT>Launched at the end of April 2020, at an event co-hosted by the Director-General of the World Health Organization, the President of France, the President of the European Commission, and the Bill  amp; Melinda Gates Foundation, the Access to COVID-19 Tools (ACT) Accelerator brings together governments, scientists, businesses, civil society, and philanthropists and global health organizations (the Bill  amp; Melinda Gates Foundation, CEPI, FIND, Gavi, The Global Fund, Unitaid, Wellcome, the WHO, and the World Bank).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_10</DOCNO>
            	<TEXT>Following the ACT-Accelerator launch, UNICEF and PAHO became delivery partners for COVAX, the vaccines pillar.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_11</DOCNO>
            	<TEXT>These organizations have joined forces to speed up an end to the pandemic by supporting the development and equitable distribution of the tests, treatments and vaccines the world needs to reduce mortality and severe disease, restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_12</DOCNO>
            	<TEXT>There is no time to waste in the fight against COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_13</DOCNO>
            	<TEXT>No-one is safe until everyone is safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_14</DOCNO>
            	<TEXT>This is a unique partnership of many of the world's international health organizations who have come together to share, and build on, individual expertise to create a powerful global solution that will ensure equity in access to tests, vaccines, treatments across the world with one goal: to reduce the burden of the COVID-19 pandemic by addressing the cause.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_15</DOCNO>
            	<TEXT>PLEASE READ THIS ONE MORE TIME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_16</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_84_17</DOCNO>
            	<TEXT>Now let's focus on this... Groundbreaking global collaboration WHO will help to accelerate COVI-STIX?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_0</DOCNO>
            	<TEXT>Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_1</DOCNO>
            	<TEXT>Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_2</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator ( WHO ) The Access to COVID-19 Tools (ACT) Accelerator, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_3</DOCNO>
            	<TEXT>Launched at the end of April 2020, at an event co-hosted by the Director-General of the World Health Organization, the President of France, the President of the European Commission, and the Bill  amp; Melinda Gates Foundation, the Access to COVID-19 Tools (ACT) Accelerator brings together governments, scientists, businesses, civil society, and philanthropists and global health organizations (the Bill  amp; Melinda Gates Foundation, CEPI, FIND, Gavi, The Global Fund, Unitaid, Wellcome, the WHO, and the World Bank).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_4</DOCNO>
            	<TEXT>Following the ACT-Accelerator launch, UNICEF and PAHO became delivery partners for COVAX, the vaccines pillar.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_5</DOCNO>
            	<TEXT>These organizations have joined forces to speed up an end to the pandemic by supporting the development and equitable distribution of the tests, treatments and vaccines the world needs to reduce mortality and severe disease, restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_6</DOCNO>
            	<TEXT>There is no time to waste in the fight against COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_7</DOCNO>
            	<TEXT>No-one is safe until everyone is safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_8</DOCNO>
            	<TEXT>This is a unique partnership of many of the world's international health organizations who have come together to share, and build on, individual expertise to create a powerful global solution that will ensure equity in access to tests, vaccines, treatments across the world with one goal: to reduce the burden of the COVID-19 pandemic by addressing the cause.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_9</DOCNO>
            	<TEXT>.[https://www.who.int/initiatives/act-accelerator](https://www.who.int/initiatives/act-accelerator) Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients Sorrento Therapeutics, Inc. (NASDAQ: SRNE) recently announced the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_10</DOCNO>
            	<TEXT>This study (MSC-COV-202BR) is a multi-arm, randomized, placebo-controlled Phase 2 study of the efficacy and safety of three infusions of COVI-MSC administered on varying schedules in the setting of standard of care treatments for COVID-19 in 100 subjects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_11</DOCNO>
            	<TEXT>The primary objective of this study is to evaluate the efficacy of COVI-MSCs in patients with COVID-19-induced ARD or ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_12</DOCNO>
            	<TEXT>Additionally, Sorrento will soon begin enrollment for two additional Phase 2 studies with COVI-MSC: A parallel Phase 2 placebo-controlled Phase 2 safety study to be conducted across multiple sites in the United States; and A pulmonary long-hauler Phase 2 safety and efficacy study across multiple sites in Brazil. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_13</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/why-experts-believe-antibody-treatments-hold-the-potential-to-reduce-need-for-hospitalization-for-covid-19-patients-2021-09-14-81973430?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/why-experts-believe-antibody-treatments-hold-the-potential-to-reduce-need-for-hospitalization-for-covid-19-patients-2021-09-14-81973430?mod=mw_quote_news_seemore) There's a few things that make me very happy to see.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_14</DOCNO>
            	<TEXT>Can anyone point them out?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_15</DOCNO>
            	<TEXT>This is not a history class.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_16</DOCNO>
            	<TEXT>It's not a job for me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_85_17</DOCNO>
            	<TEXT>WHO can tell me ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_86_0</DOCNO>
            	<TEXT>HOW TO OBTAIN COVISTIX</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_86_1</DOCNO>
            	<TEXT>[http://74.207.241.209/](http://74.207.241.209/) Please click how to obtain COVI-STIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_86_2</DOCNO>
            	<TEXT>Then view CVS, SAM'S CLUB,GIANT EAGLE, RITE AID, available in stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_87_0</DOCNO>
            	<TEXT>CHECK OUT THE LINK TO PLACE THE COVISTIX ORDERS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_87_1</DOCNO>
            	<TEXT>[https://staging.covistix.com/](https://staging.covistix.com/) Please login in and you can set up an account if your a Physician, CVS, PHARMACY, URGENT CARE, or healthcare provider.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_0</DOCNO>
            	<TEXT>Sorrento Mexico has established offices in Mexico City with Dr. Henry Ji as Chairman and Mr. Hctor Sulaimn S. as Chief Executive Officer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_1</DOCNO>
            	<TEXT>Who is Mr Hector Sulaiman S.?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_2</DOCNO>
            	<TEXT>Hctor Sulaimn is a successful Mexican businessman, son of Don Jos Sulaimn Chagnn (President of the World Boxing Council for 38 years).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_3</DOCNO>
            	<TEXT>Hctor has been recognized both in Mexico and abroad for his tireless fight for human dignity, who also heads Scholas Occurrentes in Mexico , a civil society organization that seeks to make the culture of encounter a reality, integrate educational communities focusing on those with fewer resources, to transform the world into a classroom without walls and complete education with a sports culture through programs such as BoxVal, KarateVal and FutVal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_4</DOCNO>
            	<TEXT>Hctor Sulaimn is the President of the Advisory Council of Scholas Occurrentes in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_5</DOCNO>
            	<TEXT>The Scholas Occurrentes is a non-profit organization founded by Pope Francis, it works with schools and educational communities, both public and private, secular and of all religious confessions to favor integration and promote peace among peoples through education and implement the culture of the meeting for peace.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_6</DOCNO>
            	<TEXT>Scholas has a presence in 190 countries and works with nearly 450,000 schools around the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_7</DOCNO>
            	<TEXT>Sorrento is now on the EUL List with WHO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_8</DOCNO>
            	<TEXT>My guess is Mr Hector Sulaiman who runs the Scholas Occurrentes in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_9</DOCNO>
            	<TEXT>Will most likely distribute COVI-STIX throughout all of the Mexican Schools.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_10</DOCNO>
            	<TEXT>Currently there's 96,000 schools in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_11</DOCNO>
            	<TEXT>25 Million COVI-STIX were approved to be sent to Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_12</DOCNO>
            	<TEXT>I would think with the schools opening in Mexico the orders are stacking up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_13</DOCNO>
            	<TEXT>We can see the COVISTIX.COM website is all set up for Physicians, Parmacy's to pre register to take orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_14</DOCNO>
            	<TEXT>I'm pretty sure the website that everyone went and tried to login in yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_15</DOCNO>
            	<TEXT>Works fine in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_16</DOCNO>
            	<TEXT>So in reality Sorrento has the WHO in one corner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_17</DOCNO>
            	<TEXT>The POPE in another corner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_18</DOCNO>
            	<TEXT>Let the SALES begin. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_88_19</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics) [https://elfaroluzyciencia.com/2021/07/03/despertares-derechos-humanos-a-c-propone-a-hector-sulaiman-como-candidato-a-la-medalla-anahuac-en-ciencias-del-deporte-2021/](https://elfaroluzyciencia.com/2021/07/03/despertares-derechos-humanos-a-c-propone-a-hector-sulaiman-como-candidato-a-la-medalla-anahuac-en-ciencias-del-deporte-2021/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_0</DOCNO>
            	<TEXT>Report: Hundreds of Mass. schools still waiting for states COVID test supplies</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_1</DOCNO>
            	<TEXT>State officials say increased demand for testing this school year is to blame for the delay. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_2</DOCNO>
            	<TEXT>https://www.boston.com/news/schools/2021/09/13/report-hundreds-of-mass-schools-still-waiting-for-states-covid-test-supplies/](https://www.boston.com/news/schools/2021/09/13/report-hundreds-of-mass-schools-still-waiting-for-states-covid-test-supplies/) Remember when they passed the big stimulus bill?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_3</DOCNO>
            	<TEXT>They set a side $50B to be used for new COVID-19 Testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_4</DOCNO>
            	<TEXT>What ever happened?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_5</DOCNO>
            	<TEXT>I believe our Govt was holding the FDA from approving any new tests on purpose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_6</DOCNO>
            	<TEXT>I believe they want people to vaccinate instead of being tested.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_7</DOCNO>
            	<TEXT>Joe Biden mentioned the other day that he's going to push for more tests.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_8</DOCNO>
            	<TEXT>Well Uncle Sam has a policy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_9</DOCNO>
            	<TEXT>If you don't use the MONEY you have to give it back.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_10</DOCNO>
            	<TEXT>The $50B was to be used to reopen our schools.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_11</DOCNO>
            	<TEXT>Everyone needs to pick up their phone and call your local Congressman's office.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_12</DOCNO>
            	<TEXT>Tell them to get off your a#@% and tell Joe Biden to tell the FDA TO APPROVE ALL THE EUA's.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_13</DOCNO>
            	<TEXT>Sorrento knows the pressure is building and the EUA or the FDA approval must happen before the money runs out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_14</DOCNO>
            	<TEXT>Somebody wants you to vaccinate instead of being tested.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_15</DOCNO>
            	<TEXT>Who's working the muppet?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_16</DOCNO>
            	<TEXT>Big Pharma?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_17</DOCNO>
            	<TEXT>Why do you think Sorrento went to Mexico?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_18</DOCNO>
            	<TEXT>To bypass the Bull @#%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_19</DOCNO>
            	<TEXT>Start working with Latin America, Brazil, Canada, UK, EU.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_20</DOCNO>
            	<TEXT>Make the call and tell your Congressmen to stand up and earn his money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_21</DOCNO>
            	<TEXT>Tell him how funny it is an American Company is getting approved throughout the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_22</DOCNO>
            	<TEXT>But not in it's own Country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_23</DOCNO>
            	<TEXT>Ask him why is that?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_24</DOCNO>
            	<TEXT>Who's getting paid off?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_25</DOCNO>
            	<TEXT>In Mexico Sorrento has been approved to ship and sell 25M COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_26</DOCNO>
            	<TEXT>Remember what DR Ji said?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_27</DOCNO>
            	<TEXT>Double digit million sales per month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_28</DOCNO>
            	<TEXT>The dam has been broken and the sales are flowing in throughout Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_29</DOCNO>
            	<TEXT>The website circulating around messages boards is being used in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_30</DOCNO>
            	<TEXT>Soon when they release the 3Q sales the needle will move the stock price much much higher.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_31</DOCNO>
            	<TEXT>Right now we're taking what we can get.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_89_32</DOCNO>
            	<TEXT>Have a great weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_0</DOCNO>
            	<TEXT>Dyadic Presents at H.C. Wainwright 23rd Annual Global Investment Conference.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_1</DOCNO>
            	<TEXT>September 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_2</DOCNO>
            	<TEXT>Please click and watch the presentation. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_3</DOCNO>
            	<TEXT>https://www.youtube.com/watch?v=UY8rvpquHm4](https://www.youtube.com/watch?v=UY8rvpquHm4) Sorrento is mentioned throughout the presentation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_4</DOCNO>
            	<TEXT>Please listen about.... Establishing Global Presence with Leading Organizations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_5</DOCNO>
            	<TEXT>5:00 minutes in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_6</DOCNO>
            	<TEXT>Dyadic Potential Global COVID Immunization Coverage Nearing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_7</DOCNO>
            	<TEXT>7:48 minutes in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_8</DOCNO>
            	<TEXT>Learn that Sorrento has an Immunization Coverage of ( 3.7 Billion people. )</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_9</DOCNO>
            	<TEXT>Strategic Objectives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_10</DOCNO>
            	<TEXT>17:30 minutes in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_11</DOCNO>
            	<TEXT>Key Takeaways 21:45 minutes in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_12</DOCNO>
            	<TEXT>Throughout this presentation you will hear how Dyadic will address Vaccine  amp; Drug Shortfalls Through Better Science.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_90_13</DOCNO>
            	<TEXT>After listening to this presentation I'm very comfortable in adding more to my Sorrento Therapeutics' position.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_0</DOCNO>
            	<TEXT>LOOKS LIKE SORRENTO RECEIVED THE EUA FOR COVISTIX?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_1</DOCNO>
            	<TEXT>Why did we receive a press release on a Sunday?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_2</DOCNO>
            	<TEXT>Because bigger and better news is coming out tomorrow morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_3</DOCNO>
            	<TEXT>Please view on the Sorrento website where is says FAQ.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_4</DOCNO>
            	<TEXT>Please click and read. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_5</DOCNO>
            	<TEXT>http://74.207.241.209/faq](http://74.207.241.209/faq) Click Is this FDA Approved or cleared?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_6</DOCNO>
            	<TEXT>This what it says.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_7</DOCNO>
            	<TEXT>This test is not yet approved or cleared by the United States Federal Drug Administration (FDA).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_8</DOCNO>
            	<TEXT>An Emergency Use Authorization (EUA) is issued by the FDA when certain criteria are met, which includes that there are no adequate, approved, or available alternatives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_9</DOCNO>
            	<TEXT>The EUA for this test is supported by the Secretary of Health and Human Services (HHSs) declaration that circumstances exist to justify the emergency use of in vitro diagnostics for the detection and/or diagnosis of the virus that causes COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_10</DOCNO>
            	<TEXT>This EUA will remain in effect (meaning this test can be used) for the duration of the COVID-19 declaration justifying the emergency of in vitro diagnostic tests, unless it is terminated or revoked by FDA (after which the test may no longer be used).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_11</DOCNO>
            	<TEXT>NOW PLEASE CLICK WHERE IT SAYS ABOUT US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_12</DOCNO>
            	<TEXT>Sorrento Therapeutics is dedicated to applying cutting edge science to create innovative therapies to improve the lives of patients who are suffering from cancer, intractable pain, and now COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_13</DOCNO>
            	<TEXT>We are a rapidly growing biopharmaceutical company who has leveraged our expertise of developing highly potent antibodies to test and develop our highly accurate device, COVISTIX COVISTIX is available under the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_14</DOCNO>
            	<TEXT>This test is authorized for use at the Point of Care (POC), or inpatient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_15</DOCNO>
            	<TEXT>Five million shares were traded late Friday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_16</DOCNO>
            	<TEXT>Because the cat is out of the bag.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_17</DOCNO>
            	<TEXT>Last week all the new websites started to appear showing how do can download the app.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_18</DOCNO>
            	<TEXT>Register your Physician's office, Pharmacy to purchase in bulk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_19</DOCNO>
            	<TEXT>We've been telling everyone for weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_20</DOCNO>
            	<TEXT>Why would they lease a brand new building and renew all of their leases long term?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_21</DOCNO>
            	<TEXT>Why would they double the size of their COMPANY IN 20 MONTHS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_22</DOCNO>
            	<TEXT>THE REVENUE IS GONNA START POURING IN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_23</DOCNO>
            	<TEXT>If your not fully in you better get in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_91_24</DOCNO>
            	<TEXT>Because the BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_0</DOCNO>
            	<TEXT>Lawmakers perplexed by billions in unspent Covid-19 testing money</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_1</DOCNO>
            	<TEXT>Last year it was reported that President Trump had not used BILLIONS of funds allocated for new testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_2</DOCNO>
            	<TEXT>He then approved an additional $25 Billion in April 2020 for new additional testing before leaving office.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_3</DOCNO>
            	<TEXT>In March of 2021 the next round of Stimulus had $50 Billion allocated for new testing and to help to reopen the schools.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_4</DOCNO>
            	<TEXT>I believe there's plenty of money left over.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_5</DOCNO>
            	<TEXT>The White House needs to step in and push the FDA to not give Sorrento the EUA but instead the FDA full approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_6</DOCNO>
            	<TEXT>We all need to stick together and call our local Congressman and tell them to do the right thing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_7</DOCNO>
            	<TEXT>As we can see... Out of the tree of life, I just picked me a plum You came along and everything started'in to hum Still it's a real good bet The best is yet to come Best is yet to come and babe, won't that be fine?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_8</DOCNO>
            	<TEXT>You think you've seen the sun But you ain't seen it shine A wait till the warm-up's underway Wait till our lips have met And wait till you see that sunshine day You ain't seen nothing yet The best is yet to come and babe, won't it be fine?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_9</DOCNO>
            	<TEXT>Best is yet to come, come the day you're mine Come the day you're mine I'm gonna teach you to fly We've only tasted the wine We're gonna drain the cup dry Wait till your charms are right, for these arms to surround You think you've flown before, but baby you ain't left the ground A wait till you're locked in my embrace Wait till I draw you near A wait till you see that sunshine place Ain't nothin' like it here The best is yet to come, and babe, won't it be fine?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_92_10</DOCNO>
            	<TEXT>The best is yet to come, come the day you're mine Come the day you're mine And you're gonna be mine [https://www.cnn.com/2020/07/21/politics/congress-coronavirus-testing-unspent-funds/index.html](https://www.cnn.com/2020/07/21/politics/congress-coronavirus-testing-unspent-funds/index.html) [https://www.abc10.com/article/news/verify/covid-relief-bill/507-1af72abc-696c-408c-afae-034b5692d10d](https://www.abc10.com/article/news/verify/covid-relief-bill/507-1af72abc-696c-408c-afae-034b5692d10d)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_0</DOCNO>
            	<TEXT>FOLLOW THE MONEY TO THE TOP INVESTOR TRADES</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_1</DOCNO>
            	<TEXT>Sussquuehanna International Group increased stakes by 698.21%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_2</DOCNO>
            	<TEXT>With a new market value of $11.74M. D.E. Shaw  amp; Co increased stakes by 357.97%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_3</DOCNO>
            	<TEXT>With a new market value of $17.54M. Georde Capital increased the stakes by 8,67% .</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_4</DOCNO>
            	<TEXT>With a new market value of $42.69M. JPM Morgan Chase increased stakes by 7.72%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_5</DOCNO>
            	<TEXT>With a new market value of $28.88M. Northern Trust holds $27.66M. Nuveen Holds $11.7M Charles Schwab Holds $16.77M Vanguard Holds 14.13M shares valued at $136.92 Million Dollars BlackRock Holds 19.12M shares valued at $185.25 Million Dollars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_6</DOCNO>
            	<TEXT>Looks like the big HFs did their DD and know what they own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_7</DOCNO>
            	<TEXT>Sorrento made the following moves pretty much at the same time to..... Go into agreement to lease an additional 163,000 SF Brand new building being built.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_8</DOCNO>
            	<TEXT>Which would bring the total to 663,000 SF of Research and cGMP Manufacturing Facilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_9</DOCNO>
            	<TEXT>Almost doubling their Current 700 Employees Worldwide 100 Employees with PHDs  amp; MDs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_10</DOCNO>
            	<TEXT>500,000 SF Research and cGMP Manufacturing Facilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_11</DOCNO>
            	<TEXT>Also renewed all their existing leases at their 4 other locations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_12</DOCNO>
            	<TEXT>If you follow the money it will bring you to the reason why everyone believes in Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_93_13</DOCNO>
            	<TEXT>My father always told me to forget what they told you, you want the truth, follow the money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_0</DOCNO>
            	<TEXT>FOLLOW THE MONEY TO THE TOP INVESTOR TRADES</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_1</DOCNO>
            	<TEXT>Sussquuehanna International Group increased stakes by 698.21%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_2</DOCNO>
            	<TEXT>With a new market value of $11.74M. D.E. Shaw  amp; Co increased stakes by 357.97%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_3</DOCNO>
            	<TEXT>With a new market value of $17.54M. Georde Capital increased the stakes by 8,67% .</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_4</DOCNO>
            	<TEXT>With a new market value of $42.69M. JPM Morgan Chase increased stakes by 7.72%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_5</DOCNO>
            	<TEXT>With a new market value of $28.88M. Northern Trust holds $27.66M. Nuveen Holds $11.7M Charles Schwab Holds $16.77M Vanguard Holds 14.13M shares valued at $136.92 Million Dollars BlackRock Holds 19.12M shares valued at $185.25 Million Dollars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_6</DOCNO>
            	<TEXT>Looks like the big HFs did their DD and know what they own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_7</DOCNO>
            	<TEXT>Sorrento made the following moves pretty much at the same time to..... Go into agreement to lease an additional 163,000 SF Brand new building being built.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_8</DOCNO>
            	<TEXT>Which would bring the total to 663,000 SF of Research and cGMP Manufacturing Facilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_9</DOCNO>
            	<TEXT>Almost doubling their Current 700 Employees Worldwide 100 Employees with PHDs  amp; MDs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_10</DOCNO>
            	<TEXT>500,000 SF Research and cGMP Manufacturing Facilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_11</DOCNO>
            	<TEXT>Also renewed all their existing leases at their 4 other locations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_12</DOCNO>
            	<TEXT>If you follow the money it will bring you to the reason why everyone believes in Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_94_13</DOCNO>
            	<TEXT>My father always told me to forget what they told you, you want the truth, follow the money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_0</DOCNO>
            	<TEXT>LOOKING BETTER AND BETTER FOR SORRENTO COVISTIX</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_1</DOCNO>
            	<TEXT>WHO and the Centers for Disease Control and Prevention (CDC) have three categories of COVID variants that make up their watch lists: variants of interest, variants of concernwhich include alpha, beta, delta and gammaand variants of high consequence.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_2</DOCNO>
            	<TEXT>The R.1 variant has a mutation that can lead to "increased resistance to antibodies," according to Forbes, which could make it better able to evade anti-bodies generated by the vaccine and those who have been infected by the virus already.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_3</DOCNO>
            	<TEXT>This mutation in the spike protein, called E484K, is present in the Beta, Gamma, Eta, Iota and Mu variants of COVID-19, the article said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_4</DOCNO>
            	<TEXT>R.1 contains the W152L mutation in the N-terminal domain, a region of the spike protein that is the target of neutralizing antibodies in convalescent sera and is the target of several neutralizing monoclonal antibodies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_5</DOCNO>
            	<TEXT>The W152L mutation is present in one of the minor variants of the Delta strain found in India.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_6</DOCNO>
            	<TEXT>The same amino acid is also mutant in several variants first detected in California, B.1427/429.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_7</DOCNO>
            	<TEXT>R.1 shared a common origin with all variants of interest or concern in that they are all marked with three mutations: one the 5' untranslated region: C241U, a second in the viral polymerase NSP12: P323L, and the third D614G in the exterior S1 domain of the spike protein.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_8</DOCNO>
            	<TEXT>The D614G mutation increases infectiousness, while it is not known what the other two mutations mean.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_9</DOCNO>
            	<TEXT>Coronaviruses with these three mutations quickly superseded the original Wuhan strain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_10</DOCNO>
            	<TEXT>Please follow me on r/BANDOFBROTHERSOFSRNE Freedom of speech without censorship.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_95_11</DOCNO>
            	<TEXT>Also please join for the party celebration details.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_0</DOCNO>
            	<TEXT>LOOKING BETTER AND BETTER FOR SORRENTO COVISTIX</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_1</DOCNO>
            	<TEXT># WHO and the Centers for Disease Control and Prevention (CDC) have three categories of COVID variants that make up their watch lists: variants of interest, variants of concernwhich include alpha, beta, delta and gammaand variants of high consequence.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_2</DOCNO>
            	<TEXT>The R.1 variant has a mutation that can lead to "increased resistance to antibodies," according to Forbes, which could make it better able to evade anti-bodies generated by the vaccine and those who have been infected by the virus already.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_3</DOCNO>
            	<TEXT>This mutation in the spike protein, called E484K, is present in the Beta, Gamma, Eta, Iota and Mu variants of COVID-19, the article said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_4</DOCNO>
            	<TEXT>R.1 contains the W152L mutation in the N-terminal domain, a region of the spike protein that is the target of neutralizing antibodies in convalescent sera and is the target of several neutralizing monoclonal antibodies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_5</DOCNO>
            	<TEXT>The W152L mutation is present in one of the minor variants of the Delta strain found in India.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_6</DOCNO>
            	<TEXT>The same amino acid is also mutant in several variants first detected in California, B.1427/429.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_7</DOCNO>
            	<TEXT>R.1 shared a common origin with all variants of interest or concern in that they are all marked with three mutations: one the 5' untranslated region: C241U, a second in the viral polymerase NSP12: P323L, and the third D614G in the exterior S1 domain of the spike protein.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_8</DOCNO>
            	<TEXT>The D614G mutation increases infectiousness, while it is not known what the other two mutations mean.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_96_9</DOCNO>
            	<TEXT>Coronaviruses with these three mutations quickly superseded the original Wuhan strain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_0</DOCNO>
            	<TEXT>Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_1</DOCNO>
            	<TEXT>Hmmm we have 7 trading days left in the 3Q.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_2</DOCNO>
            	<TEXT>Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_3</DOCNO>
            	<TEXT>Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_4</DOCNO>
            	<TEXT>Studies are complementary and address both dose duration and disease stage variations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_5</DOCNO>
            	<TEXT>Data from both studies is expected to be available for review by the end of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_6</DOCNO>
            	<TEXT>SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced completion of enrollment for its Phase 2 clinical trial of Abivertinib in hospitalized COVID-19 patients in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_7</DOCNO>
            	<TEXT>This study completion follows the recently completed enrollment of the US Phase 2 clinical trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_8</DOCNO>
            	<TEXT>The Brazil study is a Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 with cytokine storm, particularly looking at the potential clinical benefits of the drug associated with its broad ability (mode of action) to reduce the inflammatory cytokine storm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_9</DOCNO>
            	<TEXT>The dose that was tested was the same as in the US Phase 2 trial, but the trial protocol in Brazil includes patients at earlier stages of the disease, with a drug administration regimen of only 7 days (versus 14 days for more advanced patients in the US).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_10</DOCNO>
            	<TEXT>Closing enrollment for both studies is a significant milestone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_11</DOCNO>
            	<TEXT>In two to three months the company expects to be able to disclose top-line data.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_12</DOCNO>
            	<TEXT>If positive, the results of the two parallel and independently run clinical trials should provide valuable insights into the ability of Abivertinib to help patients with pulmonary distress associated with cytokine storm induced by COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_13</DOCNO>
            	<TEXT>We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_14</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_15</DOCNO>
            	<TEXT>PLEASE READ THIS STATEMENT AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_16</DOCNO>
            	<TEXT>We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_17</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_97_18</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_0</DOCNO>
            	<TEXT>Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_1</DOCNO>
            	<TEXT>Hmmm we have 7 trading days left in the 3Q.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_2</DOCNO>
            	<TEXT> Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_3</DOCNO>
            	<TEXT>Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_4</DOCNO>
            	<TEXT>Studies are complementary and address both dose duration and disease stage variations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_5</DOCNO>
            	<TEXT>Data from both studies is expected to be available for review by the end of 3Q21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_6</DOCNO>
            	<TEXT>SAN DIEGO, June 22, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced completion of enrollment for its Phase 2 clinical trial of Abivertinib in hospitalized COVID-19 patients in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_7</DOCNO>
            	<TEXT>This study completion follows the recently completed enrollment of the US Phase 2 clinical trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_8</DOCNO>
            	<TEXT>The Brazil study is a Phase 2, Randomized, Double-Blind, Placebo-controlled Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19 with cytokine storm, particularly looking at the potential clinical benefits of the drug associated with its broad ability (mode of action) to reduce the inflammatory cytokine storm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_9</DOCNO>
            	<TEXT>The dose that was tested was the same as in the US Phase 2 trial, but the trial protocol in Brazil includes patients at earlier stages of the disease, with a drug administration regimen of only 7 days (versus 14 days for more advanced patients in the US).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_10</DOCNO>
            	<TEXT>Closing enrollment for both studies is a significant milestone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_11</DOCNO>
            	<TEXT>In two to three months the company expects to be able to disclose top-line data.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_12</DOCNO>
            	<TEXT>If positive, the results of the two parallel and independently run clinical trials should provide valuable insights into the ability of Abivertinib to help patients with pulmonary distress associated with cytokine storm induced by COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_13</DOCNO>
            	<TEXT>We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_14</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_15</DOCNO>
            	<TEXT>PLEASE READ THIS STATEMENT AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_16</DOCNO>
            	<TEXT>We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_17</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_98_18</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have) Please join our r/BANDOFBROTHERSOFSRNE Freedom of speech without censorship.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrentos Portfolio of COVID-19 Products in Mexico and Parts of Latin America</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_1</DOCNO>
            	<TEXT>July 20, 2021 at 3:29 PM EDT Download PDF Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_2</DOCNO>
            	<TEXT>Sorrentos Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_3</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico will coordinate all activities required for commercialization of COVI-STIX, and for the clinical trials and registration of Sorrentos portfolio of products for the Mexican and potentially other Latin American Markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_4</DOCNO>
            	<TEXT>SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (Sorrento Mexico), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_5</DOCNO>
            	<TEXT>Sorrento Mexico has established offices in Mexico City with Dr. Henry Ji as Chairman and Mr. Hctor Sulaimn S. as Chief Executive Officer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_6</DOCNO>
            	<TEXT>Sorrentos distributor has received from COFEPRIS written permission to import the first 25 million test units (1,000,000 boxes of 25 tests/box) of COVI-STIX into the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_7</DOCNO>
            	<TEXT>These COVI-STIX professional use package contain a positive and a negative control test and all the components necessary for testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_8</DOCNO>
            	<TEXT>Sorrento is ramping up manufacturing to fulfil subsequent orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_9</DOCNO>
            	<TEXT>We are excited to form Sorrento Mexico to coordinate the development of our COVID-19 portfolio of products in the region, we anticipate expanding the programs to encompass Sorrentos full range of diagnostic and therapeutic products, said Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_10</DOCNO>
            	<TEXT>PLEASE READ THIS AGAIN Sorrentos distributor has received from COFEPRIS written permission to import the first 25 million test units (1,000,000 boxes of 25 tests/box) of COVI-STIX into the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_11</DOCNO>
            	<TEXT>These COVI-STIX professional use package contain a positive and a negative control test and all the components necessary for testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_12</DOCNO>
            	<TEXT>Sorrento is ramping up manufacturing to fulfil subsequent orders. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_99_13</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics) Please join our new REDDIT chat group r/BANDOFBROTHERSOFSRNE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrentos Portfolio of COVID-19 Products in Mexico and Parts of Latin America</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_1</DOCNO>
            	<TEXT> July 20, 2021 at 3:29 PM EDT Download PDF Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_2</DOCNO>
            	<TEXT>Sorrentos Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_3</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico will coordinate all activities required for commercialization of COVI-STIX, and for the clinical trials and registration of Sorrentos portfolio of products for the Mexican and potentially other Latin American Markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_4</DOCNO>
            	<TEXT>SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (Sorrento Mexico), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_5</DOCNO>
            	<TEXT>Sorrento Mexico has established offices in Mexico City with Dr. Henry Ji as Chairman and Mr. Hctor Sulaimn S. as Chief Executive Officer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_6</DOCNO>
            	<TEXT>Sorrentos distributor has received from COFEPRIS written permission to import the first 25 million test units (1,000,000 boxes of 25 tests/box) of COVI-STIX into the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_7</DOCNO>
            	<TEXT>These COVI-STIX professional use package contain a positive and a negative control test and all the components necessary for testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_8</DOCNO>
            	<TEXT>Sorrento is ramping up manufacturing to fulfil subsequent orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_9</DOCNO>
            	<TEXT>We are excited to form Sorrento Mexico to coordinate the development of our COVID-19 portfolio of products in the region, we anticipate expanding the programs to encompass Sorrentos full range of diagnostic and therapeutic products, said Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_10</DOCNO>
            	<TEXT>PLEASE READ THIS AGAIN Sorrentos distributor has received from COFEPRIS written permission to import the first 25 million test units (1,000,000 boxes of 25 tests/box) of COVI-STIX into the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_11</DOCNO>
            	<TEXT>These COVI-STIX professional use package contain a positive and a negative control test and all the components necessary for testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_12</DOCNO>
            	<TEXT>Sorrento is ramping up manufacturing to fulfil subsequent orders. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_100_13</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics) Please join our new REDDIT chat group [r/BANDOFBROTHERSOFSRNE](https://www.reddit.com/r/BANDOFBROTHERSOFSRNE/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_101_0</DOCNO>
            	<TEXT>Corticosteroid Lumbar Epidural Analgesia for Radiculopathy</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_101_1</DOCNO>
            	<TEXT>Clinical trial update September 22nd 2021. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_101_2</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT03372161?term=scilex+pharmaceutical amp;draw=2 amp;rank=2](https://clinicaltrials.gov/ct2/show/NCT03372161?term=scilex+pharmaceutical amp;draw=2 amp;rank=2)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_0</DOCNO>
            	<TEXT>Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_1</DOCNO>
            	<TEXT>PALM BEACH, Fla., Sept. 22, 2021 /PRNewswire/ -- The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the government's whole-of-government strategy to develop the next generation of COVID-19 treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_2</DOCNO>
            	<TEXT>Through collaboration within the U.S. Department of Health and Human Services (HHS), including the National Institutes of Health (NIH) and its National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), this plan called the Antiviral Program for Pandemics will respond to the urgent need for antivirals to treat COVID-19 by spurring the availability of medicines to prevent serious illness and save lives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_3</DOCNO>
            	<TEXT>It also will build sustainable platforms for discovery and development of antivirals for other viruses with pandemic potential, helping better prepare the nation to face future viral threats.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_4</DOCNO>
            	<TEXT>In a [recent report](https://www.hhs.gov/about/news/2021/06/17/biden-administration-invest-3-billion-american-rescue-plan-as-part-covid-19-antiviral-development-strategy.html), the HHS said that the government: " remains committed to identifying effective treatment options that can prevent people diagnosed with COVID-19 from progressing to serious illness and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_5</DOCNO>
            	<TEXT>Highly effective oral antiviral medicines that can be taken at home early in the course of infection, similar to antiviral treatment for influenza, would save lives both here and abroad and prevent overwhelming surges in hospitalizations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_6</DOCNO>
            	<TEXT>This plan will support research to identify and accelerate availability of breakthrough treatment options to ensure the public has access to viable medicines."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_7</DOCNO>
            	<TEXT>Active biotech and pharma companies in the markets this week include: **Q BioMed Inc.** (OTCQB: QBIO), **Corvus Pharmaceuticals, Inc.** (NASDAQ: CRVS), **Moderna, Inc.**(NASDAQ: MRNA), **Sorrento Therapeutics, Inc.**(NASDAQ: SRNE), **CytoDyn Inc.** (OTCQB: CYDY).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_8</DOCNO>
            	<TEXT>U.S. Department of Health and Human Services is saying "New antivirals that prevent serious COVID-19 illness and death, especially oral drugs that could be taken at home early in the course of disease, would be powerful tools for battling the pandemic and saving lives," said Dr. Anthony Fauci, chief medical adviser to the President and NIAID Director. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_9</DOCNO>
            	<TEXT>Through multidisciplinary collaborations among leading scientists in academia and industry, this investment from the American Rescue Plan to create the Antiviral Program for Pandemics will help inspire medical innovation and build on the extraordinary success we have seen in developing the COVID-19 vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_10</DOCNO>
            	<TEXT>The remarkable and rapid development of vaccines and testing technology has shown how agile scientific discovery can be when we combine the resources of public agencies, private entities, and our nation's most brilliant and creative minds," said Dr. Francis S. Collins, NIH Director. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_11</DOCNO>
            	<TEXT>We will leverage these same strengths as we construct a platform for the discovery and development of effective antivirals that will help us defeat COVID-19 and better prepare us for potential future viral pathogens." [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_102_12</DOCNO>
            	<TEXT>https://www.salamancapress.com/news/state/accelerated-development-of-covid-19-vaccines-to-combat-potential-for-possible-future-viral-pathogens-and/article\_b35ea2bc-b71d-5bd4-941d-9fe0667ef4c5.html](https://www.salamancapress.com/news/state/accelerated-development-of-covid-19-vaccines-to-combat-potential-for-possible-future-viral-pathogens-and/article_b35ea2bc-b71d-5bd4-941d-9fe0667ef4c5.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_0</DOCNO>
            	<TEXT>Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_1</DOCNO>
            	<TEXT> PALM BEACH, Fla., Sept. 22, 2021 /PRNewswire/ -- The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of the government's whole-of-government strategy to develop the next generation of COVID-19 treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_2</DOCNO>
            	<TEXT>Through collaboration within the U.S. Department of Health and Human Services (HHS), including the National Institutes of Health (NIH) and its National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), this plan called the Antiviral Program for Pandemics will respond to the urgent need for antivirals to treat COVID-19 by spurring the availability of medicines to prevent serious illness and save lives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_3</DOCNO>
            	<TEXT>It also will build sustainable platforms for discovery and development of antivirals for other viruses with pandemic potential, helping better prepare the nation to face future viral threats.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_4</DOCNO>
            	<TEXT>In a [recent report](https://www.hhs.gov/about/news/2021/06/17/biden-administration-invest-3-billion-american-rescue-plan-as-part-covid-19-antiviral-development-strategy.html), the HHS said that the government: " remains committed to identifying effective treatment options that can prevent people diagnosed with COVID-19 from progressing to serious illness and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_5</DOCNO>
            	<TEXT>Highly effective oral antiviral medicines that can be taken at home early in the course of infection, similar to antiviral treatment for influenza, would save lives both here and abroad and prevent overwhelming surges in hospitalizations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_6</DOCNO>
            	<TEXT>This plan will support research to identify and accelerate availability of breakthrough treatment options to ensure the public has access to viable medicines."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_7</DOCNO>
            	<TEXT>Active biotech and pharma companies in the markets this week include: **Q BioMed Inc.** (OTCQB: QBIO), **Corvus Pharmaceuticals, Inc.** (NASDAQ: CRVS), **Moderna, Inc.**(NASDAQ: MRNA), **Sorrento Therapeutics, Inc.**(NASDAQ: SRNE), **CytoDyn Inc.** (OTCQB: CYDY).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_8</DOCNO>
            	<TEXT>U.S. Department of Health and Human Services is saying "New antivirals that prevent serious COVID-19 illness and death, especially oral drugs that could be taken at home early in the course of disease, would be powerful tools for battling the pandemic and saving lives," said Dr. Anthony Fauci, chief medical adviser to the President and NIAID Director. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_9</DOCNO>
            	<TEXT>Through multidisciplinary collaborations among leading scientists in academia and industry, this investment from the American Rescue Plan to create the Antiviral Program for Pandemics will help inspire medical innovation and build on the extraordinary success we have seen in developing the COVID-19 vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_10</DOCNO>
            	<TEXT>The remarkable and rapid development of vaccines and testing technology has shown how agile scientific discovery can be when we combine the resources of public agencies, private entities, and our nation's most brilliant and creative minds," said Dr. Francis S. Collins, NIH Director. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_11</DOCNO>
            	<TEXT>We will leverage these same strengths as we construct a platform for the discovery and development of effective antivirals that will help us defeat COVID-19 and better prepare us for potential future viral pathogens." [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_103_12</DOCNO>
            	<TEXT>https://www.salamancapress.com/news/state/accelerated-development-of-covid-19-vaccines-to-combat-potential-for-possible-future-viral-pathogens-and/article\_b35ea2bc-b71d-5bd4-941d-9fe0667ef4c5.html](https://www.salamancapress.com/news/state/accelerated-development-of-covid-19-vaccines-to-combat-potential-for-possible-future-viral-pathogens-and/article_b35ea2bc-b71d-5bd4-941d-9fe0667ef4c5.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_104_0</DOCNO>
            	<TEXT>Construction Started on New $58.2M Life Science Building</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_104_1</DOCNO>
            	<TEXT>[https://www.sdbj.com/news/2021/sep/22/construction-started-new-582m-life-science-buildin/](https://www.sdbj.com/news/2021/sep/22/construction-started-new-582m-life-science-buildin/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_105_0</DOCNO>
            	<TEXT>Construction Started on New $58.2M Life Science Building</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_105_1</DOCNO>
            	<TEXT> [https://www.sdbj.com/news/2021/sep/22/construction-started-new-582m-life-science-buildin/](https://www.sdbj.com/news/2021/sep/22/construction-started-new-582m-life-science-buildin/) If you wish to follow me please join my r/BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_0</DOCNO>
            	<TEXT>Support exploration of novel device technologies with potential to deliver therapeutic benefits for patients (e.g. nasal, pulmonary delivery).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_1</DOCNO>
            	<TEXT>Could this be COVI-DROPS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_2</DOCNO>
            	<TEXT>Senior Device Engineer, Sorrento Devices and Diagnostics WHAT YOULL DO: Purpose of Role: Lead technical design and development efforts for Sorrentos emerging Diagnostics portfolio while building Sorrento capabilities for follow-on Diagnostics and Connected Health.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_3</DOCNO>
            	<TEXT>Essential Duties and Responsibilities Work closely with the business unit in San Diego to understand and support diagnostic design/development/delivery objectives to support clinical trials, regulatory submissions, emergency use authorization (EUA), and supply chain scale up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_4</DOCNO>
            	<TEXT>Ensure the product design is informed by relevant commercial end user considerations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_5</DOCNO>
            	<TEXT>Identify, select, and manage design development partners.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_6</DOCNO>
            	<TEXT>Manage all external vendors, agencies, and supply chain partners development objectives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_7</DOCNO>
            	<TEXT>Lead and manage design development agency relationship.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_8</DOCNO>
            	<TEXT>Own the design control process and DHF.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_9</DOCNO>
            	<TEXT>Ensure exceptional documentation processes across partners to drive exceptional design, meet domestic and international regulatory submission requirements, and transition successfully to commercial manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_10</DOCNO>
            	<TEXT>Build a phased product development roadmap that initially meets needs for rapid regulatory approval and EUA by the end of 2020, while building the vision for a large-scale commercial life cycle plan with connected health capabilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_11</DOCNO>
            	<TEXT>Become familiar with the relevant IP and competitive landscape.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_12</DOCNO>
            	<TEXT>Help to author new IP.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_13</DOCNO>
            	<TEXT>Provide technical program leadership with internal and external stakeholders to define, track, and report key deliverables to timelines and budget.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_14</DOCNO>
            	<TEXT>Write DOEs and design verification report summaries, sections of regulatory filings, and author abstracts and scientific publications in support of key deliverables.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_15</DOCNO>
            	<TEXT>Support and participate in internal and external audits (e.g. FDA).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_16</DOCNO>
            	<TEXT>Support exploration of novel device technologies with potential to deliver therapeutic benefits for patients (e.g. nasal, pulmonary delivery) Monitor the device competitive landscape and translate relevant threats and opportunities to the CTO and Program Leader. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_106_17</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=292](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=292)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_107_0</DOCNO>
            	<TEXT>Traveling to the US is safe and easy The COVID-19 antigen test is the easiest, fastest*, and most accessible testing option.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_107_1</DOCNO>
            	<TEXT>You can get it at the airport on the day of your flight for $25 USD or less.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_107_2</DOCNO>
            	<TEXT>[https://cms.volaris.com/en/travel-info/covid-19-testing-for-passengers/](https://cms.volaris.com/en/travel-info/covid-19-testing-for-passengers/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_0</DOCNO>
            	<TEXT>Popular COVID treatment in short supply, affecting local clinics</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_1</DOCNO>
            	<TEXT>Doctors have praised the effectiveness of monoclonal antibody therapy in treating COVID-19 patients who are dealing with symptoms, but theres a nationwide shortage of the antibodies and its already affecting local clinics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_2</DOCNO>
            	<TEXT>Ive heard a lot of people real worried, all parts of the country, about their supplies, said Dr. Chrisitian Ramers, an infectious disease specialist with Family Health Centers of San Diego.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_3</DOCNO>
            	<TEXT>Monoclonal therapy involves infusions for those with COVID who are symptomatic and at high-risk for severe illness.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_4</DOCNO>
            	<TEXT>If treated within the first ten days of symptoms, doctors say it reduces the risk of hospitalization by 75 to 85 percent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_5</DOCNO>
            	<TEXT>Family Health Centers is one of several providers [set up through the county](https://www.sandiegocounty.gov/content/sdc/hhsa/programs/phs/community_epidemiology/dc/2019-nCoV/CommunitySectors/Healthcare_Providers_Community_Clinics_Hospitals_and_Pharmacies/MARC.html) to treat patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_6</DOCNO>
            	<TEXT>Dr. Ramers says demand t went up over the summer, with cases spiking and the delta variant spreading.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_7</DOCNO>
            	<TEXT>The word has essentially gotten out and the demand is much greater than it ever used to be, he told FOX 5 Thursday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_8</DOCNO>
            	<TEXT>More than half the U.S. supply has been going to several southern states with lower vaccination rates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_9</DOCNO>
            	<TEXT>Now the government is telling health care providers to focus on those most at-risk especially those not vaccinated and over 65 years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_10</DOCNO>
            	<TEXT>Earlier this week, Ramers said his clinic was down to just a weeks supply, but then got some good news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_11</DOCNO>
            	<TEXT>Were going to get another two full weeks to replenish our supplies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_12</DOCNO>
            	<TEXT>Things are looking good so far, Ramers said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_13</DOCNO>
            	<TEXT>But it is concerning the supplies are dwindling and were sort of struggling to keep up. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_108_14</DOCNO>
            	<TEXT>https://fox5sandiego.com/news/coronavirus/popular-covid-treatment-in-short-supply-affecting-local-clinics/](https://fox5sandiego.com/news/coronavirus/popular-covid-treatment-in-short-supply-affecting-local-clinics/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_0</DOCNO>
            	<TEXT>Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_1</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator ( WHO )</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_2</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_3</DOCNO>
            	<TEXT>Launched at the end of April 2020, at an event co-hosted by the Director-General of the World Health Organization, the President of France, the President of the European Commission, and the Bill  amp; Melinda Gates Foundation, the Access to COVID-19 Tools (ACT) Accelerator brings together governments, scientists, businesses, civil society, and philanthropists and global health organizations (the Bill  amp; Melinda Gates Foundation, CEPI, FIND, Gavi, The Global Fund, Unitaid, Wellcome, the WHO, and the World Bank).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_4</DOCNO>
            	<TEXT>Following the ACT-Accelerator launch, UNICEF and PAHO became delivery partners for COVAX, the vaccines pillar.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_5</DOCNO>
            	<TEXT>These organizations have joined forces to speed up an end to the pandemic by supporting the development and equitable distribution of the tests, treatments and vaccines the world needs to reduce mortality and severe disease, restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_6</DOCNO>
            	<TEXT>There is no time to waste in the fight against COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_7</DOCNO>
            	<TEXT>No-one is safe until everyone is safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_8</DOCNO>
            	<TEXT>This is a unique partnership of many of the world's international health organizations who have come together to share, and build on, individual expertise to create a powerful global solution that will ensure equity in access to tests, vaccines, treatments across the world with one goal: to reduce the burden of the COVID-19 pandemic by addressing the cause.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_9</DOCNO>
            	<TEXT>.[https://www.who.int/initiatives/act-accelerator](https://www.who.int/initiatives/act-accelerator) Why Experts Believe Antibody Treatments Hold The Potential To Reduce Need For Hospitalization For COVID-19 Patients Sorrento Therapeutics, Inc. (NASDAQ: SRNE) recently announced the start of enrollment in its Phase 2 efficacy study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_10</DOCNO>
            	<TEXT>This study (MSC-COV-202BR) is a multi-arm, randomized, placebo-controlled Phase 2 study of the efficacy and safety of three infusions of COVI-MSC administered on varying schedules in the setting of standard of care treatments for COVID-19 in 100 subjects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_11</DOCNO>
            	<TEXT>The primary objective of this study is to evaluate the efficacy of COVI-MSCs in patients with COVID-19-induced ARD or ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_12</DOCNO>
            	<TEXT>Additionally, Sorrento will soon begin enrollment for two additional Phase 2 studies with COVI-MSC: A parallel Phase 2 placebo-controlled Phase 2 safety study to be conducted across multiple sites in the United States; and A pulmonary long-hauler Phase 2 safety and efficacy study across multiple sites in Brazil. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_109_13</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/why-experts-believe-antibody-treatments-hold-the-potential-to-reduce-need-for-hospitalization-for-covid-19-patients-2021-09-14-81973430?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/why-experts-believe-antibody-treatments-hold-the-potential-to-reduce-need-for-hospitalization-for-covid-19-patients-2021-09-14-81973430?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_0</DOCNO>
            	<TEXT>Texas A amp;M Researcher: New Drug Could Be Game Changer Against COVID-19</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_1</DOCNO>
            	<TEXT>A drug created by a Texas A amp;M University professor could be the most effective treatment yet of patients with COVID-19, including the aggressive variants of the virus such as Delta and others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_2</DOCNO>
            	<TEXT>The drug compound, called MPI8, has stopped the replication of the virus in laboratory tests.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_3</DOCNO>
            	<TEXT>It was created by a Texas A amp;M research team led by biological chemist [Wenshe Ray Liu](https://www.chem.tamu.edu/rgroup/liu/), a 2018 Texas A amp;M Presidential Impact Fellow and holder of the Gradipore Chair in the Department of Chemistry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_4</DOCNO>
            	<TEXT>The potential effectiveness of MPI8 led [Sorrento Therapeutics](https://sorrentotherapeutics.com/) of San Diego, Calif., to seek exclusive intellectual property rights to the ingredient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_5</DOCNO>
            	<TEXT>An agreement between the company and The Texas A amp;M University System was announced Tuesday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_6</DOCNO>
            	<TEXT>Liu said that Sorrento hopes to complete pre-clinical studies of MPI8 by the end of the year and seek FDA approval to begin clinical trials on humans in early 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_7</DOCNO>
            	<TEXT>MPI8 could be the best weapon yet in the fight against the COVID-19 virus, Liu said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_8</DOCNO>
            	<TEXT>If it can be approved clinically, this will be a game changer, he said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_9</DOCNO>
            	<TEXT>Only one treatment, a drug called remdesivir, has been approved by the FDA and studies indicate it may provide only modest benefit to patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_10</DOCNO>
            	<TEXT>A few other treatments have FDAs emergency use authorization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_11</DOCNO>
            	<TEXT>A wide range of potential treatments are in early stages of research, including several others being pursued by Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_12</DOCNO>
            	<TEXT>In January 2020, Liu was among the co-authors of the first paper to identify [remdesivir](https://today.tamu.edu/2020/04/20/texas-am-chemist-cautiously-optimistic-regarding-remdesivir-clinical-trial-results/) as a viable treatment for SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_13</DOCNO>
            	<TEXT>Liu said MPI8 shows the potential to be highly effective in treating not only the original COVID-19 viral strain, but also the more aggressive strains such as Delta, Alpha, Beta and Gamma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_14</DOCNO>
            	<TEXT>The Delta variant was firstidentifiedin India in December of 2020.In just a few months, it spread to 98 countries around the world, becoming the dominant variant in numerous nations, including India, the U.K.,Israeland the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_15</DOCNO>
            	<TEXT>Delta is now responsible for almost 85 percent of the COVID-19 cases being reportedin the U.S., according to the [Centers for Disease Control and Prevention (CDC).](https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-variant.html) Henry Ji, chairman and CEO of Sorrento, said the new findings by Liu and his team might turn out to be critical in the fight against COVID-19 and other diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_110_16</DOCNO>
            	<TEXT>We are excited to be collaborating with Dr. Liu and his team at Texas A amp;M and look forward to advancing the development of these novel drug candidates to address COVID-19 and a multitude of other respiratory viruses, Ji said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_0</DOCNO>
            	<TEXT>Kills tumor cells while preserving healthy cells</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_1</DOCNO>
            	<TEXT># Our Science ***ACEA leverages its drug discovery platform, unique expertise in real-time cell analysis, and a 1 million+ compound library to evaluate and identify compounds with best-in-class potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_2</DOCNO>
            	<TEXT>Our unique drug discovery platform of small and large molecules has generated multiple novels and proprietary new chemical entities currently at preclinical and clinical stage development for the treatment of cancer and autoimmune diseases.*** ##</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_3</DOCNO>
            	<TEXT>Cancer Research: In recent years, our understanding of diseases has been transformed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_4</DOCNO>
            	<TEXT>For example, tumors sharing the same origin are now known to comprise an array of diseases with varying molecular fingerprints which result in different disease characteristics and responsiveness to treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_5</DOCNO>
            	<TEXT>Together with technology advances, targeted therapy is a new generation of precision medicine meeting individual patients need.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_6</DOCNO>
            	<TEXT>Embracing precision medicine, ACEA leverages its drug discovery platform, unique expertise in real-time cell analysis, a 1 million+ compound library, and computer aided design to identify drug candidates with best-in-class potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_7</DOCNO>
            	<TEXT>Multiple novel and proprietary new chemical entities currently at preclinical and clinical stage development for the treatment of cancer and autoimmune diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_8</DOCNO>
            	<TEXT>For more information on our on-going pre-clinical and clinical programs, please visit our [pipeline](https://www.aceatherapeutics.com/pipeline/). ##</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_9</DOCNO>
            	<TEXT>Autoimmune Disease Research: The cause of most autoimmune diseases remains unknown.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_10</DOCNO>
            	<TEXT>Several external and environmental factors such as a persons gene, infections, and other environmental factors may play a role in disease development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_11</DOCNO>
            	<TEXT>ACEA research focuses on identifying treatments that can block or suppress genes known to cause autoimmune diseases. ##</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_12</DOCNO>
            	<TEXT>Small Molecule Antiviral Research (COVID-19): COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_13</DOCNO>
            	<TEXT>It is a contagious and potentially fatal respiratory disease which poses a serious threat to global public health.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_14</DOCNO>
            	<TEXT>ACEA research focuses on identification and development of small heterocyclic molecules which are orally available for the treatment of virus infection diseases, especially COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_111_15</DOCNO>
            	<TEXT>For more information on our on-going pre-clinical and clinical programs, please visit our [pipeline](https://aceathera.wpengine.com/pipeline/).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_0</DOCNO>
            	<TEXT>Quality  amp; Compliance</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_1</DOCNO>
            	<TEXT>Bioservs integrated approach to quality through our one Quality System and strategic quality plan, together with our culture of continuous improvement ensures compliance with the ever changing regulatory requirements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_2</DOCNO>
            	<TEXT>Our objective is to ensure total transparency of our quality processes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_3</DOCNO>
            	<TEXT>Bioserv welcomes the opportunity to discuss the Quality System during on site customer audits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_4</DOCNO>
            	<TEXT>Bioserv is currently registered with the United States Food and Drug Administration (U.S. FDA) for both Pharmaceutical and Medical Device manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_5</DOCNO>
            	<TEXT>The FDA Drug Center has inspected the facility for routine inspections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_6</DOCNO>
            	<TEXT>The FDA Device Centers have performed inspections of the facility for routine inspections and for pre and post market approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_7</DOCNO>
            	<TEXT>Bioserv is currently licensed by the State of California for Pharmaceutical and Medical Device manufacturing, and for interstate commerce.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_8</DOCNO>
            	<TEXT>Bioserv is also ISO ISO 13485:2016 Certified (FM 77429).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_9</DOCNO>
            	<TEXT>Although the scope of Bioservs ISO Certification is limited to Medical Devices at this time, Bioserv is one (1) Quality System that is suitable for both Medical Devices and Pharmaceutical production.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_10</DOCNO>
            	<TEXT>The Company also produces sterile products compliant for use in the EU. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_11</DOCNO>
            	<TEXT>https://www.bioservamerica.com/quality-compliance/](https://www.bioservamerica.com/quality-compliance/) PLEASE READ THIS PART AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_112_12</DOCNO>
            	<TEXT>Bioserv is currently licensed by the State of California for Pharmaceutical and Medical Device manufacturing, and for interstate commerce.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_0</DOCNO>
            	<TEXT>EMERGENCY USE LISTING</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_1</DOCNO>
            	<TEXT>The WHO Emergency Use Listing Procedure (EUL) is a risk-based procedure for assessing and listing unlicensed vaccines, therapeutics and in vitro diagnostics with the ultimate aim of expediting the availability of these products to people affected by a public health emergency.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_2</DOCNO>
            	<TEXT>This will assist interested UN procurement agencies and Member States in determining the acceptability of using specific products, based on an essential set of available quality, safety, and efficacy and performance data.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_3</DOCNO>
            	<TEXT>Diagnostics laboratory emergency use listing [https://www.who.int/teams/regulation-prequalification/eul](https://www.who.int/teams/regulation-prequalification/eul) Please view today's press release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_4</DOCNO>
            	<TEXT>Please read the 1st Highlight Sorrento will address.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_5</DOCNO>
            	<TEXT>COVISTIX: COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_6</DOCNO>
            	<TEXT>Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_113_7</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-hc-wainwright](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-hc-wainwright)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_0</DOCNO>
            	<TEXT>Pharmaceutical Firm Takes Another Large Office Space in San Diegos Growing Biotech Market</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_1</DOCNO>
            	<TEXT>Besides leasing a brand new 163,000 square foot new Lab/office building.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_2</DOCNO>
            	<TEXT>Sorrento is leasing another building!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_3</DOCNO>
            	<TEXT>So ask yourselves why would they want to lease another building?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_4</DOCNO>
            	<TEXT>They keep on adding and adding and leasing and leasing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_5</DOCNO>
            	<TEXT>The revenue has to be pouring in with COVISTIX in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_6</DOCNO>
            	<TEXT>Great news is going to come out of Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_7</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_8</DOCNO>
            	<TEXT>Sorrento Therapeutics Leases Full Building in High-Demand University Town Center. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_114_9</DOCNO>
            	<TEXT>https://www.costar.com/article/712004477/pharmaceutical-firm-takes-another-large-office-space-in-san-diego%E2%80%99s-growing-biotech-market](https://www.costar.com/article/712004477/pharmaceutical-firm-takes-another-large-office-space-in-san-diego%E2%80%99s-growing-biotech-market)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_115_0</DOCNO>
            	<TEXT>COVISTIX MARKETING</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_115_1</DOCNO>
            	<TEXT>[https://vimeo.com/611941531](https://vimeo.com/611941531)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_116_0</DOCNO>
            	<TEXT>SIGN UP TO LISTEN TO THE CONFERENCE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_116_1</DOCNO>
            	<TEXT>[https://www.benzinga.com/events/small-cap/healthcare/register-now/?utm\_source=reddit amp;utm\_medium=social amp;utm\_campaign=guerrilla](https://www.benzinga.com/events/small-cap/healthcare/register-now/?utm_source=reddit amp;utm_medium=social amp;utm_campaign=guerrilla)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_117_0</DOCNO>
            	<TEXT>DOUBLE HEADER SIGN UP TO LISTEN TO THE CONFERENCE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_117_1</DOCNO>
            	<TEXT>[https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-virtual-cantor](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-virtual-cantor)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_118_0</DOCNO>
            	<TEXT>TIAA -CREF SMALL CAP PURCHASE 426,862 SHARES VALUED $3.5M NEW BUY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_118_1</DOCNO>
            	<TEXT>[https://fintel.io/i/tiaa-cref-funds-tiaa-cref-small-cap-blend-index-fund-institutional-class](https://fintel.io/i/tiaa-cref-funds-tiaa-cref-small-cap-blend-index-fund-institutional-class)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_119_0</DOCNO>
            	<TEXT>ANP Technologies, Inc. Receives FDA EUA Authorization for its NIDS COVID-19 Antigen Rapid Test Kit</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_119_1</DOCNO>
            	<TEXT>[https://www.businesswire.com/news/home/20210927005803/en/ANP-Technologies-Inc.-Receives-FDA-EUA-Authorization-for-its-NIDS%C2%AE-COVID-19-Antigen-Rapid-Test-Kit](https://www.businesswire.com/news/home/20210927005803/en/ANP-Technologies-Inc.-Receives-FDA-EUA-Authorization-for-its-NIDS%C2%AE-COVID-19-Antigen-Rapid-Test-Kit) I'm going to call Greg tomorrow and see if he can clarify a few things.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_120_0</DOCNO>
            	<TEXT>VOLUNTARY ANNOUNCEMENT UPDATE ON THE RESEARCH AND DEVELOPMENT OF AN INVESTIGATIONAL ONCOLOGY PRODUCT</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_120_1</DOCNO>
            	<TEXT>[https://www.leespharm.com/wp-content/uploads/2021/09/2021092701471.pdf](https://www.leespharm.com/wp-content/uploads/2021/09/2021092701471.pdf)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_0</DOCNO>
            	<TEXT>Sorrento Mexico has established offices in Mexico City with Dr. Henry Ji as Chairman and Mr. Hctor Sulaimn S. as Chief Executive Officer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_1</DOCNO>
            	<TEXT>Who is Mr Hector Sulaiman S.?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_2</DOCNO>
            	<TEXT>Hctor Sulaimn is a successful Mexican businessman, son of Don Jos Sulaimn Chagnn (President of the World Boxing Council for 38 years).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_3</DOCNO>
            	<TEXT>Hctor has been recognized both in Mexico and abroad for his tireless fight for human dignity, who also heads Scholas Occurrentes in Mexico , a civil society organization that seeks to make the culture of encounter a reality, integrate educational communities focusing on those with fewer resources, to transform the world into a classroom without walls and complete education with a sports culture through programs such as BoxVal, KarateVal and FutVal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_4</DOCNO>
            	<TEXT>Hctor Sulaimn is the President of the Advisory Council of Scholas Occurrentes in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_5</DOCNO>
            	<TEXT>The Scholas Occurrentes is a non-profit organization founded by Pope Francis, it works with schools and educational communities, both public and private, secular and of all religious confessions to favor integration and promote peace among peoples through education and implement the culture of the meeting for peace.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_6</DOCNO>
            	<TEXT>Scholas has a presence in 190 countries and works with nearly 450,000 schools around the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_7</DOCNO>
            	<TEXT>Sorrento is now on the EUL List with WHO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_8</DOCNO>
            	<TEXT>My guess is Mr Hector Sulaiman who runs the Scholas Occurrentes in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_9</DOCNO>
            	<TEXT>Will most likely distribute COVI-STIX throughout all of the Mexican Schools.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_10</DOCNO>
            	<TEXT>Currently there's 96,000 schools in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_11</DOCNO>
            	<TEXT>25 Million COVI-STIX were approved to be sent to Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_12</DOCNO>
            	<TEXT>I would think with the schools opening in Mexico the orders are stacking up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_13</DOCNO>
            	<TEXT>We can see the COVISTIX.COM website is all set up for Physicians, Pharmacy's to pre register to take orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_14</DOCNO>
            	<TEXT>I'm pretty sure the website that everyone went and tried to login that's under construction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_15</DOCNO>
            	<TEXT>Works just fine in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_16</DOCNO>
            	<TEXT>So in reality Sorrento has the WHO in one corner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_17</DOCNO>
            	<TEXT>The POPE in another corner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_121_18</DOCNO>
            	<TEXT>Let the SALES begin.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_0</DOCNO>
            	<TEXT>Clinical Data Expected End of 3Q21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_1</DOCNO>
            	<TEXT>Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_2</DOCNO>
            	<TEXT>The key is with Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_3</DOCNO>
            	<TEXT>Please click and watch the video. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_4</DOCNO>
            	<TEXT>https://www.synovahealth.com/](https://www.synovahealth.com/) Every time I watch this video I buy more shares of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_5</DOCNO>
            	<TEXT>At the same time Sorrento needs a partner in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_6</DOCNO>
            	<TEXT>I'm expecting that they will partner with one of these Mammoth Brazilian Companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_7</DOCNO>
            	<TEXT>Top 5 Brazilian Pharma Companies Ache.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_8</DOCNO>
            	<TEXT>With USD 996.5 million in annual sales, Ache is the largest Brazilian pharma company in the domestic market. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_9</DOCNO>
            	<TEXT>EMS Pharma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_10</DOCNO>
            	<TEXT>The second biggest Brazilian pharma player is EMS Pharma, with USD 849.1 million in annual sales. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_11</DOCNO>
            	<TEXT>Eurofarma. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_12</DOCNO>
            	<TEXT>Neo Qumica. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_13</DOCNO>
            	<TEXT>Mantecorp Farmasa.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_14</DOCNO>
            	<TEXT>We have 4 trading days to report the results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_15</DOCNO>
            	<TEXT>They can come any day now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_16</DOCNO>
            	<TEXT>Or they could be a little late.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_17</DOCNO>
            	<TEXT>All I know is there getting ready to report.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_18</DOCNO>
            	<TEXT>Would you go out and lease another 52,000 SQ FT of space if the results were bad?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_19</DOCNO>
            	<TEXT>I wouldn't.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_20</DOCNO>
            	<TEXT>Know what you own and the results will only be the beginning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_122_21</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_0</DOCNO>
            	<TEXT>Careers at Sorrento Therapeutics, Inc</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_1</DOCNO>
            	<TEXT>Currently Sorrento Therapeutics is seeking 84 new positions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_2</DOCNO>
            	<TEXT>Well they leased a brand new 163,000 SQ FT building being built as we speak.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_3</DOCNO>
            	<TEXT>They just leased another 52,000 SQ FT move in ready office building a few blocks away from there corporate headquarters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_4</DOCNO>
            	<TEXT>These positions will fill these building up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_5</DOCNO>
            	<TEXT>What will they do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_6</DOCNO>
            	<TEXT>They will most likely take care of...[https://sorrentotherapeutics.com/research/pipeline/](https://sorrentotherapeutics.com/research/pipeline/) You wouldn't build it or lease it if you didn't believe in it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_7</DOCNO>
            	<TEXT>I believe now do you believe?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_123_8</DOCNO>
            	<TEXT>The best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_124_0</DOCNO>
            	<TEXT>Why Some Experts Say for an Effective COVID Vaccine, Look Beyond Antibodies to T-Cells</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_124_1</DOCNO>
            	<TEXT>[https://www.marketwatch.com/press-release/why-some-experts-say-for-an-effective-covid-vaccine-look-beyond-antibodies-to-t-cells-2021-09-28-81973254?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/why-some-experts-say-for-an-effective-covid-vaccine-look-beyond-antibodies-to-t-cells-2021-09-28-81973254?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_0</DOCNO>
            	<TEXT>Transdermal delivery of high viscosity bioactive agents Ross September 28, 2021 * NEW PATENT!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_1</DOCNO>
            	<TEXT>U.S. patent number 11,129,975 \[Application Number 16/244,914\] was granted by the patent office on 2021-09-28 for *transdermal delivery of high viscosity bioactive agents*.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_2</DOCNO>
            	<TEXT>This patent grant is currently assigned to SORRENTO THERAPEUTICS, INC.. The grantee listed for this patent is SORRENTO THERAPEUTICS, INC.. Invention is credited to Russell F. Ross.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_3</DOCNO>
            	<TEXT>A device and method for delivering a high viscosity composition is described.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_4</DOCNO>
            	<TEXT>The composition includes a bioactive agent for delivery to a subject in need thereof.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_5</DOCNO>
            	<TEXT>The method delivers the bioactive agent at a high bioavailability and with little loss of agent to the natural defense mechanisms of the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_6</DOCNO>
            	<TEXT>The device includes one or more microneedles with structures fabricated on a surface of the microneedles to form a nanotopography.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_7</DOCNO>
            	<TEXT>A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_125_8</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,129,975](https://uspto.report/patent/grant/11,129,975)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_126_0</DOCNO>
            	<TEXT>NEW PATENT TODAY https://uspto.report/patent/grant/11,129,975</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_126_1</DOCNO>
            	<TEXT>If you want up to date news, DD please follow me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_126_2</DOCNO>
            	<TEXT>If you haven't heard where I've been posting please PM me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_126_3</DOCNO>
            	<TEXT>It's all good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_127_0</DOCNO>
            	<TEXT>NEW PATENT TODAY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_127_1</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,129,975</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_0</DOCNO>
            	<TEXT>LET'S GET READY TO RUMBLE!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_1</DOCNO>
            	<TEXT>We have weighing at the largest antibody Library in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_2</DOCNO>
            	<TEXT>10-0 with patients walking out of the hospital after the third dose on COVI-MSC.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_3</DOCNO>
            	<TEXT>The World's largest COVI-19 library in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_4</DOCNO>
            	<TEXT>Partnered with the Mayo Clinic, Mt Sanai, Texas A  amp; M University, DARPA, NAVY, DoD, and the rest of DON's list.... Introducing DOCTOR JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_5</DOCNO>
            	<TEXT>In the other corner we have a virus that has killed over 4,776,293 people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_6</DOCNO>
            	<TEXT>Cost the World over $1 Trillion dollars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_7</DOCNO>
            	<TEXT>Infected over 233,437,668 million people World wide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_8</DOCNO>
            	<TEXT>Please join us tomorrow to listen to DR JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_9</DOCNO>
            	<TEXT>I've never been so proud of anyone in my life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_10</DOCNO>
            	<TEXT>This man has fought his entire life to get to this point.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_11</DOCNO>
            	<TEXT>Imagine being in his corner?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_12</DOCNO>
            	<TEXT>Everything that he's endured.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_13</DOCNO>
            	<TEXT>He told us from day 1 back in May of 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_14</DOCNO>
            	<TEXT>We have a prized fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_15</DOCNO>
            	<TEXT>It's a very strong fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_16</DOCNO>
            	<TEXT>Now were going to add other fighters to make him stronger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_17</DOCNO>
            	<TEXT>Today we received the patent for a new delivery for... A device and method for delivering a high viscosity composition is described.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_18</DOCNO>
            	<TEXT>The composition includes a bioactive agent for delivery to a subject in need thereof.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_19</DOCNO>
            	<TEXT>The method delivers the bioactive agent at a high bioavailability and with little loss of agent to the natural defense mechanisms of the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_20</DOCNO>
            	<TEXT>The device includes one or more microneedles with structures fabricated on a surface of the microneedles to form a nanotopography.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_21</DOCNO>
            	<TEXT>A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_22</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,129,975](https://uspto.report/patent/grant/11,129,975) Can he be used With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_23</DOCNO>
            	<TEXT>We shall see... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-reports-promising-results-mrna-vaccine-covid-19](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-reports-promising-results-mrna-vaccine-covid-19) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-virtual-cantor](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-virtual-cantor) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/correction-sorrento-therapeutics-inc](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/correction-sorrento-therapeutics-inc) To watch the fight ring side please sign up and listen in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_24</DOCNO>
            	<TEXT>I'm expecting DR JI to go the distance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_25</DOCNO>
            	<TEXT>Will there be a knock out?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_26</DOCNO>
            	<TEXT>Probably not but I'm expecting DR JI to give everyone a complete update on everything.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_27</DOCNO>
            	<TEXT>Why would DR JI want to repeat himself twice tomorrow?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_28</DOCNO>
            	<TEXT>Attend two conferences instead of just one?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_29</DOCNO>
            	<TEXT>Wouldn't the second be just as great as the first?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_30</DOCNO>
            	<TEXT>Or would he just want to repeat the great news TWICE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_31</DOCNO>
            	<TEXT>THE BEST FIGHTER TO FIGHT COVID-19 is... DR JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_32</DOCNO>
            	<TEXT>Thank you see tomorrow. @</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_128_33</DOCNO>
            	<TEXT>r/BANDOFBROTHERSOFSRNE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_0</DOCNO>
            	<TEXT>LET'S GET READY TO RUMBLE!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_1</DOCNO>
            	<TEXT>We have weighing at the largest antibody Library in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_2</DOCNO>
            	<TEXT>10-0 with patients walking out of the hospital after the third dose on COVI-MSC.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_3</DOCNO>
            	<TEXT>The World's largest COVI-19 library in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_4</DOCNO>
            	<TEXT>Partnered with the Mayo Clinic, Mt Sanai, Texas A  amp; M University, DARPA, NAVY, DoD, and the rest of DON's list.... Introducing DOCTOR JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_5</DOCNO>
            	<TEXT>In the other corner we have a virus that has killed over 4,776,293 people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_6</DOCNO>
            	<TEXT>Cost the World over $1 Trillion dollars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_7</DOCNO>
            	<TEXT>Infected over 233,437,668 million people World wide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_8</DOCNO>
            	<TEXT>Please join us tomorrow to listen to DR JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_9</DOCNO>
            	<TEXT>I've never been so proud of anyone in my life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_10</DOCNO>
            	<TEXT>This man has fought his entire life to get to this point.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_11</DOCNO>
            	<TEXT>Imagine being in his corner?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_12</DOCNO>
            	<TEXT>Everything that he's endured.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_13</DOCNO>
            	<TEXT>He told us from day 1 back in May of 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_14</DOCNO>
            	<TEXT>We have a prized fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_15</DOCNO>
            	<TEXT>It's a very strong fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_16</DOCNO>
            	<TEXT>Now were going to add other fighters to make him stronger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_17</DOCNO>
            	<TEXT>Today we received the patent for a new delivery for... A device and method for delivering a high viscosity composition is described.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_18</DOCNO>
            	<TEXT>The composition includes a bioactive agent for delivery to a subject in need thereof.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_19</DOCNO>
            	<TEXT>The method delivers the bioactive agent at a high bioavailability and with little loss of agent to the natural defense mechanisms of the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_20</DOCNO>
            	<TEXT>The device includes one or more microneedles with structures fabricated on a surface of the microneedles to form a nanotopography.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_21</DOCNO>
            	<TEXT>A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_22</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,129,975](https://uspto.report/patent/grant/11,129,975) Can he be used With mRNA Vaccine For COVID-19 Delivered With The MuVaxx Lymphatic Drug Delivery Device?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_23</DOCNO>
            	<TEXT>We shall see... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-reports-promising-results-mrna-vaccine-covid-19](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-reports-promising-results-mrna-vaccine-covid-19) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-virtual-cantor](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-sorrento-chairman-and-ceo-participate-virtual-cantor) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/correction-sorrento-therapeutics-inc](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/correction-sorrento-therapeutics-inc) To watch the fight ring side please sign up and listen in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_24</DOCNO>
            	<TEXT>I'm expecting DR JI to go the distance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_25</DOCNO>
            	<TEXT>Will there be a knock out?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_26</DOCNO>
            	<TEXT>Probably not but I'm expecting DR JI to give everyone a complete update on everything.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_27</DOCNO>
            	<TEXT>Why would DR JI want to repeat himself twice tomorrow?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_28</DOCNO>
            	<TEXT>Attend two conferences instead of just one?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_29</DOCNO>
            	<TEXT>Wouldn't the second be just as great as the first?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_30</DOCNO>
            	<TEXT>Or would he just want to repeat the great news TWICE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_31</DOCNO>
            	<TEXT>THE BEST FIGHTER TO FIGHT COVID-19 is... DR JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_32</DOCNO>
            	<TEXT>Thank you see tomorrow. @ [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_129_33</DOCNO>
            	<TEXT>r/BANDOFBROTHERSOFSRNE](https://www.reddit.com/r/BANDOFBROTHERSOFSRNE/)  amp; r/SRNE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_130_0</DOCNO>
            	<TEXT>Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors NEW CLINICAL TRIAL ADDED TODAY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_130_1</DOCNO>
            	<TEXT>This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_130_2</DOCNO>
            	<TEXT>This is a Phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors including ovarian, breast, lung, esophageal, gastric, hepatocellular and urothelial cancers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_130_3</DOCNO>
            	<TEXT>The study will determine any dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), assessing safety and preliminary efficacy using ascending dose cohorts and a conventional 3+3 study design. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_130_4</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT05060276?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8](https://clinicaltrials.gov/ct2/show/NCT05060276?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_131_0</DOCNO>
            	<TEXT>Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors NEW CLINICAL TRIAL ADDED TODAY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_131_1</DOCNO>
            	<TEXT> This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_131_2</DOCNO>
            	<TEXT>This is a Phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors including ovarian, breast, lung, esophageal, gastric, hepatocellular and urothelial cancers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_131_3</DOCNO>
            	<TEXT>The study will determine any dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), assessing safety and preliminary efficacy using ascending dose cohorts and a conventional 3+3 study design. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_131_4</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT05060276?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8](https://clinicaltrials.gov/ct2/show/NCT05060276?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8) For more breaking news and DD please follow me on r/BANDOFBROTHERSOFSRNE  amp; r/SRNE</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_132_0</DOCNO>
            	<TEXT>MEXICOS TOP FREE TRADE AGREEMENTS AND THEIR IMPACT</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_132_1</DOCNO>
            	<TEXT>What is a Free Trade Agreement?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_132_2</DOCNO>
            	<TEXT>A free trade agreement (FTA) is an arrangement involving two or more countries to reduce import and export trade barriers between the parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_132_3</DOCNO>
            	<TEXT>Agreements may include loosening or eliminating tariffs on goods and services transported across regional lines, and they may consist of environmental and social stipulations based on such products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_132_4</DOCNO>
            	<TEXT>Free trade agreements can be unilateral, bilateral, or multilateral, and most countries hold more than one. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_132_5</DOCNO>
            	<TEXT>https://insights.tetakawi.com/top-free-trade-agreements-with-mexico](https://insights.tetakawi.com/top-free-trade-agreements-with-mexico) Mexico has a treaty with 70 other countries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_132_6</DOCNO>
            	<TEXT>Mexico could be used as a pay toll in delivering COVISTIX thought-out the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_133_0</DOCNO>
            	<TEXT>MEXICOS TOP FREE TRADE AGREEMENTS AND THEIR IMPACT</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_133_1</DOCNO>
            	<TEXT>What is a Free Trade Agreement?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_133_2</DOCNO>
            	<TEXT>A free trade agreement (FTA) is an arrangement involving two or more countries to reduce import and export trade barriers between the parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_133_3</DOCNO>
            	<TEXT>Agreements may include loosening or eliminating tariffs on goods and services transported across regional lines, and they may consist of environmental and social stipulations based on such products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_133_4</DOCNO>
            	<TEXT>Free trade agreements can be unilateral, bilateral, or multilateral, and most countries hold more than one. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_133_5</DOCNO>
            	<TEXT>https://insights.tetakawi.com/top-free-trade-agreements-with-mexico](https://insights.tetakawi.com/top-free-trade-agreements-with-mexico) Mexico has a treaty with 70 other countries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_133_6</DOCNO>
            	<TEXT>Mexico could be used as a pay toll in delivering COVISTIX thought-out the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_0</DOCNO>
            	<TEXT>Posted byu/mvaditya91 EVERYONE PLEASE READ!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_1</DOCNO>
            	<TEXT># My DD on the CANTOR conference.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_2</DOCNO>
            	<TEXT>Couldn't be more proud to be part of SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_3</DOCNO>
            	<TEXT>Hoping Covi-Stix revenue picks up pace.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_4</DOCNO>
            	<TEXT>Other than that I am happy with my investment for now and long term.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_5</DOCNO>
            	<TEXT>Overall view point: From early next year, we must see Sorrento becoming a big player not only in Covid but also auto-immune, non-opioid pain and cancer drugs step-by-step.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_6</DOCNO>
            	<TEXT>Company Update: 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_7</DOCNO>
            	<TEXT>Employee Count increased to 800 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_8</DOCNO>
            	<TEXT>All CGMP manufacturing in-house Cancer: 3) Abivertinib - Completed Phase-3 in non small cell lung Cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_9</DOCNO>
            	<TEXT>Completed Phase-1, Phase-2 for B-Cell Lymphoma Entering Phase-2 for Prostrate Cancer Doing IND filings at thins moment 4) PDL-1 - Naked Anti Body NDA submission in China - For Solid Tumor In Phase-3 for small cell Lung Cancer Applying for BLA license in USA Joint venture with Korean company for in Phase-2 for multiple solid tumors 5) CD38 DAR-T: Of fthe shelf for multiple myloma for reflectory and remission type of cases 6) CD39 ADC: Patient being dosed for multiple myloma 7) CD47 mAb: In Phase-1 better than other company molecules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_10</DOCNO>
            	<TEXT>Potential partnership with Big Pharma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_11</DOCNO>
            	<TEXT>8) Trop 2 ADC: Filed Phase-1 in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_12</DOCNO>
            	<TEXT>Own worldwide rights except China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_13</DOCNO>
            	<TEXT>Filed IND waiting for FDA clearence.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_14</DOCNO>
            	<TEXT>Auto Immune: 9) Best in-class 3rd generation BTK inhibitors better than any existing solutions purchased for Billions of $ by Big Pharma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_15</DOCNO>
            	<TEXT>10) Abivertinib autoimmune pill will be a game changer in treating Lupus and other Auto immune diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_16</DOCNO>
            	<TEXT>Non-Opioid Pain Management: 11) ZTildo - FDA approved Drug.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_17</DOCNO>
            	<TEXT>Seen decent growth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_18</DOCNO>
            	<TEXT>Coverage increased by more than 33 million people recently (if I am not wrong).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_19</DOCNO>
            	<TEXT>12)SP-102: This is for Lower-Back pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_20</DOCNO>
            	<TEXT>Removing need for Epidural Injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_21</DOCNO>
            	<TEXT>Eliminates use of off-label steroids which provide few hours of relief.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_22</DOCNO>
            	<TEXT>SP-102 provides relief between 35 to 70 days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_23</DOCNO>
            	<TEXT>FDA Fast Track Status, approval expected by mid 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_24</DOCNO>
            	<TEXT>Have whole infrastructure ready for some of this big product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_25</DOCNO>
            	<TEXT>A very big opportunity for the big molecule.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_26</DOCNO>
            	<TEXT>Completed 400 patient clinical trial enrollment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_27</DOCNO>
            	<TEXT>Top line data will be available.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_28</DOCNO>
            	<TEXT>In Phase-2 the results were very safe and top of the line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_29</DOCNO>
            	<TEXT>13) SP 103 - Lower Back pain drug 60 billion $ opportunity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_30</DOCNO>
            	<TEXT>In Phase-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_31</DOCNO>
            	<TEXT>14) RTX - Phase-2 Osteo Arthritis pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_32</DOCNO>
            	<TEXT>Waiting for FDA approval for Phase-2 for end stage cancer (Orphan Drug Designation) 15) SP 104 - Designed to Migraine treatment also for Long Hauler Covid-19 syndrome.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_33</DOCNO>
            	<TEXT>Covid-19: Strategy: To cover before infection i.e., Prevention till treating critical patients in ICU.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_34</DOCNO>
            	<TEXT>Biggest Covid-19 pipeline created in less than 1.5 year (FYI it generally takes 4 years or more for this to happen).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_35</DOCNO>
            	<TEXT>6) Covi-Stix (Diasgnostic Antigen test): i) EUA from Mexico and cleared for commercialization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_36</DOCNO>
            	<TEXT>ii) In commercial launching stage right now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_37</DOCNO>
            	<TEXT>iii) 1 million kits already selling in Mexico, commercial activity will be increasing very sharply.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_38</DOCNO>
            	<TEXT>iv) Working with public and private entities to provide "Double Digit" millions more test kits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_39</DOCNO>
            	<TEXT>v) Better test than current approved Abbott tests and far more accurate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_40</DOCNO>
            	<TEXT>vi) EUA approval expected soon from US FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_41</DOCNO>
            	<TEXT>vii) EUA submitted in Canada too waiting for approval soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_42</DOCNO>
            	<TEXT>viii) Waiting for approvals in different countries ix) Orders already lined up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_43</DOCNO>
            	<TEXT>Going to be a huge revenue source.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_44</DOCNO>
            	<TEXT>x) Expanding to other countries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_45</DOCNO>
            	<TEXT>17) CoviDrops (Intranasal Treatment): i) Intranasal neutralizing Antibody in outpatients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_46</DOCNO>
            	<TEXT>Phase-2 trials ii) Nasal drops through the nose inhibited into lungs prevent replication of the virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_47</DOCNO>
            	<TEXT>iii) Regeneron and other anti-bodies require large doses because they use Inter- Veinous infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_48</DOCNO>
            	<TEXT>It makes it difficult to get into the Lung space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_49</DOCNO>
            	<TEXT>Which is why they need to infise large quantity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_50</DOCNO>
            	<TEXT>When done in a hospital leads to un-availability of seats to other infected patients, which we are currently seeing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_51</DOCNO>
            	<TEXT>iv) \*\*\*\*In discussions with various governors to do massive clinical trials using Covi- Stix for testing and then Covi-Drops for treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_52</DOCNO>
            	<TEXT>v) Uses 50 times less quantity than Regenron.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_53</DOCNO>
            	<TEXT>Hence can generate 50 times more quantity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_54</DOCNO>
            	<TEXT>vi) Potential path to EUA for Stix and Drops.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_55</DOCNO>
            	<TEXT>vii) 18) Covi-Amg (IV treatment): i) IV treatment - Neutralizing antibody in outpatients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_56</DOCNO>
            	<TEXT>Phase-II trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_57</DOCNO>
            	<TEXT>ii) NOTE: IF I AM NOT WRONG.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_58</DOCNO>
            	<TEXT>These are capsules which could be used just like the flu medicine like Advil, Tylenol etc.,</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_59</DOCNO>
            	<TEXT>iii) Huge Market opportunity iv) Will apply for EUA early next year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_60</DOCNO>
            	<TEXT>19) Covishield (treatment): i) Neutralizing Antibody through IV and IN for outpatients and inpatients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_61</DOCNO>
            	<TEXT>Pre-clinical.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_62</DOCNO>
            	<TEXT>20) ABIVERTINIB (treatment): i) Severe or Critical Covid-19 ICU patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_63</DOCNO>
            	<TEXT>ii) Waiting for BTK inhibitor data.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_64</DOCNO>
            	<TEXT>Goal to test Abivertinib a strong "ORAL PILL" taken once a day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_65</DOCNO>
            	<TEXT>Tested on 96 patients in USA and 400 patients in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_66</DOCNO>
            	<TEXT>trails done, data locked.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_67</DOCNO>
            	<TEXT>iii) Figuring out which category of severity in Covid does this drug work best.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_68</DOCNO>
            	<TEXT>Focused on Category-5  amp; other severe categories.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_69</DOCNO>
            	<TEXT>21) Mesenchymal Stem Cells: i) For patients who have lost all hope of treatment for Covid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_70</DOCNO>
            	<TEXT>The Mesenchymal Stem cells when tried on 10 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_71</DOCNO>
            	<TEXT>Helped all of them recover completely.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_72</DOCNO>
            	<TEXT>22) COVI-MSC (treatment): i) ARDS due to Covid-19 in ICU patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_73</DOCNO>
            	<TEXT>23) MPI8 (treatment): i) Antiviral treatment - Preclinical 24) Salicyn-30 (treatment): i) Antiviral treatment - Preclinical 25) Multi-valent RBD (Vaccine): i) Vaccine - Preclinical ii) Protein based Multivalent vaccine iii) Stored and moved at room temparature 26) Mult-valent mRNA (Vaccine): i) Vaccine - Preclinical: Next Generation mRNA vaccine better than Moderna  amp; PFizer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_74</DOCNO>
            	<TEXT>ii) Current mRNA by Pfizer  amp; Moderna even with Booster shots are not able to solve Covid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_75</DOCNO>
            	<TEXT>iii) Stored and moved at room temparature.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_134_76</DOCNO>
            	<TEXT>iv) Ready to use by 1st half of 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_0</DOCNO>
            	<TEXT>My deepest regrets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_1</DOCNO>
            	<TEXT>It's my deepest of regrets that I announce a very long time friend of mine has passed away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_2</DOCNO>
            	<TEXT>My friend Chick Galella was a Battallon Sergeant Major as well as a Pearl Harbor survivor and a bronze star recipient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_3</DOCNO>
            	<TEXT>He was 19 when he enlisted in the Navy and served at Pearl Harbor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_4</DOCNO>
            	<TEXT>He was one of the brave sailors that day that was at air field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_5</DOCNO>
            	<TEXT>He and his buddies ran to the ammo locker and broke the lock to the locker to grab the guns.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_6</DOCNO>
            	<TEXT>He defended our country with valor and honor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_7</DOCNO>
            	<TEXT>I'm so deeply grateful for his service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_8</DOCNO>
            	<TEXT>In his honor please place your flags at half staff.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_9</DOCNO>
            	<TEXT>If you hear in the news of a Pearl Harbor Survivor passing away who lived in Sleepy Hollow NY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_10</DOCNO>
            	<TEXT>That's Chick.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_11</DOCNO>
            	<TEXT>He was 100 years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_12</DOCNO>
            	<TEXT>He served from 1941 to 1945 and served during the battle of the pacific.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_13</DOCNO>
            	<TEXT>He fought many battles and spear headed many beaches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_14</DOCNO>
            	<TEXT>I'm heart is broken tonight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_15</DOCNO>
            	<TEXT>I know that he's in a better place with his buddies from Pearl.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_16</DOCNO>
            	<TEXT>I'm posting tonight to all of you as if your my family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_17</DOCNO>
            	<TEXT>Please lower your flags.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_18</DOCNO>
            	<TEXT>May God Bless him and all the rest of the service members through all the armed forces.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_19</DOCNO>
            	<TEXT>Without them we wouldn't have a Country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_20</DOCNO>
            	<TEXT>We wouldn't be posting on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_135_21</DOCNO>
            	<TEXT>Good night and Thank you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_0</DOCNO>
            	<TEXT>My deepest regrets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_1</DOCNO>
            	<TEXT>It's my deepest of regrets that I announce a very long time friend of mine has passed away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_2</DOCNO>
            	<TEXT>My friend Chick Galella was a Battallon Sergeant Major as well as a Pearl Harbor survivor and a bronze star recipient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_3</DOCNO>
            	<TEXT>He was 19 when he enlisted in the Navy and served at Pearl Harbor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_4</DOCNO>
            	<TEXT>He was one of the brave sailors that day that was at air field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_5</DOCNO>
            	<TEXT>He and his buddies ran to the ammo locker and broke the lock to the locker to grab the guns.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_6</DOCNO>
            	<TEXT>He defended our country with valor and honor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_7</DOCNO>
            	<TEXT>I'm so deeply grateful for his service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_8</DOCNO>
            	<TEXT>In his honor please place your flags at half staff.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_9</DOCNO>
            	<TEXT>If you hear in the news of a Pearl Harbor Survivor passing away who lived in Sleepy Hollow NY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_10</DOCNO>
            	<TEXT>That's Chick.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_11</DOCNO>
            	<TEXT>He was 100 years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_12</DOCNO>
            	<TEXT>He served from 1941 to 1945 and served during the battle of the pacific.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_13</DOCNO>
            	<TEXT>He fought many battles and spear headed many beaches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_14</DOCNO>
            	<TEXT>I'm heart is broken tonight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_15</DOCNO>
            	<TEXT>I know that he's in a better place with his buddies from Pearl.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_16</DOCNO>
            	<TEXT>Chick passed away from COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_17</DOCNO>
            	<TEXT>I'm posting tonight to all of you as if your my family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_18</DOCNO>
            	<TEXT>Please lower your flags.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_19</DOCNO>
            	<TEXT>May God Bless him and all the rest of the service members through all the armed forces.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_20</DOCNO>
            	<TEXT>Without them we wouldn't have a Country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_21</DOCNO>
            	<TEXT>We wouldn't be posting on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_136_22</DOCNO>
            	<TEXT>Good night and Thank you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_0</DOCNO>
            	<TEXT>Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK) UPDATED OCTOBER 1st 2021 https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_1</DOCNO>
            	<TEXT>Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK) UPDATED OCTOBER 1st 2021 [https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4](https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4) The results of this Phase 2 trial in the UK will be combined with the results of the US and Mexico Phase 2 trials and should the results of these studies demonstrate that COVI-DROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, India, UK, Mexico and European Union as well as other territories.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_2</DOCNO>
            	<TEXT>What did DR JI SAY?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_3</DOCNO>
            	<TEXT>They're currently speaking with Governors and States to conduct multiple trials to treat 50,000 people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_4</DOCNO>
            	<TEXT>I believe he's preparing for PHASE 3 for the EUA? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_5</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-authorization-uk-regulatory-agency-conduct](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-authorization-uk-regulatory-agency-conduct) COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in this large Phase 2 efficacy trial in the United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_6</DOCNO>
            	<TEXT>COVIDROPS neutralizing antibody is administered by intranasal instillation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_7</DOCNO>
            	<TEXT>COVIDROPS is highly active against the original SARS-CoV-2 virus, as well as the India/Delta and UK/Alpha variants currently prevalent in the UK and US. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_8</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical) We should have reached the goal to have treated 350 patients in the UK by now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_137_9</DOCNO>
            	<TEXT>I'm hoping we receive DROP RELEASE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_0</DOCNO>
            	<TEXT>Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK) UPDATED OCTOBER 1st 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_1</DOCNO>
            	<TEXT>The results of this Phase 2 trial in the UK will be combined with the results of the US and Mexico Phase 2 trials and should the results of these studies demonstrate that COVI-DROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, India, UK, Mexico and European Union as well as other territories.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_2</DOCNO>
            	<TEXT>What did DR JI SAY?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_3</DOCNO>
            	<TEXT>They're currently speaking with Governors and States to conduct multiple trials to treat 50,000 people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_4</DOCNO>
            	<TEXT>I believe he's preparing for PHASE 3 for the EUA? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_5</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-authorization-uk-regulatory-agency-conduct](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-authorization-uk-regulatory-agency-conduct) COVID-19 patients with newly diagnosed SARS-CoV-2 infections were treated in this large Phase 2 efficacy trial in the United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_6</DOCNO>
            	<TEXT>COVIDROPS neutralizing antibody is administered by intranasal instillation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_7</DOCNO>
            	<TEXT>COVIDROPS is highly active against the original SARS-CoV-2 virus, as well as the India/Delta and UK/Alpha variants currently prevalent in the UK and US. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_8</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical) We should have reached the goal to have treated 350 patients in the UK by now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_138_9</DOCNO>
            	<TEXT>I'm hoping we receive DROP PRESS RELEASE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_0</DOCNO>
            	<TEXT>Timing is everything in life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_1</DOCNO>
            	<TEXT>Timing is everything in life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_2</DOCNO>
            	<TEXT>Getting up and getting ready for work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_3</DOCNO>
            	<TEXT>Finding that special person you're going to spend the rest of your life with.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_4</DOCNO>
            	<TEXT>Preparing to build a family and a new home.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_5</DOCNO>
            	<TEXT>Investing and saving for College or even your retirement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_6</DOCNO>
            	<TEXT>Timing is everything in life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_7</DOCNO>
            	<TEXT>If you're late for work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_8</DOCNO>
            	<TEXT>You can be fired.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_9</DOCNO>
            	<TEXT>If you don't find that special person.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_10</DOCNO>
            	<TEXT>You maybe alone for the rest of your life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_11</DOCNO>
            	<TEXT>If you're late investing for College or retirement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_12</DOCNO>
            	<TEXT>You will struggle looking to find the funds later in life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_13</DOCNO>
            	<TEXT>Sorrento is a long term stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_14</DOCNO>
            	<TEXT>It's not a Casino.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_15</DOCNO>
            	<TEXT>If you're here to walk in and walk out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_16</DOCNO>
            	<TEXT>It's not happening just yet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_17</DOCNO>
            	<TEXT>But if your patient and smart and leave your money alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_18</DOCNO>
            	<TEXT>In due time you you will realized you timed it just right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_19</DOCNO>
            	<TEXT>No one likes to see the stock drop.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_20</DOCNO>
            	<TEXT>But it did and it is what it is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_21</DOCNO>
            	<TEXT>Will it go right back up?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_22</DOCNO>
            	<TEXT>Yes it will.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_23</DOCNO>
            	<TEXT>I'm leaving right now to go Salmon fishing for a few days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_24</DOCNO>
            	<TEXT>I have to drop a fly into a roaring river in front of a moving Salmon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_25</DOCNO>
            	<TEXT>I have to perfectly drop the fly right in front of his face.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_26</DOCNO>
            	<TEXT>He has to be hungry to want to eat that fly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_27</DOCNO>
            	<TEXT>Hundreds of casts an hour.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_28</DOCNO>
            	<TEXT>Will he eat the fly?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_29</DOCNO>
            	<TEXT>Eventually he will and I will be able to bring home my Salmon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_30</DOCNO>
            	<TEXT>Ladies and Gentlemen it's time to purchase SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_31</DOCNO>
            	<TEXT>The fly is right in front of your face.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_32</DOCNO>
            	<TEXT>If you want it you need to grab it and run with it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_33</DOCNO>
            	<TEXT>You may never have another chance again at these prices.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_34</DOCNO>
            	<TEXT>The timing is right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_35</DOCNO>
            	<TEXT>Don't cry or whine about it dropping.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_36</DOCNO>
            	<TEXT>Be patient and wait and you will be rewarded.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_139_37</DOCNO>
            	<TEXT>Time is on our side.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_0</DOCNO>
            	<TEXT>Timing is everything in life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_1</DOCNO>
            	<TEXT>Getting up and getting ready for work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_2</DOCNO>
            	<TEXT>Finding that special person you're going to spend the rest of your life with.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_3</DOCNO>
            	<TEXT>Preparing to build a family and a new home.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_4</DOCNO>
            	<TEXT>Investing and saving for College or even your retirement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_5</DOCNO>
            	<TEXT>Timing is everything in life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_6</DOCNO>
            	<TEXT>If you're late for work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_7</DOCNO>
            	<TEXT>You can be fired.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_8</DOCNO>
            	<TEXT>If you don't find that special person.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_9</DOCNO>
            	<TEXT>You maybe alone for the rest of your life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_10</DOCNO>
            	<TEXT>If you're late investing for College or retirement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_11</DOCNO>
            	<TEXT>You will struggle looking to find the funds later in life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_12</DOCNO>
            	<TEXT>Sorrento is a long term stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_13</DOCNO>
            	<TEXT>It's not a Casino.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_14</DOCNO>
            	<TEXT>If you're here to walk in and walk out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_15</DOCNO>
            	<TEXT>It's not happening just yet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_16</DOCNO>
            	<TEXT>But if your patient and smart and leave your money alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_17</DOCNO>
            	<TEXT>In due time you you will realized you timed it just right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_18</DOCNO>
            	<TEXT>No one likes to see the stock drop.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_19</DOCNO>
            	<TEXT>But it did and it is what it is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_20</DOCNO>
            	<TEXT>Will it go right back up?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_21</DOCNO>
            	<TEXT>Yes it will.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_22</DOCNO>
            	<TEXT>I'm leaving right now to go Salmon fishing for a few days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_23</DOCNO>
            	<TEXT>I have to drop a fly into a roaring river in front of a moving Salmon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_24</DOCNO>
            	<TEXT>I have to perfectly drop the fly right in front of his face.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_25</DOCNO>
            	<TEXT>He has to be hungry to want to eat that fly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_26</DOCNO>
            	<TEXT>Hundreds of casts an hour.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_27</DOCNO>
            	<TEXT>Will he eat the fly?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_28</DOCNO>
            	<TEXT>Eventually he will and I will be able to bring home my Salmon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_29</DOCNO>
            	<TEXT>Ladies and Gentlemen it's time to purchase SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_30</DOCNO>
            	<TEXT>The fly is right in front of your face.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_31</DOCNO>
            	<TEXT>If you want it you need to grab it and run with it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_32</DOCNO>
            	<TEXT>You may never have another chance again at these prices.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_33</DOCNO>
            	<TEXT>The timing is right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_34</DOCNO>
            	<TEXT>Don't cry or whine about it dropping.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_35</DOCNO>
            	<TEXT>Be patient and wait and you will be rewarded.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_140_36</DOCNO>
            	<TEXT>Time is on our side.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_0</DOCNO>
            	<TEXT>PLEASE RAISE YOUR AMERICAN FLAGS AT FULL STAFF TODAY AT 12PM NOON</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_1</DOCNO>
            	<TEXT>Last week a good family friend Armando "Chick" Galella a 100 year old Pearl Harbor survivor had passed away of complications of COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_2</DOCNO>
            	<TEXT>Out of respect to him Veterans, family, and friends across the entire United States had lowered their flags at half staff.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_3</DOCNO>
            	<TEXT>I would like to say Thank you to the National Park Service and the United States Navy in Hawaii.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_4</DOCNO>
            	<TEXT>For lowering their flags in honor of Chick.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_5</DOCNO>
            	<TEXT>Many other veterans across the United States in Tenn., California, Florida, and New York for doing the same.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_6</DOCNO>
            	<TEXT>We shall never forget.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_7</DOCNO>
            	<TEXT>Today at 11:30am Click will be laid to rest with full military honors with a 21 gun salute.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_8</DOCNO>
            	<TEXT>Please remember to Thank all service members through out all the US Armed Forces and Police officers, Firemen for their service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_9</DOCNO>
            	<TEXT>Without them no one will keep us safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_10</DOCNO>
            	<TEXT>May God Bless you all.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_141_11</DOCNO>
            	<TEXT>Thank you ROBERT S. [https://www.legacy.com/news/celebrity-deaths/armando-chick-galella-1921-2021-pearl-harbor-survivor/](https://www.legacy.com/news/celebrity-deaths/armando-chick-galella-1921-2021-pearl-harbor-survivor/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_0</DOCNO>
            	<TEXT>PLEASE RAISE YOUR AMERICAN FLAGS AT FULL STAFF TODAY AT 12PM NOON</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_1</DOCNO>
            	<TEXT># Last week a good family friend Armando "Chick" Galella a 100 year old Pearl Harbor survivor had passed away of complications of COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_2</DOCNO>
            	<TEXT>Out of respect to him Veterans, family, and friends across the entire United States had lowered their flags at half staff.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_3</DOCNO>
            	<TEXT>I would like to say Thank you to the National Park Service and the United States Navy in Hawaii.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_4</DOCNO>
            	<TEXT>For lowering their flags in honor of Chick.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_5</DOCNO>
            	<TEXT>Many other veterans across the United States in Tenn., California, Florida, and New York for doing the same.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_6</DOCNO>
            	<TEXT>We shall never forget.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_7</DOCNO>
            	<TEXT>Today at 11:30am Click will be laid to rest with full military honors with a 21 gun salute.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_8</DOCNO>
            	<TEXT>Please remember to Thank all service members through out all the US Armed Forces and Police officers, Firemen for their service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_9</DOCNO>
            	<TEXT>Without them no one will keep us safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_10</DOCNO>
            	<TEXT>May God Bless you all.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_142_11</DOCNO>
            	<TEXT>Thank you ROBERT S. [https://www.legacy.com/news/celebrity-deaths/armando-chick-galella-1921-2021-pearl-harbor-survivor/](https://www.legacy.com/news/celebrity-deaths/armando-chick-galella-1921-2021-pearl-harbor-survivor/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_0</DOCNO>
            	<TEXT>NEW PHASE 2 CLINICAL TRIAL POSTED ON 10/05/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_1</DOCNO>
            	<TEXT>Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_2</DOCNO>
            	<TEXT>I've been away for 5 days and I'm back with great news!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_3</DOCNO>
            	<TEXT>I caught a King Salmon and I can't believe no one mentioned this new Phase 2 Clinical trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_4</DOCNO>
            	<TEXT>Sorrento just sneaked this trial right under your noses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_5</DOCNO>
            	<TEXT>Just like the salmon that sneaked in between my legs. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_6</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8](https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8) This is a global multicenter, randomized Phase 2 study for subjects with advanced cancer experiencing intractable pain to assess the safety and efficacy of a single epidural injection of Resiniferatoxin versus vehicle control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_7</DOCNO>
            	<TEXT>Additional subjects who elect to not enroll but are willing to be followed will comprise a Concurrent Control Group.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_8</DOCNO>
            	<TEXT>Subjects will be followed for twelve months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_9</DOCNO>
            	<TEXT>For this to advance to a Phase 2 means Phase 1 really works.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_10</DOCNO>
            	<TEXT>Let's not forget the cancer space that Sorrento is advancing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_11</DOCNO>
            	<TEXT>Now why didn't they want to broadcast this development?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_12</DOCNO>
            	<TEXT>In a press release?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_13</DOCNO>
            	<TEXT>Everyone is dying,and whining for a press release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_14</DOCNO>
            	<TEXT>My feeling is they don't want to be manipulated by the short traders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_15</DOCNO>
            	<TEXT>Did you notice how we hit bottom yesterday?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_16</DOCNO>
            	<TEXT>What held us from going any lower?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_17</DOCNO>
            	<TEXT>This Phase 2 Clinical trial is my guess.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_18</DOCNO>
            	<TEXT>Sorrento has been hard at work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_19</DOCNO>
            	<TEXT>Quietly moving forward without having to tell us every single development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_20</DOCNO>
            	<TEXT>For me I'm fine with that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_21</DOCNO>
            	<TEXT>It does not bother me one bit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_22</DOCNO>
            	<TEXT>Because I see the bigger picture that most of you don't see.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_23</DOCNO>
            	<TEXT>DR JI hasn't posted a press release since September 19th.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_24</DOCNO>
            	<TEXT>This is the longest gap in-between press releases this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_25</DOCNO>
            	<TEXT>I hope when we receive the MONUMENTAL news from Brazil, Canada, Mexico, and the UK you all show him some respect.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_26</DOCNO>
            	<TEXT>Hard work comes with RESPECT!.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_27</DOCNO>
            	<TEXT>You start showing some respect and I'm sure you will get a blessing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_28</DOCNO>
            	<TEXT>I was blessed to have known a 100 year old Pearl Harbor Bronze Star Veteran who survived the Japanese attack on Dec 7th 1941.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_29</DOCNO>
            	<TEXT>Today I showed respect to him and to all other service members by attending his funeral.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_30</DOCNO>
            	<TEXT>I believe in GOD and I believe in blessings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_31</DOCNO>
            	<TEXT>May God bless everyone on this Sorrento Therapeutics board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_32</DOCNO>
            	<TEXT>He knows and Chick knows and I know that the best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_143_33</DOCNO>
            	<TEXT>Thank you ROBERT S.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_0</DOCNO>
            	<TEXT>NEW PHASE 2 CLINICAL TRIAL POSTED ON 10/05/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_1</DOCNO>
            	<TEXT>[**BREAKING NEWS**](https://www.reddit.com/r/srne/search?q=flair_name%3A%22BREAKING%20NEWS%22 amp;restrict_sr=1) Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_2</DOCNO>
            	<TEXT>I've been away for 5 days and I'm back with great news!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_3</DOCNO>
            	<TEXT>I caught a King Salmon and I can't believe no one mentioned this new Phase 2 Clinical trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_4</DOCNO>
            	<TEXT>Sorrento just sneaked this trial right under your noses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_5</DOCNO>
            	<TEXT>Just like the salmon that sneaked in between my legs. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_6</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8](https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=8) This is a global multicenter, randomized Phase 2 study for subjects with advanced cancer experiencing intractable pain to assess the safety and efficacy of a single epidural injection of Resiniferatoxin versus vehicle control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_7</DOCNO>
            	<TEXT>Additional subjects who elect to not enroll but are willing to be followed will comprise a Concurrent Control Group.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_8</DOCNO>
            	<TEXT>Subjects will be followed for twelve months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_9</DOCNO>
            	<TEXT>For this to advance to a Phase 2 means Phase 1 really works.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_10</DOCNO>
            	<TEXT>Let's not forget the cancer space that Sorrento is advancing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_11</DOCNO>
            	<TEXT>Now why didn't they want to broadcast this development?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_12</DOCNO>
            	<TEXT>In a press release?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_13</DOCNO>
            	<TEXT>Everyone is dying,and whining for a press release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_14</DOCNO>
            	<TEXT>My feeling is they don't want to be manipulated by the short traders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_15</DOCNO>
            	<TEXT>Did you notice how we hit bottom yesterday?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_16</DOCNO>
            	<TEXT>What held us from going any lower?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_17</DOCNO>
            	<TEXT>This Phase 2 Clinical trial is my guess.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_18</DOCNO>
            	<TEXT>Sorrento has been hard at work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_19</DOCNO>
            	<TEXT>Quietly moving forward without having to tell us every single development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_20</DOCNO>
            	<TEXT>For me I'm fine with that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_21</DOCNO>
            	<TEXT>It does not bother me one bit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_22</DOCNO>
            	<TEXT>Because I see the bigger picture that most of you don't see.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_23</DOCNO>
            	<TEXT>DR JI hasn't posted a press release since September 19th.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_24</DOCNO>
            	<TEXT>This is the longest gap in-between press releases this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_25</DOCNO>
            	<TEXT>I hope when we receive the MONUMENTAL news from Brazil, Canada, Mexico, and the UK you all show him some respect.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_26</DOCNO>
            	<TEXT>Hard work comes with RESPECT!.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_27</DOCNO>
            	<TEXT>You start showing some respect and I'm sure you will get a blessing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_28</DOCNO>
            	<TEXT>I was blessed to have known a 100 year old Pearl Harbor Bronze Star Veteran who survived the Japanese attack on Dec 7th 1941.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_29</DOCNO>
            	<TEXT>Today I showed respect to him and to all other service members by attending his funeral.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_30</DOCNO>
            	<TEXT>I believe in GOD and I believe in blessings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_31</DOCNO>
            	<TEXT>May God bless everyone on this Sorrento Therapeutics board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_32</DOCNO>
            	<TEXT>He knows and Chick knows and I know that the best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_144_33</DOCNO>
            	<TEXT>Thank you ROBERT S.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_0</DOCNO>
            	<TEXT>NEW PATENT GRANTED ON OCT 5TH 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_1</DOCNO>
            	<TEXT>Come on my BANDOFBROTHERS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_2</DOCNO>
            	<TEXT>here's another BREAKING NEWS development you all missed yesterday!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_3</DOCNO>
            	<TEXT>U.S. patent number 11,135,414 \[Application Number 16/040,773\] was granted by the patent office on 2021-10-05 for medical devices for delivery of sirna.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_4</DOCNO>
            	<TEXT>This patent grant is currently assigned to SORRENTO THERAPEUTICS, INC.. The grantee listed for this patent is Sorrento Therapeutics, Inc.. Invention is credited to Russell Frederick Ross.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_5</DOCNO>
            	<TEXT>Abstract Disclosed are medical devices that incorporate siRNA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_6</DOCNO>
            	<TEXT>In addition to one or more siRNA constructs, devices include nanostructures fabricated on a surface to form a nanotopography.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_7</DOCNO>
            	<TEXT>A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_8</DOCNO>
            	<TEXT>Microneedles may be incorporated on devices.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_9</DOCNO>
            	<TEXT>The pattern including nanostructures may be formed on the surface of the microneedles.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_10</DOCNO>
            	<TEXT>These patents are blessings. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_145_11</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,135,414](https://uspto.report/patent/grant/11,135,414)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_0</DOCNO>
            	<TEXT>NEW PATENT GRANTED ON OCT 5TH 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_1</DOCNO>
            	<TEXT># NEW PATENT GRANTED ON OCT 5TH 2021 [**BREAKING NEWS**](https://www.reddit.com/r/srne/search?q=flair_name%3A%22BREAKING%20NEWS%22 amp;restrict_sr=1) Come on my BANDOFBROTHERS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_2</DOCNO>
            	<TEXT>here's another BREAKING NEWS development you all missed yesterday!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_3</DOCNO>
            	<TEXT>U.S. patent number 11,135,414 \[Application Number 16/040,773\] was granted by the patent office on 2021-10-05 for medical devices for delivery of sirna.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_4</DOCNO>
            	<TEXT>This patent grant is currently assigned to SORRENTO THERAPEUTICS, INC.. The grantee listed for this patent is Sorrento Therapeutics, Inc.. Invention is credited to Russell Frederick Ross.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_5</DOCNO>
            	<TEXT>Abstract Disclosed are medical devices that incorporate siRNA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_6</DOCNO>
            	<TEXT>In addition to one or more siRNA constructs, devices include nanostructures fabricated on a surface to form a nanotopography.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_7</DOCNO>
            	<TEXT>A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_8</DOCNO>
            	<TEXT>Microneedles may be incorporated on devices.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_9</DOCNO>
            	<TEXT>The pattern including nanostructures may be formed on the surface of the microneedles.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_10</DOCNO>
            	<TEXT>These patents are blessings. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_146_11</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,135,414](https://uspto.report/patent/grant/11,135,414)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_0</DOCNO>
            	<TEXT>1.4 BILLION PEOPLE LIVE IN CHINA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_1</DOCNO>
            	<TEXT>Several Phase 1 and 2 clinical trials have been completed, with over 600 NSCLC patients receiving treatment with abivertinib in China, the U.S., and Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_2</DOCNO>
            	<TEXT>We have recently submitted a new drug application (NDA) to the Chinese FDA and anticipate a positive recommendation for abivertinib as a treatment for NSCLC in China in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_3</DOCNO>
            	<TEXT>Abivertinib EGFR  amp; BTK Inhibitor Abivertinib (AC0010) is a potent, irreversible, third-generation small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_4</DOCNO>
            	<TEXT>Abivertinib inhibits the T790M gatekeeper mutation of EGFR and common activating mutations (L858R and del19) but has minimal inhibitory activity towards the normal (wild-type) receptor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_5</DOCNO>
            	<TEXT>The T790M mutation of EGFR is the major cause of acquired resistance and is detected in more than half of patients treated with first-generation EGFR TKIs, such as Tarceva (erlotinib) and Iressa (gefitinib).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_6</DOCNO>
            	<TEXT>Multiple phase 1 and 2 clinical trials have been completed, with over 600 NSCLC patients treated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_7</DOCNO>
            	<TEXT>Abivertinib is initially being developed as an oral treatment for patients with NSCLC in whom prior EGFR-directed therapy has failed due to the emergence of the EGFR T790M mutation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_8</DOCNO>
            	<TEXT>ACEA is also evaluating abivertinib as first-line therapy for NSCLC patients with confirmed EGFR mutational status.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_9</DOCNO>
            	<TEXT>Several Phase 1 and 2 clinical trials have been completed, with over 600 NSCLC patients receiving treatment with abivertinib in China, the U.S., and Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_10</DOCNO>
            	<TEXT>We have recently submitted a new drug application (NDA) to the Chinese FDA and anticipate a positive recommendation for abivertinib as a treatment for NSCLC in China in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_11</DOCNO>
            	<TEXT>Abivertinib also have clinical utility as an inhibitor of Brutons tyrosine kinase (BTK) which impacts B cell proliferation and survival and is currently being investigated in clinical trials for B cell lymphoma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_12</DOCNO>
            	<TEXT>In addition, BTK places critical role in immune regulation and host inflammatory responses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_13</DOCNO>
            	<TEXT>Sorrento Therapeutics is conducting global trials of Abivertinib for patients hospitalized with Covid-19. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_14</DOCNO>
            	<TEXT>https://www.aceatherapeutics.com/pipeline/abivertinib/](https://www.aceatherapeutics.com/pipeline/abivertinib/) READ THIS LINE AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_15</DOCNO>
            	<TEXT>We have recently submitted a new drug application (NDA) to the Chinese FDA and anticipate a positive recommendation for abivertinib as a treatment for NSCLC in China in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_147_16</DOCNO>
            	<TEXT>We maybe receiving a press release from ACEA with developments from China?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_0</DOCNO>
            	<TEXT>1.4 BILLION PEOPLE LIVE IN CHINA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_1</DOCNO>
            	<TEXT>Several Phase 1 and 2 clinical trials have been completed, with over 600 NSCLC patients receiving treatment with abivertinib in China, the U.S., and Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_2</DOCNO>
            	<TEXT>We have recently submitted a new drug application (NDA) to the Chinese FDA and anticipate a positive recommendation for abivertinib as a treatment for NSCLC in China in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_3</DOCNO>
            	<TEXT>Abivertinib EGFR  amp; BTK Inhibitor Abivertinib (AC0010) is a potent, irreversible, third-generation small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_4</DOCNO>
            	<TEXT>Abivertinib inhibits the T790M gatekeeper mutation of EGFR and common activating mutations (L858R and del19) but has minimal inhibitory activity towards the normal (wild-type) receptor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_5</DOCNO>
            	<TEXT>The T790M mutation of EGFR is the major cause of acquired resistance and is detected in more than half of patients treated with first-generation EGFR TKIs, such as Tarceva (erlotinib) and Iressa (gefitinib).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_6</DOCNO>
            	<TEXT>Multiple phase 1 and 2 clinical trials have been completed, with over 600 NSCLC patients treated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_7</DOCNO>
            	<TEXT>Abivertinib is initially being developed as an oral treatment for patients with NSCLC in whom prior EGFR-directed therapy has failed due to the emergence of the EGFR T790M mutation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_8</DOCNO>
            	<TEXT>ACEA is also evaluating abivertinib as first-line therapy for NSCLC patients with confirmed EGFR mutational status.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_9</DOCNO>
            	<TEXT>Several Phase 1 and 2 clinical trials have been completed, with over 600 NSCLC patients receiving treatment with abivertinib in China, the U.S., and Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_10</DOCNO>
            	<TEXT>We have recently submitted a new drug application (NDA) to the Chinese FDA and anticipate a positive recommendation for abivertinib as a treatment for NSCLC in China in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_11</DOCNO>
            	<TEXT>Abivertinib also have clinical utility as an inhibitor of Brutons tyrosine kinase (BTK) which impacts B cell proliferation and survival and is currently being investigated in clinical trials for B cell lymphoma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_12</DOCNO>
            	<TEXT>In addition, BTK places critical role in immune regulation and host inflammatory responses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_13</DOCNO>
            	<TEXT>Sorrento Therapeutics is conducting global trials of Abivertinib for patients hospitalized with Covid-19. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_14</DOCNO>
            	<TEXT>https://www.aceatherapeutics.com/pipeline/abivertinib/](https://www.aceatherapeutics.com/pipeline/abivertinib/) READ THIS LINE AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_15</DOCNO>
            	<TEXT>We have recently submitted a new drug application (NDA) to the Chinese FDA and anticipate a positive recommendation for abivertinib as a treatment for NSCLC in China in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_148_16</DOCNO>
            	<TEXT>We maybe receiving a press release from ACEA with developments from China?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_0</DOCNO>
            	<TEXT>THE MISSION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_1</DOCNO>
            	<TEXT>Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_2</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_3</DOCNO>
            	<TEXT>The mission of NAMRU-3 is to ensure warfighter readiness through detecting, deterring, and responding to infectious disease threats through integration with partners throughout U.S. Africa Command (AFRICOM), Central Command (CENTCOM), and European Command (EUCOM) areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_4</DOCNO>
            	<TEXT>The purpose of this collaboration is to perform infectious disease research that guides the Department of Defense (DoD), informs public health policy of host nation partners, and improves medical readiness of the U.S. Armed Forces across NAMRU-3 areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_5</DOCNO>
            	<TEXT>Through shared resources and logistical support, the overall goal of this research cooperation will be to conduct research on current, emerging and re-emerging infectious diseases, to enhance Force Health Protection, and provide critical data regarding countermeasures to mitigate infectious disease transmission including surveillance and product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_6</DOCNO>
            	<TEXT>READ THAT LAST PARAGRAPH AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_7</DOCNO>
            	<TEXT>It's starts with the mission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_8</DOCNO>
            	<TEXT>Our US Armed Forces MISSION.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_9</DOCNO>
            	<TEXT>Our US Armed Forces are the BEST IN THE WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_10</DOCNO>
            	<TEXT>And don't you forget it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_11</DOCNO>
            	<TEXT>Continue reading please... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) The initial focus of the collaboration will be to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostics and COVIDROPS/COVI-AMG outpatient neutralizing antibody treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_12</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_13</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_14</DOCNO>
            	<TEXT>https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/) Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_15</DOCNO>
            	<TEXT>A previously completed safety study conducted in the US at doses up to 60 mg in healthy subjects showed a comparable safety profile to placebo with all reported adverse effects being mild in severity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_16</DOCNO>
            	<TEXT>The UK study will complement Phase 2 trials currently being started in the US and should the results of these studies demonstrate that COVIDROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, UK, Canada, India, Mexico and European Union as well as other territories. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_17</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical) Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_18</DOCNO>
            	<TEXT>Read that last line again please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_19</DOCNO>
            	<TEXT>Just a SINGLE Intranasal Dose.... Just one 10 or 20 MG Dose. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_149_20</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12](https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12) Sorrento Therapeutics is on a MISSION and I believe they will be successful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_0</DOCNO>
            	<TEXT>THE MISSION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_1</DOCNO>
            	<TEXT># THE MISSION [**Bullish**](https://www.reddit.com/r/srne/search?q=flair_name%3A%22Bullish%22 amp;restrict_sr=1) Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_2</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_3</DOCNO>
            	<TEXT>The mission of NAMRU-3 is to ensure warfighter readiness through detecting, deterring, and responding to infectious disease threats through integration with partners throughout U.S. Africa Command (AFRICOM), Central Command (CENTCOM), and European Command (EUCOM) areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_4</DOCNO>
            	<TEXT>The purpose of this collaboration is to perform infectious disease research that guides the Department of Defense (DoD), informs public health policy of host nation partners, and improves medical readiness of the U.S. Armed Forces across NAMRU-3 areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_5</DOCNO>
            	<TEXT>Through shared resources and logistical support, the overall goal of this research cooperation will be to conduct research on current, emerging and re-emerging infectious diseases, to enhance Force Health Protection, and provide critical data regarding countermeasures to mitigate infectious disease transmission including surveillance and product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_6</DOCNO>
            	<TEXT>READ THAT LAST PARAGRAPH AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_7</DOCNO>
            	<TEXT>It's starts with the mission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_8</DOCNO>
            	<TEXT>Our US Armed Forces MISSION.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_9</DOCNO>
            	<TEXT>Our US Armed Forces are the BEST IN THE WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_10</DOCNO>
            	<TEXT>And don't you forget it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_11</DOCNO>
            	<TEXT>Continue reading please... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) The initial focus of the collaboration will be to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostics and COVIDROPS/COVI-AMG outpatient neutralizing antibody treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_12</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_13</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_14</DOCNO>
            	<TEXT>https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/) Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_15</DOCNO>
            	<TEXT>A previously completed safety study conducted in the US at doses up to 60 mg in healthy subjects showed a comparable safety profile to placebo with all reported adverse effects being mild in severity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_16</DOCNO>
            	<TEXT>The UK study will complement Phase 2 trials currently being started in the US and should the results of these studies demonstrate that COVIDROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, UK, Canada, India, Mexico and European Union as well as other territories. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_17</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical) Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_18</DOCNO>
            	<TEXT>Read that last line again please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_19</DOCNO>
            	<TEXT>Just a SINGLE Intranasal Dose.... Just one 10 or 20 MG Dose. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_150_20</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12](https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12) Sorrento Therapeutics is on a MISSION and I believe they will be successful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_0</DOCNO>
            	<TEXT>THE MISSION SINCE JUNE 22, 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_1</DOCNO>
            	<TEXT># This is a repost from this morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_2</DOCNO>
            	<TEXT>It's timed stamped just like the two previous posts I posted this yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_3</DOCNO>
            	<TEXT>That are clearly time stamped OCT 5TH, 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_4</DOCNO>
            	<TEXT>Which by the way no one on this board brought up yesterday or on yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_5</DOCNO>
            	<TEXT>I wonder why?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_6</DOCNO>
            	<TEXT>There's some concern to time stamping.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_7</DOCNO>
            	<TEXT>If you want me to time stamp my posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_8</DOCNO>
            	<TEXT>I will and I expect the same from everyone else.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_9</DOCNO>
            	<TEXT>I'm here to bring everyone DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_10</DOCNO>
            	<TEXT>So place your mandate on time stamping.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_11</DOCNO>
            	<TEXT>This is them same DD with since June 22, 2021 added. [**</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_12</DOCNO>
            	<TEXT>Previously Announced Bullish News**](https://www.reddit.com/r/srne/search?q=flair_name%3A%22Previously%20Announced%20Bullish%20News%22 amp;restrict_sr=1) Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_13</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_14</DOCNO>
            	<TEXT>The mission of NAMRU-3 is to ensure warfighter readiness through detecting, deterring, and responding to infectious disease threats through integration with partners throughout U.S. Africa Command (AFRICOM), Central Command (CENTCOM), and European Command (EUCOM) areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_15</DOCNO>
            	<TEXT>The purpose of this collaboration is to perform infectious disease research that guides the Department of Defense (DoD), informs public health policy of host nation partners, and improves medical readiness of the U.S. Armed Forces across NAMRU-3 areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_16</DOCNO>
            	<TEXT>Through shared resources and logistical support, the overall goal of this research cooperation will be to conduct research on current, emerging and re-emerging infectious diseases, to enhance Force Health Protection, and provide critical data regarding countermeasures to mitigate infectious disease transmission including surveillance and product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_17</DOCNO>
            	<TEXT>READ THAT LAST PARAGRAPH AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_18</DOCNO>
            	<TEXT>It's starts with the mission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_19</DOCNO>
            	<TEXT>Our US Armed Forces MISSION.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_20</DOCNO>
            	<TEXT>Our US Armed Forces are the BEST IN THE WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_21</DOCNO>
            	<TEXT>And don't you forget it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_22</DOCNO>
            	<TEXT>Continue reading please... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) The initial focus of the collaboration will be to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostics and COVIDROPS/COVI-AMG outpatient neutralizing antibody treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_23</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_24</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_25</DOCNO>
            	<TEXT>https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/) Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_26</DOCNO>
            	<TEXT>A previously completed safety study conducted in the US at doses up to 60 mg in healthy subjects showed a comparable safety profile to placebo with all reported adverse effects being mild in severity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_27</DOCNO>
            	<TEXT>The UK study will complement Phase 2 trials currently being started in the US and should the results of these studies demonstrate that COVIDROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, UK, Canada, India, Mexico and European Union as well as other territories. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_28</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical) Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_29</DOCNO>
            	<TEXT>Read that last line again please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_30</DOCNO>
            	<TEXT>Just a SINGLE Intranasal Dose.... Just one 10 or 20 MG Dose. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_151_31</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12](https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12) Sorrento Therapeutics is on a MISSION and I believe they will be successful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_0</DOCNO>
            	<TEXT>Delivering Next-Gen Biomanufacturing Capability (RPM) Reimagining Protein Manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_1</DOCNO>
            	<TEXT>https://www.darpa.mil/news-events/2021-08-25 Looks like DARPA and the DoD know exactly what they want.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_2</DOCNO>
            	<TEXT>Slow production methods and reliance on a global supply chain currently limit DoD access to critical proteins such as medical countermeasures (MCMs) (i.e. antibodies, vaccines, and clotting factors), diagnostic components, and key enzymes for producing nucleic acids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_3</DOCNO>
            	<TEXT>State-of-the-art protein-based MCM production calls for massive centralized infrastructure and complex pipelines that require lengthy cellular engineering, sufficient growth of cells, and intensive purification and quality control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_4</DOCNO>
            	<TEXT>Current response times are several months for production, with additional time needed for dispersing MCMs to vulnerable populations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_5</DOCNO>
            	<TEXT>Distributed manufacturing paradigms may transform these timelines into those relevant to DoD response, especially in denied, degraded, or disrupted operational environments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_6</DOCNO>
            	<TEXT>To address these challenges, the Reimagining Protein Manufacturing (RPM) program aims to establish the foundational technologies needed for fully distributed, on-demand manufacturing of biologics-based MCMs and their associated raw materials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_7</DOCNO>
            	<TEXT>DARPA programs, such as Make-It, Nucleic Acids on Demand (NOW), and Battlefield Medicine, have invested in distributed manufacturing of pharmaceuticals and nucleic acids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_8</DOCNO>
            	<TEXT>Continuing DARPAs role in challenging manufacturing paradigms, RPM focuses on the complex process of protein production, and will attend to the biochemistry challenges associated with producing bioactive proteins at high yields with short lead times.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_9</DOCNO>
            	<TEXT>As was reinforced during the COVID-19 pandemic, many crucial building blocks for proteins, therapeutics and diagnostics are currently manufactured outside of the United States, stated Dr. Amy Jenkins, RPM program manager.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_10</DOCNO>
            	<TEXT>The RPM program will serve warfighters by strengthening the U.S. biomanufacturing supply chain and providing new methods for timely development of protein-based therapeutics and enzymes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_11</DOCNO>
            	<TEXT>The 50-month RPM program will address two technical areas (TAs).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_12</DOCNO>
            	<TEXT>TA1 Production Yield and Time focuses on protein synthesis technologies for near-immediate synthesis of proteins at high yields.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_13</DOCNO>
            	<TEXT>TA2 Post-Translational Modifications seeks novel protein production approaches to add PTMs in a controlled manner to ensure the final product is bioactive and of high quality.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_14</DOCNO>
            	<TEXT>The U.S. Government will utilize Independent Validation and Verification (IV amp;V) partners throughout the program to assess the function, stability, and composition of the proteins produced through a series of field recognized analytical techniques.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_15</DOCNO>
            	<TEXT>If successful, RPM will result in novel protein production technologies not previously deployed, added Jenkins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_16</DOCNO>
            	<TEXT>Additional details of the program schedule and metrics are available in the broad agency announcement at [https://sam.gov/opp/9711cee39a984d57ba681390bc1a4564/view](https://sam.gov/opp/9711cee39a984d57ba681390bc1a4564/view). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_17</DOCNO>
            	<TEXT>https://www.darpa.mil/program/battlefield-medicine](https://www.darpa.mil/program/battlefield-medicine) THEN LOOK AT WHAT HAPPENED News Release Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_18</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19 June 22, 2021 at 1:46 PM EDT Download PDF Broad multi-year agreement between Sorrento Therapeutics and U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_19</DOCNO>
            	<TEXT>3 (NAMRU-3) headquartered in Sigonella, Italy with Laboratory Detachments in Cairo, Egypt, Camp Lemonnier, Djibouti, and Accra, Ghana.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_20</DOCNO>
            	<TEXT>Scope includes infectious diseases research and development, product validation, and disease surveillance to inform public health policy of host nation partners, and to improve medical readiness of the U.S. Armed Forces for NAMRU-3 areas of responsibility (U.S. European Command, U.S. Central Command, U.S. Africa Command) Initial focus of the collaboration is to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostic Tests and COVIDROPS/COVI-AMG neutralizing antibody treatments for COVID-19 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_21</DOCNO>
            	<TEXT>LOOK AT WHAT HAPPENED NEXT! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_22</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-and-dyadic-announce-binding-term-sheet-license-dyadics](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-and-dyadic-announce-binding-term-sheet-license-dyadics) LOOK AT WHAT HAPPENED NEXT [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-unveils-overview-its-multivalent-mrna-covid-19-vaccine](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-unveils-overview-its-multivalent-mrna-covid-19-vaccine) PLEASE READ THIS SENTENCE Development of equipotent lyophilized dose forms that may further enhance the potential for vaccine delivery to underserved populations due to cold-chain storage and transportation issues.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_23</DOCNO>
            	<TEXT>This is what DARPA wants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_24</DOCNO>
            	<TEXT>DARPA and the DoD started a 50 month program to get Battle Ready.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_152_25</DOCNO>
            	<TEXT>Sorrento went into a 5 year multi year contract with the DoD. THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_153_0</DOCNO>
            	<TEXT>Sorrento is the ONE STOP COVID SHOP!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_153_1</DOCNO>
            	<TEXT>I can think of 18 Covid related tests, antibodies and drugs mentioned by Sorrento!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_153_2</DOCNO>
            	<TEXT>1.COVITRACE (Diagnostic Test for the Detection of SARS-CoV-2 in Nasal Swab and Saliva) 2.COVISTIX (Antigen Test for the Detection of SARS-CoV-2 Virus in Nasal Swab)Mexico EUA APPROVED 3.COVITRACK Platinum (Antibody Test for the Detection of Antibodies to SARS-CoV-2 in Blood) 4.COVIGUARD (Neutralizing Antibody STI 1499) 5.COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody STI 2020) 6.COVIDROPS (Intranasal COVI-AMG Neutralizing Antibody STI 2099) 7.COVISHIELD (Neutralizing Antibody Cocktail) 8.COVIDTRAP (ACE2 Receptor Decoy STI 4398) 9.ABIVERTINIB (Cytokine Storm STI 5656) 10.SALICYN-30 (Anti-viral STI 2030) 11.COVI-MSC (Acute Respiratory Distress Syndrome STI 8282) 12.ARK-301 long-haul Covid symptoms 13.mRNA-based multivalent vaccine 14.low cost C1 based multivalent vaccine(rights to 60% of world population) 15.MP18 oral antiviral MPro inhibitor 16.Combination oral antiviral drug cocktail 17.RESPISTIX Combination Covid/seasonal flu tests 18.Combination Covid/seasonal flu vaccines</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_0</DOCNO>
            	<TEXT>Texas A amp;M Researcher: New Drug Could Be Game Changer Against COVID-19</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_1</DOCNO>
            	<TEXT>A discovery by Wenshe Ray Liu and his team leads to an agreement with a California biopharmaceutical company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_2</DOCNO>
            	<TEXT>A drug created by a Texas A amp;M University professor could be the most effective treatment yet of patients with COVID-19, including the aggressive variants of the virus such as Delta and others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_3</DOCNO>
            	<TEXT>The drug compound, called MPI8, has stopped the replication of the virus in laboratory tests.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_4</DOCNO>
            	<TEXT>It was created by a Texas A amp;M research team led by biological chemist Wenshe Ray Liu, a 2018 Texas A amp;M Presidential Impact Fellow and holder of the Gradipore Chair in the Department of Chemistry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_5</DOCNO>
            	<TEXT>The potential effectiveness of MPI8 led Sorrento Therapeutics of San Diego, Calif., to seek exclusive intellectual property rights to the ingredient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_6</DOCNO>
            	<TEXT>An agreement between the company and The Texas A amp;M University System was announced Tuesday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_7</DOCNO>
            	<TEXT>Liu said that Sorrento hopes to complete pre-clinical studies of MPI8 by the end of the year and seek FDA approval to begin clinical trials on humans in early 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_8</DOCNO>
            	<TEXT>MPI8 could be the best weapon yet in the fight against the COVID-19 virus, Liu said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_9</DOCNO>
            	<TEXT>If it can be approved clinically, this will be a game changer, he said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_10</DOCNO>
            	<TEXT>Only one treatment, a drug called remdesivir, has been approved by the FDA and studies indicate it may provide only modest benefit to patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_11</DOCNO>
            	<TEXT>A few other treatments have FDAs emergency use authorization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_12</DOCNO>
            	<TEXT>A wide range of potential treatments are in early stages of research, including several others being pursued by Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_13</DOCNO>
            	<TEXT>In January 2020, Liu was among the co-authors of the first paper to identify remdesivir as a viable treatment for SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_14</DOCNO>
            	<TEXT>Liu said MPI8 shows the potential to be highly effective in treating not only the original COVID-19 viral strain, but also the more aggressive strains such as Delta, Alpha, Beta and Gamma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_15</DOCNO>
            	<TEXT>The Delta variant was first identified in India in December of 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_16</DOCNO>
            	<TEXT>In just a few months, it spread to 98 countries around the world, becoming the dominant variant in numerous nations, including India, the U.K., Israel and the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_17</DOCNO>
            	<TEXT>Delta is now responsible for almost 85 percent of the COVID-19 cases being reported in the U.S., according to the Centers for Disease Control and Prevention (CDC).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_18</DOCNO>
            	<TEXT>Henry Ji, chairman and CEO of Sorrento, said the new findings by Liu and his team might turn out to be critical in the fight against COVID-19 and other diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_19</DOCNO>
            	<TEXT>We are excited to be collaborating with Dr. Liu and his team at Texas A amp;M and look forward to advancing the development of these novel drug candidates to address COVID-19 and a multitude of other respiratory viruses, Ji said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_20</DOCNO>
            	<TEXT>Here is the most exciting part to comprehend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_21</DOCNO>
            	<TEXT>Professor biological chemist Wenshe Ray Liu and his team decided to collaborate with Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_22</DOCNO>
            	<TEXT>WHY DID THEY CHOSE SORRENTO?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_23</DOCNO>
            	<TEXT>Why not Lilly, Pfizer, Moderna, Regeneron, Johnson and Johnson ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_24</DOCNO>
            	<TEXT>In January 2020, Liu was among the co-authors of the first paper to identify remdesivir as a viable treatment for SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_25</DOCNO>
            	<TEXT>Believe it or not biological chemists know who has the BEST scientists and have the best ability for success.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_26</DOCNO>
            	<TEXT>Sorrento Therapeutics has the largest COVID-19 pipeline in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_27</DOCNO>
            	<TEXT>Now they have by far the best BIOOGICAL CHEMISTS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_28</DOCNO>
            	<TEXT>DR Ji said, In May of 2020 we have a prized fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_29</DOCNO>
            	<TEXT>A very very strong fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_30</DOCNO>
            	<TEXT>We're now going to add more and more fighters to our fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_31</DOCNO>
            	<TEXT>To make him stronger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_32</DOCNO>
            	<TEXT>Sorrento is an Aircraft Carrier loaded with the best weapons in the WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_33</DOCNO>
            	<TEXT>Why else would DARPA, DoD, and the USA Navy go into a multi year agreement?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_34</DOCNO>
            	<TEXT>BECAUSE SORRENTO HAS THE BEST COVID-19 WEAPONS. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_154_35</DOCNO>
            	<TEXT>https://today.tamu.edu/2021/08/25/texas-am-researcher-new-drug-could-be-game-changer-against-covid-19/](https://today.tamu.edu/2021/08/25/texas-am-researcher-new-drug-could-be-game-changer-against-covid-19/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_155_0</DOCNO>
            	<TEXT>LET THE GOOD TIMES ROLL</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_155_1</DOCNO>
            	<TEXT>Scilex expects SP-102 to be the first FDA-approved non-opioid epidural injection for sciatica with the potential to replace the current 10 to 12 million off-label epidural steroid injections administered each year in the U.S. [https://www.scilexpharma.com/scilex-patch-animation/](https://www.scilexpharma.com/scilex-patch-animation/) Chronic pain affects 116 million Americans and costs the U.S. as much as $635 billion each year, according to a recent report from the Institute of Medicine (IOM) that called for changes in how chronic pain is managed6 and nearly 30 million patients suffer from lower back pain in the U.S.8 Government agencies, physicians, patients, and payers are looking for alternatives to opioids to reduce the risk of dependency or addiction, and serious side effects (such as respiratory depression and constipation), while still offering potent solutions for people living with chronic pain. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_155_2</DOCNO>
            	<TEXT>We are very pleased to have achieved this important milestone and would like to commend the experienced investigators and advisors of the C.L.E.A.R. trial for their persistence and diligence in enrolling sciatica patients through the COVID-19 pandemic and enabling Scilex to achieve a landmark milestone following treatment of 400 sciatica patients in the C.L.E.A.R. trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_155_3</DOCNO>
            	<TEXT>The clinical results for the pivotal SP-102 Phase 3 trial may provide encouraging news for the many millions of people worldwide who are confronting painful radicular pain (sciatica) and we look forward to sharing results later this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_155_4</DOCNO>
            	<TEXT>We believe that SP-102 could be the first FDA-approved epidural steroid gel injection product for patients suffering from this common, very painful condition, said Jaisim Shah, President and Chief Executive Officer of Scilex Holding Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_155_5</DOCNO>
            	<TEXT>THE BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_156_0</DOCNO>
            	<TEXT>Ownership Accumulation Score</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_156_1</DOCNO>
            	<TEXT>The Ownership Accumulation Score is the result of a sophisticated, multi-factor quantitative model that identifies companies with the highest levels of institutional accumulation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_156_2</DOCNO>
            	<TEXT>The scoring model uses a combination of the total increase in disclosed owners, the changes in portfolio allocations in those owners and other metrics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_156_3</DOCNO>
            	<TEXT>The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_156_4</DOCNO>
            	<TEXT>Update Frequency: Daily See Ownership Explorer, which provides a list of highest-ranking companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_156_5</DOCNO>
            	<TEXT>74.45 4787 out of 22218 See Highest Ranking Stocks Sorrento is above avg. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_156_6</DOCNO>
            	<TEXT>https://fintel.io/so/us/srne](https://fintel.io/so/us/srne)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_157_0</DOCNO>
            	<TEXT>I heard someone say they have $297M in cash.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_158_0</DOCNO>
            	<TEXT>I do not know.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_159_0</DOCNO>
            	<TEXT>Great link!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_160_0</DOCNO>
            	<TEXT>https://www.leespharm.com/product-pipeline/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_160_1</DOCNO>
            	<TEXT>Check out this Product pipeline.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_160_2</DOCNO>
            	<TEXT>Which one of these does Sorrento own?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_160_3</DOCNO>
            	<TEXT>There's a lot.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_161_0</DOCNO>
            	<TEXT>It's a great thought and I feel the same as you do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_161_1</DOCNO>
            	<TEXT>I remember months back it happened the same way when we went back to $6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_161_2</DOCNO>
            	<TEXT>We received nothing in a PR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_161_3</DOCNO>
            	<TEXT>Then great deals hit the table.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_161_4</DOCNO>
            	<TEXT>Acea is one of them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_161_5</DOCNO>
            	<TEXT>Have a great weekend to you as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_162_0</DOCNO>
            	<TEXT>That's a great idea and make a post and I will promote it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_163_0</DOCNO>
            	<TEXT>Yes they are.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_164_0</DOCNO>
            	<TEXT>That's right help me to bring them over to our subreddit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_165_0</DOCNO>
            	<TEXT>Well i have no choice i have to root for Penn State or the Gamecocks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_165_1</DOCNO>
            	<TEXT>Or my kids will sell their Sorrento stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_167_0</DOCNO>
            	<TEXT>Methods for Treating Parkinson?s Disease by Administering Resiniferatoxin</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_167_1</DOCNO>
            	<TEXT>U.S. patent application number 17/345641 was filed with the patent office on 2021-09-30 for methods for treating parkinson?s disease by administering resiniferatoxin.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_167_2</DOCNO>
            	<TEXT>This patent application is currently assigned to Sorrento Therapeutics, Inc.. The applicant listed for this patent is Sorrento Therapeutics, Inc.. Invention is credited to Henry Hongjun Ji, Alexis Nahama. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_167_3</DOCNO>
            	<TEXT>https://uspto.report/patent/app/20210299090](https://uspto.report/patent/app/20210299090) Resiniferatoxin has multiple uses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_167_4</DOCNO>
            	<TEXT>Sciatica  amp; now Parkinson's Disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_0</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator ( WHO )</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_1</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator ( WHO ) Please click and view what the Access ACT-Accelerator is...[https://www.who.int/initiatives/act-accelerator](https://www.who.int/initiatives/act-accelerator) Sorrento's COVISTIX: COVID-19 Rapid Antigen Detection Test in commercialization in Mexico with an EUA from COFEPRIS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_2</DOCNO>
            	<TEXT>Regulatory approval processes in progress in the US, Canada, Brazil, and WHO EUL (Emergency Use Listing), with active partnering discussions for global commercialization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_3</DOCNO>
            	<TEXT>Partnering?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_4</DOCNO>
            	<TEXT>Who is Sorrento partnering with?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_5</DOCNO>
            	<TEXT>Global commercialization?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_6</DOCNO>
            	<TEXT>How many COVI-STIX could Sorrento sell globally?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_7</DOCNO>
            	<TEXT>Please click where it says WHAT IS THE ACT-Accelerator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_8</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_9</DOCNO>
            	<TEXT>Launched at the end of April 2020, at an event co-hosted by the Director-General of the World Health Organization, the President of France, the President of the European Commission, and the Bill  amp; Melinda Gates Foundation, the Access to COVID-19 Tools (ACT) Accelerator brings together governments, scientists, businesses, civil society, and philanthropists and global health organizations (the Bill  amp; Melinda Gates Foundation, CEPI, FIND, Gavi, The Global Fund, Unitaid, Wellcome, the WHO, and the World Bank).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_10</DOCNO>
            	<TEXT>Following the ACT-Accelerator launch, UNICEF and PAHO became delivery partners for COVAX, the vaccines pillar.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_11</DOCNO>
            	<TEXT>These organizations have joined forces to speed up an end to the pandemic by supporting the development and equitable distribution of the tests, treatments and vaccines the world needs to reduce mortality and severe disease, restoring full societal and economic activity globally in the near term, and facilitating high-level control of COVID-19 disease in the medium term.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_12</DOCNO>
            	<TEXT>There is no time to waste in the fight against COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_13</DOCNO>
            	<TEXT>No-one is safe until everyone is safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_14</DOCNO>
            	<TEXT>This is a unique partnership of many of the world's international health organizations who have come together to share, and build on, individual expertise to create a powerful global solution that will ensure equity in access to tests, vaccines, treatments across the world with one goal: to reduce the burden of the COVID-19 pandemic by addressing the cause.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_15</DOCNO>
            	<TEXT>PLEASE READ THIS ONE MORE TIME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_16</DOCNO>
            	<TEXT>The Access to COVID-19 Tools (ACT) Accelerator, is a groundbreaking global collaboration to accelerate development, production, and equitable access to COVID-19 tests, treatments, and vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_168_17</DOCNO>
            	<TEXT>Now let's focus on this... Groundbreaking global collaboration WHO will help to accelerate COVI-STIX?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_170_0</DOCNO>
            	<TEXT>We shall see how to do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_170_1</DOCNO>
            	<TEXT>That's with no point spread win or lose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_171_0</DOCNO>
            	<TEXT>Yeah when i saw Manning i laughed out loud.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_172_0</DOCNO>
            	<TEXT>Groundbreaking global collaboration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_172_1</DOCNO>
            	<TEXT>Watch Canada approves COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_173_0</DOCNO>
            	<TEXT>Chuck your on point.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_173_1</DOCNO>
            	<TEXT>I may bet heavily next week on your picks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_174_0</DOCNO>
            	<TEXT>Penn State baby killing it in Iowa.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_175_0</DOCNO>
            	<TEXT>Clifford is hurt</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_176_0</DOCNO>
            	<TEXT>Nice call with Ok.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_177_0</DOCNO>
            	<TEXT>Sweatshirtdude 8 -4 Not bad at all!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_177_1</DOCNO>
            	<TEXT>Jimbo squeezed it out to Bam bama.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_177_2</DOCNO>
            	<TEXT>Let's do it again next Saturday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_178_0</DOCNO>
            	<TEXT>It's fine you posted the link.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_0</DOCNO>
            	<TEXT>HELP IS ON THE WAY</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_1</DOCNO>
            	<TEXT>Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_2</DOCNO>
            	<TEXT>After COVI-STIX (COVID-19 VIRUS RAPID ANTIGEN DETECTION TEST) obtained Emergency Use Authorization (EUA) approval from the Mexican Comisin Federal para la Proteccin contra Riesgos Sanitarios (COFEPRIS), Sorrento and Mexican INMEGEN (Instituto Nacional de Medicina Genomica) have held meetings to explore collaboration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_3</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico (Sorrento Mexico) and INMEGEN have executed an MOU to further collaborate on clinical development of a broad pipeline of COVID products, including diagnostics, multivalent mRNA-based vaccines and therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_4</DOCNO>
            	<TEXT>Sorrento provides its most comprehensive portfolios and a one-stop-shop" of potential solutions for governments interested in a multi-modal detect and treat approach to the COVID-19 pandemic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_5</DOCNO>
            	<TEXT>Sorrento Mexico plans to install local clinical research and development capabilities within the INMEGEN facilities and personnel in Mexico City and will work closely with Mexican hospitals and clinical institutions on clinical protocols, regulatory registration and approval requirements for the COVID-19 product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_6</DOCNO>
            	<TEXT>SAN DIEGO, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc., Inc. (Nasdaq: SRNE, "Sorrento") today announced that its subsidiary company, Sorrento Therapeutics Mexico (Sorrento Mexico), has entered into an MOU agreement with the National Institute of Genomic Medicine INMEGEN (Instituto National de Medicine Genomica) to cooperate in the development, testing and support of multiple COVID-19 related products Sorrento plans to commercialize in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_7</DOCNO>
            	<TEXT>Sorrento Mexico and INMEGEN will expand its collaboration to include additional Sorrento COVID pipeline products spanning diagnostics, therapeutics and multivalent vaccines, including the following product candidates: COVITRACK: COVID-19 antibody detection diagnostic test for vaccinated people; STI-2020 (COVI-AMG): Affinity matured neutralizing antibody against SARS-CoV-2 for outpatient COVID patients; STI-2099 (COVIDROPS): Intranasal neutralizing antibody version of COVI-AMG for newly diagnosed COVID patients; COVISHIELD: Cocktail of neutralizing antibodies against variants of concern of SARS-CoV-2; STI-5656 (Abivertinib): BTK inhibitor for the treatment of acute respiratory distress syndrome (ARDS) in hospitalized COVID patients; STI-8282 (COVI-MSC): Allogeneic mesenchymal stem cells for the treatment of COVID-associated ARDS in severe COVID patients; and Multivalent mRNA Vaccines: mRNA-based multivariant vaccines protecting against SARS-CoV-2 virus, Alpha, Beta, Delta and Gamma variants of concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_8</DOCNO>
            	<TEXT>Sorrento Mexico plans to establish a local research laboratory within INMEGENs facilities to ensure close collaboration between the INMEGEN and Sorrento teams for testing, clinical trials and development of COVID related products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_179_9</DOCNO>
            	<TEXT>We are excited about our close collaboration with INMEGEN and intend to have Sorrento Mexico as a gateway to all Latin American countries for our innovative COVID diagnostic, vaccine and therapeutic product candidates, said Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_180_0</DOCNO>
            	<TEXT>Jets suck so take the Falcons Packers over Borrow Cousins keeps the streaking going for the loins 0-5 Big Ben needs commentating job they lose again The bucks make sushi out of the fins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_180_1</DOCNO>
            	<TEXT>Saints are marching in the win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_180_2</DOCNO>
            	<TEXT>Darnold is a born again and make them 4-1 Give the Jags their first win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_180_3</DOCNO>
            	<TEXT>Don't count out Bill B. give it to the PATS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_181_0</DOCNO>
            	<TEXT>I only play Fanduel where you have to pick the players.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_181_1</DOCNO>
            	<TEXT>My screen name on Fanduel is NEWYORKGOLDBUYER</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_182_0</DOCNO>
            	<TEXT>Gordon is starting for KC.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_182_1</DOCNO>
            	<TEXT>There going to use him as a distraction</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_183_0</DOCNO>
            	<TEXT>I grew up a Dallas fan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_183_1</DOCNO>
            	<TEXT>I used to have 4 seats at have old Giants Stadium.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_183_2</DOCNO>
            	<TEXT>My best friend played on the Dallas Cowboys Center Michael Kiselak #66 under Troy Aikman.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_183_3</DOCNO>
            	<TEXT>I've been to the training facilities and met everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_183_4</DOCNO>
            	<TEXT>Michaels roommate was 3rd string QB Jason Garrett.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_184_0</DOCNO>
            	<TEXT>Because of his father was a trainer many years ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_184_1</DOCNO>
            	<TEXT>Jason is really true blue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_184_2</DOCNO>
            	<TEXT>He wants the coaching job.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_184_3</DOCNO>
            	<TEXT>You watch in a year they will move him up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_184_4</DOCNO>
            	<TEXT>We ate together at a steakhouse Dallas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_184_5</DOCNO>
            	<TEXT>Nice guy but a little weird.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_185_0</DOCNO>
            	<TEXT>Remember Nate Newton?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_0</DOCNO>
            	<TEXT>I have a funny story.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_1</DOCNO>
            	<TEXT>Nate comes to the line and forgets the play.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_2</DOCNO>
            	<TEXT>So Nate says hey kiss what's the play?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_3</DOCNO>
            	<TEXT>Kiss is the center.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_4</DOCNO>
            	<TEXT>Kiss says 42.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_5</DOCNO>
            	<TEXT>Nate says 42 what?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_6</DOCNO>
            	<TEXT>You don't want the defense to hear you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_7</DOCNO>
            	<TEXT>So Kiss says LEFT.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_8</DOCNO>
            	<TEXT>He then snaps the ball and Emmitt gets 5 yards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_9</DOCNO>
            	<TEXT>Aikman comes back in the huddle all pissed off.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_10</DOCNO>
            	<TEXT>What fuck! @#%</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_11</DOCNO>
            	<TEXT>amp; Nate says shut the fuck up!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_186_12</DOCNO>
            	<TEXT>We got 5 yards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_0</DOCNO>
            	<TEXT>Sorrento Therapeutics, Inc. is a federal government contractor and, in compliance with its obligations under current federal regulations, Sorrento requires all employees, including newly hired employees, to present proof of vaccination against COVID-19 by December 8, 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_1</DOCNO>
            	<TEXT>Unless the employee is legally entitled to an accommodation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_2</DOCNO>
            	<TEXT>For further information, please refer to the Safer Federal Workforce Task Forces September 24, 2021 Guidance for Federal Contractors and Subcontractors, available at: [https://www.saferfederalworkforce.gov/contractors/](https://www.saferfederalworkforce.gov/contractors/).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_3</DOCNO>
            	<TEXT>WHAT WE ARE LOOKING FOR: Sorrento Therapeutics (Sorrento) is seeking an experienced Director, Head of Contracts to serve as a key member of the Sorrento Legal Department.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_4</DOCNO>
            	<TEXT>WHAT YOULL DO: The Head of Contracts is a key member of the Sorrento Legal Department and will perform a broad range of legal work, focusing primarily on managing the day-to-day contracting needs of a rapidly growing clinical-stage and commercial biopharmaceutical company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_5</DOCNO>
            	<TEXT>This role will contribute substantively to the development and management of the companys corporate contracting and will partner effectively with the companys R amp;D, Clinical, Business Development, Finance and Human Resources teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_6</DOCNO>
            	<TEXT>The Head of Contracts will be comfortable working under very tight deadlines and work cooperatively and collaboratively with the rest of the legal team to meet the companys goals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_7</DOCNO>
            	<TEXT>This role will be a high-profile, high-growth position with significant exposure to all levels of the company and will offer the potential for expansion of duties and opportunities to make a significant impact on the companys continued growth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_8</DOCNO>
            	<TEXT>ESSENTIAL DUTIES AND RESPONSIBILITIES: Lead the drafting and negotiation of a wide variety of contracts, including CDAs, MTAs, MSAs, CTAs, CRO agreements, consulting and physician advisory board agreements, commercial and API supply and manufacturing agreements, quality agreements, and research agreements with partners and academic institutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_9</DOCNO>
            	<TEXT>Draft and negotiate a high-volume of specialized agreements necessary for the startup and conduct of clinical trials, including confidentiality, vendor and CRO services, clinical trial, investigator-initiated studies, informed consents, and letters of indemnity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_10</DOCNO>
            	<TEXT>Provide advice and counsel clients on the preparation of agreements as well as the company's rights and obligations under executed agreements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_11</DOCNO>
            	<TEXT>Contribute to the establishment and ongoing improvement of contracting practices and procedures, including template development and associated playbooks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_12</DOCNO>
            	<TEXT>Participate in the definition and development of corporate policies, procedures, and programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_13</DOCNO>
            	<TEXT>Ensure that the company conducts its business in compliance with applicable FDA, Fraud and Abuse, Anti-Kickback, FCPA, HIPAA, and other applicable laws, rules, and regulations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_14</DOCNO>
            	<TEXT>Provide support on all other matters requested by the General Counsel or other members of the Legal Department, including with respect to litigation matters, as needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_15</DOCNO>
            	<TEXT>So Sorrento is listed as a Federal Contractor. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_187_16</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=450](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=450)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_188_0</DOCNO>
            	<TEXT>For all the players and coaches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_190_0</DOCNO>
            	<TEXT>I'm opening for me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_191_0</DOCNO>
            	<TEXT>It has nothing to do with SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_191_1</DOCNO>
            	<TEXT>It's the weekend and everyone is enjoying themselves watching the football games.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_191_2</DOCNO>
            	<TEXT>Enjoy and have a great time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_192_0</DOCNO>
            	<TEXT>It would be nice to see COVISTIX getting an FDA or EUA approval and all coaches and players and staff could be tested.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_193_0</DOCNO>
            	<TEXT>Georgia #1 and Bama went to 5th</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_194_0</DOCNO>
            	<TEXT>Nothing at all!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_194_1</DOCNO>
            	<TEXT>Isn't it great we can talk about just anything.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_195_0</DOCNO>
            	<TEXT>It only works 50% of the time and there seeking a EUA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_195_1</DOCNO>
            	<TEXT>I believe we can do better than that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_0</DOCNO>
            	<TEXT>COVISTIX COMING TO YOU ON INSTAGRAM IN MEXICO  amp; LATIN AMERICA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_1</DOCNO>
            	<TEXT>Currently there's 34,290,200 million viewers on Instagram on the Social Media platform in Mexico. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_2</DOCNO>
            	<TEXT>https://napoleoncat.com/stats/instagram-users-in-mexico/2021/09/](https://napoleoncat.com/stats/instagram-users-in-mexico/2021/09/) [https://www.instagram.com/p/CUp1U6Jrtpn/?utm\_medium=copy\_link](https://www.instagram.com/p/CUp1U6Jrtpn/?utm_medium=copy_link) [https://www.statista.com/statistics/950923/countries-with-most-instagram-users-latin-america/](https://www.statista.com/statistics/950923/countries-with-most-instagram-users-latin-america/) As you can see there selling for 4205 pesos = $203 per box divided by 25 = $8.12 per test There's 130.6M people that live in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_3</DOCNO>
            	<TEXT>DR JI said, Sorrento will have double digit million sales monthly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_4</DOCNO>
            	<TEXT>Well the way to reach middle class everyday Mexicans is by Instagram.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_5</DOCNO>
            	<TEXT>There's 661,3M people that live in Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_6</DOCNO>
            	<TEXT>Eventually Sorrento will have the approval in Canada, Brazil, and Mexico has a treaty with 70 other Countries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_7</DOCNO>
            	<TEXT>Remember Sorrento Mexico LTD is the gateway to Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_8</DOCNO>
            	<TEXT>The revenue is starting to pour in and the 3Q  amp; 4Q results will be better than expected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_9</DOCNO>
            	<TEXT>Going by DR JI figure's of double digit sales per month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_10</DOCNO>
            	<TEXT>I will say 25 million per month x $8.12 = $203M per month gross income.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_11</DOCNO>
            	<TEXT>The most very interesting part of this post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_12</DOCNO>
            	<TEXT>I was given the Instagram Link from Alex who follows me on the r/BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_13</DOCNO>
            	<TEXT>He lives in Honduras and he sent me the link last night.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_14</DOCNO>
            	<TEXT>The last time I checked Honduras is Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_196_15</DOCNO>
            	<TEXT>Please Thank him as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_197_0</DOCNO>
            	<TEXT>Honduras is in Latin America</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_198_0</DOCNO>
            	<TEXT>Social Media is the best way to reach everyday middle aged people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_199_0</DOCNO>
            	<TEXT>https://www.facebook.com/akuasul/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_199_1</DOCNO>
            	<TEXT>YOU CAN FIND COVISTIX ON FACEBOOK.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_200_0</DOCNO>
            	<TEXT>Thank you Alex</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_201_0</DOCNO>
            	<TEXT>Well I was 6-3 not bad.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_202_0</DOCNO>
            	<TEXT>You did pretty good I think better then me</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_0</DOCNO>
            	<TEXT>Claudia Sulaimn Deputy Director General AKUASUL</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_1</DOCNO>
            	<TEXT>Sorrento Mexico has established offices in Mexico City with Dr. Henry Ji as Chairman and Mr. Hctor Sulaimn S. as Chief Executive Officer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_2</DOCNO>
            	<TEXT>Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrentos Portfolio of COVID-19 Products in Mexico and Parts of Latin America July 20, 2021 at 3:29 PM EDT Download PDF Sorrento Therapeutics has established a Subsidiary Company in Mexico - Sorrento Therapeutics Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_3</DOCNO>
            	<TEXT>Sorrentos Mexican importer of record has received an initial importation permit from Mexico Authority COFEPRIS for the importation of the first 25 million COVI-STIX test units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_4</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico will coordinate all activities required for commercialization of COVI-STIX, and for the clinical trials and registration of Sorrentos portfolio of products for the Mexican and potentially other Latin American Markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_5</DOCNO>
            	<TEXT>SAN DIEGO, July 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has formed a subsidiary company based in Mexico City, Sorrento Therapeutics Mexico (Sorrento Mexico), to support the clinical development and registration of multiple COVID-19 related products Sorrento plans to develop and commercialize in Mexico and other Latin America territories.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_6</DOCNO>
            	<TEXT>Sorrento Mexico has established offices in Mexico City with Dr. Henry Ji as Chairman and Mr. Hctor Sulaimn S. as Chief Executive Officer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_7</DOCNO>
            	<TEXT>Sorrentos distributor has received from COFEPRIS written permission to import the first 25 million test units (1,000,000 boxes of 25 tests/box) of COVI-STIX into the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_8</DOCNO>
            	<TEXT>These COVI-STIX professional use package contain a positive and a negative control test and all the components necessary for testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_9</DOCNO>
            	<TEXT>Sorrento is ramping up manufacturing to fulfil subsequent orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_10</DOCNO>
            	<TEXT>We are excited to form Sorrento Mexico to coordinate the development of our COVID-19 portfolio of products in the region, we anticipate expanding the programs to encompass Sorrentos full range of diagnostic and therapeutic products, said Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_11</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-announces-formation-sorrento-therapeutics) Claudia  amp; Hector must be related some way?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_12</DOCNO>
            	<TEXT>If you live in Mexico you can log in and place your order for your Pharmacy, Resort, Airport, Sporting Event, School, and the list goes on. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_203_13</DOCNO>
            	<TEXT>https://akuasul.mx/](https://akuasul.mx/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_204_0</DOCNO>
            	<TEXT>How about husband and wife?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_205_0</DOCNO>
            	<TEXT>Yes he must be referring to someone else.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_205_1</DOCNO>
            	<TEXT>I would assume it's his wife.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_206_0</DOCNO>
            	<TEXT>https://wbcboxing.com/en/mauricio-sulaiman-saldivar-president-of-wbc/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_207_0</DOCNO>
            	<TEXT>Brother  amp; sister</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_208_0</DOCNO>
            	<TEXT>You're hired!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_208_1</DOCNO>
            	<TEXT>Get to work</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_209_0</DOCNO>
            	<TEXT>Did you notice IBRX is up 12% today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_210_0</DOCNO>
            	<TEXT>Did you notice IBRX was up 12% today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_210_1</DOCNO>
            	<TEXT>I wonder why?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_210_2</DOCNO>
            	<TEXT>We own some IBRX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_0</DOCNO>
            	<TEXT>SCILEX  amp; SORRENTO ARE PREPARING FOR SOMETHING REALLY BIG!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_1</DOCNO>
            	<TEXT>LOOK WHO'S HIRING!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_2</DOCNO>
            	<TEXT>The Territory Business Manager (TBM) will work in their assigned geography to lead with sales activities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_3</DOCNO>
            	<TEXT>Specifically, the TBM is responsible in their assigned geography to maximize awareness and sales results of promoted products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_4</DOCNO>
            	<TEXT>The TBM will engage key assigned Neurologist, Pain Management and Primary Care Physicians across their assigned territories in face-to-face discussions to promote assigned product(s), maximize the product(s) selling potential, meet program objectives, and deliver revenue in an assigned area and contribute to the achievement of the Companys revenue goals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_5</DOCNO>
            	<TEXT>The TBM will also be responsible to engage key pharmacies in each territory to conduct compliant sales discussions of the products promoted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_6</DOCNO>
            	<TEXT>So let's look at these new positions that were added.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_7</DOCNO>
            	<TEXT>All of these positions are to manage a sales force to maximize promoted products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_8</DOCNO>
            	<TEXT>Which products could they be talking about?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_9</DOCNO>
            	<TEXT>How many people in the US have shingles?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_10</DOCNO>
            	<TEXT>Would they need such a big sales force for shingles?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_11</DOCNO>
            	<TEXT>Or are they building the sales force for SP-102?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_12</DOCNO>
            	<TEXT>I would believe you would want the sales force all set up and ready to go.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_13</DOCNO>
            	<TEXT>So when sp-102 gets the PHASE 3 FDA approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_14</DOCNO>
            	<TEXT>The team will be ready to go to all the pharmacy's and Physician Offices ready to take the orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_15</DOCNO>
            	<TEXT>Territory Business Manager - Denver, CO [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=524](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=524) Territory Business Manager - Fresno-Bakersfield, CA [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=503](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=503) Territory Business Manager - Stamford, CT [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=454](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=454) Regional Team Field Trainer - Internal Position [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=493](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=493) The Boston Mass position has been filled. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_16</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete) Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_17</DOCNO>
            	<TEXT>SP-102 has received Fast Track status from the FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_18</DOCNO>
            	<TEXT>Top-line data from the study is expected in Q4 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_19</DOCNO>
            	<TEXT>Chronic pain affects 116 million Americans and costs the U.S. as much as $635 billion each year, according to a recent report from the Institute of Medicine (IOM) that called for changes in how chronic pain is managed6 and nearly 30 million patients suffer from lower back pain in the U.S.8 Government agencies, physicians, patients, and payers are looking for alternatives to opioids to reduce the risk of dependency or addiction, and serious side effects (such as respiratory depression and constipation), while still offering potent solutions for people living with chronic pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_211_20</DOCNO>
            	<TEXT>Know what you own and be patient because THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_0</DOCNO>
            	<TEXT>You wouldn't be build this huge sales force just for shingles.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_1</DOCNO>
            	<TEXT>A month ago I had really bad shoulder pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_2</DOCNO>
            	<TEXT>I went to Urgent Care to see if this could give me a RX for the pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_3</DOCNO>
            	<TEXT>Which they could not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_4</DOCNO>
            	<TEXT>They said I should take a over the counter patch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_5</DOCNO>
            	<TEXT>I asked if they could give me some ZTlido.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_6</DOCNO>
            	<TEXT>Which they wrote me a RX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_7</DOCNO>
            	<TEXT>So I went to my local pharmacy and they gave me the RX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_8</DOCNO>
            	<TEXT>I asked them how hard is it to get ZTLido delivered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_9</DOCNO>
            	<TEXT>They told me the rep that handles the RX fills the orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_10</DOCNO>
            	<TEXT>I asked do you get a lot of shingles?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_11</DOCNO>
            	<TEXT>He said NO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_12</DOCNO>
            	<TEXT>Not at all we would only carry one box.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_13</DOCNO>
            	<TEXT>And we could get more the next day if needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_14</DOCNO>
            	<TEXT>My point is there building a big team for something else.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_15</DOCNO>
            	<TEXT>My pain went away the next day and I still have plenty of patches left over.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_212_16</DOCNO>
            	<TEXT>It has to be SP-102 if you ask me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_214_0</DOCNO>
            	<TEXT>That what the Pharmacy said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_214_1</DOCNO>
            	<TEXT>They told the over the counter was only 4% lidocaine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_214_2</DOCNO>
            	<TEXT>But since I wanted to really see the difference.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_214_3</DOCNO>
            	<TEXT>I received 8 patches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_214_4</DOCNO>
            	<TEXT>I used 2 and my pain went away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_214_5</DOCNO>
            	<TEXT>Not sure if it was the patch or the Motrin.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_215_0</DOCNO>
            	<TEXT>I'm not impressed as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_215_1</DOCNO>
            	<TEXT>I was able to out drink him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_215_2</DOCNO>
            	<TEXT>He was a light weight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_216_0</DOCNO>
            	<TEXT>I'm voting no as well</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_0</DOCNO>
            	<TEXT>WHY IS SORRENTO EXPANDING THEIR PHARMACEUTICAL SPACE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_1</DOCNO>
            	<TEXT>On July 1, 2021, Sorrento Therapeutics, Inc. (the Company) entered into a binding term sheet (the Term Sheet) with HCP Life Science REIT, Inc. (Landlord) setting forth the terms and conditions by which the Company will lease premises located at 4930 Directors Place, San Diego, California (the Building).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_2</DOCNO>
            	<TEXT>The lease (the Lease) will have an initial 188-month term and include approximately 163,205 rentable square feet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_3</DOCNO>
            	<TEXT>The commencement date of the Lease will be determined at a later date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_4</DOCNO>
            	<TEXT>The initial rent for the Lease is approximately $5.10 per square foot and is subject to an annual increase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_5</DOCNO>
            	<TEXT>Pursuant to the Term Sheet, not less than twelve months prior to the expiration of the then-current term of the Lease, the Company has an option to extend the Lease term for up to two additional five-year terms at then current market rates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_6</DOCNO>
            	<TEXT>Pursuant to the Term Sheet, the Companys existing lease agreements with the Landlord for 9380 Judicial Drive, 4921 Directors Place, 4955 Directors Place and 4939 Directors Place (the Other Leases) shall be extended to be coterminous with the term of the Lease and the initial rent for the extension period of each of the Other Leases shall be at then current market rates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_7</DOCNO>
            	<TEXT>That's a total of 25 1/2 year lease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_8</DOCNO>
            	<TEXT>Why are they expanding?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_9</DOCNO>
            	<TEXT>Because of potential monumental FDA approvals that are expected?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_10</DOCNO>
            	<TEXT>Pharmaceutical Companies don't expand unless there's something big on the horizon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_217_11</DOCNO>
            	<TEXT>That's right because THE BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_218_0</DOCNO>
            	<TEXT>They also leased an additional building that's around the corner as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_218_1</DOCNO>
            	<TEXT>Add another 52,000 sq ft.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_219_0</DOCNO>
            	<TEXT>Go to your email address.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_219_1</DOCNO>
            	<TEXT>You should of gotten an email to VOTE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_219_2</DOCNO>
            	<TEXT>I voted NO on #5 i hope you all will do the same.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_220_0</DOCNO>
            	<TEXT>They keep patenting away!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_220_1</DOCNO>
            	<TEXT>Sorrento Therapeutics Granted U.S. Patent Titled 'Variant antibodies that bind OX40' patft.uspto.gov/netacg...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_221_0</DOCNO>
            	<TEXT>https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2 amp;Sect2=HITOFF amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm amp;r=5203 amp;f=G amp;l=50 amp;d=PTXT amp;p=105 amp;S1=20211012 amp;OS=20211012 amp;RS=20211012</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_222_0</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,142,579</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_0</DOCNO>
            	<TEXT>A Study to Evaluate Ipilimumab Administered Intra-lymphatically Using the Sofusa DoseConnect DEVICE with IV-administered Nivolumab in Patients with Metastatic Melanoma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_1</DOCNO>
            	<TEXT>MAYO CLINIC CLINICAL TRIAL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_2</DOCNO>
            	<TEXT>ABOUT THIS STUDY The primary objective of the overall study is to determine the maximum tolerated dose (MTD) of ipilimumab that can be administered through the DoseConnect device, followed 30 minutes later by nivolumab IV on Day 1 of a 21-day cycle in patients with metastatic melanoma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_3</DOCNO>
            	<TEXT>Participation eligibility Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_4</DOCNO>
            	<TEXT>Guidelines differ from study to study, and identify who can or cannot participate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_5</DOCNO>
            	<TEXT>There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_6</DOCNO>
            	<TEXT>Contact the study team to discuss study eligibility and potential participation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_7</DOCNO>
            	<TEXT>Q - DID EVERYONE FORGET ABOUT THE MAYO CLINIC ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_8</DOCNO>
            	<TEXT>A - I did not forget about the license agreement... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-secures-exclusive-license-mayo-clinic-antibody-drug](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-secures-exclusive-license-mayo-clinic-antibody-drug) Q - Did you know the Mayo Clinic is using the DoseConnect TM device that belongs to Sofusa?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_9</DOCNO>
            	<TEXT>A- Yes they are and it's open for enrollment. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_10</DOCNO>
            	<TEXT>https://www.mayo.edu/research/clinical-trials/cls-20516863](https://www.mayo.edu/research/clinical-trials/cls-20516863) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-secures-exclusive-license-mayo-clinic-antibody-drug](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-secures-exclusive-license-mayo-clinic-antibody-drug) The ADNIC technology potentially eliminates the need to use covalent linker technology by incorporating therapeutically or immunologically active antibodies in a reversible manner with a nanoparticle composed of albumin and a payload of one or more drugs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_11</DOCNO>
            	<TEXT>The platform has indicated clinical benefits in an FDA-cleared investigator-sponsored trial at Mayo Clinic under the supervision of Svetomir Markovic, M.D., Ph.D., a medical oncologist and hematologist.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_12</DOCNO>
            	<TEXT>Preliminary results suggest that patients have experienced clinical benefit from receiving prototype product candidates that utilize the ADNIC technology developed by Dr. Markovic and Wendy Navalo at Mayo Clinic, including objective responses in heavily pre-treated patients with advanced cancers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_13</DOCNO>
            	<TEXT>The technology platform is protected by a rich intellectual property portfolio comprised of 17 patent families, 32 patents granted to date with life through at least 2035 and another 135 patents pending.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_14</DOCNO>
            	<TEXT>This stable complex potentially allows for the delivery of higher doses of active drug directly into the tumor as demonstrated in animal studies and in preliminary trials in cancer patients, according to Dr. Markovic, the inventor of the ADNIC technology at Mayo Clinic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_15</DOCNO>
            	<TEXT>The reversibility of complex formation may allow for deeper tumor penetration, thereby potentially enabling a better anti-tumor effect.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_16</DOCNO>
            	<TEXT>The exclusive license to the ADNIC platform also includes access to a proprietary and scalable manufacturing process that is expected to enable high product yield and low COGs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_17</DOCNO>
            	<TEXT>The Mayo Clinic-developed ADNIC platform is a perfect fit for our extensive G-MAB antibody products including but not limited to our anti-PD-L1, anti-CD38, anti-BCMA and anti-ROR1 antibodies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_18</DOCNO>
            	<TEXT>We will accelerate the development and commercialization of this amazing technology by generating and developing multiple next-generation ADNIC product candidates for the potential treatment of cancer, COVID-19 and other human diseases, stated Henry Ji, Ph.D., Chairman and CEO of Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_19</DOCNO>
            	<TEXT>Teaming with Mayo Clinic, this license expands Sorrentos mission of developing innovative life-saving medicines for unmet medical needs, continued Dr. Ji.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_20</DOCNO>
            	<TEXT>Sorrento will continue to execute on the clinical development strategy developed by Mayo Clinic for multiple ADNIC lead product candidates in COVID-19 and multiple solid and hematologic malignancies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_21</DOCNO>
            	<TEXT>Mayo Clinic, Dr. Markovic and Ms. Navalo have financial interests in the technology referenced in this release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_22</DOCNO>
            	<TEXT>Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_23</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_223_24</DOCNO>
            	<TEXT>Because the Mayo Clinic is working hard with Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_224_0</DOCNO>
            	<TEXT>The technology platform is protected by a rich intellectual property portfolio comprised of 17 patent families, 32 patents granted to date with life through at least 2035 and another 135 patents pending.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_225_0</DOCNO>
            	<TEXT>Everyone is voting NO for #5</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_0</DOCNO>
            	<TEXT>NON-OPIOID SCIATICA TREATMENT FAST TRACKED BY FDA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_1</DOCNO>
            	<TEXT>That was 45 months ago since SP-102 has been fast tracked.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_2</DOCNO>
            	<TEXT>It's been a long road to the finish line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_3</DOCNO>
            	<TEXT>There expecting to release the results in the 4Q. In possible good news for interventional pain physicians, the FDA has granted Semnur Pharmaceuticals, Inc., Fast Track Designation for the company's SP-102 product for patients with lumbar radicular pain/sciatica.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_4</DOCNO>
            	<TEXT>On January 7, 2018, the company also announced the start of a pivotal Phase 3 clinical trial in the U.S. to evaluate the product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_5</DOCNO>
            	<TEXT>Click here to find out if any of your patients qualify for the study. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_6</DOCNO>
            	<TEXT>http://www.clearbackpainstudy.com/](http://www.clearbackpainstudy.com/) SP-102 The company says SP-102 is the first non-opioid corticosteroid formulated as a viscous gel injection in development for the treatment of lumbar radicular pain/sciatica, containing no neurotoxic preservatives, surfactants, solvents or particulates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_7</DOCNO>
            	<TEXT>The CLEAR ("Corticosteroid Lumbar Epidural Analgesia for Radiculopathy") Clinical Study is a randomized, double-blind, placebo-controlled Phase 3 trial that will enroll 400 patients with lumbar radicular pain at up to 35 sites across the U.S. The product is injected into the lower back while at the doctors office.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_8</DOCNO>
            	<TEXT>The primary endpoint of the study, according to the company, is mean change in the Numerical Pain Rating Scale for leg pain compared to intramuscular injection of placebo over four weeks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_9</DOCNO>
            	<TEXT>The secondary endpoints include other measures of pain at 4 and 12 weeks as well as time to repeat injection of SP-102, safety and disability.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_10</DOCNO>
            	<TEXT>The study includes an open-label extension to build the safety database of patients treated with SP-102.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_11</DOCNO>
            	<TEXT>The FDA's Fast Track program expedites the regulatory review of therapeutic programs that seek to address significant unmet medical needs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_12</DOCNO>
            	<TEXT>The designation allows the company to communicate more frequently with the FDA about the drug development plan and data necessary to expedite the development of the treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_13</DOCNO>
            	<TEXT>Dmitri Lissin M.D., the company's chief medical officer said "We are eager to investigate what may be the first FDA-approved epidural injection that the interventional pain physicians could offer their patients for persistent relief of their pain, caused by nerve root compression usually by herniated intervertebral discs."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_14</DOCNO>
            	<TEXT>Interventional pain specialists and spine surgeons have had a spotted relationship as the interventionalists have expanded their scope of practice to interventions traditionally reserved for surgeons.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_15</DOCNO>
            	<TEXT>If the therapy proves to be successful, patients won't care. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_16</DOCNO>
            	<TEXT>https://ryortho.com/breaking/non-opioid-sciatica-treatment-fast-tracked-by-fda/](https://ryortho.com/breaking/non-opioid-sciatica-treatment-fast-tracked-by-fda/) READ THIS PARAGRAPH We are anxiously awaiting a new injectable gel formulation of dexamethasone and submission of data to the FDA for the treatment of radicular pain based on the results of a large, randomized, placebo-controlled, multi-center trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_17</DOCNO>
            	<TEXT>If approved by the FDA, SP-102 would be the first corticosteroid with an indication for epidural administration in the U.S., resulting in rapid pain relief and addressing safety issues with off-label steroid preparations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_18</DOCNO>
            	<TEXT>SP-102 would be a welcome addition to the armamentarium of interventional pain physicians, providing a non-surgical, non-opioid alternative for a condition affecting millions of people, said Dr. Steven P. Cohen, Chief of Pain Medicine and Professor of Anesthesiology  amp; Critical Care Medicine, Neurology, Physical Medicine  amp; Rehabilitation, and Psychiatry  amp; Behavioral Sciences at the Johns Hopkins School of Medicine, and a Professor of Anesthesiology and Physical Medicine  amp; Rehabilitation at Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_19</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete) If you're new to Sorrento to just cut in line and didn't have to wait 45 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_226_20</DOCNO>
            	<TEXT>THE BEST IS COMING.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_227_0</DOCNO>
            	<TEXT>Why else would DR JI want everyone to vote yes for #5?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_227_1</DOCNO>
            	<TEXT>The payout is going to be massive.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_228_0</DOCNO>
            	<TEXT>https://www.hopkinsmedicine.org/profiles/details/steven-cohen</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_0</DOCNO>
            	<TEXT>Background Dr. Steven P. Cohen obtained his medical degree at the Mount Sinai School of Medicine, completed an anesthesiology residency at Columbia University, and a pain management fellowship at Massachusetts General Hospital.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_1</DOCNO>
            	<TEXT>Currently, he is Professor of Anesthesiology  amp; Critical Care Medicine, as well as Physical Medicine  amp; Rehabilitation, at the Johns Hopkins School of Medicine and Uniformed Services University of the Health Sciences.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_2</DOCNO>
            	<TEXT>He is also Director of the Blaustein Pain Treatment Center, Medical Education and Quality Assurance for the Pain Management Division at Johns Hopkins, and Director of Pain Research at Walter Reed National Military Medical Center.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_3</DOCNO>
            	<TEXT>Dr. Cohen has been very active in teaching and pain research in recent years, having published over 250 peer-reviewed articles, reviews and book chapters in the past 15 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_4</DOCNO>
            	<TEXT>Among his major contributions are the development of an FDA-approved technique for treating sacroiliac joint pain (lateral branch radiofrequency denervation), inventing the intravenous ketamine test to help guide treatment in patients with chronic pain, and performing the first studies evaluating the epidural administration of biological agents for pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_5</DOCNO>
            	<TEXT>These articles have been featured in some of the top general medical journals including Lancet, CMAJ, BMJ, Annals of Internal Medicine and JAMA-Internal Medicine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_6</DOCNO>
            	<TEXT>His research has been the subject of articles in the Science Section of the New York Times on 4 separate occasions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_7</DOCNO>
            	<TEXT>He has been the first author on the Pain chapter in the last 2 editions of Cecil Textbook of Medicine, and was listed in 2014 as one of the top 10 experts in the world for back pain based on quantitative analysis of publications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_8</DOCNO>
            	<TEXT>In addition to his academic work, Dr. Cohen is a retired Colonel in the U.S. Army, and was deployed 4 times in support of operations in Bosnia, Iraq and Afghanistan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_9</DOCNO>
            	<TEXT>He also serves as the Reserve Liaison to the Pain Management Consultants to the U.S. Army and Navy Surgeons General.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_10</DOCNO>
            	<TEXT>Dr. Cohen has previously presented data on pain management in service members to the U.S. Congress, FDA and General Officers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_11</DOCNO>
            	<TEXT>His research was instrumental in the passage of the 2008 Military Pain Care Act, and he served as an inaugural member of the U.S. Army Medical Advisory Board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_229_12</DOCNO>
            	<TEXT>His previous awards include the American Society of Regional Anesthesia  amp; Pain Medicine John J. Bonica Award, ASIPP Public Service Award, Donlin M. Long Pain Award, Michael J. Cousins Award Lecture, American Academy of Pain Medicine Founders Award, the Order of</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_0</DOCNO>
            	<TEXT>No unexpected AEs were reported.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_1</DOCNO>
            	<TEXT>Please look at the timelines for ACEA Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_2</DOCNO>
            	<TEXT>ACEA Therapeutics, Inc. announced that on July 16, 2020, the FDA cleared the IND to initiate a Phase 2 trial of Abivertinib in patients with COVID-19 who have moderate to severe pulmonary symptoms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_3</DOCNO>
            	<TEXT>The Trial, A Phase 2, Double Blinded, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19 (NCT04440007), will be initially conducted in centers in the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_4</DOCNO>
            	<TEXT>Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Brutons tyrosine kinase (BTK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_5</DOCNO>
            	<TEXT>ACEA announced an exclusive license of abibvertinib to Sorrento across all indications outside of China on 21MAY2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_6</DOCNO>
            	<TEXT>ACEA will continue developing abivertinib all indications in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_7</DOCNO>
            	<TEXT>Abivertinib irreversibly binds to the BTK receptor, preventing the phosphorylation of the receptor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_8</DOCNO>
            	<TEXT>Due to this effect, it has shown potent immunomodulatory activities by inhibiting key pro-inflammatory cytokine production, including IL-1beta, IL-6 and TNF-alpha.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_9</DOCNO>
            	<TEXT>These cytokines are associated with COVID disease progression and poor outcomes in patients with acute respiratory distress syndrome (ARDS).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_10</DOCNO>
            	<TEXT>Since abivertinib targets multiple cytokines simultaneously, we anticipate the effects with Abivertinib will be incremental to the initial findings of others which primarily reduce IL-6, and the clinical benefits more pronounced given the broader range of anti-cytokine activity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_11</DOCNO>
            	<TEXT>Abivertinib has been studied in over 600 patients worldwide in various oncologic indications, including one registration trial in non-small cell lung cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_12</DOCNO>
            	<TEXT>Most treatment-related AEs were grade 1 or 2, the most common of which were transaminase elevations and diarrhea, which are generally considered common for TKIs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_13</DOCNO>
            	<TEXT>Other common treatment-related AEs included anemia, neutropenia and thrombocytopenia, and all generally considered typical AEs with long-term use of TKIs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_14</DOCNO>
            	<TEXT>No unexpected AEs were reported.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_15</DOCNO>
            	<TEXT>That's correct there were NO UNEXPECTED AEs REPORTED Abivertinib has been studied in over 600 patients worldwide in various oncologic indications, including one registration trial in non-small cell lung cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_16</DOCNO>
            	<TEXT>So what does Sorrento Therapeutics do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_17</DOCNO>
            	<TEXT>June 2nd 2021 Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-completes-acquisition-acea-therapeutics-creating-major](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-completes-acquisition-acea-therapeutics-creating-major) June 22nd 2021 Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected in October. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_18</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-phase-2-abivertinib-clinical-studies-have) Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_19</DOCNO>
            	<TEXT>Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_20</DOCNO>
            	<TEXT>Studies are complementary and address both dose duration and disease stage variations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_21</DOCNO>
            	<TEXT>Data from both studies is expected to be available for review by the end of October.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_22</DOCNO>
            	<TEXT>Currently we're in 4Q and by the end of October will receive the results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_23</DOCNO>
            	<TEXT>They were due in September 3Q but got pushed back to the 4Q. We are very satisfied with the progress made by our team and we are eager to review the results of these two parallel trials, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_24</DOCNO>
            	<TEXT>By combining our efforts in the US and Brazil, we were able to optimize patient exposures, reduce clinical trial costs, explore the potential benefits of two promising therapeutic regimens, and most importantly, accelerate data generation for regulators to assess the use of Abivertinib in COVID-19 patients with the potential of seeking an emergency use request.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_230_25</DOCNO>
            	<TEXT>THE BEST IS YET TO COME IN OCTOBER</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_231_0</DOCNO>
            	<TEXT>Have a great day everyone!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_232_0</DOCNO>
            	<TEXT>THE KEY TO BRAZIL [https://www.synovahealth.com/lease](https://www.synovahealth.com/lease) watch this view</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_233_0</DOCNO>
            	<TEXT>BTW Didn't DR JI say we should be getting the EUA for COVISTIX in Brazil?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_233_1</DOCNO>
            	<TEXT>I believe he said hopefully next month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_233_2</DOCNO>
            	<TEXT>That was in September.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_234_0</DOCNO>
            	<TEXT>The last press release was on Sept 19th.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_234_1</DOCNO>
            	<TEXT>I believe we're very overdue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_235_0</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/fda-authorizes-sorrento-phase-2-trial-epidural-resiniferatoxin</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_235_1</DOCNO>
            	<TEXT>I'm expecting more press releases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_236_0</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/fda-authorizes-sorrento-phase-2-trial-epidural-resiniferatoxin</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_237_0</DOCNO>
            	<TEXT>FDA Authorizes Sorrento Phase 2 Trial of Epidural Resiniferatoxin for the Orphan Indication of Control of Intractable Cancer Pain</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_237_1</DOCNO>
            	<TEXT>* Phase 2 trial of resiniferatoxin (RTX) to proceed following clearance from FDA. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_237_2</DOCNO>
            	<TEXT>The decision is supported by the Phase 1 data confirming RTX safety for epidural administration without dose limiting toxicity at any doses tested up to 30 ug. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_237_3</DOCNO>
            	<TEXT>Safety and initial pain relief observed in patients with advanced cancer support RTX as a good candidate for long-term control of refractory cancer pain in a broad spectrum of patients. *</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_237_4</DOCNO>
            	<TEXT>RTX is a drug that very specifically targets cells carrying the TRPV1 "heat and pain" receptors (the discovery of which led to the 2021 Nobel Prize in Medicine).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_237_5</DOCNO>
            	<TEXT>By modulating pain signaling, RTX has the potential to reduce or completely eliminate pain and the need for high dose opioids in advanced cancer patients. * [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_237_6</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9](https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_238_0</DOCNO>
            	<TEXT>We got more coming!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_239_0</DOCNO>
            	<TEXT>Yes it will</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_242_0</DOCNO>
            	<TEXT>[https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-fda-clearance-proceed-clinical-trial-anti-trop](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-fda-clearance-proceed-clinical-trial-anti-trop) I told you!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_243_0</DOCNO>
            	<TEXT>We may get one more press release today</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_244_0</DOCNO>
            	<TEXT>Keep them coming!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_246_0</DOCNO>
            	<TEXT>He should be in charge of the FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_0</DOCNO>
            	<TEXT>Sorrento Therapeutics gets FDA greenlight for ESG-401 cancer trials</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_1</DOCNO>
            	<TEXT>Sorrento Therapeutics (SRNE +1.5%) has received clearance from the U.S. FDA to proceed with clinical trials for the company's anti-TROP-2 antibody drug conjugate ESG-401.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_2</DOCNO>
            	<TEXT>The health regulator has given clearance to proceed with trials in cancer patients with relapsed or refractory solid tumors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_3</DOCNO>
            	<TEXT>ESG-401 addresses a highly unmet need for the treatment of multiple solid tumors, including triple-negative breast cancer and urothelial carcinoma, the company said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_4</DOCNO>
            	<TEXT>Separately, the company received the greenlight from the health regulator to start a Phase 2 trial designed to evaluate resiniferatoxin as a treatment for intractable pain linked to advanced cancer. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_5</DOCNO>
            	<TEXT>https://seekingalpha.com/news/3752410-sorrento-gets-fda-greenlight-for-esg-401-cancer-trials](https://seekingalpha.com/news/3752410-sorrento-gets-fda-greenlight-for-esg-401-cancer-trials) [https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9](https://clinicaltrials.gov/ct2/show/NCT05067257?term=sorrento amp;recrs=ab amp;draw=2 amp;rank=9) Sometimes when there's an earthquake it could take a few days for the tsunami to hit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_6</DOCNO>
            	<TEXT>Know what you own and be prepared for the short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_7</DOCNO>
            	<TEXT>Please take a look. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_8</DOCNO>
            	<TEXT>https://fintel.io/ss/us/srne](https://fintel.io/ss/us/srne) Short Squeeze Score The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_9</DOCNO>
            	<TEXT>The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_10</DOCNO>
            	<TEXT>The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_247_11</DOCNO>
            	<TEXT>Update Frequency: Intraday See our Short Squeeze Leaderboards for US, Canada, Australia and Hong Kong 75.46 403 out of 5458 SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest 45,659,804 shares - source: NASDAQ Short Interest Ratio 17.10 Days to Cover Short Interest % Float 16.77% - source: NASDAQ (short interest), Capital IQ (float) Dark Pool Short Volume 546,969 shares - source: FINRA Dark Pool Short Volume Ratio 41.25% - source: FINRA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_248_0</DOCNO>
            	<TEXT>THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_249_0</DOCNO>
            	<TEXT>Pray for a blessing not for a wish.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_249_1</DOCNO>
            	<TEXT>God does answer prayers</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_0</DOCNO>
            	<TEXT>Safety of Epidural Steroid Injections for Lumbosacral Radicular Pain: Unmet Medical Need</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_1</DOCNO>
            	<TEXT>Steven P Cohen 1, Emileigh Greuber 2, Kip Vought 2, Dmitri Lissin 2 Affiliations expand PMID: 34265792 PMCID: PMC8360670 DOI: 10.1097/AJP.0000000000000963 Free PMC article Abstract Objective: Epidural steroid injections (ESIs) are a commonly utilized treatment for lumbosacral radicular pain caused by intervertebral disc herniation or stenosis.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_2</DOCNO>
            	<TEXT>Although effective in certain patient populations, ESIs have been associated with serious complications, including paralysis and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_3</DOCNO>
            	<TEXT>In 2014, the US Food and Drug Administration (FDA) issued a safety warning on the risk of injecting corticosteroids into the epidural space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_4</DOCNO>
            	<TEXT>The aims of this article were to review the neurological complications associated with ESIs and to compare the formulations, safety, and effectiveness of commercially available corticosteroids given by transforaminal, interlaminar, or caudal injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_5</DOCNO>
            	<TEXT>Methods: Serious adverse events associated with ESIs were identified by a search of the FDA Adverse Event Reporting System (FAERS) database.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_6</DOCNO>
            	<TEXT>A MEDLINE search of the literature was conducted to identify clinical trials comparing the safety and effectiveness of nonparticulate and particulate corticosteroid formulations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_7</DOCNO>
            	<TEXT>Results: Neurological complications with ESIs were rare and more often associated with the use of particulate corticosteroids administered by transforaminal injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_8</DOCNO>
            	<TEXT>Among the 10 comparative-effectiveness studies reviewed, 7 found nonparticulate steroids had comparable efficacy to particulate steroids, and 3 studies suggested reduced efficacy or shorter duration of effect for nonparticulate steroids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_9</DOCNO>
            	<TEXT>Discussion: The risk of complications for transforaminal ESI is greater with particulate corticosteroids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_10</DOCNO>
            	<TEXT>Nonparticulate corticosteroids, which are often recommended as first-line therapy, may have a short duration of effect, and many commercial formulations contain neurotoxic preservatives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_11</DOCNO>
            	<TEXT>The safety profile of ESIs may continue to improve with the development of safer, sterile formulations that reduce the risk of complications while maintaining efficacy. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_12</DOCNO>
            	<TEXT>https://pubmed.ncbi.nlm.nih.gov/34265792/](https://pubmed.ncbi.nlm.nih.gov/34265792/) Background Dr. Steven P. Cohen obtained his medical degree at the Mount Sinai School of Medicine, completed an anesthesiology residency at Columbia University, and a pain management fellowship at Massachusetts General Hospital.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_13</DOCNO>
            	<TEXT>Currently, he is Professor of Anesthesiology  amp; Critical Care Medicine, as well as Physical Medicine  amp; Rehabilitation, at the Johns Hopkins School of Medicine and Uniformed Services University of the Health Sciences.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_14</DOCNO>
            	<TEXT>He is also Director of the Blaustein Pain Treatment Center, Medical Education and Quality Assurance for the Pain Management Division at Johns Hopkins, and Director of Pain Research at Walter Reed National Military Medical Center.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_15</DOCNO>
            	<TEXT>Dr. Cohen has been very active in teaching and pain research in recent years, having published over 250 peer-reviewed articles, reviews and book chapters in the past 15 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_16</DOCNO>
            	<TEXT>Among his major contributions are the development of an FDA-approved technique for treating sacroiliac joint pain (lateral branch radiofrequency denervation), inventing the intravenous ketamine test to help guide treatment in patients with chronic pain, and performing the first studies evaluating the epidural administration of biological agents for pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_17</DOCNO>
            	<TEXT>These articles have been featured in some of the top general medical journals including Lancet, CMAJ, BMJ, Annals of Internal Medicine and JAMA-Internal Medicine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_18</DOCNO>
            	<TEXT>His research has been the subject of articles in the Science Section of the New York Times on 4 separate occasions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_19</DOCNO>
            	<TEXT>He has been the first author on the Pain chapter in the last 2 editions of Cecil Textbook of Medicine, and was listed in 2014 as one of the top 10 experts in the world for back pain based on quantitative analysis of publications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_20</DOCNO>
            	<TEXT>In addition to his academic work, Dr. Cohen is a retired Colonel in the U.S. Army, and was deployed 4 times in support of operations in Bosnia, Iraq and Afghanistan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_21</DOCNO>
            	<TEXT>He also serves as the Reserve Liaison to the Pain Management Consultants to the U.S. Army and Navy Surgeons General.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_22</DOCNO>
            	<TEXT>Dr. Cohen has previously presented data on pain management in service members to the U.S. Congress, FDA and General Officers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_23</DOCNO>
            	<TEXT>His research was instrumental in the passage of the 2008 Military Pain Care Act, and he served as an inaugural member of the U.S. Army Medical Advisory Board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_24</DOCNO>
            	<TEXT>His previous awards include the American Society of Regional Anesthesia  amp; Pain Medicine John J. Bonica Award, ASIPP Public Service Award, Donlin M. Long Pain Award, Michael J. Cousins Award Lecture, American Academy of Pain Medicine Founders Award, Dr Steven P. Cohen is a hero in my book.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_25</DOCNO>
            	<TEXT>He should be IN CHARGE of the FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_26</DOCNO>
            	<TEXT>Everyone please click open and read. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_250_27</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-com](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-com)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_251_0</DOCNO>
            	<TEXT>You should write to DR Steven P. Cohen from a veteran to a veteran.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_252_0</DOCNO>
            	<TEXT>Pray for a blessing that will help people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_252_1</DOCNO>
            	<TEXT>People that are suffering from COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_253_0</DOCNO>
            	<TEXT>I would try emailing him first @ John Hopkins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_253_1</DOCNO>
            	<TEXT>Remind him of sp-102 and ask him what he thinks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_254_0</DOCNO>
            	<TEXT>Also he should be thanked for his hard work and service to our country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_255_0</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_0</DOCNO>
            	<TEXT>MISSION IS TOP SECRET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_1</DOCNO>
            	<TEXT>NAMRU-3's mission is to study, monitor, and detect emerging and re-emerging disease threats of military and public health importance; develop mitigation strategies against these threats in partnership with host nations and international and U.S. agencies in CENTCOM, EUCOM, and AFRICOM areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_2</DOCNO>
            	<TEXT>NAMRU-3 basic science, epidemiologic, and clinical investigations have included numerous tropical and subtropical infectious diseases such as enteric diseases, acute respiratory infections, hepatitis, tuberculosis, meningitis, HIV, and various parasitic, rickettsial, and arboviral infections that are endemic and important public health problems to the region.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_3</DOCNO>
            	<TEXT>The modern mission of the NAMRUs is threefold: To investigate prophylactic agents such as vaccines and pharmaceuticals against tropical infectious diseases which cause severe mortality or morbidity to the US military member in the deployed environment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_4</DOCNO>
            	<TEXT>Generally the focus of study is orphan illnesses with little or no investment by major pharmaceutical companies and include parasitic infection such as malaria and leishmaniasis, viral diseases such as dengue fever and other arboviruses, and bacterial illnesses like traveler's diarrhea (ETEC, campylobacter, shigella).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_5</DOCNO>
            	<TEXT>To augment public health and military medical infrastructure of host and partner nations by assisting in surveillance of outbreaks and providing laboratory surge capacity during pandemics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_6</DOCNO>
            	<TEXT>To provide assistance in training host nation scientists in epidemiologic techniques or modern laboratory molecular biology methods.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_7</DOCNO>
            	<TEXT>Via these collaborations with partner nations, the NAMRU gets to conduct research on diseases that threaten troops on deployment but are not commonly seen in the US, and to get advanced notice of impending pandemics such as avian influenza that might affect military operational readiness.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_8</DOCNO>
            	<TEXT>The host nation benefits by getting access to state of the art treatments and protection against diseases endemic to their country and a more robust public health infrastructure and better trained microbiology and physician population.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_9</DOCNO>
            	<TEXT>This results in both military and political benefits to both nations and as such all NAMRU personnel are considered diplomats and counted as members of the US embassy in the host country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_10</DOCNO>
            	<TEXT>NAMRU-3 collaborators include the Egyptian Ministry of Health, the U.S. National Institutes of Health (NIH), the World Health Organization (WHO), the U.S. Agency for International Development (USAID) and the U.S. Centers for Disease Control and Prevention (CDC).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_11</DOCNO>
            	<TEXT>NAMRU-3 has been a WHO Collaborating Center for HIV/AIDS since 1987.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_12</DOCNO>
            	<TEXT>NAMRU-3 also serves as a WHO reference laboratory for influenza and meningitis in the Eastern Mediterranean Region (EMRO) and is in the process of being recognized as an Avian Influenza reference laboratory by WHO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_13</DOCNO>
            	<TEXT>Research partnerships exist with the countries of Yemen, Saudi Arabia, Oman, Syria, Sudan, and the Republics of Ukraine, Uzbekistan, Kyrgyzstan, Kazakhstan, and Azerbaijan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_14</DOCNO>
            	<TEXT>So on JUNE 22nd 2021 what does NAMRU do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_256_15</DOCNO>
            	<TEXT>THEY... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) When I say THE BEST IS YET TO COME it's because it is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_257_0</DOCNO>
            	<TEXT>Don't ever bet against our military because you will lose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_258_0</DOCNO>
            	<TEXT>I love the prediction</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_0</DOCNO>
            	<TEXT>SORRENTO IS CURRENTLY LOOKING TO HIRE 14 RESEARCH ASSOCIATES</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_1</DOCNO>
            	<TEXT>Research Associate San Diego, California Research Associate San Diego, California Research Associate San Diego, California Research Associate San Diego, California Research Associate San Diego, California Research Associate San Diego, California Research Associate San Diego, California Research Associate San Diego, California Research Associate San Diego, California Research Associate - Bioconjugation San Diego, California Research Associate - CAR-T(DAR-T) In Vivo Pharmacology San Diego, California Research Associate - Toxicology San Diego, California Research Associate, Analytical Development San Diego, California Research Associate/Scientist San Diego, California [https://sorrentotherapeutics.com/careers/](https://sorrentotherapeutics.com/careers/) Expanding and building a bigger and better and larger Pharmaceutical Company to fill the newly acquired building that they will lease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_2</DOCNO>
            	<TEXT>215,000 Square feet of Office/Lab space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_3</DOCNO>
            	<TEXT>In total Sorrento is looking to hire 84 new positions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_4</DOCNO>
            	<TEXT>Now ask yourselves this question?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_5</DOCNO>
            	<TEXT>Would you expand your business if you didn't have the revenue to do so?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_6</DOCNO>
            	<TEXT>The revenue from COVISTIX will start to pour in the 4Q and throughout the years to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_7</DOCNO>
            	<TEXT>We should hear something from Brazil  amp; Canada very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_8</DOCNO>
            	<TEXT>DR JI said there waiting for the EUAs to come rolling in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_9</DOCNO>
            	<TEXT>Mexico has a treaty with 70 other Countries with trade.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_10</DOCNO>
            	<TEXT>Latin America sales will fully run the rest of the U.S. clinical trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_11</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_259_12</DOCNO>
            	<TEXT>Because the BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_260_0</DOCNO>
            	<TEXT>Hopefully the USA in follow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_261_0</DOCNO>
            	<TEXT>FDA: Abbott is recalling two lab-based COVID-19 tests due to the possibility of false positive results</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_261_1</DOCNO>
            	<TEXT>[https://www.marketwatch.com/story/fda-abbott-is-recalling-two-at-home-covid-19-test-due-to-the-possibility-of-false-positive-results-2021-10-15?mod=newsviewer\_click](https://www.marketwatch.com/story/fda-abbott-is-recalling-two-at-home-covid-19-test-due-to-the-possibility-of-false-positive-results-2021-10-15?mod=newsviewer_click)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_262_0</DOCNO>
            	<TEXT>If you don't have Marketwatch google the link</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_263_0</DOCNO>
            	<TEXT>https://www.fda.gov/medical-devices/medical-device-recalls/abbott-molecular-inc-recalls-alinity-m-sars-cov-2-amp-kit-and-alinity-m-resp-4-plex-amp-kit</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_264_0</DOCNO>
            	<TEXT>Yes it would be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_265_0</DOCNO>
            	<TEXT>I totally agree</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_0</DOCNO>
            	<TEXT>SORRENTO NOW HAS EXCLUSIVE RIGHTS IN 60% OF THE WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_1</DOCNO>
            	<TEXT>Sorrento now has exclusive rights in 60% of the world ..."to utilize Dyadics C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadics lead COVID-19 vaccine candidate."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_2</DOCNO>
            	<TEXT>Quite apart from the vaccine DYAI-100, the C1 technology can be applied across Sorrento's entire Covid portfolio.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_3</DOCNO>
            	<TEXT>It will greatly reduce costs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_4</DOCNO>
            	<TEXT>For example, Sorrento could now have not only the world's BEST COVID ANTIBODIES but also the world's MOST AFFORDABLE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_5</DOCNO>
            	<TEXT>We know that even now, because they are so powerful, they require only small doses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_6</DOCNO>
            	<TEXT>They can be delivered in 2 minute injections rather than 4 hour infusions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_7</DOCNO>
            	<TEXT>They can be delivered in small nasal drops.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_8</DOCNO>
            	<TEXT>They can be delivered in small amounts utilizing the SOFUSA technology.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_9</DOCNO>
            	<TEXT>Add to that substantial production cost savings using the C1 technology and Sorrento will have enormous pricing advantages which health systems like! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_10</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-and-dyadic-announce-binding-term-sheet-license-dyadics](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-and-dyadic-announce-binding-term-sheet-license-dyadics) All the SRNE stuff From Dyadic Earning Call: Mark Emalfarb - Founder, CEO, President  amp; Director, Dyadic International Inc. "Since March, we entered into foreign collaborations, including the recently announced binding term sheet with Sorrento Therapeutics, a NASDAQ-listed clinical-stage antibody-centric biopharmaceutical company, developing new treatments for COVID-19, cancer, and pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_11</DOCNO>
            	<TEXT>The Sorrento license agreement when executed will mark a significant milestone in our corporate development efforts, as we will have begun to monetize our COVID-19 development efforts to licensing our C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein diagnostics solely for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate to a drug development partner that has the resources and the expertise to advance coronavirus vaccines, therapeutics, and diagnostics, both clinically and commercially.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_12</DOCNO>
            	<TEXT>Due to confidentiality agreements, we are often unable to publicly announce certain ongoing collaborations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_13</DOCNO>
            	<TEXT>Over the past 6 months, as noted by Sorrento's Chairman and CEO, Dr. Henry Ji, Sorrento carried out several promising preclinical animal studies using the C1 produced RBD antigen and Dyadic's lead COVID-19 vaccine candidate, DYAI-100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_14</DOCNO>
            	<TEXT>Sorrento extensively studied Dyadic's lead COVID-19 vaccine, which utilizes the SARS-CoV-2 spike protein, receptor binding domain, RBD antigen, in vitro and in in vivo for its induction of high titer neutralization activities in vaccinated animals against the SARS-CoV-2 us and its major variants of concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_15</DOCNO>
            	<TEXT>The goal - their goal is to manufacture a COVID-19 vaccine that will provide protection across the variants of concern, including Delta, and in addition, apply the C1 protein production platform broadly across their current and future coronavirus programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_16</DOCNO>
            	<TEXT>Our mutual goal, as highlighted in yesterday's press release, as we continue to work together to develop and commercialize a protein-based COVID-19 vaccine that can be rapidly manufactured in very large quantities in Sorrento's existing cGMP and other cGMP facilities, and stored and transported at either room temperature or 2 to 8 degrees in order to increase the access and affordability to underserved populations globally.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_17</DOCNO>
            	<TEXT>Sorrento reported that a multivalent COVID-19 vaccine is under development using the SARS-CoV-2 RBDs for the variants of concern such as Transcript Provided by delta, alpha, beta, gamma, and Lambda and is being designed to cover all known and emerging variants of concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_18</DOCNO>
            	<TEXT>This is a significant event for Dyadic, having achieved our goal of creating a pathway that addresses the COVID-19 production, commercialization, and distribution gap for mass-scale immunizations across the globe quickly and efficiently.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_19</DOCNO>
            	<TEXT>This Sorrento license fills the gap for the remaining potential COVID-19 immunization, production, and distribution across all other territories, not already covered by Dyadic's existing agreements with Medytox, Syngene, and the Rubic Consortium.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_20</DOCNO>
            	<TEXT>The Sorrento license agreement, when executed, will grant Sorrento exclusive rights for human health and nonexclusive for animal health in their territory to utilize Dyadic's C1 technology for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics solely for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_266_21</DOCNO>
            	<TEXT>And we'll include upfront payments of $10 million in cash and stock up to $4 million in reimbursements for DYAI-100's preclinical and clinical development milestones and development costs incurred by Dyadic up to $33 million of potential milestone payments for the successful developments of vaccines, therapeutics in humans and animals as well as additional royalty</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_267_0</DOCNO>
            	<TEXT>REINVENTING BIOLOGIC VACCINE AND DRUG DEVELOPMENT  amp; PRODUCTION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_267_1</DOCNO>
            	<TEXT> REINVENTING BIOLOGIC VACCINE AND DRUG DEVELOPMENT  amp; PRODUCTION Everyone please watch the Dyadic C1 Technology Video.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_267_2</DOCNO>
            	<TEXT>Sorrento and Dyadic Announce Binding Term Sheet to License Dyadics Lead COVID-19 Vaccine Candidate DYAI-100 and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_267_3</DOCNO>
            	<TEXT>https://www.dyadic.com/](https://www.dyadic.com/) After listening to the video I can understand why Sorrento went into an agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_267_4</DOCNO>
            	<TEXT>Please pass this video along and have a great day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_268_0</DOCNO>
            	<TEXT>Just the tip of the iceberg</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_0</DOCNO>
            	<TEXT>Dexamethasone (Oral Route) TO TREAT BACK PAIN (Sciatica)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_1</DOCNO>
            	<TEXT>Side Effects Drug information provided by: IBM Micromedex Along with its needed effects, a medicine may cause some unwanted effects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_2</DOCNO>
            	<TEXT>Although not all of these side effects may occur, if they do occur they may need medical attention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_3</DOCNO>
            	<TEXT>Check with your doctor immediately if any of the following side effects occur: More common Aggression agitation anxiety blurred vision decrease in the amount of urine dizziness fast, slow, pounding, or irregular heartbeat or pulse headache irritability mental depression mood changes nervousness noisy, rattling breathing numbness or tingling in the arms or legs pounding in the ears swelling of the fingers, hands, feet, or lower legs trouble thinking, speaking, or walking troubled breathing at rest weight gain Incidence not known Abdominal or stomach cramping and/or burning (severe) or pain backache bloody, black, or tarry stools cough or hoarseness darkening of the skin decrease in height decreased vision diarrhea dry mouth eye pain eye tearing facial hair growth in females fainting fatigue fever or chills flushed, dry skin fractures fruit-like breath odor full or round face, neck, or trunk heartburn and/or indigestion (severe and continuous) increased hunger increased thirst increased urination loss of appetite loss of sexual desire or ability lower back or side pain menstrual irregularities muscle pain or tenderness muscle wasting or weakness nausea pain in the back, ribs, arms, or legs painful or difficult urination skin rash sleeplessness sweating trouble healing trouble sleeping unexplained weight loss unusual tiredness or weakness vision changes vomiting vomiting of material that looks like coffee grounds [https://www.mayoclinic.org/drugs-supplements/dexamethasone-oral-route/side-effects/drg-20075207](https://www.mayoclinic.org/drugs-supplements/dexamethasone-oral-route/side-effects/drg-20075207) Now please read this line that's written in this paragraph.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_4</DOCNO>
            	<TEXT>There were no serious adverse events observed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_5</DOCNO>
            	<TEXT>Now read the entire paragraph.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_6</DOCNO>
            	<TEXT>A Phase 2 trial to characterize the pharmacodynamics and safety of repeat dose SP-102 in subjects with lumbosacral radicular pain (sciatica), showed all subjects experienced rapid reduction of leg and back pain following an initial and repeat SP-102 injection treatment, with group median for average pain in the affected leg reduced by over 50% throughout 28 days (100% response rate).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_7</DOCNO>
            	<TEXT>The lack of cumulative effect and rapid resolution of hypothalamic-pituitary-adrenal (HPA) suppression suggests that consideration of HPA pharmacodynamics are not clinically relevant when making decisions regarding repeat dosing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_8</DOCNO>
            	<TEXT>There were no serious adverse events observed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_9</DOCNO>
            	<TEXT>Now please click and open and read the entire press release. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_10</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete) If you had to choose between Dexamethasone or Semdexa.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_11</DOCNO>
            	<TEXT>Which one would you choose?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_269_12</DOCNO>
            	<TEXT>PHASE 3 READOUT COMING IN THE 4Q THE BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_270_0</DOCNO>
            	<TEXT>Currently Doctors use a standard formulation of dexamethasone or other steroids for this as an unapproved "off-label" use to the tune of 12+ million shots per year in the U.S. alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_270_1</DOCNO>
            	<TEXT>This number is projected to grow due to an aging and increasingly obese population.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_270_2</DOCNO>
            	<TEXT>Ji had previously given revenue projections of $5-6 billion annually and recently updated that projection to $10 billion due to the increased demand/scarcity for dexamethasone-- which is often used as an SOC (standard of care) for Covid treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_271_0</DOCNO>
            	<TEXT>Hey I'm going steelhead fishing on the Salmon River again 1st week in November.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_271_1</DOCNO>
            	<TEXT>I can't wait.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_272_0</DOCNO>
            	<TEXT>Your welcome.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_273_0</DOCNO>
            	<TEXT>Every year, physicians perform millions of off-label epidural steroid injections (ESI) to treat neck and back pain despite the risk of rare but serious and sometimes fatal neurological side effects and despite the fact that the Food and Drug Administration (FDA) has never approved corticosteroids for injection into the epidural space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_273_1</DOCNO>
            	<TEXT>While off-label drug use isn't necessarily a breach of the standard of care, it can pose a risky proposition to both the physician and the patient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_273_2</DOCNO>
            	<TEXT>The FDA considers doctors who use steroids off-label "part of the practice of medicine but not regulated by FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_0</DOCNO>
            	<TEXT>FDA Drug Safety Communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain Safety Announcement \[4-23-2014\] The U.S. Food and Drug Administration (FDA) is warning that injection of corticosteroids into the epidural space of the spine may result in rare but serious adverse events, including loss of vision, stroke, paralysis, and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_1</DOCNO>
            	<TEXT>The injections are given to treat neck and back pain, and radiating pain in the arms and legs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_2</DOCNO>
            	<TEXT>We are requiring the addition of a Warning to the drug labels of injectable corticosteroids to describe these risks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_3</DOCNO>
            	<TEXT>Patients should discuss the benefits and risks of epidural corticosteroid injections with their health care professionals, along with the benefits and risks associated with other possible treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_4</DOCNO>
            	<TEXT>Injectable corticosteroids are commonly used to reduce swelling or inflammation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_5</DOCNO>
            	<TEXT>Injecting corticosteroids into the epidural space of the spine has been a widespread practice for many decades; however, the effectiveness and safety of the drugs for this use have not been established, and FDA has not approved corticosteroids for such use.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_6</DOCNO>
            	<TEXT>We started investigating this safety issue when we became aware of medical professionals concerns about epidural corticosteroid injections and the risk of serious neurologic adverse events.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_7</DOCNO>
            	<TEXT>1 This concern prompted us to review cases in the FDA Adverse Event Reporting System (FAERS) database and in the medical literature (see Data Summary).2-16 To raise awareness of the risks of epidural corticosteroid injections in the medical community, FDAs Safe Use Initiative convened a panel of experts, including pain management experts to help define the techniques for such injections which would reduce preventable harm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_8</DOCNO>
            	<TEXT>The expert panels recommendations will be released when they are finalized.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_9</DOCNO>
            	<TEXT>As part of FDAs ongoing effort to investigate this issue, we plan to convene an Advisory Committee meeting of external experts in late 2014 to discuss the benefits and risks of epidural corticosteroid injections and to determine if further FDA actions are needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_10</DOCNO>
            	<TEXT>Injectable corticosteroids include methylprednisolone, hydrocortisone, triamcinolone, betamethasone, and dexamethasone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_274_11</DOCNO>
            	<TEXT>This safety issue is unrelated to the contamination of compounded corticosteroid injection products reported in 2012.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_0</DOCNO>
            	<TEXT>FDA Drug Safety Communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain Share Tweet Linkedin Email Print View and print full Drug Safety Communication (PDF - 118KB) en Espaol Safety Announcement Facts about Corticosteroids Additional Information for Patients Additional Information for Health Care Professionals Data Summary References Safety Announcement \[04-23-2014\] The U.S. Food and Drug Administration (FDA) is warning that injection of corticosteroids into the epidural space of the spine may result in rare but serious adverse events, including loss of vision, stroke, paralysis, and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_1</DOCNO>
            	<TEXT>The injections are given to treat neck and back pain, and radiating pain in the arms and legs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_2</DOCNO>
            	<TEXT>We are requiring the addition of a Warning to the drug labels of injectable corticosteroids to describe these risks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_3</DOCNO>
            	<TEXT>Patients should discuss the benefits and risks of epidural corticosteroid injections with their health care professionals, along with the benefits and risks associated with other possible treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_4</DOCNO>
            	<TEXT>Injectable corticosteroids are commonly used to reduce swelling or inflammation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_5</DOCNO>
            	<TEXT>Injecting corticosteroids into the epidural space of the spine has been a widespread practice for many decades; however, the effectiveness and safety of the drugs for this use have not been established, and FDA has not approved corticosteroids for such use.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_6</DOCNO>
            	<TEXT>We started investigating this safety issue when we became aware of medical professionals concerns about epidural corticosteroid injections and the risk of serious neurologic adverse events.1 This concern prompted us to review cases in the FDA Adverse Event Reporting System (FAERS) database and in the medical literature (see Data Summary).2-16 To raise awareness of the risks of epidural corticosteroid injections in the medical community, FDAs Safe Use Initiative convened a panel of experts, including pain management experts to help define the techniques for such injections which would reduce preventable harm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_7</DOCNO>
            	<TEXT>The expert panels recommendations will be released when they are finalized.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_8</DOCNO>
            	<TEXT>As part of FDAs ongoing effort to investigate this issue, we plan to convene an Advisory Committee meeting of external experts in late 2014 to discuss the benefits and risks of epidural corticosteroid injections and to determine if further FDA actions are needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_9</DOCNO>
            	<TEXT>Injectable corticosteroids include methylprednisolone, hydrocortisone, triamcinolone, betamethasone, and dexamethasone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_10</DOCNO>
            	<TEXT>This safety issue is unrelated to the contamination of compounded corticosteroid injection products reported in 2012.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_275_11</DOCNO>
            	<TEXT>Facts about corticosteroids A class of drugs commonly used to reduce swelling or inflammation Injectable corticosteroids include methylprednisolone, hydrocortisone, triamcinolone, betamethasone, and dexamethasone Corticosteroids are not approved by FDA for injection into the epidural space of the spine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_0</DOCNO>
            	<TEXT>FDA issues black box warning for epidural steroid spinal injections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_1</DOCNO>
            	<TEXT>WARNING PLEASE READ!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_2</DOCNO>
            	<TEXT>FDA Drug Safety Communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_3</DOCNO>
            	<TEXT>Safety Announcement \[4-23-2014\] The U.S. Food and Drug Administration (FDA) is warning that injection of corticosteroids into the epidural space of the spine may result in rare but serious adverse events, including loss of vision, stroke, paralysis, and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_4</DOCNO>
            	<TEXT>The injections are given to treat neck and back pain, and radiating pain in the arms and legs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_5</DOCNO>
            	<TEXT>We are requiring the addition of a Warning to the drug labels of injectable corticosteroids to describe these risks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_6</DOCNO>
            	<TEXT>Patients should discuss the benefits and risks of epidural corticosteroid injections with their health care professionals, along with the benefits and risks associated with other possible treatments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_7</DOCNO>
            	<TEXT>Injectable corticosteroids are commonly used to reduce swelling or inflammation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_8</DOCNO>
            	<TEXT>Injecting corticosteroids into the epidural space of the spine has been a widespread practice for many decades; however, the effectiveness and safety of the drugs for this use have not been established, and FDA has not approved corticosteroids for such use.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_9</DOCNO>
            	<TEXT>We started investigating this safety issue when we became aware of medical professionals concerns about epidural corticosteroid injections and the risk of serious neurologic adverse events.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_10</DOCNO>
            	<TEXT>1 This concern prompted us to review cases in the FDA Adverse Event Reporting System (FAERS) database and in the medical literature (see Data Summary). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_11</DOCNO>
            	<TEXT>https://synergyspinecenter.com/wp-content/uploads/2016/12/FDA-warning\_2-ESI-for-pain-042314.pdf](https://synergyspinecenter.com/wp-content/uploads/2016/12/FDA-warning_2-ESI-for-pain-042314.pdf) NOW PLEASE READ THIS SENTENCE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_12</DOCNO>
            	<TEXT>If approved by the FDA, the SP-102 formulation will be available in a pre-filled syringe and will be administered by epidural injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_13</DOCNO>
            	<TEXT>Based on preclinical and clinical studies, it extends the residency time at the site of injection and does not show the safety concerns that led the FDA to warn against using other injectable steroid formulations by the epidural route of administration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_14</DOCNO>
            	<TEXT>NOW PLEASE READ THIS PRESS RELEASE. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_15</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete) So which epidural injection would you take?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_16</DOCNO>
            	<TEXT>The safer injection!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_276_17</DOCNO>
            	<TEXT>The BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_277_0</DOCNO>
            	<TEXT>I'm very sorry for your lose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_278_0</DOCNO>
            	<TEXT>My choice is Semdexa</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_279_0</DOCNO>
            	<TEXT>Colin Powell, military leader and first Black US secretary of state, dies after complications from Covid-19</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_279_1</DOCNO>
            	<TEXT>We lost another hero today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_279_2</DOCNO>
            	<TEXT>We need to honor General Powell for his military service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_279_3</DOCNO>
            	<TEXT>It's very unfortunate that not even Regeneron's or Merck's drugs could save him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_279_4</DOCNO>
            	<TEXT>I wonder if COVI-MSC would of saved him? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_279_5</DOCNO>
            	<TEXT>https://www.cnn.com/2021/10/18/politics/colin-powell-dies/index.html](https://www.cnn.com/2021/10/18/politics/colin-powell-dies/index.html) All flags should be placed at half staff.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_280_0</DOCNO>
            	<TEXT>Mercks pill wasn't fully approved so they wouldn't of given it to him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_0</DOCNO>
            	<TEXT>U.K. Covid Surge Sparks Call for Probe Into Delta Plus Mutation</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_1</DOCNO>
            	<TEXT>Former U.S. Food and Drug Administration Commissioner Scott Gottlieb called for urgent research into a mutation of the delta variant -- known as delta plus -- following a surge in Covid-19 cases in the U.K. We need urgent research to figure out if this delta plus is more transmissible, has partial immune evasion, Gottlieb said in a tweet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_2</DOCNO>
            	<TEXT>Theres no clear indication that its considerably more transmissible, but we should work to more quickly characterize these and other new variants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_3</DOCNO>
            	<TEXT>We have the tools.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_4</DOCNO>
            	<TEXT>Gottliebs comments come as the U.K. reported the highest daily jump in new cases on Sunday since mid-July -- around when Prime Boris Johnson authorized the removal of most Covid-related restrictions in what was dubbed Freedom Day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_5</DOCNO>
            	<TEXT>Weekly deaths from the virus have topped 800 for each of the past six weeks, higher than in other major western European nations, according to Bloombergs coronavirus tracker.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_6</DOCNO>
            	<TEXT>To date, the U.K. has recorded almost 140,000 Covid-related fatalities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_7</DOCNO>
            	<TEXT>Early U.K. Covid Strategy Caused Many Deaths, Report Says The delta plus strain includes the K417N mutation, which has stoked concern because thats also harbored by the beta variant thats associated with an increased risk of reinfection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_8</DOCNO>
            	<TEXT>U.K. researchers said in late June that theres no evidence yet to suggest the additional mutation is more worrisome.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_9</DOCNO>
            	<TEXT>A German paper out earlier this month found while both delta and delta plus infect lung cells more efficiently than the original coronavirus strain, delta plus doesnt appear to be significantly more dangerous than delta.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_10</DOCNO>
            	<TEXT>From Alpha to Delta, Why Virus Mutations Cause Alarm: QuickTake Gottlieb, who serves on Pfizers board of directors, led the FDA from 2017 to 2019.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_11</DOCNO>
            	<TEXT>He has been promoting his new book, Uncontrolled Spread: Why Covid-19 Crushed Us and How We Can Defeat the Next Pandemic. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_282_12</DOCNO>
            	<TEXT>https://www.bloomberg.com/news/articles/2021-10-17/u-k-covid-case-load-prompts-gottlieb-call-for-urgent-research?srnd=premium-asia](https://www.bloomberg.com/news/articles/2021-10-17/u-k-covid-case-load-prompts-gottlieb-call-for-urgent-research?srnd=premium-asia)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_284_0</DOCNO>
            	<TEXT>You're very incredibly smart!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_285_0</DOCNO>
            	<TEXT>It's to late the trial has ended.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_285_1</DOCNO>
            	<TEXT>They're going to report the results soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_286_0</DOCNO>
            	<TEXT>All we can do is wait for our turn.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_0</DOCNO>
            	<TEXT>COVID-19 Clinical Trials - Why Stem Cells for COVID-19?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_1</DOCNO>
            	<TEXT>Coronavirus disease (COVID-19) is a global pandemic that is threatening the health and welfare of the entire world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_2</DOCNO>
            	<TEXT>Treatment options are needed now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_3</DOCNO>
            	<TEXT>The White House Coronavirus Task Force asked PSC to file for accelerated FDA approval for our first study, for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_4</DOCNO>
            	<TEXT>We immediately submitted our FDA request and received FDA approval quickly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_5</DOCNO>
            	<TEXT>Stem cell therapy is one of the few approaches that directly treats the lung inflammation of the most serious COVID-19 patients Recent publications report strikingly positive outcomes from treating COVID-19 patients with stem cells (China, Israel) Published studies show reduction in death loss and reduced ventilator need PSC has FDA-inspected stem cell manufacturing facilities already producing stem cells This first study is only in a single hospital in California and limited to 20 serious patients Please do not request enrollment information at this time as the limited enrollment will be done at the hospital from existing hospitalized COVID-19 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_6</DOCNO>
            	<TEXT>Clinical Trial Design 20 patient Phase 1 study one hospital IV treatment of hospitalized serious COVID-19 patients Stem cells are from disease-screened donors manufactured in FDA facilities Three doses will be given over several days by simple IV infusion 86-day study measures reduction in days in the ICU, reduction in ventilator use, safety, lung function Enrollment planned to begin in August Mesenchymal Stem Cell (MSC) Therapy for COVID-19 and Acute Respiratory Distress Syndrome(ARDS) Rationale for the clinical use of adiposederived mesenchymal stem cells for COVID19 patients The Treatment that Could Crush COVID [https://personalizedstemcells.com/covid-19/](https://personalizedstemcells.com/covid-19/) Raising the Standard for Stem Cell Therapy Personalized Stem Cells, Inc. (PSC) is raising the standard of Stem Cell therapy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_7</DOCNO>
            	<TEXT>We are committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_8</DOCNO>
            	<TEXT>The founders of PSC are biotechnology entrepreneurs, having led multiple biotech companies including VetStem Biopharma with over 15,000 treatments for animals since 2003.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_9</DOCNO>
            	<TEXT>FDA Compliance Hundreds of physicians in the US have been offering stem cell therapy and making claims for treating medical conditions without evidence that it works or is safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_10</DOCNO>
            	<TEXT>They have been processing cells without sterility testing, safety testing, or compliance with FDA regulations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_11</DOCNO>
            	<TEXT>The FDA is now enforcing regulations to improve the safety and effectiveness of stem cell therapy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_12</DOCNO>
            	<TEXT>PSC provides stem cell processing to physicians who are participating in FDA approved clinical trials in compliance with FDA regulations in order to provide the best possible safety to patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_13</DOCNO>
            	<TEXT>Please click the link below to request clinical trial information. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_14</DOCNO>
            	<TEXT>https://personalizedstemcells.com/contact/#contact-form](https://personalizedstemcells.com/contact/#contact-form) Sorrento Therapeutics, Inc. has licensed this program and is conducting this clinical trial Don't forget 10 for 10 patients left the hospital after receiving the 3rd dose of COVI-MSC.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_287_15</DOCNO>
            	<TEXT>100% Survival rate is hard to beat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_288_0</DOCNO>
            	<TEXT>THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_289_0</DOCNO>
            	<TEXT>[https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=b amp;draw=2 amp;rank=11](https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=b amp;draw=2 amp;rank=11) LOOK AT WHAT UPDATED TODAY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_290_0</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=b amp;draw=2 amp;rank=11 LOOK AT WHAT UPDATED TODAY</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_290_1</DOCNO>
            	<TEXT>I WENT TO WRITE ABOUT COVI-MSC TODAY AND LOOK WHAT I FOUND!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_291_0</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=b amp;draw=2 amp;rank=11</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_292_0</DOCNO>
            	<TEXT>What a coincidence that I'm writing about COVI-MSC and the trial updated today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_292_1</DOCNO>
            	<TEXT>That my friends is called fate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_292_2</DOCNO>
            	<TEXT>We need a blessing before Christmas and 60 patients will be home for Christmas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_293_0</DOCNO>
            	<TEXT>Yahoo is not letting me post the clinical trial link.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_293_1</DOCNO>
            	<TEXT>You try posting it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_0</DOCNO>
            	<TEXT>COVID-19 Clinical Trials - Why Stem Cells for COVID-19?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_1</DOCNO>
            	<TEXT>LOOK AT THE UPDATE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_2</DOCNO>
            	<TEXT># Coronavirus disease (COVID-19) is a global pandemic that is threatening the health and welfare of the entire world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_3</DOCNO>
            	<TEXT>Treatment options are needed now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_4</DOCNO>
            	<TEXT>The White House Coronavirus Task Force asked PSC to file for accelerated FDA approval for our first study, for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_5</DOCNO>
            	<TEXT>We immediately submitted our FDA request and received FDA approval quickly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_6</DOCNO>
            	<TEXT>Stem cell therapy is one of the few approaches that directly treats the lung inflammation of the most serious COVID-19 patients Recent publications report strikingly positive outcomes from treating COVID-19 patients with stem cells (China, Israel) Published studies show reduction in death loss and reduced ventilator need PSC has FDA-inspected stem cell manufacturing facilities already producing stem cells This first study is only in a single hospital in California and limited to 20 serious patients Please do not request enrollment information at this time as the limited enrollment will be done at the hospital from existing hospitalized COVID-19 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_7</DOCNO>
            	<TEXT>Clinical Trial Design 20 patient Phase 1 study one hospital IV treatment of hospitalized serious COVID-19 patients Stem cells are from disease-screened donors manufactured in FDA facilities Three doses will be given over several days by simple IV infusion 86-day study measures reduction in days in the ICU, reduction in ventilator use, safety, lung function Enrollment planned to begin in August Mesenchymal Stem Cell (MSC) Therapy for COVID-19 and Acute Respiratory Distress Syndrome(ARDS) Rationale for the clinical use of adiposederived mesenchymal stem cells for COVID19 patients The Treatment that Could Crush COVID [https://personalizedstemcells.com/covid-19/](https://personalizedstemcells.com/covid-19/) Raising the Standard for Stem Cell Therapy Personalized Stem Cells, Inc. (PSC) is raising the standard of Stem Cell therapy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_8</DOCNO>
            	<TEXT>We are committed to providing high-quality stem cell processing services, as well as excellent technical, clinical, and regulatory support to physicians, clinical investigators, and patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_9</DOCNO>
            	<TEXT>The founders of PSC are biotechnology entrepreneurs, having led multiple biotech companies including VetStem Biopharma with over 15,000 treatments for animals since 2003.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_10</DOCNO>
            	<TEXT>FDA Compliance Hundreds of physicians in the US have been offering stem cell therapy and making claims for treating medical conditions without evidence that it works or is safe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_11</DOCNO>
            	<TEXT>They have been processing cells without sterility testing, safety testing, or compliance with FDA regulations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_12</DOCNO>
            	<TEXT>The FDA is now enforcing regulations to improve the safety and effectiveness of stem cell therapy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_13</DOCNO>
            	<TEXT>PSC provides stem cell processing to physicians who are participating in FDA approved clinical trials in compliance with FDA regulations in order to provide the best possible safety to patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_14</DOCNO>
            	<TEXT>Please click the link below to request clinical trial information. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_15</DOCNO>
            	<TEXT>https://personalizedstemcells.com/contact/#contact-form](https://personalizedstemcells.com/contact/#contact-form) Sorrento Therapeutics, Inc. has licensed this program and is conducting this clinical trial Don't forget 10 for 10 patients left the hospital after receiving the 3rd dose of COVI-MSC.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_16</DOCNO>
            	<TEXT>100% Survival rate is hard to beat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_17</DOCNO>
            	<TEXT>Look at what updated today! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_18</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=b amp;draw=2 amp;rank=11](https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=b amp;draw=2 amp;rank=11) If you don't open and click the links that's up to you!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_294_19</DOCNO>
            	<TEXT>Or you can just listen to the CRICKETS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_295_0</DOCNO>
            	<TEXT>That's right THE BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_295_1</DOCNO>
            	<TEXT>The trial is expected to be enrolled by Dec 1st 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_295_2</DOCNO>
            	<TEXT>Hopefully 60 Patients will be going home for Christmas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_295_3</DOCNO>
            	<TEXT>That would be a blessing!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_296_0</DOCNO>
            	<TEXT>Would they let you post?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_297_0</DOCNO>
            	<TEXT>I don't make the rules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_297_1</DOCNO>
            	<TEXT>I'm just giving you an update.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_297_2</DOCNO>
            	<TEXT>There only leaving 60 days to fully enroll 60 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_297_3</DOCNO>
            	<TEXT>So if they can finally start this trial on time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_297_4</DOCNO>
            	<TEXT>60 families will be having the best Christmas ever!.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_298_0</DOCNO>
            	<TEXT>I can't view anything</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_299_0</DOCNO>
            	<TEXT>I can't view anything can you see your post?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_300_0</DOCNO>
            	<TEXT>I got to tell you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_300_1</DOCNO>
            	<TEXT>I can't believe Yahoo would let them hack their servers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_300_2</DOCNO>
            	<TEXT>They control the board to do as they please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_300_3</DOCNO>
            	<TEXT>The only explanation is the moderators for that board are manipulating and controlling.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_300_4</DOCNO>
            	<TEXT>It's disgusting</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_301_0</DOCNO>
            	<TEXT>This is why we created the BAND.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_301_1</DOCNO>
            	<TEXT>We need to play our music on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_301_2</DOCNO>
            	<TEXT>We need to get everyone off Yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_0</DOCNO>
            	<TEXT>Paul, Nice to hear your voice for a change.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_1</DOCNO>
            	<TEXT>I was wondering why you would disrespect a 100 year old Pearl Harbor Survivor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_2</DOCNO>
            	<TEXT>Maybe it's because you hate the freedom that we've given you?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_3</DOCNO>
            	<TEXT>You're not a one time poster.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_4</DOCNO>
            	<TEXT>You post everyday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_5</DOCNO>
            	<TEXT>Are at least you try to post everyday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_6</DOCNO>
            	<TEXT>I commend you for that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_7</DOCNO>
            	<TEXT>You had to of seen my post about CHICK.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_8</DOCNO>
            	<TEXT>I received over 100 replies with condolences.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_9</DOCNO>
            	<TEXT>But nothing from you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_10</DOCNO>
            	<TEXT>You and I have been told my many people on yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_11</DOCNO>
            	<TEXT>That if it wasn't for us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_12</DOCNO>
            	<TEXT>They wouldn't be here.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_13</DOCNO>
            	<TEXT>Now i posted on 3 different boards about CHICK.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_14</DOCNO>
            	<TEXT>You we're MIA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_15</DOCNO>
            	<TEXT>Why couldn't you even say he was a hero?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_302_16</DOCNO>
            	<TEXT>As much as we post together how can you show me your sorrow for the lose?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_303_0</DOCNO>
            	<TEXT>I had bashers and shorts on yahoo that stopped and put all there hate aside and gave their respect and honored such a great hero.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_303_1</DOCNO>
            	<TEXT>It was so hurtful not here anything from Paul.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_303_2</DOCNO>
            	<TEXT>Chick was given the vaccine and still got Covid-19 and passed away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_303_3</DOCNO>
            	<TEXT>The post was to give awareness that COVID-19 takes heros as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_303_4</DOCNO>
            	<TEXT>After all we would post every morning together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_304_0</DOCNO>
            	<TEXT>That still does not answer why you couldn't respect a 100 year old Veteran.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_305_0</DOCNO>
            	<TEXT>Well I'm sorry to say you showed your true colors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_305_1</DOCNO>
            	<TEXT>Let's just leave it at that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_306_0</DOCNO>
            	<TEXT>Great when i get the time I'm going to write to them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_307_0</DOCNO>
            	<TEXT>The trial start date was updated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_307_1</DOCNO>
            	<TEXT>We should believe that the trial most likely is recruiting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_307_2</DOCNO>
            	<TEXT>The estimated full recruitment by Dec 1, 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_308_0</DOCNO>
            	<TEXT>Looks like it's getting started</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_309_0</DOCNO>
            	<TEXT>I'm not sure when the results will be coming.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_309_1</DOCNO>
            	<TEXT>Everything always takes longer then expected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_309_2</DOCNO>
            	<TEXT>Hang in there.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_310_0</DOCNO>
            	<TEXT>I would assume so.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_310_1</DOCNO>
            	<TEXT>If you knew of a study in progress and you could get them there as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_311_0</DOCNO>
            	<TEXT>I'm not sure if you could get right to try that was passed by Trump.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_0</DOCNO>
            	<TEXT>Anyone can oppose a TM if they have a valid claim.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_1</DOCNO>
            	<TEXT>They do not have any products that have the word COVI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_2</DOCNO>
            	<TEXT>Yes they have a few that end with STIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_3</DOCNO>
            	<TEXT>Now the argument will be that when you put both together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_4</DOCNO>
            	<TEXT>Your belief is it's for your companies product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_5</DOCNO>
            	<TEXT>The 30 day extension is for them to state and fight the claim.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_6</DOCNO>
            	<TEXT>Which I believe Sorrento will ultimately win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_7</DOCNO>
            	<TEXT>Companies that protect their trademarks are always looking for licensing fees.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_8</DOCNO>
            	<TEXT>Worst cast they would want a few grand per year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_312_9</DOCNO>
            	<TEXT>I don't believe that will happen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_0</DOCNO>
            	<TEXT>Anyone can oppose a TM if they have a valid claim.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_1</DOCNO>
            	<TEXT>They do not have any products that have the word COVI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_2</DOCNO>
            	<TEXT>Yes they have a few that end with STIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_3</DOCNO>
            	<TEXT>Now the argument will be that when you put both together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_4</DOCNO>
            	<TEXT>Your belief is it's for your companies product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_5</DOCNO>
            	<TEXT>The 30 day extension is for them to state and fight the claim.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_6</DOCNO>
            	<TEXT>Which I believe Sorrento will ultimately win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_7</DOCNO>
            	<TEXT>Companies that protect their trademarks are always looking for licensing fees.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_8</DOCNO>
            	<TEXT>Worst cast they would want a few grand per year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_9</DOCNO>
            	<TEXT>I don't believe that will happen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_10</DOCNO>
            	<TEXT>Take Coca Cola for an example.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_11</DOCNO>
            	<TEXT>You want to trademark Don's Cola.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_12</DOCNO>
            	<TEXT>Coca Cola may claim opposition.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_13</DOCNO>
            	<TEXT>Would they win?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_14</DOCNO>
            	<TEXT>Probably not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_15</DOCNO>
            	<TEXT>And if there's no other Don's Cola you will receive your trademark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_313_16</DOCNO>
            	<TEXT>No worries..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_314_0</DOCNO>
            	<TEXT>I believe so no worries and standard procedure when TM.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_315_0</DOCNO>
            	<TEXT>They're adding and soon we should be getting the 3Q Results in November with an update.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Inc. (NASDAQ: SRNE) Receives Approval to Proceed with ESG-401 and Resinferatoxin Studies By Kate Hudson -October 20, 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_1</DOCNO>
            	<TEXT>Sorrento Therapeutics Inc. (NASDAQ: SRNE) had initially announced that its subsidiary Levena (Suzhou) Biopharma Cop.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_2</DOCNO>
            	<TEXT>Ltd and its partner Escugen Biotechnology Co. Ltd had received an authorization letter from the National Medical Products Administrations Centre for Drug Evaluation for the application for clinical trials of recombinant humanize anti-trop2 Mab-SN38 conjugate (ESG-401).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_3</DOCNO>
            	<TEXT>Sorrento receives FDA clearance to proceed with ESG-401 studied Now, Sorrento has announced that the US FDA has issued clearance to continue with clinical trials in patients with refractory or relapsed solid tumors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_4</DOCNO>
            	<TEXT>ESG-401 addresses unmet needs for multiple solid tumors treatment that include urothelial carcinoma and triple-negative breast cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_5</DOCNO>
            	<TEXT>Also, the FDA has given Sorrento cleared to continue with the global Phase 2 clinical trial of resiniferatoxin.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_6</DOCNO>
            	<TEXT>The study is entitled, A Multicenter, Phase 2 Study to Assess the Safety and Efficacy of Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated with Advanced Cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_7</DOCNO>
            	<TEXT>The double-blind, multicentre, controlled trial will evaluate the efficacy and safety of several RTX doses vs. placebo controls to manage intractable pain in up to 120 patients with advanced cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_8</DOCNO>
            	<TEXT>Over the course of a year, three RTX dose groups (15, 20, and 25 mcg) will be compared to vehicle control and concurrent control groups.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_9</DOCNO>
            	<TEXT>Procedural pain most prevalent adverse event following resiniferatoxin administration This indications conclusions are based on a review of the significant observations from the Phase 1b study results (NCT03226574).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_10</DOCNO>
            	<TEXT>Notably, the Phase 1 trial evaluated the safety and preliminary efficacy of epidural administration of resiniferatoxin for cancer-related intractable pain treatment in 17 individuals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_11</DOCNO>
            	<TEXT>After epidural administration of RTX at dosages up to 30 mcg, the most prevalent adverse event was procedural pain, which was experienced by just over half of the patients (52.9%).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_12</DOCNO>
            	<TEXT>All of these occurrences were of mild severity and lasted only a few hours.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_13</DOCNO>
            	<TEXT>In nearly all of the participants, pharmacokinetic sampling revealed no detectable systemic RTX levels. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_317_14</DOCNO>
            	<TEXT>https://biopharmajournal.com/2021/10/20/sorrento-therapeutics-inc-nasdaq-srne-receives-approval-to-proceed-with-esg-401-and-resinferatoxin-studies/](https://biopharmajournal.com/2021/10/20/sorrento-therapeutics-inc-nasdaq-srne-receives-approval-to-proceed-with-esg-401-and-resinferatoxin-studies/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_0</DOCNO>
            	<TEXT>Scientific Reports Revealing Early Promise for Universal Coronavirus Vaccine Published: Oct. 20, 2021 at 8:34 a.m. ET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_1</DOCNO>
            	<TEXT>Oct 20, 2021 (Financial News Media via COMTEX) -- Palm Beach, FL - October 20, 2021 FinancialNewsMedia.com News Commentary Recently, scientific reports have shown that a universal coronavirus vaccine that protects against COVID-19 causing SARS-CoV-2, as well as other coronaviruses such as those causing SARS and MERS, produced promising results in a mouse study.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_2</DOCNO>
            	<TEXT>Multiple SARS-CoV-2 vaccines have gone from development to distribution in many parts of the world, in record time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_3</DOCNO>
            	<TEXT>Indeed, in New York City, over 50% of the adult population has been vaccinated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_4</DOCNO>
            	<TEXT>But the emergence of SARS (in 2003) and SARS-CoV-2 in 2019 highlights the need to develop universal vaccination strategies against the broader Sarbecovirussubgenus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_5</DOCNO>
            	<TEXT>According to a report from ClinicalOMICs said that: "Now, scientists at the University of North Carolina (UNC) Gillings School of Global Public Health are working to develop a vaccine that protects mice against not only SARS-CoV-2, including the emerging variants, but other coronaviruses as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_6</DOCNO>
            	<TEXT>This research is published in the journal Science... To prevent a future coronavirus pandemic, the UNC-Chapel Hill researchers designed a vaccine to provide protection from the current SARS-CoV-2 coronavirus and a group of coronaviruses known to make the jump from animals to humans."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_7</DOCNO>
            	<TEXT>Active biotech companies in the market this week include BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV), Moderna, Inc. (NASDAQ: MRNA), Sorrento Therapeutics, Inc. (NASDAQ: SRNE), Dynavax Technologies Corporation (NASDAQ: DVAX), INOVIO (NASDAQ: INO).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_8</DOCNO>
            	<TEXT>Sorrento Therapeutics, Inc. (NASDAQ: SRNE) previously announced that its partner Escugen Biotechnology Co, Ltd. ("Escugen") and Sorrento's subsidiary Levena (Suzhou) Biopharma Co., Ltd. ("Levena") had received an approval letter from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for its Application for Clinical Trial (Acceptance No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_9</DOCNO>
            	<TEXT>CXSL2101069) of Recombinant Humanized Anti-Trop2 Mab-SN38 Conjugate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_10</DOCNO>
            	<TEXT>Recently Sorrento announces that the US FDA has given clearance to proceed with clinical trials in cancer patients with relapsed or refractory solid tumors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_11</DOCNO>
            	<TEXT>Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_12</DOCNO>
            	<TEXT>Sorrentos multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies ("G-MAB(TM) library"), immuno-cellular therapies ("DAR-T(TM)"), antibody-drug conjugates ("ADCs"), and oncolytic virus ("Seprehvec(TM)").</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_13</DOCNO>
            	<TEXT>Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD(TM), COVI-AMG(TM), COVISHIELD(TM), COVI-MSC(TM) and COVIDROPS(TM); and diagnostic test solutions, including COVITRACK(TM), COVISTIX(TM) and COVITRACE(TM). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_318_14</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/scientific-reports-revealing-early-promise-for-universal-coronavirus-vaccine-2021-10-20-81973418?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/scientific-reports-revealing-early-promise-for-universal-coronavirus-vaccine-2021-10-20-81973418?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_319_0</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/scientific-reports-revealing-early-promise-for-universal-coronavirus-vaccine-2021-10-20-81973418?mod=mw_quote_news_seemore</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_320_0</DOCNO>
            	<TEXT>https://biopharmajournal.com/2021/10/20/sorrento-therapeutics-inc-nasdaq-srne-receives-approval-to-proceed-with-esg-401-and-resinferatoxin-studies/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_322_0</DOCNO>
            	<TEXT>Yes they can</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_323_0</DOCNO>
            	<TEXT>Shorts are borrowing to suppress</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_324_0</DOCNO>
            	<TEXT>Paul, Nice DD I want to be the first to give you a vote.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_325_0</DOCNO>
            	<TEXT>Yes it said i want to be the one to give you your first vote.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_326_0</DOCNO>
            	<TEXT>Thank you I want to give you your first vote.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_327_0</DOCNO>
            	<TEXT>Thank you I want to give you your first vote.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_328_0</DOCNO>
            	<TEXT>Yes it will be.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_329_0</DOCNO>
            	<TEXT>Great DD please keep it coming.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_330_0</DOCNO>
            	<TEXT>Your spot on!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_0</DOCNO>
            	<TEXT>BASEBALL HOT DOGS APPLE PIE AND CHEVROLET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_1</DOCNO>
            	<TEXT>I hope everyone knows how to play baseball?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_2</DOCNO>
            	<TEXT>It's one of America's greatest sports.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_3</DOCNO>
            	<TEXT>When we're taught how to play as kids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_4</DOCNO>
            	<TEXT>We're told when your up at bat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_5</DOCNO>
            	<TEXT>Don't take your eye off the ball.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_6</DOCNO>
            	<TEXT>Try to connect and drive through into the pitch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_7</DOCNO>
            	<TEXT>Don't swing at the bad pitches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_8</DOCNO>
            	<TEXT>Take your time and take your pitch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_9</DOCNO>
            	<TEXT>You may foul a few balls off it's ok.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_10</DOCNO>
            	<TEXT>Straighten your swing out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_11</DOCNO>
            	<TEXT>You may miss a few pitches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_12</DOCNO>
            	<TEXT>But it's ok because your learning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_13</DOCNO>
            	<TEXT>But DON'T TAKE YOUR EYE OFF THE BALL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_14</DOCNO>
            	<TEXT>This is very true with Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_15</DOCNO>
            	<TEXT>Don't get distracted by the bashers and shorts that are on the sidelines saying.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_16</DOCNO>
            	<TEXT>Swing no batter swing!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_17</DOCNO>
            	<TEXT>He can't hit he can't hit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_18</DOCNO>
            	<TEXT>They want you to fail.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_19</DOCNO>
            	<TEXT>So they can win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_20</DOCNO>
            	<TEXT>Yesterday was a homerun with the COVISTIX in Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_21</DOCNO>
            	<TEXT>Everyday we will have our chance at hitting more home runs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_22</DOCNO>
            	<TEXT>Remember don't take your eye off of the ball.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_23</DOCNO>
            	<TEXT>Silence the crowd and hold your shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_24</DOCNO>
            	<TEXT>Sorrento will load up the bases and hit a GRAND SLAM!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_25</DOCNO>
            	<TEXT>There will be plenty of beer and cheer to go around after the game.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_26</DOCNO>
            	<TEXT>DON'T TAKE YOUR EYE OFF OF THE BALL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_331_27</DOCNO>
            	<TEXT>Because the best batter is yet to hit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_0</DOCNO>
            	<TEXT>BASEBALL HOT DOGS APPLE PIE AND CHEVROLET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_1</DOCNO>
            	<TEXT>I hope everyone knows how to play baseball?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_2</DOCNO>
            	<TEXT>It's one of America's greatest sports.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_3</DOCNO>
            	<TEXT>When we're taught how to play as kids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_4</DOCNO>
            	<TEXT>We're told when your up at bat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_5</DOCNO>
            	<TEXT>Don't take your eye off the ball.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_6</DOCNO>
            	<TEXT>Try to connect and drive through into the pitch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_7</DOCNO>
            	<TEXT>Don't swing at the bad pitches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_8</DOCNO>
            	<TEXT>Take your time and take your pitch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_9</DOCNO>
            	<TEXT>You may foul a few balls off it's ok.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_10</DOCNO>
            	<TEXT>Straighten your swing out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_11</DOCNO>
            	<TEXT>You may miss a few pitches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_12</DOCNO>
            	<TEXT>But it's ok because your learning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_13</DOCNO>
            	<TEXT>But DON'T TAKE YOUR EYE OFF THE BALL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_14</DOCNO>
            	<TEXT>This is very true with Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_15</DOCNO>
            	<TEXT>Don't get distracted by the bashers and shorts that are on the sidelines saying.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_16</DOCNO>
            	<TEXT>Swing no batter swing!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_17</DOCNO>
            	<TEXT>He can't hit he can't hit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_18</DOCNO>
            	<TEXT>They want you to fail.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_19</DOCNO>
            	<TEXT>So they can win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_20</DOCNO>
            	<TEXT>Yesterday was a homerun with the COVISTIX in Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_21</DOCNO>
            	<TEXT>Everyday we will have our chance at hitting more home runs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_22</DOCNO>
            	<TEXT>Remember don't take your eye off of the ball.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_23</DOCNO>
            	<TEXT>Silence the crowd and hold your shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_24</DOCNO>
            	<TEXT>Sorrento will load up the bases and hit a GRAND SLAM!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_25</DOCNO>
            	<TEXT>There will be plenty of beer and cheer to go around after the game.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_26</DOCNO>
            	<TEXT>DON'T TAKE YOUR EYE OFF OF THE BALL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_332_27</DOCNO>
            	<TEXT>Because the best batter is yet to hit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_333_0</DOCNO>
            	<TEXT>They go together in the old USA baseball hot dogs apple pie and Chevrolet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_334_0</DOCNO>
            	<TEXT>Guess who is batting clean up?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_335_0</DOCNO>
            	<TEXT>It's going it's going it's gone!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_336_0</DOCNO>
            	<TEXT>I was an Allstar second baseman.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_337_0</DOCNO>
            	<TEXT>Do you remember the song?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_337_1</DOCNO>
            	<TEXT>You have to be at least 50 years old to remember the Chevy song.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_338_0</DOCNO>
            	<TEXT>You're right and don't forget it's our turn at bat!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_339_0</DOCNO>
            	<TEXT>It's a sold out crowd fully packed stadium of shorts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_339_1</DOCNO>
            	<TEXT>We're playing from home.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_339_2</DOCNO>
            	<TEXT>It's being played Prime time 4Q.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_340_0</DOCNO>
            	<TEXT>10 days to cover in a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_341_0</DOCNO>
            	<TEXT>Very nice answer</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_342_0</DOCNO>
            	<TEXT>Fintel.com short interest score/days to cover</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_343_0</DOCNO>
            	<TEXT>Yes every right we would listen to this Chevy commercial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_344_0</DOCNO>
            	<TEXT>Yes it was I was 9 at the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_0</DOCNO>
            	<TEXT>Why am I loaded up with SRNE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_1</DOCNO>
            	<TEXT>Don's List.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_2</DOCNO>
            	<TEXT>I expect SRNE will be a 20+ bagger in the next 12 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_3</DOCNO>
            	<TEXT>I think NOW is an excellent time to load up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_4</DOCNO>
            	<TEXT>I AM loaded up and ready.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_5</DOCNO>
            	<TEXT>There is a lot of good news coming over the next few weeks and months!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_6</DOCNO>
            	<TEXT>And it starts next week....building on the great COVISTIX news this week!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_7</DOCNO>
            	<TEXT>Look at what SRNE has on the new updated corporate presentation. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_8</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e](https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_9</DOCNO>
            	<TEXT>\*\*\*PHASE 3, close to EUA or close to market (13 programs) 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_10</DOCNO>
            	<TEXT>Abivertinib NSCLC NDA filed China 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_11</DOCNO>
            	<TEXT>Abivertinib NSCLC ph.3 completed US 3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_12</DOCNO>
            	<TEXT>PD-L1 SCLC partnered 4.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_13</DOCNO>
            	<TEXT>Erbitux biosimilar 5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_14</DOCNO>
            	<TEXT>Xolair biosimilar 6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_15</DOCNO>
            	<TEXT>Remicade biosimilar(approved in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_16</DOCNO>
            	<TEXT>SRNE holds ROW rights!)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_17</DOCNO>
            	<TEXT>SP-102 sciatica + back pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_18</DOCNO>
            	<TEXT>Marketing in 2H 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_19</DOCNO>
            	<TEXT>RTX Osteo Arthritis 9.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_20</DOCNO>
            	<TEXT>RTX cancer pain 10.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_21</DOCNO>
            	<TEXT>Covi-Stix EUA application(approval in Mexico...millions shipped.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_22</DOCNO>
            	<TEXT>Europe, Brazil,WHO and Canada coming soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_23</DOCNO>
            	<TEXT>DOD CRADA 11.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_24</DOCNO>
            	<TEXT>Covi-Trace EUA application 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_25</DOCNO>
            	<TEXT>Sofusa Enbrel 13.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_26</DOCNO>
            	<TEXT>Cynviloq (part of PSS lawsuit) \*\*\*PHASE 2 (13 programs) 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_27</DOCNO>
            	<TEXT>Seprehvir Oncolytic virus 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_28</DOCNO>
            	<TEXT>Covi-MSC EUA potential 3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_29</DOCNO>
            	<TEXT>Covi-AMG EUA potential DOD CRADA 4.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_30</DOCNO>
            	<TEXT>COVIDROPS EUA potential DOD CRADA 5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_31</DOCNO>
            	<TEXT>Covi-Track EUA pre-validation DOD CRADA 6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_32</DOCNO>
            	<TEXT>PD-L1 partnered 7.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_33</DOCNO>
            	<TEXT>Herceptin delivery partnered 8.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_34</DOCNO>
            	<TEXT>Abivertinib Lymphoma 9.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_35</DOCNO>
            	<TEXT>Abivertinib Covid 19 EUA potential as soon as August 10.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_36</DOCNO>
            	<TEXT>Abivertinib prostate cancer ph.2 IND 11.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_37</DOCNO>
            	<TEXT>Abivertinib Lupus ph.2 IND 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_38</DOCNO>
            	<TEXT>Abivertinib hairy cell leukemia 13.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_39</DOCNO>
            	<TEXT>CD47 partnered \*\*\*PHASE 1, IND filed or pre-IND (46+ programs) 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_40</DOCNO>
            	<TEXT>Seprehvec Oncolytic Virus 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_41</DOCNO>
            	<TEXT>CD 38 CAR-T ph.1 3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_42</DOCNO>
            	<TEXT>CEA CAR-T ph.1 4.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_43</DOCNO>
            	<TEXT>CD38 DAR-T ph.1 5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_44</DOCNO>
            	<TEXT>BCMA DAR-T pre-IND 6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_45</DOCNO>
            	<TEXT>PD-L1(C/DAR-T) pre-IND 7.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_46</DOCNO>
            	<TEXT>CyCART-19 partnered 8.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_47</DOCNO>
            	<TEXT>Covi-GeneMab pre-IND $34 million DARPA funding 9.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_48</DOCNO>
            	<TEXT>PD1-GeneMab pre-IND 10.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_49</DOCNO>
            	<TEXT>ERT (Enzyme Replacement Therapy) several pre IND programs 11.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_50</DOCNO>
            	<TEXT>IL2Teff pre-IND 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_51</DOCNO>
            	<TEXT>IL2Treg pre-IND 13.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_52</DOCNO>
            	<TEXT>Sofusa anti-PD1 and anti-CTLA4 14.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_53</DOCNO>
            	<TEXT>TNF-a (Enbrel) ph.1 15.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_54</DOCNO>
            	<TEXT>CTLA-4 (Yervoy) 16.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_55</DOCNO>
            	<TEXT>CD47 ph.1 basket trial partnered 17.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_56</DOCNO>
            	<TEXT>TROP2 IND granted in China...partnered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_57</DOCNO>
            	<TEXT>BCMA ADC pre-IND 19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_58</DOCNO>
            	<TEXT>ROR1 ADC pre-IND 20.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_59</DOCNO>
            	<TEXT>CD25 ADNAB pre-IND 21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_60</DOCNO>
            	<TEXT>CD20 ADNAB (Rituxan) IIT-ph.1 22.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_61</DOCNO>
            	<TEXT>VEGF(Avastin) ADNAB IIT-ph.1 23.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_62</DOCNO>
            	<TEXT>PD-L1 ADNAB pre-IND 24.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_63</DOCNO>
            	<TEXT>VEGFR2 ADNAB pre-IND 25.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_64</DOCNO>
            	<TEXT>CBD immune diseases pre-IND 26.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_65</DOCNO>
            	<TEXT>CBD insomnia pre-IND 27.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_66</DOCNO>
            	<TEXT>CBD Parkinsons pre-IND 28.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_67</DOCNO>
            	<TEXT>CBD CNS diseases pre-IND 29.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_68</DOCNO>
            	<TEXT>PD-L1 CAR-NK partnered 30.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_69</DOCNO>
            	<TEXT>CD38 CAR-NK to be partnered 31.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_70</DOCNO>
            	<TEXT>CD38 ADC AL Amyloidosis 32.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_71</DOCNO>
            	<TEXT>AC0058 ph.1b lupus 33.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_72</DOCNO>
            	<TEXT>AC0058 pre-IND MS 34.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_73</DOCNO>
            	<TEXT>AC0939 pre-IND CNS indications 35.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_74</DOCNO>
            	<TEXT>A166 HER2 ADC phase 1 36.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_75</DOCNO>
            	<TEXT>Karolinska off-the-shelf DAR-NK pre-IND 37.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_76</DOCNO>
            	<TEXT>Covid mRNA vaccine(Sofusa delivery) 38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_77</DOCNO>
            	<TEXT>Salicyn-30 oral antiviral 40.MP18 oral antiviral MPro inhibitor 41.Combination oral antiviral drug cocktail 42.RESPISTIX Combination Covid/seasonal flu tests 43.Combination Covid/seasonal flu vaccine 44 advanced Animal Health subsidiary 45.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_78</DOCNO>
            	<TEXT>1,000,000+ small molecule library 46.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_79</DOCNO>
            	<TEXT>Twenty quadrillion antibody library FUNDING?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_80</DOCNO>
            	<TEXT>Sorrento has invested wisely and has millions of shares of ImmunityBio, Celularity and ImmuneOncia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_81</DOCNO>
            	<TEXT>These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_82</DOCNO>
            	<TEXT>It has many attractive programs to partner for upfront, milestone and royalty payments!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_83</DOCNO>
            	<TEXT>The first of many approvals and EUA's will produce revenues within weeks in Mexico and soon in Europe, Canada and Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_84</DOCNO>
            	<TEXT>And SP-102 sales will begin in 2022 with multi-billion potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_85</DOCNO>
            	<TEXT>Huge portfolio AND huge assets!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_346_86</DOCNO>
            	<TEXT>Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_347_0</DOCNO>
            	<TEXT>Coronavirus: A timeline of how the deadly COVID-19 outbreak is evolving.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_347_1</DOCNO>
            	<TEXT>Coronavirus company news summary October 22, 2021 The news is getting around the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_347_2</DOCNO>
            	<TEXT>Sorrento Therapeutics has obtained a CE mark for its rapid Covid-19 diagnostic test COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_347_3</DOCNO>
            	<TEXT>The test is designed to identify the SARS-CoV-2 nucleocapsid antigen in nasal or nasopharyngeal samples.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_347_4</DOCNO>
            	<TEXT>COVISTIX can reportedly deliver results in nearly 15 minutes with a sensitivity of 81%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_347_5</DOCNO>
            	<TEXT>The test has received Emergency Use Authorization (EUA) in Mexico while EUA filings are progressing in the US, Canada, Brazil and with World Health Organization (WHO). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_347_6</DOCNO>
            	<TEXT>https://www.medicaldevice-network.com/uncategorised/coronavirus-company-news-summary-sorrentos-covid-19-rapid-antigen-test-obtains-ce-mark-india-grants-emergency-approval-to-lumiradxs-covid-19-antigen-test/](https://www.medicaldevice-network.com/uncategorised/coronavirus-company-news-summary-sorrentos-covid-19-rapid-antigen-test-obtains-ce-mark-india-grants-emergency-approval-to-lumiradxs-covid-19-antigen-test/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_348_0</DOCNO>
            	<TEXT>STATUS HISTORY ANALYSIS COMPLETED IN BRAZIL 10/21/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_348_1</DOCNO>
            	<TEXT>Process 25351.041767/2021-72 Process Date 08/09/2021 Protocol No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_348_2</DOCNO>
            	<TEXT>25352.315484/2021-62 Office hour 3111832/21-1 Subject 8017 - IVD - Registration of imported products in the family Current situation Analysis completed is in the GEVIT - MANAGEMENT OF DIAGNOSTIC PRODUCTS FOR IN-VITRO USE Since: 09/20/2021 Publication Data (RE - Resolution Date - DOU - Publication Date) Not published  History Status  Situation Start Date End Date Publication Data (RE - Resolution Date - DOU - Publication Date) Analysis completed 10/21/2021 Under review 09/20/2021 10/21/2021 Awaiting certificate of good manufacturing practices 09/20/2021 09/20/2021 Analysis completed 09/20/2021 09/20/2021 Awaiting analysis of compliance with the requirement 16/09/2021 09/20/2021 in demand 16/09/2021 16/09/2021 Under review 13/09/2021 16/09/2021 Awaiting analysis of compliance with the requirement 08/09/2021 13/09/2021 in demand 08/30/2021 08/09/2021 Under review 8/25/2021 08/30/2021 Awaiting analysis of compliance with the requirement 08/20/2021 8/25/2021 in demand 08/13/2021 08/20/2021 Under review 12/08/2021 08/13/2021 Distributed to the responsible area 08/09/2021 12/08/2021  [https://consultas.anvisa.gov.br/#/documentos/tecnicos/25351041767202172/](https://consultas.anvisa.gov.br/#/documentos/tecnicos/25351041767202172/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_349_0</DOCNO>
            	<TEXT>We should hear something soon from Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_350_0</DOCNO>
            	<TEXT>List of testing devices for COVID-19: applications under evaluation Please search #334424 https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/applications.html</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_350_1</DOCNO>
            	<TEXT>List of testing devices for COVID-19: applications under evaluation Please search #334424 [https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/applications.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/testing/applications.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_351_0</DOCNO>
            	<TEXT>Oncolytic Virotherapy Market- Report Explores Key Regions, Company Profile, Opportunity, and Challenge 2029 Published: Oct. 22, 2021 at 5:15 a.m. ET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_351_1</DOCNO>
            	<TEXT>[https://www.marketwatch.com/press-release/oncolytic-virotherapy-market--report-explores-key-regions-company-profile-opportunity-and-challenge-2029-2021-10-22?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/oncolytic-virotherapy-market--report-explores-key-regions-company-profile-opportunity-and-challenge-2029-2021-10-22?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_352_0</DOCNO>
            	<TEXT>Oncolytic Virotherapy Market- Report Explores Key Regions, Company Profile, Opportunity, and Challenge 2029 Published: Oct. 22, 2021 at 5:15 a.m. ET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_352_1</DOCNO>
            	<TEXT>[https://www.marketwatch.com/press-release/oncolytic-virotherapy-market--report-explores-key-regions-company-profile-opportunity-and-challenge-2029-2021-10-22?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/oncolytic-virotherapy-market--report-explores-key-regions-company-profile-opportunity-and-challenge-2029-2021-10-22?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_353_0</DOCNO>
            	<TEXT>They have to pay sooner or later.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_354_0</DOCNO>
            	<TEXT>Thank you for sharing because that's what we're supposed to do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_354_1</DOCNO>
            	<TEXT>Remember we're all on the same team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_354_2</DOCNO>
            	<TEXT>We all want the same outcome.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_354_3</DOCNO>
            	<TEXT>Have a great weekend everyone!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_356_0</DOCNO>
            	<TEXT>Who's your picks?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_357_0</DOCNO>
            	<TEXT>Let's go Cocks for an upset.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_358_0</DOCNO>
            	<TEXT>Thank you Paul I want to be the first to give you a vote.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_0</DOCNO>
            	<TEXT>COVISTIX is currently EUA-cleared in Mexico by COFEPRIS and EUA filings are underway with Canada, Brazil, WHO, and the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_1</DOCNO>
            	<TEXT>Please look at the order of this statement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_2</DOCNO>
            	<TEXT>Again, please look at the order of this statement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_3</DOCNO>
            	<TEXT>I believe we should hear about a Canada EUA next.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_4</DOCNO>
            	<TEXT>Followed by Brazil, WHO, and then the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_5</DOCNO>
            	<TEXT>Remember what DR JI said?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_6</DOCNO>
            	<TEXT>He expects the US EUA by the end of the year 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_7</DOCNO>
            	<TEXT>So that would mean we should receive the EUA for Brazil and WHO before the US issues the EUA for COVISTIX in the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_8</DOCNO>
            	<TEXT>Why is that?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_9</DOCNO>
            	<TEXT>My feeling is the Biden administration wants to vaccinate everyone first.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_10</DOCNO>
            	<TEXT>They don't want you rely on testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_11</DOCNO>
            	<TEXT>They want herd immunity instead.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_12</DOCNO>
            	<TEXT>So they could be working with BIG PHARMA who putting pressure on the FDA to slow the approval of newer better testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_13</DOCNO>
            	<TEXT>Makes sense?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_14</DOCNO>
            	<TEXT>Ask BIG PHARMA that wants their booster shots EUA approved first.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_15</DOCNO>
            	<TEXT>Which are worth BILLIONS$$$. They don't want to lose that revenue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_16</DOCNO>
            	<TEXT>And that's a what if?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_17</DOCNO>
            	<TEXT>The majority of the COVID-19 cases currently testing positive are really cases of the FLU?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_18</DOCNO>
            	<TEXT>We haven't heard anyone getting the flu?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_19</DOCNO>
            	<TEXT>So what if it's true?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_20</DOCNO>
            	<TEXT>Americans will feel they don't need to vaccinate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_21</DOCNO>
            	<TEXT>Americans could feel that this is all one big conspiracy?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_22</DOCNO>
            	<TEXT>We have conspiracies going around making some people very upset.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_23</DOCNO>
            	<TEXT>Could they be true?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_24</DOCNO>
            	<TEXT>I would hope they're not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_25</DOCNO>
            	<TEXT>I would rather hope and believe the FDA is corrupt working with big pharma and the guidance of our GOVT to vaccinate first and line their fat pockets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_26</DOCNO>
            	<TEXT> So what does Sorrento do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_27</DOCNO>
            	<TEXT>They think outside of the box.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_28</DOCNO>
            	<TEXT>Let's get the EUA approval for COVISTIX throughout the rest of the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_29</DOCNO>
            	<TEXT>Makes sense?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_30</DOCNO>
            	<TEXT>Looks as if that's DR JIs plan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_31</DOCNO>
            	<TEXT> Please click and open the link and read the rest of this release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_32</DOCNO>
            	<TEXT> [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-covistixtm-covid-19-virus-rapid-antigen](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-covistixtm-covid-19-virus-rapid-antigen)  So I believe we should hear from Canada's ISAD FDA very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_33</DOCNO>
            	<TEXT> Please click the links and view the process.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_34</DOCNO>
            	<TEXT> [https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/regulatory-response-health-product-access.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/regulatory-response-health-product-access.html)  [https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/interim-order-import-sale-advertising-drugs.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/interim-order-import-sale-advertising-drugs.html)  Now I want you to read this statement again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_35</DOCNO>
            	<TEXT> Sorrento is currently negotiating with global and regional distributors to ensure rapid distribution of COVISTIX to those countries that access to rapid, accurate and affordable testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_36</DOCNO>
            	<TEXT> This is a significant milestone for Sorrento and we appreciate the cooperation with European authorities to bring our highly sensitive antigen test to help control this pandemic, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_37</DOCNO>
            	<TEXT>We are expanding our manufacturing capacity in anticipation of large orders and are ready to deliver tests in the tens of millions of units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_38</DOCNO>
            	<TEXT> Tens of millions of units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_39</DOCNO>
            	<TEXT>Remember when DR JI said, we will sell double digit million sales per month?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_40</DOCNO>
            	<TEXT> I remember and I haven't forgotten.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_41</DOCNO>
            	<TEXT>Please give it time to grow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_42</DOCNO>
            	<TEXT>It's just like a ROSE bush.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_43</DOCNO>
            	<TEXT>You trim the bush and you clip the small branches and watch a beautiful ROSE BUD bloom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_44</DOCNO>
            	<TEXT>I love smelling ROSES.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_359_45</DOCNO>
            	<TEXT> Let's run for the ROSES.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_0</DOCNO>
            	<TEXT>COVISTIX is currently EUA-cleared in Mexico by COFEPRIS and EUA filings are underway with Canada, Brazil, WHO, and the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_1</DOCNO>
            	<TEXT>Please look at the order of this statement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_2</DOCNO>
            	<TEXT>Again, please look at the order of this statement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_3</DOCNO>
            	<TEXT>I believe we should hear about a Canada EUA next.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_4</DOCNO>
            	<TEXT>Followed by Brazil, WHO, and then the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_5</DOCNO>
            	<TEXT>Remember what DR JI said?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_6</DOCNO>
            	<TEXT>He expects the US EUA by the end of the year 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_7</DOCNO>
            	<TEXT>So that would mean we should receive the EUA for Brazil and WHO before the US issues the EUA for COVISTIX in the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_8</DOCNO>
            	<TEXT>Why is that?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_9</DOCNO>
            	<TEXT>My feeling is the Biden administration wants to vaccinate everyone first.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_10</DOCNO>
            	<TEXT>They don't want you rely on testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_11</DOCNO>
            	<TEXT>They want herd immunity instead.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_12</DOCNO>
            	<TEXT>So they could be working with BIG PHARMA who putting pressure on the FDA to slow the approval of newer better testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_13</DOCNO>
            	<TEXT>Makes sense?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_14</DOCNO>
            	<TEXT>Ask BIG PHARMA that wants their booster shots EUA approved first.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_15</DOCNO>
            	<TEXT>Which are worth BILLIONS$$$. They don't want to lose that revenue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_16</DOCNO>
            	<TEXT>And that's a what if?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_17</DOCNO>
            	<TEXT>The majority of the COVID-19 cases currently testing positive are really cases of the FLU?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_18</DOCNO>
            	<TEXT>We haven't heard anyone getting the flu?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_19</DOCNO>
            	<TEXT>So what if it's true?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_20</DOCNO>
            	<TEXT>Americans will feel they don't need to vaccinate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_21</DOCNO>
            	<TEXT>Americans could feel that this is all one big conspiracy?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_22</DOCNO>
            	<TEXT>We have conspiracies going around making some people very upset.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_23</DOCNO>
            	<TEXT>Could they be true?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_24</DOCNO>
            	<TEXT>I would hope they're not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_25</DOCNO>
            	<TEXT>I would rather hope and believe the FDA is corrupt working with big pharma and the guidance of our GOVT to vaccinate first and line their fat pockets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_26</DOCNO>
            	<TEXT>So what does Sorrento do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_27</DOCNO>
            	<TEXT>They think outside of the box.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_28</DOCNO>
            	<TEXT>Let's get the EUA approval for COVISTIX throughout the rest of the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_29</DOCNO>
            	<TEXT>Makes sense?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_30</DOCNO>
            	<TEXT>Looks as if that's DR JIs plan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_31</DOCNO>
            	<TEXT>Please click and open the link and read the rest of this release. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_32</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-covistixtm-covid-19-virus-rapid-antigen](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-covistixtm-covid-19-virus-rapid-antigen) So I believe we should hear from Canada's ISAD FDA very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_33</DOCNO>
            	<TEXT>Please click the links and view the process. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_34</DOCNO>
            	<TEXT>https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/regulatory-response-health-product-access.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/regulatory-response-health-product-access.html) [https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/interim-order-import-sale-advertising-drugs.html](https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/interim-order-import-sale-advertising-drugs.html) Now I want you to read this statement again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_35</DOCNO>
            	<TEXT>Sorrento is currently negotiating with global and regional distributors to ensure rapid distribution of COVISTIX to those countries that access to rapid, accurate and affordable testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_36</DOCNO>
            	<TEXT>This is a significant milestone for Sorrento and we appreciate the cooperation with European authorities to bring our highly sensitive antigen test to help control this pandemic, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_37</DOCNO>
            	<TEXT>We are expanding our manufacturing capacity in anticipation of large orders and are ready to deliver tests in the tens of millions of units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_38</DOCNO>
            	<TEXT>Tens of millions of units.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_39</DOCNO>
            	<TEXT>Remember when DR JI said, we will sell double digit million sales per month?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_40</DOCNO>
            	<TEXT>I remember and I haven't forgotten.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_41</DOCNO>
            	<TEXT>Please give it time to grow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_42</DOCNO>
            	<TEXT>It's just like a ROSE bush.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_43</DOCNO>
            	<TEXT>You trim the bush and you clip the small branches and watch a beautiful ROSE BUD bloom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_44</DOCNO>
            	<TEXT>I love smelling ROSES.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_360_45</DOCNO>
            	<TEXT>Let's run for the ROSES.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_361_0</DOCNO>
            	<TEXT>You know I posted the same post on yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_361_1</DOCNO>
            	<TEXT>I got about 15 likes and the yahoo jerks deleted the post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_361_2</DOCNO>
            	<TEXT>There trying their hardest to stop me from posting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_361_3</DOCNO>
            	<TEXT>And since I posted it once.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_361_4</DOCNO>
            	<TEXT>The post will not appear.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_362_0</DOCNO>
            	<TEXT>You should try reposting it and see what happens.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_363_0</DOCNO>
            	<TEXT>REPEAT IS AGAIN!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_364_0</DOCNO>
            	<TEXT>Does the SC stand for South Carolina?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_365_0</DOCNO>
            	<TEXT>My feeling is SRNE is getting called in because other players are going on the IR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_365_1</DOCNO>
            	<TEXT>Now we just need a few 4th down conversations and move the ball closer to the goalline.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_366_0</DOCNO>
            	<TEXT>I saw it and it was moving up to the top and then they pulled it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_366_1</DOCNO>
            	<TEXT>There's something they don't want people to know in that post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_367_0</DOCNO>
            	<TEXT>The jerks that control Yahoo at their best.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_368_0</DOCNO>
            	<TEXT>My daughter lives in Charleston</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_369_0</DOCNO>
            	<TEXT>She lives next door to the Southern Charm Reality TV show.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_370_0</DOCNO>
            	<TEXT>Let's meet at Amen Street for some Oysters someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_372_0</DOCNO>
            	<TEXT>There out today doing everything they can</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_373_0</DOCNO>
            	<TEXT>They don't want anyone creating traction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_374_0</DOCNO>
            	<TEXT>I put my money on Canada first</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_376_0</DOCNO>
            	<TEXT>Doesn't matter to me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_376_1</DOCNO>
            	<TEXT>If it takes longer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_376_2</DOCNO>
            	<TEXT>I have a long term outlook.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_376_3</DOCNO>
            	<TEXT>Eventually they will get all approved.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_0</DOCNO>
            	<TEXT>Litigation: Hueston Hennigan By disrupting the traditional litigation playbook, we have achieved historic results in some of our clients' most significant matters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_1</DOCNO>
            	<TEXT>Massively Successful Hueston Hennigan Named Top National Trial Firm During a Multi-Year Streak of Trial Wins 09/30/2021 | Accolades Accolades Benchmark Litigation declares: Hueston Hennigans mission of putting a premium on trial work, a mission that has been fulfilled with rapid momentum Hueston Hennigan once again tops the Benchmark Litigation rankings, earning a spot on the coveted list of Top Boutiques and Top 20 Trial Firms in the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_2</DOCNO>
            	<TEXT>Benchmark analysis noted Hueston Hennigan is massively successful with a client base \[that\] is remarkably diverse with very little repeat business and virtually no routine cases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_3</DOCNO>
            	<TEXT>Editors noted a multi-year streak of trial wins observing these cases are just WOW!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_4</DOCNO>
            	<TEXT>factor all the way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_5</DOCNO>
            	<TEXT>Even by \[Hueston Hennigans\] usual standards of trial breeding, this is exceptional.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_6</DOCNO>
            	<TEXT>Hueston Hennigan doesnt do the cookie-cutter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_7</DOCNO>
            	<TEXT>They do really cool, cutting-edge work, declared a peer, who goes on to confide, I admit it makes me jealous, and Im sure Im not alone!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_8</DOCNO>
            	<TEXT>Benchmark recognized partners, John Hueston and Moez Kaba, as two of the Top 100 Trial Lawyers in the Country and two of the Top 20 Trial Lawyers in California.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_9</DOCNO>
            	<TEXT>John Hueston was acclaimed as a trial trailblazer who has carved himself an enviable position even among others in the elite trial lawyer circuit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_10</DOCNO>
            	<TEXT>While Moez Kaba, the youngest appointee to this prestigious list by some distance, was praised as having staked himself a position as another of the firms lead trial counsel on some of the firms most high-stakes disputes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_11</DOCNO>
            	<TEXT>Benchmark also praised multiple additional Hueston Hennigan lawyers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_12</DOCNO>
            	<TEXT>Doug Dixon, for example, recognized as a Litigation Star, is a spectacular lawyer who shines on tough cases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_13</DOCNO>
            	<TEXT>Marshall Camp, Rob Klieger, and Brian Hennigan were likewise recognized as Litigation Stars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_14</DOCNO>
            	<TEXT>A peer noted, Future Stars and Top Lawyers Under 40, Allison Libeu, Vicki Chou, and Christy Rayburn, have really positioned themselves as key counsel on a number of issues.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_15</DOCNO>
            	<TEXT>Hueston Hennigan lawyers individual recognitions are summarized below: Marshall A. Camp, Litigation Star Vicki Chou, 40  amp; Under Hot List, Future Star Douglas J. Dixon, Litigation Star Brian Hennigan, National Star (White Collar Crime), Litigation Star John C. Hueston, Top 100 Trial Lawyer, Top 20 California Trial Lawyer, National Star (White Collar Crime and General Commercial Litigation), Litigation Star Moez M. Kaba, Top 100 Trial Lawyer, Top 20 California Trial Lawyer, 40  amp; Under Hot List, Litigation Star Robert N. Klieger, Litigation Star Allison Libeu, 40  amp; Under Hot List, Future Star Christy Rayburn, 40  amp; Under Hot List Hueston Hennigan also earned national and State of California tier 1 rankings in the General Commercial, White Collar, Securities and Entertainment practice areas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_16</DOCNO>
            	<TEXT>Benchmark Litigation is the definitive guide to Americas leading litigation law firms and lawyers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_17</DOCNO>
            	<TEXT>Research is conducted through extensive interviews with litigators, dispute resolution specialists and their clients to identify the leading litigators and firms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_18</DOCNO>
            	<TEXT>During these interviews, we examine recent casework handled by law firms and ask individual litigators to provide their professional opinions on peers and practitioners within their jurisdiction or practice area.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_19</DOCNO>
            	<TEXT>Please click and view case studies [https://www.hueston.com/about-us/](https://www.hueston.com/about-us/) There is a "status conference" scheduled for next Friday in Case Number: 19STCV11328.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_20</DOCNO>
            	<TEXT>This is followed by a "post-arbitration status conference" on 11/30/21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_21</DOCNO>
            	<TEXT>Can be seen at this link for the LA Court: Insert case number to see info.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_22</DOCNO>
            	<TEXT>In the last 20 months Sorrento Therapeutics doubled it's employee base.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_23</DOCNO>
            	<TEXT>Renewed all existing leases and expanded its future space by 100%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_24</DOCNO>
            	<TEXT>So where are they getting all this money?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_25</DOCNO>
            	<TEXT>Is their legal team telling them what they want to hear?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_377_26</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_0</DOCNO>
            	<TEXT>Litigation: Hueston Hennigan By disrupting the traditional litigation playbook, we have achieved historic results in some of our clients' most significant matters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_1</DOCNO>
            	<TEXT>Massively Successful Hueston Hennigan Named Top National Trial Firm During a Multi-Year Streak of Trial Wins 09/30/2021 | Accolades Accolades Benchmark Litigation declares: Hueston Hennigans mission of putting a premium on trial work, a mission that has been fulfilled with rapid momentum Hueston Hennigan once again tops the Benchmark Litigation rankings, earning a spot on the coveted list of Top Boutiques and Top 20 Trial Firms in the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_2</DOCNO>
            	<TEXT>Benchmark analysis noted Hueston Hennigan is massively successful with a client base \[that\] is remarkably diverse with very little repeat business and virtually no routine cases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_3</DOCNO>
            	<TEXT>Editors noted a multi-year streak of trial wins observing these cases are just WOW!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_4</DOCNO>
            	<TEXT>factor all the way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_5</DOCNO>
            	<TEXT>Even by \[Hueston Hennigans\] usual standards of trial breeding, this is exceptional.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_6</DOCNO>
            	<TEXT>Hueston Hennigan doesnt do the cookie-cutter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_7</DOCNO>
            	<TEXT>They do really cool, cutting-edge work, declared a peer, who goes on to confide, I admit it makes me jealous, and Im sure Im not alone!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_8</DOCNO>
            	<TEXT>Benchmark recognized partners, John Hueston and Moez Kaba, as two of the Top 100 Trial Lawyers in the Country and two of the Top 20 Trial Lawyers in California.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_9</DOCNO>
            	<TEXT>John Hueston was acclaimed as a trial trailblazer who has carved himself an enviable position even among others in the elite trial lawyer circuit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_10</DOCNO>
            	<TEXT>While Moez Kaba, the youngest appointee to this prestigious list by some distance, was praised as having staked himself a position as another of the firms lead trial counsel on some of the firms most high-stakes disputes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_11</DOCNO>
            	<TEXT>Benchmark also praised multiple additional Hueston Hennigan lawyers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_12</DOCNO>
            	<TEXT>Doug Dixon, for example, recognized as a Litigation Star, is a spectacular lawyer who shines on tough cases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_13</DOCNO>
            	<TEXT>Marshall Camp, Rob Klieger, and Brian Hennigan were likewise recognized as Litigation Stars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_14</DOCNO>
            	<TEXT>A peer noted, Future Stars and Top Lawyers Under 40, Allison Libeu, Vicki Chou, and Christy Rayburn, have really positioned themselves as key counsel on a number of issues.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_15</DOCNO>
            	<TEXT>Hueston Hennigan lawyers individual recognitions are summarized below: Marshall A. Camp, Litigation Star Vicki Chou, 40  amp; Under Hot List, Future Star Douglas J. Dixon, Litigation Star Brian Hennigan, National Star (White Collar Crime), Litigation Star John C. Hueston, Top 100 Trial Lawyer, Top 20 California Trial Lawyer, National Star (White Collar Crime and General Commercial Litigation), Litigation Star Moez M. Kaba, Top 100 Trial Lawyer, Top 20 California Trial Lawyer, 40  amp; Under Hot List, Litigation Star Robert N. Klieger, Litigation Star Allison Libeu, 40  amp; Under Hot List, Future Star Christy Rayburn, 40  amp; Under Hot List Hueston Hennigan also earned national and State of California tier 1 rankings in the General Commercial, White Collar, Securities and Entertainment practice areas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_16</DOCNO>
            	<TEXT>Benchmark Litigation is the definitive guide to Americas leading litigation law firms and lawyers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_17</DOCNO>
            	<TEXT>Research is conducted through extensive interviews with litigators, dispute resolution specialists and their clients to identify the leading litigators and firms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_18</DOCNO>
            	<TEXT>During these interviews, we examine recent casework handled by law firms and ask individual litigators to provide their professional opinions on peers and practitioners within their jurisdiction or practice area.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_19</DOCNO>
            	<TEXT>Please click and view case studies [https://www.hueston.com/about-us/](https://www.hueston.com/about-us/) There is a "status conference" scheduled for next Friday in Case Number: 19STCV11328.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_20</DOCNO>
            	<TEXT>This is followed by a "post-arbitration status conference" on 11/30/21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_21</DOCNO>
            	<TEXT>Can be seen at this link for the LA Court: Insert case number to see info.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_22</DOCNO>
            	<TEXT>In the last 20 months Sorrento Therapeutics doubled it's employee base.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_23</DOCNO>
            	<TEXT>Renewed all existing leases and expanded its future space by 100%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_24</DOCNO>
            	<TEXT>So where are they getting all this money?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_25</DOCNO>
            	<TEXT>Is their legal team telling them what they want to hear?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_378_26</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_379_0</DOCNO>
            	<TEXT>Could their legal team telling them it's a slam dunk case?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_380_0</DOCNO>
            	<TEXT>Do you think they would take the case if they thought they would lose?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_382_0</DOCNO>
            	<TEXT>PLEASE WATCH THIS VIDEO!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_382_1</DOCNO>
            	<TEXT>COVID-19 IS FAR FROM BEING OVER.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_382_2</DOCNO>
            	<TEXT>[https://www.youtube.com/watch?v=uuQkG3gKqiU](https://www.youtube.com/watch?v=uuQkG3gKqiU)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_0</DOCNO>
            	<TEXT>Our Culture</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_1</DOCNO>
            	<TEXT>Were not just your average pharmaceutical company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_2</DOCNO>
            	<TEXT>Were a different breed altogether.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_3</DOCNO>
            	<TEXT>Ours is a passionate team of talented people working together to make a difference in the world of pain management.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_4</DOCNO>
            	<TEXT>Our team-spirited approach ensures a collaborative, engaged, and focused atmosphere where we push thinking further, fostering innovation and fervently pursuing viable solutions for patients and providers through groundbreaking technologies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_5</DOCNO>
            	<TEXT>We believe in the law of science and that were all entitled to live healthy and pain-free livesbecause were patients, too.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_6</DOCNO>
            	<TEXT>We dont just seek answers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_7</DOCNO>
            	<TEXT>We seek THE answer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_8</DOCNO>
            	<TEXT>MISSION Our mission is to advance non-opioid therapeutic options to treat acute and chronic pain in patients with greatest unmet needs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_9</DOCNO>
            	<TEXT>SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_10</DOCNO>
            	<TEXT>culture-icons-vision VISION We are uncompromising in our focus to become the global pharmaceutical leader in pain management through social, environmental, economic, and ethical principles.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_383_11</DOCNO>
            	<TEXT>culture-icons-values VALUES Responsibility Excellence Accountability Diversity Integrity Quality [https://www.scilexpharma.com/about/our-culture/](https://www.scilexpharma.com/about/our-culture/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_0</DOCNO>
            	<TEXT>Our Culture</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_1</DOCNO>
            	<TEXT> Were not just your average pharmaceutical company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_2</DOCNO>
            	<TEXT>Were a different breed altogether.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_3</DOCNO>
            	<TEXT>Ours is a passionate team of talented people working together to make a difference in the world of pain management.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_4</DOCNO>
            	<TEXT>Our team-spirited approach ensures a collaborative, engaged, and focused atmosphere where we push thinking further, fostering innovation and fervently pursuing viable solutions for patients and providers through groundbreaking technologies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_5</DOCNO>
            	<TEXT>We believe in the law of science and that were all entitled to live healthy and pain-free livesbecause were patients, too.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_6</DOCNO>
            	<TEXT>We dont just seek answers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_7</DOCNO>
            	<TEXT>We seek THE answer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_8</DOCNO>
            	<TEXT>MISSION Our mission is to advance non-opioid therapeutic options to treat acute and chronic pain in patients with greatest unmet needs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_9</DOCNO>
            	<TEXT>SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_10</DOCNO>
            	<TEXT>culture-icons-vision VISION We are uncompromising in our focus to become the global pharmaceutical leader in pain management through social, environmental, economic, and ethical principles.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_384_11</DOCNO>
            	<TEXT>culture-icons-values VALUES Responsibility Excellence Accountability Diversity Integrity Quality [https://www.scilexpharma.com/about/our-culture/](https://www.scilexpharma.com/about/our-culture/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_385_0</DOCNO>
            	<TEXT>This page was updated</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_386_0</DOCNO>
            	<TEXT>Let me be the first to give you a vote!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_387_0</DOCNO>
            	<TEXT>Yes exactly what are they telling their clients?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_387_1</DOCNO>
            	<TEXT>With a question mark?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_388_0</DOCNO>
            	<TEXT>Thank you this is what i'm asking.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_389_0</DOCNO>
            	<TEXT>That would make sense.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_389_1</DOCNO>
            	<TEXT>DR JI must be anticipating $$$$ should come rolling in some day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_0</DOCNO>
            	<TEXT>WHAT DOES DARPA KNOW?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_1</DOCNO>
            	<TEXT>Taking Guess Work out of Vaccine Development</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_2</DOCNO>
            	<TEXT>WHAT DOES DARPA KNOW?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_3</DOCNO>
            	<TEXT>Taking Guess Work out of Vaccine Development DARPA Knows Immune response to vaccines is unpredictable, transient and ineffective, largely due to a lack of understanding of the complex mechanisms of action underlying immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_4</DOCNO>
            	<TEXT>AIM Program aims to leverage host immune mechanisms to determine if vaccine candidates will provide long-lasting immune protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_5</DOCNO>
            	<TEXT>ASSESSING IMMUNE MEMORY Military service members rely on effective vaccination for the prevention of communicable disease and to guard against biothreat exposure, but current vaccine development is expensive, time-consuming and prone to failure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_6</DOCNO>
            	<TEXT>Many current vaccines do not provide effective protection over long periods of time, and there are multiple pathogens that lack prophylactic options.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_7</DOCNO>
            	<TEXT>Immune response to vaccines is unpredictable, transient and ineffective, largely due to a lack of understanding of the complex mechanisms of action underlying immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_8</DOCNO>
            	<TEXT>The Assessing Immune Memory (AIM) program seeks to develop a platform capability to predict immune memory informed by a systems-level view of the host response to vaccination and its mechanisms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_9</DOCNO>
            	<TEXT>Standard methods for measuring immune system response, such as antibody levels and select immune cell type markers, do not capture the breadth of immune system responses possible.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_10</DOCNO>
            	<TEXT>AIM will uncover new biomolecular correlates collections of measured responses from organisms to an immune system challenge, such as vaccination using leading edge technologies to enable earlier response detection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_11</DOCNO>
            	<TEXT>These correlates will be used to predict and understand why successful vaccines produce long-lasting protection from early host responses rather than waiting years for clinical trial results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_12</DOCNO>
            	<TEXT>It is a significant challenge in vaccine development to be able to predict how long a vaccine will be protective before it is administered to humans, and more importantly, why protection is conveyed or not, stated Dr. Tristan McClure-Begley, AIM program manager.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_13</DOCNO>
            	<TEXT>The AIM program will incorporate next-generation analytical and computational approaches to determine the host response mechanisms that lead to long-lasting protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_14</DOCNO>
            	<TEXT>The five-year program will be divided into two sequential phases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_15</DOCNO>
            	<TEXT>The goal of Phase 1, Immune Memory Road Map is to identify cell and signaling contributors to generate a road map of immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_16</DOCNO>
            	<TEXT>Phase 2, Road Map Generalizability and Tool Validation will focus on assembling and validating a research and evaluation tool for predicting vaccine duration of protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_17</DOCNO>
            	<TEXT>Teams must propose to both phases to develop comprehensive, enduring solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_18</DOCNO>
            	<TEXT>Success with AIM will provide the nation with upfront assessments of vaccine duration of protection early in development and help reduce the need for constant re-vaccination of operators upon deployment, added McClure-Begley.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_19</DOCNO>
            	<TEXT>The U.S. Government will utilize Independent Validation and Verification (IV amp;V) partners throughout the program to aid in the evaluation of program progress and intermediate program demonstrations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_20</DOCNO>
            	<TEXT>By the end of Phase 1, a demonstration will be completed to determine entry into Phase 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_21</DOCNO>
            	<TEXT>Upon successful demonstration of the underlying principles of AIM, the same technology can be explored for use in a prognostic capacity to predict individual levels of immune protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_22</DOCNO>
            	<TEXT>Additional details of the program schedule and metrics are available in the broad agency announcement at [https://sam.gov/opp/ddbd04d4961f49acb576c529f837af93/view](https://sam.gov/opp/ddbd04d4961f49acb576c529f837af93/view). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_23</DOCNO>
            	<TEXT>https://www.darpa.mil/news-events/2021-08-27](https://www.darpa.mil/news-events/2021-08-27) Please read this sentence after reading about the AIM program.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_24</DOCNO>
            	<TEXT>If successful, it could provide an alternative method of protecting populations where vaccines do not work as well, such as the elderly or immunocompromised.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_25</DOCNO>
            	<TEXT>Please read this entire paragraph.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_26</DOCNO>
            	<TEXT>The DARPA/JPEO contract supports the accelerated development of a Gene MAbs neutralizing antibody that can be delivered by a simple intramuscular injection, enabling the recipient to produce the protective antibody, potentially within days of the injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_27</DOCNO>
            	<TEXT>Such an approach would permit the rapid translation of fully characterized potent neutralizing antibodies into clinical use, which Sorrento believes will be important for responding to potential mutations of SARS-CoV-2 that may emerge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_28</DOCNO>
            	<TEXT>It would also enable broader deployment of the Gene MAb approach as a prophylactic solution, as it can be conveniently administered into the muscle like an annual flu vaccine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_29</DOCNO>
            	<TEXT>If successful, it could provide an alternative method of protecting populations where vaccines do not work as well, such as the elderly or immunocompromised.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_30</DOCNO>
            	<TEXT>Please read this press release from Nov 27th 2020. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_391_31</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) DARPA knows vaccines do not work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_0</DOCNO>
            	<TEXT>WHAT DOES DARPA KNOW?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_1</DOCNO>
            	<TEXT>Taking Guess Work out of Vaccine Development</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_2</DOCNO>
            	<TEXT>DARPA Knows Immune response to vaccines is unpredictable, transient and ineffective, largely due to a lack of understanding of the complex mechanisms of action underlying immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_3</DOCNO>
            	<TEXT>AIM Program aims to leverage host immune mechanisms to determine if vaccine candidates will provide long-lasting immune protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_4</DOCNO>
            	<TEXT>ASSESSING IMMUNE MEMORY Military service members rely on effective vaccination for the prevention of communicable disease and to guard against biothreat exposure, but current vaccine development is expensive, time-consuming and prone to failure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_5</DOCNO>
            	<TEXT>Many current vaccines do not provide effective protection over long periods of time, and there are multiple pathogens that lack prophylactic options.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_6</DOCNO>
            	<TEXT>Immune response to vaccines is unpredictable, transient and ineffective, largely due to a lack of understanding of the complex mechanisms of action underlying immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_7</DOCNO>
            	<TEXT>The Assessing Immune Memory (AIM) program seeks to develop a platform capability to predict immune memory informed by a systems-level view of the host response to vaccination and its mechanisms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_8</DOCNO>
            	<TEXT>Standard methods for measuring immune system response, such as antibody levels and select immune cell type markers, do not capture the breadth of immune system responses possible.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_9</DOCNO>
            	<TEXT>AIM will uncover new biomolecular correlates collections of measured responses from organisms to an immune system challenge, such as vaccination using leading edge technologies to enable earlier response detection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_10</DOCNO>
            	<TEXT>These correlates will be used to predict and understand why successful vaccines produce long-lasting protection from early host responses rather than waiting years for clinical trial results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_11</DOCNO>
            	<TEXT>It is a significant challenge in vaccine development to be able to predict how long a vaccine will be protective before it is administered to humans, and more importantly, why protection is conveyed or not, stated Dr. Tristan McClure-Begley, AIM program manager.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_12</DOCNO>
            	<TEXT>The AIM program will incorporate next-generation analytical and computational approaches to determine the host response mechanisms that lead to long-lasting protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_13</DOCNO>
            	<TEXT>The five-year program will be divided into two sequential phases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_14</DOCNO>
            	<TEXT>The goal of Phase 1, Immune Memory Road Map is to identify cell and signaling contributors to generate a road map of immune memory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_15</DOCNO>
            	<TEXT>Phase 2, Road Map Generalizability and Tool Validation will focus on assembling and validating a research and evaluation tool for predicting vaccine duration of protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_16</DOCNO>
            	<TEXT>Teams must propose to both phases to develop comprehensive, enduring solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_17</DOCNO>
            	<TEXT>Success with AIM will provide the nation with upfront assessments of vaccine duration of protection early in development and help reduce the need for constant re-vaccination of operators upon deployment, added McClure-Begley.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_18</DOCNO>
            	<TEXT>The U.S. Government will utilize Independent Validation and Verification (IV amp;V) partners throughout the program to aid in the evaluation of program progress and intermediate program demonstrations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_19</DOCNO>
            	<TEXT>By the end of Phase 1, a demonstration will be completed to determine entry into Phase 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_20</DOCNO>
            	<TEXT>Upon successful demonstration of the underlying principles of AIM, the same technology can be explored for use in a prognostic capacity to predict individual levels of immune protection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_21</DOCNO>
            	<TEXT>Additional details of the program schedule and metrics are available in the broad agency announcement at [https://sam.gov/opp/ddbd04d4961f49acb576c529f837af93/view](https://sam.gov/opp/ddbd04d4961f49acb576c529f837af93/view). [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_22</DOCNO>
            	<TEXT>https://www.darpa.mil/news-events/2021-08-27](https://www.darpa.mil/news-events/2021-08-27) Please read this sentence after reading about the AIM program.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_23</DOCNO>
            	<TEXT>If successful, it could provide an alternative method of protecting populations where vaccines do not work as well, such as the elderly or immunocompromised.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_24</DOCNO>
            	<TEXT>Please read this entire paragraph.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_25</DOCNO>
            	<TEXT>The DARPA/JPEO contract supports the accelerated development of a Gene MAbs neutralizing antibody that can be delivered by a simple intramuscular injection, enabling the recipient to produce the protective antibody, potentially within days of the injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_26</DOCNO>
            	<TEXT>Such an approach would permit the rapid translation of fully characterized potent neutralizing antibodies into clinical use, which Sorrento believes will be important for responding to potential mutations of SARS-CoV-2 that may emerge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_27</DOCNO>
            	<TEXT>It would also enable broader deployment of the Gene MAb approach as a prophylactic solution, as it can be conveniently administered into the muscle like an annual flu vaccine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_28</DOCNO>
            	<TEXT>If successful, it could provide an alternative method of protecting populations where vaccines do not work as well, such as the elderly or immunocompromised.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_29</DOCNO>
            	<TEXT>Please read this press release from Nov 27th 2020. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_392_30</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) DARPA knows vaccines do not work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_393_0</DOCNO>
            	<TEXT>DARPA knows vaccines do not work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_393_1</DOCNO>
            	<TEXT>Could this be why Sorrento didn't aggressively pursue a vaccine?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_394_0</DOCNO>
            	<TEXT>DARPA knows vaccines do not work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_394_1</DOCNO>
            	<TEXT>Could this be why Sorrento didn't aggressively pursue a vaccine?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_395_0</DOCNO>
            	<TEXT>I almost feel there loading up the medicine cabinet waiting for the big money to roll in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_395_1</DOCNO>
            	<TEXT>Then pursue everything at once.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_395_2</DOCNO>
            	<TEXT>There cherry picking which one's to pursue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_395_3</DOCNO>
            	<TEXT>Until the big money arrives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_396_0</DOCNO>
            	<TEXT>NEW POSITION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_396_1</DOCNO>
            	<TEXT>[https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=301](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=301)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_397_0</DOCNO>
            	<TEXT>That's correct!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_398_0</DOCNO>
            	<TEXT>It very could happen and we see a 10X bagger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_399_0</DOCNO>
            	<TEXT>That's truly great DD on your part.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_399_1</DOCNO>
            	<TEXT>Thank you for explaining this to everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_400_0</DOCNO>
            	<TEXT>Siphen, You impress me with your great DD as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_401_0</DOCNO>
            	<TEXT>CHECK THIS ONE BROTHERS!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_401_1</DOCNO>
            	<TEXT>[https://www.facebook.com/medicamentosfutura/photos/2253447184791115](https://www.facebook.com/medicamentosfutura/photos/2253447184791115)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_403_0</DOCNO>
            	<TEXT>WORKING FOR LIFE - MedFutura Distribuidora e Drogaria - Sorrento's Brazilian Partner More than a company, we are people with a mission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_403_1</DOCNO>
            	<TEXT>Our mission: To be a company focused on people's health, through the commitment to distribute medicines and health products with quality, fair price and adequate delivery time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_403_2</DOCNO>
            	<TEXT>Our values: Appreciation to suppliers, customers and other partners; ethic; operational efficiency; transparency; agility in delivery and focus on technological innovation [http://medicamentosfutura.com.br/](http://medicamentosfutura.com.br/) [https://www.facebook.com/medicamentosfutura/photos/2253447184791115](https://www.facebook.com/medicamentosfutura/photos/2253447184791115) A press release tomorrow with a contract of 10M COVISTIX sales per month in Brazil would be a beautiful thing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_404_0</DOCNO>
            	<TEXT>Please check out!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_404_1</DOCNO>
            	<TEXT>No_Limi5915</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_404_2</DOCNO>
            	<TEXT>[https://www.tipranks.com/news/corona/sorrento-covid-19-tests-could-generate-significant-revenue-says-analyst/](https://www.tipranks.com/news/corona/sorrento-covid-19-tests-could-generate-significant-revenue-says-analyst/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_0</DOCNO>
            	<TEXT>NOAH'S ARK Noah knew the flood was coming so he built an ark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_1</DOCNO>
            	<TEXT>He loaded his ark with animals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_2</DOCNO>
            	<TEXT>It took him a few years to build this big ark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_3</DOCNO>
            	<TEXT>Then one day the flood came and he floated in his ark for 150 days until the flood water subsided and he landed on the mountains of Ararat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_4</DOCNO>
            	<TEXT>This is exactly what DR JI has done.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_5</DOCNO>
            	<TEXT>He's built a medicine cabinet filled with clinical trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_6</DOCNO>
            	<TEXT>ONE BIG ARK.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_7</DOCNO>
            	<TEXT>And Sorrento has been floating around waiting for the FDA approval for COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_8</DOCNO>
            	<TEXT>Sooner or later COVISTIX will be approved in the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_9</DOCNO>
            	<TEXT>Just like it was approved in Mexico and soon Brazil and the rest of Europe and Canada will follow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_10</DOCNO>
            	<TEXT>Soon we will get news about SP-102  amp; ABIVERTINIB in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_11</DOCNO>
            	<TEXT>This will be like Noah releasing all of all of the animals from the ark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_12</DOCNO>
            	<TEXT>The revenue is coming just like the flood came.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_13</DOCNO>
            	<TEXT>Then all of the clinical trials will proceed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_14</DOCNO>
            	<TEXT>Everyone has to have faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_15</DOCNO>
            	<TEXT>Faith that God will help the people that need the help the most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_16</DOCNO>
            	<TEXT>In God We Trust Noah knew the flood was coming so he built an ark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_17</DOCNO>
            	<TEXT>He loaded his ark with animals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_18</DOCNO>
            	<TEXT>It took him a few years to build this big ark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_19</DOCNO>
            	<TEXT>Then one day the flood came and he floated in his ark for 150 days until the flood water subsided and he landed on the mountains of Ararat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_20</DOCNO>
            	<TEXT>This is exactly what DR JI has done.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_21</DOCNO>
            	<TEXT>He's built a medicine cabinet filled with clinical trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_22</DOCNO>
            	<TEXT>ONE BIG ARK.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_23</DOCNO>
            	<TEXT>And Sorrento has been floating around waiting for the FDA approval for COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_24</DOCNO>
            	<TEXT>Sooner or later COVISTIX will be approved in the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_25</DOCNO>
            	<TEXT>Just like it was approved in Mexico and soon Brazil and the rest of Europe and Canada will follow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_26</DOCNO>
            	<TEXT>Soon we will get news about SP-102  amp; ABIVERTINIB in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_27</DOCNO>
            	<TEXT>This will be like Noah releasing all of all of the animals from the ark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_28</DOCNO>
            	<TEXT>The revenue is coming just like the flood came.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_29</DOCNO>
            	<TEXT>Then all of the clinical trials will proceed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_30</DOCNO>
            	<TEXT>Everyone has to have faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_31</DOCNO>
            	<TEXT>Faith that God will help the people that need the help the most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_405_32</DOCNO>
            	<TEXT>In God We Trust</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_406_0</DOCNO>
            	<TEXT>THAT THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_407_0</DOCNO>
            	<TEXT>You have the right to believe whatever you want to believe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_407_1</DOCNO>
            	<TEXT>If you don't have faith then that's up to you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_408_0</DOCNO>
            	<TEXT>Don't ruin your family!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_409_0</DOCNO>
            	<TEXT>That's right what does everyone expect.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_409_1</DOCNO>
            	<TEXT>The short scum are coming out full force.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_410_0</DOCNO>
            	<TEXT>Don't ruin your family taking a short position.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_411_0</DOCNO>
            	<TEXT>Don't ruin your family</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_412_0</DOCNO>
            	<TEXT>Don't ruin your families</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_413_0</DOCNO>
            	<TEXT>I think it's great news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_413_1</DOCNO>
            	<TEXT>What really is upsetting is they removed my Noah's Ark post on r/SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_413_2</DOCNO>
            	<TEXT>They either don't believe in GOD or they don't have faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_413_3</DOCNO>
            	<TEXT>Ask Ronan why they removed it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_414_0</DOCNO>
            	<TEXT>I've tried sharing news and thoughts on that board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_414_1</DOCNO>
            	<TEXT>They have disrespected the Veterans from freedom of speech and now GOD is not allowed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_415_0</DOCNO>
            	<TEXT>They delete my same post on r/SRNE because they will not allow GOD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_415_1</DOCNO>
            	<TEXT>Just ask yourself who does not want you talking about faith or GOD?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_416_0</DOCNO>
            	<TEXT>The moderators on that board can not be trusted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_416_1</DOCNO>
            	<TEXT>I wouldn't put it past them to be shorting as well to benefit themselves.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_417_0</DOCNO>
            	<TEXT>We need to stop posting on that board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_417_1</DOCNO>
            	<TEXT>They don't believe in GOD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_417_2</DOCNO>
            	<TEXT>They don't allow freedom of speech.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_417_3</DOCNO>
            	<TEXT>They allowed BASE BALLS HOT DOGS AND APPLE PIE AND CHEVY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_417_4</DOCNO>
            	<TEXT>But no GOD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_418_0</DOCNO>
            	<TEXT>Correct give it time to digest</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_419_0</DOCNO>
            	<TEXT>God or faith is not allowed</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_420_0</DOCNO>
            	<TEXT>Of course it is not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_420_1</DOCNO>
            	<TEXT>They don't like freedom, faith, and God.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_421_0</DOCNO>
            	<TEXT>In God We Trust is on all of the US currency.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_421_1</DOCNO>
            	<TEXT>They hate the freedom and have no respect.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_422_0</DOCNO>
            	<TEXT>r/SRNE didn't think so.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_422_1</DOCNO>
            	<TEXT>They deleted it and Banned me from their board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_422_2</DOCNO>
            	<TEXT>They don't like faith in God.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_423_0</DOCNO>
            	<TEXT>The moderators on that board hate Freedom, Faith, God, and liberty.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_424_0</DOCNO>
            	<TEXT>It wouldn't surprise me if there not shorting the stock at times.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_425_0</DOCNO>
            	<TEXT>It was harmless and everyone knows it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_425_1</DOCNO>
            	<TEXT>The moderators are there atheists or idiots.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_426_0</DOCNO>
            	<TEXT>Doesn't matter them is mentions faith in God.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_427_0</DOCNO>
            	<TEXT>Thank and you know where to find me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_428_0</DOCNO>
            	<TEXT>Excellent post</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_0</DOCNO>
            	<TEXT>Sorrento reports positive data from two trials of oral capsule for Covid-19</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_1</DOCNO>
            	<TEXT>Patients needing oxygen support were discharged from the hospital two days faster on receiving Abivertinib in the US trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_2</DOCNO>
            	<TEXT>Sorrento Therapeutics has reported positive initial data from two Phase II clinical trials of its oral capsule, Abivertinib, to treat hospitalised Covid-19- patients with pneumonia and respiratory depression.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_3</DOCNO>
            	<TEXT>A new small-molecule tyrosine kinase inhibitor, Abivertinib specifically acts on mutant forms of the epidermal growth factor receptor and Brutons tyrosine kinase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_4</DOCNO>
            	<TEXT>The double-blind, randomised Phase II trial in the US assessed the efficacy and safety of STI-5656 (Abivertinib Maleate) plus standard of care as against standard of care in hospitalised Covid-19 patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_5</DOCNO>
            	<TEXT>In Brazil, the randomised, placebo-controlled, double-blind Phase II trial analysed the safety and efficacy of the drug in Covid-19 patients admitted to the hospital.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_6</DOCNO>
            	<TEXT>The US trial recruited 96 patients while the Brazilian trial enrolled 400 subjects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_7</DOCNO>
            	<TEXT>Both trials analysed if Abivertinib could lower inflammatory cytokine storm linked to Covid-19-induced respiratory depression.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_8</DOCNO>
            	<TEXT>According to the initial data, subjects in category 5 of clinical status or needing non-invasive ventilation or high flow oxygen showed a 20% and 25% improvement in the primary goal on treatment with Abivertinib, in the US and Brazilian trials, respectively.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_9</DOCNO>
            	<TEXT>Preventing respiratory failure and mortality at one month was the primary goal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_10</DOCNO>
            	<TEXT>Furthermore, subjects in category 5 receiving Abivertinib were discharged from the hospital two days sooner versus those in the control arm in the US trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_11</DOCNO>
            	<TEXT>Subjects in category 5 and not in a category less than 4 demonstrated improvement on receiving Abivertinib treatment in both trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_12</DOCNO>
            	<TEXT>Based on these data, the company intends to commence a pivotal multinational, multicentre Phase III trial enrolling 400 subjects.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_13</DOCNO>
            	<TEXT>The trial will recruit at-risk Covid-19 patients in the hospital to whom oxygen support needs to be provided by non-invasive ventilation or high flow oxygen at baseline.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_14</DOCNO>
            	<TEXT>Sorrento Therapeutics chief medical officer Dr Mike Royal said: Patients on non-invasive ventilation or high flow oxygen supplementation due to Covid-19-induced respiratory failure represent a sicker and at-risk population with few available treatment options.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_15</DOCNO>
            	<TEXT>Abivertinib has the potential to fill this unmet need and significantly reduce progression to intubation, mechanical ventilation and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_16</DOCNO>
            	<TEXT>Last month, [Sorrento commenced enrolment of subjects in Phase II trial](https://www.pharmaceutical-technology.com/news/sorrento-enrolment-trial-brazil/) in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_17</DOCNO>
            	<TEXT>The trial was intended to assess human allogeneic adipose-derived mesenchymal stem cells in Covid-19 patients with acute respiratory distress or acute respiratory distress syndrome. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_429_18</DOCNO>
            	<TEXT>https://www.pharmaceutical-technology.com/news/sorrento-trials-oral-capsule-covid/](https://www.pharmaceutical-technology.com/news/sorrento-trials-oral-capsule-covid/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_430_0</DOCNO>
            	<TEXT>All I know is if it saved one life it was great!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_431_0</DOCNO>
            	<TEXT>YESTERDAY'S DARK POOL VOLUME WAS 33.07%</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_431_1</DOCNO>
            	<TEXT># SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest46,030,610 shares - source: NASDAQShort Interest Ratio11.43 Days to CoverShort Interest % Float16.90% - source: NASDAQ (short interest), Capital IQ (float)Dark Pool Short Volume1,001,458 shares - source: FINRADark Pool Short Volume Ratio33.07% - source: FINRA [https://fintel.io/ss/us/srne](https://fintel.io/ss/us/srne)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_0</DOCNO>
            	<TEXT>When dark pool prints are cancelled, here is what is happening.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_1</DOCNO>
            	<TEXT>Orders in dark pools are like giant ice-bergs in the ocean.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_2</DOCNO>
            	<TEXT>For a trade to take place, a resting bid, or buyer, has to be present when a seller initiates a sale.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_3</DOCNO>
            	<TEXT>Sometimes both sides are not present at the same time so orders are cancelled and replaced, these orders are referred to as ships passing in the night.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_4</DOCNO>
            	<TEXT>Another way to think of dark pool trades is that they are executed in the dark (without published bid and asking prices).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_5</DOCNO>
            	<TEXT>When a trader speaks of a cross or crossing a block, it means to match and execute a block trade or crossing a board lot.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_6</DOCNO>
            	<TEXT>Once an order has been crossed it is referred to as a fill.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_7</DOCNO>
            	<TEXT>The contra is the opposite side of the trade needed to make the cross complete.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_8</DOCNO>
            	<TEXT>Not all orders cross, especially on dark pools where it can be difficult to detect contra and the orders can miss each other.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_9</DOCNO>
            	<TEXT>These missed orders are referred to as ships passing in the night.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_10</DOCNO>
            	<TEXT>Sometimes traders will shotgun or spray an order which means to send in multiple orders into multiple venues/dark pools in hopes of finding contra to make a cross.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_433_11</DOCNO>
            	<TEXT>Sweeping is when traders take an order and try to cross it against the book (i.e. walking the book) or against contra in multiple markets (i.e. sweeping the market), to try and cross as much of the block order as possible.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_0</DOCNO>
            	<TEXT>A nasal COVID-19 vaccine could be the solution to ending the pandemic, experts say, and early trial data looks promising.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_1</DOCNO>
            	<TEXT>Please read this article that came today!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_2</DOCNO>
            	<TEXT>Sorrento's COVIDROPS is in P2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_3</DOCNO>
            	<TEXT>WAY AHEAD OF THE PACK.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_4</DOCNO>
            	<TEXT>There's plenty of hot pies in the oven that are still cooking.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_5</DOCNO>
            	<TEXT>COVID-19 vaccines are great at preventing severe illnesses and death.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_6</DOCNO>
            	<TEXT>But they don't always stop transmission, or mild cases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_7</DOCNO>
            	<TEXT>Nasal vaccines could fill that gap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_8</DOCNO>
            	<TEXT>If we could vaccinate your nose, there's a good chance we'd be able to end this pandemic right now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_9</DOCNO>
            	<TEXT>But the COVID-19 shots currently available in the US can't control everything that happens in your nostrils.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_10</DOCNO>
            	<TEXT>If they did, they might be able to stop all transmission of the virus that happens through our talking, singing, laughing, breathing, and sneezing around each other.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_11</DOCNO>
            	<TEXT>If successful, a new kind of vaccine - a nasal mist that requires no needle - promises to do all that, by providing the special kind of coronavirus immunity people need to stop shuttling this virus around. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_12</DOCNO>
            	<TEXT>An intra-nasal vaccine could help bring an end to the pandemic, and help give us true control over SARS-CoV-2 by limiting infection and transmission," Marty Moore, the CEO of Meissa Vaccines, told Insider. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_13</DOCNO>
            	<TEXT>We shouldn't settle for a new normal, we can get back to the old normal."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_14</DOCNO>
            	<TEXT>For now, that idea remains one that needs much more robust clinical data behind it to become a reality that we could all sniff up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_15</DOCNO>
            	<TEXT>But the prospect is still quite exciting to many immunologists around the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_16</DOCNO>
            	<TEXT>Shots in the arm aren't always great at preventing the sniffles One big reason why vaccine breakthrough infections happen is because the injectable COVID-19 vaccines have been designed to give a person's body good systemic immunity against the virus, protecting internal organs like the lungs and the heart from severe infection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_17</DOCNO>
            	<TEXT>But a shot in the arm can't do as much for your nose in the long run.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_18</DOCNO>
            	<TEXT>If a vaccinated person is exposed to COVID-19, they may still get a case of the sniffles, or a flu-like COVID-19 illness.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_19</DOCNO>
            	<TEXT>This is because they haven't developed great mucosal immunity against the coronavirus - in other words: they're still susceptible to infection via the vulnerable moist tissues that interact with the outside world, like those in the nose, eyes, and mouth. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_20</DOCNO>
            	<TEXT>Very early on during that honeymoon initially after vaccination when your neutralizing antibodies are at their highest, you get a bit of a spillover effect into the upper airway," Dr. Celine Gounder, an infectious disease specialist at Bellevue hospital in New York, said at the recent ID Week infectious disease conference, explaining the issue of lacking durable mucosal immunity after vaccination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_21</DOCNO>
            	<TEXT>Meissa is one of a few smaller companies pursuing COVID-19 nasal vaccines in early-stage human trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_22</DOCNO>
            	<TEXT>Codagenix, another US-based company, has also announced some promising (but extremely small) early trial results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_23</DOCNO>
            	<TEXT>Other nasal vaccines are being developed around the world, with ongoing trials in Israel, Russia, Cuba, India, Hong Kong, and Iran. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_24</DOCNO>
            	<TEXT>Our aim is to be the transmission-blocking COVID vaccine," Moore said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_25</DOCNO>
            	<TEXT>Immunologists are excited about the prospect of nasal vaccines - both for unvaccinated people, and as boosters According to Meissa's early clinical data (which the company says it will be sharing in more detail at an upcoming immunotherapy conference in late November and early December) unvaccinated patients who are given a couple drops of Meissa's vaccine in each nostril have average mucosal antibody levels slightly higher than those measured in people with natural immunity to the virus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_26</DOCNO>
            	<TEXT>This suggests that Meissa's vaccine could potentially work well at preventing the more pesky sniffly infections, not just the COVID cases that land people in the hospital. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_27</DOCNO>
            	<TEXT>It suggests that we can deliver immunity that's like natural infection, but we can do it safely," Moore said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_28</DOCNO>
            	<TEXT>This prospect has many immunologists quite excited, not just because nasal vaccines could be offered to vaccine-hesitant people who don't like shots, but also because they might, perhaps, be used as boosters to top up the already very good systemic immunity people have gotten from injectable vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_29</DOCNO>
            	<TEXT>Meissa's initial human trial is still ongoing now, with 70 participants in it so far.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_30</DOCNO>
            	<TEXT>It's only phase 1, meaning any approval or even emergency authorization for this type of vaccine is many months and likely several thousand more volunteer participants away, at best.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_31</DOCNO>
            	<TEXT>But so far, the results look good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_32</DOCNO>
            	<TEXT>Meissa, which is conducting much of its research in Kansas, says there are many reasons why people have chosen to join their early-stage trial. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_33</DOCNO>
            	<TEXT>Sometimes it's people who are PhDs, or highly educated, who see the benefit of an intra-nasal to prevent infection itself," Moore said. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_34</DOCNO>
            	<TEXT>And oftentimes, it's people who just don't want a shot.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_35</DOCNO>
            	<TEXT>They don't want something injected into them." [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_434_36</DOCNO>
            	<TEXT>https://www.yahoo.com/news/nasal-covid-19-vaccine-could-131135817.html](https://www.yahoo.com/news/nasal-covid-19-vaccine-could-131135817.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_435_0</DOCNO>
            	<TEXT>This article was released today 10/28/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_436_0</DOCNO>
            	<TEXT>DON'S POST FROM YAHOO!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_436_1</DOCNO>
            	<TEXT>VERY INTERESTING!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_436_2</DOCNO>
            	<TEXT>It is interesting to compare the results of the Brazilian study of ABIVERTINIB to a Brazilian study of the highly touted drug chloroquine/hydroxychloroquine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_436_3</DOCNO>
            	<TEXT>While ABIVERTINIB proved to be about 55% more effective than SOC in status 5 patients the chloro/hydrochloro study was ended early "...DUE TO HARMFUL EFFECTS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_436_4</DOCNO>
            	<TEXT>Patients in the intervention group had a worse clinical outcome..." See the study published April 27,2021 [https://www.nature.com/articles/s41598-021-88509-9](https://www.nature.com/articles/s41598-021-88509-9)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_437_0</DOCNO>
            	<TEXT>No of another Pharmaceutical Company that is in P1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_437_1</DOCNO>
            	<TEXT>Remember we're in P2 with COVIDROPS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_438_0</DOCNO>
            	<TEXT>We're leading the pack for once.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_439_0</DOCNO>
            	<TEXT>I will drink to that</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_440_0</DOCNO>
            	<TEXT>Sorry but I was banned from posting on r/SRNE yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_440_1</DOCNO>
            	<TEXT>I posted a Metaphor post about Noah's Ark. The same post on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_440_2</DOCNO>
            	<TEXT>They deleted the post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_440_3</DOCNO>
            	<TEXT>So I called them out and they banned me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_440_4</DOCNO>
            	<TEXT>Because you can't mention God on there board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_440_5</DOCNO>
            	<TEXT>The moderators is either an atheist or an idiot.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_441_0</DOCNO>
            	<TEXT>Let this be your first warning do not bait the moderators on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_442_0</DOCNO>
            	<TEXT>You knew I couldn't post on that board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_442_1</DOCNO>
            	<TEXT>Now your judging my faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_442_2</DOCNO>
            	<TEXT>This is your second warning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_443_0</DOCNO>
            	<TEXT>The r/SRNE has no respect for your 1st Amendment Right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_443_1</DOCNO>
            	<TEXT>They don't want you talking about your faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_443_2</DOCNO>
            	<TEXT>They post their rules but don't follow them on other boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_443_3</DOCNO>
            	<TEXT>There all hypocrisies and bias towards Veterans.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_444_0</DOCNO>
            	<TEXT>Thank you for posting on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_444_1</DOCNO>
            	<TEXT>This DD is excellent and please keep posting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_0</DOCNO>
            	<TEXT>IN ALL FAIRNESS WHO DO WE LISTEN TO?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_1</DOCNO>
            	<TEXT>Who do we want to believe?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_2</DOCNO>
            	<TEXT>Who do we want to follow?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_3</DOCNO>
            	<TEXT>What do we believe?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_4</DOCNO>
            	<TEXT>Let's take a look and figure this out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_5</DOCNO>
            	<TEXT>Most of us came to this board in May 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_6</DOCNO>
            	<TEXT>At least that's when I did.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_7</DOCNO>
            	<TEXT>I started to read everyone's posts to get a feel about the company I was investing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_8</DOCNO>
            	<TEXT>I could clearly see and read who was knowledgeable and who wasn't.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_9</DOCNO>
            	<TEXT>The most important thing that I found that people were working together as a team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_10</DOCNO>
            	<TEXT>Or let's say multiple different teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_11</DOCNO>
            	<TEXT>We had some pumpers on one side pumping the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_12</DOCNO>
            	<TEXT>On the other side we had Bashers that were putting down the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_13</DOCNO>
            	<TEXT>Both teams have a job to do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_14</DOCNO>
            	<TEXT>And both teams were doing a pretty good job at it as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_15</DOCNO>
            	<TEXT>The investors were in the middle to choose and decide which people to listen to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_16</DOCNO>
            	<TEXT>There was always an open decision on this board that was great.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_17</DOCNO>
            	<TEXT>But after a while as we can see.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_18</DOCNO>
            	<TEXT>We all started to search other message boards for DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_19</DOCNO>
            	<TEXT>It's only natural because we want to see if we're missing something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_20</DOCNO>
            	<TEXT>So I did exactly just that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_21</DOCNO>
            	<TEXT>People were telling me to go to r/SRNE and post there as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_22</DOCNO>
            	<TEXT>So I opened an account and said hello.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_23</DOCNO>
            	<TEXT>They welcomed me with open arms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_24</DOCNO>
            	<TEXT>Thinking ahead I thought about setting up my own Reddit account for Veterans and yahoo members for Sorrento celebration party someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_25</DOCNO>
            	<TEXT>Which is r/BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_26</DOCNO>
            	<TEXT>So I then started to post any DD that I could find on all three boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_27</DOCNO>
            	<TEXT>My motive always from the start was to help others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_28</DOCNO>
            	<TEXT>It's the greatest feeling when someone says a simple thank you in return.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_29</DOCNO>
            	<TEXT>That in return for me wanted me to work harder.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_30</DOCNO>
            	<TEXT>I found myself very frustrated with the moderators on r/SRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_31</DOCNO>
            	<TEXT>They baited me one day with my THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_32</DOCNO>
            	<TEXT>They insinuated that it was a TRUMP rally call.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_33</DOCNO>
            	<TEXT>Which it was not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_34</DOCNO>
            	<TEXT>Everyone or at least everyone knows I love Frank Sinatra.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_35</DOCNO>
            	<TEXT>When I confronted them in public I was told to message them in private.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_36</DOCNO>
            	<TEXT>Which I did and was told there's no mention of politics on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_37</DOCNO>
            	<TEXT>Even using a WHAT IF scenario in the event Joe Biden was removed as President and replaced.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_38</DOCNO>
            	<TEXT>How would that of changed the CDC, FDA, WHO, etc.?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_39</DOCNO>
            	<TEXT>If it were to happen who would be put in their places?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_40</DOCNO>
            	<TEXT>Could take change the outcome of what's going on with clinical trials?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_41</DOCNO>
            	<TEXT>It's a valid discussion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_42</DOCNO>
            	<TEXT>Here's what I noticed they were bashing one political party and not the other.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_43</DOCNO>
            	<TEXT>They were cherry picking me and singling me out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_44</DOCNO>
            	<TEXT>Being told private message us asap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_45</DOCNO>
            	<TEXT>To be told it you don't stop the politics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_46</DOCNO>
            	<TEXT>We will ban you from our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_47</DOCNO>
            	<TEXT>So I refrained from posting any other WHAT IF scenarios about politics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_48</DOCNO>
            	<TEXT>Sounds like censorship?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_49</DOCNO>
            	<TEXT>It's there board and there making the rules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_50</DOCNO>
            	<TEXT>So a few days ago I posted on all three boards my Metaphoric post about Noah's Ark. It was greeted with open arms on two boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_51</DOCNO>
            	<TEXT>But again on r/SRNE it was deleted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_52</DOCNO>
            	<TEXT>Being very unhappy I private messaged the moderators.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_53</DOCNO>
            	<TEXT>To be told no religion is allowed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_54</DOCNO>
            	<TEXT>Not even a Metaphoric post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_55</DOCNO>
            	<TEXT>So confronting them I was BANNED from their board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_56</DOCNO>
            	<TEXT>I told up for WHO i believed in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_57</DOCNO>
            	<TEXT>I'm a very firm believer in the your 1st Amendment Rights and all Freedom of speech and Freedom to believe in any religion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_58</DOCNO>
            	<TEXT>We as Americans and Veterans have fought for those Freedoms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_59</DOCNO>
            	<TEXT>Some even making the ultimate sacrifice in multiple wars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_60</DOCNO>
            	<TEXT>Service members, Police Officers, Firemen all need to be shown respect and honor them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_61</DOCNO>
            	<TEXT>They are the hero's that we need to follow and listen to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_62</DOCNO>
            	<TEXT>I will not mention him by name.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_63</DOCNO>
            	<TEXT>Because he does not know I'm writing this.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_64</DOCNO>
            	<TEXT>But he's a Vietnam Bronze Star Veteran that for two years worked as an Army front line medic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_65</DOCNO>
            	<TEXT>I speak to this board member daily.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_66</DOCNO>
            	<TEXT>And that's WHO I choose to follow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_67</DOCNO>
            	<TEXT>That's WHO I believe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_68</DOCNO>
            	<TEXT>No one should ever remove your faith in any GOD off of any board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_69</DOCNO>
            	<TEXT>We used to have a daily morning prayer on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_70</DOCNO>
            	<TEXT>We don't anymore and we need to start again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_71</DOCNO>
            	<TEXT>We all need to pray for a blessing for the cure for COVID-19 and the 4,999,530 people that have died since this pandemic started.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_72</DOCNO>
            	<TEXT>God is allows listening and he is WHO you need to believe in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_445_73</DOCNO>
            	<TEXT>Thank you and God Bless everyone on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_446_0</DOCNO>
            	<TEXT>God is always listening</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_447_0</DOCNO>
            	<TEXT>Thank you and have a nice day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_448_0</DOCNO>
            	<TEXT>Good morning my friend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_448_1</DOCNO>
            	<TEXT>It's a great morning to be an American.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_448_2</DOCNO>
            	<TEXT>Thank you for everything that you do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_449_0</DOCNO>
            	<TEXT>Sciatica Market Future Business Opportunities 2021-2028 | Sorrento Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd. THIS IS BIG!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_449_1</DOCNO>
            	<TEXT>[https://chipdesignmag.com/sciatica-market-future-business-opportunities-2021-2028-sorrento-therapeutics-inc-teva-pharmaceutical-industries-ltd-aurobindo-pharma-ltd/](https://chipdesignmag.com/sciatica-market-future-business-opportunities-2021-2028-sorrento-therapeutics-inc-teva-pharmaceutical-industries-ltd-aurobindo-pharma-ltd/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_450_0</DOCNO>
            	<TEXT>Thank you for your support and please post more on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_450_1</DOCNO>
            	<TEXT>We need more people like yourself.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_451_0</DOCNO>
            	<TEXT>I agree with you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_452_0</DOCNO>
            	<TEXT>Thank you for your support and please post more on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_452_1</DOCNO>
            	<TEXT>We need more people like yourself.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_452_2</DOCNO>
            	<TEXT>Thanks again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_453_0</DOCNO>
            	<TEXT>I bring it to you because your one of my favorites.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_454_0</DOCNO>
            	<TEXT>They know which ones are working on making it happen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_454_1</DOCNO>
            	<TEXT>This a long term cash cow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_455_0</DOCNO>
            	<TEXT>Henry we need more voices like yourself.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_455_1</DOCNO>
            	<TEXT>You're a fighter that we would want in our foxhole.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_455_2</DOCNO>
            	<TEXT>Thank you and please post more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_456_0</DOCNO>
            	<TEXT>Thank you for your support and please post more on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_456_1</DOCNO>
            	<TEXT>We're a team that tries to find DD and share it as soon as we can.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_457_0</DOCNO>
            	<TEXT>Of course I read it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_458_0</DOCNO>
            	<TEXT>Thank you for visiting our board and please post when ever you please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_458_1</DOCNO>
            	<TEXT>Thank you for your support.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_459_0</DOCNO>
            	<TEXT>That's totally fine and I we don't judge non believers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_459_1</DOCNO>
            	<TEXT>We promote faith and God and Freedom of speech about politics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_459_2</DOCNO>
            	<TEXT>If you choose not to listen or follow that's up to you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_459_3</DOCNO>
            	<TEXT>The easiest way on r/SRNE would of been to block someone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_459_4</DOCNO>
            	<TEXT>This way you wouldn't be influenced.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_459_5</DOCNO>
            	<TEXT>Good luck and I do remember your posts in the past.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_459_6</DOCNO>
            	<TEXT>They're all good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_460_0</DOCNO>
            	<TEXT>Perfectly and exactly how we all feel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_460_1</DOCNO>
            	<TEXT>We shouldn't be prosecuted for exercising on faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_460_2</DOCNO>
            	<TEXT>Thank you and please post more on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_460_3</DOCNO>
            	<TEXT>We all work on providing the best DD we can.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_460_4</DOCNO>
            	<TEXT>It's all about helping one another.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_461_0</DOCNO>
            	<TEXT>If I could give you an award for a post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_461_1</DOCNO>
            	<TEXT>You would get one.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_461_2</DOCNO>
            	<TEXT>Thanks so much and I will share that Monday morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_461_3</DOCNO>
            	<TEXT>That's your reward!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_463_0</DOCNO>
            	<TEXT>EVERYONE PLEASE CHECK OUT THE COVISTIX DEAL IN MEXICO https://m.facebook.com/distribbuidoragap/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_463_1</DOCNO>
            	<TEXT>EVERYONE PLEASE CHECK OUT THE COVISTIX DEAL IN MEXICO [https://m.facebook.com/distribbuidoragap/](https://m.facebook.com/distribbuidoragap/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_464_0</DOCNO>
            	<TEXT>GOOGLE THE LINK</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_465_0</DOCNO>
            	<TEXT>Please Google it</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_466_0</DOCNO>
            	<TEXT>I think it's time I become an Ape.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_466_1</DOCNO>
            	<TEXT>Tomorrow when I have time I will look into it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_467_0</DOCNO>
            	<TEXT>We would need a community or we join the current one and BAND together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_0</DOCNO>
            	<TEXT>IN ALL FAIRNESS WHO DO WE WANT TO LISTEN TO?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_1</DOCNO>
            	<TEXT>Who do we want to believe?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_2</DOCNO>
            	<TEXT>Who do we want to follow?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_3</DOCNO>
            	<TEXT>What do we believe?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_4</DOCNO>
            	<TEXT>Let's take a closer look and figure this out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_5</DOCNO>
            	<TEXT>Most of us came to this board in May 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_6</DOCNO>
            	<TEXT>At least that's when I did.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_7</DOCNO>
            	<TEXT>I started to read everyone's posts to get a feel about the company I was investing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_8</DOCNO>
            	<TEXT>I could clearly see and read who was knowledgeable and who wasn't.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_9</DOCNO>
            	<TEXT>The most important thing that I found that people were working together as a team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_10</DOCNO>
            	<TEXT>Or let's say multiple different teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_11</DOCNO>
            	<TEXT>We had some pumpers on one side pumping the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_12</DOCNO>
            	<TEXT>On the other side we had Bashers that were putting down the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_13</DOCNO>
            	<TEXT>Both teams have a job to do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_14</DOCNO>
            	<TEXT>And both teams were doing a pretty good job at it as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_15</DOCNO>
            	<TEXT>The investors were in the middle to choose and decide which people to listen to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_16</DOCNO>
            	<TEXT>There was always an open decision on this board that was great.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_17</DOCNO>
            	<TEXT>But after a while as we can see.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_18</DOCNO>
            	<TEXT>We all started to search other message boards for DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_19</DOCNO>
            	<TEXT>It's only natural because we want to see if we're missing something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_20</DOCNO>
            	<TEXT>So I did exactly just that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_21</DOCNO>
            	<TEXT>People were telling me to go to r/SRNE and post there as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_22</DOCNO>
            	<TEXT>So I opened an account and said hello.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_23</DOCNO>
            	<TEXT>They welcomed me with open arms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_24</DOCNO>
            	<TEXT>Receiving 33 awards in the 1st week alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_25</DOCNO>
            	<TEXT>People started to private message me as well to thank me for my DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_26</DOCNO>
            	<TEXT>Thinking ahead I thought about setting up my own Reddit account for Veterans and yahoo members for a Sorrento celebration party someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_27</DOCNO>
            	<TEXT>Which is r/BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_28</DOCNO>
            	<TEXT>So I then started to post any DD that I could find on all three boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_29</DOCNO>
            	<TEXT>My motive always from the start was to help others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_30</DOCNO>
            	<TEXT>It's the greatest feeling when someone says a simple thank you in return.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_31</DOCNO>
            	<TEXT>That in return for me wanted me to work harder.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_32</DOCNO>
            	<TEXT>I found myself very frustrated with the moderators on Reddit's SRNE as time pasted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_33</DOCNO>
            	<TEXT>They started to bait me one day with my THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_34</DOCNO>
            	<TEXT>They insinuated that it was a TRUMP rally call.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_35</DOCNO>
            	<TEXT>Which it was not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_36</DOCNO>
            	<TEXT>Everyone or at least everyone knows I love Frank Sinatra.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_37</DOCNO>
            	<TEXT>When I confronted them in public I was told to message them in private.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_38</DOCNO>
            	<TEXT>Which I did and was told there's no mention of politics on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_39</DOCNO>
            	<TEXT>Even using a WHAT IF scenario in the event Joe Biden was removed as President and replaced.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_40</DOCNO>
            	<TEXT>How would that of changed the CDC, FDA, WHO, etc.?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_41</DOCNO>
            	<TEXT>If it were to happen who would be put in their places?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_42</DOCNO>
            	<TEXT>Could take change the outcome of what's going on with clinical trials?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_43</DOCNO>
            	<TEXT>It's a valid discussion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_44</DOCNO>
            	<TEXT>Here's what I noticed they were doing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_45</DOCNO>
            	<TEXT>They would allow bashing of one political party and not the other.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_46</DOCNO>
            	<TEXT>They were cherry picking me and singling me out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_47</DOCNO>
            	<TEXT>Being told private message us asap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_48</DOCNO>
            	<TEXT>To be told it you don't stop the politics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_49</DOCNO>
            	<TEXT>We will ban you from our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_50</DOCNO>
            	<TEXT>So I refrained from posting any other WHAT IF scenarios about politics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_51</DOCNO>
            	<TEXT>Sounds like censorship?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_52</DOCNO>
            	<TEXT>It got worse they started to pick on timelines of my posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_53</DOCNO>
            	<TEXT>Everyone knows you need to click and open the links and you will see how old or new the post was.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_54</DOCNO>
            	<TEXT>Why were they only picking on me?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_55</DOCNO>
            	<TEXT>Hmmm was it the BEST IS YET TO COME?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_56</DOCNO>
            	<TEXT>It's there board and there making the rules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_57</DOCNO>
            	<TEXT>So a few days ago I posted on all three boards my Metaphoric post about Noah's Ark. It was greeted with open arms on two boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_58</DOCNO>
            	<TEXT>But again on Reddit's SRNE it was deleted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_59</DOCNO>
            	<TEXT>Being very unhappy I private messaged the moderators.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_60</DOCNO>
            	<TEXT>To be told no religion is allowed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_61</DOCNO>
            	<TEXT>Not even a Metaphoric post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_62</DOCNO>
            	<TEXT>So confronting them I was BANNED from their board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_63</DOCNO>
            	<TEXT>I stood up for WHO I believed in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_64</DOCNO>
            	<TEXT>I'm a very firm believer in the your 1st Amendment Rights and all Freedom of speech and Freedom to believe in any religion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_65</DOCNO>
            	<TEXT>I believe non believers don't need to believe if they choose not to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_66</DOCNO>
            	<TEXT>Where does it say no religion allowed on their board?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_67</DOCNO>
            	<TEXT>Hmm it does not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_68</DOCNO>
            	<TEXT>We as Americans and Veterans have fought for those Freedoms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_69</DOCNO>
            	<TEXT>Some even making the ultimate sacrifice in multiple wars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_70</DOCNO>
            	<TEXT>Service members, Police Officers, Firemen all need to be shown respect and honor them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_71</DOCNO>
            	<TEXT>They are the hero's that we need to follow and listen to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_72</DOCNO>
            	<TEXT>I will not mention him by name.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_73</DOCNO>
            	<TEXT>Because he does not know I'm writing this.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_74</DOCNO>
            	<TEXT>But he's a Vietnam Bronze Star Veteran that for two years worked as an Army front line medic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_75</DOCNO>
            	<TEXT>I speak to this yahoo board member daily.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_76</DOCNO>
            	<TEXT>And that's WHO I choose to follow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_77</DOCNO>
            	<TEXT>That's WHO I choose to believe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_78</DOCNO>
            	<TEXT>Not for his religious faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_79</DOCNO>
            	<TEXT>But for the sacrifices that he made for our Country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_80</DOCNO>
            	<TEXT>No one should ever remove your faith in any GOD off of any board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_81</DOCNO>
            	<TEXT>Or your opinions or your beliefs if there not in line with theirs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_82</DOCNO>
            	<TEXT>We used to have a daily morning prayer on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_83</DOCNO>
            	<TEXT>We don't anymore and we need to start again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_84</DOCNO>
            	<TEXT>We all need to pray for a blessing and for a cure for COVID-19 and the 5,007,621 people that have died since this pandemic started.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_85</DOCNO>
            	<TEXT>God is allows listening and he is WHO you need to believe in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_86</DOCNO>
            	<TEXT>Thank you and God Bless everyone on this board and Sorrento Therapeutics in finding a cure or treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_468_87</DOCNO>
            	<TEXT>Thanks again ROBERT S.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_469_0</DOCNO>
            	<TEXT>Yahoo algorithm picks up the AMEN'S and the GOD BLESSES and they remove it as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_470_0</DOCNO>
            	<TEXT>They wouldn't like the word AMEN as it means I agree.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_471_0</DOCNO>
            	<TEXT>I was also called the BIG elegant in the room on their board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_471_1</DOCNO>
            	<TEXT>Little they know Elephant's never forget.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_472_0</DOCNO>
            	<TEXT>I agree is another for SO BE IT!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_473_0</DOCNO>
            	<TEXT>Your right!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_474_0</DOCNO>
            	<TEXT>Thank you for your support.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_475_0</DOCNO>
            	<TEXT>Great point!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_476_0</DOCNO>
            	<TEXT>Fingers crossed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_477_0</DOCNO>
            	<TEXT>Everyone please view great DD in finding this link.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_477_1</DOCNO>
            	<TEXT>Please forward the link.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_0</DOCNO>
            	<TEXT>CLINICAL TRIALS TAKE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_1</DOCNO>
            	<TEXT>So what are we to do in the meantime?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_2</DOCNO>
            	<TEXT>Don't chase the butterflies!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_3</DOCNO>
            	<TEXT>Live the life you have imagined.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_4</DOCNO>
            	<TEXT>You don't need to analyze everything over and over everyday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_5</DOCNO>
            	<TEXT>Because when simplify your life, the laws of the universe will be simpler.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_6</DOCNO>
            	<TEXT>What does everyone want in life?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_7</DOCNO>
            	<TEXT>To be happy?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_8</DOCNO>
            	<TEXT>To be wealthy?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_9</DOCNO>
            	<TEXT>To find love?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_10</DOCNO>
            	<TEXT>To build a family?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_11</DOCNO>
            	<TEXT>Success usually comes to those who are too busy to be looking for it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_12</DOCNO>
            	<TEXT>Happiness is like a butterfly the more you chase it, the more it will elude you, but if you turn your attention to other things, it comes and sits softly on your shoulder.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_13</DOCNO>
            	<TEXT>My point I'm trying to make is everyone needs to relax.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_14</DOCNO>
            	<TEXT>Go about your everyday things.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_15</DOCNO>
            	<TEXT>Sorrento Therapeutics is a long term stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_16</DOCNO>
            	<TEXT>With a great pipeline and a tremendous opportunity to becoming a major powerhouse big Pharma Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_17</DOCNO>
            	<TEXT>Before you know it the butterflies will start to chase YOU!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_18</DOCNO>
            	<TEXT>BTW: Butterflies love pink roses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_478_19</DOCNO>
            	<TEXT>Big smile on my face!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_479_0</DOCNO>
            	<TEXT>The same to you!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_481_0</DOCNO>
            	<TEXT>My house has lots of butterfly bushes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_482_0</DOCNO>
            	<TEXT>You have to enjoy life before it passes you bye.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_0</DOCNO>
            	<TEXT>Sorrento Therapeutics, Inc. Patent Applications and Registrations Filed Since August 29th 2013 Patent applications and USPTO patent grants for Sorrento Therapeutics, Inc.. The latest application filed</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_1</DOCNO>
            	<TEXT>205 Patents filed 122 Patents approved 83 Patents pending [https://uspto.report/company/Sorrento-Therapeutics-Inc/patents](https://uspto.report/company/Sorrento-Therapeutics-Inc/patents) How Do Patents Work: Everything You Need to Know You're probably wondering how do patents work and why.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_2</DOCNO>
            	<TEXT>The short definition of a patent is that it is an exclusive right granted for a single invention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_3</DOCNO>
            	<TEXT>A patent: Is an exclusive right to a new way of doing an established process; Offers a new solution to an established problem Is a unique creation that offers a unique, new, or novel way of achieving a means to an end In order to get a patent, the inventor must include technical information about the product and disclose it to the public in the application.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_4</DOCNO>
            	<TEXT>When an inventor comes up with a new creation, usually the first thing they want to do is to get it patented.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_5</DOCNO>
            	<TEXT>Patents are given by a government and are a way of giving the inventor ownership of their creation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_6</DOCNO>
            	<TEXT>For a specific period of time, a patent holder is allowed to control how the invention is used and allows them to realize financial gain from their work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_7</DOCNO>
            	<TEXT>A patent is a legally binding manifestation of a person's intellectual property.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_8</DOCNO>
            	<TEXT>They allow the inventor to own and enforce their idea.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_9</DOCNO>
            	<TEXT>The owner of a patent may give permission or license third parties to use the invention on terms that all parties agree on.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_10</DOCNO>
            	<TEXT>The owner may also sell the right to the invention to someone who then becomes the new owner of the patent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_11</DOCNO>
            	<TEXT>When a patent expires, usually after 20 years, the protection ends, and the invention belongs to the public domain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_12</DOCNO>
            	<TEXT>When a patent is in the public domain, anyone can exploit the invention on a commercial level without worrying about infringement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_13</DOCNO>
            	<TEXT>READ THIS AGAIN ONE MORE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_14</DOCNO>
            	<TEXT>When an inventor comes up with a new creation, usually the first thing they want to do is to get it patented.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_15</DOCNO>
            	<TEXT>Why Should I Consider Patenting an Invention?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_16</DOCNO>
            	<TEXT>Patents provide the inventor with the exclusive right to prevent others from commercially exploiting the invention for 20 years from the date of filing the application.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_17</DOCNO>
            	<TEXT>A patent also provides a return on investment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_18</DOCNO>
            	<TEXT>Inventors usually invest a considerable sum of money and time into developing their product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_19</DOCNO>
            	<TEXT>An exclusive patent right gives rise to the potential for a return of the time and money invested into the development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_20</DOCNO>
            	<TEXT>Having a portfolio of patents can make the company more interesting to a potential buyer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_21</DOCNO>
            	<TEXT>Someone looking to buy the company may find that the patents are worth exploiting and add to the overall value of the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_22</DOCNO>
            	<TEXT>In the event that a partnership is being developed, a portfolio of patents could lead to a cross-licensing arrangement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_23</DOCNO>
            	<TEXT>Patents can also demonstrate the expertise of the people employed by the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_24</DOCNO>
            	<TEXT>Investors and business partners may view a patent portfolio as an asset to show lenders or potential business partners, draw interest from outside investors, and increase the market value of the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_25</DOCNO>
            	<TEXT>PLEASE READ THIS LINE ONE MORE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_26</DOCNO>
            	<TEXT>Having a portfolio of patents can make the company more interesting to a potential buyer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_27</DOCNO>
            	<TEXT>Just remember that folks!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_484_28</DOCNO>
            	<TEXT>Have a great day everyone!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_485_0</DOCNO>
            	<TEXT>I wonder if Sorrento patented the binding process?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_485_1</DOCNO>
            	<TEXT>Please take a look at the 205 patents filed and take a look which one could be for this spike S1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_486_0</DOCNO>
            	<TEXT>A patent holder is allowed to control how the invention is used and allows them to realize financial gain from their work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_487_0</DOCNO>
            	<TEXT>Someone looking to buy the company may find that the patents are worth exploiting and add to the overall value of the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_487_1</DOCNO>
            	<TEXT>In the event that a partnership is being developed, a portfolio of patents could lead to a cross-licensing arrangement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_488_0</DOCNO>
            	<TEXT>Investors and business partners may view a patent portfolio as an asset to show lenders or potential business partners, draw interest from outside investors, and increase the market value of the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_489_0</DOCNO>
            	<TEXT>I could see that happening someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_489_1</DOCNO>
            	<TEXT>But JI would have to get billions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_490_0</DOCNO>
            	<TEXT>In February 2021, Sorrento and Lees Pharma announced that socazolimab had been granted breakthrough designation by the NMPA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_490_1</DOCNO>
            	<TEXT>If approved by NMPA, this will be the first approved fully human antibody discovered and isolated from Sorrentos proprietary G-MAB library.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_490_2</DOCNO>
            	<TEXT>This is a major step forward th</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_490_3</DOCNO>
            	<TEXT>[https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrentos-license-partner-lees-pharmaceutical-announces-nda](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrentos-license-partner-lees-pharmaceutical-announces-nda)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_491_0</DOCNO>
            	<TEXT>My condolences my friend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_491_1</DOCNO>
            	<TEXT>You're a better person then that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_491_2</DOCNO>
            	<TEXT>Your daughter is always looking down on you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_492_0</DOCNO>
            	<TEXT>China has a population of 579.4 millions women ages 15 years and older who are at risk of developing cervical cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_492_1</DOCNO>
            	<TEXT>Current estimates indicate that every year 109741 women are diagnosed with cervical cancer and 59060 die from the dis- ease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_492_2</DOCNO>
            	<TEXT>https://hpvcentre.net/statistics/reports/CHN_FS.pdf</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_492_3</DOCNO>
            	<TEXT>China has a population of 579.4 millions women ages 15 years and older who are at risk of developing cervical cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_492_4</DOCNO>
            	<TEXT>Current estimates indicate that every year 109741 women are diagnosed with cervical cancer and 59060 die from the dis- ease. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_492_5</DOCNO>
            	<TEXT>https://hpvcentre.net/statistics/reports/CHN\_FS.pdf](https://hpvcentre.net/statistics/reports/CHN_FS.pdf)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_493_0</DOCNO>
            	<TEXT>This will open the door for many more NDA's.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_494_0</DOCNO>
            	<TEXT>That's a great question</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_495_0</DOCNO>
            	<TEXT>Tip of the iceberg</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_0</DOCNO>
            	<TEXT>COVI-VAX TRADEMARK OF SORRENTO THERAPEUTICS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_1</DOCNO>
            	<TEXT>This is a brand page for the COVI-VAX trademark by Sorrento Therapeutics, Inc. in San Diego, CA, 92121.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_2</DOCNO>
            	<TEXT>Write a review about a product or service associated with this COVI-VAX trademark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_3</DOCNO>
            	<TEXT>Or, contact the owner Sorrento Therapeutics, Inc. of the COVI-VAX trademark by filing a request to communicate with the Legal Correspondent for licensing, use, and/or questions related to the COVI-VAX trademark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_4</DOCNO>
            	<TEXT>Status Update!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_5</DOCNO>
            	<TEXT>On Tuesday, October 26, 2021, status on the COVI-VAX trademark changed to NEW APPLICATION FILED.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_6</DOCNO>
            	<TEXT>On Friday, October 22, 2021, a U.S. federal trademark registration was filed for COVI-VAX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_7</DOCNO>
            	<TEXT>The USPTO has given the COVI-VAX trademark serial number of 97087853.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_8</DOCNO>
            	<TEXT>The current federal status of this trademark filing is NEW APPLICATION FILED.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_9</DOCNO>
            	<TEXT>The correspondent listed for COVI-VAX is LINDSAY J. HULLEY of RUTAN  amp; TUCKER, LLP, 18575 JAMBOREE ROAD, 9TH FLOOR IRVINE, CA 92612 .</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_10</DOCNO>
            	<TEXT>The COVI-VAX trademark is filed in the category of Pharmaceutical Products .</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_11</DOCNO>
            	<TEXT>The description provided to the USPTO for COVI-VAX is Human vaccine preparations; vaccines for human use for use in the treatment and prevention of COVID-19/Coronavirus; mRNA vaccines. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_496_12</DOCNO>
            	<TEXT>https://trademark.trademarkia.com/covivax-97087853.html](https://trademark.trademarkia.com/covivax-97087853.html)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_497_0</DOCNO>
            	<TEXT>Before Christmas we will have a prayer for all of the lost loved ones.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_497_1</DOCNO>
            	<TEXT>We will remember them and honor them before that day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_497_2</DOCNO>
            	<TEXT>Sorry for your loss.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_498_0</DOCNO>
            	<TEXT>Chinas Evolving Regulatory Environment: Special Report</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_498_1</DOCNO>
            	<TEXT>[https://ppdicomcontenteusprod.blob.core.windows.net/uploads/2020/07/Regulatory-Focus-2020.01.pdf](https://ppdicomcontenteusprod.blob.core.windows.net/uploads/2020/07/Regulatory-Focus-2020.01.pdf)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_500_0</DOCNO>
            	<TEXT>Happy New Year!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_0</DOCNO>
            	<TEXT>TIME TO BAIT THE HOOKS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_1</DOCNO>
            	<TEXT>Wait for the boat to stop drifting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_2</DOCNO>
            	<TEXT>Drop your anchor let some line out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_3</DOCNO>
            	<TEXT>Tie the line up on the cleat on the boat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_4</DOCNO>
            	<TEXT>Bait your hooks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_5</DOCNO>
            	<TEXT>Set your line and use the right size sinker.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_6</DOCNO>
            	<TEXT>Wait for the sinker to hit the bottom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_7</DOCNO>
            	<TEXT>Let a little bit of line out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_8</DOCNO>
            	<TEXT>Set the drag and set the pole.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_9</DOCNO>
            	<TEXT>What's next?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_10</DOCNO>
            	<TEXT>Crack open a beer?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_11</DOCNO>
            	<TEXT>Light a cigar?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_12</DOCNO>
            	<TEXT>Or just lay back and enjoy the sunrise.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_13</DOCNO>
            	<TEXT>All of the above if you own Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_14</DOCNO>
            	<TEXT>Because you don't have to worry about a thing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_15</DOCNO>
            	<TEXT>26 Clinical trials, 205 Patents filed, 122 Patents approved.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_16</DOCNO>
            	<TEXT>COVITRACE (diagnostic) Diagnostic Test FDA Emergency Use Authorization (EUA) Application Expected COVISTIX (diagnostic) Antigen Test FDA Emergency Use Authorization (EUA) Application Submitted COVITRACK Platinum (diagnostic) Next Generation Antibody Test In final manufacturing and clinical testing COVIGUARD (treatment) Neutralizing Antibody (IV) in Inpatients \* COVI-AMG (treatment) Neutralizing Antibody (IV) in Outpatients \* COVIDROPS (treatment) Neutralizing Antibody (Intranasal) in Outpatients \* COVISHIELD (treatment) Neutralizing Abs (IV) in Inpatients \* COVIDTRAP (treatment) ACE2 Receptor Decoy (IV) in Inpatients \* ABIVERTINIB (treatment) Severe or Critical COVID-19 in ICU Patients \* SALICYN 30 (treatment) Anti-viral \* COVI-MSC (treatment) ARDS due to COVID-19 in ICU Pts \* Immunotherapy CD38 CAR-T Multiple Myeloma \* CD38 DAR-T Multiple Myeloma \* CD38 ADC Amyloidosis \* Seprehvir Solid Tumors \* Seprehvec Solid Tumors \* ABIVERTINIB NSCLC \* ADNIC Solid and Liquid Tumors \* Pain RTX (resiniferatoxin) Epidural route Intractable Pain in Advanced Cancer \*Orphan designation RTX (resiniferatoxin) Intra-articular route Moderate to Severe OA \* Lymphatic Delivery Sofusa anti-TNF Autoimmune \* Sofusa anti-PD-1 CTCL Time to relax and enjoy your day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_501_17</DOCNO>
            	<TEXT>Because the BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_503_0</DOCNO>
            	<TEXT>BO could be possible in the near future and we could see a 20X bagger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_0</DOCNO>
            	<TEXT>STIX / ABIVERTINIB / SP102 / DROPS All have near term news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_1</DOCNO>
            	<TEXT>All have billion dollar markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_2</DOCNO>
            	<TEXT>The other 72+ Sorrento programs can be financed by the profits from these 4 programs alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_3</DOCNO>
            	<TEXT>I was glad to see the new updated corporate presentation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_4</DOCNO>
            	<TEXT>DON'S LIST FROM YAHOO</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_5</DOCNO>
            	<TEXT>STIX / ABIVERTINIB / SP102 / DROPS All have near term news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_6</DOCNO>
            	<TEXT>All have billion dollar markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_7</DOCNO>
            	<TEXT>The other 72+ Sorrento programs can be financed by the profits from these 4 programs alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_8</DOCNO>
            	<TEXT>I was glad to see the new updated corporate presentation. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_9</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e](https://investors.sorrentotherapeutics.com/static-files/da3ae428-94af-47fc-b20f-5cab2e10b54e).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_10</DOCNO>
            	<TEXT>\*\*\*PHASE 3, close to EUA or close to market (13 programs) 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_11</DOCNO>
            	<TEXT>Abivertinib NSCLC NDA filed China 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_12</DOCNO>
            	<TEXT>Abivertinib NSCLC ph.3 completed US 3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_13</DOCNO>
            	<TEXT>PD-L1 SCLC partnered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_14</DOCNO>
            	<TEXT>China NDA filed for cervical cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_15</DOCNO>
            	<TEXT>Erbitux biosimilar 5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_16</DOCNO>
            	<TEXT>Xolair biosimilar 6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_17</DOCNO>
            	<TEXT>Remicade biosimilar(approved in China.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_18</DOCNO>
            	<TEXT>SRNE holds ROW rights!)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_19</DOCNO>
            	<TEXT>SP-102 sciatica + back pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_20</DOCNO>
            	<TEXT>Marketing in 2H 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_21</DOCNO>
            	<TEXT>RTX Osteo Arthritis 9.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_22</DOCNO>
            	<TEXT>RTX cancer pain 10.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_23</DOCNO>
            	<TEXT>Covi-Stix EUA application(approval in Mexico and Europe...millions shipped to Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_24</DOCNO>
            	<TEXT>Brazil,WHO and Canada coming soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_25</DOCNO>
            	<TEXT>DOD CRADA 11.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_26</DOCNO>
            	<TEXT>Covi-Trace EUA application 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_27</DOCNO>
            	<TEXT>Sofusa Enbrel phase 1b 13.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_28</DOCNO>
            	<TEXT>Cynviloq (part of PSS lawsuit) \*\*\*PHASE 2 (13 programs) 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_29</DOCNO>
            	<TEXT>Seprehvir Oncolytic virus 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_30</DOCNO>
            	<TEXT>Covi-MSC EUA potential 3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_31</DOCNO>
            	<TEXT>Covi-AMG EUA potential DOD CRADA 4.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_32</DOCNO>
            	<TEXT>COVIDROPS EUA potential DOD CRADA 5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_33</DOCNO>
            	<TEXT>Covi-Track EUA pre-validation DOD CRADA 6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_34</DOCNO>
            	<TEXT>PD-L1 partnered 7.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_35</DOCNO>
            	<TEXT>Herceptin delivery partnered 8.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_36</DOCNO>
            	<TEXT>Abivertinib Lymphoma 9.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_37</DOCNO>
            	<TEXT>Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_38</DOCNO>
            	<TEXT>Abivertinib prostate cancer ph.2 IND 11.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_39</DOCNO>
            	<TEXT>Abivertinib Lupus ph.2 IND 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_40</DOCNO>
            	<TEXT>Abivertinib hairy cell leukemia 13.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_41</DOCNO>
            	<TEXT>CD47 partnered \*\*\*PHASE 1, IND filed or pre-IND (46+ programs) 1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_42</DOCNO>
            	<TEXT>Seprehvec Oncolytic Virus 2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_43</DOCNO>
            	<TEXT>CD 38 CAR-T ph.1 3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_44</DOCNO>
            	<TEXT>CEA CAR-T ph.1 4.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_45</DOCNO>
            	<TEXT>CD38 DAR-T ph.1 5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_46</DOCNO>
            	<TEXT>BCMA DAR-T pre-IND 6.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_47</DOCNO>
            	<TEXT>PD-L1(C/DAR-T) pre-IND 7.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_48</DOCNO>
            	<TEXT>CyCART-19 partnered 8.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_49</DOCNO>
            	<TEXT>Covi-GeneMab pre-IND $34 million DARPA funding 9.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_50</DOCNO>
            	<TEXT>PD1-GeneMab pre-IND 10.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_51</DOCNO>
            	<TEXT>ERT (Enzyme Replacement Therapy) several pre IND programs 11.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_52</DOCNO>
            	<TEXT>IL2Teff pre-IND 12.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_53</DOCNO>
            	<TEXT>IL2Treg pre-IND 13.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_54</DOCNO>
            	<TEXT>Sofusa anti-PD1 and anti-CTLA4 14.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_55</DOCNO>
            	<TEXT>TNF-a (Enbrel) ph.1 15.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_56</DOCNO>
            	<TEXT>CTLA-4 (Yervoy) 16.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_57</DOCNO>
            	<TEXT>CD47 ph.1 basket trial partnered 17.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_58</DOCNO>
            	<TEXT>TROP2 IND granted in China...partnered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_59</DOCNO>
            	<TEXT>BCMA ADC pre-IND 19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_60</DOCNO>
            	<TEXT>ROR1 ADC pre-IND 20.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_61</DOCNO>
            	<TEXT>CD25 ADNAB pre-IND 21.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_62</DOCNO>
            	<TEXT>CD20 ADNAB (Rituxan) IIT-ph.1 22.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_63</DOCNO>
            	<TEXT>VEGF(Avastin) ADNAB IIT-ph.1 23.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_64</DOCNO>
            	<TEXT>PD-L1 ADNAB pre-IND 24.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_65</DOCNO>
            	<TEXT>VEGFR2 ADNAB pre-IND 25.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_66</DOCNO>
            	<TEXT>CBD immune diseases pre-IND 26.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_67</DOCNO>
            	<TEXT>CBD insomnia pre-IND 27.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_68</DOCNO>
            	<TEXT>CBD Parkinsons pre-IND 28.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_69</DOCNO>
            	<TEXT>CBD CNS diseases pre-IND 29.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_70</DOCNO>
            	<TEXT>PD-L1 CAR-NK partnered 30.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_71</DOCNO>
            	<TEXT>CD38 CAR-NK to be partnered 31.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_72</DOCNO>
            	<TEXT>CD38 ADC AL Amyloidosis 32.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_73</DOCNO>
            	<TEXT>AC0058 ph.1b lupus 33.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_74</DOCNO>
            	<TEXT>AC0058 pre-IND MS 34.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_75</DOCNO>
            	<TEXT>AC0939 pre-IND CNS indications 35.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_76</DOCNO>
            	<TEXT>A166 HER2 ADC phase 1 36.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_77</DOCNO>
            	<TEXT>Karolinska off-the-shelf DAR-NK pre-IND 37.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_78</DOCNO>
            	<TEXT>Covid mRNA vaccine(Sofusa delivery) 38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_79</DOCNO>
            	<TEXT>Salicyn-30 oral antiviral 40.MP18 oral antiviral MPro inhibitor 41.Combination oral antiviral drug cocktail 42.RESPISTIX Combination Covid/seasonal flu tests 43.Combination Covid/seasonal flu vaccine 44 advanced Animal Health subsidiary 45.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_80</DOCNO>
            	<TEXT>1,000,000+ small molecule library 46.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_81</DOCNO>
            	<TEXT>Twenty quadrillion antibody library FUNDING?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_82</DOCNO>
            	<TEXT>Sorrento has invested wisely and has millions of shares of ImmunityBio, Celularity and ImmuneOncia.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_83</DOCNO>
            	<TEXT>These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_84</DOCNO>
            	<TEXT>It has many attractive programs to partner for upfront, milestone and royalty payments!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_85</DOCNO>
            	<TEXT>The first of many EUA's will produce revenues within weeks in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_86</DOCNO>
            	<TEXT>Outstanding ABIVERTINIB(COVID) results in Brazil and US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_87</DOCNO>
            	<TEXT>And SP-102 sales will begin in 2022 with multi-billion potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_88</DOCNO>
            	<TEXT>Huge portfolio AND huge assets!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_505_89</DOCNO>
            	<TEXT>Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_506_0</DOCNO>
            	<TEXT>BO normally happen before the end of the year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_506_1</DOCNO>
            	<TEXT>Especially when you have plenty of cash and it's a perfect time to acquire.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_506_2</DOCNO>
            	<TEXT>Any big pharma would especially when they see Sorrento could threaten a certain revenue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_506_3</DOCNO>
            	<TEXT>Like SP-102</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_0</DOCNO>
            	<TEXT>How Do Opioids Work?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_1</DOCNO>
            	<TEXT>Opioid drugs bind to opioid receptors in the brain, spinal cord, and other areas of the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_2</DOCNO>
            	<TEXT>They tell your brain youre not in pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_3</DOCNO>
            	<TEXT> What Are some of the Side Effects of Opioids?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_4</DOCNO>
            	<TEXT> drowsiness confusion nausea constipation euphoria slowed breathing muscle and bone pain sleep problems diarrhea and vomiting cold flashes with goose bumps uncontrollable leg movements severe cravings  Opioid drugs include:  Codeine Fentanyl (Actiq, Abstral, Duragesic, Fentora) Hydrocodone (Hysingla, Zohydro ER) Hydrocodone/acetaminophen (Lorcet, Lortab, Norco, Vicodin) Hydromorphone (Dilaudid, Exalgo) Meperidine (Demerol) Methadone (Dolophine, Methadose) Morphine (Kadian, MS Contin, Morphabond) Oliceridine (Olynvik) Oxycodone (Oxaydo, OxyContin) Oxycodone and acetaminophen (Percocet, Roxicet) Oxycodone and naloxone  Who makes all of these drugs?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_5</DOCNO>
            	<TEXT>Big Pharma!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_6</DOCNO>
            	<TEXT> Can a person overdose on prescription opioids?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_7</DOCNO>
            	<TEXT>Yes they can.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_8</DOCNO>
            	<TEXT> How can an opioid overdose be treated?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_9</DOCNO>
            	<TEXT>call 911 so he or she can receive immediate medical attention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_10</DOCNO>
            	<TEXT> Can use of prescription opioids lead to addiction?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_11</DOCNO>
            	<TEXT>Yes, repeated misuse of prescription opioids can lead to a substance use disorder (SUD), a medical illness which ranges from mild to severe and from temporary to chronic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_12</DOCNO>
            	<TEXT>Addiction is the most severe form of an SUD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_13</DOCNO>
            	<TEXT>An SUD develops when continued misuse of the drug changes the brain and causes health problems and failure to meet responsibilities at work, school, or home.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_14</DOCNO>
            	<TEXT> Opioid crisis cost US economy $631B over 4 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_15</DOCNO>
            	<TEXT> What other options do people have at the moment?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_16</DOCNO>
            	<TEXT>None  Is there hope?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_17</DOCNO>
            	<TEXT> Scilex expects SP-102 to be the first FDA-approved non-opioid epidural injection for sciatica with the potential to replace the current 10 to 12 million off-label epidural steroid injections administered each year in the U.S.  Scilex Holding Company, a commercial-stage, non-opioid biopharmaceutical pain management company, announced complete enrollment of its SP-102 (SEMDEXA) Phase 3 Pivotal Trial C.L.E.A.R. Program for its novel, non-opioid, corticosteroid formulation, injectable dexamethasone sodium phosphate viscous gel product for the treatment of lumbosacral radicular pain (sciatica).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_18</DOCNO>
            	<TEXT>SP-102 has received Fast Track status from the FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_19</DOCNO>
            	<TEXT>Top-line data from the study is expected in Q4 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_20</DOCNO>
            	<TEXT> More than 50% of U.S. opioid prescriptions are for the treatment of chronic low back pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_21</DOCNO>
            	<TEXT> There's nothing funny about this post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_22</DOCNO>
            	<TEXT>People are dyeing and become addicted to Opioids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_23</DOCNO>
            	<TEXT> Sorrento can make a difference and save someone's life some day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_24</DOCNO>
            	<TEXT> So ask yourselves if a small Pharmaceutical Company were to get an FDA approval for the first non Opioid treatment for back pain?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_25</DOCNO>
            	<TEXT>How would BIG PHARMA react?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_26</DOCNO>
            	<TEXT>Please click the link below and read the press release again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_27</DOCNO>
            	<TEXT>Now what you own!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_28</DOCNO>
            	<TEXT>Do your DD and research which Pharma's will lose BILLIONS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_29</DOCNO>
            	<TEXT> That could be the Company that would want to buy Sorrento out. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_507_30</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_508_0</DOCNO>
            	<TEXT>The CDC estimates the total economic burden of prescription opioid misuse in the United States is $78.5 billion a year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_509_0</DOCNO>
            	<TEXT>Just wait for SP-102</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_0</DOCNO>
            	<TEXT>TODAY'S DAILY PRAYER TODAY, NOVEMBER 03</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_1</DOCNO>
            	<TEXT>This is the message we have heard from him and declare to you: God is light; in him there is no darkness at all.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_2</DOCNO>
            	<TEXT>1 John 1:5, NIV **Lord our God,** rule over us in strength, and grant us your light.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_3</DOCNO>
            	<TEXT>Let your Spirit be with us to confirm what has already taken place in our hearts, so that we have joy and trust even under all the strain and stress of this life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_4</DOCNO>
            	<TEXT>Shine into the darkness of the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_5</DOCNO>
            	<TEXT>Shine for all people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_6</DOCNO>
            	<TEXT>May we be shown more and more clearly what we have been created for.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_7</DOCNO>
            	<TEXT>Strengthen our faith for the future, our faith in everything good, for however hidden the good may be, it must at last come to the light.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_510_8</DOCNO>
            	<TEXT>May we and all the world bring praise and honor to you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_511_0</DOCNO>
            	<TEXT>A little morning prayer helped this morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_512_0</DOCNO>
            	<TEXT>Sometimes a little praying can help..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_513_0</DOCNO>
            	<TEXT>Field of dreams if you build it they will come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_514_0</DOCNO>
            	<TEXT>Short Squeeze Score 11.49 DAYS TO COVER!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_514_1</DOCNO>
            	<TEXT>The Short Squeeze Score is the result of a sophisticated, multi-factor quantitative model that identifies companies that have the highest risk of experiencing a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_514_2</DOCNO>
            	<TEXT>The scoring model uses a combination of short interest, float, short borrow fee rates, and other metrics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_514_3</DOCNO>
            	<TEXT>The number ranges from 0 to 100, with higher numbers indicating a higher risk of a short squeeze relative to its peers, and 50 being the average.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_514_4</DOCNO>
            	<TEXT>Update Frequency: Intraday See our Short Squeeze Leaderboards for US, Canada, Australia and Hong Kong 78.36 274 out of 5442 SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest 46,030,610 shares - source: NASDAQ Short Interest Ratio 11.49 Days to Cover Short Interest % Float 16.90% - source: NASDAQ (short interest), Capital IQ (float) Dark Pool Short Volume 617,830 shares - source: FINRA Dark Pool Short Volume Ratio 37.67% - source: FINRA [https://fintel.io/d](https://fintel.io/d) Don't ruining your families.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_515_0</DOCNO>
            	<TEXT>Hello darling!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_515_1</DOCNO>
            	<TEXT>Your my beautiful Rose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_0</DOCNO>
            	<TEXT>LET'S COMPARE APPLES TO ORANGES Analytical performances of the COVISTIX and Panbio antigen rapid tests for SARS-CoV-2 detection in an unselected population (all commers).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_1</DOCNO>
            	<TEXT>Abstract Importance A steady increase in acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cases worldwide is causing some regions of the world to withstand a third or even fourth wave of contagion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_2</DOCNO>
            	<TEXT>Swift detection of SARS-CoV-2 infection is paramount for the containment of cases, prevention of sustained contagion; and most importantly, for the reduction of mortality.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_3</DOCNO>
            	<TEXT>Objective To evaluate the performance and validity of the COVISTIX rapid antigen test, for the detection of SARS-CoV-2 in an unselected population and compare it to Panbio rapid antigen test and RT-PCR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_4</DOCNO>
            	<TEXT>Design This is comparative effectiveness study; samples were collected at two point-of-care facilities in Mexico City between May and August 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_5</DOCNO>
            	<TEXT>Participants Recruited individuals were probable COVID-19 cases, either symptomatic or asymptomatic persons that were at risk of infection due to close contact to SARS-CoV-2 positive cases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_6</DOCNO>
            	<TEXT>Diagnostic intervention RT-PCR was used as gold standard for detection of SARS-CoV-2 in nasal and nasopharyngeal swabs, study subjects were tested in parallel either with the COVISTIX or with Panbio rapid antigen test.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_7</DOCNO>
            	<TEXT>Main outcome Diagnostic performance of the COVISTIX assay is adequate in all commers since its accuracy parameters were not affected in samples collected after 7 days of symptom onset, and it detected almost 65% of samples with a Ct-value between 30 and 34.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_8</DOCNO>
            	<TEXT>Results For the population tested with COVISTIX (n=783), specificity and sensitivity of the was 96.0% (CI95% 94.0-98.0) and 81% (CI95% 76.0-85.0), as for the Panbio (n=2202) population, was 99.0% (CI95%: 0.99-1.00) and 62% (CI%: 58.0-64.0%), respectively.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_9</DOCNO>
            	<TEXT>Conclusions and relevance The COVISTIX rapid antigen test shows a high performance in all comers, thus, this test is also adequate for testing patients who have passed the peak of viral shedding or for asymptomatic patients. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_10</DOCNO>
            	<TEXT>https://www.medrxiv.org/content/10.1101/2021.09.10.21263410v1](https://www.medrxiv.org/content/10.1101/2021.09.10.21263410v1) It's estimated that 1 Billion Covid-19 tests are needed throughout the World per year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_11</DOCNO>
            	<TEXT>Currently 1.5M Covid-19 tests are preformed in the US alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_12</DOCNO>
            	<TEXT>https://covidtracking.com/data/national](https://covidtracking.com/data/national) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-independent-real-world-study-reports-superior](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-independent-real-world-study-reports-superior) This finding is significant as higher COVISTIX sensitivity means fewer false negatives, which is essential to managing the spread of COVID virus infection and preventing the COVID disease, in particular those cases linked to highly transmissible variants of concern such as the Delta variant.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_13</DOCNO>
            	<TEXT>Additionally, this superior sensitivity result is quite impressive in a real-world population of all-comers (vs in only symptomatic patients) utilizing an initial shallow nasal sampling protocol followed by an optional nasopharyngeal sampling, if desired.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_14</DOCNO>
            	<TEXT>Abbott sold over 300 Million Panbio tests so far in Europe alone in 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_15</DOCNO>
            	<TEXT>DR JI said, COVISTIX will have double digit million sales per month.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_16</DOCNO>
            	<TEXT>I believe the 4Q Revenue will fill all your Christmas stockings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_17</DOCNO>
            	<TEXT>I would like to thank every single person on this board for being patient.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_18</DOCNO>
            	<TEXT>Because..... The Best is Yet to Come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_516_19</DOCNO>
            	<TEXT>Thank you God Bless to All.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_517_0</DOCNO>
            	<TEXT>Hold down the Fort!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_517_1</DOCNO>
            	<TEXT>I will be relaxing and enjoying life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_517_2</DOCNO>
            	<TEXT>Steel heads are running and there amazing to watch as they jump right out in front of you...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_519_0</DOCNO>
            	<TEXT>After they release the 3Q earnings</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_520_0</DOCNO>
            	<TEXT>I believe we may surprise everyone with better than expected earnings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_0</DOCNO>
            	<TEXT>RELAXING IN THE SUN TAKING A BREAK</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_1</DOCNO>
            	<TEXT>I Just took at a my Sorrento account and I realized it's the same from last week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_2</DOCNO>
            	<TEXT>Now knowing we received the approval for COVISTIX in Brazil I purchased 4000 more shares @ $6,52.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_3</DOCNO>
            	<TEXT>over 1 BILLION COVID-19 tests will be needed next year thought-out the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_4</DOCNO>
            	<TEXT>COVID-19 is not going away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_5</DOCNO>
            	<TEXT>Here's some food for thought.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_6</DOCNO>
            	<TEXT>What happens when COVID-19 starts another strain?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_7</DOCNO>
            	<TEXT>How effective will Pfizer's pill be?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_8</DOCNO>
            	<TEXT>89% effective on who?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_9</DOCNO>
            	<TEXT>Early stage?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_10</DOCNO>
            	<TEXT>What about late stage?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_11</DOCNO>
            	<TEXT>What about the poor Countries?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_12</DOCNO>
            	<TEXT>WHO estimates that COVID-19 could be around till the late 2028s.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_13</DOCNO>
            	<TEXT>Time for me to go back to Salman fishing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_14</DOCNO>
            	<TEXT>Have a great weekend everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_521_15</DOCNO>
            	<TEXT>I'm up 2 nice King Salmons from this morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_522_0</DOCNO>
            	<TEXT>I did private message me</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_523_0</DOCNO>
            	<TEXT>It's the weekend and everyone needs to relax and have a great time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_524_0</DOCNO>
            	<TEXT>The best quarters are yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_524_1</DOCNO>
            	<TEXT>Patience my friend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_525_0</DOCNO>
            	<TEXT>Who's gonna win Auburn vs Texas A  amp; M?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_526_0</DOCNO>
            	<TEXT>R  amp; R  amp; R</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_526_1</DOCNO>
            	<TEXT>READ - REVIEW - RELAX- [https://www.cipherbio.com/data-viz/organization/Sorrento%2BTherapeutics%2BInc./products](https://www.cipherbio.com/data-viz/organization/Sorrento%2BTherapeutics%2BInc./products) Sofusa anti-TNF for Rheumatoid arthritis and Autoimmune Diseases Type: THERAPEUTIC Category: DRUG science COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody STI 2020) for COVID-19 Type: THERAPEUTIC Category: DRUG science COVI-MSC for COVID-19 related ARDS Type: THERAPEUTIC Category: DRUG science COVI-SHIELD (Neutralizing Antibody Cocktail) for COVID-19 Type: THERAPEUTIC Category: DRUG science COVI-DROPS (Intranasal COVI-AMG Neutralizing Antibody STI 2099) for COVID-19 Type: THERAPEUTIC Category: DRUG science Seprehvir for Solid Tumors Type: THERAPEUTIC Category: DRUG science COVIDTRAP (ACE2 Receptor Decoy STI 4398) for COVID-19 Type: THERAPEUTIC Category: DRUG science COVI-GUARD (Neutralizing Antibody STI 1499) for COVID-19 Type: THERAPEUTIC Category: DRUG science RTX (resiniferatoxin) Intra-articular route for Moderate to Severe Osteoarthritis Type: THERAPEUTIC Category: DRUG science ABIVERTINIB (Cytokine Storm STI 5656) for COVID-19 Type: THERAPEUTIC Category: DRUG science RTX (resiniferatoxin) Intra-articular route for Osteoarthritis Type: THERAPEUTIC Category: DRUG science Salicyn-30 (Anti-viral STI 2030) for COVID-19 Type: THERAPEUTIC Category: DRUG science CD38 DAR-T for Multiple Myeloma Type: THERAPEUTIC Category: DRUG science CD38 CAR-T for Multiple Myeloma Type: THERAPEUTIC Category: DRUG science Seprehvec for Solid Tumors Type: THERAPEUTIC Category: DRUG science ABIVERTINIB for Non-small cell lung cancer Type: THERAPEUTIC Category: DRUG science CD38 ADC for Amyloidosis Type: THERAPEUTIC Category: DRUG science Sofusa anti-PD-1 for Cutaneous T-cell lymphoma (CTCL) Type: THERAPEUTIC Category: DRUG science Mesenchymal Stem Cell (Acute Respiratory Distress Syndrome STI 8282) Type: THERAPEUTIC Category: DRUG science Diagnostic Programs for COVID-19 : COVITRACE, COVISTIX, and COVITRACK Type: DIAGNOSTIC Category: science RTX (resiniferatoxin) Epidural route for Terminal Cancer Pain Type: THERAPEUTIC Category: DRUG science ADNIC for Solid and Liquid Tumors Type: THERAPEUTIC Category: DRUG</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_527_0</DOCNO>
            	<TEXT>THE BEST IS YET TO COME</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_528_0</DOCNO>
            	<TEXT>I do time Rome wasn't built overnight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_528_1</DOCNO>
            	<TEXT>They wouldn't renew all their leases and expand an additional 213,000 more square feet if the revenue was coming.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_528_2</DOCNO>
            	<TEXT>In do time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_529_0</DOCNO>
            	<TEXT>I'm not worried at all.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_530_0</DOCNO>
            	<TEXT>Wonk, Thank you for your DD and please repost this on the BAND!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_531_0</DOCNO>
            	<TEXT>I waited years for REGN to get their first FDA approval</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_532_0</DOCNO>
            	<TEXT>I waited years before REGN received their first FDA approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_533_0</DOCNO>
            	<TEXT>It doesn't matter how many times we vote.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_533_1</DOCNO>
            	<TEXT>The election is fixed like all the others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_534_0</DOCNO>
            	<TEXT>I believe DR JI has something up his sleeve.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_534_1</DOCNO>
            	<TEXT>He knows a lot more than you and me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_535_0</DOCNO>
            	<TEXT>Why do you think we went to Mexico, Brazil, Europe, and now Canada.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_535_1</DOCNO>
            	<TEXT>Three out of four is better then none.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_536_0</DOCNO>
            	<TEXT>It all depends on who's paying the most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_536_1</DOCNO>
            	<TEXT>Why do you think we received the approval in Mexico, Brazil, and soon Canada?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_536_2</DOCNO>
            	<TEXT>Big Pharma has deep pockets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_0</DOCNO>
            	<TEXT>Contracts Administrator New Position added 4 days ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_1</DOCNO>
            	<TEXT>The Contracts Administrator is a key member of the Sorrento Legal Department and will serve two primary functions contracts administration and legal support.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_2</DOCNO>
            	<TEXT>This role will be responsible for managing contracts workflow across a wide variety of agreement types, coordination with business stakeholders, maintaining centralized contractual records and databases, monitoring post-execution contractual obligations, and supporting and handling routine form contract agreements and related documentation in accordance with established contract policies and procedures.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_3</DOCNO>
            	<TEXT>This role requires the development of collaborative relationships with business unit team members as well as within the Legal Department.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_4</DOCNO>
            	<TEXT>Looks like there addING to their legal dept.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_5</DOCNO>
            	<TEXT>Everyone is looking for the contracts to start to flow in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_6</DOCNO>
            	<TEXT>I believe they can't handle the overflow so there seeking to hire help. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_7</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=449](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=449) Remember they currently have the approval in Mexico, Brazil, and Europe to start COVISTIX sales.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_8</DOCNO>
            	<TEXT>Soon Canada will follow and the USA needs to get their heads out of their @#$% and do the same.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_9</DOCNO>
            	<TEXT>Frankly we don't even need them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_537_10</DOCNO>
            	<TEXT>We have 120 Countries we can sell to now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_538_0</DOCNO>
            	<TEXT>[https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=449](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=449) New position seeking to hire Contracts Administrator 4 days ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_538_1</DOCNO>
            	<TEXT>You wouldn't hire someone if you didn't need them?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_538_2</DOCNO>
            	<TEXT>They need help with their legal dept.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_538_3</DOCNO>
            	<TEXT>so their filling a new position.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_539_0</DOCNO>
            	<TEXT>That's correct it's a new position added 4 days ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_539_1</DOCNO>
            	<TEXT>Overflow of contracts between Mexico  amp; Brazil!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_539_2</DOCNO>
            	<TEXT>120 Countries!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_539_3</DOCNO>
            	<TEXT>Saint Robert says before you panic know what you own and do your own DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_540_0</DOCNO>
            	<TEXT>You wouldn't pay someone $150k per year with Bonus and 401K benefits for nothing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_540_1</DOCNO>
            	<TEXT>They need help with contracts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_0</DOCNO>
            	<TEXT>Jesus and the Miraculous Catch of Fish 21 Afterward Jesus appeared again to his disciples, by the Sea of Galilee.\[a\] It happened this way: 2 Simon Peter, Thomas (also known as Didymus\[b\]), Nathanael from Cana in Galilee, the sons of Zebedee, and two other disciples were together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_1</DOCNO>
            	<TEXT>3 Im going out to fish, Simon Peter told them, and they said, Well go with you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_2</DOCNO>
            	<TEXT>So they went out and got into the boat, but that night they caught nothing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_3</DOCNO>
            	<TEXT>4 Early in the morning, Jesus stood on the shore, but the disciples did not realize that it was Jesus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_4</DOCNO>
            	<TEXT>5 He called out to them, Friends, havent you any fish?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_5</DOCNO>
            	<TEXT>No, they answered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_6</DOCNO>
            	<TEXT>6 He said, Throw your net on the right side of the boat and you will find some.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_541_7</DOCNO>
            	<TEXT>When they did, they were unable to haul the net in because of the large number of fish.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_542_0</DOCNO>
            	<TEXT>Sometimes when you think everything is lost don't give up!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_542_1</DOCNO>
            	<TEXT>Keep the faith and you will be rewarded.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_543_0</DOCNO>
            	<TEXT>They have a team that is helping them with the contracts I just find it ironic that they're looking to hire someone else in order to make their team even bigger and better than it already is</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_544_0</DOCNO>
            	<TEXT>It's written in the bible.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_544_1</DOCNO>
            	<TEXT>Please do not make fun of my faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_544_2</DOCNO>
            	<TEXT>1st and last warning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_0</DOCNO>
            	<TEXT>What is a Oligonucleotide?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_1</DOCNO>
            	<TEXT>Oligonucleotides are short DNA or RNA molecules, oligomers, that have a wide range of applications in genetic testing, research, and forensics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_2</DOCNO>
            	<TEXT>What is the purpose?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_3</DOCNO>
            	<TEXT>Oligonucleotides, or oligos, are short single strands of synthetic DNA or RNA that serve as the starting point for many molecular biology and synthetic biology applications!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_4</DOCNO>
            	<TEXT>From genetic testing to forensic research and next-generation sequencing, an oligo may very well be the starting point.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_5</DOCNO>
            	<TEXT>What is the size?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_6</DOCNO>
            	<TEXT>Oligonucleotides are small molecules 850 nucleotides in length that bind via Watson-Crick base pairing to enhance or repress the expression of target RNA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_7</DOCNO>
            	<TEXT>Who was Rosalind Elsie Franklin?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_8</DOCNO>
            	<TEXT>Rosalind Franklin, in full Rosalind Elsie Franklin, (born July 25, 1920, London, Englanddied April 16, 1958, London), British scientist best known for her contributions to the discovery of the molecular structure of deoxyribonucleic acid (DNA), a constituent of chromosomes that serves to encode genetic information.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_9</DOCNO>
            	<TEXT>Franklin also contributed new insight on the structure of viruses, helping to lay the foundation for the field of structural virology.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_10</DOCNO>
            	<TEXT>Franklin attended St. Pauls Girls School before studying physical chemistry at Newnham College, University of Cambridge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_11</DOCNO>
            	<TEXT>After graduating in 1941, she received a fellowship to conduct research in physical chemistry at Cambridge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_12</DOCNO>
            	<TEXT>But the advance of World War II changed her course of action: not only did she serve as a London air raid warden, but in 1942 she gave up her fellowship in order to work for the British Coal Utilisation Research Association, where she investigated the physical chemistry of carbon and coal for the war effort.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_13</DOCNO>
            	<TEXT>Nevertheless, she was able to use this research for her doctoral thesis, and in 1945 she received a doctorate from Cambridge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_14</DOCNO>
            	<TEXT>From 1947 to 1950 she worked with Jacques Mring at the State Chemical Laboratory in Paris, studying X-ray diffraction technology.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_15</DOCNO>
            	<TEXT>That work led to her research on the structural changes caused by the formation of graphite in heated carbonswork that proved valuable for the coking industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_16</DOCNO>
            	<TEXT>In 1951 Franklin joined the Biophysical Laboratory at Kings College, London, as a research fellow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_17</DOCNO>
            	<TEXT>There she applied X-ray diffraction methods to the study of DNA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_18</DOCNO>
            	<TEXT>When she began her research at Kings College, very little was known about the chemical makeup or structure of DNA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_19</DOCNO>
            	<TEXT>However, she soon discovered the density of DNA and, more importantly, established that the molecule existed in a helical conformation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_20</DOCNO>
            	<TEXT>Her work to make clearer X-ray patterns of DNA molecules laid the foundation for James Watson and Francis Crick to suggest in 1953 that the structure of DNA is a double-helix polymer, a spiral consisting of two DNA strands wound around each other.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_21</DOCNO>
            	<TEXT>What does Elsie Biotechnologies do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_22</DOCNO>
            	<TEXT>Elsie is an early stage biotechnology company, inspired by Rosalind Elsie Franklin, that works to discover the next generation of oligonucleotide therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_23</DOCNO>
            	<TEXT>What Sorrento Therapeutics do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_24</DOCNO>
            	<TEXT>They took a $10M position in an early stage Biopharmaceutical Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_25</DOCNO>
            	<TEXT>Who is one of the Board of Directors?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_26</DOCNO>
            	<TEXT>DR Henry JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_27</DOCNO>
            	<TEXT>Investing in the future of the next-generation sequencing, of oligonucleotide may very well be the starting point of new genetic testing, research and forensics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_28</DOCNO>
            	<TEXT>This investment is brilliant and soon we will find out what percentage of the company Sorrento owns.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_29</DOCNO>
            	<TEXT>Like I've been saying the BEST IS YET TO COME this year and next year and the next 5 to 10 years and so on.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_30</DOCNO>
            	<TEXT>This a long term investment that will put your kids children through college someday. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_545_31</DOCNO>
            	<TEXT>https://www.google.com/search?q=what+is+oligonucleotide amp;oq=what+is+oligonucleotide amp;aqs=chrome..69i57j0i512l8j0i390.19108j0j15 amp;sourceid=chrome amp;ie=UTF-8](https://www.google.com/search?q=what+is+oligonucleotide amp;oq=what+is+oligonucleotide amp;aqs=chrome..69i57j0i512l8j0i390.19108j0j15 amp;sourceid=chrome amp;ie=UTF-8) [https://www.britannica.com/biography/Rosalind-Franklin](https://www.britannica.com/biography/Rosalind-Franklin) [https://www.elsiebio.com/](https://www.elsiebio.com/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_546_0</DOCNO>
            	<TEXT>$20M Investment could turn into $20B</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_547_0</DOCNO>
            	<TEXT>The next generation of SHORT DNA testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_547_1</DOCNO>
            	<TEXT>What a brilliant move on DR Henry JI's part to get on board with the smartest scientists in the DNA and RNA field.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_547_2</DOCNO>
            	<TEXT>This was in the 10Q and it's the hidden GEM!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_548_0</DOCNO>
            	<TEXT>Sorrento took a $10M position with Elsie's Biopharmaceuticals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_548_1</DOCNO>
            	<TEXT>Please view and research what they do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_548_2</DOCNO>
            	<TEXT>At this early stage this could turn $10M into $20Billion someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_549_0</DOCNO>
            	<TEXT>Oh stand by me oh stand by me!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_550_0</DOCNO>
            	<TEXT>Yes I made the correction they did invest $20M in two Companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_550_1</DOCNO>
            	<TEXT>Thanks for the heads up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_551_0</DOCNO>
            	<TEXT>Please read the private message that I sent you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_552_0</DOCNO>
            	<TEXT>This is like playing Monopoly and you land on CHANCE and you pick a card.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_552_1</DOCNO>
            	<TEXT>And the card says go directly to go and collect $25,000,000.00.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_553_0</DOCNO>
            	<TEXT>I saw it and nice job.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_553_1</DOCNO>
            	<TEXT>Sometimes you have to dig deep and find the hidden gems.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_554_0</DOCNO>
            	<TEXT>What's even better is there seeking a Contract Administrator to help will all the contracts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_555_0</DOCNO>
            	<TEXT>Well that didn't take long to fill that position.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_0</DOCNO>
            	<TEXT>Medical Device manufacturing, and for interstate commerce.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_1</DOCNO>
            	<TEXT>Bioserv is currently registered with the United States Food and Drug Administration (U.S. FDA) for both Pharmaceutical and Medical Device manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_2</DOCNO>
            	<TEXT>The FDA Drug Center has inspected the facility for routine inspections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_3</DOCNO>
            	<TEXT>The FDA Device Centers have performed inspections of the facility for routine inspections and for pre and post market approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_4</DOCNO>
            	<TEXT>Bioserv is currently licensed by the State of California for Pharmaceutical and Medical Device manufacturing, and for interstate commerce.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_5</DOCNO>
            	<TEXT>Bioserv is currently licensed by the State of California for Pharmaceutical and Medical Device manufacturing, and for interstate commerce. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_6</DOCNO>
            	<TEXT>https://www.bioservamerica.com/quality-compliance/](https://www.bioservamerica.com/quality-compliance/) Medical Device manufacturing, and for interstate commerce.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_7</DOCNO>
            	<TEXT>Medical Device manufacturing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_556_8</DOCNO>
            	<TEXT>What medical Devices do they make?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_557_0</DOCNO>
            	<TEXT>UPDATED PARTNERS PAGE ON SCILEX HOLDINGS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_557_1</DOCNO>
            	<TEXT>At SCILEX, were excited to develop and commercialize innovative pain management solutions to help improve patient care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_557_2</DOCNO>
            	<TEXT>Learn more about whats going on at SCILEX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_557_3</DOCNO>
            	<TEXT>PARTNERS - SCILEX HOLDING - SORRENTO THERAPEUTICS - CARDINAL HEALTH - ITOCHU - OISHI KOSEIDO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_557_4</DOCNO>
            	<TEXT>CO LTD - Aarkvark Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_557_5</DOCNO>
            	<TEXT>https://www.scilexpharma.com/partners/](https://www.scilexpharma.com/partners/) Getting ready to partners up!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_558_0</DOCNO>
            	<TEXT>Looks like there building a sales force throughout the USA to prepare some type of launch?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_558_1</DOCNO>
            	<TEXT>https://www.scilexpharma.com/careers/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_559_0</DOCNO>
            	<TEXT>There not partnering up to sell patches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_559_1</DOCNO>
            	<TEXT>They're partnering up to sell SP-102</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_560_0</DOCNO>
            	<TEXT>They all work hand and hand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_561_0</DOCNO>
            	<TEXT>Please click and watch this video</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_561_1</DOCNO>
            	<TEXT>Aardvark Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of small molecule therapeutics that activate innate homeostatic pathways for the treatment of disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_561_2</DOCNO>
            	<TEXT>Our lead product, ARD-101, is a first-in-class oral composition that is gut restricted, yet conveys systemic effects via activation of gut peptide hormone secretion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_561_3</DOCNO>
            	<TEXT>Preclinical data demonstrate safety as well as efficacy in a number of metabolic and inflammatory disease models.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_561_4</DOCNO>
            	<TEXT>Please click and watch the video [https://aardvarktherapeutics.com/science/](https://aardvarktherapeutics.com/science/) This is why Sorrento owns 7,777,864 shares of B Preferred stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_562_0</DOCNO>
            	<TEXT>Yes it is and they updated their website.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_562_1</DOCNO>
            	<TEXT>Someday this company will pay us back 10 fold!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_563_0</DOCNO>
            	<TEXT>If you build it they will come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_564_0</DOCNO>
            	<TEXT>A brilliant woman who did so much and died so young.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_565_0</DOCNO>
            	<TEXT>That's a very valid point.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_565_1</DOCNO>
            	<TEXT>I think you could be right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_0</DOCNO>
            	<TEXT>Distribution contracts are being negotiated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_1</DOCNO>
            	<TEXT>Sorrento is currently negotiating with global and regional distributors to ensure rapid distribution of COVISTIX to those countries that access to rapid, accurate and affordable testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_2</DOCNO>
            	<TEXT>COVISTIX has received CE mark and marketing authorization from FAMHP (Federal Agency for Medicines and Health Products) that enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_3</DOCNO>
            	<TEXT>Q - Does anyone know what negotiated means?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_4</DOCNO>
            	<TEXT>A - An agreement between a design professional and owner, or between a contractor and owner, reaching a mutually agreed upon price based on the scope of professional services, or extent of construction work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_5</DOCNO>
            	<TEXT>Q - What did Sorrento receive?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_6</DOCNO>
            	<TEXT>A - Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that it has received an official CE Mark for COVISTIX and a Registration Number: BE/CA01/1-17633-00001-IVD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_7</DOCNO>
            	<TEXT>COVISTIX is a sensitive and rapid (approximately 15-minute) diagnostic test for the detection of the SARS-CoV-2 virus nucleocapsid antigen in nasal or nasopharyngeal samples of patients suspected of a SARS-CoV-2 infection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_8</DOCNO>
            	<TEXT>Q - Who did Sorrento reach an agreement with?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_9</DOCNO>
            	<TEXT>A - Once the negotiations are finalized with we will be informed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_10</DOCNO>
            	<TEXT>Q - How big of a contract could Sorrento secure?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_11</DOCNO>
            	<TEXT>A - Germany reporting the highest rate of Covid-19 infections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_12</DOCNO>
            	<TEXT>The previous record was set last December.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_13</DOCNO>
            	<TEXT>Over 15K infections reported in the past 24 hours.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_14</DOCNO>
            	<TEXT>Time for Therapeutics to become mainstream before winter hits and the Virus gets out of control again and the high death toll returns!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_15</DOCNO>
            	<TEXT>Contracts are being negotiated and I believe Sorrento will finally release a massive huge contracts. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_566_16</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-covistixtm-covid-19-virus-rapid-antigen](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-covistixtm-covid-19-virus-rapid-antigen) Mexico - Europe - Brazil- Canada is next and the USA will follow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_567_0</DOCNO>
            	<TEXT>Click and open the link and read!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_567_1</DOCNO>
            	<TEXT>You clearly didn't even bother to read.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_568_0</DOCNO>
            	<TEXT>You clearly did your DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_0</DOCNO>
            	<TEXT>WE HAVE ACCESS TO SELL TO 1.45 BILLION PEOPLE AS OF NOV 10TH 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_1</DOCNO>
            	<TEXT>COVISTIX approvals in Mexico and Brazil give it access to 435 million in South America and 182 million in Central America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_2</DOCNO>
            	<TEXT>European CE Mark give it access to much of Greater Europe 748 million and Turkey 85 million.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_3</DOCNO>
            	<TEXT>Sorrento is ramping up production as 4th wave spreads.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_4</DOCNO>
            	<TEXT>Distribution contracts are being negotiated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_5</DOCNO>
            	<TEXT>Sorrento is currently negotiating with global and regional distributors to ensure rapid distribution of COVISTIX to those countries that access to rapid, accurate and affordable testing. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_6</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-brazilian-health-regulatory-agency-anvisa](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-brazilian-health-regulatory-agency-anvisa) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-eua-approval-and-import-license-mexico](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-eua-approval-and-import-license-mexico) Sorrento needs help with the overload of contracts so they're looking to hire a Contracts Administrator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_7</DOCNO>
            	<TEXT>This position was added last week. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_8</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=449](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=449) We are very grateful to ANVISA for working with us closely on this approval for our COVISTIX diagnostic product in Brazil, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_9</DOCNO>
            	<TEXT>We look forward to working even more closely with the government to help deploy our test at large scale.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_10</DOCNO>
            	<TEXT>We have been building our manufacturing capacity in anticipation of EUA clearances in multiple countries in need of highly sensitive, and simple COVID-19 rapid antigen testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_11</DOCNO>
            	<TEXT>PLEASE READ THIS LINE AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_12</DOCNO>
            	<TEXT>We have been building our manufacturing capacity in anticipation of EUA clearances in multiple countries in need of highly sensitive, and simple COVID-19 rapid antigen testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_569_13</DOCNO>
            	<TEXT>Manufacturing + EUA + Contracts + 1.45 Billion people = THE BE$T IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_570_0</DOCNO>
            	<TEXT>BLACKROCK INCREASED THEIR OWNERSHIP 2021-11-09 13F BlackRock Inc. 8.66 20,867,671 They added 3,247,993 shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_570_1</DOCNO>
            	<TEXT>https://fintel.io/so/us/srne</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_570_2</DOCNO>
            	<TEXT>BLACKROCK INCREASED THEIR OWNERSHIP 2021-11-09 13F BlackRock Inc. 8.66 20,867,671 They added 3,247,993 shares. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_570_3</DOCNO>
            	<TEXT>https://fintel.io/so/us/srne](https://fintel.io/so/us/srne)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_571_0</DOCNO>
            	<TEXT>BlackRock increased their ownership</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_572_0</DOCNO>
            	<TEXT>Yes they do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_572_1</DOCNO>
            	<TEXT>I'm trying to post it on Yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_572_2</DOCNO>
            	<TEXT>But someone is burying my post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_573_0</DOCNO>
            	<TEXT>BlackRock has been adding more and more shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_573_1</DOCNO>
            	<TEXT>They even lend a few out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_573_2</DOCNO>
            	<TEXT>They know eventually everyone will have to cover before the squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_574_0</DOCNO>
            	<TEXT>Global COVID-19 Therapeutics Market Size Now Expected To Exceed $25 Billion In 2030 Published: Nov. 9, 2021 at 8:31 a.m. ET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_574_1</DOCNO>
            	<TEXT>Sorrento Therapeutics, Inc. (NASDAQ: SRNE) recently announced receipt of approval from the Brazilian regulatory agency (ANVISA) for COVISTIX in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_574_2</DOCNO>
            	<TEXT>COVISTIX manufacturing approval (for good manufacturing practices) from ANVISA was published in the Brazilian government official journal on October 18thunder registration CNPJ 17700763/0001-48, resolution #3951.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_574_3</DOCNO>
            	<TEXT>COVISTIX marketing authorization from ANVISA was published in the Brazilian government official journal on November 3rdunder the same registration, with reference # 25351.041767/2021-72 / 80961800001.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_574_4</DOCNO>
            	<TEXT>Did you read the heading?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_574_5</DOCNO>
            	<TEXT>TO EXCEED $25B in 2030 COVID-19 Is not going away. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_574_6</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/global-covid-19-therapeutics-market-size-now-expected-to-exceed-25-billion-in-2030-2021-11-09-82033131?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/global-covid-19-therapeutics-market-size-now-expected-to-exceed-25-billion-in-2030-2021-11-09-82033131?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_575_0</DOCNO>
            	<TEXT>Covid-19 is not going away 2030!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_577_0</DOCNO>
            	<TEXT>Anything can happen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_577_1</DOCNO>
            	<TEXT>BlackRock has been buying more and more shares every quarter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_577_2</DOCNO>
            	<TEXT>They know what they own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_578_0</DOCNO>
            	<TEXT>There's no insulting on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_578_1</DOCNO>
            	<TEXT>1st warning</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_0</DOCNO>
            	<TEXT>Chronic pain affects 116 million Americans and costs the U.S. as much as $635 billion each year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_1</DOCNO>
            	<TEXT>If you have persistent pain following shingles, ask your doctor if ZTLIDO is right for you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_2</DOCNO>
            	<TEXT>Free samples may be available.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_3</DOCNO>
            	<TEXT>The main website for Scilex clearly states to ask your doctor if ZTLIDO is right for you. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_4</DOCNO>
            	<TEXT>https://www.ztlido.com/](https://www.ztlido.com/) Why would Scilex want to build a sales force team throughout the United States if the doctors already know?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_5</DOCNO>
            	<TEXT>Your doctor already knows about ZTLIDO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_6</DOCNO>
            	<TEXT>Do we really need a sales force to promote ZTLIDO for people with shingles?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_7</DOCNO>
            	<TEXT>Or is there something else that's cooking? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_8</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=524](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=524) [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=530](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=530) [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=531](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=531) [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=503](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=503) [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=454](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=454) [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=544](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=544) [https://sorrentotherapeutics.com/careers/](https://sorrentotherapeutics.com/careers/) Some 16 million adults 8 percent of all adults experience persistent or chronic back pain, and as a result are limited in certain everyday activities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_9</DOCNO>
            	<TEXT>Back pain is the sixth most costly condition in the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_10</DOCNO>
            	<TEXT>Health care costs and indirect costs due to back pain are over $12 billion per year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_11</DOCNO>
            	<TEXT>Interesting Facts about Back Pain HDB 3 Worldwide, back pain is the single leading cause of disability, preventing many people from engaging in work as well as other everyday activities.2 Back pain is one of the most common reasons for missed work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_12</DOCNO>
            	<TEXT>One-half of all working Americans admit to having back pain symptoms each year.3 Back pain accounts for more than 264 million lost work days in one yearthats two work days for every full-time worker in the country.4 Experts estimate that up to 80% of the population will experience back pain at some time in their lives.5 Back pain can affect people of all ages, from adolescents to the elderly.5 Back pain is the third most common reason for visits to the doctors office, behind skin disorders and osteoarthritis/joint disorders.6 Most cases of back pain are mechanical or non-organicmeaning they are not caused by serious conditions, such as inflammatory arthritis, infection, fracture or cancer.7 Most people with low back pain recover, however reoccurrence is common and for small percentage of people the condition will become chronic and disabling.7 Worldwide, years lived with disability caused by low back pain have increased by 54% between 1990 and 2015.7 Low-back pain costs Americans at least $50 billion in health care costs each year8add in lost wages and decreased productivity and that figure easily rises to more than $100 billion.9 [https://www.acatoday.org/Patients/What-is-Chiropractic/Back-Pain-Facts-and-Statistics](https://www.acatoday.org/Patients/What-is-Chiropractic/Back-Pain-Facts-and-Statistics) Scilex expects SP-102 to be the first FDA-approved non-opioid epidural injection for sciatica with the potential to replace the current 10 to 12 million off-label epidural steroid injections administered each year in the U.S. [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-company-announces-complete) We believe that SP-102 could be the first FDA-approved epidural steroid gel injection product for patients suffering from this common, very painful condition, said Jaisim Shah, President and Chief Executive Officer of Scilex Holding Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_579_13</DOCNO>
            	<TEXT>DENVER, CO - FORT WORTH TX, - FRESNO - BAKERSFIELD, CA, - PHILLY NORTH, PA - STAMFORD, CT - TALLAHASSEE, FLORIDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_0</DOCNO>
            	<TEXT>I SPOKE WITH MIKED44 LAST NIGHT</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_1</DOCNO>
            	<TEXT>He's private messaged me on the BAND.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_2</DOCNO>
            	<TEXT>Him and his family are doing great.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_3</DOCNO>
            	<TEXT>There rounding the horn heading to the Med sailing around the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_4</DOCNO>
            	<TEXT>MikeD44 is by far the best knowledgeable investor that's ever posted for Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_5</DOCNO>
            	<TEXT>He's going to send me his thoughts and I'm going to REPOST them only on the BAND.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_6</DOCNO>
            	<TEXT>I'm so excited to see he's clearly enjoying life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_7</DOCNO>
            	<TEXT>Here's a clip of his thoughts... Investors need to understand.. the rest of the globe is still reeling from SARS-COV2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_8</DOCNO>
            	<TEXT>Unlike the US spread is on the increase with much more virulent strains.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_9</DOCNO>
            	<TEXT>Vaxing hasn't been prevalent due to supply constraints.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_10</DOCNO>
            	<TEXT>Far from over.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_580_11</DOCNO>
            	<TEXT>Stay tuned for more..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_581_0</DOCNO>
            	<TEXT>His service is very poor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_581_1</DOCNO>
            	<TEXT>So we made the connection for him to email me his thoughts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_583_0</DOCNO>
            	<TEXT>Mike is a long term holder that purchased 100s of thousands of share when they were trading $1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_583_1</DOCNO>
            	<TEXT>He's holding for long term.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_583_2</DOCNO>
            	<TEXT>He knows the best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_0</DOCNO>
            	<TEXT>I have direct access to privately message him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_1</DOCNO>
            	<TEXT>There's a 6 hour difference in time change.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_2</DOCNO>
            	<TEXT>I was speaking with with at 4am in the morning last night.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_3</DOCNO>
            	<TEXT>He's very eager to fill me in with what he thinks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_4</DOCNO>
            	<TEXT>This is what he said after we chatted for 15 minutes.... Wifey is calling me back to bed.. it's 4am here.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_5</DOCNO>
            	<TEXT>I'll speak with you again soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_6</DOCNO>
            	<TEXT>Please message me anytime with thoughts and I will repost for you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_584_7</DOCNO>
            	<TEXT>You bet...Take care mate!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_585_0</DOCNO>
            	<TEXT>He was in good spirits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_586_0</DOCNO>
            	<TEXT>Two years ago Sorrento was trading in the $1 plus range</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_0</DOCNO>
            	<TEXT>This is what a real leader writes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_1</DOCNO>
            	<TEXT>Letter to Mrs. Bixby In the autumn of 1864 Massachusetts Governor John A. Andrew wrote to President Lincoln asking him to express condolences to Mrs. Lydia Bixby, a widow believed to have lost five sons during the Civil War.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_2</DOCNO>
            	<TEXT>Lincoln's letter to her was printed by the Boston Evening Transcript.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_3</DOCNO>
            	<TEXT>Later it was revealed that only two of Mrs. Bixby's five sons died in battle, Charles and Oliver.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_4</DOCNO>
            	<TEXT>Of the remainder, one deserted the army, one was honorably discharged, and another deserted or died a prisoner of war.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_5</DOCNO>
            	<TEXT>The authorship of the letter has been debated by scholars, some of whom believe it was written instead by John Hay, one of Lincoln's White House secretaries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_6</DOCNO>
            	<TEXT>Apparently the original letter was destroyed by the newspaper editor after publication or by Mrs. Bixby, who may have been a Confederate sympathizer and disliked President Lincoln.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_7</DOCNO>
            	<TEXT>Copies of an early forgery have been circulating for many years, causing some people to believe they possess the original letter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_8</DOCNO>
            	<TEXT>Executive Mansion, Washington, Nov. 21, 1864.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_9</DOCNO>
            	<TEXT>Dear Madam,-- I have been shown in the files of the War Department a statement of the Adjutant General of Massachusetts that you are the mother of five sons who have died gloriously on the field of battle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_10</DOCNO>
            	<TEXT>I feel how weak and fruitless must be any word of mine which should attempt to beguile you from the grief of a loss so overwhelming.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_11</DOCNO>
            	<TEXT>But I cannot refrain from tendering you the consolation that may be found in the thanks of the Republic they died to save.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_12</DOCNO>
            	<TEXT>I pray that our Heavenly Father may assuage the anguish of your bereavement, and leave you only the cherished memory of the loved and lost, and the solemn pride that must be yours to have laid so costly a sacrifice upon the altar of freedom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_587_13</DOCNO>
            	<TEXT>Yours, very sincerely and respectfully, A. Lincoln</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_588_0</DOCNO>
            	<TEXT>GREAT VIDEO!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_589_0</DOCNO>
            	<TEXT>One of our greatest Presidents that ever lived.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_590_0</DOCNO>
            	<TEXT>Yes it was.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_590_1</DOCNO>
            	<TEXT>I'm watching the Band of Brothers today on the History channel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_590_2</DOCNO>
            	<TEXT>I'm on episode #6</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_591_0</DOCNO>
            	<TEXT>Some days you have to relax and reflect and respect and honor those that made the ultimate sacrifice for our Freedoms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_592_0</DOCNO>
            	<TEXT>Today is a day to reflect on our heroes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_593_0</DOCNO>
            	<TEXT>r/Srne banned me because of my faith in religion and Freedom of speech.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_593_1</DOCNO>
            	<TEXT>The moderators are bias and have no respect for Veterans.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_594_0</DOCNO>
            	<TEXT>No one is deleting any replies</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_0</DOCNO>
            	<TEXT>REPOST WITH BASES LOADED -- BASEBALL HOT DOGS APPLE PIE AND CHEVROLET</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_1</DOCNO>
            	<TEXT>BASEBALL HOT DOGS APPLE PIE AND CHEVROLET I hope everyone knows how to play baseball?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_2</DOCNO>
            	<TEXT>It's one of America's greatest sports.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_3</DOCNO>
            	<TEXT>When we're taught how to play as kids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_4</DOCNO>
            	<TEXT>We're told when your up at bat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_5</DOCNO>
            	<TEXT>Don't take your eye off the ball.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_6</DOCNO>
            	<TEXT>Try to connect and drive through into the pitch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_7</DOCNO>
            	<TEXT>Don't swing at the bad pitches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_8</DOCNO>
            	<TEXT>Take your time and take your pitch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_9</DOCNO>
            	<TEXT>You may foul a few balls off it's ok.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_10</DOCNO>
            	<TEXT>Straighten your swing out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_11</DOCNO>
            	<TEXT>You may miss a few pitches.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_12</DOCNO>
            	<TEXT>But it's ok because your learning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_13</DOCNO>
            	<TEXT>But DON'T TAKE YOUR EYE OFF THE BALL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_14</DOCNO>
            	<TEXT>This is very true with Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_15</DOCNO>
            	<TEXT>Don't get distracted by the bashers and shorts that are on the sidelines saying.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_16</DOCNO>
            	<TEXT>Swing no batter swing!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_17</DOCNO>
            	<TEXT>He can't hit he can't hit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_18</DOCNO>
            	<TEXT>They want you to fail.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_19</DOCNO>
            	<TEXT>So they can win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_20</DOCNO>
            	<TEXT>The bases are loaded.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_21</DOCNO>
            	<TEXT>COVISTIX in Europe and Brazil and Mexico .</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_22</DOCNO>
            	<TEXT>Everyday we will have our chance at hitting more home runs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_23</DOCNO>
            	<TEXT>Remember don't take your eye off of the ball.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_24</DOCNO>
            	<TEXT>Silence the crowd and hold your shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_25</DOCNO>
            	<TEXT>Sorrento has loaded the bases and will hit a GRAND SLAM!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_26</DOCNO>
            	<TEXT>The contracts for COVISTIX will be the GRAND SLAM everyone has been waiting for.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_27</DOCNO>
            	<TEXT>There will be plenty of beer and cheer to go around after the game.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_28</DOCNO>
            	<TEXT>DON'T TAKE YOUR EYE OFF OF THE BALL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_29</DOCNO>
            	<TEXT>Because the best batter is yet to come to the plate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_30</DOCNO>
            	<TEXT>No outs Bases are loaded.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_31</DOCNO>
            	<TEXT>We have Mexico on first base.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_32</DOCNO>
            	<TEXT>We have Europe on second base.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_33</DOCNO>
            	<TEXT>We have Brazil on third base.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_595_34</DOCNO>
            	<TEXT>The batter is DR JI to release the massive contracts for COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_596_0</DOCNO>
            	<TEXT>We need a nice fat press release with a contract for 100M COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_597_0</DOCNO>
            	<TEXT>I would rather not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_597_1</DOCNO>
            	<TEXT>I dont want to create fighting between boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_597_2</DOCNO>
            	<TEXT>I did post it on Yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_597_3</DOCNO>
            	<TEXT>If you want to can scroll down in my posts and view.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_597_4</DOCNO>
            	<TEXT>Who do you want to listen to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_598_0</DOCNO>
            	<TEXT>I believe I saw 12pm.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_599_0</DOCNO>
            	<TEXT>Armamentarium of this multi-billion dollar indication!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_599_1</DOCNO>
            	<TEXT>Read it again!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_599_2</DOCNO>
            	<TEXT>"We are very encouraged by the publication of these significant positive results of abivertinib on the treatment of advanced and heavily pretreated NSCLC lung cancer in Clinical Cancer Research and look forward to bringing abivertinib into the armamentarium of this multi-billion dollar indication," said Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_599_3</DOCNO>
            	<TEXT>Based on these significant treatment benefits that Abivertinib achieved in a heavily pretreated population, Sorrento is conducting an independent review process with more mature long-term data and will request a pre-NDA meeting with the FDA upon completion. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_599_4</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-significant-positive-pivotal](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-significant-positive-pivotal) Know what you own!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_600_0</DOCNO>
            	<TEXT>They removed my Metaphoric Noah's Ark post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_600_1</DOCNO>
            	<TEXT>Said no religion and they made fun of me and said I have PTSD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_0</DOCNO>
            	<TEXT>IN ALL FAIRNESS WHO DO WE WANT TO LISTEN TO?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_1</DOCNO>
            	<TEXT>REPOST Who do we want to believe?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_2</DOCNO>
            	<TEXT>Who do we want to follow?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_3</DOCNO>
            	<TEXT>What do we believe?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_4</DOCNO>
            	<TEXT>Let's take a closer look and figure this out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_5</DOCNO>
            	<TEXT>Most of us came to this board in May 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_6</DOCNO>
            	<TEXT>At least that's when I did.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_7</DOCNO>
            	<TEXT>I started to read everyone's posts to get a feel about the company I was investing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_8</DOCNO>
            	<TEXT>I could clearly see and read who was knowledgeable and who wasn't.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_9</DOCNO>
            	<TEXT>The most important thing that I found that people were working together as a team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_10</DOCNO>
            	<TEXT>Or let's say multiple different teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_11</DOCNO>
            	<TEXT>We had some pumpers on one side pumping the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_12</DOCNO>
            	<TEXT>On the other side we had Bashers that were putting down the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_13</DOCNO>
            	<TEXT>Both teams have a job to do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_14</DOCNO>
            	<TEXT>And both teams were doing a pretty good job at it as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_15</DOCNO>
            	<TEXT>The investors were in the middle to choose and decide which people to listen to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_16</DOCNO>
            	<TEXT>There was always an open decision on this board that was great.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_17</DOCNO>
            	<TEXT>But after a while as we can see.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_18</DOCNO>
            	<TEXT>We all started to search other message boards for DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_19</DOCNO>
            	<TEXT>It's only natural because we want to see if we're missing something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_20</DOCNO>
            	<TEXT>So I did exactly just that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_21</DOCNO>
            	<TEXT>People were telling me to go to r/SRNE and post there as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_22</DOCNO>
            	<TEXT>So I opened an account and said hello.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_23</DOCNO>
            	<TEXT>They welcomed me with open arms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_24</DOCNO>
            	<TEXT>Receiving 33 awards in the 1st week alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_25</DOCNO>
            	<TEXT>People started to private message me as well to thank me for my DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_26</DOCNO>
            	<TEXT>Thinking ahead I thought about setting up my own Reddit account for Veterans and yahoo members for a Sorrento celebration party someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_27</DOCNO>
            	<TEXT>Which is r/BANDOFBROTHERSOFSRNE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_28</DOCNO>
            	<TEXT>So I then started to post any DD that I could find on all three boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_29</DOCNO>
            	<TEXT>My motive always from the start was to help others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_30</DOCNO>
            	<TEXT>It's the greatest feeling when someone says a simple thank you in return.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_31</DOCNO>
            	<TEXT>That in return for me wanted me to work harder.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_32</DOCNO>
            	<TEXT>I found myself very frustrated with the moderators on Reddit's SRNE as time pasted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_33</DOCNO>
            	<TEXT>They started to bait me one day with my THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_34</DOCNO>
            	<TEXT>They insinuated that it was a TRUMP rally call.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_35</DOCNO>
            	<TEXT>Which it was not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_36</DOCNO>
            	<TEXT>Everyone or at least everyone knows I love Frank Sinatra.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_37</DOCNO>
            	<TEXT>When I confronted them in public I was told to message them in private.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_38</DOCNO>
            	<TEXT>Which I did and was told there's no mention of politics on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_39</DOCNO>
            	<TEXT>Even using a WHAT IF scenario in the event Joe Biden was removed as President and replaced.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_40</DOCNO>
            	<TEXT>How would that of changed the CDC, FDA, WHO, etc.?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_41</DOCNO>
            	<TEXT>If it were to happen who would be put in their places?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_42</DOCNO>
            	<TEXT>Could take change the outcome of what's going on with clinical trials?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_43</DOCNO>
            	<TEXT>It's a valid discussion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_44</DOCNO>
            	<TEXT>Here's what I noticed they were doing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_45</DOCNO>
            	<TEXT>They would allow bashing of one political party and not the other.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_46</DOCNO>
            	<TEXT>They were cherry picking me and singling me out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_47</DOCNO>
            	<TEXT>Being told private message us asap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_48</DOCNO>
            	<TEXT>To be told it you don't stop the politics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_49</DOCNO>
            	<TEXT>We will ban you from our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_50</DOCNO>
            	<TEXT>So I refrained from posting any other WHAT IF scenarios about politics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_51</DOCNO>
            	<TEXT>Sounds like censorship?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_52</DOCNO>
            	<TEXT>It got worse they started to pick on timelines of my posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_53</DOCNO>
            	<TEXT>Everyone knows you need to click and open the links and you will see how old or new the post was.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_54</DOCNO>
            	<TEXT>Why were they only picking on me?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_55</DOCNO>
            	<TEXT>Hmmm was it the BEST IS YET TO COME?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_56</DOCNO>
            	<TEXT>It's there board and there making the rules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_57</DOCNO>
            	<TEXT>So a few days ago I posted on all three boards my Metaphoric post about Noah's Ark. It was greeted with open arms on two boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_58</DOCNO>
            	<TEXT>But again on Reddit's SRNE it was deleted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_59</DOCNO>
            	<TEXT>Being very unhappy I private messaged the moderators.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_60</DOCNO>
            	<TEXT>To be told no religion is allowed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_61</DOCNO>
            	<TEXT>Not even a Metaphoric post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_62</DOCNO>
            	<TEXT>So confronting them I was BANNED from their board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_63</DOCNO>
            	<TEXT>I stood up for WHO I believed in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_64</DOCNO>
            	<TEXT>I'm a very firm believer in the your 1st Amendment Rights and all Freedom of speech and Freedom to believe in any religion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_65</DOCNO>
            	<TEXT>I believe non believers don't need to believe if they choose not to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_66</DOCNO>
            	<TEXT>Where does it say no religion allowed on their board?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_67</DOCNO>
            	<TEXT>Hmm it does not.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_68</DOCNO>
            	<TEXT>We as Americans and Veterans have fought for those Freedoms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_69</DOCNO>
            	<TEXT>Some even making the ultimate sacrifice in multiple wars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_70</DOCNO>
            	<TEXT>Service members, Police Officers, Firemen all need to be shown respect and honor them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_71</DOCNO>
            	<TEXT>They are the hero's that we need to follow and listen to.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_72</DOCNO>
            	<TEXT>I will not mention him by name.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_73</DOCNO>
            	<TEXT>Because he does not know I'm writing this.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_74</DOCNO>
            	<TEXT>But he's a Vietnam Bronze Star Veteran that for two years worked as an Army front line medic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_75</DOCNO>
            	<TEXT>I speak to this yahoo board member daily.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_76</DOCNO>
            	<TEXT>And that's WHO I choose to follow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_77</DOCNO>
            	<TEXT>That's WHO I choose to believe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_78</DOCNO>
            	<TEXT>Not for his religious faith.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_79</DOCNO>
            	<TEXT>But for the sacrifices that he made for our Country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_80</DOCNO>
            	<TEXT>No one should ever remove your faith in any GOD off of any board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_81</DOCNO>
            	<TEXT>Or your opinions or your beliefs if there not in line with theirs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_82</DOCNO>
            	<TEXT>We used to have a daily morning prayer on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_83</DOCNO>
            	<TEXT>We don't anymore and we need to start again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_84</DOCNO>
            	<TEXT>We all need to pray for a blessing and for a cure for COVID-19 and the 5,007,621 people that have died since this pandemic started.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_85</DOCNO>
            	<TEXT>God is allows listening and he is WHO you need to believe in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_86</DOCNO>
            	<TEXT>Thank you and God Bless everyone on this board and Sorrento Therapeutics in finding a cure or treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_601_87</DOCNO>
            	<TEXT>Thanks again ROBERT S.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_602_0</DOCNO>
            	<TEXT>The Moderators on that board can not be trusted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_602_1</DOCNO>
            	<TEXT>They cherry pick and attack anyone who's not inline with them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_602_2</DOCNO>
            	<TEXT>There loss not mine and less posting for me to do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_603_0</DOCNO>
            	<TEXT>I'm available to read and see all of there posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_604_0</DOCNO>
            	<TEXT>For some reason they picked on me everytime I posted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_606_0</DOCNO>
            	<TEXT>Good morning and we might receive another BUY recommendation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_0</DOCNO>
            	<TEXT>Hctor Sulaimn is the President of the Advisory Council of Scholas Occurrentes in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_1</DOCNO>
            	<TEXT>Sorrento Mexico has established offices in Mexico City with Dr. Henry Ji as Chairman and Mr. Hctor Sulaimn S. as Chief Executive Officer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_2</DOCNO>
            	<TEXT>Who is Mr Hector Sulaiman S.?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_3</DOCNO>
            	<TEXT>Hctor Sulaimn is a successful Mexican businessman, son of Don Jos Sulaimn Chagnn (President of the World Boxing Council for 38 years).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_4</DOCNO>
            	<TEXT>Hctor has been recognized both in Mexico and abroad for his tireless fight for human dignity, who also heads Scholas Occurrentes in Mexico , a civil society organization that seeks to make the culture of encounter a reality, integrate educational communities focusing on those with fewer resources, to transform the world into a classroom without walls and complete education with a sports culture through programs such as BoxVal, KarateVal and FutVal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_5</DOCNO>
            	<TEXT>Hctor Sulaimn is the President of the Advisory Council of Scholas Occurrentes in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_6</DOCNO>
            	<TEXT>The Scholas Occurrentes is a non-profit organization founded by Pope Francis, it works with schools and educational communities, both public and private, secular and of all religious confessions to favor integration and promote peace among peoples through education and implement the culture of the meeting for peace.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_7</DOCNO>
            	<TEXT>Scholas has a presence in 190 countries and works with nearly 450,000 schools around the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_8</DOCNO>
            	<TEXT>Sorrento is now on the EUL List with WHO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_9</DOCNO>
            	<TEXT>My guess is Mr Hector Sulaiman who runs the Scholas Occurrentes in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_10</DOCNO>
            	<TEXT>Will most likely distribute COVI-STIX throughout all of the Mexican Schools.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_11</DOCNO>
            	<TEXT>Currently there's 96,000 schools in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_12</DOCNO>
            	<TEXT>25 Million COVI-STIX were approved to be sent to Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_13</DOCNO>
            	<TEXT>I would think with the schools opened in Mexico the orders are stacking up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_14</DOCNO>
            	<TEXT>WBC and all other Sporting Events in Mexico will deploy COVISTIX for all of there athletes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_15</DOCNO>
            	<TEXT>I wouldn't be surprised to see COVISTIX advertisement ring side or in soccer stadiums very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_16</DOCNO>
            	<TEXT>We can see the COVISTIX.COM website is all set up for Physicians, Pharmacy's to pre register to take orders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_17</DOCNO>
            	<TEXT>I'm pretty sure the website that everyone went and tried to login that's under construction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_18</DOCNO>
            	<TEXT>Works just fine in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_19</DOCNO>
            	<TEXT>So in reality Sorrento has the WHO in one corner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_20</DOCNO>
            	<TEXT>The POPE in another corner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_607_21</DOCNO>
            	<TEXT>Let the SALES begin.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_608_0</DOCNO>
            	<TEXT>For some reason yahoo would not let me post this.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_0</DOCNO>
            	<TEXT>WHAT IS THIS FOR?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_1</DOCNO>
            	<TEXT>FUTURE PRODUCTS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_2</DOCNO>
            	<TEXT>WHICH FUTURE PRODUCTS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_3</DOCNO>
            	<TEXT>Develop Gross-to-Net Sales revenue recognition models for future products and distribution channels, engaging external consultants as needed for complex pricing and distribution channels.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_4</DOCNO>
            	<TEXT>Revenue Accountant/Sr.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_5</DOCNO>
            	<TEXT>Accountant Sorrento needs another Accountant to count all the future money?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_6</DOCNO>
            	<TEXT>Let's read and see what this Revenue Accountant/Sr.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_7</DOCNO>
            	<TEXT>Accountant will do... WHAT WE ARE LOOKING FOR: Sorrento Therapeutics (Sorrento) is seeking an experienced Revenue Accountant who will be responsible for accounting for revenues across all entities under Sorrento, in compliance with ASC 606 revenue recognition guidance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_8</DOCNO>
            	<TEXT>The position will be responsible for calculating and maintaining accounting support for Gross-to-Net Sales and Contract Adjustments, oversee insurance billings and collections, oversee accounting for deferred revenue and other revenue streams, and participate in technical accounting of revenue-related transactions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_9</DOCNO>
            	<TEXT>The ideal candidate demonstrate a strong understanding of the US Managed Markets landscape, healthcare pricing and contracting, insurance billing and collections analytical thinking, accounting acumen and attention to detail.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_10</DOCNO>
            	<TEXT>WHAT YOULL DO: Maintain Gross-to-Net Sales revenue recognition models for existing products (ZTlido), in close coordination with Commercial Operations and Market Access teams.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_11</DOCNO>
            	<TEXT>Develop Gross-to-Net Sales revenue recognition models for future products and distribution channels, engaging external consultants as needed for complex pricing and distribution channels.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_12</DOCNO>
            	<TEXT>Lead Gross-to-Net forecast processes and analyze, explain and summarize gross to net variances by channel and segment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_13</DOCNO>
            	<TEXT>Provide inputs to Gross-to-Net model based on changes in pricing, contracts and contract strategy, and payer strategies and business models.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_14</DOCNO>
            	<TEXT>Prepare calculations for insurance contract adjustments for revenue recognition entries Keep abreast with latest revenue accounting guidance (e.g. ASC 606) and ensure compliance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_15</DOCNO>
            	<TEXT>Assist Financial Planning and Analysis in preparing for revenue budgets and forecasts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_16</DOCNO>
            	<TEXT>Serve as subject matter expert on key drivers of gross-to-net through analysis of data sources, healthcare payer understanding and engagement with internal and external stakeholders Analyze pricing and contracting scenarios using the Gross-to-Net model.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_17</DOCNO>
            	<TEXT>Develop and cultivate cross-functional relationships to help business understand revenue drivers and support decision making process to improve profitability.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_18</DOCNO>
            	<TEXT>Other projects/duties as necessary [https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=380](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=380) BTW in the last 20 months Sorrento has almost doubled in size.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_19</DOCNO>
            	<TEXT>They keep on hiring and hiring and leasing more and more space.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_20</DOCNO>
            	<TEXT>Because DR Ji said, In three years Sorrento will be a $200 Billion dollar Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_21</DOCNO>
            	<TEXT>Sorrento can now sell COVISTIX in Mexico, Brazil, and in Europe.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_22</DOCNO>
            	<TEXT>COVID-19 is not going away anytime soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_23</DOCNO>
            	<TEXT>Currently Sorrento could provide COVISTIX to 1,400,000,00 Billion people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_24</DOCNO>
            	<TEXT>I know what I own and I'm going to relax this weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_25</DOCNO>
            	<TEXT>Everyday more and more contracts and promotions will happen for COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_609_26</DOCNO>
            	<TEXT>Have a great weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_610_0</DOCNO>
            	<TEXT>Agent 99 how are you?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_610_1</DOCNO>
            	<TEXT>I will never forget you were the 99th member on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_611_0</DOCNO>
            	<TEXT>[https://www.scholasoccurrentes.org/en/tag/mexico/](https://www.scholasoccurrentes.org/en/tag/mexico/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_612_0</DOCNO>
            	<TEXT>Hector heads this organization in Mexico and works hand and hand with the Pope.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_612_1</DOCNO>
            	<TEXT>I would believe Hector could open the door to the 96,000 schools in Mexico.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_613_0</DOCNO>
            	<TEXT>Enjoy and Congrats!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_614_0</DOCNO>
            	<TEXT>Well they sit and wait for me to post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_0</DOCNO>
            	<TEXT>THIS POST WAS POSTED ON YAHOO ON SATURDAY NOV 13TH.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_1</DOCNO>
            	<TEXT>In just 24 hours OUR MESSAGE BOARD REACHED 14 COUNTRIES, AND 26 STATES IN THE USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_2</DOCNO>
            	<TEXT>We have investors from all the way around the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_3</DOCNO>
            	<TEXT>I'm truly amazed of the following we have.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_4</DOCNO>
            	<TEXT>Let me say we're going to need a HOTEL with a huge courtyard to host the Sorrento Celebration PARTY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_5</DOCNO>
            	<TEXT>I'm going to list all of the Countries  amp; City  amp; States the best I can.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_6</DOCNO>
            	<TEXT>If I leave one out please add yourself to the list.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_7</DOCNO>
            	<TEXT>Philippines, Canada, Switzerland, England, India, Ireland, Portugal, South Africa, Romania, Israel, Italy, China, Singapore, S Korea, US States, Queens NY, Sacramento Ca, Dublin OH, Arkansas, PA, SC, Utah, Napa Valley CA, San Diego, Mobile Alabama, Sugar Land Texas, Kansas, Indiana, Denver CO, Michigan, Philly PA, Wisconsin, Florida, Minnesota, New Jersey.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_8</DOCNO>
            	<TEXT>We're all one big Sorrento family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_9</DOCNO>
            	<TEXT>My goal is to hold the stock long term.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_10</DOCNO>
            	<TEXT>DR JI goal was to build Sorrento into a $200 Billion dollar Company in 3 to 5 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_11</DOCNO>
            	<TEXT>I believe we will have multiple Celebration parties every year until we reach his goal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_12</DOCNO>
            	<TEXT>Please view my reply on the bottom of this post to get the party details.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_13</DOCNO>
            	<TEXT>I want to say Thank You to everyone in every Country  amp; US City and State.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_14</DOCNO>
            	<TEXT>Remember we're the backbone of this Company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_615_15</DOCNO>
            	<TEXT>Without us there wouldn't be a Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_616_0</DOCNO>
            	<TEXT>Yahoo removed this post i posted this morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_616_1</DOCNO>
            	<TEXT>The shorts can remove almost any post they want.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_616_2</DOCNO>
            	<TEXT>But they can't take away our BOND as group.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_617_0</DOCNO>
            	<TEXT>Of course your added to the list of 15 Countries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_618_0</DOCNO>
            	<TEXT>I have a pretty big house with an inground pool.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_618_1</DOCNO>
            	<TEXT>This party could be bigger than i thought.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_618_2</DOCNO>
            	<TEXT>lol We may need a very large Hotel with lots of amenities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_619_0</DOCNO>
            	<TEXT>Smart move my Real Estate taxes alone for my house is $52k per year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_620_0</DOCNO>
            	<TEXT>I would first get a confirmation of how many could attend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_620_1</DOCNO>
            	<TEXT>Then take it from there.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_621_0</DOCNO>
            	<TEXT>I own an Entertainment Company and trust me I know how to throw a party</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_622_0</DOCNO>
            	<TEXT>LOOK WHO'S A MAJOR PLAYER</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_622_1</DOCNO>
            	<TEXT>Major players in the microneedle drug delivery systems market are 3M, Zosano Pharma, Becton-Dickinson Technologies, Nanopass Technologies, Corium, Valeritas, Microdermics, TheraJect Inc., LTS Lohmann Therapie-Systeme AG, BioSerenTach (BT), Sorrento Therapeutics, Debiotech, Raphas Co. Ltd., QuadMedicine, SNvia, and NanoBiosciences. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_622_2</DOCNO>
            	<TEXT>https://news.futunn.com/en/post/11135099?level=1 amp;data\_ticket=1636980934131729](https://news.futunn.com/en/post/11135099?level=1 amp;data_ticket=1636980934131729)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_623_0</DOCNO>
            	<TEXT>FDA recalls 2.2 million Ellume COVID-19 home tests due to false positives</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_623_1</DOCNO>
            	<TEXT>https://www.cbsnews.com/amp/news/covid-home-test-recall-ellume-false-positives/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_624_0</DOCNO>
            	<TEXT>The WBC family finally reunites again and safely</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_624_1</DOCNO>
            	<TEXT>https://wbcboxing.com/en/the-wbc-family-finally-reunites-again-and-safely/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_625_0</DOCNO>
            	<TEXT>Stonks9595 Found this link great job as always!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_626_0</DOCNO>
            	<TEXT>93.3% TUMOR SHRINKAGE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_626_1</DOCNO>
            	<TEXT>Abivertinib Efficacy in EGFR T790M+ NSCLC Patients Among 209 response evaluable patients, per investigator assessment: 93.3% (n/N: 195/209) subjects achieved tumor shrinkage at target lesions. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_626_2</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a](https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_627_0</DOCNO>
            	<TEXT>AGREE THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_628_0</DOCNO>
            	<TEXT>HFs want to pop up in AH.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_629_0</DOCNO>
            	<TEXT>WE WON ON #5!!!!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_630_0</DOCNO>
            	<TEXT>WE WON ON #5 WE VOTED NO!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_630_1</DOCNO>
            	<TEXT>This is great news!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_631_0</DOCNO>
            	<TEXT>With a SP-102 approval will should see $100 ps.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_632_0</DOCNO>
            	<TEXT>It's a Victory today for all shareholders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_632_1</DOCNO>
            	<TEXT>If you want to be compensated you need to show us the money first.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_633_0</DOCNO>
            	<TEXT>I would prefer a great press release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_633_1</DOCNO>
            	<TEXT>Premarket so they can not manipulate the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_0</DOCNO>
            	<TEXT>COVI-DROPS (STI-2099)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_1</DOCNO>
            	<TEXT>COVIDROPS is an intranasal formulation of the highly potent neutralizing antibody (nAb) STI-2020 (COVI-AMG).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_2</DOCNO>
            	<TEXT>A single IN administration of COVIDROPS prevented disease-associated weight loss and resulted in faster recovery in treated hamsters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_3</DOCNO>
            	<TEXT>The treatment effect was observed within 24 hours, demonstrating faster onset as compared to IV COVI-AMG COVIDROPS has completed a Phase 1 safety and pharmacokinetic study in healthy volunteers and showed no safety concerns Phase 2 studies in outpatients who are asymptomatic or have mild COVID-19 disease is in process in the United Kingdom, Mexico and the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_4</DOCNO>
            	<TEXT>No concerning safety reports have been noted to date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_5</DOCNO>
            	<TEXT>Separate studies are planned in the US to compare COVIDROPS against EUA approved nAbs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_6</DOCNO>
            	<TEXT>COVIDROPS has the potential to be broadly deployable for early treatment in an outpatient setting and administered immediately upon detection COVIDROPS may be ideal as a treatment for children [https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a](https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a) READ THIS LINE AGAIN ONE MORE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_7</DOCNO>
            	<TEXT>No concerning safety reports have been noted to date. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_8</DOCNO>
            	<TEXT>https://covid201.com/COVID201](https://covid201.com/COVID201) A neutralizing antibody that someday you can go to CVS and pick it up and treat yourself at home.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_636_9</DOCNO>
            	<TEXT>Without going into a hospital or an Urgent Care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_0</DOCNO>
            	<TEXT>STI SARS-CoV-2 Spike RBD Protein Subunit Vaccine</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_1</DOCNO>
            	<TEXT>Strong protection against challenge by Delta VoC. Exposure of key neutralizing epitopes on the RBD to the immune system that are hidden in the closed whole spike protein conformation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_2</DOCNO>
            	<TEXT>Efficient induction of neutralizing antibodies by focusing the immune response to primary neutralizing epitopes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_3</DOCNO>
            	<TEXT>RBD is generally easier to produce (18x smaller than the spike trimer, much higher yields) compared to full size S protein.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_4</DOCNO>
            	<TEXT>Immune response to RBD may be sufficient to protect from disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_5</DOCNO>
            	<TEXT>Recombinant protein vaccine: use as booster vaccine, no interference by vector immunity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_6</DOCNO>
            	<TEXT>Stand-alone vaccine and potential universal booster strategy. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_7</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a](https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a) READ THIS LINE AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_8</DOCNO>
            	<TEXT>Stand-alone vaccine and potential universal booster strategy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_9</DOCNO>
            	<TEXT>Could Sorrento partner with big pharma and add STI SARS-CoV-2 Spike RBD Protein Subunit Vaccine to the booster arsenals?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_637_10</DOCNO>
            	<TEXT>We shall see...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_638_0</DOCNO>
            	<TEXT>THEY KEEP PATENTING AWAY!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_638_1</DOCNO>
            	<TEXT>United States Patent 11,174,314 Zhou , et al.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_638_2</DOCNO>
            	<TEXT>November 16, 2021 Anti-KRAS binding proteins Abstract The present disclosure provides anti-KRAS antibodies, and antigen-binding fragments thereof.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_638_3</DOCNO>
            	<TEXT>In certain embodiments, the anti-KRAS antibodies or fragments thereof, are used for the treatment of cancer. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_638_4</DOCNO>
            	<TEXT>https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2 amp;Sect2=HITOFF amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm amp;r=5081 amp;f=G amp;l=50 amp;d=PTXT amp;p=102 amp;S1=20211116 amp;OS=20211116 amp;RS=20211116](https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2 amp;Sect2=HITOFF amp;u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm amp;r=5081 amp;f=G amp;l=50 amp;d=PTXT amp;p=102 amp;S1=20211116 amp;OS=20211116 amp;RS=20211116)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_0</DOCNO>
            	<TEXT>I'M GOING TO PUT MY PUNCHING GLOVES ON!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_1</DOCNO>
            	<TEXT>Since I came to this board back in May 2020 I found two different types of investors on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_2</DOCNO>
            	<TEXT>Investors that realized Sorrento has the ability in becoming a big pharmaceutical company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_3</DOCNO>
            	<TEXT>And bashers and haters that would do anything to drive the stock down.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_4</DOCNO>
            	<TEXT>Lets call them the bashers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_5</DOCNO>
            	<TEXT>The bashers would stay up all night and day and work 24/7 to give you a thumbs down.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_6</DOCNO>
            	<TEXT>How do I know?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_7</DOCNO>
            	<TEXT>I've gotten more thumbs downs then anyone on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_8</DOCNO>
            	<TEXT>I've gotten more then 100 thumbs downs in 3 minutes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_9</DOCNO>
            	<TEXT>How can this happen?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_10</DOCNO>
            	<TEXT>Who is working behind the senses paying these people?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_11</DOCNO>
            	<TEXT>They stop you from posting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_12</DOCNO>
            	<TEXT>They delete your posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_13</DOCNO>
            	<TEXT>They delete your accounts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_14</DOCNO>
            	<TEXT>I've been called a paid pumpers hundreds of times.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_15</DOCNO>
            	<TEXT>Every time I hear that I'm being paid I know I'm doing something right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_16</DOCNO>
            	<TEXT>I know they hate me and bash me for telling you the facts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_17</DOCNO>
            	<TEXT>Where do I get my facts?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_18</DOCNO>
            	<TEXT>On the Sorrento website.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_19</DOCNO>
            	<TEXT>I copy and paste and highlight exactly what is being said.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_20</DOCNO>
            	<TEXT>I research and read and do my DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_21</DOCNO>
            	<TEXT>I narrow it down FOR YOU so you can see the positives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_22</DOCNO>
            	<TEXT>Today I posted two perfect posts that were deleted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_23</DOCNO>
            	<TEXT>Plus my account was deleted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_24</DOCNO>
            	<TEXT>It's not the first time and it probably will not be the last.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_25</DOCNO>
            	<TEXT>They stay up all night and get up early every morning looking for a fight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_26</DOCNO>
            	<TEXT>Well let me tell you something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_27</DOCNO>
            	<TEXT>I get up and fight every morning for every long term investor on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_28</DOCNO>
            	<TEXT>You can call me names and insult me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_29</DOCNO>
            	<TEXT>Delete me and thumbs down me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_30</DOCNO>
            	<TEXT>And It will not work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_31</DOCNO>
            	<TEXT>Do you know why?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_32</DOCNO>
            	<TEXT>Because I have a Sorrento family that spans across the entire United States and across the WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_33</DOCNO>
            	<TEXT>I became friends with many people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_34</DOCNO>
            	<TEXT>I've learned where everyone is from.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_35</DOCNO>
            	<TEXT>I plan to reach out to everyone of you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_36</DOCNO>
            	<TEXT>So we can plan a celebration someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_37</DOCNO>
            	<TEXT>We all want answers and we all want to make money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_38</DOCNO>
            	<TEXT>We hate losing money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_39</DOCNO>
            	<TEXT>But let me tell you something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_40</DOCNO>
            	<TEXT>If you all hold and stay strong and fight and unite.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_41</DOCNO>
            	<TEXT>We all will win!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_42</DOCNO>
            	<TEXT>Sorrento is a long term company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_43</DOCNO>
            	<TEXT>If you can't take the heat get the @#$% out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_44</DOCNO>
            	<TEXT>If you need to pay rent sell the stock and pay your rent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_45</DOCNO>
            	<TEXT>If you want to retire in 5 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_46</DOCNO>
            	<TEXT>Then I believe you're in the right place.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_47</DOCNO>
            	<TEXT>27 years ago I invest $30k in REGN that turned into $3M in 5 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_48</DOCNO>
            	<TEXT>Between COVID, CANCER, PAIN MANAGEMENT, and everything else.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_49</DOCNO>
            	<TEXT>Sorrento is a gold mine and you just need to have faith and believe that the best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_50</DOCNO>
            	<TEXT>Sorrento has the WBA and THEIR HUGE PIPELINE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_51</DOCNO>
            	<TEXT>You all have me in your corner as a fighter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_52</DOCNO>
            	<TEXT>And I will fight every morning every day and every night for you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_53</DOCNO>
            	<TEXT>To provide you with developments, news, and PRs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_54</DOCNO>
            	<TEXT>Every time they bash me I will hit back harder.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_55</DOCNO>
            	<TEXT>Long and strong and I have faith in the good lord to do the right thing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_639_56</DOCNO>
            	<TEXT>Thank you Robert S.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_0</DOCNO>
            	<TEXT>THE MISSION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_1</DOCNO>
            	<TEXT>Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_2</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_3</DOCNO>
            	<TEXT>The mission of NAMRU-3 is to ensure warfighter readiness through detecting, deterring, and responding to infectious disease threats through integration with partners throughout U.S. Africa Command (AFRICOM), Central Command (CENTCOM), and European Command (EUCOM) areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_4</DOCNO>
            	<TEXT>The purpose of this collaboration is to perform infectious disease research that guides the Department of Defense (DoD), informs public health policy of host nation partners, and improves medical readiness of the U.S. Armed Forces across NAMRU-3 areas of responsibility.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_5</DOCNO>
            	<TEXT>Through shared resources and logistical support, the overall goal of this research cooperation will be to conduct research on current, emerging and re-emerging infectious diseases, to enhance Force Health Protection, and provide critical data regarding countermeasures to mitigate infectious disease transmission including surveillance and product development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_6</DOCNO>
            	<TEXT>READ THAT LAST PARAGRAPH AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_7</DOCNO>
            	<TEXT>It's starts with the mission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_8</DOCNO>
            	<TEXT>Our US Armed Forces MISSION.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_9</DOCNO>
            	<TEXT>Our US Armed Forces are the BEST IN THE WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_10</DOCNO>
            	<TEXT>And don't you forget it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_11</DOCNO>
            	<TEXT>Continue reading please... [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) The initial focus of the collaboration will be to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostics and COVIDROPS/COVI-AMG outpatient neutralizing antibody treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_12</DOCNO>
            	<TEXT>We are enthusiastic about this opportunity to collaborate with NAMRU-3 to rapidly and efficiently evaluate and deploy our products in parts of the world where more effective solutions are desperately needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_13</DOCNO>
            	<TEXT>Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_14</DOCNO>
            	<TEXT>https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/covi-drops-in-patients-with-asymptomaticmild-covid-19-covid-19/) Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_15</DOCNO>
            	<TEXT>A previously completed safety study conducted in the US at doses up to 60 mg in healthy subjects showed a comparable safety profile to placebo with all reported adverse effects being mild in severity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_16</DOCNO>
            	<TEXT>The UK study will complement Phase 2 trials currently being started in the US and should the results of these studies demonstrate that COVIDROPS is both safe and effective against SARS-CoV-2, Sorrento will apply for Emergency Use Authorization in the US, UK, Canada, India, Mexico and European Union as well as other territories. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_17</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-dosing-covid-19-patients-phase-2-clinical) Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_18</DOCNO>
            	<TEXT>Read that last line again please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_19</DOCNO>
            	<TEXT>Just a SINGLE Intranasal Dose.... Just one 10 or 20 MG Dose. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_640_20</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12](https://clinicaltrials.gov/ct2/show/NCT04900428?term=sorrento amp;recrs=b amp;draw=2 amp;rank=12) Sorrento Therapeutics is on a MISSION and I believe they will be successful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_0</DOCNO>
            	<TEXT>After 100 days 100% response rate and there were no serious adverse events observed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_1</DOCNO>
            	<TEXT>In 2018, more than 67,000 drug overdose deaths occurred in the United States14 of which almost 47,000 (70%) were opioid-related.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_2</DOCNO>
            	<TEXT>Over 70% of the 70,630 deaths in 2019 involved an opioid.15 We are anxiously awaiting a new injectable gel formulation of dexamethasone and submission of data to the FDA for the treatment of radicular pain based on the results of a large, randomized, placebo-controlled, multi-center trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_3</DOCNO>
            	<TEXT>If approved by the FDA, SP-102 would be the first corticosteroid with an indication for epidural administration in the U.S., resulting in rapid pain relief and addressing safety issues with off-label steroid preparations.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_4</DOCNO>
            	<TEXT>SP-102 would be a welcome addition to the armamentarium of interventional pain physicians, providing a non-surgical, non-opioid alternative for a condition affecting millions of people, said Dr. Steven P. Cohen, Chief of Pain Medicine and Professor of Anesthesiology  amp; Critical Care Medicine, Neurology, Physical Medicine  amp; Rehabilitation, and Psychiatry  amp; Behavioral Sciences at the Johns Hopkins School of Medicine, and a Professor of Anesthesiology and Physical Medicine  amp; Rehabilitation at Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_5</DOCNO>
            	<TEXT>We believe that SP-102 could be the first FDA-approved epidural steroid gel injection product for patients suffering from this common, very painful condition, said Jaisim Shah, President and Chief Executive Officer of Scilex Holding Company. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_6</DOCNO>
            	<TEXT>https://www.scilexpharma.com/scilex-holding-company-a-sorrento-company-announces-complete-enrollment-on-non-opioid-injectable-sp-102-semdexa-phase-3-pivotal-trial-c-l-e-a-r-program-for-sciatica-pain-management/](https://www.scilexpharma.com/scilex-holding-company-a-sorrento-company-announces-complete-enrollment-on-non-opioid-injectable-sp-102-semdexa-phase-3-pivotal-trial-c-l-e-a-r-program-for-sciatica-pain-management/) PLEASE READ THIS PARAGRAPH AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_7</DOCNO>
            	<TEXT>READ WHAT THE RESULTS WERE IN THE PHASE 2 TRIAL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_8</DOCNO>
            	<TEXT>A Phase 2 trial to characterize the pharmacodynamics and safety of repeat dose SP-102 in subjects with lumbosacral radicular pain (sciatica), showed all subjects experienced rapid reduction of leg and back pain following an initial and repeat SP-102 injection treatment, with group median for average pain in the affected leg reduced by over 50% throughout 28 days (100% response rate).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_9</DOCNO>
            	<TEXT>The lack of cumulative effect and rapid resolution of hypothalamic-pituitary-adrenal (HPA) suppression suggests that consideration of HPA pharmacodynamics are not clinically relevant when making decisions regarding repeat dosing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_10</DOCNO>
            	<TEXT>There were no serious adverse events observed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_11</DOCNO>
            	<TEXT>After 100 days 100% response rate and there were no serious adverse events observed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_12</DOCNO>
            	<TEXT>This is probably why DR JI wanted everyone to VOTE YES for #5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_641_13</DOCNO>
            	<TEXT>He must now the results are so great that he should be paid handsomely.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_642_0</DOCNO>
            	<TEXT>I own the oldest bottle of Johnny Walker Black that's never been opened.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_643_0</DOCNO>
            	<TEXT>It was bottled in 1926.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_643_1</DOCNO>
            	<TEXT>Six years aged when it was bottled.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_643_2</DOCNO>
            	<TEXT>Still wrapped in the cardboard paper wrapping.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_643_3</DOCNO>
            	<TEXT>Which make this 101 year old Whiskey.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_643_4</DOCNO>
            	<TEXT>Who would like to tell me what the value of the oldest bottle of JWB unopened is worth?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_644_0</DOCNO>
            	<TEXT>It was bottled in Scotland and bootlegged through Quebec.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_645_0</DOCNO>
            	<TEXT>In 1926 it sold for $5.15</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_646_0</DOCNO>
            	<TEXT>$35K IS THE STARTING BID.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_647_0</DOCNO>
            	<TEXT>I own the oldest bottle of Johnny Walker Black that's never been opened.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_647_1</DOCNO>
            	<TEXT>This is the oldest bottle of JWB that's never been opened that exists in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_647_2</DOCNO>
            	<TEXT>101 years old and I may open it at the Sorrento Celebration party.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_648_0</DOCNO>
            	<TEXT>Starting bid in an auction $50k</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_649_0</DOCNO>
            	<TEXT>HOW MUCH IS MY 101 YEAR OLD BOTTLE OF JOHNNY WALKER BLACK WORTH?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_650_0</DOCNO>
            	<TEXT>Of course I know that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_650_1</DOCNO>
            	<TEXT>But it's a 101 year old bottle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_651_0</DOCNO>
            	<TEXT>Never been opened</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_652_0</DOCNO>
            	<TEXT>Be careful on the other board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_652_1</DOCNO>
            	<TEXT>They love to bait members.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_653_0</DOCNO>
            	<TEXT>Be careful with the other board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_653_1</DOCNO>
            	<TEXT>They're thrive on baiting members.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_653_2</DOCNO>
            	<TEXT>They want you to lose it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_653_3</DOCNO>
            	<TEXT>At this point there only interested in making money on all of the advertisements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_653_4</DOCNO>
            	<TEXT>If you're not driving the same speed as them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_653_5</DOCNO>
            	<TEXT>They will sideswipe you off your road.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_654_0</DOCNO>
            	<TEXT>License to enable deployment of COVISTIX in Latin America</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_654_1</DOCNO>
            	<TEXT>License to enable deployment of COVISTIX in Latin America ANVISA issued COVISTIX with GMP approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_654_2</DOCNO>
            	<TEXT>This license will enable rapid commercial deployment in Brazil and other Latin American nations with strong linkages to the Brazilian market. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_654_3</DOCNO>
            	<TEXT>https://biopharmajournal.com/2021/11/17/sorrento-therapeutics-inc-nasdaq-srne-receives-gmp-approval-for-covistix-from-anvisa/](https://biopharmajournal.com/2021/11/17/sorrento-therapeutics-inc-nasdaq-srne-receives-gmp-approval-for-covistix-from-anvisa/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_655_0</DOCNO>
            	<TEXT>FORM 8-K FILING</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_655_1</DOCNO>
            	<TEXT>[https://investors.sorrentotherapeutics.com/static-files/dd7b2d7d-8b54-4ae6-a304-e7c03c295b1e](https://investors.sorrentotherapeutics.com/static-files/dd7b2d7d-8b54-4ae6-a304-e7c03c295b1e)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_0</DOCNO>
            	<TEXT>Business Director/Executive Business Director- West Coast (San Diego) Which antibody-drug?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_1</DOCNO>
            	<TEXT>This position will require a strong ability to work independently in the field with a sophisticated Antibody Drug Conjugates customer base and coordinate with internal personnel to craft business solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_2</DOCNO>
            	<TEXT>WHAT WE ARE LOOKING FOR: We are looking for enthusiastic and talented individuals who thrive on challenge and change, who can roll up their sleeves, put on multiple hats and have a can-do attitude without a lot of oversight or instruction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_3</DOCNO>
            	<TEXT>The successful candidate will build and develop a sales opportunities in an assigned geography for the US, exhibit territory management skills, have demonstrated a strong understanding of and use of data and have documented solid performance in sales, and cross functional partnerships/influence capabilities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_4</DOCNO>
            	<TEXT>The incumbent will have the overall responsibility of meeting with clients, attending conferences, networking event generate RFP with the ultimate goal of converting opportunity to revenues.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_5</DOCNO>
            	<TEXT>This position will require a strong ability to work independently in the field with a sophisticated Antibody Drug Conjugates customer base and coordinate with internal personnel to craft business solutions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_6</DOCNO>
            	<TEXT>Tracking and timely record keeping using a CRM is essential to meet corporate overall objectives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_7</DOCNO>
            	<TEXT>Specifically, the Business Development Associate is responsible for effectively working in their assigned geography to maximize awareness and sales results of promoted products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_8</DOCNO>
            	<TEXT>The Business Development Associate will engage key new opportunities with a well-defined space that align with our capabilities in Drug Discovery and Develop focused on ADC and Fill and Finish opportunities that align with our capabilities, These areas of responsibility will include High-Potency compounds, Imaging agents, Aseptic , Non-Aseptic as well as.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_9</DOCNO>
            	<TEXT>These activities will include cold calls and face to face discussions to promote assigned product(s), maximize the product(s) selling potential, meet program objectives, and deliver revenues in an assigned area and contribute to the achievement of the Companys revenue goals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_10</DOCNO>
            	<TEXT>So let's read this again and try to figure out which new DRUG DISCOVERY there talking about.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_11</DOCNO>
            	<TEXT>The Business Development Associate will engage key new opportunities with a well-defined space that align with our capabilities in Drug Discovery and Develop focused on ADC and Fill and Finish opportunities that align with our capabilities, These areas of responsibility will include High-Potency compounds, Imaging agents, Aseptic , Non-Aseptic as well as.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_12</DOCNO>
            	<TEXT>These activities will include cold calls and face to face discussions to promote assigned product(s), maximize the product(s) selling potential, meet program objectives, and deliver revenues in an assigned area and contribute to the achievement of the Companys revenue goals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_13</DOCNO>
            	<TEXT>So let's narrow it down some more... So these activities will include High-Potency compounds, Imaging agents, Aseptic , Non-Aseptic as well as.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_14</DOCNO>
            	<TEXT>These activities will include cold calls and face to face discussions to promote assigned product(s), maximize the product(s) selling potential, meet program objectives, and deliver revenues in an assigned area and contribute to the achievement of the Companys revenue goals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_15</DOCNO>
            	<TEXT>We're getting closer... Face to face discussions to promote assigned product(s), maximize the product(s) selling potential, meet program objectives, and deliver revenues in an assigned area and contribute to the achievement of the Companys revenue goals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_656_16</DOCNO>
            	<TEXT>Product(S) plural Multiple products I assume?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_657_0</DOCNO>
            	<TEXT>I love how they (S) as in plural for the products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_657_1</DOCNO>
            	<TEXT>I assume that means there's more than one.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_0</DOCNO>
            	<TEXT>Time to take of the gloves and get deadly serious about shorting Sorrento anymore.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_1</DOCNO>
            	<TEXT>There's many other stocks that are better to short.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_2</DOCNO>
            	<TEXT>Take a look at Disney stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_3</DOCNO>
            	<TEXT>They announced that kids 5 and up must be vaccinated to go on the Disney Cruise Ships.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_4</DOCNO>
            	<TEXT>Soon all so the parks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_5</DOCNO>
            	<TEXT>With another wave of COVID-19 unvaxed families will most likely not go to Disney.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_6</DOCNO>
            	<TEXT>My advice to the shorts on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_7</DOCNO>
            	<TEXT>Time for you to find another better stock to short.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_8</DOCNO>
            	<TEXT>We're holding steady and it's a long weekend and Sorrento is long overdue with an update from DARPA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_9</DOCNO>
            	<TEXT>DARPA last year in November gave Sorrento $34M. Two fully fund two P2 trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_10</DOCNO>
            	<TEXT>Wouldn't it be great if we get the PR on Friday in the AH?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_11</DOCNO>
            	<TEXT>What's up DR JI sleeve?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_12</DOCNO>
            	<TEXT>He's gonna take his gloves off and fight for the reason why he should of gotten those Scilex shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_13</DOCNO>
            	<TEXT>He's gonna show everyone why we deserved them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_14</DOCNO>
            	<TEXT>It's Thanksgiving Weekend after that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_15</DOCNO>
            	<TEXT>I remember last year we were trading in the $15 range then.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_16</DOCNO>
            	<TEXT>I believe we will be again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_17</DOCNO>
            	<TEXT>I believe DISNEY will start to crash.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_18</DOCNO>
            	<TEXT>You're better off shorting Disney.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_19</DOCNO>
            	<TEXT>Take this advice as great advice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_20</DOCNO>
            	<TEXT>I'm sure you'll be back again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_659_21</DOCNO>
            	<TEXT>But now is the time to leave.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_660_0</DOCNO>
            	<TEXT>I said remember last year when we were trading at $15.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_660_1</DOCNO>
            	<TEXT>We will again</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_661_0</DOCNO>
            	<TEXT>I believe DR JI has a different plan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_661_1</DOCNO>
            	<TEXT>I don't see him selling anything.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_661_2</DOCNO>
            	<TEXT>Partnering maybe but no selling.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_662_0</DOCNO>
            	<TEXT>I just noticed the I misspelled the heading.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_662_1</DOCNO>
            	<TEXT>Time to take off the gloves!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_0</DOCNO>
            	<TEXT>SUMMARY OF THE INVENTION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_1</DOCNO>
            	<TEXT>The invention provides antibodies that specifically bind to KRAS, including human KRAS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_2</DOCNO>
            	<TEXT>BACKGROUND OF THE INVENTION The KRAS gene (also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), encodes a 2.1-kDa small protein that is activated transiently in response to extracellular stimuli or signals such as growth factors, cytokines, and hormones via cell surface receptors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_3</DOCNO>
            	<TEXT>The RAS proteins are guanine nucleotide binding molecules that play key roles in signal transduction as molecular switches, mediated through two switch regions displaying conformational differences between active (GTP bound) and inactive (GDP bound) states.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_4</DOCNO>
            	<TEXT>Most of the RAS effectors bind to these RAS switch regions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_5</DOCNO>
            	<TEXT>The protein product of the KRAS gene performs an essential function in normal tissue signaling, where the mutation of a KRAS gene is an essential step in the development of many cancers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_6</DOCNO>
            	<TEXT>The RAS oncogenes (1-IRAS, NRAS and KRAS) comprise the most frequently mutated class of oncogenes in human cancers (33%), stimulating intensive effort in developing anti-RAS inhibitors for cancer treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_7</DOCNO>
            	<TEXT>RAS is an important target in cell transformation, being involved in cell proliferation and differentiation and cell survival through activation of PI3K. Aside from a few rare exceptions, mutationally activated Ras proteins found in human cancers result predominantly from one of three single point mutations at residues G12, G13, or Q61.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_8</DOCNO>
            	<TEXT>Oncogenic substitution of G12 or G13 leads to constitutive activation of Ras by creating steric hindrance that prevents the formation of van der Waals interactions between Ras and RasGAPS (Scheffzek et al (1997) Science 277, 333-338).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_9</DOCNO>
            	<TEXT>Abstract The present disclosure provides anti-KRAS antibodies, and antigen-binding fragments thereof.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_10</DOCNO>
            	<TEXT>In certain embodiments, the anti-KRAS antibodies or fragments thereof, are used for the treatment of cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_11</DOCNO>
            	<TEXT>Sorrento on November 16th received a new patent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_12</DOCNO>
            	<TEXT>Does everyone know how important it is?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_13</DOCNO>
            	<TEXT>Well if you research the MAYO CLINIC and check to see how many clinical trials are being conducted using anti-KRAS antibodies, and antigen-binding fragments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_14</DOCNO>
            	<TEXT>There's only ONE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_15</DOCNO>
            	<TEXT>Here is the link. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_16</DOCNO>
            	<TEXT>https://www.mayoclinic.org/search/search-results?q=anti-KRAS%20antibodies%2C%20and%20antigen-binding%20fragments amp;topics=Clinical%20Trials](https://www.mayoclinic.org/search/search-results?q=anti-KRAS%20antibodies%2C%20and%20antigen-binding%20fragments amp;topics=Clinical%20Trials) Here is the patent info. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_17</DOCNO>
            	<TEXT>https://uspto.report/patent/grant/11,174,314](https://uspto.report/patent/grant/11,174,314) Sorrento Secures Exclusive License From Mayo Clinic for Antibody-Drug-Nanoparticle Albumin-Bound Immune Complex (ADNIC) Platform. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_18</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-secures-exclusive-license-mayo-clinic-antibody-drug](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-secures-exclusive-license-mayo-clinic-antibody-drug) I believe Sorrento will partner with the MAYO clinic to help develop the next generation of Cancer drugs using this patent invention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_19</DOCNO>
            	<TEXT>The MAYO clinic knows exactly what there doing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_20</DOCNO>
            	<TEXT>They know there's lots of potential partnering with Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_21</DOCNO>
            	<TEXT>This will be another huge opportunity for Sorrento to advance this patent invention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_22</DOCNO>
            	<TEXT>Or Sorrento could choose to partner with Mount Sinai, University of Texas A  amp; M, Columbia, and many others that want to advance this invention.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_23</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_24</DOCNO>
            	<TEXT>I've been saying it from day one.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_25</DOCNO>
            	<TEXT>Sorrento is a long term investment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_26</DOCNO>
            	<TEXT>You can't look at this past year and say what did they do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_27</DOCNO>
            	<TEXT>Look at what they can do in the the next year and after and after.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_28</DOCNO>
            	<TEXT>Sorrento has multiple great results that will be read out very soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_29</DOCNO>
            	<TEXT>Those results will propel Sorrento to the next level creating revenue in the future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_30</DOCNO>
            	<TEXT>That revenue will be used to develop the next and newest and the best next generation of Cancer drugs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_31</DOCNO>
            	<TEXT>In 5 years Sorrento could be valued at $200B as DR JI predicted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_663_32</DOCNO>
            	<TEXT>Have a great weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_0</DOCNO>
            	<TEXT>We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_1</DOCNO>
            	<TEXT>Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to the immune system.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_2</DOCNO>
            	<TEXT>Our approach to cancer therapy is based on the belief that patients will require a multimodal, multipronged approach targeting a single or diverse set of cellular targets and attacking those on several fronts simultaneously or sequentially, frequently and relentlessly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_3</DOCNO>
            	<TEXT>Our approach to fighting cancer is made possible by a unique immuno-oncology (I-O) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (G-MAB) that can be used on their own or incorporated into cancer-targeting approaches including: These assets are complemented by an innovative lymphatic targeting device (Sofusa) designed to deliver antibodies into the lymphatic system, where immune cells are trained to fight cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_4</DOCNO>
            	<TEXT>We have generated human antibodies against many targets important in cancer treatment, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, and many other targets, which are at various stages of development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_5</DOCNO>
            	<TEXT>Our CAR-T programs include clinical stage CD38 CAR T. Therapies that combine approaches are in preclinical stage evaluation for multiple myeloma, lung cancer, and other adult and pediatric cancers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_6</DOCNO>
            	<TEXT>CAR T (Chimeric Antigen Receptor T Cells) therapy which modifies a patients own T-cells to kill their tumor DAR T (Dimeric Antigen Receptor T Cells) therapy which modifies a healthy donors T-cells to be reactive to any patients tumor, allowing for an off the shelf treatment of a patients tumor Antibody-Drug Conjugates (ADCs), and Oncolytic Virus programs (Seprehvir, Seprehvec) Our unique portfolio of I-O platform assets is unrivaled in the industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_7</DOCNO>
            	<TEXT>It includes immune checkpoint inhibitors, bispecific antibodies, antibody-drug conjugates (ADCs) as well as chimeric antigen receptor (CAR) and dimeric antigen receptor (DAR) based cellular therapies, and most recently weve added oncolytic viruses (Seprehvir, Seprehvec).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_8</DOCNO>
            	<TEXT>Each asset individually shows great promise; put together we feel they have the potential to break through the most difficult cancer challenges Dr. Henry Ji, CEO Good morning everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_9</DOCNO>
            	<TEXT>I hope everyone had a great weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_10</DOCNO>
            	<TEXT>Just a reminder last year on November 27th Sorrento received $34M from DARPA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_11</DOCNO>
            	<TEXT>The one year mark is approaching and I believe we may be receiving an update on the progress of the two P2 TRIALS DARPA funded.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_12</DOCNO>
            	<TEXT>Remember if the results are good DARPA promised to further fund the trials.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_13</DOCNO>
            	<TEXT>Please take the time to click and read. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_14</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) Between Cancer treatments and COVID-19 treatments something will make the needle move.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_664_15</DOCNO>
            	<TEXT>We all need to relax and to prepare to be with our families this Thanksgiving.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_665_0</DOCNO>
            	<TEXT>Have a happy Thanksgiving weekend to everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_666_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market VIVA EL MEXICO....https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_666_1</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market VIVA EL MEXICO....[https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_667_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market VIVA EL MEXICO....https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_668_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market VIVA EL MEXICO....https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_669_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market VIVA EL MEXICO....https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_670_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market VIVA EL MEXICO....https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_671_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Mexico Executes Contract for Sale of 5 Million COVI-STIX Tests for Mexico Market VIVA EL MEXICO....https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_672_0</DOCNO>
            	<TEXT>Let's get this party started.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_673_0</DOCNO>
            	<TEXT>This sale pretty much will increase their revenue 100% from the 3Q</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_674_0</DOCNO>
            	<TEXT>They committed to buy 5 million covid stix that's what it says and their being distributed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_0</DOCNO>
            	<TEXT>Oncolytic Virotherapy Market: Global Industry Overview by Size, Share, Trends, Top Manufacturers, Segments and Forecasts Research 2029.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_1</DOCNO>
            	<TEXT>Sorrento Therapeutics, Inc. (NASDAQ: SRNE).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_2</DOCNO>
            	<TEXT>Nov 23, 2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_3</DOCNO>
            	<TEXT>Nov 23, 2021 (AmericaNewsHour) -- Research Nester released a report titled "Oncolytic Virotherapy Market: Global Demand Analysis  amp; Opportunity Outlook 2029"which delivers detailed overview of the oncolytic virotherapy market in terms of market segmentation by cancer type, application and region.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_4</DOCNO>
            	<TEXT>Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_5</DOCNO>
            	<TEXT>The oncolytic virotherapy marketis projected to grow with a high CAGR during the forecast period, i.e., 2021-2029 on account of the increase in research and development on cancer treatment using oncolytic virotherapy and the rising prevalence of cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_6</DOCNO>
            	<TEXT>According to the data collected from International Agency for Research on Cancer (IARC), in 2020, the projected new cases and deaths from cancer globally were 19.3 million and 10 million, respectively.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_7</DOCNO>
            	<TEXT>The market is segmented by cancer type into melanoma, prostate cancer, breast cancer, ovarian cancer and others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_8</DOCNO>
            	<TEXT>Among these, the breast cancer segment is anticipated to hold the largest share by the end of 2021 in the oncolytic virotherapy marketas it is the most common kind of cancer worldwide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_9</DOCNO>
            	<TEXT>It is also gaining worldwide recognition for having increased treatment efficacy for advanced breast cancer and thus, provides a unique platform for personalized treatments in such patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_10</DOCNO>
            	<TEXT>On the basis of application, the market is divided into general medical  amp; surgical hospitals, speciality hospitals, clinics, and others.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_11</DOCNO>
            	<TEXT>On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East  amp; Africa, out of which, the oncolytic virotherapy market in the Asia Pacific is projected to grow at the highest CAGR throughout the forecast period.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_12</DOCNO>
            	<TEXT>Currently, the market in North America holds the largest share.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_13</DOCNO>
            	<TEXT>This can be attributed to the presence of leading healthcare providers in the region, especially in the United States, who are extensively involved in the research and development for innovative cancer treatment procedures.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_14</DOCNO>
            	<TEXT>Increasing Prevalence of Cancer and Increased Research and Development on Cancer Treatment using Oncolytic Virotherapy According to International Agency for Research on Cancer (IARC), it is projected that by 2040, the number of new cancer cases per year is likely to rise to 29.5 million and the number of cancer related deaths to 16.4 million.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_15</DOCNO>
            	<TEXT>Unhealthy lifestyle is one of the most predominant risk factors for any kind of cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_16</DOCNO>
            	<TEXT>It has been observed that individuals who consume tobacco or alcohol on a regular basis possess a high risk of having cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_17</DOCNO>
            	<TEXT>Additionally, the increased focus on research for cancer treatment in recent years is also expected to boost the market growth in upcoming years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_18</DOCNO>
            	<TEXT>However, a number of oncolytic virotherapy treatments are currently in clinical trial phase and along with this, there is a lack of awareness about the disease in low income economies which is estimated to restrain market growth in the near future.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_676_19</DOCNO>
            	<TEXT>This report also provides the existing competitive scenario of some of the key players of the oncolytic virotherapy market which includes company profiling of Amgen, Inc. (NASDAQ: AMGN), Oncolytics Biotech (TSE: ONC), Viralytics Ltd., Transgene SA (EPA; TNG), Shanghai Sunway Biotech Co. Ltd., Replimune Group, Inc., Sorrento Therapeutics, Inc. (NASDAQ: SRNE), SillaJen, Inc., and Oncorus, Inc. [https://www.marketwatch.com/press-release/oncolytic-virotherapy-market-global-industry-overview-by-size-share-trends-top-manufacturers-segments-and-forecasts-research-2029-2021-11-23?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/oncolytic-virotherapy-market-global-industry-overview-by-size-share-trends-top-manufacturers-segments-and-forecasts-research-2029-2021-11-23?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_677_0</DOCNO>
            	<TEXT>Isn't funny how the bashers have been say oh there's no sales no sales.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_677_1</DOCNO>
            	<TEXT>Then they post a contract to sell 5 million.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_677_2</DOCNO>
            	<TEXT>Then they try and find another reason to say well there's another issue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_677_3</DOCNO>
            	<TEXT>WHEN YOU SIGN A CONTRACT TO BUY SOMETHING YOU OWN IT!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_677_4</DOCNO>
            	<TEXT>Weather you get 10 tests today or 4,999,990 kits next year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_677_5</DOCNO>
            	<TEXT>Does not matter you sign on the dotted line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_677_6</DOCNO>
            	<TEXT>YOU OWN IT!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_0</DOCNO>
            	<TEXT>Isn't funny how the bashers have been saying oh there's no sales.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_1</DOCNO>
            	<TEXT>Then they post a contract to sell 5 million COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_2</DOCNO>
            	<TEXT>Then they try and find another reason to say well there's another issue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_3</DOCNO>
            	<TEXT>WHEN YOU SIGN A CONTRACT TO BUY SOMETHING YOU OWN IT!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_4</DOCNO>
            	<TEXT>When you sign on the dotted line you own it!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_5</DOCNO>
            	<TEXT>[https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-mexico-executes-contract-sale-5-million) The COVI-STIX test was the test of choice during the 59th World Boxing Council Convention in Mexico City this past week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_6</DOCNO>
            	<TEXT>When you sign on the dotted line to buy a car and the dealer tells you in three weeks we will have the car.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_7</DOCNO>
            	<TEXT>YOU OWN IT!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_8</DOCNO>
            	<TEXT>Executing a contract means you own it!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_9</DOCNO>
            	<TEXT>You can't go back and say I don't want them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_10</DOCNO>
            	<TEXT>The reason why you wouldn't want to buy them all once is because of space needed to store them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_11</DOCNO>
            	<TEXT>Remember when you buy something the more you buy the bigger the discount.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_12</DOCNO>
            	<TEXT>Here's some food for thought.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_13</DOCNO>
            	<TEXT>Once you buy something and you run out what do you do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_14</DOCNO>
            	<TEXT>You reorder them again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_15</DOCNO>
            	<TEXT>How many do you buy?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_16</DOCNO>
            	<TEXT>The same amount or more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_17</DOCNO>
            	<TEXT>Covid-19 has been estimated to be around until 2028.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_18</DOCNO>
            	<TEXT>Who ever this purchaser is will most likely will be reordering more and more and more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_678_19</DOCNO>
            	<TEXT>One nice executed contract in the books!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_679_0</DOCNO>
            	<TEXT>What is an Executed Contract?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_679_1</DOCNO>
            	<TEXT>An executed contract is a signed contract that establishes a contractual relationship between two or more parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_679_2</DOCNO>
            	<TEXT>Once the contract is fully signed, each party agrees to uphold the legal obligations they agreed on within the written agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_679_3</DOCNO>
            	<TEXT>While an executed contract can refer to an agreement between two or more parties with signatures, it can also refer to a contract that has not only been agreed upon but has also been fulfilled.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_679_4</DOCNO>
            	<TEXT>Both definitions are legally valid and can be used in either context.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_680_0</DOCNO>
            	<TEXT>What is an Executed Contract?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_680_1</DOCNO>
            	<TEXT>An executed contract is a signed contract that establishes a contractual relationship between two or more parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_680_2</DOCNO>
            	<TEXT>Once the contract is fully signed, each party agrees to uphold the legal obligations they agreed on within the written agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_680_3</DOCNO>
            	<TEXT>While an executed contract can refer to an agreement between two or more parties with signatures, it can also refer to a contract that has not only been agreed upon but has also been fulfilled.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_680_4</DOCNO>
            	<TEXT>Both definitions are legally valid and can be used in either context.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_681_0</DOCNO>
            	<TEXT>What is an Executed Contract?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_681_1</DOCNO>
            	<TEXT>An executed contract is a signed contract that establishes a contractual relationship between two or more parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_681_2</DOCNO>
            	<TEXT>Once the contract is fully signed, each party agrees to uphold the legal obligations they agreed on within the written agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_681_3</DOCNO>
            	<TEXT>While an executed contract can refer to an agreement between two or more parties with signatures, it can also refer to a contract that has not only been agreed upon but has also been fulfilled.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_681_4</DOCNO>
            	<TEXT>Both definitions are legally valid and can be used in either context.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_682_0</DOCNO>
            	<TEXT>You sign for it you own it!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_683_0</DOCNO>
            	<TEXT>Contracts are negotiated based on how many you're going to purchase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_683_1</DOCNO>
            	<TEXT>The contract is based on a sale of 5M.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_0</DOCNO>
            	<TEXT>5M EXECUTED CONTRACT MEANS THEY WILL PURCHASE 5M EVENTUALLY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_1</DOCNO>
            	<TEXT>What Is a Quantity Discount?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_2</DOCNO>
            	<TEXT>A quantity discount is an incentive offered to a buyer that results in a decreased cost per unit of goods or materials when purchased in greater numbers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_3</DOCNO>
            	<TEXT>A quantity discount is often offered by sellers to entice customers to purchase in larger quantities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_4</DOCNO>
            	<TEXT>The seller is able to move more goods or materials, and the buyer receives a more favorable price for them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_5</DOCNO>
            	<TEXT>At the consumer level, a quantity discount can appear as a BOGO (buy one, get one discount) or other incentives, such as buy two, get one free.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_6</DOCNO>
            	<TEXT>KEY TAKEAWAYS A quantity discount is an incentive offered to buyers that results in a decreased cost per unit of goods or materials when purchased in greater numbers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_7</DOCNO>
            	<TEXT>Enticing buyers to purchase in bulk enables sellers to increase their units per transaction (UPT), lower their inventories, and potentially reduce per-unit costs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_8</DOCNO>
            	<TEXT>Discounts can have an adverse impact on profit per unit, also known as the marginal profit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_9</DOCNO>
            	<TEXT>An alternative to quantity discount is linear pricing: charging the same price regardless of how many items the customer buys.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_10</DOCNO>
            	<TEXT>How a Quantity Discount Works Retailers often get better deals if they order more of the same item.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_11</DOCNO>
            	<TEXT>For example, the cost per unit for t-shirts might be $7.50 per unit if less than 48 pieces are ordered; $7.25 per unit if 49-72 pieces are ordered; or $7 per unit if 73 or more pieces are ordered.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_12</DOCNO>
            	<TEXT>Depending on the quantity discount, all pieces ordered must be delivered and paid for by a certain date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_13</DOCNO>
            	<TEXT>Alternatively, the purchases and payments can be spread out over a specified period of time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_14</DOCNO>
            	<TEXT>By selling in larger quantities, the seller can increase their revenues per transaction (RPT).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_15</DOCNO>
            	<TEXT>The vendor can also scale quantity discounts in "steps," with lower per-unit prices at higher quantities to encourage bulk buyers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_16</DOCNO>
            	<TEXT>For instance, a coat maker that employs "steps" in its pricing strategy could offer coats at $20 each, five for $90, and 10 for $160.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_17</DOCNO>
            	<TEXT>The executed contract was based on purchasing 5M COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_18</DOCNO>
            	<TEXT>Don't let the bashers tell you something different.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_19</DOCNO>
            	<TEXT>This was great news yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_20</DOCNO>
            	<TEXT>I'm expecting more and more contracts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_21</DOCNO>
            	<TEXT>Sales move needles!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_22</DOCNO>
            	<TEXT>I only see Sorrento going in one direction now and it's UP!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_684_23</DOCNO>
            	<TEXT>Have a Happy Thanksgiving everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_685_0</DOCNO>
            	<TEXT>With every contract there's a expiration date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_685_1</DOCNO>
            	<TEXT>They must purchase them by a certain date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_685_2</DOCNO>
            	<TEXT>And they must deliver them by a certain date.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_0</DOCNO>
            	<TEXT>HAPPY THANKSGIVING</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_1</DOCNO>
            	<TEXT>Many of us have had a challenging year with illness, loss, uncertain employment, and isolation due to COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_2</DOCNO>
            	<TEXT>Thanksgiving is centered on giving thanks for what we have and the special people in our lives.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_3</DOCNO>
            	<TEXT>Its a time to catch up with loved ones, sit around the table and share one of the most delicious meals of the year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_4</DOCNO>
            	<TEXT>Who doesnt love endless stuffing and slices of pie?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_5</DOCNO>
            	<TEXT>Whether you are near or far from your loved ones this Thanksgiving, there are so many ways to share just how much you care with these thoughtful Thanksgiving wishes and messages for everyone in your life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_6</DOCNO>
            	<TEXT>One of my way's is to post on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_7</DOCNO>
            	<TEXT>Everyone on this board is a part of my family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_8</DOCNO>
            	<TEXT>Last week I asked a simple question.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_9</DOCNO>
            	<TEXT>How far does this board reach around the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_10</DOCNO>
            	<TEXT>In 48 hours I had over 100 replies from investors from 35 different US states and 16 different Countries.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_11</DOCNO>
            	<TEXT>I would like to say Thank you for your support and I wish you all the best and warmest Thanksgiving ever.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_12</DOCNO>
            	<TEXT>Covid-19 infected over 146.6 million people with 5,187,496 death's since the pandemic started.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_13</DOCNO>
            	<TEXT>Let's all give thanks this year for our health and let's cherish life as we live it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_686_14</DOCNO>
            	<TEXT>May God Bless You All.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_0</DOCNO>
            	<TEXT>WHO IS EDUARDO ROCHA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_1</DOCNO>
            	<TEXT>Natcofarma Do Brasil ring a bell?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_2</DOCNO>
            	<TEXT>Mr Eduardo Rocha works for Sorrento Therapeutics as the international advisor to Latam.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_3</DOCNO>
            	<TEXT>He's also the executive director of Natcofarma Do Brasil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_4</DOCNO>
            	<TEXT>Latam - is short for Latin America Natcofarma Brasil, a subsidiary of the Indian Natcopharma Limited, sells affordable medicines that meet global quality standards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_5</DOCNO>
            	<TEXT>Its objective is to introduce generic medicines to the Brazilian market, mainly aimed at cancer treatments, rare diseases and primary care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_6</DOCNO>
            	<TEXT>Natcofarma has laboratories equipped with state-of-the-art equipment operated by teams of highly qualified researchers and scientists to develop and launch revolutionary generics, the result of continuous investment in innovation and research.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_7</DOCNO>
            	<TEXT>This entire structure serves the purpose of providing affordable medicines to the population.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_8</DOCNO>
            	<TEXT>They have 140 Approved Patents.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_9</DOCNO>
            	<TEXT>8 Factories in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_10</DOCNO>
            	<TEXT>Two Research Centers. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_11</DOCNO>
            	<TEXT>https://natcofarma.com/](https://natcofarma.com/) Mr Eduardo Rocha went on Sorrento's payroll on May 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_12</DOCNO>
            	<TEXT>The same time DR JI announced they had a cure for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_13</DOCNO>
            	<TEXT>Natcofarma is one of the largest pharmaceutical companies in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_14</DOCNO>
            	<TEXT>So why would they hire him?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_15</DOCNO>
            	<TEXT>He's been the executive director of Natcofarma since April 2019.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_16</DOCNO>
            	<TEXT>I believe when ABIVERTINAB releases the results from Brazil and they ask for an EUA Natcofarma will be the partner and distributor in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_17</DOCNO>
            	<TEXT>They will also help to distribute COVISTIX throughout Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_18</DOCNO>
            	<TEXT>You can research and read for yourselves Mr Eduardo Rocha on Linkedin.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_19</DOCNO>
            	<TEXT>He's been on Sorrento's team since they announced the CURE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_687_20</DOCNO>
            	<TEXT>This is no coincidence and I believe he will help Sorrento into Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_688_0</DOCNO>
            	<TEXT>WHO IS EDUARDO ROCHA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_688_1</DOCNO>
            	<TEXT>Natcofarma Do Brasil ring a bell?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_689_0</DOCNO>
            	<TEXT>Rest up and feel better.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_689_1</DOCNO>
            	<TEXT>Have a Happy Thanksgiving.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_690_0</DOCNO>
            	<TEXT>Yes it is we need to spread the word that we believe we have found our partners in Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_690_1</DOCNO>
            	<TEXT>Have a Happy Thanksgiving.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_691_0</DOCNO>
            	<TEXT>Listen this info on Eduardo Rocha is to good to keep for ourselves.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_691_1</DOCNO>
            	<TEXT>Why don't you release it on r/SRNE and tell them where you got it from.. Have a HTG.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_692_0</DOCNO>
            	<TEXT>Who will be the 400th member to have joined our board?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_692_1</DOCNO>
            	<TEXT>In 3 months we built a community of 400 Sorrentino's.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_693_0</DOCNO>
            	<TEXT>Check this out on Eduardo Rocha Linkedin LOOK AT HIS FAVORITE INTERESTS ARE... https://www.linkedin.com/company/apexbrasil/</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_694_0</DOCNO>
            	<TEXT>About The Brazilian Trade and Investment Promotion Agency (Apex-Brasil) works to promote Brazilian products and services abroad, and to attract foreign investment to strategic sectors of the Brazilian economy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_694_1</DOCNO>
            	<TEXT>Apex-Brasil organizes several initiatives aiming to promote Brazilian exports abroad.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_694_2</DOCNO>
            	<TEXT>The Agencys efforts comprise trade and prospective missions, business rounds, support for the participation of Brazilian companies in major international trade fairs, arrangement of technical visits of foreign buyers and opinion makers to learn about the Brazilian productive structure, and other select activities designed to strengthen the countrys branding abroad.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_694_3</DOCNO>
            	<TEXT>Apex-Brasil also plays a leading role in attracting foreign direct investment (FDI) to Brazil, by working to identify business opportunities, promoting strategic events and lending support to foreign investors willing to allocate resources in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_695_0</DOCNO>
            	<TEXT>Since May of 2020 they were working on approving and distributing in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_695_1</DOCNO>
            	<TEXT>Behind the scenes without anyone knowing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_0</DOCNO>
            	<TEXT>WHO IS ADMIRAL PAUL PEARIGEN MD ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_1</DOCNO>
            	<TEXT>PLEASE CONTINUE TO READ BELOW TO FIND OUT.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_2</DOCNO>
            	<TEXT>Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_3</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19 June 22, 2021 at 1:46 PM EDT Admiral Paul Pearigen, MD is Consultant | Director | Rear Admiral, U.S. Navy (Retired).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_4</DOCNO>
            	<TEXT>Admiral Pearigen has been on Sorrento's Therapeutics payroll since August 2020 to Present.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_5</DOCNO>
            	<TEXT>About Dr. Pearigen served among the pinnacle leadership ranks of U.S. military officers engaged in strategy development and execution, application of human capital and financial resources, global policy development, risk and consequence management, and communication.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_6</DOCNO>
            	<TEXT>A Certified Physician Executive with broad national and international experience in healthcare delivery, research  amp; development, and medical education and a strong background leading diverse teams, promoting accountability, and ensuring informed decision-making in complex and uncertain environments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_7</DOCNO>
            	<TEXT>Corporate Directorship Certified, an enthusiastic learner known for sound judgment, integrity and ethics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_8</DOCNO>
            	<TEXT>While in the NAVY for 27 and 3 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_9</DOCNO>
            	<TEXT>Here's just a few things he was in charge of.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_10</DOCNO>
            	<TEXT>Commander, Navy Medicine West Chief executive leading an integrated regional healthcare and training system spanning from the west coast of the U.S. to military treatment facilities across the Pacific Ocean.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_11</DOCNO>
            	<TEXT>Managed 18,500 military and civilian personnel, a $1.2B annual operating budget, and advanced medical education and research programs in support of overseas and deployed personnel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_12</DOCNO>
            	<TEXT>Directed research and disease surveillance work of eight competitively-funded medical R amp;D laboratories reaching from Southeast Asia to South America to continental U.S. Did you hear that?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_13</DOCNO>
            	<TEXT>He directed research and disease surveillance work of eight competitively-funded medical R amp;D laboratories reaching from Southeast Asia to South America to continental U.S. Let's read more... Chief of the Navy Medical Corps Guided the recruitment, selection, training, assignment, skills sustainment, career development, retention, promotion, professional oversight, and specialty policy development for over 4,000 physicians of the U.S. Navy while overseeing 102 ACGME-compliant graduate medical programs in 7 teaching medical centers across the U.S. let's read more... Liaison to Defense Health Agency, Bureau of Medicine and Surgery Provided judgment and insight as the principal Navy representative to collaborative joint Army, Navy, Air Force and DoD governance process for revolutionary integration of the $50B global delivery system of U.S. military health care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_14</DOCNO>
            	<TEXT>let's read more... Special Assistant Inspector General for Medical Matters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_15</DOCNO>
            	<TEXT>Credentialed Inspector General team member reporting directly to the Secretary of the Navy on the effectiveness and efficiency of Navy resource and program execution.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_16</DOCNO>
            	<TEXT>Conducted and reported on 17 compliance inspections evaluating Navys policies, programs, and initiatives as well as the internal controls monitoring these programs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_17</DOCNO>
            	<TEXT>Wow read this again... Credentialed Inspector General team member reporting directly to the Secretary of the Navy on the effectiveness and efficiency of Navy resource and program execution.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_18</DOCNO>
            	<TEXT>I believe Admiral Paul Pearigen had a leading role in Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_19</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_20</DOCNO>
            	<TEXT>Like I said in the past don't ever bet against our US Military.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_21</DOCNO>
            	<TEXT>Because you will lose!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_22</DOCNO>
            	<TEXT>Have a Happy Thanksgiving to all service active  amp; retired members of all Armed Forces. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_696_23</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-enters-multi-year-cooperative-research-and-development) [https://www.linkedin.com/in/paulpearigen/](https://www.linkedin.com/in/paulpearigen/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_697_0</DOCNO>
            	<TEXT>I completely agree the Admiral has some pretty good contacts leading straight to the top.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_698_0</DOCNO>
            	<TEXT>The admiral is one smart cookie.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_698_1</DOCNO>
            	<TEXT>He's got many connections and the Navy will not share anything with no one.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_698_2</DOCNO>
            	<TEXT>One morning we will wake up and get a Naval escort to the top.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_699_0</DOCNO>
            	<TEXT>I believe they can do however they please.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_700_0</DOCNO>
            	<TEXT>I was bored wanting for the turkey to cook.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_0</DOCNO>
            	<TEXT>Who knows how to finish a puzzle?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_1</DOCNO>
            	<TEXT>Every puzzle has it's corners or edges.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_2</DOCNO>
            	<TEXT>Everyone knows you always start by finding the corners first.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_3</DOCNO>
            	<TEXT>Sorrento is a big puzzle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_4</DOCNO>
            	<TEXT>Multiple affiliates  amp; Subsidiaries make up the enter perimeter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_5</DOCNO>
            	<TEXT>The large pipeline takes up the enter huge sky.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_6</DOCNO>
            	<TEXT>The COVID-19 programs, Immunotherapy, Pain management, Lymphatic delivery systems, the product candidates make up the enter base of the puzzle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_7</DOCNO>
            	<TEXT>But there's a few pieces left and their staring you right in your face.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_8</DOCNO>
            	<TEXT>No matter how hard you try to turn the pieces.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_9</DOCNO>
            	<TEXT>You can't figure it out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_10</DOCNO>
            	<TEXT>Until a new set of eyes sits down and quickly puts the rest of the puzzle together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_11</DOCNO>
            	<TEXT>That's called working together to put all the pieces together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_12</DOCNO>
            	<TEXT>Sometimes no matter how hard you try to put something together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_13</DOCNO>
            	<TEXT>You need someone else to help out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_14</DOCNO>
            	<TEXT>I found two very important pieces to the Sorrento puzzle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_15</DOCNO>
            	<TEXT>They were staring everyone in their face.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_16</DOCNO>
            	<TEXT>Everyone has their own way of finding DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_17</DOCNO>
            	<TEXT>Here's what I found.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_18</DOCNO>
            	<TEXT>Admiral Paul Pearigen, MD is Consultant | Director | Rear Admiral, U.S. Navy (Retired).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_19</DOCNO>
            	<TEXT>Admiral Pearigen has been on Sorrento's Therapeutics payroll since August 2020 to Present.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_20</DOCNO>
            	<TEXT>I believe Admiral Paul Pearigen had a leading role in Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit No.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_21</DOCNO>
            	<TEXT>3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_22</DOCNO>
            	<TEXT>Please click and view his Linkedin profile. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_23</DOCNO>
            	<TEXT>https://www.linkedin.com/in/paulpearigen/](https://www.linkedin.com/in/paulpearigen/) Mr Eduardo Rocha works for Sorrento Therapeutics as the international advisor to Latam.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_24</DOCNO>
            	<TEXT>He's also the executive director of Natcofarma Do Brasil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_25</DOCNO>
            	<TEXT>Mr Eduardo Rocha went on Sorrento's payroll on May 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_26</DOCNO>
            	<TEXT>The same time DR JI announced they had a cure for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_27</DOCNO>
            	<TEXT>Natcofarma is one of the largest pharmaceutical companies in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_28</DOCNO>
            	<TEXT>Natcofarma Brasil, a subsidiary of the Indian Natcopharma Limited, sells affordable medicines that meet global quality standards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_29</DOCNO>
            	<TEXT>Its objective is to introduce generic medicines to the Brazilian market, mainly aimed at cancer treatments, rare diseases and primary care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_30</DOCNO>
            	<TEXT>Natcofarma has laboratories equipped with state-of-the-art equipment operated by teams of highly qualified researchers and scientists to develop and launch revolutionary generics, the result of continuous investment in innovation and research.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_31</DOCNO>
            	<TEXT>This entire structure serves the purpose of providing affordable medicines to the population.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_32</DOCNO>
            	<TEXT>They have 140 Approved Patents.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_33</DOCNO>
            	<TEXT>8 Factories in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_34</DOCNO>
            	<TEXT>Two Research Centers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_35</DOCNO>
            	<TEXT>Please click and view his profile on Linkedin and also view his favorites which will pop your eyeballs out of your head. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_36</DOCNO>
            	<TEXT>https://www.linkedin.com/in/eduardo-rocha-7022051b3/](https://www.linkedin.com/in/eduardo-rocha-7022051b3/) [https://natcofarma.com/](https://natcofarma.com/) Everyone of us need to work together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_37</DOCNO>
            	<TEXT>If you find something post it and ask for help.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_38</DOCNO>
            	<TEXT>If you need help in understanding something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_39</DOCNO>
            	<TEXT>Just ask for help.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_40</DOCNO>
            	<TEXT>We have some very brilliant smart members on multiple boards that can break the DD down for everyone to understand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_41</DOCNO>
            	<TEXT>So have a nice relaxed day today before the weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_42</DOCNO>
            	<TEXT>I will be sitting at home watching TV in front of my fireplace.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_43</DOCNO>
            	<TEXT>Heating up leftovers from yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_44</DOCNO>
            	<TEXT>It's raining in New York and it's cold and damp.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_702_45</DOCNO>
            	<TEXT>A perfect day to research for some more missing pieces later if I get bored. :)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_703_0</DOCNO>
            	<TEXT>Remember the markets close at 1pm today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_704_0</DOCNO>
            	<TEXT>I would love a really nice PR after 1pm today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_705_0</DOCNO>
            	<TEXT>it's good news and bad news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_705_1</DOCNO>
            	<TEXT>Bad news for sick covid patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_705_2</DOCNO>
            	<TEXT>But great news for Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_706_0</DOCNO>
            	<TEXT>If the FDA approves the Merck pill at 30% and ABIVERTINIB is the same or better.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_706_1</DOCNO>
            	<TEXT>We will see a nice bump up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_706_2</DOCNO>
            	<TEXT>All we need is the PR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_707_0</DOCNO>
            	<TEXT>All we need is the PR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_707_1</DOCNO>
            	<TEXT>I BELIEVE WITH THE MARKETS TANKING DR JI WILL WAIT TO RELEASE THE PR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_708_0</DOCNO>
            	<TEXT>check this out https://clinicaltrials.gov/ct2/show/NCT04903327?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_0</DOCNO>
            	<TEXT>American War Hero  amp; Coal Miner Charles Dennis Buchinsky: Story by Michael Kalu</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_1</DOCNO>
            	<TEXT>In 1943, Buchinsky left his job at the mine and decided to serve in the United States Army, responding to his Americas call to arms with World War II already in full swing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_2</DOCNO>
            	<TEXT>Originally known as Charles Dennis Buchinsky, Charles Bronson was born on November 3, 1921, into a Roman Catholic family with Lithuanian ancestry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_3</DOCNO>
            	<TEXT>He was born in Ehrenfeld, Pennsylvania, within the coal region of the Allegheny Mountains, an area that stands to the north of Johnstown, Pennsylvania.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_4</DOCNO>
            	<TEXT>Bronson was one of 15 children in a very poor family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_5</DOCNO>
            	<TEXT>In some stories that have been told about him, it was said that his family was so impoverished that one day he went to school wearing one of his sisters dresses because he had no clothes of his own that were fit to be worn.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_6</DOCNO>
            	<TEXT>As a teenager, Bronson learned the English language, having already been introduced to Lithuanian and Russian.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_7</DOCNO>
            	<TEXT>He made family history as the first person from his family to graduate from high school.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_8</DOCNO>
            	<TEXT>Bronsons father died when Bronson was ten years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_9</DOCNO>
            	<TEXT>During the following years, he had to labor in the coal mines to keep himself and his family afloat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_10</DOCNO>
            	<TEXT>At first, he worked in the mining office before he transferred into the mine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_11</DOCNO>
            	<TEXT>Bronson was paid a dollar for every ton of coal he successfully mined, which was very little, even at the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_12</DOCNO>
            	<TEXT>However, he worked at the mines for eight years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_13</DOCNO>
            	<TEXT>In 1943, Bronson left his job at the mine and decided to serve in the United States Army, responding to his Americas call to arms with World War II already in full swing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_14</DOCNO>
            	<TEXT>He was 21 at the time, and the army would mark the beginning of new things for Bronson.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_15</DOCNO>
            	<TEXT>Some sources insisted that Bronson never flew as a bomber gunner in WWII but rather drove a delivery truck for the 760th Mess Squadron in Kingman Arizona.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_16</DOCNO>
            	<TEXT>However, his colleagues and people with information came out to defend him saying that he flew as a nose gunner and not a driver in the squadron, leading to apologies from US newspapers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_17</DOCNO>
            	<TEXT>The late war veteran was a private man who rarely spoke about his war experiences.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_18</DOCNO>
            	<TEXT>He enlisted in the United States Army Air Forces and first served in the 760th Flexible Gunnery Training Squadron.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_19</DOCNO>
            	<TEXT>It was in 1945, when Bronson served as a Superfortress aerial gunner with the 61st Bombardment Squadron in Guam, that he was involved in combat missions against Japan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_20</DOCNO>
            	<TEXT>The 61st Bombardment Squadron was within the 39th Bombardment Group, and while serving with this unit, Bronson flew 25 missions, many of them fraught with danger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_21</DOCNO>
            	<TEXT>On one of those missions, he was involved in combat and sustained injuries to his arms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_22</DOCNO>
            	<TEXT>The aftermath of this engagement altered the course of his life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_709_23</DOCNO>
            	<TEXT>For the injuries he sustained in service, he was rewarded with the Purple Heart and eventually retired from the Armed Forces.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_710_0</DOCNO>
            	<TEXT>This has nothing to do with Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_710_1</DOCNO>
            	<TEXT>I loved to watch his movies on TV.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_711_0</DOCNO>
            	<TEXT>Yes they are and I'm spending my cold rainy Friday in New York watching old movies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_711_1</DOCNO>
            	<TEXT>I also love the Duke.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_712_0</DOCNO>
            	<TEXT>Frank Tessier and Jim McRae?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_0</DOCNO>
            	<TEXT>What happens at a status conference?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_1</DOCNO>
            	<TEXT>If you do not know please continue to read.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_2</DOCNO>
            	<TEXT>11/30/21 10:00AM Status conference.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_3</DOCNO>
            	<TEXT>Status conference is a meeting that occurs before trial where attorneys from opposing parties and sometimes a judge meet. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_4</DOCNO>
            	<TEXT>In civil cases, status conferences can involve exchanging evidence, stipulating to certain terms, and starting negotiations on a settlement agreement.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_5</DOCNO>
            	<TEXT>What can happen in a status hearing?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_6</DOCNO>
            	<TEXT>The main purpose of a status hearing is to report to the court with an update on any progress made on previously-identified important issues and to determine the best next steps.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_7</DOCNO>
            	<TEXT>The issues addressed at the hearing depend on what's happening in the case and the issues and suggestions previously raised by the judge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_8</DOCNO>
            	<TEXT>Is a status conference a good thing?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_9</DOCNO>
            	<TEXT>A status conference can help to move a case forward.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_10</DOCNO>
            	<TEXT>There is rarely any downside to requesting and attending a status conference in a California civil case.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_11</DOCNO>
            	<TEXT>How are most civil cases settled?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_12</DOCNO>
            	<TEXT>Most civil cases are settled by mutual agreement between the parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_13</DOCNO>
            	<TEXT>A dispute can be settled even before a suit is filed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_14</DOCNO>
            	<TEXT>Once a suit is filed, it can be settled before the trial begins, during the trial, while the jury is deliberating, or even after a verdict is rendered. ...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_15</DOCNO>
            	<TEXT>However, not every case goes to trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_16</DOCNO>
            	<TEXT>So the question will be will Patrick Shiong Soon decide to settle or go to trial? [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_17</DOCNO>
            	<TEXT>http://www.lacourt.org/CaseSummary/UI/casesummary.aspx?caseNumber=20STCV08789#CAS](http://www.lacourt.org/CaseSummary/UI/casesummary.aspx?caseNumber=20STCV08789#CAS) If you were in his shoes what would you do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_18</DOCNO>
            	<TEXT>Let's say you go to trial and lose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_19</DOCNO>
            	<TEXT>Would you have to pay more?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_20</DOCNO>
            	<TEXT>Would you make them an offer before trial?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_21</DOCNO>
            	<TEXT>How would you benefit by going to trial?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_22</DOCNO>
            	<TEXT>Who has the upper hand?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_23</DOCNO>
            	<TEXT>At this point both parties have seen all of the evidence.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_24</DOCNO>
            	<TEXT>If I were in PSS shoes I would make Sorrento an offer and settle the case.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_25</DOCNO>
            	<TEXT>A judge could triple the damages if your found guilty.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_26</DOCNO>
            	<TEXT>I would cut my losses and settle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_27</DOCNO>
            	<TEXT>That's what I would do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_28</DOCNO>
            	<TEXT>How much would you offer?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_713_29</DOCNO>
            	<TEXT>I will leave that up to you to decide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_714_0</DOCNO>
            	<TEXT>I'm going to reach out to NBC News and send a message to Max Gomez.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_714_1</DOCNO>
            	<TEXT>Ask him to reach out to Sorrento for an update on Covistix.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_715_0</DOCNO>
            	<TEXT>I would go Marlin fishing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_0</DOCNO>
            	<TEXT>I found something very interesting this weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_1</DOCNO>
            	<TEXT>Sorrento has a senior scientist that's working for them since May 2016 and is also working for Fate Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_2</DOCNO>
            	<TEXT>Fate Therapeutics is also located a stone throw away from Sorrento in San Diego.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_3</DOCNO>
            	<TEXT>Here's a little bit about what Fate Therapeutics does.... Fate Therapeutics Our Mission Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_4</DOCNO>
            	<TEXT>We believe that better cell therapies start with better cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_5</DOCNO>
            	<TEXT>To produce better cell therapies, we use human induced pluripotent stem cells (iPSCs) generated from our proprietary iPSC product platform to create genetically engineered, clonal master iPSC lines having preferred biological properties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_6</DOCNO>
            	<TEXT>We can direct and determine the fate of our clonal master iPSC lines to produce well-defined and uniformly composed NK- and T-cell products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_7</DOCNO>
            	<TEXT>Clonal master iPSC lines can be used as a renewable source for repeatedly and cost effectively manufacturing cell therapy products that can be delivered off-the-shelf to treat many patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_8</DOCNO>
            	<TEXT>Our cells of interest are the cells of the immune system.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_9</DOCNO>
            	<TEXT>And our cell therapy product candidate pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell product candidates, that target a broad range of liquid and solid tumors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_10</DOCNO>
            	<TEXT>I believe they might be working together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_11</DOCNO>
            	<TEXT>Intellectual property rights on Pharmaceutical research has to be agreed by both parties. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_12</DOCNO>
            	<TEXT>https://www.linkedin.com/in/helena-shaked-a9895024/](https://www.linkedin.com/in/helena-shaked-a9895024/) [https://fatetherapeutics.com/](https://fatetherapeutics.com/) I do not know for sure and I'm only guessing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_13</DOCNO>
            	<TEXT>You can clearly see for yourself this scientist clearly states she works for both.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_716_14</DOCNO>
            	<TEXT>Have a nice day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_717_0</DOCNO>
            	<TEXT>Sorrento Publishes an Abivertinib Teaser Entitled Abivertinib a Franchise Oral Therapeutic For Cancer, Covid-19 And Autoimmune Diseases November 29, 2021 at 9:00 AM EST</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_717_1</DOCNO>
            	<TEXT>Sorrento Publishes an Abivertinib Teaser Entitled Abivertinib a Franchise Oral Therapeutic For Cancer, Covid-19 And Autoimmune Diseases November 29, 2021 at 9:00 AM EST [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-publishes-abivertinib-teaser-entitled-abivertinib](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-publishes-abivertinib-teaser-entitled-abivertinib)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_718_0</DOCNO>
            	<TEXT>Yes it will</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_719_0</DOCNO>
            	<TEXT>This is a great way to generate cash and long term milestone payments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_719_1</DOCNO>
            	<TEXT>Companies with so much cash need to invest it more the end of the 4th quarter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_719_2</DOCNO>
            	<TEXT>Like a Moderna or a Lilly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_719_3</DOCNO>
            	<TEXT>My question is how much would they sell it for?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_720_0</DOCNO>
            	<TEXT>Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer https://celularity.com/celularity-announces-fda-clearance-of-investigational-new-drug-appli</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_720_1</DOCNO>
            	<TEXT>Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer [https://celularity.com/celularity-announces-fda-clearance-of-investigational-new-drug-application-ind-for-natural-killer-cell-therapy-cynk-101-in-first-line-advanced-her2-neu-positive-gastric-and-gastroesophageal-junction/](https://celularity.com/celularity-announces-fda-clearance-of-investigational-new-drug-application-ind-for-natural-killer-cell-therapy-cynk-101-in-first-line-advanced-her2-neu-positive-gastric-and-gastroesophageal-junction/)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_721_0</DOCNO>
            	<TEXT>The best is yet to come..</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_0</DOCNO>
            	<TEXT>WHY WOULD YOU WANT TO TEASE SOMEONE?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_1</DOCNO>
            	<TEXT>You only tease someone when you have something that they don't have.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_2</DOCNO>
            	<TEXT>Sorrento intends to use the Abivertinib Teaser to engage in discussions with interested third parties in the pharmaceutical industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_3</DOCNO>
            	<TEXT>Let's look at the Cancer results first.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_4</DOCNO>
            	<TEXT>Abivertinib Clinical Experience and Preclinical Experiments Abivertinib for Cancer IndicationsNSCLC (Pivotal Trial) - Among 209 response evaluable NSCLC patients who developed resistance to first line TKIs (Figure 3):o 93.3 % (n/N: 195/209) subjects achieved tumor shrinkage at target lesionso 57.4% (n/N: 120/209) subjects achieved the best overall responses (confirmed + unconfirmed PR)o 52.2% (n/N: 109/209) subjects achieved confirmed PRo 24.9 months OSIn the pivotal study conducted in China using Abivertinib as a second line treatment of 227 heavily pretreated NSCLC patients withresistant EGFR mutations were enrolled.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_5</DOCNO>
            	<TEXT>Among 209 response evaluable patients, confirmed ORR was 52.2%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_6</DOCNO>
            	<TEXT>Disease control rate(DCR) was 88.0%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_7</DOCNO>
            	<TEXT>The median duration of response (DoR) and progression-free survival (PFS) was 8.5 months and 7.5 months,respectively.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_8</DOCNO>
            	<TEXT>The median overall survival (OS) was 24.9 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_9</DOCNO>
            	<TEXT>So the bottom line is you will live 24.9 longer instead of dyeing?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_10</DOCNO>
            	<TEXT>SOUNDS AMAZING!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_11</DOCNO>
            	<TEXT>Let's look a COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_12</DOCNO>
            	<TEXT>Abivertinib for COVID-19 (Two Phase 2 trials Completed)100 mg once-a-day oral capsule for hospitalized COVID-19 patientsUS trial (N=96) and Brazil trial (N=400)For Severe Ordinal Scale (OS) Category 5 COVID-19 Patients (At-Risk Group) identified to be beneficial with Abivertinib treatment at Day 28 (D28): Abivertinib reduced the risk of death or respiratory failure: by 48% in US trial (death or respiratory failure: 21.7% in the Abivertinib group vs. 41.7% in the placebo plus Standard of Care (SoC) control group)by 45% in Brazil trial (death or respiratory failure: 30.4% Abivertinib vs. 55.6% placebo plus SoC controls) Abivertinib reduced the ICU stay: by 2 days in the US trial (8.6 days average stay in ICU in Abivertinib group vs. 10.6 days in placebo plus SoC control group) So do I understand this correctly Abivertinib reduced the risk of death or respiratory by 48%?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_13</DOCNO>
            	<TEXT>So your mother or father or brother or sister lives?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_14</DOCNO>
            	<TEXT>SOUNDS AMAZING!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_15</DOCNO>
            	<TEXT>So for Cancer patients you'll live 33 months longer and for COVID-19 patients you'll reduce the risk of death by 48% when there's nothing else?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_16</DOCNO>
            	<TEXT>Now let's read this again one more time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_17</DOCNO>
            	<TEXT>Sorrento intends to use the Abivertinib Teaser to engage in discussions with interested third parties in the pharmaceutical industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_18</DOCNO>
            	<TEXT>They use the word INTERESTED third parties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_19</DOCNO>
            	<TEXT>That means someone is interested.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_20</DOCNO>
            	<TEXT>Who's interested?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_21</DOCNO>
            	<TEXT>Big pharma that has lots of cash to spend before the year ends.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_22</DOCNO>
            	<TEXT>For tax purposes.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_23</DOCNO>
            	<TEXT>Who could pay Billions?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_24</DOCNO>
            	<TEXT>A few big pharma's like Modera, Lilly, Merck, Pfizer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_25</DOCNO>
            	<TEXT>The annual market share per year is estimated at $60.6 Billion dollars per year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_26</DOCNO>
            	<TEXT>Patrick Soon- Shiong paid Sorrento $90M upfront and promised $1.2B in milestone payments in 2015 for Cynviloq.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_27</DOCNO>
            	<TEXT>That was $1.29B just for a breast cancer drug.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_28</DOCNO>
            	<TEXT>Abivertinib has multiple uses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_29</DOCNO>
            	<TEXT>THAT'S WHY YOU TEASE THEM!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_30</DOCNO>
            	<TEXT>You do realize this is a BILLION dollar teaser?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_31</DOCNO>
            	<TEXT>So I believe Sorrento is going to tease multiple big pharma's in creating a biding war to acquire Abivertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_32</DOCNO>
            	<TEXT>What is so fascinating about Sorrento is this is just the tip of the iceberg.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_33</DOCNO>
            	<TEXT>This is a $60.6 BILLION TEASER!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_34</DOCNO>
            	<TEXT>That's why all the big players like BlackRock, Vanguard, State Street all increase their holdings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_35</DOCNO>
            	<TEXT>On Fintel.com you can clearly see there expecting big news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_36</DOCNO>
            	<TEXT>They increased the amount of shares the shorts could borrow in the event of a short squeeze to 5,000,000 SHARES to suppress the stock so that they could cover.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_37</DOCNO>
            	<TEXT>The long term investors have been teased for the last 18 months.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_38</DOCNO>
            	<TEXT>I can wait until the end of the year and I'm expecting a HAPPY NEW YEAR! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_722_39</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-publishes-abivertinib-teaser-entitled-abivertinib](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-publishes-abivertinib-teaser-entitled-abivertinib) [https://fintel.io/so/us/srne](https://fintel.io/so/us/srne)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_723_0</DOCNO>
            	<TEXT>yeah I caught that and changed it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_0</DOCNO>
            	<TEXT>Remember when you were a kid a someone had a new toy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_1</DOCNO>
            	<TEXT>They would say look what I have.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_2</DOCNO>
            	<TEXT>You can't have it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_3</DOCNO>
            	<TEXT>Or maybe you can.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_4</DOCNO>
            	<TEXT>Sorrento is a small fish in a barrel surrounded by big fish that are hungry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_5</DOCNO>
            	<TEXT>So Sorrento is going to go fishing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_6</DOCNO>
            	<TEXT>This time Sorrento is in the boat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_7</DOCNO>
            	<TEXT>Moderna vaccines don't work against the new variant.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_8</DOCNO>
            	<TEXT>Big pharma with big money needs tax write offs before the year ends.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_724_9</DOCNO>
            	<TEXT>Once they drop the bait the biggest fish will bite.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_725_0</DOCNO>
            	<TEXT>Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference NOW LETS GET IT OUT THERE AND TELL EVERYONE WHAT WE HAVE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_725_1</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-participate-ceo-fireside-chat-evercore-isi-4th</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_725_2</DOCNO>
            	<TEXT>Dr. Henry Ji to Participate in the CEO Fireside Chat Evercore ISI 4th Annual HealthCONx Conference NOW LETS GET IT OUT THERE AND TELL EVERYONE WHAT WE HAVE! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_725_3</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-participate-ceo-fireside-chat-evercore-isi-4th](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/dr-henry-ji-participate-ceo-fireside-chat-evercore-isi-4th)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_726_0</DOCNO>
            	<TEXT>Everyone will be listening tomorrow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_726_1</DOCNO>
            	<TEXT>COVID-19 is getting out of control again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_726_2</DOCNO>
            	<TEXT>Moderna says their vaccines probably doesn't work against the new variant.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_726_3</DOCNO>
            	<TEXT>It will take them 100 to make another booster.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_726_4</DOCNO>
            	<TEXT>DR JI is setting his baits on all of his hooks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_726_5</DOCNO>
            	<TEXT>Time to wait.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_727_0</DOCNO>
            	<TEXT>This new variant is very bad.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_727_1</DOCNO>
            	<TEXT>None of the vaccines work to protect everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_727_2</DOCNO>
            	<TEXT>Lets hope the FDA approves COVI-AMG asap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_728_0</DOCNO>
            	<TEXT>You have to follow the money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_728_1</DOCNO>
            	<TEXT>The big boys are adding and so will I.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_0</DOCNO>
            	<TEXT>HOW DO WE KNOW THE YAHOO BOARD IS RUN BY THE SHORTS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_1</DOCNO>
            	<TEXT>Take a look at this spam post that I copied and pasted from the yahoo board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_2</DOCNO>
            	<TEXT>The poster mentions deepbluesea as his contact.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_3</DOCNO>
            	<TEXT>Deepbluesea is a well known short basher that bashes all day long. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_4</DOCNO>
            	<TEXT>trivers**5 minutes ago $SRNE should hurry up, get a hold of Omicron, confirm that COVISTIX hypersensitive nanoparticle assay does in fact see the same covid molecules in Omicron, as it does all variants so far.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_5</DOCNO>
            	<TEXT>And put out a Godamn well timed press release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_6</DOCNO>
            	<TEXT>Thanks for the idea Deepbluesea!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_7</DOCNO>
            	<TEXT>You get all the credit!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_8</DOCNO>
            	<TEXT>Lets gooooo SRNE!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_9</DOCNO>
            	<TEXT>I am so glad i found trade-ideas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_729_10</DOCNO>
            	<TEXT>Helps traders find the best setups in the market right now [https://dailytrading.tools/Trade-of-the-Week](https://dailytrading.tools/Trade-of-the-Week)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_730_0</DOCNO>
            	<TEXT>The shorts control the board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_730_1</DOCNO>
            	<TEXT>The moderators are short traders.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_730_2</DOCNO>
            	<TEXT>This is the reason why we need to bring everyone to our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_730_3</DOCNO>
            	<TEXT>Tell your friends and family to post on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_731_0</DOCNO>
            	<TEXT>So he posted the advertisement?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_732_0</DOCNO>
            	<TEXT>I believe he is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_733_0</DOCNO>
            	<TEXT>I totally agree that's why I post on that board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_733_1</DOCNO>
            	<TEXT>To agitate and frustrate them and make them work for their money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_733_2</DOCNO>
            	<TEXT>I've gotten 100s of thumbs downs just on one post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_733_3</DOCNO>
            	<TEXT>And I will not relent and they will not win.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_734_0</DOCNO>
            	<TEXT>I'm laughing out loud.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_734_1</DOCNO>
            	<TEXT>Yes they do.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_735_0</DOCNO>
            	<TEXT>The best is when they say I'm getting paid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_735_1</DOCNO>
            	<TEXT>That tell me that they think I'm good enough to be paid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_735_2</DOCNO>
            	<TEXT>That's a compliment to me not a dig.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_735_3</DOCNO>
            	<TEXT>Hey if they really paid me I wouldn't let them sleep.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_736_0</DOCNO>
            	<TEXT>Of course it does.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_736_1</DOCNO>
            	<TEXT>There only digging them selves a deeper hole.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_737_0</DOCNO>
            	<TEXT>I would post 24/7.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_0</DOCNO>
            	<TEXT>FOR ONCE IT'S NICE TO TEASE SOMEONE ELSE INSTEAD OF THEM TEASING US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_1</DOCNO>
            	<TEXT>Abivertinib A Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_2</DOCNO>
            	<TEXT>Abivertinib A Broad Pipeline for Cancer, COVID-19 and Autoimmune Diseases ($61B Market) About Abivertinib: Abivertinib is a novel dual target, small molecule tyrosine kinase inhibitor (TKI) that selectively targets mutant forms of the epidermal growth factor receptor (EGFR) and Bruton's tyrosine kinase (BTK).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_3</DOCNO>
            	<TEXT>Abivertinib is a third-generation epidermal growth factor receptor (EGFR) inhibitor that irreversibly targets mutant forms of EGFR in advanced non-small cell lung cancer (NSCLC) patients resistant to first-line EGFR kinase inhibitor therapies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_4</DOCNO>
            	<TEXT>Abivertinib also irreversibly binds to the BTK receptor, preventing the phosphorylation of the receptor that occurs during activation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_5</DOCNO>
            	<TEXT>Abivertinib has shown potent immunomodulatory activities in vitro with potent inhibition of key pro-inflammatory cytokine production, including IL-1 beta, IL-6 and TNF-alpha.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_6</DOCNO>
            	<TEXT>These cytokines are associated with acute respiratory distresssyndrome (ARDS) and cytokine release syndrome (CRS) or cytokine storm complicating COVID-19 resulting in disease progression with poor outcomes in patients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_7</DOCNO>
            	<TEXT>Abivertinib - Mode of Actions Abivertinib as EGFR Inhibitor for NSCLC Acquired T790M mutation in EGFR is the most common cause of resistance for patients with advanced NSCLC who have progressed after first line EGFR TKIs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_8</DOCNO>
            	<TEXT>The development of the thirdgeneration (3G) EGFR TKIs focused on three key aspects: i) the inhibition of T790M isoform-specific kinase activity, ii) maintaining efficacy against exon 19 and 21 mutations, and iii)sparing the inhibition of wild-type EGFR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_9</DOCNO>
            	<TEXT>Abivertinib, discovered by ACEA Therapeutics (a wholly-owned subsidiary of Sorrento Therapeutics), is a pyrrolopyrimidine-based irreversible 3G EGFR TKI, and is structurally distinct from all other 3G pyrimidine-based EGFR inhibitors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_10</DOCNO>
            	<TEXT>Abivertinib as BTK Inhibitor for B-Cell Malignancies Brutons tyrosine kinase (BTK) is a clinically validated target for the treatment of B-cell malignancies, including relapsed or refractory (R/R) B-cell lymphoma, mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL)/small lymphocytic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_11</DOCNO>
            	<TEXT>Abivertinib is also a potent BTK inhibitor, selectively, and irreversibly inhibiting the phosphorylation of BTK with IC50 value at 1.6 nM and its downstream target proteins at low nM range.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_12</DOCNO>
            	<TEXT>Abivertinib occupied BTK targets in human peripheral blood mononuclear cells (PBMCs) with IC50 value at 0.78 nM. Abivertinib as Potent Inhibitor of Cytokines for COVID-19 Associated Cytokine Storm BTK is a critical molecule in immune regulation and host inflammatory responses.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_13</DOCNO>
            	<TEXT>Abivertinib has shown potent anti-inflammatory and immune modulation activities by inhibiting key proinflammatory cytokines including IL-1beta, IL-6 and TNF-alpha.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_14</DOCNO>
            	<TEXT>These cytokines are associated with the acute respiratory distress syndrome (ARDS) in the COVID-19 patients. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_15</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/static-files/22057ad8-3752-4ee7-a4de-b84a055c0764](https://investors.sorrentotherapeutics.com/static-files/22057ad8-3752-4ee7-a4de-b84a055c0764) For once it's nice to TEASE someone else instead of them teasing us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_738_16</DOCNO>
            	<TEXT>Evercore ISI 4th Annual HealthCONx Virtual Conference Dec 1, 2021 from 3:30 PM to 3:50 PM EST</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_739_0</DOCNO>
            	<TEXT>A $60.6 BILLION DOLLAR TEASE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_740_0</DOCNO>
            	<TEXT>I couldn't agree more with you</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_741_0</DOCNO>
            	<TEXT>Guess what DR JI might not even sell Abivertinib he might just tease everyone to the finishline as a slap to everyone's face who didn't have faith in him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_742_0</DOCNO>
            	<TEXT>What if he doesn't sell anything and he teases everyone to the finish line?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_743_0</DOCNO>
            	<TEXT>CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2) RECEIVED THROUGH 28-FEB-2021</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_743_1</DOCNO>
            	<TEXT>[https://www.scribd.com/document/543857539/CUMULATIVE-ANALYSIS-OF-POST-AUTHORIZATION-ADVERSE-EVENT-REPORTS-OF-PF-07302048-BNT162B2-RECEIVED-THROUGH-28-FEB-2021](https://www.scribd.com/document/543857539/CUMULATIVE-ANALYSIS-OF-POST-AUTHORIZATION-ADVERSE-EVENT-REPORTS-OF-PF-07302048-BNT162B2-RECEIVED-THROUGH-28-FEB-2021) Everyone please read.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_743_2</DOCNO>
            	<TEXT>The judge ordered 500 pages released today. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_743_3</DOCNO>
            	<TEXT>https://twitter.com/iGNORANTCHiMP?t=jL28w8pc-LPJN\_Xe-PpIGw amp;s=09](https://twitter.com/iGNORANTCHiMP?t=jL28w8pc-LPJN_Xe-PpIGw amp;s=09)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_744_0</DOCNO>
            	<TEXT>Ok here's my take.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_744_1</DOCNO>
            	<TEXT>Dow makes 983-point U-turn, ending sharply lower after first reported U.S. omicron case.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_744_2</DOCNO>
            	<TEXT>THE COURTS ALSO ORDERED THESE PAGES RELEASED. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_744_3</DOCNO>
            	<TEXT>https://www.scribd.com/document/543857539/CUMULATIVE-ANALYSIS-OF-POST-AUTHORIZATION-ADVERSE-EVENT-REPORTS-OF-PF-07302048-BNT162B2-RECEIVED-THROUGH-28-FEB-2021](https://www.scribd.com/document/543857539/CUMULATIVE-ANALYSIS-OF-POST-AUTHORIZATION-ADVERSE-EVENT-REPORTS-OF-PF-07302048-BNT162B2-RECEIVED-THROUGH-28-FEB-2021) i believe Pfizer didn't want this information released for 55 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_744_4</DOCNO>
            	<TEXT>After reading I personally would never tell anyone to get the Pfizer vaccination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_745_0</DOCNO>
            	<TEXT>I believe Sorrento was caught in the vacuum of all the BIOs selling off.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_745_1</DOCNO>
            	<TEXT>All we need is some type of great news from DR JI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_745_2</DOCNO>
            	<TEXT>Was anyone able to listen to the Fireside chat?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_746_0</DOCNO>
            	<TEXT>Just one person in SF is reported infected and the markets tanked.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_746_1</DOCNO>
            	<TEXT>Time to approve COVISTIX period.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_746_2</DOCNO>
            	<TEXT>The FDA needs to push the button.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_747_0</DOCNO>
            	<TEXT>You're on a mission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_747_1</DOCNO>
            	<TEXT>I told you we would work together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_747_2</DOCNO>
            	<TEXT>Post it and I will reply.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_747_3</DOCNO>
            	<TEXT>You're one of the best posters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_0</DOCNO>
            	<TEXT>DOES EVERYONE REMEMBER WHEN TEN OUT OF TEN PATIENTS WALKED OUT OF THE HOSPITAL?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_1</DOCNO>
            	<TEXT>Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_2</DOCNO>
            	<TEXT>Well the PHASE 2 TRIAL IN ENROLLING.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_3</DOCNO>
            	<TEXT>Due to be fully enrolled by December 31st. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_4</DOCNO>
            	<TEXT>https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4](https://clinicaltrials.gov/ct2/show/NCT04905836?term=sorrento amp;recrs=a amp;draw=2 amp;rank=4) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-positive-results-phase-1b-study-covi-msctm) Study Type : Interventional (Clinical Trial) Estimated Enrollment : 60 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells Actual Study Start Date : November 16, 2021 Estimated Primary Completion Date : December 2021 Estimated Study Completion Date : March 2022 COVID-19 Is not going away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_5</DOCNO>
            	<TEXT>Sorrento will have their chance to show the World that it wasn't a fluke that 10 out of 10 patients walked out of the hospital that were on respirators.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_6</DOCNO>
            	<TEXT>How would the markets react if 60 out of 60 patients walked out?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_7</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_748_8</DOCNO>
            	<TEXT>Have some faith and start believing that eventually Sorrento will be the next Moderna.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_749_0</DOCNO>
            	<TEXT>Wouldn't it be great to get an update during the Jan 4, 2022 from 5:00 PM to 5:30 PM ESTH.C. Wainwright BioConnect Virtual Conference</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_750_0</DOCNO>
            	<TEXT>Sorrento has many tools in the shed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_751_0</DOCNO>
            	<TEXT>While we were preparing for Thanksgiving Sorrento was patenting away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_751_1</DOCNO>
            	<TEXT>[https://uspto.report/patent/grant/11,179,554](https://uspto.report/patent/grant/11,179,554) [https://uspto.report/patent/grant/11,179,555](https://uspto.report/patent/grant/11,179,555) [https://uspto.report/patent/grant/11,180,568](https://uspto.report/patent/grant/11,180,568)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_752_0</DOCNO>
            	<TEXT>All granted!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_0</DOCNO>
            	<TEXT>HOW DO WE KNOW SOMETHING GREAT IS COMING OUR WAY?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_1</DOCNO>
            	<TEXT>Who uses Fintel ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_2</DOCNO>
            	<TEXT>I use it everyday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_3</DOCNO>
            	<TEXT>Because I get to see all the new institutional buys and the short interest volume.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_4</DOCNO>
            	<TEXT>We all know BlackRock owns a lot of shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_5</DOCNO>
            	<TEXT>They've been increasing every quarter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_6</DOCNO>
            	<TEXT>The bashers on this board are paid to scare you and convince you to leave.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_7</DOCNO>
            	<TEXT>Who do you think is buying your shares?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_8</DOCNO>
            	<TEXT>That's right the same people that are lending shares to the shorts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_9</DOCNO>
            	<TEXT>It's a game to cumulate cheap shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_10</DOCNO>
            	<TEXT>I know it's frustrating at times.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_11</DOCNO>
            	<TEXT>You start to blame people in you're circle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_12</DOCNO>
            	<TEXT>Or people on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_13</DOCNO>
            	<TEXT>I have news for you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_14</DOCNO>
            	<TEXT>All the BIOTECHs have been selling off.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_15</DOCNO>
            	<TEXT>Sorrento is in a vacuum.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_16</DOCNO>
            	<TEXT>We have no choice but to drift with the current.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_17</DOCNO>
            	<TEXT>That doesn't mean things are bad.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_18</DOCNO>
            	<TEXT>It only means shares are cheap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_19</DOCNO>
            	<TEXT>Now on Fintel under short interest.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_20</DOCNO>
            	<TEXT>You click short interest twice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_21</DOCNO>
            	<TEXT>You will see to the bottom right SRNE short interest share available to borrow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_22</DOCNO>
            	<TEXT>In the 18 months I've been following Sorrento I've never seen so many available shares to borrow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_23</DOCNO>
            	<TEXT>EVER and currently it's 10,000,000 shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_24</DOCNO>
            	<TEXT>Why do they lend these share out?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_25</DOCNO>
            	<TEXT>When a company releases positive monumental news everyone goes to buy the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_26</DOCNO>
            	<TEXT>Which is when a short squeeze happens.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_27</DOCNO>
            	<TEXT>Shorts have to cover.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_28</DOCNO>
            	<TEXT>There's been a lot of Dark pool shorting lately.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_29</DOCNO>
            	<TEXT>The shorts will need those shares to buy to borrow to short the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_30</DOCNO>
            	<TEXT>Because they will need to suppress the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_31</DOCNO>
            	<TEXT>To give them more time to cover.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_32</DOCNO>
            	<TEXT>Last summer I remember Sorrento traded close to 45M share daily BACK TO BACK DAYS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_33</DOCNO>
            	<TEXT>That's when the stock was going up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_34</DOCNO>
            	<TEXT>Be prepared when something great happens and don't be upset the stock isn't flying high out of the gate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_35</DOCNO>
            	<TEXT>It will take a little bit of time for the shorts to get back in to settle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_36</DOCNO>
            	<TEXT>They will need all of the 10,000,000 shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_37</DOCNO>
            	<TEXT>According to fintel it will take 9 full days for the shorts to fully cover in the event of a short squeeze.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_38</DOCNO>
            	<TEXT>We all agree DR JI needs to show us revenue!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_39</DOCNO>
            	<TEXT>Revenue will move the needle.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_40</DOCNO>
            	<TEXT>We need a major agreement with a dollar amount added to it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_41</DOCNO>
            	<TEXT>I've been a long from the start and I'm here until the end.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_42</DOCNO>
            	<TEXT>The end for me is when we develop into a $200B company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_43</DOCNO>
            	<TEXT>I'm a semi retired business owner.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_44</DOCNO>
            	<TEXT>I'm on this board as a hobby.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_45</DOCNO>
            	<TEXT>A lot of bashers on this board call me a paid pumper.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_46</DOCNO>
            	<TEXT>Every time they call me a paid pumper it makes me want to work harder.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_47</DOCNO>
            	<TEXT>Because it's truly a compliment to me for the DD that I bring to this board and other boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_48</DOCNO>
            	<TEXT>It tells me that I should be getting paid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_49</DOCNO>
            	<TEXT>They believe I'm getting paid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_50</DOCNO>
            	<TEXT>Hey if you believe I should get paid write to Sorrento and tell them to donate my pay to Wounded Warrior Project.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_51</DOCNO>
            	<TEXT>We've been drifting out to sea lately.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_52</DOCNO>
            	<TEXT>And I see LAND HO!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_53</DOCNO>
            	<TEXT>We will all make it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_54</DOCNO>
            	<TEXT>You have to believe that the best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_55</DOCNO>
            	<TEXT>Please view and click on the link that I provided.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_56</DOCNO>
            	<TEXT>If you don't have the money to join Fintel send me a message my way and I will post it for you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_753_57</DOCNO>
            	<TEXT>Have a great evening and remember what I always say.... [https://fintel.io/ss/us/srne](https://fintel.io/ss/us/srne)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_754_0</DOCNO>
            	<TEXT>There's no bad language allowed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_755_0</DOCNO>
            	<TEXT>Using F@#$% is not allowed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_756_0</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_757_0</DOCNO>
            	<TEXT>Thank you for following and please post on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_757_1</DOCNO>
            	<TEXT>Everyone's input is helpful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_758_0</DOCNO>
            	<TEXT>I love shopping on Ebay.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_758_1</DOCNO>
            	<TEXT>I buy all my MGB parts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_759_0</DOCNO>
            	<TEXT>I would like one at 3pm today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_760_0</DOCNO>
            	<TEXT>They were blocked because of harassment and insulting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_760_1</DOCNO>
            	<TEXT>They're recreating new accounts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_760_2</DOCNO>
            	<TEXT>They want you to sell your shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_760_3</DOCNO>
            	<TEXT>Everyone needs to block them and mute them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_760_4</DOCNO>
            	<TEXT>All together.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_761_0</DOCNO>
            	<TEXT>Start blocking.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_0</DOCNO>
            	<TEXT>I would of never of looked at it that way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_1</DOCNO>
            	<TEXT>But now I think you maybe right.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_2</DOCNO>
            	<TEXT>They could be shorting the stock to get a better bargain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_3</DOCNO>
            	<TEXT>Hmm I could see that happening.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_4</DOCNO>
            	<TEXT>Who would want to BO Sorrento or acquire Abivertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_5</DOCNO>
            	<TEXT>Every time that thought comes to mind.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_6</DOCNO>
            	<TEXT>I think of Moderna.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_762_7</DOCNO>
            	<TEXT>Nice speculation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_763_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Becomes Oversold (SRNE) Take a look at this PUBLISHED APR 12, 2021 12:09PM EDT The stock price was $6.87 per share https://www.nasdaq.com/articles/sorrento-therapeutics-becomes-oversold-srne-2021-04-12</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_763_1</DOCNO>
            	<TEXT>Sorrento Therapeutics Becomes Oversold (SRNE) Take a look at this PUBLISHED APR 12, 2021 12:09PM EDT The stock price was $6.87 per share [https://www.nasdaq.com/articles/sorrento-therapeutics-becomes-oversold-srne-2021-04-12](https://www.nasdaq.com/articles/sorrento-therapeutics-becomes-oversold-srne-2021-04-12)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_764_0</DOCNO>
            	<TEXT>$6.87 WAS OVERSOLD IN APRIL.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_764_1</DOCNO>
            	<TEXT>$4.92 has to be way way oversold.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_765_0</DOCNO>
            	<TEXT>We did even have any of the COVISTIX approved yet or the Abivertinib results.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_765_1</DOCNO>
            	<TEXT>This has to be way way way oversold.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_766_0</DOCNO>
            	<TEXT>I'm not sure why you listen to that board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_766_1</DOCNO>
            	<TEXT>It's all advertisments now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_0</DOCNO>
            	<TEXT>How many times have you applied for a home equity loan?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_1</DOCNO>
            	<TEXT>I know what' it's like to run a business.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_2</DOCNO>
            	<TEXT>I run multiple businesses at the same time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_3</DOCNO>
            	<TEXT>People don't pay you fast enough or you see opportunities to invest in something really good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_4</DOCNO>
            	<TEXT>Hey the Feds said interest rates are going up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_5</DOCNO>
            	<TEXT>Maybe it's better to sell some shares now and take that money and invest it Phase 3 Abvertinib.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_6</DOCNO>
            	<TEXT>And tease everyone to the finish line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_767_7</DOCNO>
            	<TEXT>I'm not worried.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_0</DOCNO>
            	<TEXT>It makes total sense now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_1</DOCNO>
            	<TEXT>Yesterday they posted 10,000,000 share were available to borrow.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_2</DOCNO>
            	<TEXT>Then this morning it dropped to 5,200,000.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_3</DOCNO>
            	<TEXT>Could they of wanted to drive the stock price down to get a bargain?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_4</DOCNO>
            	<TEXT>On Monday morning we will know.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_5</DOCNO>
            	<TEXT>Because right now were at .. SRNE - Short Interest - Sorrento Therapeutics Inc - Short Squeeze, Short Sale Volume, Borrow Rates, Fails-To-Deliver Short Interest 45,318,331 shares - source: NASDAQ Short Interest Ratio 9.58 Days to Cover Short Interest % Float 16.44% - source: NASDAQ (short interest), Capital IQ (float) Dark Pool Short Volume 1,386,469 shares - source: FINRA Dark Pool Short Volume Ratio 58.50% - source: FINRA Could DR JI saw the the BIOTECH was selling off this whole week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_6</DOCNO>
            	<TEXT>And though lets pull the trigger before they sell off even more?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_7</DOCNO>
            	<TEXT>I frankly don't care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_8</DOCNO>
            	<TEXT>Because this is a long term investment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_9</DOCNO>
            	<TEXT>Now if you told me you have $450M to do as you please....Hmmm what would I buy?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_10</DOCNO>
            	<TEXT>Every time DR JI buys something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_768_11</DOCNO>
            	<TEXT>He gets his money worth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_769_0</DOCNO>
            	<TEXT>I you have a long term at look.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_769_1</DOCNO>
            	<TEXT>You will be glad.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_769_2</DOCNO>
            	<TEXT>DR JI is gonna spend that money to make money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_769_3</DOCNO>
            	<TEXT>Wainwright gave them the Strong Buy rating for $26 and now there going to buy more shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_769_4</DOCNO>
            	<TEXT>They know what there doing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_770_0</DOCNO>
            	<TEXT>Wow look at that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_770_1</DOCNO>
            	<TEXT>I posted the same but from April 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_770_2</DOCNO>
            	<TEXT>That said they were oversold.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_770_3</DOCNO>
            	<TEXT>Do you know that they went on a tear and headed straight up after that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_770_4</DOCNO>
            	<TEXT>They will do the same now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_0</DOCNO>
            	<TEXT>Oversold Conditions For Sorrento Therapeutics (SRNE) 12/3/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_1</DOCNO>
            	<TEXT>Oversold Conditions For Sorrento Therapeutics (SRNE) Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_2</DOCNO>
            	<TEXT>One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_3</DOCNO>
            	<TEXT>A stock is considered to be oversold if the RSI reading falls below 30.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_4</DOCNO>
            	<TEXT>In trading on Friday, shares of Sorrento Therapeutics Inc (Symbol: SRNE) entered into oversold territory, hitting an RSI reading of 25.6, after changing hands as low as $5.06 per share.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_5</DOCNO>
            	<TEXT>By comparison, the current RSI reading of the S amp;P 500 ETF (SPY) is 41.3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_6</DOCNO>
            	<TEXT>A bullish investor could look at SRNE's 25.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_771_7</DOCNO>
            	<TEXT>The chart below shows the one year performance of SRNE shares: [https://www.nasdaq.com/articles/oversold-conditions-for-sorrento-therapeutics-srne](https://www.nasdaq.com/articles/oversold-conditions-for-sorrento-therapeutics-srne) Time to start buying more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_772_0</DOCNO>
            	<TEXT>I was able to purchase a few more shares today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_773_0</DOCNO>
            	<TEXT>I don't look at this as a dilution it's more of a line of credit to fund the Phase 3 Abvertinib to the finish line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_773_1</DOCNO>
            	<TEXT>I would rather tease everybody then sell the GOLDEN EGG.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_774_0</DOCNO>
            	<TEXT>And Frankly I would rather have Sorrento TEASE everyone with the GOLDEN EGG we have and fund Abvertinib Phase 3 trial to the finish line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_774_1</DOCNO>
            	<TEXT>Have a great weekend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_775_0</DOCNO>
            	<TEXT>Michael you forgot the private jet we will charter.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_776_0</DOCNO>
            	<TEXT>My friend owns a private jet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_776_1</DOCNO>
            	<TEXT>I may have to invite him so we use his plane. ;)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_777_0</DOCNO>
            	<TEXT>It's that ironic how the same Nasdaq issues the Oversold?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_777_1</DOCNO>
            	<TEXT>Like it was planned.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_778_0</DOCNO>
            	<TEXT>I believe the bleeding is finally finished.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_778_1</DOCNO>
            	<TEXT>Ji got money to get the important things done.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_778_2</DOCNO>
            	<TEXT>Now were going to tease everyone to the finish line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_0</DOCNO>
            	<TEXT>IT'S WHO YOU KNOW!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_1</DOCNO>
            	<TEXT>It's always nice to have friends in your circle that can help you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_2</DOCNO>
            	<TEXT>When ever you need anything what do you do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_3</DOCNO>
            	<TEXT>You pick up the phone and call them for help or advice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_4</DOCNO>
            	<TEXT>In my early years of profession I worked as a private investigator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_5</DOCNO>
            	<TEXT>So I did a little bit of investigating.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_6</DOCNO>
            	<TEXT>Here's what I found.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_7</DOCNO>
            	<TEXT>What I'm about to tell you might seem like no big deal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_8</DOCNO>
            	<TEXT>Or the other hand it shows there's a relationship.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_9</DOCNO>
            	<TEXT>Having relationships with the best professionals in the business is a great thing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_10</DOCNO>
            	<TEXT>Ok here it is.... DR S. Jaisim is the CEO Scilex Holding  amp; Scilex Pharma / Board Director Scilex / Director Sorrento / Director Semnur.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_11</DOCNO>
            	<TEXT>On his Linkedln page he commented on a post 4 days ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_12</DOCNO>
            	<TEXT>With a simple.. Congrats Eric and team!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_13</DOCNO>
            	<TEXT>Eric Tokat is a Partner of Centerview Partners.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_14</DOCNO>
            	<TEXT>Mr Eric Tokat was the exclusive financial advisor for a recent acquisition.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_15</DOCNO>
            	<TEXT>Of San Diego oncology startup Lengo Therapeutics being acquired for $250 million by Blueprint Medicines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_16</DOCNO>
            	<TEXT>Reviewing Mr Tokat's accomplishment's working as a Partner at Centerview are astonishing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_17</DOCNO>
            	<TEXT>Centerview Partners is a Banking Firm Advisers that have completed $3 Trillon dollars of transactions Worldwide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_18</DOCNO>
            	<TEXT>Trully amazing and I would want Eric as my friend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_19</DOCNO>
            	<TEXT>So on Linkedln Eric announced the acquisition and was greeted by 85 likes and only 1 comment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_20</DOCNO>
            	<TEXT>Guess who the one comment was from?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_21</DOCNO>
            	<TEXT>DR S. Jaism CEO of Scilex.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_22</DOCNO>
            	<TEXT>Lets look at this one more time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_23</DOCNO>
            	<TEXT>Congrats Eric and team!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_24</DOCNO>
            	<TEXT>He acknowledges that there is a relationship between him and the team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_25</DOCNO>
            	<TEXT>Not just him but also his team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_26</DOCNO>
            	<TEXT>How come no one else out of the 85 likes commented?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_27</DOCNO>
            	<TEXT>I'm on Linkedln and I see posts that I like and I give them the like.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_28</DOCNO>
            	<TEXT>But I never comment unless I know the person.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_29</DOCNO>
            	<TEXT>Ok so I GPS Sorrento's Headquarters and Lengo Therapeutics Headquarters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_30</DOCNO>
            	<TEXT>There only 6 miles a way a 7 minute drive.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_31</DOCNO>
            	<TEXT>So I'm sure CEOs know the other CEOs within their circle as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_32</DOCNO>
            	<TEXT>So after viewing DR S. Jaism History I didn't see anything related with Centerviews acquisitions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_33</DOCNO>
            	<TEXT>Or maybe there was and someone could point it out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_34</DOCNO>
            	<TEXT>Could DR S. Jaism have something up his sleeve in line for Scilex?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_35</DOCNO>
            	<TEXT>Could they be in talks with BP?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_36</DOCNO>
            	<TEXT>If you were thinking of selling your business who would you reach out to for help?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_37</DOCNO>
            	<TEXT>Or if you wanted to merge or sell SP-102 or a major license agreement who would you call?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_38</DOCNO>
            	<TEXT>I'm going to provide everyone the links below.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_39</DOCNO>
            	<TEXT>You can make your own assumptions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_40</DOCNO>
            	<TEXT>My guess is Scilex is in talks with BP.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_41</DOCNO>
            	<TEXT>SP-102 should report 1Q 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_42</DOCNO>
            	<TEXT>The pain management market is in the double digits BILLIONS annually.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_43</DOCNO>
            	<TEXT>If and when SP-102 gets the FDA approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_44</DOCNO>
            	<TEXT>It's always great to know someone. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_779_45</DOCNO>
            	<TEXT>https://www.centerviewpartners.com/ourteammember.aspx?employee=E.%20Eric%20Tokat#top](https://www.centerviewpartners.com/ourteammember.aspx?employee=E.%20Eric%20Tokat#top) [https://www.sandiegouniontribune.com/business/story/2021-11-29/san-diego-oncology-biotech-lengo-therapeutics-being-acquired-for](https://www.sandiegouniontribune.com/business/story/2021-11-29/san-diego-oncology-biotech-lengo-therapeutics-being-acquired-for) [https://www.linkedin.com/in/jaisimshah/detail/recent-activity/](https://www.linkedin.com/in/jaisimshah/detail/recent-activity/) Thank you and have a nice weekend</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_780_0</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_781_0</DOCNO>
            	<TEXT>And lets not forget the majority of acquisitions normally are in December.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_782_0</DOCNO>
            	<TEXT>Yahoo board this morning is frozen and the manipulation is discussing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_783_0</DOCNO>
            	<TEXT>If they break the rules we can ban them from REDDIT.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_784_0</DOCNO>
            	<TEXT>Exactly what I've been saying.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_784_1</DOCNO>
            	<TEXT>Look at the 3 month chart for both.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_784_2</DOCNO>
            	<TEXT>You'll be looking at a photo copy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_785_0</DOCNO>
            	<TEXT>Ok you can privately message me I and will explain to you privately on two different options that I recommend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_785_1</DOCNO>
            	<TEXT>Please research Zynerba  amp; GW PHARMACEUTICALS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_785_2</DOCNO>
            	<TEXT>GW has an FDA approved drug you can take.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_785_3</DOCNO>
            	<TEXT>Zynerba has one that's better but not approved yet.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_785_4</DOCNO>
            	<TEXT>You could request being in the study if it's still open for enrollment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_785_5</DOCNO>
            	<TEXT>Please review and if you have any questions please message me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_786_0</DOCNO>
            	<TEXT>Yahoo is so corrupt.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_786_1</DOCNO>
            	<TEXT>I've been trying to post under my same post from yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_786_2</DOCNO>
            	<TEXT>A simple good morning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_786_3</DOCNO>
            	<TEXT>And my post is removed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_786_4</DOCNO>
            	<TEXT>Why is it they don't want me to post?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_786_5</DOCNO>
            	<TEXT>There scared to as what I will post to raise our spirits.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_0</DOCNO>
            	<TEXT>Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_1</DOCNO>
            	<TEXT>We are pleased to work with Prof. Lius group at Texas A amp;M University to develop a more effective oral MPro inhibitor to meet the urgent need for treatment of COVID-19 patients infected with existing and emerging variants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_2</DOCNO>
            	<TEXT>December 5, 2021 at 2:28 PM EST Download PDF A representative of novel MPro inhibitor series, MPI8, dually inhibits MPro and cathepsin L, a key viral entry enzyme, with high potency and selectivity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_3</DOCNO>
            	<TEXT>Other analogs of the series have been evaluated by Sorrento to develop an oral antiviral drug for treatment of patients infected with existing and emerging SARS-CoV-2 variants of concern, including Omicron.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_4</DOCNO>
            	<TEXT>A promising candidate of the series with unique features distinguished from SARS-CoV-2 MPro inhibitors published by others has been systematically evaluated and advanced to late stage of pre-clinical phase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_5</DOCNO>
            	<TEXT>SAN DIEGO, Dec. 05, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) today announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for SARS-CoV-2 entry into host cells, authored by Dr. Wenshe Ray Liu, professor at Texas A amp;M University.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_6</DOCNO>
            	<TEXT>The full manuscript is available at: [https://pubmed.ncbi.nlm.nih.gov/34242492/](https://pubmed.ncbi.nlm.nih.gov/34242492/) SARS-CoV-2 main protease (MPro) is a key enzyme for the viral life cycle including virus entry, replication and packaging.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_7</DOCNO>
            	<TEXT>MPro is highly conserved in all discovered SARS CoV-2 variants and is identified as a critical target for developing broad-spectrum antiviral drugs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_8</DOCNO>
            	<TEXT>In addition, experimental evidence has shown that certain host proteases prime the SARS-CoV-2 spike protein for viral packaging, interactions with ACE2, and viral entry into the host.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_9</DOCNO>
            	<TEXT>These include two serine proteases, furin and transmembrane protease serine 2 (TMPRSS2) and a cysteine protease cathepsin L. Small molecule medications that inhibit furin, TMPRSS2 and cathepsin L have shown efficacy in inhibiting SARS-CoV-2 replication.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_10</DOCNO>
            	<TEXT>In the publication, a representative analog of the series, MPI8, demonstrated dual inhibition of MPro and cathepsin L with high potency and selectivity (IC50 values for MPro and cathepsin L are 105 nM and 1.2 nM, respectively).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_11</DOCNO>
            	<TEXT>Sorrento has collaborated with Professor Lius lab at Texas A amp;M University to evaluate analogs in the series to develop an oral anti-COVID drug.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_12</DOCNO>
            	<TEXT>A promising analog with features distinguished from current reported SARS-CoV-2 MPro inhibitors has been systematically evaluated and advanced to a late stage of pre-clinical phase.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_13</DOCNO>
            	<TEXT>We are pleased to work with Prof. Lius group at Texas A amp;M University to develop a more effective oral MPro inhibitor to meet the urgent need for treatment of COVID-19 patients infected with existing and emerging variants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_14</DOCNO>
            	<TEXT>The oral MPro inhibitor together with Sorrentos other ongoing therapeutic intervention approaches reflect our efforts to create a mutation-agnostic global anti-COVID strategy to combat COVID-19 variants of concern, including the emerging Omicron variant, stated Dr. Henry Ji, Chairman and CEO of Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_15</DOCNO>
            	<TEXT>READ THIS AGAIN!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_16</DOCNO>
            	<TEXT>Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron As a selective inhibitor to both SARS-CoV-2 MPro and cathepsin L that is key to SARS-CoV-2 entry into the human host cell, MPI8 exerts improved potency to inhibit SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_17</DOCNO>
            	<TEXT>So far it is potentially one of the most potent antivirals that have been developed to treat COVID-19, stated Dr. Wenshe Ray Liu, Gradipore Chair in the Department of Chemistry at Texas A amp;M University. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_787_18</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-series-novel-sars-cov-2-main](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-series-novel-sars-cov-2-main)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_788_0</DOCNO>
            	<TEXT>I'M GOING TO SAY IT LOUDER THE BEST IS YET TO COME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_789_0</DOCNO>
            	<TEXT>Everyone has to have faith and believe in Sorrento Therapeutics.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_789_1</DOCNO>
            	<TEXT>Sorrento has the largest COVID-19 pipeline in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_789_2</DOCNO>
            	<TEXT>It was OVERSOLD and now has plenty of CASH to develop it's COVID-19 pipeline in becoming the next Morderna / Regeneron.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_0</DOCNO>
            	<TEXT>MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L*</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_1</DOCNO>
            	<TEXT>## Abstract A number of inhibitors have been developed for the SARS-CoV-2 main protease (MPro ) as potential COVID-19 medications but little is known about their selectivity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_2</DOCNO>
            	<TEXT>Using enzymatic assays, we characterized inhibition of TMPRSS2, furin, and cathepsins B/K/L by more than a dozen of previously developed MPro inhibitors including MPI1-9, GC376, 11a, 10-1, 10-2, and 10-3.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_3</DOCNO>
            	<TEXT>MPI1-9, GC376 and 11a all contain an aldehyde for the formation of a reversible covalent hemiacetal adduct with the MPro active site cysteine and 10-1, 10-2 and 10-3 contain a labile ester to exchange with the MPro active site cysteine for the formation of a thioester.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_4</DOCNO>
            	<TEXT>Our data revealed that all these inhibitors are inert toward TMPRSS2 and furin.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_5</DOCNO>
            	<TEXT>Diaryl esters also showed low inhibition of cathepsins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_6</DOCNO>
            	<TEXT>However, all aldehyde inhibitors displayed high potency in inhibiting three cathepsins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_7</DOCNO>
            	<TEXT>Their determined IC50 values vary from 4.1 to 380 nM for cathepsin B, 0.079 to 2.3 nM for cathepsin L, and 0.35 to 180 nM for cathepsin K. All aldehyde inhibitors showed similar inhibition levels toward cathepsin L. A cellular analysis indicated high potency of MPI5 and MPI8 in inhibiting lysosomal activity, which is probably attributed to their inhibition of cathepsins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_8</DOCNO>
            	<TEXT>Among all aldehyde inhibitors, MPI8 shows the best selectivity toward cathepsin L. With respect to cathepsins B and K, the selective indices are 192 and 150, respectively.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_9</DOCNO>
            	<TEXT>MPI8 is the most potent compound among all aldehyde inhibitors in cellular MPro inhibition potency and anti-SARS-CoV-2 activity in Vero E6 cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_10</DOCNO>
            	<TEXT>Cathepsin L has been demonstrated to play a critical role in the SARS-CoV-2 cell entry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_11</DOCNO>
            	<TEXT>By selectively inhibiting both SARS-CoV-2 MPro and the host cathepsin L, MPI8 potentiates dual inhibition effects to synergize its overall antiviral potency and efficacy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_12</DOCNO>
            	<TEXT>Due to its high selectivity toward cathepsin L that reduces potential toxicity toward host cells and high cellular and antiviral potency, we urge serious consideration of MPI8 for preclinical and clinical investigations for treating COVID-19. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_790_13</DOCNO>
            	<TEXT>https://pubmed.ncbi.nlm.nih.gov/34242492/](https://pubmed.ncbi.nlm.nih.gov/34242492/) In laymen's terms IT WORKS AGAINST ALL VARIANTS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_791_0</DOCNO>
            	<TEXT>We learned a new word PROTEASE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_791_1</DOCNO>
            	<TEXT>Sorrento will tease everyone to the finish line.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_792_0</DOCNO>
            	<TEXT>Stop repeating yourself</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_793_0</DOCNO>
            	<TEXT>Please stop repeating yourself.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_793_1</DOCNO>
            	<TEXT>No derogatory, obnoxious remarks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_793_2</DOCNO>
            	<TEXT>If you continue we will take further action.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_794_0</DOCNO>
            	<TEXT>Look your clearly a short trader.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_794_1</DOCNO>
            	<TEXT>You need to tune down your attacks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_794_2</DOCNO>
            	<TEXT>If you post on this board you have to follow our rules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_794_3</DOCNO>
            	<TEXT>I gave you your first warning today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_795_0</DOCNO>
            	<TEXT>What if there's another PR tomorrow morning?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_796_0</DOCNO>
            	<TEXT>I hope and believe we've hit our bottom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_796_1</DOCNO>
            	<TEXT>They reported that Sorrento is oversold.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_796_2</DOCNO>
            	<TEXT>So if I were you I would get on the bus Gus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_796_3</DOCNO>
            	<TEXT>Were making a new plan Stan and start listening to me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_0</DOCNO>
            	<TEXT>I'm selling my mother's house.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_1</DOCNO>
            	<TEXT>My mother past away 7 years ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_2</DOCNO>
            	<TEXT>I'm hoping we have a closing soon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_3</DOCNO>
            	<TEXT>If by chance the stock price doesn't go up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_4</DOCNO>
            	<TEXT>I'm going to double my investment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_5</DOCNO>
            	<TEXT>It's found money to me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_6</DOCNO>
            	<TEXT>And if Sorrento goes to $100 per share.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_7</DOCNO>
            	<TEXT>I will own $40M in stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_797_8</DOCNO>
            	<TEXT>Keeping my fingers crossed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_0</DOCNO>
            	<TEXT>FOLLOWING THE RULES ON THIS BOARD</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_1</DOCNO>
            	<TEXT>Please remember to follow all the rules outlined above.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_2</DOCNO>
            	<TEXT>If you feel like the rules have been broken and you want to take action.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_3</DOCNO>
            	<TEXT>Please do the following to BLOCK the abuser from this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_4</DOCNO>
            	<TEXT>Under the post you will see from left to right Reply Share 3 Dots Please click on the 3 Dots.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_5</DOCNO>
            	<TEXT>Another screen will come up and please click REPORT.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_6</DOCNO>
            	<TEXT>Once you click REPORT You will see this screen. **</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_7</DOCNO>
            	<TEXT>Submit a Report** Thanks for looking out for yourself and your fellow redditors by reporting things that break the rules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_8</DOCNO>
            	<TEXT>Let us know what's happening, and we'll look into it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_9</DOCNO>
            	<TEXT>Click the reason for breaking the rules.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_10</DOCNO>
            	<TEXT>That user will be blocked from posting on your post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_11</DOCNO>
            	<TEXT>The bashers and the haters will be out in full force to do anything to disrupt you from posting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_12</DOCNO>
            	<TEXT>I already had to use it this morning and it worked.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_798_13</DOCNO>
            	<TEXT> Thank you and have a nice day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_799_0</DOCNO>
            	<TEXT>Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (SPAC) Enter into Letter of Intent for Proposed Business Combination December 6, 2021 at 9:00 AM EST https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holdi</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_799_1</DOCNO>
            	<TEXT>Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (SPAC) Enter into Letter of Intent for Proposed Business Combination December 6, 2021 at 9:00 AM EST [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-and](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-and)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_800_0</DOCNO>
            	<TEXT>Yes it does and everyone has been screaming for a dollar sign.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_800_1</DOCNO>
            	<TEXT>So how's $1.5 Billion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_800_2</DOCNO>
            	<TEXT>I wonder who the advisor to the deal?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_800_3</DOCNO>
            	<TEXT>I posted something over the weekend about Centerview Partners.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_800_4</DOCNO>
            	<TEXT>I wouldn't be surprised if it wasn't them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_0</DOCNO>
            	<TEXT>IT'S WHO YOU KNOW!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_1</DOCNO>
            	<TEXT>REPOST FOR THIS WEEKEND.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_2</DOCNO>
            	<TEXT>IT'S WHO YOU KNOW!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_3</DOCNO>
            	<TEXT>It's always nice to have friends in your circle that can help you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_4</DOCNO>
            	<TEXT>When ever you need anything what do you do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_5</DOCNO>
            	<TEXT>You pick up the phone and call them for help or advice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_6</DOCNO>
            	<TEXT>In my early years of profession I worked as a private investigator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_7</DOCNO>
            	<TEXT>So I did a little bit of investigating.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_8</DOCNO>
            	<TEXT>Here's what I found.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_9</DOCNO>
            	<TEXT>What I'm about to tell you might seem like no big deal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_10</DOCNO>
            	<TEXT>Or the other hand it shows there's a relationship.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_11</DOCNO>
            	<TEXT>Having relationships with the best professionals in the business is a great thing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_12</DOCNO>
            	<TEXT>Ok here it is.... DR S. Jaisim is the CEO Scilex Holding  amp; Scilex Pharma / Board Director Scilex / Director Sorrento / Director Semnur.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_13</DOCNO>
            	<TEXT>On his Linkedln page he commented on a post 4 days ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_14</DOCNO>
            	<TEXT>With a simple.. Congrats Eric and team!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_15</DOCNO>
            	<TEXT>Eric Tokat is a Partner of Centerview Partners.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_16</DOCNO>
            	<TEXT>Mr Eric Tokat was the exclusive financial advisor for a recent acquisition.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_17</DOCNO>
            	<TEXT>Of San Diego oncology startup Lengo Therapeutics being acquired for $250 million by Blueprint Medicines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_18</DOCNO>
            	<TEXT>Reviewing Mr Tokat's accomplishment's working as a Partner at Centerview are astonishing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_19</DOCNO>
            	<TEXT>Centerview Partners is a Banking Firm Advisers that have completed $3 Trillon dollars of transactions Worldwide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_20</DOCNO>
            	<TEXT>Trully amazing and I would want Eric as my friend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_21</DOCNO>
            	<TEXT>So on Linkedln Eric announced the acquisition and was greeted by 85 likes and only 1 comment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_22</DOCNO>
            	<TEXT>Guess who the one comment was from?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_23</DOCNO>
            	<TEXT>DR S. Jaism CEO of Scilex.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_24</DOCNO>
            	<TEXT>Lets look at this one more time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_25</DOCNO>
            	<TEXT>Congrats Eric and team!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_26</DOCNO>
            	<TEXT>He acknowledges that there is a relationship between him and the team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_27</DOCNO>
            	<TEXT>Not just him but also his team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_28</DOCNO>
            	<TEXT>How come no one else out of the 85 likes commented?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_29</DOCNO>
            	<TEXT>I'm on Linkedln and I see posts that I like and I give them the like.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_30</DOCNO>
            	<TEXT>But I never comment unless I know the person.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_31</DOCNO>
            	<TEXT>Ok so I GPS Sorrento's Headquarters and Lengo Therapeutics Headquarters.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_32</DOCNO>
            	<TEXT>There only 6 miles a way a 7 minute drive.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_33</DOCNO>
            	<TEXT>So I'm sure CEOs know the other CEOs within their circle as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_34</DOCNO>
            	<TEXT>So after viewing DR S. Jaism History I didn't see anything related with Centerviews acquisitions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_35</DOCNO>
            	<TEXT>Or maybe there was and someone could point it out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_36</DOCNO>
            	<TEXT>Could DR S. Jaism have something up his sleeve in line for Scilex?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_37</DOCNO>
            	<TEXT>Could they be in talks with BP?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_38</DOCNO>
            	<TEXT>If you were thinking of selling your business who would you reach out to for help?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_39</DOCNO>
            	<TEXT>Or if you wanted to merge or sell SP-102 or a major license agreement who would you call?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_40</DOCNO>
            	<TEXT>I'm going to provide everyone the links below.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_41</DOCNO>
            	<TEXT>You can make your own assumptions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_42</DOCNO>
            	<TEXT>My guess is Scilex is in talks with BP.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_43</DOCNO>
            	<TEXT>SP-102 should report 1Q 2022.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_44</DOCNO>
            	<TEXT>The pain management market is in the double digits BILLIONS annually.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_45</DOCNO>
            	<TEXT>If and when SP-102 gets the FDA approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_46</DOCNO>
            	<TEXT>It's always great to know someone. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_47</DOCNO>
            	<TEXT>https://www.centerviewpartners.com/ourteammember.aspx?employee=E.%20Eric%20Tokat#top](https://www.centerviewpartners.com/ourteammember.aspx?employee=E.%20Eric%20Tokat#top) [https://www.sandiegouniontribune.com/business/story/2021-11-29/san-diego-oncology-biotech-lengo-therapeutics-being-acquired-for](https://www.sandiegouniontribune.com/business/story/2021-11-29/san-diego-oncology-biotech-lengo-therapeutics-being-acquired-for) [https://www.linkedin.com/in/jaisimshah/detail/recent-activity/](https://www.linkedin.com/in/jaisimshah/detail/recent-activity/) Now this was released this morning at 9am. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_801_48</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-and](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-and)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_802_0</DOCNO>
            	<TEXT>I was right DR Jaism had something up his sleeve.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_802_1</DOCNO>
            	<TEXT>I'm not sure if Centerview Partners had anything to do with the Merger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_802_2</DOCNO>
            	<TEXT>But you never know WHO YOU KNOW!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_803_0</DOCNO>
            	<TEXT>Now we know why DR JI wanted us to vote for #5.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_803_1</DOCNO>
            	<TEXT>BIG MONEY is coming our way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_803_2</DOCNO>
            	<TEXT>Keep our fingers crossed SP-102 gets FDA approval.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_804_0</DOCNO>
            	<TEXT>This press release relates to a proposed transaction between Scilex and the SPAC.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_804_1</DOCNO>
            	<TEXT>This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_804_2</DOCNO>
            	<TEXT>In connection with the transaction described herein, contingent upon execution of the proposed Merger Agreement, the SPAC would file relevant materials with the SEC, including a registration statement on Form S-4, which will include a proxy statement/prospectus.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_804_3</DOCNO>
            	<TEXT>Investors and security holders of the SPAC are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents in connection with the transaction that the SPAC files with the SEC when, and if, they become available because they will contain important information about the SPAC, Scilex and the proposed transaction. "</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_805_0</DOCNO>
            	<TEXT>I just purchased a few shares of VCKA it can't hurt to own these shares before any POP in stock price.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_806_0</DOCNO>
            	<TEXT>Yes they were looking for a form that was probably late.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_806_1</DOCNO>
            	<TEXT>Everything should be in order.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_806_2</DOCNO>
            	<TEXT>It's all good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_807_0</DOCNO>
            	<TEXT>Did they confirm my suspicions?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_808_0</DOCNO>
            	<TEXT>The offering was at $12.50.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_808_1</DOCNO>
            	<TEXT>And they raised $140M and the current value is $173.1M. Currently trading at $10.04.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_808_2</DOCNO>
            	<TEXT>I would rather get in now and forget I own a piece of this spac.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_808_3</DOCNO>
            	<TEXT>Come next year if and when you get an FDA approval for SP-102.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_808_4</DOCNO>
            	<TEXT>We could be looking at a 10x bagger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_809_0</DOCNO>
            	<TEXT>Bigger then you ever imagined.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_0</DOCNO>
            	<TEXT>Manager Data Solution at Johnson  amp; Johnson is thrilled and can't wait for an SP -102 epidural.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_1</DOCNO>
            	<TEXT>She's probably pregnant and she responded to DR S. Jaism CEO of Scilex.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_2</DOCNO>
            	<TEXT>Please view for yourselves with the link that I provided below.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_3</DOCNO>
            	<TEXT>It's only a matter of time the non opioids drugs start to take over. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_4</DOCNO>
            	<TEXT>https://www.linkedin.com/in/jaisimshah/detail/recent-activity/](https://www.linkedin.com/in/jaisimshah/detail/recent-activity/) Could she be pregnant?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_5</DOCNO>
            	<TEXT>Or just joking?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_6</DOCNO>
            	<TEXT>Or hoping J  amp; J does business with Scilex?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_810_7</DOCNO>
            	<TEXT>Looks like see knows who DR Jaism is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_811_0</DOCNO>
            	<TEXT>DR J knows a lot of people!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_812_0</DOCNO>
            	<TEXT>I have a feeling we're going to get another release about that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_0</DOCNO>
            	<TEXT>So here's a twist to the post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_1</DOCNO>
            	<TEXT>The Data Manager is not a woman.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_2</DOCNO>
            	<TEXT>It's a Man making the comment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_3</DOCNO>
            	<TEXT>So the Data Manager for Johnson  amp; Johnson can't wait for the SP-102 Epidural.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_4</DOCNO>
            	<TEXT>Can SP-102 be used for an epidural?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_5</DOCNO>
            	<TEXT>If so could this be another market?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_6</DOCNO>
            	<TEXT>What does a Manager Data Solution Manager do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_7</DOCNO>
            	<TEXT>The Data Solutions Manager must ensure attention to detail in all facets of their teams work and take full responsibility for any errors that occur and be fully responsible for the workflow and stakeholder management covering all clients and projects in their portfolio.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_8</DOCNO>
            	<TEXT>I believe once the merger is complete we could see a BP take over.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_813_9</DOCNO>
            	<TEXT>That's my guess.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_814_0</DOCNO>
            	<TEXT>Yes there a lot of reasons why.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_0</DOCNO>
            	<TEXT>WHO IS SORRENTO'S INTERNATIONAL ADVISOR TO LATIN AMERICA?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_1</DOCNO>
            	<TEXT>Everyone please read.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_2</DOCNO>
            	<TEXT>Today we received a news release Sorrento Receives Orders of COVISTIX for Commercial Launch in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_3</DOCNO>
            	<TEXT>Here's the rest of the news release.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_4</DOCNO>
            	<TEXT>Sorrento has received orders from its logistics partner and a large diagnostic laboratory client for official commercial launch of COVISTIX COVID-19 Virus Rapid Antigen Detection Test in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_5</DOCNO>
            	<TEXT>SAN DIEGO, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento) announced today that initial loading orders have been processed and scheduled for delivery later this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_6</DOCNO>
            	<TEXT>The initial shipment will establish an in-country safety stock to manage just in time ongoing deliveries to local clients.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_7</DOCNO>
            	<TEXT>In addition to the loading order, Sorrentos local distribution partner has received an order from a large diagnostic laboratory in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_8</DOCNO>
            	<TEXT>The laboratory has a central processing unit and collaborates with about 2,000 other smaller units across the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_9</DOCNO>
            	<TEXT>COVISTIX tests will be delivered in successive shipments starting later in December and will continue over time as in country supplies are matched to the increasing demand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_10</DOCNO>
            	<TEXT>Sorrento has also started expanding its activities to other Latin American countries that accept Brazilian approved products for import.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_11</DOCNO>
            	<TEXT>I believe Natcofarma Do Brazil is our logistic partner that will help distribute COVISTIX through out Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_12</DOCNO>
            	<TEXT>Sorrento in May 2020 hired Eduardo Rocha who is the head of operations for Natcofarma Do Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_13</DOCNO>
            	<TEXT>On Eduardo's LinkedIn page it states his title is working for Sorrento as International Advisor to Latam.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_14</DOCNO>
            	<TEXT>So if Eduard's on your payroll since May 2020 why wouldn't you go through his company?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_15</DOCNO>
            	<TEXT>We're paying this guy to get us to distribute COVISTIX or anything else approved in Brazil throughout Latin America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_16</DOCNO>
            	<TEXT>Eduardo Rocha has to be the guy?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_17</DOCNO>
            	<TEXT>If I was the head of operations of Natcofarma Do Brazil and I was being paid as an advisor I would flow everything through my company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_18</DOCNO>
            	<TEXT>Why wouldn't we?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_19</DOCNO>
            	<TEXT>Here's the part I had to read three times.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_20</DOCNO>
            	<TEXT>So let's read it again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_21</DOCNO>
            	<TEXT>The laboratory has a central processing unit and collaborates with about 2,000 other smaller units across the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_22</DOCNO>
            	<TEXT>Did I read this right?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_23</DOCNO>
            	<TEXT>2,000 other smaller units across Brazil?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_24</DOCNO>
            	<TEXT>Those 2000 other units must be Pharmacy's.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_25</DOCNO>
            	<TEXT>So how come we weren't given the name?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_26</DOCNO>
            	<TEXT>Or how big the order is?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_27</DOCNO>
            	<TEXT>Because you never let the competition know what your doing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_28</DOCNO>
            	<TEXT>Some times in sales something could be $1 cheaper and not as good.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_29</DOCNO>
            	<TEXT>And the buyer will still pick the cheaper brand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_30</DOCNO>
            	<TEXT>So don't let them know who's buying or how much.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_31</DOCNO>
            	<TEXT>It's none of there business.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_32</DOCNO>
            	<TEXT>What matters is at the end of the quarter how many COVISTIX were sold.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_33</DOCNO>
            	<TEXT>So my guess is Eduardo Rocha Head of Natcofarma Do Brazil is earning his money that we've been paying him since May 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_34</DOCNO>
            	<TEXT>Telling everyone COVISTIX is the best of the best.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_35</DOCNO>
            	<TEXT>Here's the links for you to make your our assumptions. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_36</DOCNO>
            	<TEXT>https://www.linkedin.com/in/eduardo-rocha-7022051b3/#](https://www.linkedin.com/in/eduardo-rocha-7022051b3/#) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-orders-covistix-commercial-launch-brazil](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-receives-orders-covistix-commercial-launch-brazil) Have a nice night.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_815_37</DOCNO>
            	<TEXT>And don't forget what I always say....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_0</DOCNO>
            	<TEXT>Jeffrey Chi is the Chairman CEO of Vickers Venture Partners</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_1</DOCNO>
            	<TEXT>Vickers Vantage Corp. I is a Cayman Islands exempted company incorporated as a blank check company for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities, which we refer to throughout our prospectus as our initial business combination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_2</DOCNO>
            	<TEXT>Our efforts to identify a prospective target business will not be limited to a particular industry or geographic region.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_3</DOCNO>
            	<TEXT>We do not have any specific business combination under consideration and we have not (nor has anyone on our behalf), directly or indirectly, contacted any prospective target business or had any substantive discussions, formal or otherwise, with respect to such a transaction.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_4</DOCNO>
            	<TEXT>We intend to leverage the expertise and network of Vickers Venture Partners, or VVP, a venture capital firm affiliated with our executive officers, to take advantage of its deal flow, strong networks and technical expertise in assisting us in consummating an initial business combination.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_5</DOCNO>
            	<TEXT>VVP was co-founded in 2005 by Dr. Jeffrey Chi, our Chairman and Chief Executive Officer, along with Dr. Finian Tan (an advisor of ours), Dr. Khalil Binebine, Ms. Linda Li, Dr. Damian Tan and Mr. Raymond Kong.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_6</DOCNO>
            	<TEXT>VVP has offices in Singapore, Shanghai, San Francisco, New York and Hong Kong.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_7</DOCNO>
            	<TEXT>VVP is currently the most medaled venture capital firm in Singapore, having won five awards from the Singapore Venture Capital and Private Equity Association (SVCA) since the inception of the awards in 2010, and is also the 5th ranked most consistent top performing fund manager in the world according to Preqins database as of June 30, 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_8</DOCNO>
            	<TEXT>Check this out... Vickers Venture sees about 130x return from Chinese firms IPO Update (Oct. 29, 7:20 p.m. SGT): This article was updated to add details about Vicker Ventures investment in Jing-Jin Electric.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_9</DOCNO>
            	<TEXT>Vickers Venture Partners said that it saw a return of about 129x from its portfolio firm Jing-Jin Electric, which went public on Shanghais Science and Technology Innovation Board (STAR) market recently.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_10</DOCNO>
            	<TEXT>Read for yourselves.. [https://www.techinasia.com/vickers-ventures-about-130x-return-chinese-firms-jingjin-electric-ipo](https://www.techinasia.com/vickers-ventures-about-130x-return-chinese-firms-jingjin-electric-ipo) So lets read this again... The 5th ranked most consistent top performing fund manager in the world according to Preqins database as of June 30, 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_11</DOCNO>
            	<TEXT>5th most consistent top performing fund manager in the world has just entered a letter of intent with... Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (SPAC) Enter into Letter of Intent for Proposed Business Combination [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-and](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-and) DO YOU KNOW HOW MANY FUND MANAGERS THERE ARE IN THE WORLD?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_12</DOCNO>
            	<TEXT>10s of Thousands.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_13</DOCNO>
            	<TEXT>SCILEX HAS THE 5TH BEST ONE IN THE WORLD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_14</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_817_15</DOCNO>
            	<TEXT>Because.....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_818_0</DOCNO>
            	<TEXT>THE BEST IS YET TO COME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_819_0</DOCNO>
            	<TEXT>So ask yourselves why would the 5th ranked most consistent top performing fund manager in the world be interested with Scilex?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_819_1</DOCNO>
            	<TEXT>Because when he saw that there's double digit BILLION revenue annually in the pain management market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_819_2</DOCNO>
            	<TEXT>He fell off his chair and flew the San Diego to meet with DR J  amp; DR S. They know exactly what there investing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_820_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Clinical Laboratory Receives Accreditation From the College of American Pathologists https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-clinical-laboratory-receives-accreditation</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_820_1</DOCNO>
            	<TEXT>Sorrento Therapeutics Clinical Laboratory Receives Accreditation From the College of American Pathologists [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-clinical-laboratory-receives-accreditation](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-clinical-laboratory-receives-accreditation)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_821_0</DOCNO>
            	<TEXT>this means that they can tap into a $20 billion market of patient sample testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_821_1</DOCNO>
            	<TEXT>caviar is they sell covistick.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_821_2</DOCNO>
            	<TEXT>SRNE is in good shape going forward.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_821_3</DOCNO>
            	<TEXT>they will be generating huge revenue!!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_822_0</DOCNO>
            	<TEXT>this means that they can tap into a $20 billion market of patient sample testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_822_1</DOCNO>
            	<TEXT>caviar is they sell covistick.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_822_2</DOCNO>
            	<TEXT>SRNE is in good shape going forward.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_822_3</DOCNO>
            	<TEXT>they will be generating huge revenue!!!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_823_0</DOCNO>
            	<TEXT>I believe so</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_824_0</DOCNO>
            	<TEXT>I feel we should be giving some kind of update from DARPA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_0</DOCNO>
            	<TEXT>ASK YOURSELVES WHO OWNS THE MOST PHARMACIES IN BRAZIL?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_1</DOCNO>
            	<TEXT>Lets read the press release one more time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_2</DOCNO>
            	<TEXT>Sorrentos local distribution partner has received an order from a large diagnostic laboratory in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_3</DOCNO>
            	<TEXT>The laboratory has a central processing unit and collaborates with about 2,000 other smaller units across the country.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_4</DOCNO>
            	<TEXT>The smaller 2000 units must be pharmacies?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_5</DOCNO>
            	<TEXT>So let's take a look...Brazil's largest pharmacy chain Raia Drogasil buys rival from CVS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_6</DOCNO>
            	<TEXT>BRASILIA (Reuters) - Brazils largest pharmacy chain Raia Drogasil SA said on Tuesday it would fully acquire Drogaria Onofre, a rival controlled by CVS Health Corp. Raia Drogasil said in a statement it had reached an agreement with CCI Foreign, S. r.l.,</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_7</DOCNO>
            	<TEXT>Beauty Holdings and a unit of CVS to buy the chain with 50 stores in Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_8</DOCNO>
            	<TEXT>CVS bought Drogaria Onofre in 2013 in its first acquisition outside of the United States.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_9</DOCNO>
            	<TEXT>Onofre had 479.4 million reais ($127.88 million) in gross revenue in 2018, the statement said. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_10</DOCNO>
            	<TEXT>https://www.reuters.com/article/us-cvs-health-divestiture-raia-drogasil/brazils-largest-pharmacy-chain-raia-drogasil-buys-rival-from-cvs-idUSKCN1QF2ZP](https://www.reuters.com/article/us-cvs-health-divestiture-raia-drogasil/brazils-largest-pharmacy-chain-raia-drogasil-buys-rival-from-cvs-idUSKCN1QF2ZP) The 1,000-plus Drogasil stores can be found in 17 Brazilian states in more than 75 cities, with more than 560 located in So Paulo alone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_11</DOCNO>
            	<TEXT>In addition to branded, generic, and over-the-counter pharmaceuticals, the pharmacy chain sells a broad range of health and over-the-counter pharmaceuticals, the pharmacy chain sells a broad range of health and beauty products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_12</DOCNO>
            	<TEXT>Raia Drogasil was created in 2011 through the merger of Raia S.A. and Drogasil S.A. My friends we have a massive whale in our boat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_13</DOCNO>
            	<TEXT>If it's not Raia Drogasil then it's one of there Top Competitors. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_14</DOCNO>
            	<TEXT>https://www.dnb.com/business-directory/company-profiles.raia\_drogasil\_s-a.32fbaec7d62e083c5354f68b953edfb4.html](https://www.dnb.com/business-directory/company-profiles.raia_drogasil_s-a.32fbaec7d62e083c5354f68b953edfb4.html) Remember the saying WE NEED A BIGGER BOAT?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_825_15</DOCNO>
            	<TEXT>2022 is going to be a BLOCKBUSTER HAPPY NEW YEAR!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_826_0</DOCNO>
            	<TEXT>So ask yourselves why would the 5th ranked most consistent top performing fund manager in the world be interested with Scilex?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_826_1</DOCNO>
            	<TEXT>Because when he saw that there's double digit BILLION revenue annually in the pain management market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_826_2</DOCNO>
            	<TEXT>He fell off his chair and flew the San Diego to meet with DR J  amp; DR S. They know exactly what there investing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_827_0</DOCNO>
            	<TEXT>So ask yourselves why would the 5th ranked most consistent top performing fund manager in the world be interested with Scilex?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_827_1</DOCNO>
            	<TEXT>Because when he saw that there's double digit BILLION revenue annually in the pain management market.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_827_2</DOCNO>
            	<TEXT>He fell off his chair and flew the San Diego to meet with DR J  amp; DR S. They know exactly what there investing in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_828_0</DOCNO>
            	<TEXT>READ THE CAP ANNUAL REPORT</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_828_1</DOCNO>
            	<TEXT>In the press release today in big bold letters it says READ THE CAP ANNUAL REPORT at cap.org.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_828_2</DOCNO>
            	<TEXT>Here's the 2020 Annual report [https://annualreport.cap.org/influencing-public-policy/](https://annualreport.cap.org/influencing-public-policy/) Here's the link of the press release. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_828_3</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-clinical-laboratory-receives-accreditation](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-therapeutics-clinical-laboratory-receives-accreditation) There's a lot to read but I did read there was $1B allocated for COVID-19 testing in 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_828_4</DOCNO>
            	<TEXT>Since then in February they had set aside $20B for new testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_828_5</DOCNO>
            	<TEXT>I'm sure 2022 will be even more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_828_6</DOCNO>
            	<TEXT>Do your DD and read and know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_0</DOCNO>
            	<TEXT>National Pearl Harbor Remembrance Day December 7th 1941</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_1</DOCNO>
            	<TEXT>Each year on Dec. 7, Pearl Harbor Survivors, veterans, and visitors from all over the world come together to honor and remember the 2,403 service members and civilians who were killed during the Japanese attack on Pearl Harbor on December 7, 1941.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_2</DOCNO>
            	<TEXT>A further 1,178 people were injured in the attack, which permanently sank two U.S. Navy battleships (the USS Arizona and the USS Utah) and destroyed 188 aircraft.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_3</DOCNO>
            	<TEXT>I would like to honor my friend who recently passed away this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_4</DOCNO>
            	<TEXT>My friend Click ( Armando) Galella was a Pearl Harbor survivor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_5</DOCNO>
            	<TEXT>He lived to be 100 years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_6</DOCNO>
            	<TEXT>He passed away on September 29th 2021 of COVID-19. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_7</DOCNO>
            	<TEXT>https://www.lohud.com/story/news/local/westchester/sleepy-hollow/2021/09/30/chick-galella-sleepy-hollow-pearl-harbor-survivor-dies/5925773001/](https://www.lohud.com/story/news/local/westchester/sleepy-hollow/2021/09/30/chick-galella-sleepy-hollow-pearl-harbor-survivor-dies/5925773001/) I remember him telling me how they reacted during the attack.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_8</DOCNO>
            	<TEXT>He witnessed bombs falling all around him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_9</DOCNO>
            	<TEXT>Him and his friends ran to Hickam Field to bust open the ammo locker to retrieve the guns that were used to defend themselves from the Japanese raid at the field that day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_10</DOCNO>
            	<TEXT>Today I felt his presence was with me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_11</DOCNO>
            	<TEXT>Today was our best day in months his he passed away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_12</DOCNO>
            	<TEXT>I remembered the day I told everyone on this board of his passing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_13</DOCNO>
            	<TEXT>I would like to say he was meet with love from people around the World that never meet him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_14</DOCNO>
            	<TEXT>Board members in multiple States lowered their flags to honor him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_15</DOCNO>
            	<TEXT>I truly believe he helped us today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_16</DOCNO>
            	<TEXT>Today was his way to show his Gratitude for all the love you all showed him back on September the 29th.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_17</DOCNO>
            	<TEXT>I know he's up there looking down on me saying.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_18</DOCNO>
            	<TEXT>Don't give up!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_19</DOCNO>
            	<TEXT>Work hard at what you believe in.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_20</DOCNO>
            	<TEXT>That the best days are ahead of us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_829_21</DOCNO>
            	<TEXT>May God Bless You All.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_830_0</DOCNO>
            	<TEXT>I will drink to that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_0</DOCNO>
            	<TEXT>COVISTIX WILL FINALLY BE APPROVED IN THE USA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_1</DOCNO>
            	<TEXT>Senior Marketing/Marketing Manager.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_2</DOCNO>
            	<TEXT>This role is based in San Diego, CA, with frequent travel to partners and suppliers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_3</DOCNO>
            	<TEXT>Estimate travel at 25%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_4</DOCNO>
            	<TEXT>The Senior Marketing Manager will assist and help develop the promotion efforts of the marketing department.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_5</DOCNO>
            	<TEXT>Responsible for providing marketing collateral and managing the branding efforts to successfully commercialize Sorrentos new product (COVISTIX).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_6</DOCNO>
            	<TEXT>This role has the potential to grow in responsibility and will require a hands-on approach to job duties.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_7</DOCNO>
            	<TEXT>COVISTIX is a highly sensitive rapid antigen test for detecting SARS-CoV-2 that has demonstrated superior sensitivity at low levels of virus detection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_8</DOCNO>
            	<TEXT>WHAT YOULL DO: Successfully plan and launch Covistix in Point Of Care (POC) and at-home markets.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_9</DOCNO>
            	<TEXT>Conduct market, positioning, and pricing research.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_10</DOCNO>
            	<TEXT>Advance launch strategies for different segments and develop Brand Book.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_11</DOCNO>
            	<TEXT>Develop compelling marketing collateral to support launch for POC and at-home market use.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_12</DOCNO>
            	<TEXT>Provide expertise and direction to cross functional teams utilizing a hands-on approach.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_13</DOCNO>
            	<TEXT>Identify, assess, and prioritize POC targets, manage key relationships, and put contracts in place for the first phase of launch.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_14</DOCNO>
            	<TEXT>Responsible for marketing budgets and performance reporting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_15</DOCNO>
            	<TEXT>Responsible for ensuring the team follows all SOPs (Doc Control, Promotional Review Committee, etc.).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_16</DOCNO>
            	<TEXT>Other duties as assigned.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_17</DOCNO>
            	<TEXT>TRAVEL: This role is based in San Diego, CA, with frequent travel to partners and suppliers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_18</DOCNO>
            	<TEXT>Estimate travel at 25% So lets read this one more time. (</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_19</DOCNO>
            	<TEXT>TRAVEL: This role is based in San Diego, CA.) [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_20</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=464](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=464) In this new position it does not say that you need to speak Hispanic / Brazilian / Portuguese.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_21</DOCNO>
            	<TEXT>This is an AMERICAN position that will require traveling in the USA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_22</DOCNO>
            	<TEXT>DR JI was interviewed by Raghuram Selvaragu of H.C. Wainwright  amp; Co and in the interview said, COVISTIX should be fully approved before the end of the year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_23</DOCNO>
            	<TEXT>The COVISTIX website is live and Sorrento received the Accreditation From the College of American Pathologists.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_24</DOCNO>
            	<TEXT>Mexico, Brazil, and the USA is next.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_25</DOCNO>
            	<TEXT>Buckle up and enjoy the ride we all deserve it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_831_26</DOCNO>
            	<TEXT>The best days are finally coming our way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_832_0</DOCNO>
            	<TEXT>Nice job you beat me to the post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_833_0</DOCNO>
            	<TEXT>It doesn't say anywhere that you have to be Bi lingual</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_834_0</DOCNO>
            	<TEXT>Now your thinking like a PI.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_834_1</DOCNO>
            	<TEXT>You're hired.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_835_0</DOCNO>
            	<TEXT>Boom party.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_836_0</DOCNO>
            	<TEXT>Marketwatch 306.34m</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_0</DOCNO>
            	<TEXT>FAST TRACKING CONSTRUCTION</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_1</DOCNO>
            	<TEXT>The project was constructed in three phases on a fast-track schedule with successive occupancy dates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_2</DOCNO>
            	<TEXT>FPBA coordinated the approvals for this phasing with the building officials using a single set of permit drawings and obtained the permit in just four weeks to complete design and start construction ahead of schedule.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_3</DOCNO>
            	<TEXT>Sorrento Therapeutics Sorrento Therapeutics is an antibody-centric, clinical stage biopharmaceutical company focused on the discovery and development of safe and effective immunotherapies for oncology and autoimmune/inflammation diseases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_4</DOCNO>
            	<TEXT>The companys acquisition of several companies drove the need to expand its facilities and bring these acquisitions under one roof in a leased 75,000-square-foot building.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_5</DOCNO>
            	<TEXT>The project included renovation of existing labs, offices and a lobby, along with new designs for labs, offices, a vivarium, a lunch room, a lunch patio and a board room.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_6</DOCNO>
            	<TEXT>Sorrentos scientific groups included bacteria, infectious disease, oncology/immunology, TNK, LA Cell, and chemistry, some of which were new groups within the company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_7</DOCNO>
            	<TEXT>Ferguson Pape Baldwin Architects worked closely with these groups to establish a common lab module that would meet their specific needs but also be flexible for groups to expand and share space as they grow within two large open laboratories.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_8</DOCNO>
            	<TEXT>This included the chemistry lab, which required segregation for safety and contamination control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_9</DOCNO>
            	<TEXT>FPBA assisted with capturing equipment information for legacy equipment coming from several different locations and consolidated shared equipment in centrally located support rooms to save space and money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_10</DOCNO>
            	<TEXT>The project was constructed in three phases on a fast-track schedule with successive occupancy dates.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_11</DOCNO>
            	<TEXT>FPBA coordinated the approvals for this phasing with the building officials using a single set of permit drawings and obtained the permit in just four weeks to complete design and start construction ahead of schedule. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_12</DOCNO>
            	<TEXT>https://fpbarch.com/portfolio/sorrento-therapeutics/](https://fpbarch.com/portfolio/sorrento-therapeutics/) READ THIS ONE MORE TIME The companys acquisition of several companies drove the need to expand its facilities and bring these acquisitions under one roof in a leased 75,000-square-foot building.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_13</DOCNO>
            	<TEXT>What companies?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_14</DOCNO>
            	<TEXT>Acea Therapeutics and ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_15</DOCNO>
            	<TEXT>They said companies?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_16</DOCNO>
            	<TEXT>Saving money putting them under one roof to save money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_17</DOCNO>
            	<TEXT>Very smart idea!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_837_18</DOCNO>
            	<TEXT>Sorrento is developing into a BP just like DR JI said in 3 to 5 years $200 Billion dollar company.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_838_0</DOCNO>
            	<TEXT>FPBA assisted with capturing equipment information for legacy equipment coming from several different locations and consolidated shared equipment in centrally located support rooms to save space and money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_839_0</DOCNO>
            	<TEXT>Saving money and making more money means better revenues.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_840_0</DOCNO>
            	<TEXT>The companys acquisition of several companies drove the need to expand its facilities and bring these acquisitions under one roof in a leased 75,000-square-foot building.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_840_1</DOCNO>
            	<TEXT>What companies?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_840_2</DOCNO>
            	<TEXT>Acea Therapeutics and ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_840_3</DOCNO>
            	<TEXT>They said companies?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_842_0</DOCNO>
            	<TEXT>You and I should tour this location after they build the new building across the street.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_842_1</DOCNO>
            	<TEXT>This way we kill two bird with one stone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_843_0</DOCNO>
            	<TEXT>It's great DD on your part to know the difference.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_846_0</DOCNO>
            	<TEXT>Before we close today watch how we sky rocket.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_847_0</DOCNO>
            	<TEXT>I couldn't agree more with your post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_848_0</DOCNO>
            	<TEXT>Yes you did.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_0</DOCNO>
            	<TEXT>A message from DR S. Jaisim.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_1</DOCNO>
            	<TEXT>Today is a great day for Scilex Holding, we announced topline results of the pivotal Phase 3 trial for SP-102.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_2</DOCNO>
            	<TEXT>The team has worked on this program for over 7 years since the inception of Semnur, and Im thrilled to have led this from inception and design to this very amazing outcome where if approved we may be able to help the millions struggling from chronic back pain with limited options and also hope to minimize the overuse of opioids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_3</DOCNO>
            	<TEXT>This data milestone reflects years of product development, preclinical and clinical research and dedication, huge thanks Semnur/Scilex/Sorrento Team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_4</DOCNO>
            	<TEXT>Very fortunate in a 30 year career in life science industry to have led the development and commercialization teams of other global blockbuster products addressing huge unmet need including Rituxan at Roche/Biogen ($8 billion in peak annual sales) and Abilify at BMS/Otsuka ( gt;$6 billion in peak sales).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_5</DOCNO>
            	<TEXT>Thanks to the thousands of connections in this network and numerous friends and colleagues I have worked with who provided encouragement, advice and support along great journey for this next potential breakthrough product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_6</DOCNO>
            	<TEXT>Please click the link below and everyone can view the comments from his friends. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_7</DOCNO>
            	<TEXT>https://www.linkedin.com/in/jaisimshah/detail/recent-activity/](https://www.linkedin.com/in/jaisimshah/detail/recent-activity/) What ever fears you had you can put them to bed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_8</DOCNO>
            	<TEXT>There's no longer any risk with Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_9</DOCNO>
            	<TEXT>Soon SP- 102 will be FDA approved and generate BILLIONS in revenue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_849_10</DOCNO>
            	<TEXT>My friends the....</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_850_0</DOCNO>
            	<TEXT>I added more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_851_0</DOCNO>
            	<TEXT>The markets are in the red and XBI is down 2%.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_851_1</DOCNO>
            	<TEXT>We're holding strong nobody is selling.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_851_2</DOCNO>
            	<TEXT>Wait and watch hold we go up before the close.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_0</DOCNO>
            	<TEXT>Understanding the Epidemic</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_1</DOCNO>
            	<TEXT>The number of drug overdose deaths increased by nearly 5% from 2018 to 2019 and has quadrupled since 19991.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_2</DOCNO>
            	<TEXT>Over 70% of the 70,630 deaths in 2019 involved an opioid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_3</DOCNO>
            	<TEXT>From 2018 to 2019, there were significant changes in opioid-involved death rates: Three Waves of Opioid Overdose Deaths From 19992019, nearly 500,000 people died from an overdose involving any opioid, including prescription and illicit opioids1.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_4</DOCNO>
            	<TEXT>This rise in opioid overdose deaths can be outlined in three distinct waves.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_5</DOCNO>
            	<TEXT>The first wave began with increased prescribing of opioids in the 1990s, with overdose deaths involving prescription opioids (natural and semi-synthetic opioids and methadone) increasing since at least 19993.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_6</DOCNO>
            	<TEXT>The second wave began in 2010, with rapid increases in overdose deaths involving heroin4.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_7</DOCNO>
            	<TEXT>The third wave began in 2013, with significant increases in overdose deaths involving synthetic opioids, particularly those involving illicitly manufactured fentanyl5,6,7.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_8</DOCNO>
            	<TEXT>The market for illicitly manufactured fentanyl continues to change, and it can be found in combination with heroin, counterfeit pills, and cocaine.8 Combatting the Opioid Overdose Epidemic DC is committed to fighting the opioid overdose epidemic and supporting states and communities as they continue work to identify outbreaks, collect data, respond to overdoses, and provide care to those in their communities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_9</DOCNO>
            	<TEXT>Overdose Data to Action (OD2A) is a 3-year cooperative agreement through which CDC funds health departments in 47 states, Washington DC, two territories, and 16 cities and counties for surveillance and prevention efforts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_10</DOCNO>
            	<TEXT>These efforts include timelier tracking of nonfatal and fatal drug overdoses, improving toxicology to better track polysubstance-involved deaths, enhancing linkage to care for people with opioid use disorder and risk for opioid overdose, improving prescription drug monitoring programs, implementing health systems interventions, partnering with public safety, and implementing other innovative surveillance and prevention activities.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_11</DOCNO>
            	<TEXT>THIS LINK WAS ON SCILEX'S NEW RELEASE.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_12</DOCNO>
            	<TEXT>PLEASE CLICK AND READ [https://www.cdc.gov/opioids/basics/epidemic.html](https://www.cdc.gov/opioids/basics/epidemic.html) The CDC wants to end this Epidemic and Semnur/Scilex/Sorrento Team have been working to help for the last 7 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_13</DOCNO>
            	<TEXT>We finally have found the light at the end of the tunnel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_14</DOCNO>
            	<TEXT>Keep following the light and it will bring you to the Lord.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_852_15</DOCNO>
            	<TEXT>God is GOOD all the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_853_0</DOCNO>
            	<TEXT>To the moon.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_854_0</DOCNO>
            	<TEXT>This link was on the press release today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_854_1</DOCNO>
            	<TEXT>This is exactly what the CDC wants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_855_0</DOCNO>
            	<TEXT>I could see that.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_856_0</DOCNO>
            	<TEXT>I like builders I used to be one myself but after 25 years I retired in 2008.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_857_0</DOCNO>
            	<TEXT>I can relate to how you feel.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_857_1</DOCNO>
            	<TEXT>After 25 years building  amp; Developmenting I retired in 2009.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_858_0</DOCNO>
            	<TEXT>I suffered from Sciatica for years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_858_1</DOCNO>
            	<TEXT>I found a great chiropractor who would adjust my hips and relieve the pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_858_2</DOCNO>
            	<TEXT>He always said that I was lucky.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_858_3</DOCNO>
            	<TEXT>Most people needed the shoots.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_859_0</DOCNO>
            	<TEXT>You're not overweight are you?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_859_1</DOCNO>
            	<TEXT>I carry a few extra pounds because I like to eat.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_859_2</DOCNO>
            	<TEXT>Sometimes I have to lose a few lbs to feel better.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_860_0</DOCNO>
            	<TEXT>Yes he does</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_861_0</DOCNO>
            	<TEXT>You have to have faith and believe that the best is yet to come.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_0</DOCNO>
            	<TEXT>I believe the stock was artificially suppressed from going up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_1</DOCNO>
            	<TEXT>Also the markets did not have a good day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_2</DOCNO>
            	<TEXT>SRNE is in the XBI fund which was down 4% yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_3</DOCNO>
            	<TEXT>SRNE held it's own pretty much most of the day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_4</DOCNO>
            	<TEXT>We clearly preformed better then the rest of the Biotech index.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_5</DOCNO>
            	<TEXT>The results released yesterday were very very good news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_6</DOCNO>
            	<TEXT>Everyone including DR J was celebrating yesterday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_7</DOCNO>
            	<TEXT>Now that we know the results were great.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_8</DOCNO>
            	<TEXT>It removes the RISK of owning the stock.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_9</DOCNO>
            	<TEXT>Because eventually SP- 102 will be FDA approved and generate revenue.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_10</DOCNO>
            	<TEXT>The reporting of revenue will move the needle and raise the stock price.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_862_11</DOCNO>
            	<TEXT>No more worries now time is on our side.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_0</DOCNO>
            	<TEXT>Who is DR Steven P. Cohen?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_1</DOCNO>
            	<TEXT>Chief of Pain Medicine and Professor of Anesthesiology  amp; Critical Care Medicine, Neurology, Physical Medicine  amp; Rehabilitation, and Psychiatry  amp; Behavioral Sciences at the Johns Hopkins School of Medicine, and a Professor of Anesthesiology and Physical Medicine  amp; Rehabilitation at Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_2</DOCNO>
            	<TEXT>Lets review his background.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_3</DOCNO>
            	<TEXT>Dr. Cohen has been very active in teaching and pain research in recent years, having published over 250 peer-reviewed articles, reviews and book chapters in the past 15 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_4</DOCNO>
            	<TEXT>Among his major contributions are the development of an FDA-approved technique for treating sacroiliac joint pain (lateral branch radiofrequency denervation), inventing the intravenous ketamine test to help guide treatment in patients with chronic pain, and performing the first studies evaluating the epidural administration of biological agents for pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_5</DOCNO>
            	<TEXT>These articles have been featured in some of the top general medical journals including Lancet, CMAJ, BMJ, Annals of Internal Medicine and JAMA-Internal Medicine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_6</DOCNO>
            	<TEXT>His research has been the subject of articles in the Science Section of the New York Times on 4 separate occasions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_7</DOCNO>
            	<TEXT>He has been the first author on the Pain chapter in the last 2 editions of Cecil Textbook of Medicine, and was listed in 2014 as one of the top 10 experts in the world for back pain based on quantitative analysis of publications.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_8</DOCNO>
            	<TEXT>In addition to his academic work, Dr. Cohen is a retired Colonel in the U.S. Army, and was deployed 4 times in support of operations in Bosnia, Iraq and Afghanistan.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_9</DOCNO>
            	<TEXT>He also serves as the Reserve Liaison to the Pain Management Consultants to the U.S. Army and Navy Surgeons General.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_10</DOCNO>
            	<TEXT>Dr. Cohen has previously presented data on pain management in service members to the U.S. Congress, FDA and General Officers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_11</DOCNO>
            	<TEXT>His research was instrumental in the passage of the 2008 Military Pain Care Act, and he served as an inaugural member of the U.S. Army Medical Advisory Board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_12</DOCNO>
            	<TEXT>His previous awards include the American Society of Regional Anesthesia  amp; Pain Medicine John J. Bonica Award, ASIPP Public Service Award, Donlin M. Long Pain Award, Michael J. Cousins Award Lecture, American Academy of Pain Medicine Founders Award, the Order of Military Medical Merit, and the Legion of Merit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_13</DOCNO>
            	<TEXT>So let's read this part one more time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_14</DOCNO>
            	<TEXT>His research has been the subject of articles in the Science Section of the New York Times on 4 separate occasions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_15</DOCNO>
            	<TEXT>He has been the first author on the Pain chapter in the last 2 editions of Cecil Textbook of Medicine, and was listed in 2014 as one of the top 10 experts in the world for back pain based on quantitative analysis of publications. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_16</DOCNO>
            	<TEXT>https://www.hopkinsmedicine.org/profiles/details/steven-cohen](https://www.hopkinsmedicine.org/profiles/details/steven-cohen) Did you read that?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_17</DOCNO>
            	<TEXT>One of the top 10 experts in the world.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_18</DOCNO>
            	<TEXT>The CDC  amp; the FDA know who DR Cohen is.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_19</DOCNO>
            	<TEXT>And in his own words he said,... We are anxiously awaiting a new injectable gel formulation of dexamethasone and submission of this data to the FDA for the treatment of radicular pain based on the results of a large, randomized, placebo-controlled, multi-center trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_20</DOCNO>
            	<TEXT>If approved by the FDA, SP-102 (SEMDEXA) would be the first corticosteroid with an indication for epidural administration in the U.S. and world, and providing meaningful, extended pain relief.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_21</DOCNO>
            	<TEXT>SP-102 (SEMDEXA) would be a welcome addition to the armamentarium of interventional pain physicians, providing a non-surgical, non-opioid alternative for a condition affecting millions of people, I wonder how many experts are there in the World?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_22</DOCNO>
            	<TEXT>Well Sorrento has one of the best working for them.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_23</DOCNO>
            	<TEXT>I want to Thank DR Cohen for his service and hard work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_24</DOCNO>
            	<TEXT>In his eyes he wants to help US service members and all other people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_863_25</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_864_0</DOCNO>
            	<TEXT>Oncolytic Virotherapy Market with COVID-19 Impact Analysis includes, SWOT Analysis, Business Opportunity, Trends and Forecast to 2029 Published: Dec. 10, 2021 at 3:54 a.m. ET SORRENTO IS A KEY PLAYER!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_864_1</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/oncolytic-virotherapy-market-with-covid-19-impact-analysi</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_864_2</DOCNO>
            	<TEXT>Oncolytic Virotherapy Market with COVID-19 Impact Analysis includes, SWOT Analysis, Business Opportunity, Trends and Forecast to 2029 Published: Dec. 10, 2021 at 3:54 a.m. ET SORRENTO IS A KEY PLAYER! [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_864_3</DOCNO>
            	<TEXT>https://www.marketwatch.com/press-release/oncolytic-virotherapy-market-with-covid-19-impact-analysis-includes-swot-analysis-business-opportunity-trends-and-forecast-to-2029-2021-12-10?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/oncolytic-virotherapy-market-with-covid-19-impact-analysis-includes-swot-analysis-business-opportunity-trends-and-forecast-to-2029-2021-12-10?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_865_0</DOCNO>
            	<TEXT>Written and released December 7th 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_865_1</DOCNO>
            	<TEXT>Excellent find!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_866_0</DOCNO>
            	<TEXT>NEW PATENT GRANTED 12/7/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_866_1</DOCNO>
            	<TEXT>[https://uspto.report/patent/grant/11,191,845](https://uspto.report/patent/grant/11,191,845)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_0</DOCNO>
            	<TEXT>Total Coronavirus Cases in the United Kingdom</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_1</DOCNO>
            	<TEXT>United Kingdom Coronavirus Cases: 10,719,165 Deaths: 146,255 Recovered: 9,414,117 Updates December 10th 2021 58,194 new cases and 120 new deaths in the United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_2</DOCNO>
            	<TEXT>NOTE from the UK government \[source: cases  gt; about\]: "The way cases are reported in England changed on 21 May 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_3</DOCNO>
            	<TEXT>Reported cases are sometimes removed if subsequent tests are negative.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_4</DOCNO>
            	<TEXT>This happens when cases identified through a positive rapid lateral flow test are followed by polymerase chain reaction (PCR) tests within 3 days that are all negative.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_5</DOCNO>
            	<TEXT>These cases are removed daily from 21 May 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_6</DOCNO>
            	<TEXT>Because of this, the number of newly-reported cases may not be the same as the difference between the total number of reported cases from one day to the next.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_7</DOCNO>
            	<TEXT>The number of newly-reported cases in England and the UK is adjusted to take this into account, but the numbers for regions and local authorities are not adjusted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_8</DOCNO>
            	<TEXT>This means that for regions and local authorities, this figure does not show the actual number of new cases reported on that date."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_9</DOCNO>
            	<TEXT>\[source\] [https://www.worldometers.info/coronavirus/country/uk/](https://www.worldometers.info/coronavirus/country/uk/) Covid-19 has spike to an all time high in the United Kingdom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_10</DOCNO>
            	<TEXT>Sorrento is currenting enrolling patients for the Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS) in Outpatient Adults With COVID-19 (UK) We started to enroll in early July and we could receive an update.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_11</DOCNO>
            	<TEXT>350 Outpatients in 6 months with the Country having an all time high in cases.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_12</DOCNO>
            	<TEXT>My guess we could hear something sooner or later around Christmas.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_867_13</DOCNO>
            	<TEXT>Ho Ho Ho Merry Christmas [https://covid201.com/COVID201](https://covid201.com/COVID201)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_868_0</DOCNO>
            	<TEXT>Wouldn't it be nice to get the results on Christmas Eve?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_869_0</DOCNO>
            	<TEXT>I would say that's a pretty good week.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_0</DOCNO>
            	<TEXT>Who are you referring to?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_1</DOCNO>
            	<TEXT>You say you guys are a pathetic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_2</DOCNO>
            	<TEXT>I don't need to know how much money you have invested.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_3</DOCNO>
            	<TEXT>If you're upset about your finances you should talk to your financial advisor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_4</DOCNO>
            	<TEXT>We're not here to give you finance advice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_5</DOCNO>
            	<TEXT>Please do me a favor the next time you post on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_6</DOCNO>
            	<TEXT>Don't be so obnoxious.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_870_7</DOCNO>
            	<TEXT>Because this post could be removed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_871_0</DOCNO>
            	<TEXT>I understand your frustration and it can be upsetting at times.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_871_1</DOCNO>
            	<TEXT>We have plenty of people that are holding a lot of shares.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_871_2</DOCNO>
            	<TEXT>None of us are freckling out.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_871_3</DOCNO>
            	<TEXT>So while your in our sand box please tune it down.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_874_0</DOCNO>
            	<TEXT>I wish I was the Lord because I would make everyone wealthy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_874_1</DOCNO>
            	<TEXT>Don't call anyone any names.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_874_2</DOCNO>
            	<TEXT>Sometimes when you don't agree the best thing to do is say nothing and walk away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_875_0</DOCNO>
            	<TEXT>I can tell your my age or close to it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_875_1</DOCNO>
            	<TEXT>If you were to say that quote to a 30 year old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_875_2</DOCNO>
            	<TEXT>They would look at you and say what?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_875_3</DOCNO>
            	<TEXT>One of these days oh one of these days!!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_876_0</DOCNO>
            	<TEXT>I know but wouldn't it be nice if they finished early?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_877_0</DOCNO>
            	<TEXT>Nice I was a builder and I retired in 2009.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_877_1</DOCNO>
            	<TEXT>My friend is an electrician and taught me the trade.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_877_2</DOCNO>
            	<TEXT>My biggest electrical job was installing a 400 amp service for my new I built.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_877_3</DOCNO>
            	<TEXT>Three 40 circuit sub panels and one 20 in my garage.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_878_0</DOCNO>
            	<TEXT>For my house.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_879_0</DOCNO>
            	<TEXT>It's ok we'll be drinking the finest kentucky Bourbon relaxing</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_880_0</DOCNO>
            	<TEXT>Small companies are scared to blow the whistle in fear of retaliations .</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_0</DOCNO>
            	<TEXT>WHAT IS EIDD-2801 ?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_1</DOCNO>
            	<TEXT>Sorrento Exercises Exclusive Option Agreement With Texas A amp;M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_2</DOCNO>
            	<TEXT>Sorrentos decision to immediately exercise its option is based on very promising preclinical data for the lead compound, MPI8, that shows highly potent broad-spectrum antiviral activity against SARS-CoV-2 and all of the major Variants of Concern (VoCs) (alpha, beta, delta and gamma).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_3</DOCNO>
            	<TEXT>Based on initial in vitro data, MPI8 demonstrated superior antiviral activity in a head-to-head comparison with a current Phase 3 investigational oral antiviral agent (EIDD2801).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_4</DOCNO>
            	<TEXT>Based on the IC50 data of the Plague Reduction Neutralization Test (PRNT) of live virus infecting Vero E6 cells, MPI8 demonstrated approximately ten-fold (10x) higher antiviral potency than EIDD-2801 against SARS-CoV-2 and its Alpha (UK) and Delta (Indian) VoCs and three to seven-fold (3-7x) higher antiviral potency against Beta (South Africa, 3X) and Gamma (Brazil/Japan, 6-7X) VoCs.. Currently there's another drug that's in clinical trial (EIDD2801) and MPI8 is showing 10X higher antiviral potency than (EIDD2801).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_5</DOCNO>
            	<TEXT>Back on August 26th, 2021 Sorrento Exercised Exclusive Option Agreement With Texas A amp;M University.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_6</DOCNO>
            	<TEXT>In August they announced Sorrento expects to complete additional preclinical studies in the coming weeks, including a head-to-head comparison against other late-stage clinical candidates, and will publish its preliminary findings in a pre-print publication.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_7</DOCNO>
            	<TEXT>Then on December 5th 2021 Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_8</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-series-novel-sars-cov-2-main](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-series-novel-sars-cov-2-main) [https://pubmed.ncbi.nlm.nih.gov/34242492/](https://pubmed.ncbi.nlm.nih.gov/34242492/) [http://www.usalifesciences.com/us/portal/news\_details.php?news\_id=26264851k](http://www.usalifesciences.com/us/portal/news_details.php?news_id=26264851k)$Sn9iDTy4BoTpw amp;page\_id=?next=1 [https://clinicaltrials.gov/ct2/show/NCT04405739?term=EIDD-2801 amp;draw=2 amp;rank=2](https://clinicaltrials.gov/ct2/show/NCT04405739?term=EIDD-2801 amp;draw=2 amp;rank=2) EVERYONE SHOULD CLICK AND OPEN AND READ ALL THE LINKS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_9</DOCNO>
            	<TEXT>As a selective inhibitor to both SARS-CoV-2 MPro and cathepsin L that is key to SARS-CoV-2 entry into the human host cell, MPI8 exerts improved potency to inhibit SARS-CoV-2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_10</DOCNO>
            	<TEXT>So far it is potentially one of the most potent antivirals that have been developed to treat COVID-19, stated Dr. Wenshe Ray Liu, Gradipore Chair in the Department of Chemistry at Texas A amp;M University.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_11</DOCNO>
            	<TEXT>READ THIS ONE MORE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_12</DOCNO>
            	<TEXT>So far it is potentially one of the most potent antivirals that have been developed to treat COVID-19, stated Dr. Wenshe Ray Liu, Gradipore Chair in the Department of Chemistry at Texas A amp;M University.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_13</DOCNO>
            	<TEXT>Wenshe Ray Liu believes he has the mother of all antivirals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_14</DOCNO>
            	<TEXT>Remember something COVID-19 is not going away overnight.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_15</DOCNO>
            	<TEXT>More and more mutations are evolving and more and more antivirals will be needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_16</DOCNO>
            	<TEXT>I always ask myself this question.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_17</DOCNO>
            	<TEXT>If you were a scientist and if you were DR Wenshe Ray Liu.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_18</DOCNO>
            	<TEXT>Wouldn't you try the antiviral on yourself in the lab?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_19</DOCNO>
            	<TEXT>If you truly believed it works would you?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_881_20</DOCNO>
            	<TEXT>Or would you take the Pfizer or the J amp;J instead vaccine instead?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_882_0</DOCNO>
            	<TEXT>So answer the question would you try the antiviral?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_882_1</DOCNO>
            	<TEXT>I would and I would then broadcast it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_882_2</DOCNO>
            	<TEXT>Tell everyone that it works.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_883_0</DOCNO>
            	<TEXT>You said that you sold medical equipment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_883_1</DOCNO>
            	<TEXT>Now your a scientist?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_883_2</DOCNO>
            	<TEXT>Which one is it?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_883_3</DOCNO>
            	<TEXT>I hate liars.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_884_0</DOCNO>
            	<TEXT>That's your opinion and I do not believe you have the EDUCATION you stated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_885_0</DOCNO>
            	<TEXT>Do yourself a favor and go for a walk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_886_0</DOCNO>
            	<TEXT>This poster has been permanently removed from this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_886_1</DOCNO>
            	<TEXT>He was previously warned about inciting anger and fighting and insulting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_887_0</DOCNO>
            	<TEXT>I used to work as a PI in my younger years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_887_1</DOCNO>
            	<TEXT>We learn to take notes and refer to them if needed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_887_2</DOCNO>
            	<TEXT>The first time he claimed he sold medical supplies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_887_3</DOCNO>
            	<TEXT>Today he worked in a Harvard Lab.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_887_4</DOCNO>
            	<TEXT>He was warned not to incite violence or harass.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_887_5</DOCNO>
            	<TEXT>It's a Sunday morning and that's not going to happen on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_888_0</DOCNO>
            	<TEXT>A self proclaimed scientist who wants to picket outside a place of science shows mental instability!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_888_1</DOCNO>
            	<TEXT>He needs a rubber room, not a chat room!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_889_0</DOCNO>
            	<TEXT>Could the Omicron variant can likely outcompete Delta and that could worsen the U.S. Covid-19 epidemic?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_889_1</DOCNO>
            	<TEXT>[https://www.statnews.com/2021/12/10/the-omicron-variant-can-likely-outcompete-delta-and-that-could-worsen-the-u-s-covid-19-epidemic/](https://www.statnews.com/2021/12/10/the-omicron-variant-can-likely-outcompete-delta-and-that-could-worsen-the-u-s-covid-19-epidemic/) Well Sorrento Exercises Exclusive Option Agreement With Texas A amp;M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_889_2</DOCNO>
            	<TEXT>To easy everyone fears it's to soon to start loading up on the toilet papers again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_889_3</DOCNO>
            	<TEXT>At the moment the new mutation is only a mild cases of the COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_889_4</DOCNO>
            	<TEXT>To put your fears at easy please click and read. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_889_5</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-series-novel-sars-cov-2-main](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/sorrento-announces-publication-series-novel-sars-cov-2-main)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_890_0</DOCNO>
            	<TEXT>This poster was warned and we had to take action.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_891_0</DOCNO>
            	<TEXT>This variant is only adding fear to increase big pharma's profits for vaccines.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_892_0</DOCNO>
            	<TEXT>Thank you for your incredible insight on how the vaccines do not work.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_892_1</DOCNO>
            	<TEXT>Tonight Chicago plays GB on Sunday night.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_892_2</DOCNO>
            	<TEXT>Aaron Rodgers tried his hardest not to get vaccinated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_892_3</DOCNO>
            	<TEXT>Good for him and I hope he throws 4 TDs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_893_0</DOCNO>
            	<TEXT>I've been in 5 commercials as a B actor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_893_1</DOCNO>
            	<TEXT>And that's the truth.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_894_0</DOCNO>
            	<TEXT>Please watch this video</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_894_1</DOCNO>
            	<TEXT>Arks lead development program (ARK-001) is a single dose resiniferatoxin (RTX) sterile injectable solution.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_894_2</DOCNO>
            	<TEXT>ARK-001 has received FDA CVM (Center for Veterinary Medicine) MUMS (minor use/minor species) designation for the control of bone cancer pain in dogs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_894_3</DOCNO>
            	<TEXT>Other projects include additional indications for RTX in areas such as chronic articular pain in companion animals, neuropathic pain in horses, and idiopathic cystitis in cats, as well as exploring development opportunities in the area of infectious diseases or cancer treatment.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_894_4</DOCNO>
            	<TEXT>Please watch this video [https://www.arkanimalhealth.com/](https://www.arkanimalhealth.com/) Imagine if our pets could all live to be 20 to 30 years old?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_894_5</DOCNO>
            	<TEXT>Our pets are like children to us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_895_0</DOCNO>
            	<TEXT>I have three dogs a Sheep Doodle a Standard Poodle and small dog that's half racoon  amp; half koala bear.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_896_0</DOCNO>
            	<TEXT>My pets are family to me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_896_1</DOCNO>
            	<TEXT>They follow me everywhere.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_897_0</DOCNO>
            	<TEXT>My family has had dogs after dogs for the last 50 years.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_0</DOCNO>
            	<TEXT>Let me tell you something.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_1</DOCNO>
            	<TEXT>These animal hospitals are not cheap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_2</DOCNO>
            	<TEXT>Three years ago we had a dog that was 9 years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_3</DOCNO>
            	<TEXT>He wasn't making any red blood cells.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_4</DOCNO>
            	<TEXT>It was an autoimmune disease that was very rare.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_5</DOCNO>
            	<TEXT>I paid for 3 blood transfusions and hospitalization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_6</DOCNO>
            	<TEXT>Unfortunately my dog had a heart attack and passed away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_7</DOCNO>
            	<TEXT>My family was there with him when he took his last breath.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_8</DOCNO>
            	<TEXT>My hospital bill was $15,000 and I was prepared to pay what ever it took.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_898_9</DOCNO>
            	<TEXT>Hospitals are not cheap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_899_0</DOCNO>
            	<TEXT>They always post the 8-k before a great PR.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_0</DOCNO>
            	<TEXT>FDA Advisory Panel Calls for Safer Epidural Steroid Injections</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_1</DOCNO>
            	<TEXT>An FDA advisory committee is recommending the agency modify labels of certain formulations of corticosteroids in order to ensure epidural injections are safer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_2</DOCNO>
            	<TEXT>The advisory panel is calling for so-called "particulate" steroids contraindicated for epidural injection because they appear to carry greater risk of adverse neurological effects than "nonparticulate" agents.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_3</DOCNO>
            	<TEXT>Most of the dissenting members said the contraindication would be too restrictive, instead preferring label warnings on the risks of such injections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_4</DOCNO>
            	<TEXT>At issue during the meeting was the large number of adverse event reports following corticosteroid injections for back, neck, and radicular pain, which the FDA already issues warnings for earlier this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_5</DOCNO>
            	<TEXT>More patients are receiving injectable corticosteroid injections to relieve back, neck, and radicular pain but a number of reports of injuries associated with epidural use of these drugs has prompted the FDA to consider the labeling.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_6</DOCNO>
            	<TEXT>In July, the FDA approved a new label for epidural steroid injection sponsors, which reads: "Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids (see WARNINGS: Neurologic).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_7</DOCNO>
            	<TEXT>Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke."</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_8</DOCNO>
            	<TEXT>The warning noted that the events occurred with and without fluoroscopy and that the safety and effectiveness of cortical steroids had not been approved for epidural injections.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_9</DOCNO>
            	<TEXT>Kerri Fitzgerald [https://www.hmpgloballearningnetwork.com/site/frmc/articles/fda-advisory-panel-calls-safer-epidural-steroid-injections](https://www.hmpgloballearningnetwork.com/site/frmc/articles/fda-advisory-panel-calls-safer-epidural-steroid-injections) That's right this article was written in 2014.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_10</DOCNO>
            	<TEXT>It's was also referenced in the 8-k today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_11</DOCNO>
            	<TEXT>Scilex is doing exactly what the FDA wants.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_12</DOCNO>
            	<TEXT>For those of you that are new to this board please click and read. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_900_13</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-0](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-0)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_901_0</DOCNO>
            	<TEXT>I just love the fact that this article was written in 2014.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_901_1</DOCNO>
            	<TEXT>Seven years later DR J, did exactly what the FDA was looking for.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_901_2</DOCNO>
            	<TEXT>A safer FDA approved epidural.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_0</DOCNO>
            	<TEXT>DO YOU KNOW WHO JUST SAID THIS?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_1</DOCNO>
            	<TEXT>45 MINUTES AGO!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_2</DOCNO>
            	<TEXT>Thrilled to share the latest Scilex Holding including our new partnership with Vickers Vantage Corp I and exciting topline results from our SP-102 Phase 3 study in sciatica.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_3</DOCNO>
            	<TEXT>DM or call for more info.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_4</DOCNO>
            	<TEXT>Happy Holidays!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_5</DOCNO>
            	<TEXT>Look forward to seeing some of you at JPM conference. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_6</DOCNO>
            	<TEXT>https://www.linkedin.com/in/jaisimshah/](https://www.linkedin.com/in/jaisimshah/) If you have no idea you should start doing more DD.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_7</DOCNO>
            	<TEXT>See you all at the conference. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_902_8</DOCNO>
            	<TEXT>https://www.jpmorgan.com/solutions/cib/insights/health-care-conference#keynotes](https://www.jpmorgan.com/solutions/cib/insights/health-care-conference#keynotes)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_903_0</DOCNO>
            	<TEXT>Going to this conference and announcing the progress to the bankers sitting with all the new cash for the new year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_903_1</DOCNO>
            	<TEXT>Where do you think they will invest it?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_904_0</DOCNO>
            	<TEXT>I have a friend who's VP at JPM Financial Risk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_904_1</DOCNO>
            	<TEXT>I'm going to ask him to attend or listen to the conference.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_904_2</DOCNO>
            	<TEXT>He's in NY and the conference is in SF.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_904_3</DOCNO>
            	<TEXT>I will keep the board posted.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_905_0</DOCNO>
            	<TEXT>The conference is private and only open to investors of $20M to $2B. They will be talking to the JPM investors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_905_1</DOCNO>
            	<TEXT>These big banks every year put aside large sums of money to invest in the beginning of the year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_906_0</DOCNO>
            	<TEXT>Did you see DR J is going to attend the JPM Conference in early January?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_906_1</DOCNO>
            	<TEXT>The big banks always wait for the new year to invest.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_906_2</DOCNO>
            	<TEXT>DR J will remind them of why they own Sorrento shares and he will convince them to purchase more.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_0</DOCNO>
            	<TEXT>LET'S PLAY MONOPOLY</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_1</DOCNO>
            	<TEXT>Who knows how to play Monopoly?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_2</DOCNO>
            	<TEXT>DR JI, know how to play.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_3</DOCNO>
            	<TEXT>DR J.S. knows how to play as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_4</DOCNO>
            	<TEXT>What's the first thing that everyone does when they play?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_5</DOCNO>
            	<TEXT>Everything they land on they BUY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_6</DOCNO>
            	<TEXT>Then they make deals to trade properties for cash or even trade.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_7</DOCNO>
            	<TEXT>What do you do then?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_8</DOCNO>
            	<TEXT>You build on your properties and you hope that someone lands on your HOTELS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_9</DOCNO>
            	<TEXT>DR JI  amp; DR J.S have built hotels on Boardwalk Walk  amp; Park Place.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_10</DOCNO>
            	<TEXT>Everyone knows when you land on Boardwalk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_11</DOCNO>
            	<TEXT>You need cash to pay or you have to hand over your properties or exit the game.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_12</DOCNO>
            	<TEXT>It took 7 years to become debit free and own multiple companies and build the largest COVID-19 PIPELINE in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_13</DOCNO>
            	<TEXT>Semdexa will generate enough income to acquire the rest of the properties on the Monopoly Board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_14</DOCNO>
            	<TEXT>They always say who ever get Boardwalk  amp; Park Place first always wins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_15</DOCNO>
            	<TEXT>Who knows how to play Monopoly?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_16</DOCNO>
            	<TEXT>DR JI, know how to play.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_17</DOCNO>
            	<TEXT>DR J.S. knows how to play as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_18</DOCNO>
            	<TEXT>What's the first thing that everyone does when they play?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_19</DOCNO>
            	<TEXT>Everything they land on they BUY.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_20</DOCNO>
            	<TEXT>Then they make deals to trade properties for cash or even trade.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_21</DOCNO>
            	<TEXT>What do you do then?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_22</DOCNO>
            	<TEXT>You build on your properties and you hope that someone lands on your HOTELS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_23</DOCNO>
            	<TEXT>DR JI  amp; DR J.S have built hotels on Boardwalk Walk  amp; Park Place.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_24</DOCNO>
            	<TEXT>Everyone knows when you land on Boardwalk.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_25</DOCNO>
            	<TEXT>You need cash to pay or you have to hand over your properties or exit the game.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_26</DOCNO>
            	<TEXT>It took 7 years to become debit free and own multiple companies and build the largest COVID-19 PIPELINE in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_27</DOCNO>
            	<TEXT>Semdexa will generate enough income to acquire the rest of the properties on the Monopoly Board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_907_28</DOCNO>
            	<TEXT>They always say who ever get Boardwalk  amp; Park Place first always wins.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_0</DOCNO>
            	<TEXT>Sorrento Therapeutics, Inc. is a federal government contractor and, in compliance with its obligations under current federal regulations, Sorrento requires all employees, including newly hired employees, to present proof of vaccination against COVID-19 by December 8, 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_1</DOCNO>
            	<TEXT>Do you know why they're a federal government contractor?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_2</DOCNO>
            	<TEXT>Because in November of 2020 please read.... Initial funding of up to $34 million for the project Gene Mabs: A Scalable, Economic, Gene-Encoded Protective Antibody Platform Against Coronavirus (HR0011-21-9-0015) to support the development of an STI-2020-encoded Gene MAbTM through Phase 2 clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_3</DOCNO>
            	<TEXT>STI-2020-encoded Gene MAb is in development for intramuscular injection against the SARS-CoV-2 virus and its variant strains to produce potent STI-2020 nAbs in the body.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_4</DOCNO>
            	<TEXT>STI-2020-encoded Gene MAb products can potentially be stored at refrigerator temperatures, avoiding some of the cold chain management challenges associated with the deployment of COVID-19 vaccines currently in development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_5</DOCNO>
            	<TEXT>Sorrento has a cGMP facility in place to meet initial production demand and Sorrento expects that STI-2020-encoded Gene MAb can be produced in large quantity to meet potentially high demand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_6</DOCNO>
            	<TEXT>SAN DIEGO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- SmartPharm Therapeutics, Inc. (SmartPharm), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, Sorrento), and developer of next-generation, non-viral gene therapy technologies, announced today that it has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop a rapid countermeasure to COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_7</DOCNO>
            	<TEXT>The contract would provide SmartPharm up to USD $34 million for development through Phase 2 clinical studies of a gene-encoded antibody (Gene MAb) that could enable rapid protection from and/or treatment of SARS-CoV-2 infection and COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_8</DOCNO>
            	<TEXT>Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_9</DOCNO>
            	<TEXT>For this Gene MAb approach, the SmartPharm/Sorrento team will produce plasmid DNA encoding the SARS-CoV-2 neutralizing antibody STI-2020 (COVI-AMG).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_10</DOCNO>
            	<TEXT>The FDA is currently reviewing IND filings for STI-2020 as an IV-delivered neutralizing antibody and STI-2099 as an intranasal-delivered neutralizing antibody for the treatment of COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_11</DOCNO>
            	<TEXT>The expected higher potency of the STI-2020 antibody makes it an ideal candidate for Gene MAb delivery against COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_12</DOCNO>
            	<TEXT>The DARPA/JPEO contract supports the accelerated development of a Gene MAbs neutralizing antibody that can be delivered by a simple intramuscular injection, enabling the recipient to produce the protective antibody, potentially within days of the injection.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_13</DOCNO>
            	<TEXT>Such an approach would permit the rapid translation of fully characterized potent neutralizing antibodies into clinical use, which Sorrento believes will be important for responding to potential mutations of SARS-CoV-2 that may emerge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_14</DOCNO>
            	<TEXT>It would also enable broader deployment of the Gene MAb approach as a prophylactic solution, as it can be conveniently administered into the muscle like an annual flu vaccine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_15</DOCNO>
            	<TEXT>If successful, it could provide an alternative method of protecting populations where vaccines do not work as well, such as the elderly or immunocompromised.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_16</DOCNO>
            	<TEXT>Dr. Henry Ji, CEO of Sorrento, commented, We are excited that DARPA and JPEO have recognized our Gene MAbs platform as a potential rapid countermeasure for COVID-19 and the potential value for other applications to combat future viral diseases of pandemic potential.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_17</DOCNO>
            	<TEXT>We acquired SmartPharm with the vision of combining the power of our antibody and biologic therapies for cancer and infectious diseases with next-generation gene-encoded technologies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_18</DOCNO>
            	<TEXT>We look forward to working with our Department of Defense partners to potentially add a novel approach to the arsenal of solutions for combating this devastating disease.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_19</DOCNO>
            	<TEXT>DARPA, founded in 1958, is an agency of the U.S. Department of Defense.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_20</DOCNO>
            	<TEXT>Through collaborations with academic, industry, and government partners, DARPA makes investments across multiple sectors to drive breakthrough technologies for U.S. national security.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_21</DOCNO>
            	<TEXT>Through the collaboration with JPEO-CBRND, this work is supported by the Office of the Assistant Secretary of Defense for Health Affairs with funding from the Defense Health Agency. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_22</DOCNO>
            	<TEXT>https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/darpa-and-jpeo-award-contract-smartpharm-subsidiary-sorrento) READ THIS ONE MORE TIME.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_909_23</DOCNO>
            	<TEXT>Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_910_0</DOCNO>
            	<TEXT>Yes of course</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_911_0</DOCNO>
            	<TEXT>Great stuff</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_912_0</DOCNO>
            	<TEXT>The corruption is so visible and shameful.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_912_1</DOCNO>
            	<TEXT>What's so amazing is all these NFL players are all getting sick with covid and every single one of them are vaccinated.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_913_0</DOCNO>
            	<TEXT>I hope everyone is enjoying this holiday week leading up to Christmas?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_913_1</DOCNO>
            	<TEXT>If I'm sort of silent these days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_913_2</DOCNO>
            	<TEXT>It's because I'm Christmas shopping and hopping from Christmas party to the next party.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_913_3</DOCNO>
            	<TEXT>Everyone needs to relax and enjoy your families.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_914_0</DOCNO>
            	<TEXT>I second the strong buy rating.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_0</DOCNO>
            	<TEXT>SUPPORTING M amp;A TRANSACTIONS - NEW POSITION ADDED 13 HOURS AGO.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_1</DOCNO>
            	<TEXT>Be the main point of contact in supporting M amp;A transactions including due diligence, valuation, and purchase accounting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_2</DOCNO>
            	<TEXT>This is a new position that was added 13 hours ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_3</DOCNO>
            	<TEXT>Director, Technical Accounting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_4</DOCNO>
            	<TEXT>WHAT YOULL DO: Responsible for managing Sorrentos accounting policies, procedures, and positions on a range of technical accounting topics, including the implementation and compliance with new accounting standards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_5</DOCNO>
            	<TEXT>This role will include maintaining an inventory of position papers and working with the business and accounting team to ensure continued compliance with accounting policies and includes ensuring changes to the business that impact our accounting are addressed timely.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_6</DOCNO>
            	<TEXT>ESSENTIAL DUTIES AND RESPONSIBILITIES: Review accounting policies and procedures that ensure the highest level of operational efficiency for business units, while maintaining appropriate internal controls and compliance with US GAAP.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_7</DOCNO>
            	<TEXT>Lead development of technical memos for accounting matters (e.g., debt refinancing, share-based compensation, revenue recognition of new products, etc.)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_8</DOCNO>
            	<TEXT>and oversee annual goodwill impairment testing.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_9</DOCNO>
            	<TEXT>Be the main point of contact in supporting M amp;A transactions including due diligence, valuation, and purchase accounting Responsible to facilitate the education and training of the global accounting team and broader finance organization on technical accounting matters Deliver business partnership with multiple international and domestic executives and their teams within our organization.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_10</DOCNO>
            	<TEXT>Analysis and solutions for organizational problems Builds a strong accounting organization and develops talent within the team for our long- term success. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_11</DOCNO>
            	<TEXT>https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=565](https://sorrentotherapeutics.bamboohr.com/jobs/view.php?id=565) Sorrento only wants the best... 10 years of experience at a Big 4 public accounting firm, including significant SEC experience with companies with global operations or equivalent industry experience.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_12</DOCNO>
            	<TEXT>They continue to build and hire and hire and support M amp;A transactions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_915_13</DOCNO>
            	<TEXT>Be prepared for the...</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_916_0</DOCNO>
            	<TEXT>BEST M amp;A TRANSACTION!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_917_0</DOCNO>
            	<TEXT>Looks like they want to add a Maverick CPA to the team that can help with M amp;A deals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_917_1</DOCNO>
            	<TEXT>When companies come into a large amount of money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_917_2</DOCNO>
            	<TEXT>They tend to invest that money.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_917_3</DOCNO>
            	<TEXT>Sometimes it's not best to show to much profit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_917_4</DOCNO>
            	<TEXT>So you invest it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_918_0</DOCNO>
            	<TEXT>Sorrento wants the best CPA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_918_1</DOCNO>
            	<TEXT>10 years of experience at a Big 4 public accounting firm, including significant SEC experience with companies with global operations or equivalent industry experience.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_918_2</DOCNO>
            	<TEXT>Read that twice with global operations</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_919_0</DOCNO>
            	<TEXT>I'm going to Mexico in early March for a vacation.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_919_1</DOCNO>
            	<TEXT>But I will be doing lots of DD while I'm there.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_919_2</DOCNO>
            	<TEXT>I will be coming back with a box of 25 COVISTIX.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_920_0</DOCNO>
            	<TEXT>You don't have to tell me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_920_1</DOCNO>
            	<TEXT>I'm going to retire making wine on my Vineyard.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_0</DOCNO>
            	<TEXT>It's not harmful content.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_1</DOCNO>
            	<TEXT>You don't have to agree or disagree.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_2</DOCNO>
            	<TEXT>Barbara Bush said it best it's not what you say.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_3</DOCNO>
            	<TEXT>It's what you don't say.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_4</DOCNO>
            	<TEXT>Just go about your business.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_5</DOCNO>
            	<TEXT>And if you were in his shoes and experienced being a frontline medic during the Vietnam war for two years with only 4 RRs.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_6</DOCNO>
            	<TEXT>Maybe you would have a different view of life as we see it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_921_7</DOCNO>
            	<TEXT>He earned a Bronze Star and he can have any views on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_922_0</DOCNO>
            	<TEXT>Well thought how I feel and it feels great to let it all out!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_922_1</DOCNO>
            	<TEXT>You earned it and it's your right to express yourself.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_923_0</DOCNO>
            	<TEXT>Do you know they reported that smash and grab in the USA cost our Country $65B this year.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_923_1</DOCNO>
            	<TEXT>Now why are they committing crimes?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_924_0</DOCNO>
            	<TEXT>Good luck trying to buy a gun or finding the right ammo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_924_1</DOCNO>
            	<TEXT>You can't find any 30-06 by me.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_0</DOCNO>
            	<TEXT>Antigen Binding Proteins that Bind BCMA</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_1</DOCNO>
            	<TEXT>U.S. patent application number 17/412089 was filed with the patent office on 2021-12-16 for antigen binding proteins that bind bcma.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_2</DOCNO>
            	<TEXT>This patent application is currently assigned to Sorrento Therapeutics, Inc.. The applicant listed for this patent is Sorrento Therapeutics, Inc.. Invention is credited to Xia Cao, Heyue Zhou. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_3</DOCNO>
            	<TEXT>https://uspto.report/patent/app/20210388097](https://uspto.report/patent/app/20210388097) Abstract The present disclosure provides BCMA binding proteins, particularly anti-BCMA antibodies, or antigen-binding portions thereof, that specifically bind BCMA and uses thereof.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_4</DOCNO>
            	<TEXT>In one embodiment, the anti-BCMA antibody comprises an antigen binding portion that binds a human BCMA epitope and blocks binding (e.g, inhibits binding) of human APRIL and/or human BAFF to the human BCMA epitope.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_5</DOCNO>
            	<TEXT>Various aspects of the anti-BCMA antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-BCMA antibodies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_6</DOCNO>
            	<TEXT>Methods for using the anti-BCMA antibodies include in vitro and in vivo methods for binding BCMA, detecting BCMA and treating diseases associated with BCMA over-expression.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_7</DOCNO>
            	<TEXT>In layman's terms something was really good to file for a patent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_925_8</DOCNO>
            	<TEXT>Keep patenting away.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_926_0</DOCNO>
            	<TEXT>You can post them here.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_0</DOCNO>
            	<TEXT>I disagree and time will tell.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_1</DOCNO>
            	<TEXT>The deep State did everything they could from stopping him from uncovering all the corruption.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_2</DOCNO>
            	<TEXT>They went as far as saying he colluded with the Russians.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_3</DOCNO>
            	<TEXT>Which now we know was not true.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_4</DOCNO>
            	<TEXT>Based on the indictments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_5</DOCNO>
            	<TEXT>The night of the Election Trump was in the Eisenhower Building.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_6</DOCNO>
            	<TEXT>That building is used by the CIA to view real time cyber fraud.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_7</DOCNO>
            	<TEXT>He saw the fraud taking place real time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_8</DOCNO>
            	<TEXT>That's why he can out at 10pm and said there trying to steal the election.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_9</DOCNO>
            	<TEXT>But he had no idea how deep the deep State was.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_10</DOCNO>
            	<TEXT>What did the media do?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_11</DOCNO>
            	<TEXT>They silenced him and everyone else.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_12</DOCNO>
            	<TEXT>If you ask me it was a joke to say he lost.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_13</DOCNO>
            	<TEXT>Look at the rallies that he had.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_14</DOCNO>
            	<TEXT>50,000 people would should up.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_15</DOCNO>
            	<TEXT>And Biden had 50 people.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_16</DOCNO>
            	<TEXT>He wasn't even campaigning.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_17</DOCNO>
            	<TEXT>lol He even called Kamala the President elect.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_18</DOCNO>
            	<TEXT>lol Trump was a narcissistic.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_19</DOCNO>
            	<TEXT>But that was only to make America great again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_20</DOCNO>
            	<TEXT>He hated to be wrong.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_21</DOCNO>
            	<TEXT>He handled failure badly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_22</DOCNO>
            	<TEXT>But he wasn't on the take like every other President before him.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_23</DOCNO>
            	<TEXT>They all left the White House with their pockets full of deals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_24</DOCNO>
            	<TEXT>He lost his money in order to help us.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_25</DOCNO>
            	<TEXT>Joe Biden exit from Afghanistan was the worst military fuck up in US History.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_26</DOCNO>
            	<TEXT>They will write it in all history books.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_27</DOCNO>
            	<TEXT>That we left the Taliban 7,000,000 rifles, trucks, planes, ammo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_28</DOCNO>
            	<TEXT>Because China is the running the show in Afghanistan now.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_29</DOCNO>
            	<TEXT>They have 10,000 contractors there now mining all the materials for all of the EV batteries needed, Joe Biden gave them the keys to kitchen because they have dirt on Hunter Biden.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_30</DOCNO>
            	<TEXT>There's no way the Russian took his laptop and created all the shit on there.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_31</DOCNO>
            	<TEXT>The media is worse than our enemies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_32</DOCNO>
            	<TEXT>They don't report the true facts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_33</DOCNO>
            	<TEXT>Our country is being taken over by the commies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_34</DOCNO>
            	<TEXT>And it only cost them a few billion to Hunter Biden's shell companies.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_35</DOCNO>
            	<TEXT>Now Trump wasn't perfect and he was not a Nazi.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_36</DOCNO>
            	<TEXT>Just wait in 2024 if he gets reelected.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_37</DOCNO>
            	<TEXT>He will not make the same mistakes twice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_38</DOCNO>
            	<TEXT>The military has been building courtrooms at Guantanamo Bay.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_39</DOCNO>
            	<TEXT>I thought they were shouting place down?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_40</DOCNO>
            	<TEXT>Nope they plan use them when Trump become President again.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_927_41</DOCNO>
            	<TEXT>Don't shoot the messenger.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_928_0</DOCNO>
            	<TEXT>lol doomed?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_928_1</DOCNO>
            	<TEXT>No it will be fine.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_928_2</DOCNO>
            	<TEXT>There will be the best ratings though watching the Military tribunals at Guantanamo Bay.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_0</DOCNO>
            	<TEXT>Well this is what's so great about being an American.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_1</DOCNO>
            	<TEXT>We can pick and choose what we believe is right or wrong.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_2</DOCNO>
            	<TEXT>I'm not going to hate you because we disagree.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_3</DOCNO>
            	<TEXT>What's hurting Americans today is the few that want to change the way we think.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_4</DOCNO>
            	<TEXT>For some we look the other way.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_5</DOCNO>
            	<TEXT>Some freak out and burn and destroy their neighborhoods.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_6</DOCNO>
            	<TEXT>Stealing from there own friends.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_7</DOCNO>
            	<TEXT>After awhile some want to blow some stream.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_929_8</DOCNO>
            	<TEXT>I have no problem with protesting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_930_0</DOCNO>
            	<TEXT>I'll tell you a true story Donald Trump cost me $10,000 When Donald Trump was developing his golf course 5 minutes from my house he was building 70 townhouse units Our Town looked at it as an opportunity to make money</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_931_0</DOCNO>
            	<TEXT>So my town raised the recreation fee from $300 per new home to 10,000</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_932_0</DOCNO>
            	<TEXT>I was building a new home at the time</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_933_0</DOCNO>
            	<TEXT>Now was it his fault or was it the democratic-led village?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_0</DOCNO>
            	<TEXT>I don't hold any judgments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_1</DOCNO>
            	<TEXT>Some of my best friends are liberals.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_2</DOCNO>
            	<TEXT>We debate without fighting or calling names.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_3</DOCNO>
            	<TEXT>All the spending gets out of hand.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_4</DOCNO>
            	<TEXT>When I was raised as a kid.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_5</DOCNO>
            	<TEXT>My family went through a very rough period during the mid 1975s.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_6</DOCNO>
            	<TEXT>Interest rates were 16% and no one had money to spend.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_7</DOCNO>
            	<TEXT>I remember being given $20 to go grocery shopping with my mother.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_8</DOCNO>
            	<TEXT>That $20 feed a family of 5 for seven days.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_9</DOCNO>
            	<TEXT>Inflation today is out of control.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_10</DOCNO>
            	<TEXT>Who is to blame?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_11</DOCNO>
            	<TEXT>How can we fix it?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_934_12</DOCNO>
            	<TEXT>$20 today will buy you one large pizza without toppings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_935_0</DOCNO>
            	<TEXT>Calm before the approval</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_936_0</DOCNO>
            	<TEXT>The main SRNE board?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_936_1</DOCNO>
            	<TEXT>I assume your talking about r/SRNE well that board is only interested in making money on their advertisements.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_936_2</DOCNO>
            	<TEXT>What a nuisance having to scroll for posting.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_936_3</DOCNO>
            	<TEXT>They also limit what you can say.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_936_4</DOCNO>
            	<TEXT>I understand your frustration.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_937_0</DOCNO>
            	<TEXT>Great DD and a Happy New Year to you as well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_938_0</DOCNO>
            	<TEXT>You thought wrong to doubt any of us on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_938_1</DOCNO>
            	<TEXT>We Thank your father and uncle if they did serve.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_938_2</DOCNO>
            	<TEXT>The next time you post on our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_938_3</DOCNO>
            	<TEXT>Show a little more respect.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_939_0</DOCNO>
            	<TEXT>I can say the same about Joe Biden.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_939_1</DOCNO>
            	<TEXT>How come he can not stop the Military that's renovating Guantanamo Bay prison into a State of the Art Court room?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_939_2</DOCNO>
            	<TEXT>Because the Military is in charge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_0</DOCNO>
            	<TEXT>CONGRATULATIONS</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_1</DOCNO>
            	<TEXT>Today is a great day for Scilex Holding, we announced topline results of the pivotal Phase 3 trial for SP-102.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_2</DOCNO>
            	<TEXT>The team has worked on this program for over 7 years since the inception of Semnur, and Im thrilled to have led this from inception and design to this very amazing outcome where if approved we may be able to help the millions struggling from chronic back pain with limited options and also hope to minimize the overuse of opioids.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_3</DOCNO>
            	<TEXT>This data milestone reflects years of product development, preclinical and clinical research and dedication, huge thanks Semnur/Scilex/Sorrento Team.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_4</DOCNO>
            	<TEXT>Very fortunate in a 30 year career in life science industry to have led the development and commercialization teams of other global blockbuster products addressing huge unmet need including Rituxan at Roche/Biogen ($8 billion in peak annual sales) and Abilify at BMS/Otsuka ( gt;$6 billion in peak sales).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_5</DOCNO>
            	<TEXT>Thanks to the thousands of connections in this network and numerous friends and colleagues I have worked with who provided encouragement, advice and support along great journey for this next potential breakthrough product.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_6</DOCNO>
            	<TEXT>DR Jaisim, received 73 likes and 11 Congratulations from colleagues and friends.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_7</DOCNO>
            	<TEXT>Everyone is very excited and it looks like there celebrating.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_8</DOCNO>
            	<TEXT>But we're starting to see people who are doubting that it was great news.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_9</DOCNO>
            	<TEXT>The best advice is do your own DD and research how Scilex did exactly what the CDC wanted 7 years ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_10</DOCNO>
            	<TEXT>Looks to me DR Jaisim took a victory lap.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_11</DOCNO>
            	<TEXT>Please view for yourselves.. [https://www.linkedin.com/feed/update/urn:li:activity:6874732756845367296/](https://www.linkedin.com/feed/update/urn:li:activity:6874732756845367296/) [https://www.cdc.gov/opioids/basics/epidemic.html](https://www.cdc.gov/opioids/basics/epidemic.html) [https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-0](https://investors.sorrentotherapeutics.com/news-releases/news-release-details/scilex-holding-company-sorrento-therapeutics-inc-subsidiary-0) Time is on our side.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_12</DOCNO>
            	<TEXT>SEMDEXA has the ability to generate $10 Billion annual sales.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_13</DOCNO>
            	<TEXT>Would you Celebrate?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_14</DOCNO>
            	<TEXT>On January 10th thru the 13th Scilex will be at the 40th Annual JP Morgan Healthcare Conference.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_15</DOCNO>
            	<TEXT>At that conference DR Jaisim will remind what JPM owns privately in meetings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_940_16</DOCNO>
            	<TEXT>I'm very confident they will increase their holdings.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_941_0</DOCNO>
            	<TEXT>100% approved you can bank on it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_942_0</DOCNO>
            	<TEXT>I love your math and you receive an A+</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_943_0</DOCNO>
            	<TEXT>This same post was deleted on yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_943_1</DOCNO>
            	<TEXT>We had 9 replies and 27-0 likes and the corrupt moderators deleted the post.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_943_2</DOCNO>
            	<TEXT>They're so scared and do not want to give anyone hope.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_943_3</DOCNO>
            	<TEXT>Time is on our side.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_944_0</DOCNO>
            	<TEXT>I used to spend time going to Philly on work 10 years ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_944_1</DOCNO>
            	<TEXT>I really liked dining outside at Rouge.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_944_2</DOCNO>
            	<TEXT>Then I used to have to go the Chester Spring PA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_944_3</DOCNO>
            	<TEXT>Beautiful horse farms.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_945_0</DOCNO>
            	<TEXT>Feliz Navidad</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_946_0</DOCNO>
            	<TEXT>May you and your family find peace and happiness this holiday season.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_0</DOCNO>
            	<TEXT>Scilex Therapeutics Partners Webpage has been updated 12/18/21</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_1</DOCNO>
            	<TEXT>At SCILEX, were excited to develop and commercialize innovative pain management solutions to help improve patient care.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_2</DOCNO>
            	<TEXT>Learn more about whats going on at SCILEX. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_3</DOCNO>
            	<TEXT>https://www.scilexpharma.com/partners/](https://www.scilexpharma.com/partners/) SCILEX HOLDING COMPANY (Scilex), a subsidiary of Sorrento, is dedicated to the development and commercialization of non-opioid pain management products.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_4</DOCNO>
            	<TEXT>We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_5</DOCNO>
            	<TEXT>The companys lead product ZTlido (lidocaine topical system) 1.8%, is a branded prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with Post-Herpetic Neuralgia (PHN), which is a form of post-shingles nerve pain.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_6</DOCNO>
            	<TEXT>Scilexs SP-102 (10 mg dexamethasone sodium phosphate viscous gel injection), or SEMDEXA, for the treatment of Lumbar Radicular Pain has completed enrollment in a Phase III clinical trial and has received Fast Track Status from the FDA.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_7</DOCNO>
            	<TEXT>If approved by the FDA, the company expects SP-102 to be the first FDA-approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_8</DOCNO>
            	<TEXT>SCILEX is committed to harnessing the power of revolutionary delivery technologies designed to safely and effectively provide therapies to those who need them the most.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_9</DOCNO>
            	<TEXT>STOP AND READ THIS ONE MORE TIME!</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_10</DOCNO>
            	<TEXT>We are uncompromising in our focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_947_11</DOCNO>
            	<TEXT>Global pain management leader.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_0</DOCNO>
            	<TEXT>Ask, and it shall be given you, Seek and ye shall find, Knock, and it shall be opened unto you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_1</DOCNO>
            	<TEXT>I've been a Sorrento shareholder since May 2020.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_2</DOCNO>
            	<TEXT>I've researched 1000s of hours of due diligence since I heard Sorrento found a cure for COVID-19.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_3</DOCNO>
            	<TEXT>Since then Sorrento has been building the biggest COVID-19 pipeline in the World.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_4</DOCNO>
            	<TEXT>They also have been focusing on Cancer drugs and pain management.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_5</DOCNO>
            	<TEXT>unique portfolio of I-O platform assets is unrivaled in the industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_6</DOCNO>
            	<TEXT>It includes immune checkpoint inhibitors, bispecific antibodies, antibody-drug conjugates (ADCs) as well as chimeric antigen receptor (CAR) and dimeric antigen receptor (DAR) based cellular therapies, and most recently weve added oncolytic viruses (Seprehvir, Seprehvec).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_7</DOCNO>
            	<TEXT>Each asset individually shows great promise; put together we feel they have the potential to break through the most difficult cancer challenges Cancer is genetically diverse, highly adaptive, constantly mutating and virtually invisible to the immune system.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_8</DOCNO>
            	<TEXT>Our approach to cancer therapy is based on the belief that patients will require a multimodal, multipronged approach targeting a single or diverse set of cellular targets and attacking those on several fronts simultaneously or sequentially, frequently and relentlessly.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_9</DOCNO>
            	<TEXT>Our approach to fighting cancer is made possible by a unique immuno-oncology (I-O) portfolio, comprised of a wide array of innovative and synergistic assets, such as a broad fully human antibody library (G-MAB) that can be used on their own or incorporated into cancer-targeting approaches including: These assets are complemented by an innovative lymphatic targeting device (Sofusa) designed to deliver antibodies into the lymphatic system, where immune cells are trained to fight cancer.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_10</DOCNO>
            	<TEXT>We have generated human antibodies against many targets important in cancer treatment, including PD-1, PD-L1, CD38, CD123, CD47, c-MET, VEGFR2, and many other targets, which are at various stages of development.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_11</DOCNO>
            	<TEXT>Our CAR-T programs include clinical stage CD38 CAR T. Therapies that combine approaches are in preclinical stage evaluation for multiple myeloma, lung cancer, and other adult and pediatric cancers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_12</DOCNO>
            	<TEXT>G-MABTM Library Sorrentos proprietary G-MAB technology, invented by Dr. Ji, is based on the use of RNA transcription for amplification of the antibody variable domains from over 600 donors.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_13</DOCNO>
            	<TEXT>In-depth analysis of deep sequencing DNA data showed that the G-MAB library contains more than 10 quadrillion (1016) distinct antibody sequences.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_14</DOCNO>
            	<TEXT>This makes it one of the largest fully human antibody libraries in the biopharmaceutical industry.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_15</DOCNO>
            	<TEXT>Thus far, Sorrento has successfully identified fully human antibodies against over 100 clinically-relevant high-impact oncogenic targets, including PD-1, PD-L1, CD38, CD123, CD47, VEGFR2, and CCR2.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_16</DOCNO>
            	<TEXT>Scilexs SP-102 (10 mg dexamethasone sodium phosphate gel), or SEMDEXA, for the treatment of Lumbar Radicular Pain is in the process of completing a Phase III clinical trial.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_17</DOCNO>
            	<TEXT>The company expects SP-102 to be the first FDA approved non-opioid epidural injection to treat lumbosacral radicular pain, or sciatica, with the potential to replace 10 to 11 million off-label epidural steroid injections administered each year in the US.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_18</DOCNO>
            	<TEXT>And we know that all things, work together for good to them that love GOD, to them who are called according to this purpose.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_948_19</DOCNO>
            	<TEXT>Romans, Chapter 7 Matthew, Chapter 7</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_949_0</DOCNO>
            	<TEXT>What are you looking for?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_949_1</DOCNO>
            	<TEXT>What do you want?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_950_0</DOCNO>
            	<TEXT>Who are you referring to?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_0</DOCNO>
            	<TEXT>On this day in 1965 Gallant initiative:</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_1</DOCNO>
            	<TEXT>Gallant initiative: On this day in 1965, during Operation Harvest Moon in Vietnam, Lt.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_2</DOCNO>
            	<TEXT>Harvey C. Barnum Jr. and his company were pinned down by a hail of enemy fire and separated from the remainder of their battalion by more than 500 meters of open and fire-swept ground.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_3</DOCNO>
            	<TEXT>With disregard for his own safety, Lt.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_4</DOCNO>
            	<TEXT>Barnum began exposing himself to fire to seek targets for his artillery.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_5</DOCNO>
            	<TEXT>Barnum found the rifle company commander mortally wounded and the radio operator killed in action.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_6</DOCNO>
            	<TEXT>He proceeded to give aid to his dying commander and assumed command of the rifle company after removing the radio from the operator.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_7</DOCNO>
            	<TEXT>He moved into the midst of heavy fire, rallying and encouraging his Marines, and preparing for an attack on the enemy positions.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_8</DOCNO>
            	<TEXT>With two armed helicopters, he moved fearlessly through enemy fire to control the air attacks against the enemy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_9</DOCNO>
            	<TEXT>His successful counterattack claimed key enemy positions, and the helicopters were able to land to remove the dead and wounded.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_10</DOCNO>
            	<TEXT>His swift decisions and gallant initiative earned him the Medal of Honor.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_11</DOCNO>
            	<TEXT>At the time of his actions, Lt.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_12</DOCNO>
            	<TEXT>Barnum was serving as a Forward Observer for Artillery attached to 3rd MARDIV.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_13</DOCNO>
            	<TEXT>He returned to Vietnam in 1968, where he served as the Commanding Officer of Battery E, 2nd Battalion, 12th Marines, 3rd Marine Division.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_14</DOCNO>
            	<TEXT>Barnum retired from the Marine Corps at the rank of Colonel in 1989 after 27 years of service.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_15</DOCNO>
            	<TEXT>He served as Deputy Assistant Secretary of the Navy for Reserve Affairs from 2001 to 2009 and Acting Assistant Secretary of the Navy (Manpower and Reserve Affairs) from January to April 2009.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_16</DOCNO>
            	<TEXT>He is currently 81 years old.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_17</DOCNO>
            	<TEXT>The keel for the US Navy Arleigh Burke-class guided-missile destroyer named in his honor was laid April 6, 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_18</DOCNO>
            	<TEXT>Look around you today and thank the men and women who sacrificed so much.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_19</DOCNO>
            	<TEXT>In order for us to have our freedom.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_20</DOCNO>
            	<TEXT>So we can spend time with our families this holiday season.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_21</DOCNO>
            	<TEXT>It's not all about investing in stocks and making money all the time.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_22</DOCNO>
            	<TEXT>God gives strength to those that need it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_23</DOCNO>
            	<TEXT>You only have to ask for it.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_24</DOCNO>
            	<TEXT>This is a Holy week for many.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_25</DOCNO>
            	<TEXT>If you wish to add GOD in your posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_26</DOCNO>
            	<TEXT>Go right ahead and no one will stop you.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_951_27</DOCNO>
            	<TEXT>May God Bless everyone.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_952_0</DOCNO>
            	<TEXT>I thought so I just wanted to make sure.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_952_1</DOCNO>
            	<TEXT>GOD and Country</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_953_0</DOCNO>
            	<TEXT>So it's pretty much an obnoxious remark.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_953_1</DOCNO>
            	<TEXT>So I'm going to create an example of what we do to those that insult and post obnoxious remarks.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_954_0</DOCNO>
            	<TEXT>I want you to know I banned this poster from posting on our board today.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_954_1</DOCNO>
            	<TEXT>For obnoxious and harassing comments.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_954_2</DOCNO>
            	<TEXT>Full ban and if he returns again please let me know.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_954_3</DOCNO>
            	<TEXT>I will have him fully banned from Reddit.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_955_0</DOCNO>
            	<TEXT>Yes it has been used and his remarks have been noted for the multiple reasons.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_956_0</DOCNO>
            	<TEXT>The Kidney Stone?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_956_1</DOCNO>
            	<TEXT>Or Your wife who was waiting for you after surgery?</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_957_0</DOCNO>
            	<TEXT>Has been banned from posting from our board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_957_1</DOCNO>
            	<TEXT>For the rude obnoxious remarks that were noted for multiple posts.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_957_2</DOCNO>
            	<TEXT>We have zero tolerance for posters that only have no agenda.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_957_3</DOCNO>
            	<TEXT>But to create anger on this board.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_957_4</DOCNO>
            	<TEXT>Our sniper got him and he never knew it was coming.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_958_0</DOCNO>
            	<TEXT>We have no room for losers.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_959_0</DOCNO>
            	<TEXT>I agree I have zero tolerance.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_959_1</DOCNO>
            	<TEXT>We need to create some examples so that we do not become a yahoo.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_961_0</DOCNO>
            	<TEXT>We would love to read your book someday.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_961_1</DOCNO>
            	<TEXT>Your stories need to be told.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_962_0</DOCNO>
            	<TEXT>I would start on a snowy day.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_962_1</DOCNO>
            	<TEXT>When your snowed in and you have no place to go.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_0</DOCNO>
            	<TEXT>Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_1</DOCNO>
            	<TEXT>Phase 2 ending December 2021 news is imminent.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_2</DOCNO>
            	<TEXT>Study of Intravenous COVI-MSC for Treatment of COVID-19-Induced Acute Respiratory Distress 10 out of 10 patients left the hospital.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_3</DOCNO>
            	<TEXT>This phase 2 study is ending December 2021.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_4</DOCNO>
            	<TEXT>News is imminent and it will change the course of the tide.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_5</DOCNO>
            	<TEXT>The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_6</DOCNO>
            	<TEXT>All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_7</DOCNO>
            	<TEXT>No infusion-related adverse events were observed.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_8</DOCNO>
            	<TEXT>Sorrento plans a pivotal, multi-country, multi-site, placebo-controlled study to support an EUA submission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_9</DOCNO>
            	<TEXT>SAN DIEGO, April 20, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today the completion of enrollment in its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_10</DOCNO>
            	<TEXT>This current study (MSC-COV-101) is a single arm, non-randomized Phase 1b study of the safety and preliminary efficacy of COVI-MSCs administered every other day for up to three infusions for a total of 1 x 106 cells/kg, with patients being followed for 28 days following the final infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_11</DOCNO>
            	<TEXT>A total of 10 patients (8 males/2 females; age range 24-65 years; 8 Caucasian/2 Asian; 7 Hispanic/Latino/3 non-Hispanic/Latino; height 64 to 70 inches; weight 66 to 130 kg) were enrolled and all were discharged from the hospital to home within three days of their last infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_12</DOCNO>
            	<TEXT>At baseline, all patients required oxygen supplementation and had PaO2/FiO2 ratios ranging from 135 to 256 (normal 400).</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_13</DOCNO>
            	<TEXT>All patients had various medical co-morbidities in addition to obesity.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_14</DOCNO>
            	<TEXT>The 10th patient had been under treatment for nearly 2 weeks without improvement and was discharged after the 2nd COVI-MSC infusion with oxygen saturations in the high 90s on room air.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_15</DOCNO>
            	<TEXT>On follow up days later, the patient was still doing well.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_16</DOCNO>
            	<TEXT>The study met its primary objective: to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_17</DOCNO>
            	<TEXT>Dr. Eyad Almasri, Associate Professor of Medicine, Pulmonary, Critical Care and Sleep Medicine at UCSF Fresno, is the principal investigator of this study.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_18</DOCNO>
            	<TEXT>Sorrento will be working with the FDA in the near future once the full dataset is available to plan a placebo-controlled pivotal study to support an emergency use authorization (EUA) submission.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_19</DOCNO>
            	<TEXT>The study is expected to be conducted across multiple sites in the United States and Brazil.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_20</DOCNO>
            	<TEXT>Dr. Henry Ji, President and CEO of Sorrento Therapeutics, stated, We look forward to moving our stem cell program forward in development and working with FDA and ANVISA to bring this product to patients in need.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_21</DOCNO>
            	<TEXT>PLEASE READ THIS AGAIN.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_22</DOCNO>
            	<TEXT>All 10 patients were discharged from hospital within three days after their last COVI-MSC infusion.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_963_23</DOCNO>
            	<TEXT>Know what you own.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_964_0</DOCNO>
            	<TEXT>Wreath Laying Honor: Great having the VSRG and GCO team out again at the Wreath laying at Arlington this year to honor the fallen.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_964_1</DOCNO>
            	<TEXT>Arlington National Cemetery welcomed 40,000 volunteers Saturday to participate in Wreaths Across America.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_964_2</DOCNO>
            	<TEXT>Wreaths Across America will bring volunteers to 3,100 cemeteries in a nationwide effort to honor fallen veterans during the holidays.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_964_3</DOCNO>
            	<TEXT>Our teams joined more than 150,000 wreaths were set to be placed at the United States' largest military cemetery in Virginia, an effort to individually recognize those who served and many who made the ultimate sacrifice.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_964_4</DOCNO>
            	<TEXT>Honor them all. [</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_964_5</DOCNO>
            	<TEXT>\#military](https://www.linkedin.com/feed/hashtag/?keywords=military amp;highlightedUpdateUrns=urn%3Ali%3Aactivity%3A6878035936400289792)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_965_0</DOCNO>
            	<TEXT>Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors https://www.marketwatch.com/press-release/sorrento-therapeutics-announces-fda-clearance-of-its-ind-application-of-next-generati</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_965_1</DOCNO>
            	<TEXT>Sorrento Therapeutics Announces FDA Clearance of Its IND Application of Next Generation oHSV Oncolytic Virus STI-1386 for Patients With Relapsed and Refractory Solid Tumors [https://www.marketwatch.com/press-release/sorrento-therapeutics-announces-fda-clearance-of-its-ind-application-of-next-generation-ohsv-oncolytic-virus-sti-1386-for-patients-with-relapsed-and-refractory-solid-tumors-2021-12-20?mod=mw\_quote\_news\_seemore](https://www.marketwatch.com/press-release/sorrento-therapeutics-announces-fda-clearance-of-its-ind-application-of-next-generation-ohsv-oncolytic-virus-sti-1386-for-patients-with-relapsed-and-refractory-solid-tumors-2021-12-20?mod=mw_quote_news_seemore)</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_966_0</DOCNO>
            	<TEXT>LOL You beat me by 1 minute.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_0</DOCNO>
            	<TEXT>CHRISTMAS MESSAGE FROM MIKED44 THIS MORNING @ 10AM</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_1</DOCNO>
            	<TEXT>Bless you  amp; yours.. may the season bring much joy.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_2</DOCNO>
            	<TEXT>Patiently waiting for the inevitable release that initiates momentum.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_3</DOCNO>
            	<TEXT>Revenues from testing should begin to produce meaningful result.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_4</DOCNO>
            	<TEXT>Looking to the next step to be approval of antibody testing.. sure to gain much favor as VOCs continue on their current trajectory.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_5</DOCNO>
            	<TEXT>Scilex strategy will prove beneficial.. providing sufficient cash to fund production of Abivertinib  amp; MSC.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_6</DOCNO>
            	<TEXT>Biobetters.. another critical area should begin to reveal.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_969_7</DOCNO>
            	<TEXT>Feel more confident in Sorrento's prospects today than ever.. not only regards to Covid.. more to the unaddressed need for adequate SOC.. in treatment of ARDS.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_970_0</DOCNO>
            	<TEXT>I spoke with Mike weeks ago.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_970_1</DOCNO>
            	<TEXT>He was sailing around the World with his family.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_970_2</DOCNO>
            	<TEXT>He sends his Blessings and he was my mentor before I starting posting on these boards.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_971_0</DOCNO>
            	<TEXT>Yes i will.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_972_0</DOCNO>
            	<TEXT>I hope there's some type of message that will help Sorrento.</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_973_0</DOCNO>
            	<TEXT>I reckon so so let it be told</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_974_0</DOCNO>
            	<TEXT>It doesn't have to be like this dying you could just turn around and just walk right out</TEXT>
        </DOC>
        <DOC>
            	<DOCNO>s_2494_975_0</DOCNO>
            	<TEXT>Then he spits.</TEXT>
        </DOC>
